PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Clarke, MJ				Clarke, MJ			Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Clarke, MJ (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.	mike.clarke@ctsu.ox.ac.uk						ABE O, 1992, LANCET, V339, P71; [Anonymous], 1996, Lancet, V348, P1189; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; [Anonymous], 1992, Lancet, V339, P1; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Beatson George Thos, 1911, Glasgow Med J, V76, P81; Clarke M, 1998, BRIT J CANCER, V77, P2036, DOI 10.1038/bjc.1998.339; Clarke M, 1998, LANCET, V351, P1451; DECOURMELLES FV, 1922, ARCH ELECTR MED, V32, P264; *EARL BREAST CANC, 1998, COCHR LIB; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1, P82; Lett H, 1905, LANCET, V1, P227; MCWHIRTER R, 1956, J FAC RADIOL LOND, V8, P220; NISSENMEYER R, 1965, ACTA RADIOLOGICA S, V249; OLKIN I, 1995, J CLIN EPIDEMIOL, V48, P133, DOI 10.1016/0895-4356(94)00136-E; PATERSON R, 1959, J Fac Radiol, V10, P130, DOI 10.1016/S0368-2242(59)80037-3; PIANTADOSI S, 1995, CONTROL CLIN TRIALS, V16, P202, DOI 10.1016/S0197-2456(95)80006-9; SCHINZINGER A, 1889, VERH DTSCH GES CHIR, V18, P28; SCHINZINGER AS, 1905, MUENCHENER MED WOCHE, V52, P1724; SMITH GV, 1953, SURG GYNECOL OBSTET, V97, P508; TAYLOR GW, 1939, SURG GYNECOL OBSTET, V68, P452; 1992, LANCET, V339, P95; 1963, BMJ, V2, P1390	23	41	44	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	1998	317	7167					1246	1248		10.1136/bmj.317.7167.1246	http://dx.doi.org/10.1136/bmj.317.7167.1246			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794874	Green Published			2022-12-28	WOS:000076963000039
J	Shukolyukov, A; Lugmair, GW				Shukolyukov, A; Lugmair, GW			Isotopic evidence for the Cretaceous-Tertiary impactor and its type	SCIENCE			English	Article							EARLY SOLAR-SYSTEM; BOUNDARY; SEDIMENTS; CHROMIUM; EXTINCTIONS; ABUNDANCES; METAL	High-precision mass spectrometric analysis of chromium in sediment samples from the Cretaceous-Tertiary (K-T) boundary coincident with the extinction of numerous organisms on Earth confirms the cosmic origin of the K-T phenomenon. The isotopic composition of chromium in K-T boundary samples from Stevns Klint, Denmark, and Caravaca, Spain, is different from that of Earth and indicates its extraterrestrial source. The chromium isotopic signature is consistent with a carbonaceous chondrite-type impactor. The observed differences in the chromium isotopic composition among various meteorite classes can serve as a diagnostic tool for deciphering the nature of impactors that have collided with Earth during its history.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Max Planck Inst Chem Cosmochem, D-55020 Mainz, Germany	University of California System; University of California San Diego; Scripps Institution of Oceanography; Max Planck Society	Shukolyukov, A (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.							ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BIRCK JL, 1988, NATURE, V331, P579, DOI 10.1038/331579a0; BIRCK JL, 1985, GEOPHYS RES LETT, V12, P745, DOI 10.1029/GL012i011p00745; BROWNLEE DE, 1977, COMETS ASTEROIDS MET, P137; DIA A, 1989, CHEM GEOL, V75, P291, DOI 10.1016/0009-2541(89)90002-8; EUGSTER O, 1985, EARTH PLANET SC LETT, V74, P27, DOI 10.1016/0012-821X(85)90163-3; Farley KA, 1998, SCIENCE, V280, P1250, DOI 10.1126/science.280.5367.1250; GALER SJG, 1989, GEOPHYS RES LETT, V16, P1302; HILDEBRAND AR, 1991, GEOLOGY, V19, P867, DOI 10.1130/0091-7613(1991)019<0867:CCAPCT>2.3.CO;2; HUTCHEON ID, 1992, LUNAR PLANET SCI, V23, P565; KYTE FT, 1980, NATURE, V288, P651, DOI 10.1038/288651a0; KYTE FT, 1985, EARTH PLANET SC LETT, V73, P183, DOI 10.1016/0012-821X(85)90067-6; KYTE FT, 1996, GEOL SOC AM SPEC PAP, V307, P389; KYTE FT, IN PRESS NATURE; LUCK JM, 1983, SCIENCE, V222, P613, DOI 10.1126/science.222.4624.613; LUGMAIR GW, IN PRESS GEOCHIM COS; NYQUIST LE, 1997, LUNAR PLANET SCI, V28, P1033; OFFICER CB, 1987, NATURE, V326, P143, DOI 10.1038/326143a0; PAPANASTASSIOU DA, 1986, ASTROPHYS J, V308, pL27, DOI 10.1086/184737; Podosek FA, 1997, METEORIT PLANET SCI, V32, P617, DOI 10.1111/j.1945-5100.1997.tb01547.x; RAMPINO MR, 1984, NATURE, V308, P709, DOI 10.1038/308709a0; ROTARU M, 1990, LPSC, V21, P1037; RUSSELL DA, 1979, ANNU REV EARTH PL SC, V7, P163, DOI 10.1146/annurev.ea.07.050179.001115; Schuraytz BC, 1996, SCIENCE, V271, P1573, DOI 10.1126/science.271.5255.1573; SCHURAYTZ BC, 1998, LUN PLAN SCI C, V29, P1935; SHIELDS WR, 1966, J RES NBS A PHYS CH, VA 70, P193, DOI 10.6028/jres.070A.016; Taylor S.R., 1985, CONTINENTAL CRUST IT, V94, P57	29	171	176	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					927	929		10.1126/science.282.5390.927	http://dx.doi.org/10.1126/science.282.5390.927			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794759				2022-12-28	WOS:000076727300044
J	Pringle, M				Pringle, M			Preventing ischaemic heart disease in one general practice: from one patient, through clinical audit, needs assessment, and commissioning into quality improvement	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; SECONDARY PREVENTION; RANDOMIZED TRIAL; DIETARY ADVICE; RISK-FACTORS; PRIMARY-CARE; LIPIDS; GUIDELINES		Med Ctr, Newark, Notts, England		Pringle, M (corresponding author), Med Ctr, Newark, Notts, England.	mike.pringle@nottingham.ac.uk						BAKER R, 1995, BRIT MED J, V310, P413, DOI 10.1136/bmj.310.6977.413; Byrne CD, 1996, BMJ-BRIT MED J, V313, P1273; Cairns J, 1996, BRIT MED J, V313, P6, DOI 10.1136/bmj.313.7048.6; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; *DEP HLTH, 1997, EL9741 NHS EX STAND; Dyker AG, 1997, BMJ-BRIT MED J, V314, P1584, DOI 10.1136/bmj.314.7094.1584; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; FIELD K, 1995, BRIT MED J, V310, P1109, DOI 10.1136/bmj.310.6987.1109; FREEMANTLE N, 1995, BRIT MED J, V310, P955, DOI 10.1136/bmj.310.6985.955; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HATWARD J, 1995, BMJ-BRIT MED J, V312, P1491; Hein HO, 1996, BRIT MED J, V312, P736, DOI 10.1136/bmj.312.7033.736; HUMPHRIS D, 1996, AUDIT TRENDS, V4, P59; JOHNSON R, 1994, BRIT MED J, V309, P98, DOI 10.1136/bmj.309.6947.98; LINDENSTROM E, 1994, BMJ-BRIT MED J, V309, P11, DOI 10.1136/bmj.309.6946.11; Mohan G, 1996, BRIT J GEN PRACT, V46, P529; MURRAY SA, 1995, BRIT MED J, V310, P1443, DOI 10.1136/bmj.310.6992.1443; NEIL HAW, 1995, BMJ-BRIT MED J, V310, P569, DOI 10.1136/bmj.310.6979.569; OLIVER M, 1995, BMJ-BRIT MED J, V310, P1280, DOI 10.1136/bmj.310.6990.1280; Pharoah PDP, 1996, BMJ-BRIT MED J, V312, P1443, DOI 10.1136/bmj.312.7044.1443; PRINGLE M, 1995, BRIT J GEN PRACT, V45, P537; PRINGLE M, 1995, SIGNIFICANT EVENT AU; PRINGLE M, 1994, AUDIT TRENDS, V2, P20; Rembold CM, 1996, J FAM PRACTICE, V42, P577; Rethans JJ, 1996, FAM PRACT, V13, P468, DOI 10.1093/fampra/13.5.468; ROBINSON LA, 1995, BRIT MED J, V311, P315, DOI 10.1136/bmj.311.7000.315; Roderick P, 1997, BRIT J GEN PRACT, V47, P7; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; SIRIWARDENA AN, 1995, BRIT J GEN PRACT, V45, P643; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; 1997, BANDOLIER, V4, P3	31	22	22	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	1998	317	7166					1120	1123						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784449				2022-12-28	WOS:000076755100030
J	McDonald, CJ; Overhage, JM; Dexter, PR; Blevins, L; Meeks-Johnson, J; Suico, JG; Tucker, MC; Schadow, G				McDonald, CJ; Overhage, JM; Dexter, PR; Blevins, L; Meeks-Johnson, J; Suico, JG; Tucker, MC; Schadow, G			Canopy computing - Using the web in clinical practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORLD-WIDE-WEB; MEDICAL RECORD SYSTEM; INFORMATION; TECHNOLOGY; DATABASES; REMINDERS; INTERNET; OUTCOMES	The rain forest canopy is a seamless web through which arboreal creatures efficiently move to reach the edible fruits without any atttention to the individual trees. Individual health care computer systems are rich with patient data, but rather than a canopy linking all the trees in the forest, the data "fruit" come from a diverse forest of individual computer "trees"-laboratory systems, word processing systems, pharmacy systems, and the like. These different sources of patient information are:difficult or impossible to reach by individual physicians, especially from their offices. The World Wide Web and other standardization technology provide physicians and their institutions the tools needed for seamless and secure access to their patients' data and to medical information, when and where they need it. We and others have adopted these tools to combine independent sources of clinical data. Physicians who assist in the purchase of clinical information systems should demand products in their practice settings that are Web enabled, use standard coding systems, and communicate with other computer systems via broadly accepted protocols.	Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA; Wishard Mem Hosp, Indianapolis, IN 46202 USA; Clarian Hlth Partners Inc, Indianapolis, IN USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	McDonald, CJ (corresponding author), Regenstrief Inst Hlth Care, 5th Floor RHC,1001 W 10th St, Indianapolis, IN 46202 USA.	clem@regen.rg.iupui.edu		Overhage, Joseph/0000-0003-0223-0195	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007719, U01HS008750] Funding Source: NIH RePORTER; AHRQ HHS [HS 08750, HS 07719] Funding Source: Medline; NLM NIH HHS [LM 08750] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		*AM COLL PATH, 1996, SNOMED SYST NOM MED, V1; *AM COLL PATH, 1996, SNOMED SYST NOM MED, V2; BARNES MD, 1997, INFORMATION TECHNOLO, P57; Barrows RC, 1996, J AM MED INFORM ASSN, V3, P139, DOI 10.1136/jamia.1996.96236282; Chute C G, 1995, Proc Annu Symp Comput Appl Med Care, P903; CIMINO JJ, 1995, J AM MED INFORM ASSN, V2, P273, DOI 10.1136/jamia.1995.96073829; Comm. Maint. Priv. Secur. Health Care Appl. Natl. Inf. Infrastruct. Comm. Phys. Sci. Math. Appl.. Natl. Res. Counc, 1997, REC PROT EL HLTH INF; DEESTRADA WD, 1997, P AMIA ANN FALL S, V97, P509; Denier P, 1997, INT J MED INFORM, V46, P41, DOI 10.1016/S1386-5056(97)00047-6; Dick RS, 1997, COMPUTER BASED PATIE; ELHANAN G, 1996, P AMIA ANN FALL S, V96, P348; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; Forrey AW, 1996, CLIN CHEM, V42, P81; Fraser HSF, 1997, BRIT MED J, V314, P1600, DOI 10.1136/bmj.314.7094.1600; GRAHAM IS, 1998, HTML 4 0 SOURCE BOOK; HALAMKA JD, 1997, P AMIA ANN FALL S, V97, P349; HLATKY MA, 1991, STAT MED, V10, P647, DOI 10.1002/sim.4780100415; *HLTH LEV 7, 1997, APPL PROT EL DAT EXC; *HLTH LEV 7, 1998, IMPL SUPP GUID VERS; KITTREDGE R, 1997, P AMIA ANN FALL S, V97, P320; *LOINC COMM, 1998, LOINC US GUID; MASYS DR, 1997, P AMIA ANN FALL S, V97, P340; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1991, STAT MED, V10, P511, DOI 10.1002/sim.4780100404; McDonald CJ, 1997, J AM MED INFORM ASSN, V4, P213, DOI 10.1136/jamia.1997.0040213; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDONALD CJ, 1992, M D COMPUT, V9, P206; MCDONALD CJ, 1997, P AMIA ANN FALL S, V97, P1027; MCDONALD CJ, 1998, P HIMSS ANN C FEBR 2; MURRAY P, 1998, JUMBO XML BROWSER RU; *NAT EL MAN ASS, 1995, ACR NEMADICOM STAND; PRYOR TA, 1988, M D COMPUT, V5, P22; Rind DM, 1997, ANN INTERN MED, V127, P138, DOI 10.7326/0003-4819-127-2-199707150-00008; ROBERTS ID, 1996, INTERNET PROTOCOLS H; ROSATI RA, 1973, ARCH INTERN MED, V131, P285, DOI 10.1001/archinte.131.2.285; SAFRAN C, 1991, M D COMPUT, V8, P291; SAFRAN C, 1991, STAT MED, V10, P559, DOI 10.1002/sim.4780100407; SCHADOW G, 1998, SECRUTE HL7 T USING; Sikorski R, 1998, SCIENCE, V281, P1164; STEAD WW, 1988, M D COMPUT, V5, P48; TARCZYHORNOCH P, 1997, P AMIA ANN FALL S, V97, P809; THIBAULT GE, 1980, NEW ENGL J MED, V302, P938, DOI 10.1056/NEJM198004243021703; WHITINGOKEEFE QE, 1985, JAMA-J AM MED ASSOC, V254, P1185, DOI 10.1001/jama.254.9.1185; WILLARD KE, 1994, P 2 INT WWW C MOS WE, P641	44	47	47	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1325	1329		10.1001/jama.280.15.1325	http://dx.doi.org/10.1001/jama.280.15.1325			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794311				2022-12-28	WOS:000076472500024
J	Christie, JD; Rosen, IM; Bellini, LM; Inglesby, TV; Lindsay, J; Alper, A; Asch, DA				Christie, JD; Rosen, IM; Bellini, LM; Inglesby, TV; Lindsay, J; Alper, A; Asch, DA			Prescription drug use and self-prescription among resident physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE	Context.-Self-prescription is common among practicing physicians, but little is known about the practice among resident physicians. Objective.-To determine prescription drug use and self-prescription among US resident physicians. Design and Setting.-Anonymous mail survey of all resident physicians in 4 US categorical internal medicine training programs in February 1997. Main Outcome Measures.-Self-reported use of health care services and prescription medications and how they were obtained. Results.-A total of 316 (83%) of 381 residents responded; 244 residents (78%) reported using at least 1 prescription medicine and 162 residents (52%) reported self-prescribing medications. Twenty-five percent of all medications and 42% of self-prescribed medications were obtained from a sample cabinet; 7% of all medications and 11% of self-prescribed medications were obtained directly from a pharmaceutical company representative. Conclusions.-Self-prescription is common among resident physicians. Although self-prescription is difficult to evaluate, the source of these medications and the lack of oversight of medication use raise questions about the practice.	Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA USA; Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Johns Hopkins University; Stanford University; Tulane University	Asch, DA (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, 3641 Locust Walk, Philadelphia, PA 19104 USA.			Asch, David/0000-0002-7970-286X				Allibone A, 1981, J R Coll Gen Pract, V31, P728; Asch DA, 1996, EPIDEMIOLOGY, V7, P550, DOI 10.1097/00001648-199609000-00020; CHAMBERS R, 1992, BRIT J GEN PRACT, V42, P153; CHAMBERS RM, 1993, FAM PRACT, V10, P416, DOI 10.1093/fampra/10.4.416; MCCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805; Selley P, 1988, Health Trends, V20, P128; WACHTEL TJ, 1995, J GEN INTERN MED, V10, P261, DOI 10.1007/BF02599883; Westfall JM, 1997, JAMA-J AM MED ASSOC, V278, P141, DOI 10.1001/jama.278.2.141	8	60	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1253	1255		10.1001/jama.280.14.1253	http://dx.doi.org/10.1001/jama.280.14.1253			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786376	Bronze			2022-12-28	WOS:000076357900032
J	Dix, P				Dix, P			Access to the dead: the role of relatives in the aftermath of disaster	LANCET			English	Article											Dix, P (corresponding author), 7 Firwood Close, Woking GU21 1UQ, Surrey, England.								0	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1061	1062		10.1016/S0140-6736(98)06491-5	http://dx.doi.org/10.1016/S0140-6736(98)06491-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759773				2022-12-28	WOS:000076121800053
J	Heginbotham, C				Heginbotham, C			UK mental health policy can alter the stigma of mental illness	LANCET			English	Article									E & N Hertfordshire Hlth Author, Welwyn Garden City AL8 6JL, Herts, England		Heginbotham, C (corresponding author), E & N Hertfordshire Hlth Author, Charter House, Welwyn Garden City AL8 6JL, Herts, England.		Corbin, Melody/B-8937-2009					Angermeyer MC, 1996, SOC SCI MED, V43, P1721, DOI 10.1016/S0277-9536(96)00065-2; BINGLEY W, IN PRESS MAXIMISING; Campbell T., 1991, MENTAL ILLNESS PREJU; GOLDBERG D, 1991, INDICATORS MENTAL HL; *MENT HLTH FDN, 1993, MENT ILLN FUND FACTS; Moore R. I., 1987, FORMATION PERSECUTIN	6	18	19	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1052	1053		10.1016/S0140-6736(98)08417-7	http://dx.doi.org/10.1016/S0140-6736(98)08417-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759767				2022-12-28	WOS:000076121800046
J	Lhatoo, SD; Shorvon, SD				Lhatoo, SD; Shorvon, SD			Relevance of the first seizure	LANCET			English	Editorial Material							1ST UNPROVOKED SEIZURE; NATIONAL GENERAL-PRACTICE; ADULT LIFE; RECURRENCE; EPILEPSY; POPULATION; PROGNOSIS; RISK		UCL Natl Hosp Neurol & Neurosurg, Epilepsy Res Grp, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Lhatoo, SD (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Epilepsy Res Grp, Queen Sq, London WC1N 3BG, England.		Lhatoo, Samden/L-7341-2019; Shorvon, Simon D/A-2019-2009	Shorvon, Simon/0000-0003-0313-2001				ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; CAMFIELD P, 1989, NEUROLOGY, V39, P851, DOI 10.1212/WNL.39.6.851; GOODRIDGE DMG, 1983, BRIT MED J, V287, P645, DOI 10.1136/bmj.287.6393.645; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; HOPKINS A, 1988, LANCET, V1, P721; MANFORD M, 1992, ARCH NEUROL-CHICAGO, V49, P801, DOI 10.1001/archneur.1992.00530320025008; Musicco M, 1997, NEUROLOGY, V49, P991, DOI 10.1212/WNL.49.4.991; VANDONSELAAR CA, 1991, BMJ-BRIT MED J, V302, P620, DOI 10.1136/bmj.302.6777.620	13	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 26	1998	352	9133					1003	1004		10.1016/S0140-6736(05)60070-0	http://dx.doi.org/10.1016/S0140-6736(05)60070-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759738				2022-12-28	WOS:000076121800004
J	Horton, B				Horton, B			Taking knowledge from bench to bank	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					409	410		10.1038/26533	http://dx.doi.org/10.1038/26533			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759734				2022-12-28	WOS:000076083800061
J	Sutton, RB; Fasshauer, D; Jahn, R; Brunger, AT				Sutton, RB; Fasshauer, D; Jahn, R; Brunger, AT			Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 angstrom resolution	NATURE			English	Article							MEMBRANE-FUSION COMPLEX; MACROMOLECULAR STRUCTURES; CLOSTRIDIAL NEUROTOXINS; COILED COILS; IN-VITRO; PROTEIN; SYNTAXIN; SNAP-25; PHASES; GLYCOPROTEIN	The evolutionarily conserved SNARE proteins and their complexes are involved in the fusion of vesicles with their target membranes; however, the overall organization and structural details of these complexes are unknown. Here we report the X-ray crystal structure at 2.4 Angstrom resolution of a core synaptic fusion complex containing syntaxin-1A, synaptobrevin-II and SNAP-25B. The structure reveals a highly twisted and parallel four-helix bundle that differs from the bundles described for the haemagglutinin and HIV/SIV gp41 membrane-fusion proteins. Conserved leucine-zipper-like layers are found at the centre of the synaptic fusion complex. Embedded within these leucine-ripper layers is an ionic layer consisting of an arginine and three glutamine residues contributed from each of the four alpha-helices. These residues are highly conserved across the entire SNARE family. The regions flanking the leucine-zipper-like layers contain a hydrophobic core similar to that of more general four-helix-bundle proteins. The surface of the synaptic fusion complex is highly grooved and possesses distinct hydrophilic, hydrophobic and charged regions. These characteristics may be important for membrane fusion and for the binding of regulatory factors affecting neurotransmission.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Howard Hughes Medical Institute; Yale University; Yale University; Max Planck Society	Brunger, AT (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.	brunger@laplace.csb	Fasshauer, Dirk/B-1563-2013	Fasshauer, Dirk/0000-0002-1040-4282; Brunger, Axel/0000-0001-5121-2036; Jahn, Reinhard/0000-0003-1542-3498				BERNARD A, 1995, CURR PROTOCOL PROTEI, P1; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bricogne G, 1997, METHOD ENZYMOL, V276, P361, DOI 10.1016/S0076-6879(97)76069-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hao JC, 1997, J NEUROSCI, V17, P1596; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JAHN R, 1994, ANN NY ACAD SCI, V733, P245, DOI 10.1111/j.1749-6632.1994.tb17274.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PANNU NS, IN PRESS ACTA CRYS D; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; Read RJ, 1997, METHOD ENZYMOL, V277, P110, DOI 10.1016/S0076-6879(97)77009-5; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; YONG K, 1990, ACTA CRYSTALLOGR A, V46, P41	50	1834	1889	0	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					347	353		10.1038/26412	http://dx.doi.org/10.1038/26412			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759724				2022-12-28	WOS:000076083800043
J	Finan, A; Keenan, P; O'Donovan, F; Mayne, P; Murphy, J				Finan, A; Keenan, P; O'Donovan, F; Mayne, P; Murphy, J			Lesson of the week - Methaemoglobinaemia associated with sodium nitrite in three siblings	BRITISH MEDICAL JOURNAL			English	Review							METHEMOGLOBINEMIA		Childrens Hosp, Dublin 1, Ireland	Trinity College Dublin	Finan, A (corresponding author), Market Harborough, Harborough LE16 8EP, Leics, England.							ASKEW GL, 1994, PEDIATRICS, V94, P381; BRADBERRY SM, 1994, J TOXICOL-CLIN TOXIC, V32, P173, DOI 10.3109/15563659409000447; *EUR EC COMM, 1988, DRINK WAT REG; KREUTZ RW, 1983, ORAL SURG ORAL MED O, V56, P480, DOI 10.1016/0030-4220(83)90092-0; MANSOURI A, 1985, AM J MED SCI, V289, P20; Nakajima W, 1997, LANCET, V350, P1002, DOI 10.1016/S0140-6736(05)64067-6; Saito T, 1996, J FORENSIC SCI, V41, P169	7	17	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1138	1139						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784456				2022-12-28	WOS:000076755100036
J	Murakami, I; Cavanagh, P				Murakami, I; Cavanagh, P			A jitter after-effect reveals motion-based stabilization of vision	NATURE			English	Article							EYE-MOVEMENTS; PERCEPTION; POSITION; FIELD; SENSITIVITY; DIRECTION	A shaky hand holding a video camera invariably turns a treasured moment into an annoying, jittery memento. More recent consumer cameras thoughtfully offer stabilization mechanisms to compensate for our unsteady grip. Our eyes face a similar challenge in that they are constantly making small movements even when we try to maintain a fixed gaze(1). What should be substantial, distracting jitter passes completely unseen. Position changes from large eye movements (saccades) seem to be corrected on the basis of extraretinal signals such as the motor commands sent to the eye muscle(2-5), and the resulting motion responses seem to be simply switched off(6,7). But this approach is impracticable for incessant, small displacements, and here we describe a novel visual illusion that reveals a compensation mechanism based on visual motion signals. Observers were adapted to a patch of dynamic random noise and then viewed a larger pattern of static random noise. The static noise in the unadapted regions then appeared to 'jitter' coherently in random directions. Several observations indicate that this visual jitter directly reflects fixational eye movements. We propose a model that accounts for this illusion as well as the stability of the visual world during small and/or slow eye movements such as fixational drift, smooth pursuit and low-amplitude mechanical vibrations of the eyes.	Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University	Murakami, I (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.							ABRAHAMS VC, 1979, CAN J PHYSIOL PHARM, V57, P359, DOI 10.1139/y79-054; ALLMAN J, 1985, PERCEPTION, V14, P105, DOI 10.1068/p140105; ANSTIS SM, 1976, VISION RES, V16, P1391, DOI 10.1016/0042-6989(76)90157-7; BADCOCK DR, 1990, NATURE, V343, P554, DOI 10.1038/343554a0; BARLOW HB, 1963, NATURE, V200, P1347, DOI 10.1038/2001347a0; BURR DC, 1982, J PHYSIOL-LONDON, V333, P1; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FIORENTINI A, 1982, EXP BRAIN RES, V48, P113; Haarmeier T, 1997, NATURE, V389, P849, DOI 10.1038/39872; HANSEN RM, 1977, VISION RES, V17, P919, DOI 10.1016/0042-6989(77)90067-0; HARDAGE L, 1995, VISION RES, V35, P757, DOI 10.1016/0042-6989(94)00167-K; MATIN L, 1982, SCIENCE, V216, P198, DOI 10.1126/science.7063881; NAKAYAMA K, 1981, VISION RES, V21, P427, DOI 10.1016/0042-6989(81)90089-4; POST RB, 1985, PERCEPTION, V14, P631, DOI 10.1068/p140631; RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0; RAMACHANDRAN VS, 1993, VISION RES, V33, P717, DOI 10.1016/0042-6989(93)90191-X; Seiffert AE, 1998, VISION RES, V38, P3569, DOI 10.1016/S0042-6989(98)00035-2; SHEEDY JE, 1981, AM J OPTOM PHYS OPT, V58, P149; SHIOIRI S, 1989, VISION RES, V29, P915, DOI 10.1016/0042-6989(89)90106-5; SKAVENSKI AA, 1972, PERCEPT PSYCHOPHYS, V11, P287, DOI 10.3758/BF03210380; STEINBACH MJ, 1987, VISION RES, V27, P1737, DOI 10.1016/0042-6989(87)90103-9; TANAKA K, 1986, J NEUROSCI, V6, P134; Tyler CW, 1998, PERCEPTION, V27, P203, DOI 10.1068/p270203; Von Grunau Michael, 1992, Spatial Vision, V6, P303, DOI 10.1163/156856892X00145; von Helmholtz H., 1866, HDB PHYSL OPTIK; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; ZAIDI Q, 1991, PERCEPTION, V20, P703, DOI 10.1068/p200703	27	81	81	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					798	801		10.1038/27435	http://dx.doi.org/10.1038/27435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	132AL	9796813				2022-12-28	WOS:000076607400056
J	Overpeck, MD; Brenner, RA; Trumble, AC; Trifiletti, LB; Berendes, HW				Overpeck, MD; Brenner, RA; Trumble, AC; Trifiletti, LB; Berendes, HW			Risk factors for infant homicide in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILD-ABUSE; NEGLECT; INJURY; MORTALITY; DEATH; ADOLESCENTS; PREVALENCE; PATTERNS; WOMEN	Background Homicide is the leading cause of infant deaths due to injury. More than 80 percent of infant homicides are considered to be fatal child abuse. This study assessed the timing of deaths and risk factors for infant homicide. Methods Using linked birth and death certificates for all births in the U.S, between 1983 and 1991, we identified 2776 homicides occurring during the first year of life. Birth-certificate variables were reviewed in both bivariate and multivariate stratified analyses. Variables potentially predictive of homicide were selected on the basis of increased relative risks among subcategories with adequate numbers for stable estimates, Results Half the homicides occurred by the fourth month of life, The most important risk factors were a second or subsequent infant born to a mother less than 17 years old (relative risk, 10.9) or 17 to 19 years old (relative risk, 9.3), as compared with a first infant born to a mother 25 years old or older; a maternal age of less than 15 years, as compared with an age of at least 25 years (relative risk, 6.8); no prenatal care as compared with early prenatal care (relative risk, 10.4); and less than 12 years of education among mothers who were at least 17 years old (relative risk, 8.0), as compared with 16 or more years of education. Conclusions Childbearing at an early age was strongly associated with infant homicide, particularly if the mother had given birth previously. Our findings may have implications for prevention. (N Engl J Med 1998;339:1211-6.) (C) 1998. Massachusetts Medical Society.	NICHHD, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Overpeck, MD (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, Bldg 6100,Rm 7B03,9000 Rockville Pike,MSC 7510, Bethesda, MD 20892 USA.		McKenzie, Lara/C-5122-2012	McKenzie, Lara/0000-0003-2889-0001				BAKER SP, 1992, INJURY FACT BOOK, P18; BERENSON AB, 1992, J ADOLESCENT HEALTH, V13, P466, DOI 10.1016/1054-139X(92)90008-Y; Campbell JC, 1998, AM J PUBLIC HEALTH, V88, P185, DOI 10.2105/AJPH.88.2.185; CHRISTOFFEL KK, 1990, AM J DIS CHILD, V144, P697, DOI 10.1001/archpedi.1990.02150300095025; CHRISTOFFEL KK, 1983, AM J FOREN MED PATH, V4, P129, DOI 10.1097/00000433-198306000-00006; CHRISTOFFEL KK, 1985, AM J DIS CHILD, V139, P876, DOI 10.1001/archpedi.1985.02140110030023; CREIGHTON SJ, 1985, CHILD ABUSE NEGLECT, V9, P441, DOI 10.1016/0145-2134(85)90052-3; *CTR CHILD AB PREV, 1998, ROL HOM VIS PREV CHI; CUMMINGS P, 1994, ARCH PEDIAT ADOL MED, V148, P1021, DOI 10.1001/archpedi.1994.02170100019005; *DEP HLTH HUM SERV, 1997, CHILD MALTR 1995 REP, P2; DURFEE M, 1989, PROT CHILD, V6, P9; EWIGMAN B, 1993, PEDIATRICS, V91, P330; FINGERHUT LA, 1997, INJURY CHARTBOOK HLT, P20; Gazmararian JA, 1997, JAMA-J AM MED ASSOC, V277, P1125; Gazmararian JA, 1996, JAMA-J AM MED ASSOC, V275, P1915, DOI 10.1001/jama.275.24.1915; GUARD A, 1997, VIOLENCE TEEN PREGNA; HOYERT DL, 1994, VITAL HLTH STAT, V20; JASON J, 1983, PEDIATRICS, V72, P191; Jason J, 1983, Child Abuse Negl, V7, P1, DOI 10.1016/0145-2134(83)90023-6; JASON J, 1983, AM J PUBLIC HEALTH, V73, P195, DOI 10.2105/AJPH.73.2.195; KINARD EM, 1980, AM J ORTHOPSYCHIAT, V50, P481, DOI 10.1111/j.1939-0025.1980.tb03307.x; Kunz J, 1996, J FAM VIOLENCE, V11, P347, DOI 10.1007/BF02333422; MCCLAIN PW, 1994, ARCH PEDIAT ADOL MED, V148, P82, DOI 10.1001/archpedi.1994.02170010084020; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; *NAT CTR HLTH STAT, 1988, LINK BIRTH INF DEATH; *NAT PED TRAUM REG, 1996, CHILDR AD DIS DUE TR, P3; OLDS DL, 1986, PEDIATRICS, V78, P65; *PAN RES CHILD AB, 1993, UND CHILD AB NEGL, P123; PARKER B, 1993, NURS RES, V42, P173; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P308; SCHLOESSER P, 1992, CHILD ABUSE NEGLECT, V16, P3, DOI 10.1016/0145-2134(92)90003-A; Scholer SJ, 1997, ARCH PEDIAT ADOL MED, V151, P1216, DOI 10.1001/archpedi.1997.02170490042007; SEDLAK AJ, 1996, 3 NATL INCIDENCE STU, P8; Siegel CD, 1996, ARCH PEDIAT ADOL MED, V150, P1077, DOI 10.1001/archpedi.1996.02170350079014; SORENSON SB, 1994, AM J PUBLIC HEALTH, V84, P623, DOI 10.2105/AJPH.84.4.623; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; VENTURA SJ, 1997, MON VITAL STAT RE S2, V46, P33; WANG CT, 1997, 808 NAT COMM PREV CH; *WHO, 1977, INT CLASS DIS MAN IN, V1	39	212	217	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1211	1216		10.1056/NEJM199810223391706	http://dx.doi.org/10.1056/NEJM199810223391706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	130QW	9780342				2022-12-28	WOS:000076532400006
J	Aurigemma, G				Aurigemma, G			Is harmonic imaging now fundamental?	LANCET			English	Editorial Material									Univ Massachusetts, Dept Med, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Aurigemma, G (corresponding author), Univ Massachusetts, Dept Med, Worcester, MA 01655 USA.							Grayburn PA, 1998, J AM COLL CARDIOL, V32, P230, DOI 10.1016/S0735-1097(98)00219-8; KRUMHOLZ HM, 1994, J AM COLL CARDIOL, V24, P125, DOI 10.1016/0735-1097(94)90552-5; POOLEWILSON P, 1997, NEW ENGL J MED, V336, P181; Thomas JD, 1998, J AM SOC ECHOCARDIOG, V11, P803, DOI 10.1016/S0894-7317(98)70055-0	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1239	1240		10.1016/S0140-6736(05)70482-7	http://dx.doi.org/10.1016/S0140-6736(05)70482-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788449				2022-12-28	WOS:000076573800003
J	Barr, H				Barr, H			Gastrointestinal tumours: let there be light	LANCET			English	Editorial Material							HIGH-GRADE DYSPLASIA; ND-YAG LASER; PHOTODYNAMIC THERAPY; ESOPHAGEAL CANCER; BARRETTS-ESOPHAGUS; MULTICENTER; JAPANESE		Gloucestershire Royal & Cranfield Univ, Inst Med Sci, Gloucester Gastroenterol Grp, Gloucester GL1 3NN, England	Cranfield University	Barr, H (corresponding author), Gloucestershire Royal & Cranfield Univ, Inst Med Sci, Gloucester Gastroenterol Grp, Gloucester GL1 3NN, England.							BARR H, 1987, PHOTOCHEM PHOTOBIOL, V46, P795, DOI 10.1111/j.1751-1097.1987.tb04850.x; Barr H, 1996, LANCET, V348, P584, DOI 10.1016/S0140-6736(96)03054-1; BARR H, 1990, BRIT J SURG, V77, P93, DOI 10.1002/bjs.1800770132; Ell C, 1998, GUT, V43, P345, DOI 10.1136/gut.43.3.345; Gossner L, 1998, GASTROENTEROLOGY, V114, P448, DOI 10.1016/S0016-5085(98)70527-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GROSJEAN P, 1998, EUR J SURG ONCOL, V24, P234; Hayata Y, 1996, LASER MED SCI, V11, P255, DOI 10.1007/BF02134916; HEIER SK, 1995, GASTROENTEROLOGY, V109, P63, DOI 10.1016/0016-5085(95)90269-4; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; LIGHTDALE CJ, 1995, GASTROINTEST ENDOSC, V42, P507, DOI 10.1016/S0016-5107(95)70002-1; Ortner MAEJ, 1998, GASTROENTEROLOGY, V114, P536, DOI 10.1016/S0016-5085(98)70537-2; Overholt BF, 1997, GASTROINTEST ENDOSC, V45, P206, DOI 10.1016/S1052-5157(18)30308-8; Schlemper RJ, 1997, LANCET, V349, P1725, DOI 10.1016/S0140-6736(96)12249-2; SIBILLE A, 1995, GASTROENTEROLOGY, V108, P337, DOI 10.1016/0016-5085(95)90058-6	15	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1998	352	9136					1242	1244		10.1016/S0140-6736(05)70484-0	http://dx.doi.org/10.1016/S0140-6736(05)70484-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788451				2022-12-28	WOS:000076573800005
J	Schwartz, RS				Schwartz, RS			Direct visualization of antigen-specific cytotoxic T cells - A new insight into immune defenses	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103	3	8	11	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1076	1078		10.1056/NEJM199810083391510	http://dx.doi.org/10.1056/NEJM199810083391510			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761811				2022-12-28	WOS:000076294800010
J	Xia, XM; Fakler, B; Rivard, A; Wayman, G; Johnson-Pais, T; Keen, JE; Ishii, T; Hirschberg, B; Bond, CT; Lutsenko, S; Maylie, J; Adelman, JP				Xia, XM; Fakler, B; Rivard, A; Wayman, G; Johnson-Pais, T; Keen, JE; Ishii, T; Hirschberg, B; Bond, CT; Lutsenko, S; Maylie, J; Adelman, JP			Mechanism of calcium gating in small-conductance calcium-activated potassium channels	NATURE			English	Article							GATED ION CHANNELS; CALMODULIN-BINDING; PROTEIN-KINASE; RECEPTORS; BRAIN; SUBUNITS; IDENTIFICATION; MUSCLE	The slow afterhyperpolarization that follows an action potential is generated by the activation of small-conductance calcium-activated potassium channels (SK channels). The slow afterhyperpolarization limits the bring frequency of repetitive action potentials (spike-frequency adaption) and is essential for normal neurotransmission(1-3). SK channels are voltage-independent and activated by submicromolar concentrations of intracellular calcium(1). They are high-affinity calcium sensors that transduce fluctuations in intracellular calcium concentrations into changes in membrane potential. Here we study the mechanism of calcium gating and find that SK channels are not gated by calcium binding directly to the channel alpha-subunits. Instead, the functional SK channels are heteromeric complexes with calmodulin, which is constitutively associated with the alpha-subunits in a calcium-independent manner. Our data support a model in which calcium gating of SK channels is mediated by binding of calcium to calmodulin and subsequent conformational alterations in the channel protein.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Biol Sci, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Univ Tuebingen, Dept Physiol, Tuebingen, Germany	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Eberhard Karls University of Tubingen	Adelman, JP (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.							ADELMAN JP, 1995, CURR OPIN NEUROBIOL, V5, P286, DOI 10.1016/0959-4388(95)80040-9; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FISCHER TH, 1987, BIOCHEMISTRY-US, V26, P8024, DOI 10.1021/bi00398a070; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; Hille B., 1992, IONIC CHANNELS EXCIT; HINRICHSEN RD, 1986, SCIENCE, V232, P503, DOI 10.1126/science.2421410; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LANCASTER B, 1991, J NEUROSCI, V11, P23; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; MACONOCHIE DJ, 1994, NEURON, V12, P61, DOI 10.1016/0896-6273(94)90152-X; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Oliver D, 1998, BIOPHYS J, V74, P2318, DOI 10.1016/S0006-3495(98)77941-X; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SAH P, 1995, J NEUROPHYSIOL, V74, P1772, DOI 10.1152/jn.1995.74.4.1772; SCHATZMANN HJ, 1982, MEMBRANE TRANSPORT C, P41; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WYLIE DC, 1988, CALMODULIN, P1	30	707	721	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1998	395	6701					503	507		10.1038/26758	http://dx.doi.org/10.1038/26758			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774106				2022-12-28	WOS:000076212200057
J	Elion, EA				Elion, EA			Signal transduction - Routing MAP kinase cascades	SCIENCE			English	Editorial Material							STE5; SCAFFOLD; PATHWAY; PROTEINS		Harvard Univ, Sch Med, Dept Biol Chem, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Elion, EA (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem, Boston, MA 02115 USA.							CHOI KY, 1994, CELL, V78, P499; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINTEN JA, 1994, GENETICS, V138, P609; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; YASHAR B, 1995, MOL CELL BIOL, V15, P6545	18	118	124	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1625	1626		10.1126/science.281.5383.1625	http://dx.doi.org/10.1126/science.281.5383.1625			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9767029				2022-12-28	WOS:000075856500034
J	Chu, S; DeRisi, J; Eisen, M; Mulholland, J; Botstein, D; Brown, PO; Herskowitz, I				Chu, S; DeRisi, J; Eisen, M; Mulholland, J; Botstein, D; Brown, PO; Herskowitz, I			The transcriptional program of sporulation in budding yeast	SCIENCE			English	Article							SISTER-CHROMATID COHESION; SPORE WALL MATURATION; MEIOSIS-SPECIFIC GENE; MAP KINASE CASCADE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; REPRESSOR UME6; EXPRESSION; ELEMENT	Diploid cells of budding yeast produce haploid cells through the developmental program of sporulation, which consists of meiosis and spore morphogenesis. DNA microarrays containing nearly every yeast gene were used to assay changes in gene expression during sporulation. At Least seven distinct temporal patterns of induction were observed. The transcription factor Ndt80 appeared to be important for induction of a Large group of genes at the end of meiotic prophase, Consensus sequences known or proposed to be responsible for temporal regulation could be identified solely from analysis of sequences of coordinately expressed genes. The temporal expression pattern provided clues to potential functions of hundreds of previously uncharacterized genes, some of which have vertebrate homologs that may function during gametogenesis.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; University of California System; University of California San Francisco; Stanford University; Stanford University	Brown, PO (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	pbrown@cmgm.stanford.edu; ira@cgl.ucsf.edu		Eisen, Michael/0000-0002-7528-738X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046406, R01GM046406] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18738] Funding Source: Medline; NIGMS NIH HHS [GM46406] Funding Source: Medline; CGH CDC HHS [GH00450] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CGH CDC HHS		BIGGINS S, UNPUB; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; Byers B, 1981, MOL BIOL YEAST SACCH, P59; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; CHAN CSM, 1993, GENETICS, V135, P677; CHOI KY, 1994, CELL, V78, P499; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; CHU SC, UNPUB; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; EISEN MB, UNPUB; ESPOSITO RE, 1972, MOL GEN GENET, V114, P241, DOI 10.1007/BF01788893; Esposito RE, 1981, MOL BIOL YEAST SACCH; Friesen H, 1997, MOL CELL BIOL, V17, P123, DOI 10.1128/MCB.17.1.123; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GLOTZER M, 1995, CURR BIOL, V5, P970, DOI 10.1016/S0960-9822(95)00190-4; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HEPWORTH SR, 1995, MOL CELL BIOL, V15, P3934; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; Jackson JC, 1996, NUCLEIC ACIDS RES, V24, P1322, DOI 10.1093/nar/24.7.1322; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Kohonen T., 1997, SELF ORGANIZING MAPS; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; Kupiec M., 1997, MOL CELLULAR BIOL YE, P889; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MATSUBARA N, 1995, MOL REPROD DEV, V41, P407, DOI 10.1002/mrd.1080410403; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MIYAKAWA I, 1984, J CELL SCI, V66, P21; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; MULHOLLAND JH, UNPUB; Neiman AM, 1998, J CELL BIOL, V140, P29, DOI 10.1083/jcb.140.1.29; Ozsarac N, 1997, MOL CELL BIOL, V17, P1152, DOI 10.1128/MCB.17.3.1152; Page AW, 1997, CURR OPIN GENET DEV, V7, P23, DOI 10.1016/S0959-437X(97)80105-0; PALMER DK, 1990, CHROMOSOMA, V100, P32, DOI 10.1007/BF00337600; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; PRINTEN JA, 1994, GENETICS, V138, P609; Roeder AD, 1996, GENETICS, V144, P445; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RubinBejerano I, 1996, MOL CELL BIOL, V16, P2518; SAMBROOK E, 1989, MOL CLONING LAB MANU; SCHILD D, 1978, CHROMOSOMA, V70, P109, DOI 10.1007/BF00292220; Sherman F., 1986, METHODS YEAST GENETI; SIMCHEN G, 1974, GENETICS, V76, P745; SPELLMAN P, COMMUNICATION; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; WADA Y, 1992, J BIOL CHEM, V267, P18665; XU LZ, 1995, MOL CELL BIOL, V15, P6572; Yanai A, 1997, ONCOGENE, V14, P2943, DOI 10.1038/sj.onc.1201144	60	1438	1502	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					699	705		10.1126/science.282.5389.699	http://dx.doi.org/10.1126/science.282.5389.699			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784122				2022-12-28	WOS:000076607500041
J	Springholz, G; Holy, V; Pinczolits, M; Bauer, G				Springholz, G; Holy, V; Pinczolits, M; Bauer, G			Self-organized growth of three-dimensional quantum-dot crystals with fcc-like stacking and a tunable lattice constant	SCIENCE			English	Article							ISLANDS; GAAS; SUPERLATTICES; LUMINESCENCE; GAAS(100); SURFACES; DEFECTS; INGAAS; GE	The self-organization of pyramidal PbSe islands that spontaneously form during strained-layer epitaxial growth of PbSe/Pb1-xEuxTe (x = 0.05 to 0.1) superlattices results in the formation of three-dimensional quantum-dot crystals. In these crystals, the dots are arranged in a trigonal lattice with a face-centered cubic (fcc)-like A-B-C-A-B-C vertical stacking sequence. The Lattice constant of the dot crystal can be tuned continuously by changing the superlattice period. As shown by theoretical calculations, the elastic anisotropy in these artificial dot crystals acts in a manner similar to that of the directed chemical bonds of crystalline solids. The narrow size distribution and excellent control of the dot arrangement may be advantageous for optoelectronic device applications.	Johannes Kepler Univ, Inst Halbleitertech, A-4040 Linz, Austria; Masaryk Univ, Fac Sci, Lab Thin Films & Nanostruct, CS-61137 Brno, Czech Republic	Johannes Kepler University Linz; Masaryk University Brno	Springholz, G (corresponding author), Johannes Kepler Univ, Inst Halbleitertech, A-4040 Linz, Austria.		Holy, Vaclav/E-1508-2017	Holy, Vaclav/0000-0002-0370-6928; Springholz, Gunther/0000-0003-3133-4815				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; ASARO RJ, 1972, METALL TRANS, V3, P1789, DOI 10.1007/BF02642562; Darhuber AA, 1997, PHYS REV B, V55, P15652, DOI 10.1103/PhysRevB.55.15652; EAGLESHAM DJ, 1990, PHYS REV LETT, V64, P1943, DOI 10.1103/PhysRevLett.64.1943; Fafard S, 1996, SCIENCE, V274, P1350, DOI 10.1126/science.274.5291.1350; FLOCKEN JW, 1970, PHYS REV B, V1, P2447, DOI 10.1103/PhysRevB.1.2447; Gerard JM, 1998, PHYS REV LETT, V81, P1110, DOI 10.1103/PhysRevLett.81.1110; GRUNDMANN M, 1995, PHYS REV LETT, V74, P4043, DOI 10.1103/PhysRevLett.74.4043; GUHA S, 1990, APPL PHYS LETT, V57, P2110, DOI 10.1063/1.103914; KIRSTAEDTER N, 1994, ELECTRON LETT, V30, P1416, DOI 10.1049/el:19940939; Landin L, 1998, SCIENCE, V280, P262, DOI 10.1126/science.280.5361.262; LEON R, 1995, SCIENCE, V267, P1966, DOI 10.1126/science.267.5206.1966; LEONARD D, 1993, APPL PHYS LETT, V63, P3203, DOI 10.1063/1.110199; MARZIN JY, 1994, PHYS REV LETT, V73, P716, DOI 10.1103/PhysRevLett.73.716; MASUMURA RA, 1970, J APPL PHYS, V41, P3930, DOI 10.1063/1.1658391; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; NOTZEL R, 1994, NATURE, V369, P131, DOI 10.1038/369131a0; Pinczolits M, 1998, APPL PHYS LETT, V73, P250, DOI 10.1063/1.121770; RATSCH C, 1993, SURF SCI, V293, P123, DOI 10.1016/0039-6028(93)90250-N; Sauvage S, 1997, APPL PHYS LETT, V71, P2785, DOI 10.1063/1.120133; Shchukin VA, 1998, PHYS REV B, V57, P12262, DOI 10.1103/PhysRevB.57.12262; Solomon GS, 1996, PHYS REV LETT, V76, P952, DOI 10.1103/PhysRevLett.76.952; SROLOVITZ DJ, 1989, ACTA METALL MATER, V37, P621, DOI 10.1016/0001-6160(89)90246-0; Tersoff J, 1996, PHYS REV LETT, V76, P1675, DOI 10.1103/PhysRevLett.76.1675; XIE QH, 1995, PHYS REV LETT, V75, P2542, DOI 10.1103/PhysRevLett.75.2542	25	443	451	1	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					734	737		10.1126/science.282.5389.734	http://dx.doi.org/10.1126/science.282.5389.734			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784129				2022-12-28	WOS:000076607500048
J	Sasazuki, T; Juji, T; Morishima, Y; Kinukawa, N; Kashiwabara, H; Inoko, H; Yoshida, T; Kimura, A; Akaza, T; Kamikawaji, N; Kodera, Y; Takaku, F				Sasazuki, T; Juji, T; Morishima, Y; Kinukawa, N; Kashiwabara, H; Inoko, H; Yoshida, T; Kimura, A; Akaza, T; Kamikawaji, N; Kodera, Y; Takaku, F		Japan Marrow Donor Program	Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; VERSUS-HOST DISEASE; HEMATOLOGIC MALIGNANCIES; HUMAN RECIPIENTS; NATURAL-KILLER; LEUKEMIA; GRAFT; JAPANESE; RECEPTORS; HLA-DRB1	Background The requirements with respect to HLA compatibility and the relative importance of matching for individual class I and class II HLA alleles in the transplantation of hematopoietic stem cells from unrelated donors have not yet been established. Methods We performed retrospective DNA typing of alleles at 11 polymorphic loci of HLA genes in 440 recipients of hematopoietic stem cells from unrelated donors who were serologically identical with their respective recipients for HLA-A, B, and DR antigens. Of these recipients, 80 percent had leukemia; the rest had lymphoma, marrow failure, or a congenital disorder. Results Multivariate analysis showed that incompatibility for HLA-A alleles and incompatibility for HLA-C alleles were independent risk factors for severe acute graft-versus-host disease (GVHD) (HLA-A, P=0.006; HLA-C, P=0.001). Mismatching of HLA-A, but not of HLA-C, alleles was an independent risk factor for death (P<0.001). Mismatching of HLA-C alleles was a significant risk factor for relapse of leukemia (P=0.035). HLA-B disparity was a significant risk factor for both GVHD and death in the univariate analysis, but not in the multivariate analysis. Disparities in class II HLA alleles of the DRB1, DQA1, DQB1, DPA1, and DPB1 loci were not identified as significant risk factors for acute GVHD or death in the multivariate analysis. Conclusions Genomic typing of class I HLA alleles adds substantially to the success of transplantation of hematopoietic stem cells from unrelated donors, even if the donors are serologically identical to their recipients with respect to HLA-A, B, and DR antigens. (N Engl J Med 1998;339:1177-85.) (C) 1998, Massachusetts Medical Society.	Kyushu Univ, Med Inst Bioregulat, Dept Genet, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Med Informat, Fukuoka 812, Japan; Japanese Red Cross Cent Blood Ctr, Tokyo, Japan; Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 464, Japan; Sakura Natl Hosp, Dept Surg, Chiba, Japan; Tokai Univ, Sch Med, Dept Genet Informat, Div Mol Life Sci, Kanagawa, Japan; Showa Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 142, Japan; Tokyo Med & Dent Univ, Med Res Inst, Div Adult Dis, Dept Tissue Physiol, Tokyo 113, Japan; Nagoya First Hosp, Japanese Red Cross, Dept Internal Med, Nagoya, Aichi, Japan; Jichi Med Sch, Tochigi, Japan	Kyushu University; Kyushu University; Japanese Red Cross Medical Center; Aichi Cancer Center; Tokai University; Showa University; Tokyo Medical & Dental University (TMDU); Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; Jichi Medical University	Sasazuki, T (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Genet, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Ando H, 1996, TISSUE ANTIGENS, V48, P55, DOI 10.1111/j.1399-0039.1996.tb02606.x; BEATTY PG, 1993, BLOOD, V81, P249; Bodmer JG, 1997, TISSUE ANTIGENS, V49, P297, DOI 10.1111/j.1399-0039.1997.tb02759.x; BORTIN MM, 1992, JAMA-J AM MED ASSOC, V268, P607; CHAMPLIN RE, 1984, CANCER TREAT REP, V68, P145; COX DR, 1972, J R STAT SOC B, V34, P187; Date Y, 1996, TISSUE ANTIGENS, V47, P93, DOI 10.1111/j.1399-0039.1996.tb02520.x; DAVIES SM, 1995, BLOOD, V86, P1636, DOI 10.1182/blood.V86.4.1636.bloodjournal8641636; Dixon W. J., 1992, BMDP STAT SOFTWARE M; Dupont B, 1997, IMMUNOL REV, V157, P5, DOI 10.1111/j.1600-065X.1997.tb00970.x; Fleischhauer K, 1997, TISSUE ANTIGENS, V50, P208; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Hansen JA, 1997, IMMUNOL REV, V157, P141, DOI 10.1111/j.1600-065X.1997.tb00979.x; HAUCH M, 1990, BLOOD, V75, P2250; HIRABAYASHI N, 1995, TRANSPLANT P, V27, P1380; HOROWITZ MM, 1990, BLOOD, V75, P555; HOWS JM, 1986, BLOOD, V68, P1322; INOKO H, 1993, HDB HLA TYPING TECHN, P9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KIMURA A, 1992, TISSUE ANTIGENS, V40, P5, DOI 10.1111/j.1399-0039.1992.tb01951.x; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; KIMURA A, 1992, HLA 1991, V1, P511; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MATSUBARA K, 1992, HUM IMMUNOL, V35, P132, DOI 10.1016/0198-8859(92)90021-E; MCCULLOUGH J, 1986, TRANSFUSION, V26, P315, DOI 10.1046/j.1537-2995.1986.26486262737.x; MCELLIGOTT MC, 1986, TRANSFUSION, V26, P309, DOI 10.1046/j.1537-2995.1986.26486262736.x; Moretta A, 1997, CURR OPIN IMMUNOL, V9, P694, DOI 10.1016/S0952-7915(97)80051-9; Moretta A, 1997, IMMUNOL REV, V155, P105, DOI 10.1111/j.1600-065X.1997.tb00943.x; MORISHIMA Y, 1989, BLOOD, V74, P2252, DOI 10.1182/blood.V74.6.2252.2252; Naruse TK, 1997, TISSUE ANTIGENS, V49, P152, DOI 10.1111/j.1399-0039.1997.tb02729.x; OREILLY RJ, 1983, BLOOD, V62, P941; PETERSDORF EW, 1993, BLOOD, V81, P1923; Petersdorf EW, 1996, P NATL ACAD SCI USA, V93, P15358, DOI 10.1073/pnas.93.26.15358; PETERSDORF EW, 1995, BLOOD, V86, P1606, DOI 10.1182/blood.V86.4.1606.bloodjournal8641606; Reyburn H, 1997, IMMUNOL REV, V155, P119, DOI 10.1111/j.1600-065X.1997.tb00944.x; SANTAMARIA, 1994, BLOOD, V83, P3834; SANTAMARIA P, 1994, BLOOD, V83, P280; Speiser DE, 1996, BLOOD, V87, P4455, DOI 10.1182/blood.V87.10.4455.bloodjournal87104455; SPENCER A, 1995, TRANSPLANTATION, V59, P1302, DOI 10.1097/00007890-199505000-00014; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; THOMAS ED, 1983, J CLIN ONCOL, V1, P517, DOI 10.1200/JCO.1983.1.9.517; Tokunaga K, 1997, IMMUNOGENETICS, V46, P199, DOI 10.1007/s002510050262; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; Yasunaga S, 1996, TISSUE ANTIGENS, V47, P37, DOI 10.1111/j.1399-0039.1996.tb02512.x	45	419	435	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1177	1185		10.1056/NEJM199810223391701	http://dx.doi.org/10.1056/NEJM199810223391701			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780337				2022-12-28	WOS:000076532400001
J	Borowitz, SM; Wyatt, JC				Borowitz, SM; Wyatt, JC			The origin, content, and workload of e-mail consultations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORLD-WIDE-WEB; HEALTH INFORMATION; INTERNET; PHYSICIAN; CHILDREN; QUALITY; ADVICE; CARE	Context.-Despite the common use of e-mail, little beyond anecdote or impressions has been published on patient-clinician e-mail consultation. Objective.-To report our experiences with free-of-charge e-mail consultations. Design.-Retrospective review of all e-mail consultation requests received between November 1, 1995, and June 31, 1998. Setting and Participants.-Consecutive e-mail consultation requests sent to the Division of Pediatric Gastroenterology at the Children's Medical Center of the University of Virginia in Charlottesville. Main Outcome Measures.-Number of consultation requests per month, time required to respond, who initiated the request and their geographic origin, and the kind of information requested in the consultation. Results.-During the 33-month period studied, we received 1239 requests, an average (SD) of 37.6 (1 5.9) each month. A total of 1001 consultation requests (81%) were initiated by parents, relatives, or guardians, 126 (10%) by physicians, and 112 (9%) by other health care professionals. Consultation requests were received from 39 states and 37 other countries. In 855 requests (69%), there was a specific question about the cause of a particular child's symptoms, diagnostic tests, and/or therapeutic interventions. In 112 (9%), the requester sought a second opinion about diagnosis or treatment for a particular child, and 272 consultations (22%) requested general information concerning a disorder, treatment, or medication without reference to a particular child. A total of 1078 requests (87%) were answered within 48 hours of the initial request. On average, reading and responding to each e-mail took slightly less than 4 minutes. Conclusion.-E-mail provides a means for parents, guardians, and health care professionals to obtain patient and disease-specific information from selected medical consultants in a timely manner.	Univ Virginia, Hlth Sci Ctr, Div Pediat Gastroenterol & Nutr, Charlottesville, VA 22908 USA; UCL, Sch Publ Policy, London, England	University of Virginia; University of London; University College London	Borowitz, SM (corresponding author), Univ Virginia, Hlth Sci Ctr, Div Pediat Gastroenterol & Nutr, Box 386 HSC, Charlottesville, VA 22908 USA.	Witz@Virginia.edu	Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				BERTAKIS KD, 1977, J FAM PRACTICE, V5, P217; Coeira E., 1996, BRIT MED J, V312, P3; Culver JD, 1997, J GEN INTERN MED, V12, P466, DOI 10.1046/j.1525-1497.1997.00084.x; FRIDSMA DB, 1994, J AM MED INFORM ASSN, P15; Harris ED, 1997, WESTERN J MED, V166, P123; Haynes RB, 1996, LANCET, V348, P383; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; JOHNSON BE, 1990, J GEN INTERN MED, V5, P234, DOI 10.1007/BF02600541; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; LEVINE MD, 1975, PEDIATRICS, V56, P412; Neill R A, 1994, Arch Fam Med, V3, P268, DOI 10.1001/archfami.3.3.268; Pealer LN, 1997, J SCHOOL HEALTH, V67, P232, DOI 10.1111/j.1746-1561.1997.tb06311.x; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Sonnenberg FA, 1997, ARCH INTERN MED, V157, P151, DOI 10.1001/archinte.157.2.151; Spooner SA, 1996, PEDIATRICS, V98, P1185; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; Wyatt JC, 1997, BRIT MED J, V314, P1879, DOI 10.1136/bmj.314.7098.1879	18	131	131	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1321	1324		10.1001/jama.280.15.1321	http://dx.doi.org/10.1001/jama.280.15.1321			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794310	Bronze			2022-12-28	WOS:000076472500023
J	Brueckel, J; Boehm, BO				Brueckel, J; Boehm, BO			Crisis after angiography	LANCET			English	Article							PHEOCHROMOCYTOMA		Univ Klin Ulm, Med Klin 1, D-89081 Ulm, Germany	Ulm University	Brueckel, J (corresponding author), Univ Klin Ulm, Med Klin 1, Robert Koch Str 8, D-89081 Ulm, Germany.		Boehm, Bernhard Otto/F-8750-2015					BRAVO EL, 1994, ENDOCR REV, V15, P356, DOI 10.1210/er.15.3.356; KOONCE DH, 1952, AM HEART J, V44, P901, DOI 10.1016/0002-8703(52)90138-5; ROSSI P, 1968, J AMER MED ASSOC, V205, P547, DOI 10.1001/jama.205.8.547; ZELCH JV, 1974, RADIOLOGY, V111, P279, DOI 10.1148/111.2.279	4	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1278	1278		10.1016/S0140-6736(98)05186-1	http://dx.doi.org/10.1016/S0140-6736(98)05186-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788458				2022-12-28	WOS:000076573800012
J	Gurwitz, JH; Gore, JM; Goldberg, RJ; Barron, HV; Breen, T; Rundle, AC; Sloan, MA; French, W; Rogers, WJ				Gurwitz, JH; Gore, JM; Goldberg, RJ; Barron, HV; Breen, T; Rundle, AC; Sloan, MA; French, W; Rogers, WJ		Participants Natl Registry Myocardial Infarc	Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; tissue plasminogen activator; hemorrhage; cerebral; hypertension; angioplasty; transluminal; percutaneous coronary	THROMBOLYTIC THERAPY; STROKE; TRIAL	Background: The efficacy of thrombolytic therapy in reducing mortality from acute myocardial infarction has been unequivocally shown. However, thrombolysis is related to bleeding complications, including intracranial hemorrhage. Objective: To determine the frequency of and risk factors for intracranial hemorrhage after recombinant tissue-type plasminogen activator (tPA) given for acute myocardial infarction in patients receiving usual care. Design: Large national registry of patients who have had acute myocardial infarction. Setting: 1484 U.S. hospitals. Patients: 71 073 patients who had had acute myocardial infarction from 1 June 1994 to 30 September 1996, received tPA as the initial reperfusion strategy, and did not receive a second dose of any thrombolytic agent. Measurement: Intracranial hemorrhage confirmed by computed tomography or magnetic resonance imaging. Results: 673 patients (0.95%) were reported to have had intracranial hemorrhage during hospitalization for acute myocardial infarction; 625 patients (0.88%) had the event confirmed by computed tomography or magnetic resonance imaging. Of the 625 patients with confirmed intracranial hemorrhage, 331 (53%) died during hospitalization. An additional 158 patients (25.3%) who survived to hospital discharge had residual neurologic deficit. In multivariable models for the main effects of candidate risk factors, older age, female sex, black ethnicity, systolic blood pressure of 140 mm Hg or more, diastolic blood pressure of 100 mm Hg or more, history of stroke, tPA dose more than 1.5 mg/kg, and lower body weight were significantly associated with intracranial hemorrhage. Conclusions: Intracranial hemorrhage is a rare but serious complication of tPA in patients with acute myocardial infarction. Appropriate drug dosing may reduce the risk for this complication. Other therapies, such as primary coronary angioplasty, may be preferable in patients with acute myocardial infarction who have a history of stroke.	Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Worcester, MA 01608 USA; Fallon Healthcare Syst, Worcester, MA 01608 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Genentech Inc, Med Affairs, San Francisco, CA 94080 USA; Harbin Clin, Dept Neurosci, Rome, GA 30165 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA; Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Alabama System; University of Alabama Birmingham	Gurwitz, JH (corresponding author), Univ Massachusetts, Sch Med, Meyers Primary Care Inst, 100 Cent St, Worcester, MA 01608 USA.							[Anonymous], 1997, PHYS DESK REF, P1723; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Becker, 1995, J Thromb Thrombolysis, V2, P231; Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; Betriu A, 1997, NEW ENGL J MED, V336, P1621; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Gurwitz JH, 1997, JAMA-J AM MED ASSOC, V277, P1723, DOI 10.1001/jama.277.21.1723; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOSMER DW, 1989, APPL LOGISTIC REGRES; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KLEIMAN NS, 1993, CIRCULATION, V88, P17; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	17	162	167	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					597	+		10.7326/0003-4819-129-8-199810150-00002	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786806				2022-12-28	WOS:000076431800001
J	Kato, Y; Tapping, RI; Huang, S; Watson, MH; Ulevitch, RJ; Lee, JD				Kato, Y; Tapping, RI; Huang, S; Watson, MH; Ulevitch, RJ; Lee, JD			Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor	NATURE			English	Article							ACTIVATED PROTEIN-KINASES; SIGNAL-TRANSDUCTION; EXPRESSION; PATHWAY; GENE; TRANSFORMATION; REARRANGEMENT; SYSTEM; ORIGIN; JUN	Epidermal growth factor (EGF) induces cell proliferation in a variety of cell types by binding to a prototype transmembrane tyrosine kinase receptor(1,2). Ligation of this receptor by EGF activates Erk1 and Erk2, members of the mitogen-activated protein (MAP) kinase family, through a Res-dependent signal transduction pathway(3-5). Despite our detailed understanding of these events, the exact mechanism by which EGF causes cells to proliferate is unclear. Big MAP kinase (Bmk1), also known as Erk5, is a member of the MAP kinase family that is activated in cells in response to oxidative stress, hyperosmolarity and treatment with serum(6,7). Here we show that EGF is a potent activator of Bmk1. In contrast to Erk1/2, EGF-mediated activation of Bmk1 occurs independently of Ras and requires the MAP-kinase kinase Mek5. Expression of a dominant-negative form of Bmk1 blocks EGF-induced cell proliferation and prevents cells from entering the S phase of the cell cycle. These results demonstrate that Bmk1 is part of a distinct MAP-kinase signalling pathway that is required for EGF-induced cell proliferation and progression through the cell cycle.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jdlee@scripps.edu	Ulevitch, Richard J/Q-3393-2017					Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Barr MM, 1996, MOL CELL BIOL, V16, P5597; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JOMARY C, 1994, FEBS LETT, V347, P117, DOI 10.1016/0014-5793(94)00512-5; KASTAN MB, 1991, CANCER RES, V51, P6304; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; SOULE HD, 1990, CANCER RES, V50, P6075; STEIN GS, 1994, LAB HDB, P282; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	29	348	364	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					713	716		10.1038/27234	http://dx.doi.org/10.1038/27234			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790194				2022-12-28	WOS:000076472600056
J	Vezza, PR; Montgomery, EA				Vezza, PR; Montgomery, EA			Curschmann's spirals	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Georgetown Univ, Sch Med, Washington, DC 20007 USA	Georgetown University	Vezza, PR (corresponding author), Georgetown Univ, Sch Med, Washington, DC 20007 USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1043	1043		10.1056/NEJM199810083391505	http://dx.doi.org/10.1056/NEJM199810083391505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761806				2022-12-28	WOS:000076294800005
J	Shaw, F				Shaw, F			Mistaken identity	LANCET			English	Article											Shaw, F (corresponding author), 140 Mount, York YO2 2B4, N Yorkshire, England.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1050	1051		10.1016/S0140-6736(98)07608-9	http://dx.doi.org/10.1016/S0140-6736(98)07608-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759766				2022-12-28	WOS:000076121800045
J	Wahl, PW; Savage, PJ; Psaty, BM; Orchard, TJ; Robbins, JA; Tracy, RP				Wahl, PW; Savage, PJ; Psaty, BM; Orchard, TJ; Robbins, JA; Tracy, RP			Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification	LANCET			English	Article							GLUCOSE-TOLERANCE; POPULATION; INSULIN; HEALTH; NEED	Background We aimed to compare the prevalence of abnormal glucose tolerance identified by the 1985 WHO and the 1997 American Diabetes Association (ADA) diagnostic categories based on information collected in the Cardiovascular Health Study, an epidemiological study of elderly people. Methods We measured glucose concentrations during fasting and 2 h after a 75 g oral glucose-tolerance test in participants aged 65-100 years in the Cardiovascular Health Study. From a 1989 cohort, we analysed the glucose measurements of 4515 individuals without a previous diagnosis of diabetes and of 262 additional measurements from an African-American cohort recruited in 1992-93. Findings In the 1989 cohort, the prevalence of untreated diabetes with ADA diagnostic fasting criteria was 7.7% versus a prevalence of 14.8% by the WHO criteria. In the African-American cohort, the prevalence of untreated diabetes was 2.7% with ADA criteria and 11.8% with WHO criteria. 3509 (77.7%) of the 4515 participants in the 1989 cohort had normal glucose concentrations according to ADA fasting criteria, compared with 2401 (53.2%) according to WHO criteria. In the African-American cohort, the corresponding numbers were 239 (91.2%) versus 153 (58.4%). All differences in prevalence of abnormal glucose tolerance between ADA and WHO classifications were significant (p<0.0001). Interpretation Among elderly individuals, there was a significant difference in the prevalence of diabetes identified by the WHO diagnostic criteria based on oral glucose tolerance test and the ADA fasting criteria. Consequently, many individuals currently classified as non-diabetic according to ADA criteria would previously have had a diagnosis of diabetes according to WHO criteria. Longitudinal studies are needed to assess the value of the criteria in the identification of individuals at increased risk of diabetes-associated chronic complications.	Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Med & Epidemiol, Seattle, WA 98195 USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Univ Calif, Sch Med, Dept Med, Sacramento, CA USA; Univ Vermont, Sch Med, Dept Pathol, Burlington, VT 05405 USA; Univ Vermont, Sch Med, Dept Biochem, Burlington, VT 05405 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Vermont; University of Vermont	Wahl, PW (corresponding author), Cardiovasc Hlth Study Coordinating Ctr, Century Sq,Suite 2025, Seattle, WA 98101 USA.	pwahl@u.washington.edu		orchard, trevor/0000-0001-9552-3215	NHLBI NIH HHS [N01-HC-87079] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES R, 1971, MED CLIN N AM, V55, P835, DOI 10.1016/S0025-7125(16)32479-8; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CUSHMAN M, 1995, CLIN CHEM, V41, P264; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gavin JR, 1997, DIABETES CARE, V20, P1183; HARRIS M, 1979, DIABETES, V28, P1039; Harris MI, 1996, JAMA-J AM MED ASSOC, V276, P1261, DOI 10.1001/jama.276.15.1261; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; Harris MI, 1997, DIABETES CARE, V20, P1859, DOI 10.2337/diacare.20.12.1859; McCance DR, 1997, DIABETOLOGIA, V40, P247, DOI 10.1007/s001250050671; Mooy JM, 1996, DIABETOLOGIA, V39, P298, DOI 10.1007/BF00418345; ROSNER B, 1997, FUNDAMENTALS BIOSTAT, P514; Savage PJ, 1996, ANN INTERN MED, V124, P123, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00008; STOLK RP, 1995, DIABETES CARE, V18, P1045, DOI 10.2337/diacare.18.7.1045; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; *WHO, 1980, TECH REP SERV WHO, V646	17	149	157	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 26	1998	352	9133					1012	1015		10.1016/S0140-6736(98)04055-0	http://dx.doi.org/10.1016/S0140-6736(98)04055-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759743				2022-12-28	WOS:000076121800009
J	Bliss, TVP				Bliss, TVP			Neuroscience - The saturation debate	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; SYNAPTIC ENHANCEMENT; WATER MAZE; ACQUISITION; TASK		Natl Inst Med Res, Div Neurophysiol, London NW7 1AA, England	MRC National Institute for Medical Research	Bliss, TVP (corresponding author), Natl Inst Med Res, Div Neurophysiol, Mill Hill, London NW7 1AA, England.							BARNES CA, 1994, J NEUROSCI, V14, P5793; BLISS TVP, 1993, HIPPOCAMPUS, V3, P123, DOI 10.1002/hipo.450030203; CAIN DP, 1993, HIPPOCAMPUS, V3, P153, DOI 10.1002/hipo.450030208; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; JEFFERY KJ, 1993, HIPPOCAMPUS, V3, P133, DOI 10.1002/hipo.450030205; KOROL DL, 1993, HIPPOCAMPUS, V3, P127, DOI 10.1002/hipo.450030204; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P563; Moser EI, 1998, SCIENCE, V281, P2038, DOI 10.1126/science.281.5385.2038; Petersen CCH, 1998, P NATL ACAD SCI USA, V95, P4732, DOI 10.1073/pnas.95.8.4732; ROBINSON GB, 1992, HIPPOCAMPUS, V2, P389, DOI 10.1002/hipo.450020406; SUTHERLAND RJ, 1993, HIPPOCAMPUS, V3, P141, DOI 10.1002/hipo.450030206	11	9	10	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					1975	1976		10.1126/science.281.5385.1975	http://dx.doi.org/10.1126/science.281.5385.1975			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9767047				2022-12-28	WOS:000076161800039
J	Xu, YS; McCammon, C; Poe, BT				Xu, YS; McCammon, C; Poe, BT			The effect of alumina on the electrical conductivity of silicate perovskite	SCIENCE			English	Article							EARTHS LOWER MANTLE; FERRIC IRON; PHASE	Measurements of the electrical conductivity of silicate perovskite at 25 gigapascals and 1400 degrees to 1600 degrees C show that the conductivity of (Mg,Fe)SiO3 perovskite containing 2.89 weight percent Al2O3 is about 3.5 times greater than that of aluminum-free (Mg0.915Fe0.085)SiO3 perovskite. The conduction mechanism in perovskite between 1400 degrees and 1600 degrees C is most Likely by polarons, because Mossbauer studies show that the aluminum-bearing perovskite has about 3.5 times the amount of Fe3+ as the aluminum-free sample. A conductivity-depth profile from 660 to 2900 kilometers based on aluminum-bearing perovskite is consistent with geophysical models.	Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany	University of Bayreuth	Xu, YS (corresponding author), Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany.		McCammon, Catherine/B-4983-2010	McCammon, Catherine/0000-0001-5680-9106; Poe, Brent/0000-0002-0816-0258				BAHR K, 1993, GEOPHYS RES LETT, V20, P2937, DOI 10.1029/93GL02134; BANKS RJ, 1969, GEOPHYS J ROY ASTR S, V17, P457, DOI 10.1111/j.1365-246X.1969.tb00252.x; Boehler R, 1996, ANNU REV EARTH PL SC, V24, P15, DOI 10.1146/annurev.earth.24.1.15; Duba A, 1982, HIGH PRESSURE RES GE, P375; IRIFUNE T, 1994, NATURE, V370, P131, DOI 10.1038/370131a0; IRIFUNE T, 1987, GEOPHYS MONOGR SER, V39, P231; Jackson I, 1998, GEOPHYS J INT, V134, P291, DOI 10.1046/j.1365-246x.1998.00560.x; Katsura T, 1998, NATURE, V395, P493, DOI 10.1038/26736; LI XY, 1990, J GEOPHYS RES-SOLID, V95, P5067, DOI 10.1029/JB095iB04p05067; McCammon C, 1997, SCIENCE, V278, P434, DOI 10.1126/science.278.5337.434; McCammon C, 1997, NATURE, V387, P694, DOI 10.1038/42685; McCammon CA, 1998, PHYS CHEM MINER, V25, P292, DOI 10.1007/s002690050117; MCLEOD MG, 1994, J GEOPHYS RES-SOL EA, V99, P13577, DOI 10.1029/94JB00728; Petersons HF, 1996, GEOPHYS RES LETT, V23, P1461, DOI 10.1029/96GL01412; PEYRONNEAU J, 1989, NATURE, V342, P537, DOI 10.1038/342537a0; Poirier JP, 1996, PHILOS T R SOC A, V354, P1361, DOI 10.1098/rsta.1996.0052; Ringwood A.E, 1975, COMPOSITION PETROLOG; SHANKLAND TJ, 1993, NATURE, V366, P453, DOI 10.1038/366453a0; Wood BJ, 1996, SCIENCE, V273, P1522, DOI 10.1126/science.273.5281.1522; XU Y, 1998, REV HIGH PRESSURE SC, V7, P1526; Xu YS, 1998, SCIENCE, V280, P1415, DOI 10.1126/science.280.5368.1415	21	109	122	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					922	924		10.1126/science.282.5390.922	http://dx.doi.org/10.1126/science.282.5390.922			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794757				2022-12-28	WOS:000076727300042
J	Alward, WLM				Alward, WLM			Medical management of glaucoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OPEN-ANGLE GLAUCOMA; CARBONIC-ANHYDRASE INHIBITORS; PARA-AMINOCLONIDINE HYDROCHLORIDE; LIPOPROTEIN CHOLESTEROL LEVEL; TERM CLINICAL-TRIAL; TIMOLOL EYE DROPS; INTRAOCULAR-PRESSURE; TOPICAL TIMOLOL; OPHTHALMIC TIMOLOL; DIPIVALYL EPINEPHRINE		Univ Iowa, Coll Med, Dept Ophthalmol, Glaucoma Serv, Iowa City, IA 52242 USA	University of Iowa	Alward, WLM (corresponding author), Univ Iowa, Coll Med, Dept Ophthalmol, Glaucoma Serv, 200 Hawkins Dr, Iowa City, IA 52242 USA.		Alward, Wallace/AAY-4149-2020	Alward, Wallace/0000-0001-6368-9018				ABRAMS DA, 1987, ARCH OPHTHALMOL-CHIC, V105, P1205; Alm A, 1995, OPHTHALMOLOGY, V102, P1743, DOI 10.1016/S0161-6420(95)30798-1; ARMALY MF, 1965, ARCH OPHTHALMOL-CHIC, V73, P11, DOI 10.1001/archopht.1965.00970030013005; ARMALY MF, 1973, INVEST OPHTH VISUAL, V12, P491; ATKINS JM, 1985, AM J OPHTHALMOL, V99, P173, DOI 10.1016/0002-9394(85)90227-2; Avorn J, 1993, J Glaucoma, V2, P158; BECKER B, 1954, AM J OPHTHALMOL, V37, P13, DOI 10.1016/0002-9394(54)92027-9; BECKER B, 1966, AM J OPHTHALMOL, V62, P272, DOI 10.1016/0002-9394(66)91483-8; BILL A, 1971, EXP EYE RES, V12, P275, DOI 10.1016/0014-4835(71)90149-7; BITO LZ, 1987, ARCH OPHTHALMOL-CHIC, V105, P1036, DOI 10.1001/archopht.1987.01060080038023; Burke J, 1996, SURV OPHTHALMOL, V41, pS9, DOI 10.1016/S0039-6257(96)82027-3; BUTLER P, 1995, ARCH OPHTHALMOL-CHIC, V113, P293, DOI 10.1001/archopht.1995.01100030047020; Camras CB, 1996, OPHTHALMOLOGY, V103, P138, DOI 10.1016/S0161-6420(96)30749-5; COLEMAN AL, 1990, ARCH OPHTHALMOL-CHIC, V108, P1260, DOI 10.1001/archopht.1990.01070110076028; COLEMAN AL, 1990, ARCH OPHTHALMOL-CHIC, V108, P1264, DOI 10.1001/archopht.1990.01070110080029; CRAWFORD K, 1987, ARCH OPHTHALMOL-CHIC, V105, P1112, DOI 10.1001/archopht.1987.01060080114039; CURTI PC, 1981, KLIN MONATSBL AUGENH, V179, P113, DOI 10.1055/s-2008-1057274; DAILEY RA, 1982, AM J OPHTHALMOL, V93, P232, DOI 10.1016/0002-9394(82)90419-6; DEROETTH A, 1966, AM J OPHTHALMOL, V62, P619, DOI 10.1016/0002-9394(66)92182-9; DIGGORY P, 1993, EYE, V7, P661, DOI 10.1038/eye.1993.151; DINAI Y, 1985, ANN INTERN MED, V103, P890, DOI 10.7326/0003-4819-103-6-890; DOYLE WJ, 1984, ARCH OPHTHALMOL-CHIC, V102, P1517; EAKINS KE, 1970, EXP EYE RES, V10, P87, DOI 10.1016/S0014-4835(70)80014-8; EDEKI TI, 1995, JAMA-J AM MED ASSOC, V274, P1611, DOI 10.1001/jama.274.20.1611; ELLIS PP, 1974, AM J OPHTHALMOL, V77, P71, DOI 10.1016/0002-9394(74)90608-4; EPSTEIN DL, 1977, ARCH OPHTHALMOL-CHIC, V95, P1378, DOI 10.1001/archopht.1977.04450080088009; EPSTEIN DL, 1989, OPHTHALMOLOGY, V96, P1460; EPSTEIN RJ, 1987, ANN OPHTHALMOL, V19, P48; FRAUNFELDER FT, 1985, AM J OPHTHALMOL, V100, P79, DOI 10.1016/S0002-9394(14)74987-6; FRAUNFELDER FT, 1980, OPHTHALMOLOGY, V87, P87; FREEDMAN SF, 1993, AM J OPHTHALMOL, V116, P600, DOI 10.1016/S0002-9394(14)73203-9; FRIENDENWALD JS, 1995, AM J OPHTHALMOL, V40, P139; FRISTROM B, 1993, ARCH OPHTHALMOL-CHIC, V111, P662, DOI 10.1001/archopht.1993.01090050096037; GAASTERLAND DE, 1980, ANN OPHTHALMOL, V12, P448; GOLDBERG I, 1979, AM J OPHTHALMOL, V88, P843, DOI 10.1016/0002-9394(79)90561-0; GRECO J J, 1973, Annals of Ophthalmology, V5, P57; GREEN K, 1982, ARCH OPHTHALMOL-CHIC, V100, P265; GUNNING FP, 1993, GRAEF ARCH CLIN EXP, V231, P384, DOI 10.1007/BF00919645; HARRIS LS, 1986, AM J OPHTHALMOL, V102, P274, DOI 10.1016/0002-9394(86)90157-1; HARRIS LS, 1970, ARCH OPHTHALMOL-CHIC, V84, P605; HARRISON R, 1977, ARCH OPHTHALMOL-CHIC, V95, P1368, DOI 10.1001/archopht.1977.04450080078007; HELLER I, 1985, ARCH INTERN MED, V145, P1815, DOI 10.1001/archinte.145.10.1815; HEPLER RS, 1971, J AMER MED ASSOC, V217, P1392, DOI 10.1001/jama.1971.03190100074024; HIGENBOTTAM T, 1978, POSTGRAD MED J, V54, P127, DOI 10.1136/pgmj.54.628.127; Hiscox P E, 1966, Can J Ophthalmol, V1, P274; HOWLETT SA, 1975, SOUTHERN MED J, V68, P504, DOI 10.1097/00007611-197504000-00026; JAMPEL HD, 1988, ARCH OPHTHALMOL-CHIC, V106, P1069, DOI 10.1001/archopht.1988.01060140225029; JAY WM, 1983, ARCH OPHTHALMOL-CHIC, V101, P591; JOCSON VL, 1971, ARCH OPHTHALMOL-CHIC, V86, P65, DOI 10.1001/archopht.1971.01000010067013; Johnstone MA, 1997, AM J OPHTHALMOL, V124, P544, DOI 10.1016/S0002-9394(14)70870-0; JONES FL, 1979, NEW ENGL J MED, V301, P270; KABACK MB, 1976, AM J OPHTHALMOL, V81, P768, DOI 10.1016/0002-9394(76)90360-3; KAISER HJ, 1992, J GLAUCOMA, V1, P153; Kass M A, 1983, Surv Ophthalmol, V28 Suppl, P274, DOI 10.1016/0039-6257(83)90149-2; KASS MA, 1981, OPHTHALMOLOGY, V88, P261; KASS MA, 1989, ARCH OPHTHALMOL-CHIC, V107, P1590, DOI 10.1001/archopht.1989.01070020668025; KAUFMAN PL, 1976, INVEST OPHTH VISUAL, V15, P793; KEATES EU, 1979, AM J OPHTHALMOL, V88, P565, DOI 10.1016/0002-9394(79)90516-6; KERR CR, 1982, BRIT J OPHTHALMOL, V66, P109, DOI 10.1136/bjo.66.2.109; KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224; Knupp J A, 1983, Surv Ophthalmol, V28 Suppl, P280, DOI 10.1016/0039-6257(83)90150-9; Kronfeld P C, 1970, Surv Ophthalmol, V14, P479; KRONFELD PC, 1967, ARCH OPHTHALMOL-CHIC, V78, P140, DOI 10.1001/archopht.1967.00980030142006; Laibovitz R, 1995, J Glaucoma, V4, P306; LANSCHE RK, 1966, AM J OPHTHALMOL, V61, P95, DOI 10.1016/0002-9394(66)90752-5; LEIER CV, 1986, ANN INTERN MED, V104, P197, DOI 10.7326/0003-4819-104-2-197; LESKE MC, 1983, AM J EPIDEMIOL, V118, P166, DOI 10.1093/oxfordjournals.aje.a113626; LIPPA EA, 1991, OPHTHALMOLOGY, V98, P308; LUTJENDRECOLL E, 1988, EXP EYE RES, V47, P761, DOI 10.1016/0014-4835(88)90043-7; LYNCH MG, 1988, ARCH OPHTHALMOL-CHIC, V106, P908, DOI 10.1001/archopht.1988.01060140054023; MACRI FJ, 1978, ARCH OPHTHALMOL-CHIC, V96, P2111, DOI 10.1001/archopht.1978.03910060491022; MANDELL AI, 1978, OPHTHALMOLOGY, V85, P268; MCMAHON CD, 1979, AM J OPHTHALMOL, V88, P736, DOI 10.1016/0002-9394(79)90674-3; MERRITT JC, 1980, ANN OPHTHALMOL, V12, P947; MERRITT JC, 1981, J PHARM PHARMACOL, V33, P40, DOI 10.1111/j.2042-7158.1981.tb13699.x; MERRITT JC, 1980, OPHTHALMOLOGY, V87, P222; MUSINI A, 1971, AM J OPHTHALMOL, V72, P773, DOI 10.1016/0002-9394(71)90017-1; NELSON WL, 1986, AM J OPHTHALMOL, V102, P606, DOI 10.1016/0002-9394(86)90532-5; NELSON WL, 1987, AM J OPHTHALMOL, V103, P592, DOI 10.1016/S0002-9394(14)74288-6; Neufeld A H, 1983, Surv Ophthalmol, V28 Suppl, P286, DOI 10.1016/0039-6257(83)90152-2; NORDLUND JR, 1995, ARCH OPHTHALMOL-CHIC, V113, P77, DOI 10.1001/archopht.1995.01100010079024; ORLANDO RG, 1986, AM J OPHTHALMOL, V102, P275, DOI 10.1016/0002-9394(86)90158-3; PRINGLE SD, 1987, BRIT MED J, V294, P155, DOI 10.1136/bmj.294.6565.155-a; PURNELL W D, 1975, Annals of Ophthalmology, V7, P921; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; REICHERT RW, 1991, GRAEF ARCH CLIN EXP, V229, P252, DOI 10.1007/BF00167878; REYES PF, 1987, J NEUROL NEUROSUR PS, V50, P113, DOI 10.1136/jnnp.50.1.113; ROBIN AL, 1987, ARCH OPHTHALMOL-CHIC, V105, P1208; ROBIN AL, 1987, ARCH OPHTHALMOL-CHIC, V105, P646; SCHOENE RB, 1984, AM J OPHTHALMOL, V97, P86, DOI 10.1016/0002-9394(84)90450-1; SCHOENE RB, 1981, JAMA-J AM MED ASSOC, V245, P1460, DOI 10.1001/jama.245.14.1460; SCHULZER M, 1991, OPHTHALMOLOGY, V98, P301; SEARS M. L., 1966, INVEST OPHTHALMOL, V5, P115; SEARS ML, 1975, INVEST OPHTHALMOL, V14, P3; SHAIVITZ SA, 1979, JAMA-J AM MED ASSOC, V242, P1611, DOI 10.1001/jama.1979.03300150017011; SHIN DH, 1986, AM J OPHTHALMOL, V102, P275, DOI 10.1016/0002-9394(86)90159-5; Shirato S, 1997, ARCH OPHTHALMOL-CHIC, V115, P550, DOI 10.1001/archopht.1997.01100150552021; SHORE JH, 1987, J CLIN PSYCHOPHARM, V7, P264; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; THEODORE J, 1979, AM J OPHTHALMOL, V88, P1013, DOI 10.1016/0002-9394(79)90407-0; TRIPATHI BJ, 1984, EXP EYE RES, V39, P731, DOI 10.1016/0014-4835(84)90072-1; VANBUSKIRK EM, 1980, OPHTHALMOLOGY, V87, P447; VANBUSKIRK EM, 1986, AM J OPHTHALMOL, V101, P531, DOI 10.1016/0002-9394(86)90941-4; VELDE TM, 1983, ARCH INTERN MED, V143, P1627, DOI 10.1001/archinte.143.8.1627; VILLUMSEN J, 1990, ARCH OPHTHALMOL-CHIC, V108, P1102, DOI 10.1001/archopht.1990.01070100058034; VOGEL R, 1989, ARCH OPHTHALMOL-CHIC, V107, P1303, DOI 10.1001/archopht.1989.01070020373038; WAITZMAN MB, 1967, AM J PHYSIOL, V212, P329, DOI 10.1152/ajplegacy.1967.212.2.329; WALLACE TR, 1979, ANN OPHTHALMOL, V11, P1563; Watson P, 1996, OPHTHALMOLOGY, V103, P126, DOI 10.1016/S0161-6420(96)30750-1; WAX MB, 1987, INVEST OPHTH VIS SCI, V28, P420; WEISS IS, 1974, AM J OPHTHALMOL, V78, P327, DOI 10.1016/0002-9394(74)90098-1; WERBLIN TP, 1980, OPHTHALMOLOGY, V87, P350; WEST J, 1990, BRIT J OPHTHALMOL, V74, P663, DOI 10.1136/bjo.74.11.663; WISCH N, 1973, AM J OPHTHALMOL, V75, P130, DOI 10.1016/0002-9394(73)90662-4; Zimmerman T J, 1983, Surv Ophthalmol, V28 Suppl, P243, DOI 10.1016/0039-6257(83)90140-6; ZIMMERMAN TJ, 1984, ARCH OPHTHALMOL-CHIC, V102, P551; ZIMMERMAN TJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P601, DOI 10.1001/archopht.1977.04450040067008	117	150	166	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1298	1307		10.1056/NEJM199810293391808	http://dx.doi.org/10.1056/NEJM199810293391808			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132XC	9791148				2022-12-28	WOS:000076655300008
J	Khurana, KK; Kivelson, MG; Stevenson, DJ; Schubert, G; Russell, CT; Walker, RJ; Polanskey, C				Khurana, KK; Kivelson, MG; Stevenson, DJ; Schubert, G; Russell, CT; Walker, RJ; Polanskey, C			Induced magnetic fields as evidence for subsurface oceans in Europa and Callisto	NATURE			English	Article							INTERNAL STRUCTURE; OUTER PLANETS; GANYMEDE; SIGNATURE; WATER; IO	The Galileo spacecraft has been orbiting Jupiter since 7 December 1995, and encounters one of the four galilean satellites-Io, Europa, Ganymede and Callisto-on each orbit. Initial results from the spacecraft's magnetometer(1,2) have indicated that neither Europe nor Callisto have an appreciable internal magnetic field, in contrast to Ganymede(3) and possibly Io(4). Here we report perturbations of the external magnetic fields (associated with Jupiter's inner magnetosphere) in the vicinity of both Europe and Callisto. We interpret these perturbations as arising from induced magnetic fields, generated by the moons in response to the periodically varying plasma environment. Electromagnetic induction requires eddy currents to now within the moons, and our calculations show that the most probable explanation is that there are layers of significant electrical conductivity just beneath the surfaces of both moons. We argue that these conducting layers may best be explained by the presence of salty liquid-water oceans, for which there is already indirect geological evidence(5,6) in the case of Europa.	Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Khurana, KK (corresponding author), Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA.		Russell, Christopher T/E-7745-2012; Kivelson, Margaret G/I-9019-2012	Russell, Christopher T/0000-0003-1639-8298; Kivelson, Margaret G/0000-0003-3859-8581; Khurana, Krishan/0000-0002-2856-1171				Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1998, SCIENCE, V280, P1573, DOI 10.1126/science.280.5369.1573; ANDERSON JG, IN PRESS SCIENCE; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; COLBURN DS, 1985, ICARUS, V63, P39, DOI 10.1016/0019-1035(85)90019-3; CONNERNEY JEP, 1993, J GEOPHYS RES-PLANET, V98, P18659, DOI 10.1029/93JE00980; Durham WB, 1997, J GEOPHYS RES-PLANET, V102, P16293, DOI 10.1029/97JE00916; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; JACKSON JD, 1975, CLASSICAL ELECTRODYN, P338; KARGEL JS, 1996, LUNAR PLANET SCI C, V27, P643; KHURANA KK, 1989, J GEOPHYS RES, V94, P5241, DOI 10.1029/JA094iA05p05241; Khurana KK, 1997, NATURE, V387, P262, DOI 10.1038/387262a0; Khurana KK, 1997, J GEOPHYS RES-SPACE, V102, P11295, DOI 10.1029/97JA00563; KIRK RL, 1987, ICARUS, V69, P91, DOI 10.1016/0019-1035(87)90009-1; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; Kivelson MG, 1997, SCIENCE, V276, P1239, DOI 10.1126/science.276.5316.1239; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; KIVELSON MG, UNPUB J GEOPHYS RES; Kliore AJ, 1997, SCIENCE, V277, P355, DOI 10.1126/science.277.5324.355; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; MONTGOMERY RB, 1963, AM I PHYSICS HDB, P125; NEUBAUER FM, 1980, J GEOPHYS RES-SPACE, V85, P1171, DOI 10.1029/JA085iA03p01171; Neubauer FM, 1998, J GEOPHYS RES-PLANET, V103, P19843, DOI 10.1029/97JE03370; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Owen CJ, 1996, GEOPHYS RES LETT, V23, P1263, DOI 10.1029/96GL01354; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PARKINSON WD, 1993, INTRO GEOMAGNETISM, P308; REYNOLDS RT, 1979, GEOPHYS RES LETT, V6, P121, DOI 10.1029/GL006i002p00121; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; Schubert G., 1986, SATELLITES, P224; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; STEVENSON DJ, 1996, P EUR C SAN JUAN CAP, P69	34	392	402	2	105	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					777	780		10.1038/27394	http://dx.doi.org/10.1038/27394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796812				2022-12-28	WOS:000076607400049
J	Secor, SM; Diamond, J				Secor, SM; Diamond, J			A vertebrate model of extreme physiological regulation	NATURE			English	Article							BURMESE PYTHONS; MOLURUS	Investigation of vertebrate regulatory biology is restricted by the modest response amplitudes In mammalian model species that derive from a lifestyle of frequent small meals. By contrast, ambush-hunting snakes eat huge meals after long intervals. In juvenile pythons during feeding, there are large and rapid increases In metabolism and secretion, In the activation of enzymes and transporter proteins, and in tissue growth. These responses enable an economic hypothesis concerning the evolution of regulation to be tested. Combined with other experimental advantages, these features recommend juvenile pythons as the equivalent of a squid axon in vertebrate regulatory biology.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Secor, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.	python@ucla.edu						Conlon JM, 1997, PEPTIDES, V18, P1505, DOI 10.1016/S0196-9781(97)00232-5; Conlon JM, 1997, REGUL PEPTIDES, V71, P191; DIAMOND P, 1985, AM J PHYSIOL, V248, pE75, DOI 10.1152/ajpendo.1985.248.1.E75; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Field J, 1939, J CELL COMPAR PHYSL, V14, P143, DOI 10.1002/jcp.1030140202; GARLAND T, 1992, SYST BIOL, V41, P18, DOI 10.2307/2992503; Greene H. W., 1997, SNAKES EVOLUTION MYS; JANES DN, 1995, PHYSIOL ZOOL, V68, P1029, DOI 10.1086/physzool.68.6.30163792; Kleiber M., 1961, FIRE LIFE INTRO ANIM; POPE CH, 1961, GIANT SNAKES; Secor SM, 1997, AM J PHYSIOL-REG I, V272, pR902, DOI 10.1152/ajpregu.1997.272.3.R902; Secor SM, 1997, PHYSIOL ZOOL, V70, P202, DOI 10.1086/639578; SECOR SM, 1994, ECOLOGY, V75, P1600, DOI 10.2307/1939621; SECOR SM, 1994, AM J PHYSIOL, V266, pG695, DOI 10.1152/ajpgi.1994.266.4.G695; SECOR SM, 1995, HERPETOLOGICAL MONOGRAPHS, NO 9, 1995, P169, DOI 10.2307/1467004; SECOR SM, 1995, J EXP BIOL, V198, P1313	16	208	216	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 15	1998	395	6703					659	662		10.1038/27131	http://dx.doi.org/10.1038/27131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790187				2022-12-28	WOS:000076472600041
J	Monane, M; Matthias, DM; Nagle, BA; Kelly, MA				Monane, M; Matthias, DM; Nagle, BA; Kelly, MA			Improving prescribing patterns for the elderly through an online drug utilization review intervention - A system linking the physician, pharmacist, and computer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INAPPROPRIATE MEDICATION USE; EXPLICIT CRITERIA	Context.- Pharmacotherapy is among the most powerful interventions to improve health outcomes in the elderly. However, since some medications are less appropriate for older patients, systems approaches to improving pharmacy care may be an effective way to reduce inappropriate medication use. Objective.-To determine whether a computerized drug utilization review (DUR) database linked to a telepharmacy intervention can improve suboptimal medication use in the elderly. Design.-Population-based cohort design, April 1, 1996, through March 31, 1997, Setting.-Ambulatory care. Patients.-A total of 23 269 patients aged 65 years acid older throughout the United States receiving prescription drug benefits from a large pharmaceutical benefits manager during a 12-month period. Intervention.- Evaluation of provider prescribing through a computerized online DUR database using explicit criteria to identify potentially inappropriate drug use in the elderly. Computer alerts triggered telephone calls to physicians by pharmacists with training in geriatrics, whereby principles of geriatric pharmacology were discussed along with therapeutic substitution options. Main Outcome Measures.-Contact rate with physicians and change rate to suggested drug regimen. Results.-A total of 43 007 alerts were triggered. From a total of 43 007 telepharmacy calls generated by the alerts, we were able to reach 19 368 physicians regarding 24 266 alerts (56%). Rate of change to a more appropriate therapeutic agent was 24% (5860), but ranged from 40% for long half-life benzodiazepines to 2% to 7% for drugs that theoretically were contraindicated by patients' self-reported history. Except for rate of change of beta-blockers in patients with chronic obstructive pulmonary disease, all rates of change were significantly greater than the expected baseline 2% rate of change. Conclusions.-Using a system integrating computers, pharmacists, and physicians, our large-scale intervention improved prescribing patterns and quality of care and thus provides a population-based approach to advance geriatric clinical pharmacology. Future research should focus on the demonstration of improved health outcomes resulting from improved prescribing choices for the elderly.	Merck Medco Managed Care LLC, Dept Med Affairs, Montvale, NJ 07645 USA; Merck Medco Managed Care LLC, Dept Hlth & Utilizat Management, Montvale, NJ 07645 USA		Monane, M (corresponding author), Merck Medco Managed Care LLC, Dept Med Affairs, 100 Summit Ave, Montvale, NJ 07645 USA.	mark_monane@merck.com						BAUM C, 1984, JAMA-J AM MED ASSOC, V251, P1293, DOI 10.1001/jama.251.10.1293; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; *GEN ACC OFF, 1995, GAOHEHS95152; GROVES RE, 1985, AM J HOSP PHARM, V42, P316, DOI 10.1093/ajhp/42.2.316; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Hanlon JT, 1995, THERAPEUTICS ELDERLY, P212; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; Monane M, 1996, AM J PUBLIC HEALTH, V86, P1805, DOI 10.2105/AJPH.86.12.1805; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P302; SARTOR F, 1995, AM J EPIDEMIOL, V141, P782, DOI 10.1093/oxfordjournals.aje.a117502; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; STEWART RB, 1994, DRUG AGING, V4, P449, DOI 10.2165/00002512-199404060-00002; STEWART RB, 1989, MED CLIN N AM, V73, P1551, DOI 10.1016/S0025-7125(16)30616-2; STUCK AE, 1994, ARCH INTERN MED, V154, P2195; WILCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292	22	154	164	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1249	1252		10.1001/jama.280.14.1249	http://dx.doi.org/10.1001/jama.280.14.1249			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127NR	9786375	Bronze			2022-12-28	WOS:000076357900031
J	Blaas, HG; Eik-Nes, SH; Berg, S; Torp, H				Blaas, HG; Eik-Nes, SH; Berg, S; Torp, H			In-vivo three-dimensional ultrasound reconstructions of embryos and early fetuses	LANCET			English	Article							LONGITUDINAL ULTRASOUND; VOLUME ESTIMATION; HUMAN BRAIN; GESTATION; ULTRASONOGRAPHY	Background Three-dimensional (3D) imaging of the living human embryo has become possible in the monitoring of embryological development, as described by classic human embryology. We aimed to create 3D images of organs in embryos on early pregnancy. Methods We used a specially developed 7.5 MHz annular array 3D transvaginal probe to examine embryos. We included 34 women at 7-10 weeks' gestation. We measured the crown-rump length (CRL) of the embryos and fetuses and transferred the 3D ultrasound data to an external computer for further processing to calculate volume. Findings The CRLs ranged from 9.3 mm to 39.0 mm. The quality of the images of the embryos and fetuses made it possible to outline in detail the outer contours and the contours of the brain cavities, and the calculated volumes corresponded well to the descriptions from classic human embryology. Interpretation Our 3D imaging system allowed visualisation of structures of less than 10 mm. Therefore, development and abnormal development of fetuses can be monitored.	Univ Trondheim Hosp, Dept Obstet & Gynaecol, Natl Ctr Fetal Med, N-7006 Trondheim, Norway; Univ Trondheim, Dept Physiol & Biomed Engn, N-7034 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Blaas, HG (corresponding author), Univ Trondheim Hosp, Dept Obstet & Gynaecol, Natl Ctr Fetal Med, N-7006 Trondheim, Norway.							[Anonymous], 1920, CONTRIBUTIONS EMBRYO; BLAAS HG, 1995, ULTRASOUND OBST GYN, V5, P151, DOI 10.1046/j.1469-0705.1995.05030151.x; BLAAS HG, 1995, ULTRASOUND OBST GYN, V5, P228, DOI 10.1046/j.1469-0705.1995.05040228.x; BLAAS HG, 1994, ULTRASOUND OBST GYN, V4, P183, DOI 10.1046/j.1469-0705.1994.04030183.x; BLAAS HG, 1995, ULTRASOUND OBST GYN, V6, P240, DOI 10.1046/j.1469-0705.1995.06040240.x; Born G, 1883, ARCH MIKROSK ANAT, V22, P584, DOI 10.1007/bf02952679; BRINKLEY JF, 1982, AM J OBSTET GYNECOL, V144, P715, DOI 10.1016/0002-9378(82)90443-4; DRUMM JE, 1977, AM J ANAT, V148, P555, DOI 10.1002/aja.1001480410; ELGAMMAL S, 1987, NEW FRONTIERS BRAIN, P46; GAUNT PN, 1978, 3 DIMENSIONAL RECONS, P63; GILJA OH, 1994, ULTRASOUND MED BIOL, V20, P157, DOI 10.1016/0301-5629(94)90080-9; GILJA OH, 1995, ULTRASOUND MED BIOL, V21, P25, DOI 10.1016/0301-5629(94)00082-4; His W., 1880, ANATOMIE MENSCHLICHE; HIS W, 1890, ABHANDL KS GESELLSCH, V29, P3; His W., 1887, ANAT ANZEIGER, V2, P382; JENKINS GB, 1921, CONTRIB EMBRYOL CARN, V13, P41; JIRASEK JE, 1966, AM J OBSTET GYNECOL, V96, P868, DOI 10.1016/0002-9378(66)90684-3; Kostovic I., 1990, HUMANEMBRYOLOGIE, P381; MEBAN C, 1983, J ANAT, V137, P217; MULLER F, 1990, ANAT EMBRYOL, V182, P375, DOI 10.1007/BF02433497; O'Rahilly R., 1994, EMBRYONIC HUMAN BRAI; O'Rahilly R., 1987, DEV STAGES HUMAN EMB; ORAHILLY R, 1990, AM J ANAT, V189, P285, DOI 10.1002/aja.1001890402; ORAHILLY R, 1992, HUMAN EMBRYOLOGY TER; RICCABONA M, 1995, ULTRASCHALL KLIN PRA, V10, P35; THUNE N, 1996, EUR J ULTRASOUND, V3, P83; TIMORTRITSCH IE, 1990, J CLIN ULTRASOUND, V18, P286, DOI 10.1002/jcu.1870180412; TIMORTRITSCH IE, 1988, AM J OBSTET GYNECOL, V159, P678	28	106	107	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1182	1186		10.1016/S0140-6736(98)03227-9	http://dx.doi.org/10.1016/S0140-6736(98)03227-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777835				2022-12-28	WOS:000076415400010
J	Johanson, R				Johanson, R			James Alexander ("Hamish") Chalmers - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					1019	1019		10.1136/bmj.317.7164.1019	http://dx.doi.org/10.1136/bmj.317.7164.1019			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765187	Green Published			2022-12-28	WOS:000076449300062
J	Rahman, F				Rahman, F			Angels and spirits in the world of illness	LANCET			English	Editorial Material									W Texas Med Associates, Hematol Oncol Sect, San Angelo, TX 76904 USA		Rahman, F (corresponding author), W Texas Med Associates, Hematol Oncol Sect, 3555 Knickerbocker Rd, San Angelo, TX 76904 USA.								0	1	1	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1218	1219		10.1016/S0140-6736(98)05421-X	http://dx.doi.org/10.1016/S0140-6736(98)05421-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777857				2022-12-28	WOS:000076415400043
J	Parcy, F; Nilsson, O; Busch, MA; Lee, I; Weigel, D				Parcy, F; Nilsson, O; Busch, MA; Lee, I; Weigel, D			A genetic framework for floral patterning	NATURE			English	Article							POLYCOMB-GROUP GENE; HOMEOTIC GENE; ARABIDOPSIS-THALIANA; ORGAN IDENTITY; INFLORESCENCE DEVELOPMENT; ECTOPIC EXPRESSION; FLOWER DEVELOPMENT; MERISTEM IDENTITY; LEAFY; TRANSCRIPTION	The initial steps of newer development involve two classes of consecutively acting regulatory genes. Meristem-identity genes, which act early to control the initiation of flowers, are expressed throughout the incipient floral primordium. Homeotic genes, which act later to specify the identify of individual floral organs, are expressed in distinct domains within the flower. The link between the two classes of genes has remained unknown so far. Here we show that the meristem-identity gene LEAN has a role in controlling homeotic genes that is separable from its role in specifying floral fate. On the basis of our observation that LEAFY activates different homeotic genes through distinct mechanisms, we propose a genetic framework for the control of floral patterning.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Weigel, D (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	weigel@salk.edu	Parcy, François/G-9177-2011; parcy, francois/A-6031-2009; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008; Weigel, Detlef/GSJ-0799-2022	Parcy, François/0000-0003-2191-500X; Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Nilsson, Ove/0000-0002-1033-1909				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; GUSTAFSOBROWN C, 1996, THESIS U CALIFORNIA; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HANTKE SS, 1995, DEVELOPMENT, V121, P27; HEMPEL FD, 1994, PLANTA, V192, P276, DOI 10.1007/BF01089045; Hempel FD, 1997, DEVELOPMENT, V124, P3845; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; Ingram GC, 1997, EMBO J, V16, P6521, DOI 10.1093/emboj/16.21.6521; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; Krizek BA, 1996, DEVELOPMENT, V122, P11; Kumar A, 1998, P NATL ACAD SCI USA, V95, P2417, DOI 10.1073/pnas.95.5.2417; Lee EA, 1997, KOREAN J GENETIC, V19, P95; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; LIU ZC, 1995, DEVELOPMENT, V121, P975; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NILSSON O, IN PRESS GENETICS; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; Sze JY, 1997, DEVELOPMENT, V124, P1159; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; WILKINSON MD, 1995, PLANT CELL, V7, P1485, DOI 10.1105/tpc.7.9.1485; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	49	388	430	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 8	1998	395	6702					561	566		10.1038/26903	http://dx.doi.org/10.1038/26903			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783581				2022-12-28	WOS:000076362900037
J	Dimeo, NA				Dimeo, NA			On being human	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1135	1135		10.1001/jama.280.13.1135	http://dx.doi.org/10.1001/jama.280.13.1135			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777804				2022-12-28	WOS:000076210800012
J	Nightingale, SL				Nightingale, SL			Off-label use of Haemophilus vaccine in combination with DTaP vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1128	1128		10.1001/jama.280.13.1128	http://dx.doi.org/10.1001/jama.280.13.1128			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777799				2022-12-28	WOS:000076210800007
J	Stambolic, V; Suzuki, A; de la Pompa, JL; Brothers, GM; Mirtsos, C; Sasaki, T; Ruland, J; Penninger, JM; Siderovski, DP; Mak, TW				Stambolic, V; Suzuki, A; de la Pompa, JL; Brothers, GM; Mirtsos, C; Sasaki, T; Ruland, J; Penninger, JM; Siderovski, DP; Mak, TW			Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN	CELL			English	Article							PROTEIN-KINASE-B; BREAST CARCINOMAS; PROSTATE-CANCER; GROWTH; GENE; PHOSPHATASE; MUTATIONS; AKT; IDENTIFICATION; ACTIVATION	PTEN is a tumor suppressor with sequence homology to protein tyrosine phosphatases and the cytoskeletal protein tensin. mPTEN-mutant mouse embryos display regions of increased proliferation. In contrast, mPTEN-deficient immortalized mouse embryonic fibroblasts exhibit decreased sensitivity to cell death in response to a number of apoptotic stimuli, accompanied by constitutively elevated activity and phosphorylation of protein kinase B/Akt, a crucial regulator of cell survival. Expression of exogenous PTEN in mutant cells restores both their sensitivity to agonist-induced apoptosis and normal pattern of PKB/Akt phosphorylation. Furthermore, PTEN negatively regulates intracellular levels of phosphatidylinositol (3,4,5) trisphosphate in cells and dephosphorylates it in vitro. Our results show that PTEN may exert its role as a tumor suppressor by negatively regulating the PI3'K/PKB/Akt signaling pathway.	Amgen Inst, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Mak, TW (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON, Canada.	tmak@oci.utoronto.ca	Suzuki, Akira/GYD-6697-2022; Penninger, Josef M/I-6860-2013; De La Pompa, José Luis/F-9719-2014; Siderovski, David Peter/AAA-9603-2019; Ruland, Jürgen/Q-6680-2018	Suzuki, Akira/0000-0002-5950-8808; Penninger, Josef M/0000-0002-8194-3777; De La Pompa, José Luis/0000-0001-6761-7265; Siderovski, David Peter/0000-0002-0688-8210; Ruland, Jürgen/0000-0002-8381-3597; Stambolic, Vuk/0000-0001-8853-3239; Sasaki, Takehiko/0000-0003-1837-3748				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIGNER SH, 1988, CANCER RES, V48, P405; Cairns P, 1997, CANCER RES, V57, P4997; CHAFFANET M, 1992, EUR J CANCER, V28A, P11, DOI 10.1016/0959-8049(92)90374-B; Cheney IW, 1998, CANCER RES, V58, P2331; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUKEK H, 1997, SCIENCE, V275, P661; Eng C, 1998, INT J ONCOL, V12, P701; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDMAN A, 1998, CELLS LAB MANUAL; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; HAYASHI Y, 1988, J HISTOCHEM CYTOCHEM, V36, P511, DOI 10.1177/36.5.3282006; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; Smits A, 1998, HISTOL HISTOPATHOL, V13, P511, DOI 10.14670/HH-13.511; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248	58	2007	2117	3	138	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					29	39		10.1016/S0092-8674(00)81780-8	http://dx.doi.org/10.1016/S0092-8674(00)81780-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778245	Bronze			2022-12-28	WOS:000076242300008
J	Waterston, R; Sulston, JE				Waterston, R; Sulston, JE			Genomics - The human genome project: Reaching the finish line	SCIENCE			English	Editorial Material							YAC CONTIG MAP; PHYSICAL MAP; DENSITY; SHOTGUN		Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Sanger Ctr, Cambridge CB10 1SA, England	Washington University (WUSTL); Wellcome Trust Sanger Institute	Waterston, R (corresponding author), Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA.	rw@genetics.wustl.edu; jes@sanger.ac.uk						[Anonymous], 1997, NATURE, V387, pS; BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; BENTLEY D, IN PRESS TRENDS GENE; Bouffard GG, 1997, GENOME RES, V7, P673, DOI 10.1101/gr.7.7.673; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1995, NATURE, V377, P175; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; COLLINS JE, 1995, NATURE, V377, P367; DELOUKAS P, 1998, IN PRESS SCIENC 1023; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOGGETT NA, 1995, NATURE, V377, P335; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GEMMILL RM, 1995, NATURE, V377, P299; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KRAUTER K, 1995, NATURE, V377, P321; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Olson M, 1998, GENOME RES, V8, P414, DOI 10.1101/gr.8.5.414; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Wilson RK, 1997, GENOME ANAL, V1, P397	25	54	59	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					53	54		10.1126/science.282.5386.53	http://dx.doi.org/10.1126/science.282.5386.53			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9786797				2022-12-28	WOS:000076294900031
J	Mizushima, N; Noda, T; Yoshimori, T; Tanaka, Y; Ishii, T; George, MD; Klionsky, DJ; Ohsumi, M; Ohsumi, Y				Mizushima, N; Noda, T; Yoshimori, T; Tanaka, Y; Ishii, T; George, MD; Klionsky, DJ; Ohsumi, M; Ohsumi, Y			A protein conjugation system essential for autophagy	NATURE			English	Article							NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; YEAST; DEGRADATION; MECHANISMS; VACUOLE; RANGAP1; MUTANTS; GTPASE	Autophagy is a process for the bulk degradation of proteins, in which cytoplasmic components of the cell are enclosed by double-membrane structures known as autophagosomes for delivery to lysosomes or vacuoles for degradation(1-4). This process is crucial for survival during starvation and cell differentiation. No molecules have been identified that are involved in autophagy in higher eukaryotes. We have isolated 14 autophagy-defective (apg) mutants of the yeast Saccharomyces cerevisiae(5) and examined the autophagic process at the molecular level(6-9). We show here that a unique covalent-modification system is essential for autophagy to occur. The carboxy-terminal glycine residue of Apg12, a 186-amino-acid protein, is conjugated to a lysine at residue 149 of Apg5, a 294-amino-acid protein. Of the apg mutants, we found that apg7 and apg10 were unable to form an Apg5/Apg12 conjugate. By cloning APG7, we discovered that Apg7 is a ubiquitin-E1-like enzyme. This conjugation can be reconstituted in vitro and depends on ATP. To our knowledge, this is the first report of a protein unrelated to ubiquitin that uses a ubiquitination-like conjugation system. Furthermore, Apg5 and Apg12, have mammalian homologues, suggesting that this new modification system is conserved from yeast to mammalian cells.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Teikyo Univ Sci & Technol, Dept Biosci, Yamanashi 4090193, Japan; Univ Calif Davis, Microbiol Sect, Livermore, CA 95616 USA	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); University of California System; University of California Davis	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.		Noda, Takeshi/B-7240-2008; Ohsumi, Yoshinori/C-6449-2009; Mizushima, Noboru/C-3635-2009	Noda, Takeshi/0000-0003-3581-7961; Ohsumi, Yoshinori/0000-0003-2384-2166; Mizushima, Noboru/0000-0002-6258-6444				Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Finkbeiner WE, 1992, TREATISE PULMONARY T, V1, P633; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Hammond EM, 1998, FEBS LETT, V425, P391, DOI 10.1016/S0014-5793(98)00266-X; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; KAMETAKA S, IN PRESS J BIOL CHEM; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; OSAKA E, IN PRESS GENES DEV; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X	29	1222	1273	6	299	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					395	398		10.1038/26506	http://dx.doi.org/10.1038/26506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759731				2022-12-28	WOS:000076083800057
J	Baron, JH				Baron, JH			A memorable patient - Never underestimate a placebo	BRITISH MEDICAL JOURNAL			English	Article									Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Baron, JH (corresponding author), Mt Sinai Sch Med, New York, NY 10029 USA.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1190	1190		10.1136/bmj.317.7167.1190	http://dx.doi.org/10.1136/bmj.317.7167.1190			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794852	Green Published			2022-12-28	WOS:000076963000019
J	Oakley, A				Oakley, A			Experimentation and social interventions: a forgotten but important history	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Inst Educ, Social Sci Res Unit, London WC1H 0NS, England	University of London; University College London; UCL Institute of Education	Oakley, A (corresponding author), Univ London, Inst Educ, Social Sci Res Unit, London WC1H 0NS, England.	a.oakley@ioe.ac.uk						Bloom H. S., 1990, BACK WORK TESTING RE; BORING EG, 1954, AM J PSYCHOL, V67, P573, DOI 10.2307/1418483; Boruch R. F., 1974, EVALUATION, V2, P83; BORUCH RF, 1978, EVALUATION QUART, V2, P655, DOI 10.1177/0193841X7800200411; BOTEIN B, 1965, TEX LAW REV, V43, P319; BRADBURY KL, 1981, DO HOUSING ALLOWANCE; BREARLEY HC, 1931, SOCIAL FORCES    DEC, P196; Campbell D. T., 1988, METHODOLOGY EPISTEMO, P321; Campbell D. T., 1966, EXPT QUASIEXPERIMENT; CAMPBELL DT, 1924, AM PSYCHOL, V4, P409; CAMPBELL DT, 1966, EXPT QUASIEXPERIMENT, P2; Chapin FS, 1931, J EDUC SOCIOL, V4, P541, DOI 10.2307/2961197; Chapin FS, 1947, EXPT DESIGNS SOCIOLO; Ferber R., 1982, SOCIAL EXPT EC POLIC; FRIEDMAN J, 1983, GREAT HOUSING EXPT; GOSNELL HF, 1977, GETTING OUT VOTE EXP; GRAMLICH EM, 1975, ED PERFORMANCE CONTR; GREENWOOD E, 1976, EXPT SOCIOLOGY, P72; KEHRER BH, 1979, J HUM RESOUR, V14, P434, DOI 10.2307/145316; KEHRER KC, 1978, EVALUATION STUDIES R, V3, P437; MANNING WG, 1984, NEW ENGL J MED, V310, P105; Matthews JR., 1995, QUANTIFICATION QUEST, DOI 10.1515/9781400821808; MAYNARD RA, 1977, AM ECON REV, V67, P370; MCCALL WA, 1923, EXPT ED, P38; Murphy G., 1937, EXPT SOCIAL PSYCHOL; NATHAN RP, 1988, SOCIAL SCI GOVT, P61; Rossi P.H., 1980, MONEY WORK CRIME EXP; ROSSI PH, 1984, ANNU REV SOCIOL, V10, P331, DOI 10.1146/annurev.so.10.080184.001555; ROSSI PH, 1976, REFORMING PUBLIC WEL; STANLEY JC, 1957, J EXP EDUC, V25, P195, DOI 10.1080/00220973.1957.11010571; STIGLER SM, 1986, HIST STAT, P253; Thorndike EL, 1901, PSYCHOL REV, V8, P553, DOI 10.1037/h0071363; Thorndike EL, 1901, PSYCHOL REV, V8, P384, DOI 10.1037/h0071280; Thorndike EL, 1901, PSYCHOL REV, V8, P247, DOI 10.1037/h0071363; WEBB S, 1932, METHODS SOCIAL STUDY, P224; Winch WH, 1908, BRIT J PSYCHOL, V2, P284, DOI 10.1111/j.2044-8295.1908.tb00180.x	36	79	80	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1239	1242		10.1136/bmj.317.7167.1239	http://dx.doi.org/10.1136/bmj.317.7167.1239			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138GF	9794871	Green Published			2022-12-28	WOS:000076963000036
J	Breger, L; Romanowicz, B				Breger, L; Romanowicz, B			Three-dimensional structure at the base of the mantle beneath the central Pacific	SCIENCE			English	Article							LOWERMOST MANTLE; TRAVEL-TIMES; CORE; BOUNDARY; SKS; HETEROGENEITIES; MODEL; D''	Forward modeling of differential travel times of phases sensitive to Lowermost mantle beneath the central Pacific reveals Lateral heterogeneity that is higher in amplitude than predicted by tomographic models. A broad zone of Low S velocity (-4 percent with respect to standard models), which may correspond to the base of a thermal "plume," narrows and is deflected as it extends to about 1000 kilometers above the core-mantle boundary. To the east of this zone, a localized region of fast S velocity (+1-5 percent) suggests strong heterogeneity or anisotropy related to the presence of high pressure and temperature assemblages, which may or may not involve core material, Its presence could also explain the observation of precursors to core reflected phases in this region.	Univ Calif Berkeley, Seismol Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Breger, L (corresponding author), Univ Calif Berkeley, Seismol Lab, Berkeley, CA 94720 USA.	breger@seismo.berkeley.edu	Romanowicz, barbara A/H-6726-2017	Romanowicz, barbara A/0000-0002-6208-6044				Breger L, 1998, GEOPHYS RES LETT, V25, P5, DOI 10.1029/97GL03359; CORMIER VF, 1985, J GEOPHYS-Z GEOPHYS, V57, P14; Dubrovinsky LS, 1997, NATURE, V388, P362, DOI 10.1038/41066; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GARNERO E, 1988, GEOPHYS RES LETT, V15, P609, DOI 10.1029/GL015i006p00609; GARNERO EJ, 1993, J GEOPHYS RES-SOL EA, V98, P8225, DOI 10.1029/93JB00147; Grand SP., 1997, GSA TODAY, V7, P1; HADDON RAW, 1987, GEOPHYS RES LETT, V14, P891, DOI 10.1029/GL014i009p00891; KARATO S, IN PRESS EARTH SPACE; KELLOGG LH, 1993, GEOPHYS RES LETT, V20, P379, DOI 10.1029/93GL00045; Kendall JM, 1996, NATURE, V381, P409, DOI 10.1038/381409a0; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; LAY T, 1983, GEOPHYS J ROY ASTR S, V75, P799, DOI 10.1111/j.1365-246X.1983.tb05010.x; Li XD, 1996, J GEOPHYS RES-SOL EA, V101, P22245, DOI 10.1029/96JB01306; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; LIU XF, IN PRESS EARTH PLANE; LIU XF, 1994, EOS T AM GEOPHYS U S, V75, P232; LOPER DE, 1995, J GEOPHYS RES-SOL EA, V100, P6397, DOI 10.1029/94JB02048; Masters G, 1996, PHILOS T R SOC A, V354, P1385, DOI 10.1098/rsta.1996.0054; Ritsema J, 1998, GEOPHYS RES LETT, V25, P1229, DOI 10.1029/98GL00913; Ritsema J, 1997, J GEOPHYS RES-SOL EA, V102, P20395, DOI 10.1029/97JB01507; SCHWEITZER J, 1986, GEOPHYS RES LETT, V13, P1529, DOI 10.1029/GL013i013p01529; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; STACEY FD, 1983, PHYS EARTH PLANET IN, V33, P45, DOI 10.1016/0031-9201(83)90006-7; Steinberger B, 1998, GEOPHYS J INT, V132, P412, DOI 10.1046/j.1365-246x.1998.00447.x; Stixrude L, 1998, GEODYNAMICS, V28, P83; Sylvander M, 1996, PHYS EARTH PLANET IN, V94, P1, DOI 10.1016/0031-9201(95)03093-X; Thompson PF, 1998, GEOPHYS RES LETT, V25, P1999, DOI 10.1029/98GL01228; Vidale JE, 1998, NATURE, V391, P682, DOI 10.1038/35601; VIDALE JE, 1987, THESIS CALTECH; Vinnik L, 1998, NATURE, V393, P564, DOI 10.1038/31208; Wen LX, 1998, SCIENCE, V279, P1701, DOI 10.1126/science.279.5357.1701; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; Wysession ME, 1996, NATURE, V382, P244, DOI 10.1038/382244a0; Wysession ME, 1998, GEODYNAMICS, V28, P273	35	71	71	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					718	720		10.1126/science.282.5389.718	http://dx.doi.org/10.1126/science.282.5389.718			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784124				2022-12-28	WOS:000076607500043
J	Hersh, WR; Hickam, DH				Hersh, WR; Hickam, DH			How well do physicians use electronic information retrieval systems? A framework for investigation and systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BIBLIOGRAPHIC RETRIEVAL; CLINICAL QUESTIONS; MEDICAL LITERATURE; ONLINE ACCESS; PRIMARY-CARE; MEDLINE; COMPUTER; KNOWLEDGE; SETTINGS; IMPACT	Objective.-Despite the proliferation of electronic information retrieval (IR) systems for physicians, their effectiveness has not been well assessed. The purpose of this review is to provide a conceptual framework and to apply the results of previous studies to this framework. Data Sources.-All sources of medical informatics and information science literature, including MEDLINE, along with bibliographies of textbooks in these areas, were searched from 1966 to January 1998. Study Selection.-All articles presenting either classifications of evaluation studies or their results, with an emphasis on those studying use by physicians. Data Extraction.-A framework for evaluation was developed, consisting of frequency of use, purpose of use, user satisfaction, searching utility, search failure, and outcomes. All studies were then assessed based on the framework. Data Synthesis.-Due to the heterogeneity and simplistic study designs, no meta-analysis of studies could be done. General conclusions were drawn from data where appropriate. A total of 47 articles were found to include an evaluation component and were used to develop the framework. Of these, 21 articles met the inclusion criteria for 1 or more of the categories in the framework. Most use of IR systems by physicians still occurs with bibliographic rather than full-text databases. Overall use of IR systems occurs just 0.3 to 9 times per physician per month, whereas physicians have 2 unanswered questions for every 3 patients. Conclusions.-Studies comparing IR systems with different searching features have not shown that advanced searching methods are significantly more effective than simple text word methods. Most searches retrieve only one fourth to one half of the relevant articles on a given topic and, once retrieved, little is known about how these articles are interpreted or applied. These studies imply that further research and development are needed to improve system utility and performance.	Oregon Hlth Sci Univ, Sch Med, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Portland VA Med Ctr, Dept Med, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Hersh, WR (corresponding author), Oregon Hlth Sci Univ, Sch Med, Div Med Informat & Outcomes Res, 3181 SW Sam Jackson Pk Rd,BlCC, Portland, OR 97201 USA.	hersh@ohsu.edu	Hersh, William/AAH-6106-2019; Tao, Youyou/D-2367-2014	Hersh, William/0000-0002-4114-5148; Hickman, Heather/0000-0003-4168-4894				ABATE MA, 1992, METHOD INFORM MED, V31, P153; COLLEN MF, 1985, JAMA-J AM MED ASSOC, V254, P2768, DOI 10.1001/jama.254.19.2768; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; CURLEY SP, 1990, MED DECIS MAKING, V10, P231, DOI 10.1177/0272989X9001000401; FIDEL R, 1983, J AM SOC INFORM SCI, V34, P163, DOI 10.1002/asi.4630340302; FLETCHER RH, 1993, ANN INTERN MED, V119, P1144, DOI 10.7326/0003-4819-119-11-199312010-00013; GORMAN PN, 1994, B MED LIBR ASSOC, V82, P140; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HAYNES RB, 1985, ANN INTERN MED, V103, P812, DOI 10.7326/0003-4819-103-5-812; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P285, DOI 10.1136/jamia.1994.95236159; HAYNES RB, 1991, B MED LIBR ASSOC, V79, P377; HAYNES RB, 1993, ONLINE J CURR C 0511; Hersh W, 1996, J AM SOC INFORM SCI, V47, P50, DOI 10.1002/(SICI)1097-4571(199601)47:1<50::AID-ASI5>3.0.CO;2-1; HERSH W, 1994, B MED LIBR ASSOC, V82, P382; HERSH W, 1994, J AM SOC INFORM SCI, V45, P201, DOI 10.1002/(SICI)1097-4571(199404)45:3<201::AID-ASI9>3.0.CO;2-W; HERSH WR, 1995, J AM SOC INFORM SCI, V46, P478, DOI 10.1002/(SICI)1097-4571(199508)46:7<478::AID-ASI2>3.0.CO;2-#; HERSH WR, 1996, INFORMATION RETRIEVA; HOROWITZ GL, 1983, JAMA-J AM MED ASSOC, V250, P2494, DOI 10.1001/jama.250.18.2494; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KINGLAND LC, 1993, B MED LIBR ASSOC, V81, P178; KIRBY M, 1986, Medical Reference Services Quarterly, V5, P17, DOI 10.1300/J115v05n03_02; LANCASTER FW, 1993, INFORMATION RETRIEVA; LINDBERG DAB, 1993, JAMA-J AM MED ASSOC, V269, P3124, DOI 10.1001/jama.269.24.3124; LUDWIG L, 1988, B MED LIBR ASSOC, V76, P7; MARKERT RJ, 1989, B MED LIBR ASSOC, V77, P133; MARSHALL J, 1990, P MED LIB ASS ANN M; MCKININ EJ, 1991, J AM SOC INFORM SCI, V42, P297, DOI 10.1002/(SICI)1097-4571(199105)42:4<297::AID-ASI6>3.0.CO;2-M; POISSON EH, 1986, B MED LIBR ASSOC, V74, P293; SACKETT DL, 1997, EVIDENCE BASED MED H; VEENSTRA RJ, 1992, B MED LIBR ASSOC, V80, P19; WALKER CJ, 1991, B MED LIBR ASSOC, V79, P67; WALLINGFORD KT, 1990, M D COMPUT, V7, P166; WILDEMUTH BM, 1995, J AM SOC INFORM SCI, V46, P590, DOI 10.1002/(SICI)1097-4571(199509)46:8<590::AID-ASI7>3.0.CO;2-#	35	144	148	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1347	1352		10.1001/jama.280.15.1347	http://dx.doi.org/10.1001/jama.280.15.1347			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129PQ	9794316				2022-12-28	WOS:000076472500029
J	Braatigam, M; Weidinger, G; Nolting, S				Braatigam, M; Weidinger, G; Nolting, S			Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits	BRITISH MEDICAL JOURNAL			English	Letter									Novartis Pharma, Dermatol, Nurnberg, Germany; Novartis Pharma, Therapeut Area 1, Nurnberg, Germany; Univ Munster, D-4400 Munster, Germany	Novartis; Novartis; University of Munster	Braatigam, M (corresponding author), Novartis Pharma, Dermatol, Nurnberg, Germany.			Braeutigam, Matthias/0000-0002-1961-6396				BRAUTIGAM M, 1995, BRIT MED J, V311, P919, DOI 10.1136/bmj.311.7010.919; BRAUTIGAM M, 1995, BRIT MED J, V311, P1350; DECUYPER C, 1997, AUST J DERMATOL S2, V38, P1193; TOSTI A, 1996, J EUR ACAD DERMAT S2, V7, P137	4	13	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1084	1084						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774312	Green Published			2022-12-28	WOS:000076577200061
J	Prasher, D				Prasher, D			New strategies for prevention and treatment of noise-induced hearing loss	LANCET			English	Editorial Material							AUDITORY NEURONS; PROTECTION; EXPOSURE		UCL, Inst Laryngol & Otol, London WC1X 8EE, England	University of London; University College London	Prasher, D (corresponding author), UCL, Inst Laryngol & Otol, Mortimer St, London WC1X 8EE, England.							Alberti P.W, 1998, NOISE HEALTH, V1, P3; Altschuler RA, 1996, AUDITORY SYSTEM PLASTICITY AND REGENERATION, P202; ATTIAS J, 1998, BIOL EFFECTS NOISE, P273; CANLON B, 1988, HEARING RES, V34, P197, DOI 10.1016/0378-5955(88)90107-4; Canlon Barbara, 1998, Noise Health, V1, P13; Ernfors P, 1996, NAT MED, V2, P463, DOI 10.1038/nm0496-463; Jacono AA, 1998, HEARING RES, V117, P31, DOI 10.1016/S0378-5955(97)00214-1; KOMJATHY DA, 1997, ABS ASS RES OTOLARYN, V21, P748; MORATA TC, 1993, SCAND J WORK ENV HEA, V19, P245, DOI 10.5271/sjweh.1477; PUEL JL, 1994, J COMP NEUROL, V341, P241, DOI 10.1002/cne.903410209; SEIDMAN MD, 1993, OTOLARYNG HEAD NECK, V109, P1052, DOI 10.1177/019459989310900613; SHA SH, 1997, ABS ASS RES OTOLARYN, V20, P120; SHOJI F, 1998, ABS ASS RES OTOLARYN, V21, P539; YAMANE H, 1995, ACTA OTO-LARYNGOL, P87; Yamasoba T, 1998, BRAIN RES, V784, P82, DOI 10.1016/S0006-8993(97)01156-6	15	18	23	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1240	1242		10.1016/S0140-6736(05)70483-9	http://dx.doi.org/10.1016/S0140-6736(05)70483-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788450				2022-12-28	WOS:000076573800004
J	Apfeld, J; Kenyon, C				Apfeld, J; Kenyon, C			Cell nonautonomy of C-elegans daf-2 function in the regulation of diapause and life span	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CONTROLLING DAUER FORMATION; LARVAL DEVELOPMENT; CHEMOSENSORY NEURONS; INTERACTING GENES; SEX DETERMINATION; FAMILY MEMBER; LONGEVITY; EXPRESSION; PHEROMONE	The insulin/IGF receptor homolog DAF-2 regulates the aging in C. elegans. Decreasing daf-2 activity causes fertile adults to remain active much longer than normal and to live more than twice as long. A more severe decrease in daf-2 function causes young larvae to enter a state of diapause rather than progressing to adulthood. We have asked which cells require daf-2 gene activity in order for the animal to develop to adulthood and to age normally. We found that daf-a functions cell nonautonomously in both processes. Our findings imply that the life span of C. elegans is determined by a signaling cascade in which the DAF-2 receptor acts in multiple cell lineages to regulate the production or activity of a secondary signal (or signals), which, in turn, controls the growth and longevity of individual tissues in the animal.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Apfeld, J (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	japfeld@itsa.ucsf.edu; ckenyon@biochem.ucsf.edu		Apfeld, Javier/0000-0001-9897-5671	NIA NIH HHS [AG11816] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011816, R01AG011816] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antebi A, 1998, DEVELOPMENT, V125, P1191; Armitage P, 1987, STAT METHODS MED RES, P421; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BRENNER S, 1974, GENETICS, V77, P71; Coburn CM, 1998, DEVELOPMENT, V125, P249; DORMAN JB, 1995, GENETICS, V141, P1399; Duret L, 1998, GENOME RES, V8, P348, DOI 10.1101/gr.8.4.348; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRIEDMAN DB, 1988, GENETICS, V118, P75; Gems D, 1998, GENETICS, V150, P129; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; GOTTLIEB S, 1994, GENETICS, V137, P107; HEDGECOCK EM, 1995, GENETICS, V141, P989; HORVITZ HR, 1979, MOL GEN GENET, V175, P129, DOI 10.1007/BF00425528; HUNTER CP, 1992, NATURE, V355, P551, DOI 10.1038/355551a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; KLASS MR, 1983, MECH AGEING DEV, V22, P279, DOI 10.1016/0047-6374(83)90082-9; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARSEN PL, 1995, GENETICS, V139, P1567; Leroith D, 1996, DIABETES MELLITUS FU; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LIU ZC, 1989, GENE DEV, V3, P2039, DOI 10.1101/gad.3.12b.2039; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PERRY MD, 1993, GENE DEV, V7, P216, DOI 10.1101/gad.7.2.216; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THOMAS JH, 1993, GENETICS, V134, P1105; Tissenbaum HA, 1998, GENETICS, V148, P703; VOWELS JJ, 1992, GENETICS, V130, P105; WHITE JG, 1983, COLD SPRING HARB SYM, V48, P633, DOI 10.1101/SQB.1983.048.01.067; WOOLSON RF, 1987, STAT METHODS ANAL BI, P442	44	259	280	1	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					199	210		10.1016/S0092-8674(00)81751-1	http://dx.doi.org/10.1016/S0092-8674(00)81751-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790527	Bronze			2022-12-28	WOS:000076538300008
J	Arn, EA; Macdonald, PM				Arn, EA; Macdonald, PM			Motors driving mRNA localization: New insights from in vivo imaging	CELL			English	Review							MESSENGER-RNA LOCALIZATION; DROSOPHILA OOCYTES; PROTEIN; OLIGODENDROCYTES; TRANSLOCATION; MICROTUBULES; YEAST		Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Arn, EA (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.							AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Amon A, 1996, CELL, V84, P651, DOI 10.1016/S0092-8674(00)81041-7; BERTRAND E, 1998, IN PRESS MOL CELL, V2; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Glotzer JB, 1997, CURR BIOL, V7, P326, DOI 10.1016/S0960-9822(06)00156-4; KarlinMcginness M, 1996, DEV GENET, V19, P238, DOI 10.1002/(SICI)1520-6408(1996)19:3<238::AID-DVG7>3.0.CO;2-A; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; Theurkauf WE, 1998, DEVELOPMENT, V125, P3655; VENKATESAN S, 1992, J VIROL, V66, P7469, DOI 10.1128/JVI.66.12.7469-7480.1992; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WEBSTER PJ, 1994, DEVELOPMENT, V120, P2027	19	30	31	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					151	154		10.1016/S0092-8674(00)81745-6	http://dx.doi.org/10.1016/S0092-8674(00)81745-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790521	Bronze			2022-12-28	WOS:000076538300002
J	Bartalena, L; Marcocci, C; Tanda, ML; Manetti, L; Dell'Unto, E; Bartolomei, MP; Nardi, M; Martino, E; Pinchera, A				Bartalena, L; Marcocci, C; Tanda, ML; Manetti, L; Dell'Unto, E; Bartolomei, MP; Nardi, M; Martino, E; Pinchera, A			Cigarette smoking and treatment outcomes in Graves ophthalmopathy	ANNALS OF INTERNAL MEDICINE			English	Article							RADIOIODINE THERAPY; RECEPTOR ANTAGONIST; DISEASE; CORTICOSTEROIDS; HYPERTHYROIDISM; FIBROBLASTS	Background: It is unclear whether smoking affects the course of Graves ophthalmopathy and therapeutic outcomes. Objective: To observe smoking behavior in a randomized study of the effect of radioiodine therapy on ophthalmopathy and in a case series of patients with Craves ophthalmopathy receiving orbital radiation therapy and glucocorticoids. Design: Randomized, single-blind study of smoking and mild ophthalmopathy after radioiodine therapy (study 1) and a retrospective cohort study of the association between smoking and response of severe ophthalmopathy to treatment (study 2). Setting: University medical center. Patients: 300 patients with mild ophthalmopathy (study 1) and 150 patients with severe ophthalmopathy (study 2). Intervention: In study 1, patients received radioiodine alone or radioiodine and a 3-month course of oral prednisone (initial dosage, 0.4 to 0.5 mg/kg of body weight per day). In study 2, patients received high-dose oral prednisone for 6 months (initial dosage, 80 to 100 mg/d) and underwent orbital radiation therapy by linear accelerator (cumulative dose, 20 Gy per eye over 2 weeks). Measurements: Degree of ophthalmopathy was assessed by overall evaluation (inflammatory changes, proptosis, extraocular muscle dysfunction, corneal involvement, and optic neuropathy). Results: In study 1, ophthalmopathy progressed in 4 of 68 nonsmokers (5.9% [95% CI, 3% to 9%]) and 19 of 82 smokers (23.2% [CI, 13% to 33%]) who received radioiodine alone (P = 0.007). Ophthalmopathy was alleviated in 37 of 58 nonsmokers (63.8% [CI, 51% to 78%]) and 13 of 87 smokers (14.9% [CI, 10% to 26%]) who received radioiodine plus prednisone (P < 0.001). In study 2, 61 of 65 nonsmokers (93.8% [CI, 90% to 98%]) and 58 of 85 smokers (68.2% [CI, 57% to 78%]) responded to treatment (P < 0.001). Conclusions: Cigarette smoking increases the risk for progression of ophthalmopathy after radioiodine therapy and decreases the efficacy of orbital radiation therapy and glucocorticoid therapy.	Univ Pisa, Osped Cisanello, Dipartimento Endocrinol & Metab Ortopedia & Traum, I-56122 Pisa, Italy	University of Pisa	Bartalena, L (corresponding author), Univ Pisa, Osped Cisanello, Dipartimento Endocrinol & Metab Ortopedia & Traum, Via Paradisa 2, I-56122 Pisa, Italy.	l.bartalena@endoc.med.unipi.it	Tanda, Maria Laura/AAD-4071-2020; Manetti, Luca/K-9022-2016	Manetti, Luca/0000-0001-9911-5366; nardi, marco/0000-0003-3422-9498; tanda, maria laura/0000-0001-7551-1751				Bartalena L, 1996, J CLIN ENDOCR METAB, V81, P446, DOI 10.1210/jc.81.2.446; BARTALENA L, 1989, J ENDOCRINOL INVEST, V12, P733, DOI 10.1007/BF03350047; BARTALENA L, 1983, J CLIN ENDOCR METAB, V56, P1139, DOI 10.1210/jcem-56-6-1139; BARTALENA L, 1995, EUR J ENDOCRINOL, V133, P507, DOI 10.1530/eje.0.1330507; Bartalena L, 1997, BAILLIERE CLIN ENDOC, V11, P521, DOI 10.1016/S0950-351X(97)80738-0; Bartalena L, 1998, NEW ENGL J MED, V338, P73, DOI 10.1056/NEJM199801083380201; BARTALENA L, 1989, NEW ENGL J MED, V321, P1349, DOI 10.1056/NEJM198911163212001; GORMAN CA, 1995, J CLIN ENDOCR METAB, V80, P340, DOI 10.1210/jcem.80.2.7852485; HEUFELDER AE, 1995, EUR J ENDOCRINOL, V132, P532, DOI 10.1530/eje.0.1320532; Hofbauer LC, 1997, J CLIN ENDOCR METAB, V82, P2244, DOI 10.1210/jc.82.7.2244; KUNG AWC, 1994, J CLIN ENDOCR METAB, V79, P542, DOI 10.1210/jc.79.2.542; METCALFE RA, 1994, CLIN ENDOCRINOL, V40, P67, DOI 10.1111/j.1365-2265.1994.tb02445.x; MOURITS MP, 1989, BRIT J OPHTHALMOL, V73, P639, DOI 10.1136/bjo.73.8.639; PRUMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479, DOI 10.1001/jama.269.4.479; SHINE B, 1990, LANCET, V335, P1261, DOI 10.1016/0140-6736(90)91315-2; SRIDAMA V, 1989, AM J MED, V87, P70, DOI 10.1016/S0002-9343(89)80485-1; TALLSTEDT L, 1992, NEW ENGL J MED, V326, P1733, DOI 10.1056/NEJM199206253262603; Tan GH, 1996, J CLIN ENDOCR METAB, V81, P449, DOI 10.1210/jc.81.2.449; TELLEZ M, 1992, CLIN ENDOCRINOL, V36, P291, DOI 10.1111/j.1365-2265.1992.tb01445.x	19	171	182	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					632	635		10.7326/0003-4819-129-8-199810150-00010	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786811				2022-12-28	WOS:000076431800006
J	Lan, MS; Mason, A; Coutant, R; Chen, QY; Vargas, A; Rao, JS; Gomez, R; Chalew, S; Garry, R; Maclaren, NK				Lan, MS; Mason, A; Coutant, R; Chen, QY; Vargas, A; Rao, JS; Gomez, R; Chalew, S; Garry, R; Maclaren, NK			HERV-K10s and immune-mediated (type 1) diabetes	CELL			English	Letter							HTDV/HERV-K; MELLITUS; SUPERANTIGEN		Louisiana State Univ, Sch Med, Dept Pediat, Res Inst Children,Childrens Hosp, Harahan, LA 70123 USA; Louisiana State Univ, Sch Med, Dept Biometry & Genet, Res Inst Children,Childrens Hosp, Harahan, LA 70123 USA; Alton Ochsner Med Fdn & Ochsner Clin, Sect Gastroenterol & Hepatol, New Orleans, LA 70121 USA; Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University; Ochsner Health System; Tulane University	Maclaren, NK (corresponding author), Louisiana State Univ, Sch Med, Dept Pediat, Res Inst Children,Childrens Hosp, Harahan, LA 70123 USA.		Co, Re/Z-5330-2019; Lan, Michael/CAF-1839-2022; Mason, Andrew/D-2938-2013	Garry, Robert/0000-0002-5683-3250; Mason, Andrew/0000-0002-0470-9522	NICHD NIH HHS [R01 HD 19469-14] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; Boller K, 1997, J VIROL, V71, P4581, DOI 10.1128/JVI.71.6.4581-4588.1997; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; LOWER R, 1995, J VIROL, V69, P141; Maclaren NK, 1997, MOL MED TODAY, V3, P76, DOI 10.1016/S1357-4310(96)10056-3	7	32	35	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					14	16		10.1016/S0092-8674(00)81777-8	http://dx.doi.org/10.1016/S0092-8674(00)81777-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778243	Bronze			2022-12-28	WOS:000076242300005
J	Hawkey, CJ; Tulassay, Z; Szczepanski, L; van Rensburg, CJ; Filipowicz-Sosnowska, A; Lanas, A; Wason, CM; Peacock, RA; Gillon, KRW				Hawkey, CJ; Tulassay, Z; Szczepanski, L; van Rensburg, CJ; Filipowicz-Sosnowska, A; Lanas, A; Wason, CM; Peacock, RA; Gillon, KRW			Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PEPTIC-ULCER; GASTROINTESTINAL COMPLICATIONS; RHEUMATOID-ARTHRITIS; DUODENAL-ULCERS; GASTRIC-ULCER; PREVENTION; THERAPY; INFECTION; OMEPRAZOLE	Background The effect of Helicobacter pylori in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) is unclear. We investigated the effects of H pylori eradication in patients with current or previous peptic ulceration, dyspepsia, or both who continued to use NSAIDs. Methods 285 patients were randomly assigned omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg, twice daily (n=142, H pylori eradication treatment), or omeprazole with placebo antibiotics (n=143, controls) for 1 week. All patients received omeprazole 20 mg once daily for 3 weeks until endoscopy, and, if the ulcer was not healed, 40 mg once daily until repeat endoscopy at 8 weeks. Ulcer-free patients with mild dyspepsia continued NSAIDs but not antiulcer treatment. We investigated ulcers with endoscopy at 1, 3, and 6 months and with carbon-13-labelled urea breath test at 3 months. Findings The estimated probability of being ulcer-free at 6 months was 0.56 (95% CI 0.47-0.65) on eradication treatment and 0.53 (0.44-0.62) on on control treatment (p=0.80). Time to treatment failure did not differ between groups for ulcers or dyspepsia alone, per-protocol analysis, or final H pylori status. 66% (58-74) of the eradication group compared with 14% (8-20) of the control group had a final negative H pylori result (p<0.001). Fewer baseline gastric ulcers healed among eradication-treatment patients than among controls (72 vs 100% at 8 weeks, p=0.006). Interpretation H pylori eradication in long-term users of NSAIDs with past or current peptic ulcer or troublesome dyspepsia led to impaired healing of gastric ulcers and did not affect the rate of peptic ulcers or dyspepsia over 6 months. Interpretation H pylori eradication in long-term users of NSAIDs with past or current peptic ulcer or troublesome dyspepsia led to impaired healing of gastric ulcers and did not affect the rate of peptic ulcers or dyspepsia over 6 months.	Univ Nottingham Hosp, Div Gastroenterol, Nottingham NG7 2UH, England; Belgyogyaszati Klin, Budapest, Hungary; Sch Med, Dept Rheumatol, Lublin, Poland; Tygerberg Hosp, Dept Gastroenterol, Tygerberg, South Africa; Inst Rheumatol, Warsaw, Poland; Hosp Clin, Serv Digest, Zaragoza, Spain; Astra Clin Res Unit, Edinburgh, Midlothian, Scotland	University of Nottingham; Medical University of Lublin; Tygerberg Hospital; AstraZeneca	Hawkey, CJ (corresponding author), Univ Nottingham Hosp, Div Gastroenterol, Nottingham NG7 2UH, England.	cj.hawkey@nottingham.ac.uk						Aalykke C, 1997, GASTROENTEROLOGY, V112, pA51; BELL GD, 1993, Q J MED, V86, P375; CASELLI M, 1989, DIGESTION, V44, P101, DOI 10.1159/000199898; Chan FKL, 1998, GASTROENTEROLOGY, V114, pA87, DOI 10.1016/S0016-5085(98)80353-3; Chan FKL, 1997, LANCET, V350, P975, DOI 10.1016/S0140-6736(97)04523-6; Cullen DJE, 1997, GUT, V41, P459, DOI 10.1136/gut.41.4.459; Ekstrom P, 1996, SCAND J GASTROENTERO, V31, P753, DOI 10.3109/00365529609010347; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P493, DOI 10.1016/0016-5085(92)90095-G; GRAHAM DY, 1993, SCAND J GASTROENTERO, V28, P939, DOI 10.3109/00365529309098288; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; HOGBEN CAM, 1957, J PHARMACOL EXP THER, V120, P540; Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015; HUDSON N, 1993, GUT, V34, P748, DOI 10.1136/gut.34.6.748; Hudson N, 1997, GASTROENTEROLOGY, V112, P1817, DOI 10.1053/gast.1997.v112.pm9178671; JENSEN DM, 1994, NEW ENGL J MED, V330, P382, DOI 10.1056/NEJM199402103300602; JORDE R, 1986, LANCET, V1, P119; Kim Jong G., 1994, American Journal of Gastroenterology, V89, P203; LABENZ J, 1994, DIGESTION, V55, P19, DOI 10.1159/000201117; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; Lind T, 1996, Helicobacter, V1, P138, DOI 10.1111/j.1523-5378.1996.tb00027.x; LOGAN RPH, 1991, EUR J GASTROEN HEPAT, V3, P915; Malfertheiner P, 1997, GUT, V41, P8; Malfertheiner P, 1996, EUR J GASTROEN HEPAT, V8, P53, DOI 10.1097/00042737-199601000-00010; Megraud F, 1997, ALIMENT PHARM THERAP, V11, P43, DOI 10.1046/j.1365-2036.11.s1.11.x; Megraud F, 1997, GUT, V41, pS1; Porro GB, 1996, GUT, V39, P22, DOI 10.1136/gut.39.1.22; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Taha AS, 1996, NEW ENGL J MED, V334, P1435, DOI 10.1056/NEJM199605303342204; *WHO COLL CTR DRUG, 1991, GUID DEF DAIL DOS; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104	33	291	300	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 26	1998	352	9133					1016	1021		10.1016/S0140-6736(98)04206-8	http://dx.doi.org/10.1016/S0140-6736(98)04206-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759744				2022-12-28	WOS:000076121800010
J	Kazimirov, A; Zegenhagen, J; Cardona, M				Kazimirov, A; Zegenhagen, J; Cardona, M			Isotopic mass and lattice constant: X-ray standing wave measurements	SCIENCE			English	Article							DEPENDENCE; GERMANIUM; SEMICONDUCTORS; PARAMETER; DIAMOND; CRYSTAL	The molecular volume of crystals depends on their isotopic masses. This influence originates from the zero-point motion and the resulting small differences in lattice constants. This effect was measured with high precision by using an x-ray standing wave. The standing wave is generated during Bragg reflection and thus is in phase with the planes of the substrate crystal, which is covered with a homoepitaxial film that has a different isotopic composition than the substrate. The positions of the surface planes of the film with respect to the substrate planes are revealed by the photoelectrons excited by the maxima of the standing wave. For germanium-76 on natural germanium(lll), a difference in lattice constant of -1.1 x 10(-5) and -2.5 x 10(-5) at 300 and 54 kelvin, respectively, was found. The results are in good agreement with theoretical predictions.	Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	Max Planck Society	Zegenhagen, J (corresponding author), Max Planck Inst Festkorperforsch, Heisenbergstr 1, D-70569 Stuttgart, Germany.							BATTERMAN BW, 1962, PHYS REV, V127, P690, DOI 10.1103/PhysRev.127.690; BATTERMAN BW, 1964, PHYS REV A, V133, P759; BUSCHERT RC, 1988, PHYS REV B, V38, P5219, DOI 10.1103/PhysRevB.38.5219; CARDONA M, 1994, ADV SOLID STATE PHYS, V34, P35; Debernardi A, 1996, PHYS REV B, V54, P11305, DOI 10.1103/PhysRevB.54.11305; FUCHS HD, 1995, PHYS REV B, V51, P16817, DOI 10.1103/PhysRevB.51.16817; Garro N, 1996, PHYS REV B, V54, P4732, DOI 10.1103/PhysRevB.54.4732; HOLLOWAY H, 1991, PHYS REV B, V44, P7123, DOI 10.1103/PhysRevB.44.7123; Honstra J., 1978, J CRYST GROWTH, V44, P513; KOHN VG, 1981, PHYS STATUS SOLIDI A, V64, P359, DOI 10.1002/pssa.2210640139; KOVALCHUK MV, 1986, PHYS SOLID STATE, V28, P1918; KROLZIG A, 1983, NUCL INSTRUM METHODS, V208, P613, DOI 10.1016/0167-5087(83)91193-6; London H., 1958, Z PHYS CHEM, V16, P302; Noya JC, 1997, PHYS REV B, V56, P237, DOI 10.1103/PhysRevB.56.237; PARKS C, 1994, PHYS REV B, V49, P14244, DOI 10.1103/PhysRevB.49.14244; PAVONE P, 1994, SOLID STATE COMMUN, V90, P295, DOI 10.1016/0038-1098(94)90154-6; VONLAUE M, 1960, RONTGENSTRAHLINTEFER; ZEGENHAGEN J, 1993, SURF SCI REP, V18, P199, DOI 10.1016/0167-5729(93)90025-K; ZOLLNER S, 1992, PHYS REV B, V45, P3376, DOI 10.1103/PhysRevB.45.3376	19	60	60	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					930	932		10.1126/science.282.5390.930	http://dx.doi.org/10.1126/science.282.5390.930			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794760				2022-12-28	WOS:000076727300045
J	Rohrer, SP; Birzin, ET; Mosley, RT; Berk, SC; Hutchins, SM; Shen, DM; Xiong, YS; Hayes, EC; Parmar, RM; Foor, F; Mitra, SW; Degrado, SJ; Shu, M; Klopp, JM; Cai, SJ; Blake, A; Chan, WWS; Pasternak, A; Yang, LH; Patchett, AA; Smith, RG; Chapman, KT; Schaeffer, JM				Rohrer, SP; Birzin, ET; Mosley, RT; Berk, SC; Hutchins, SM; Shen, DM; Xiong, YS; Hayes, EC; Parmar, RM; Foor, F; Mitra, SW; Degrado, SJ; Shu, M; Klopp, JM; Cai, SJ; Blake, A; Chan, WWS; Pasternak, A; Yang, LH; Patchett, AA; Smith, RG; Chapman, KT; Schaeffer, JM			Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry	SCIENCE			English	Article							MOLECULAR-CLONING; TYROSINE PHOSPHATASE; GROWTH-HORMONE; RAT-BRAIN; EXPRESSION; INHIBITION; SECRETION; GLUCAGON; RELEASE; ANALOGS	Nonpeptide agonists of each of the five somatostatin receptors were identified in combinatorial Libraries constructed on the basis of molecular modeling of known peptide agonists. In vitro experiments using these selective compounds demonstrated the role of the somatostatin subtype-2 receptor in inhibition of glucagon release from mouse pancreatic alpha cells and the somatostatin subtype-5 receptor as a mediator of insulin secretion from pancreatic beta cells. Both receptors regulated growth hormone release from the rat anterior pituitary gland. The availability of high-affinity, subtype-selective agonists for each of the somatostatin receptors provides a direct approach to defining their physiological functions.	Merck Res Labs, Dept Cell Biochem & Physiol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Design & Divers, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Rohrer, SP (corresponding author), Merck Res Labs, Dept Cell Biochem & Physiol, POB 2000, Rahway, NJ 07065 USA.	susan_rohrer@merck.com						BLOOM SR, 1974, LANCET, V2, P1106; BLOOM SR, 1975, GUT, V16, P834; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BROWN M, 1977, SCIENCE, V196, P1467, DOI 10.1126/science.867045; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; Hunyady B, 1997, ENDOCRINOLOGY, V138, P2632; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; MANDARINO L, 1981, NATURE, V291, P76, DOI 10.1038/291076a0; MEYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267, DOI 10.1073/pnas.89.21.10267; Mezey E, 1998, ENDOCRINOLOGY, V139, P414, DOI 10.1210/en.139.1.414; MITRA SW, IN PRESS ENDOCRINOLO; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; ROSSOWSKI WJ, 1994, BIOCHEM BIOPH RES CO, V205, P341, DOI 10.1006/bbrc.1994.2670; VALE W, 1974, ENDOCRINOLOGY, V95, P968, DOI 10.1210/endo-95-4-968; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; VAYSSE N, 1981, ENDOCRINOLOGY, V108, P1843, DOI 10.1210/endo-108-5-1843; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; Yang LH, 1998, P NATL ACAD SCI USA, V95, P10836, DOI 10.1073/pnas.95.18.10836; Yang LH, 1998, J MED CHEM, V41, P2175, DOI 10.1021/jm980194h; YASUDA K, 1992, J BIOL CHEM, V267, P20422	32	416	441	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					737	740		10.1126/science.282.5389.737	http://dx.doi.org/10.1126/science.282.5389.737			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784130				2022-12-28	WOS:000076607500049
J	Simini, B				Simini, B			Odorous odds and ends ...	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1322	1322		10.1016/S0140-6736(05)70546-8	http://dx.doi.org/10.1016/S0140-6736(05)70546-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788494				2022-12-28	WOS:000076573800073
J	Lu, BW; Rothenberg, M; Jan, LY; Jan, YN				Lu, BW; Rothenberg, M; Jan, LY; Jan, YN			Partner of numb colocalizes with numb during mitosis and directs numb asymmetric localization in Drosophila neural and muscle progenitors	CELL			English	Article							CELL FATES; CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; PROSPERO GENE; DAUGHTER CELL; PROTEIN; DIVISION; SEGREGATION; EMBRYOS; NOTCH	During mitosis of multiple types of precursor cells in Drosophila, Numb is asymmetrically distributed between the two daughter cells and confers distinct daughter cell fates. Here we report the identification of a novel gene product, Partner of Numb (PON), based on its physical interaction with Numb. PON is asymmetrically localized during mitosis and colocalizes with Numb. Loss of pon function disrupts Numb localization in muscle progenitors and delays Numb crescent formation in neural precursors. Moreover, ectopically expressed PON responds to the apical-basal polarity of epithelial cells and is sufficient to localize Numb basally. We propose that PON is one component of a multimolecular machinery that localizes Numb by responding to polarity cues conserved in neural precursors and epithelial cells.	Univ Calif San Francisco, Dept Physiol, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Jan, YN (corresponding author), Univ Calif San Francisco, Dept Physiol, Howard Hughes Med Inst, Box 0444, San Francisco, CA 94143 USA.	ynjan@itsa.ucsf.edu		Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299; Lu, Bingwei/0000-0002-5807-7014				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; BURCHARD S, 1995, J CELL SCI, V108, P1443; Carmena A, 1998, GENE DEV, V12, P304, DOI 10.1101/gad.12.3.304; Chang F, 1996, CURR BIOL, V6, P651, DOI 10.1016/S0960-9822(09)00440-0; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; Dye CA, 1998, DEVELOPMENT, V125, P1845; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Gomez MR, 1997, DEVELOPMENT, V124, P4857; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; Knirr S, 1997, MECH DEVELOP, V67, P69, DOI 10.1016/S0925-4773(97)00109-3; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1997, P NATL ACAD SCI USA, V94, P13005, DOI 10.1073/pnas.94.24.13005; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; Skeath JB, 1998, DEVELOPMENT, V125, P1857; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P942; ZHOU MM, 1995, NATURE, V378, P84	46	157	160	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					225	235		10.1016/S0092-8674(00)81753-5	http://dx.doi.org/10.1016/S0092-8674(00)81753-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790529	Bronze			2022-12-28	WOS:000076538300010
J	Aubert, RE; Herman, WH; Waters, J; Moore, W; Sutton, D; Peterson, BL; Bailey, CM; Koplan, JP				Aubert, RE; Herman, WH; Waters, J; Moore, W; Sutton, D; Peterson, BL; Bailey, CM; Koplan, JP			Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus; blood glucose; health maintenance organizations; case management; nursing	COMPLICATIONS; MELLITUS; MODEL; NIDDM	Background: Control of hyperglycemia delays or prevents complications of diabetes, but many persons with diabetes do not achieve optimal control. Objective: To compare diabetes control in patients receiving nurse case management and patients receiving usual care. Design: Randomized, controlled trial. Setting: Primary care clinics in a group-model health maintenance organization (HMO). Patients: 17 patients with type 1 diabetes mellitus and 121 patients with type 2 diabetes mellitus. Intervention: The nurse case manager followed written management algorithms under the direction of a family physician and an endocrinologist, Changes in therapy were communicated to primary care physicians. All patients received ongoing ca re through their primary care physicians. Measurements: The primary outcome, hemoglobin A(1c) (HbA(1c)) value, was measured at baseline and at 12 months. Fasting blood glucose levels, medication type and dose, body weight, blood pressure, lipid levels, patient-perceived health status, episodes of severe hypoglycemia, and emergency department and hospital admissions were also assessed. Results: 72% of patients completed follow-up. Patients in the nurse case management group had mean decreases of 1.7 percentage points in HbA(1c) values and 43 mg/dL (2.38 mmol/L) in fasting glucose levels; patients in the usual care group had decreases of 0.6 percentage points in HbA(1c) values and 15 mg/dL (0.83 mmol/L) in fasting glucose levels (P < 0.01). Self-reported health status improved in the nurse case management group (P = 0.02). The nurse case management intervention was not associated with statistically significant changes in medication type or dose, body weight, blood pressure, or lipids or with adverse events. Conclusions: A nurse case manager with considerable management responsibility can, in association with primary care physicians and an endocrinologist, help improve glycemic control in diabetic patients in a group-model HMO.	Prudential Ctr Hlth Care Res, Atlanta, GA 30339 USA; Univ Michigan, Sch Med, Med Ctr, IM Div Endocrinol & Metab, Ann Arbor, MI 48109 USA; Jacksonville Hlth Care Grp, Prudential Hlth Ctr, Jacksonville, FL 32204 USA; NE florida Endocrine & Diabet PA, Jacksonville, FL 32204 USA; Duke Univ, Med Ctr, Canc Ctr Biostat, Durham, NC 27708 USA	University of Michigan System; University of Michigan; Duke University	Aubert, RE (corresponding author), Prudential Ctr Hlth Care Res, 2859 Paces Ferry Rd,Suite 820, Atlanta, GA 30339 USA.							American Diabetes Association, 1997, DIABETES CARE S1, V20, pS5; Blonde L, 1997, DIABETES, V46, P612; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; Harris MI, 1996, ANN INTERN MED, V124, P117, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00007; HENNESSY CH, 1994, PUBLIC HEALTH REP, V109, P665; LEGORRETA AP, 1996, AM J MANAG CARE, V2, P1024; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Peters A L, 1995, HMO Pract, V9, P8; SADUR C, 1997, DIABETES S1, V46, pA61; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Skyler JS, 1997, ANN INTERN MED, V127, P837, DOI 10.7326/0003-4819-127-9-199711010-00011; TUTTLEMAN M, 1993, DIABETES CARE, V16, P765, DOI 10.2337/diacare.16.5.765; 1995, MMWR, V44, P195; 1994, MMWR, V43, P375	17	414	421	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					605	+		10.7326/0003-4819-129-8-199810150-00004	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786807				2022-12-28	WOS:000076431800002
J	Alderson, P				Alderson, P			Theories in health care and research - The importance of theories in health care	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Inst Educ, Social Sci Res Unit, London WC1H 0NS, England	University of London; University College London; UCL Institute of Education	Alderson, P (corresponding author), Univ London, Inst Educ, Social Sci Res Unit, London WC1H 0NS, England.	p.alderson@ioe.ac.uk		Alderson, Priscilla/0000-0003-4002-4501				ALDERSON P, 1994, WOMENS VIEWS BREAST; ANAND KJS, 1987, LANCET, V1, P243; ARMSTRON D, 1983, POLITICAL ANATOMY BO; BENDELOW G, 1993, SOCIOL HEALTH ILL, V15, P273, DOI 10.1111/1467-9566.ep10490526; DESCARTES R, 1972, TREATISE MAN, P34; Hodgkin P, 1996, BRIT MED J, V313, P1568, DOI 10.1136/bmj.313.7072.1568; Leder Drew, 1990, ABSENT BODY; MOYNIHAN C, IN PRESS BMJ; Oliver Michael, 1990, POLITICS DISABLEMENT; Parsons T., 1951, SOCIAL SYSTEM; PFEFFER N, IN PRESS BMJ; Popper K., 1959, LOGIC SCI DISCOVERY; Royal College of Surgeons of England and The College of Anaesthetists, 1990, REP WORK PART PAIN S	13	66	68	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					1007	1010		10.1136/bmj.317.7164.1007	http://dx.doi.org/10.1136/bmj.317.7164.1007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765175	Green Published			2022-12-28	WOS:000076449300035
J	Farrell, PM				Farrell, PM			Early diagnosis of cystic fibrosis can improve children's growth	BRITISH MEDICAL JOURNAL			English	Letter									Univ Wisconsin, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farrell, PM (corresponding author), Univ Wisconsin, Sch Med, Madison, WI 53706 USA.							Baroni M A, 1997, Pediatr Nurs, V23, P143; Farrell PM, 1997, NEW ENGL J MED, V337, P963, DOI 10.1056/NEJM199710023371403; Farrell PM, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.5.e2; Mischler EH, 1998, PEDIATRICS, V102, P44, DOI 10.1542/peds.102.1.44; Wald NJ, 1998, BRIT MED J, V316, P404, DOI 10.1136/bmj.316.7129.404	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					1017	1017		10.1136/bmj.317.7164.1017	http://dx.doi.org/10.1136/bmj.317.7164.1017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765185	Green Published			2022-12-28	WOS:000076449300075
J	Taffinder, NJ; McManus, IC; Gul, Y; Russell, RCG; Darzi, A				Taffinder, NJ; McManus, IC; Gul, Y; Russell, RCG; Darzi, A			Effect of sleep deprivation on surgeons' dexterity on laparoscopy simulator	LANCET			English	Article							PERFORMANCE		St Marys Hosp, Imperial Coll Sch Med, Minimal Access Surg Unit, London W2 1NY, England	Imperial College London	Darzi, A (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Minimal Access Surg Unit, Praed St, London W2 1NY, England.	a.darzi@ic.ac.uk		McManus, Ian/0000-0003-3510-4814				Dawson D, 1997, NATURE, V388, P235, DOI 10.1038/40775; KING MG, 1983, BRIT J PSYCHOL, V74, P473, DOI 10.1111/j.2044-8295.1983.tb01880.x; Taffinder N, 1998, ST HEAL T, V50, P124; Wesnes KA, 1997, BRIT J SURG, V84, P493; 1989, LANCET, V21, P138	5	358	360	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1998	352	9135					1191	1191		10.1016/S0140-6736(98)00034-8	http://dx.doi.org/10.1016/S0140-6736(98)00034-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128PQ	9777838				2022-12-28	WOS:000076415400013
J	Wilmshurst, P				Wilmshurst, P			ABC of oxygen - Diving and oxygen	BRITISH MEDICAL JOURNAL			English	Review									Royal Shrewsbury Hosp, Shrewsbury, Salop, England		Wilmshurst, P (corresponding author), Royal Shrewsbury Hosp, Shrewsbury, Salop, England.							Bove AA, 1990, DIVING MED; 1993, SPORT DIVING BRIT SU	2	17	17	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					996	999		10.1136/bmj.317.7164.996	http://dx.doi.org/10.1136/bmj.317.7164.996			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765173	Green Published			2022-12-28	WOS:000076449300028
J	Pei, ZM; Ghassemian, M; Kwak, CM; McCourt, P; Schroeder, JI				Pei, ZM; Ghassemian, M; Kwak, CM; McCourt, P; Schroeder, JI			Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss	SCIENCE			English	Article							FARNESYL-PROTEIN TRANSFERASE; ACID SIGNAL-TRANSDUCTION; CULTURED TOBACCO CELLS; ABSCISIC-ACID; ARABIDOPSIS-THALIANA; PLASMA-MEMBRANE; ION CHANNELS; WILD-TYPE; ISOPRENYLATION; MUTANTS	Desiccation of plants during drought can be detrimental to agricultural production. The phytohormone abscisic acid (ABA) reduces water loss by triggering stomatal pore closure in leaves, a process requiring ion-channel modulation by cytoplasmic proteins. Deletion of the Arabidopsis farnesyltransferase gene ERA1 or application of farnesyltransferase inhibitors resulted in ABA hypersensitivity of guard cell anion-channel activation and of stomatal closing. ERA1 was expressed in guard cells, Double-mutant analyses of era1 with the ABA-insensitive mutants abi1 and abi2 showed that era1 suppresses the ABA-insensitive phenotypes. Moreover, era1 plants exhibited a reduction in transpirational water loss during drought treatment.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Toronto	Schroeder, JI (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.			Pei, Zhen-Ming/0000-0003-1473-696X; Schroeder, Julian/0000-0002-3283-5972				ARMSTRONG F, 1995, P NATL ACAD SCI USA, V92, P9520, DOI 10.1073/pnas.92.21.9520; ASSMANN SM, 1993, ANNU REV CELL BIOL, V9, P345, DOI 10.1146/annurev.cb.09.110193.002021; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEDRICH R, 1990, EMBO J, V9, P3889, DOI 10.1002/j.1460-2075.1990.tb07608.x; HETHERINGTON AM, 1991, NEW PHYTOL, V119, P9, DOI 10.1111/j.1469-8137.1991.tb01004.x; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; MacRobbie EAC, 1997, J EXP BOT, V48, P515, DOI 10.1093/jxb/48.Special_Issue.515; MCCOURT P, UNPUB; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; MOREHEAD TA, 1995, PLANT PHYSIOL, V109, P277, DOI 10.1104/pp.109.1.277; Parmryd I, 1995, EUR J BIOCHEM, V234, P723, DOI 10.1111/j.1432-1033.1995.723_a.x; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Pei ZM, 1998, P NATL ACAD SCI USA, V95, P6548, DOI 10.1073/pnas.95.11.6548; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; Qian DQ, 1996, PLANT CELL, V8, P2381, DOI 10.1105/tpc.8.12.2381; RANDALL SK, 1993, PLANT CELL, V5, P433, DOI 10.1105/tpc.5.4.433; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; Roelfsema MRG, 1995, PHYSIOL PLANTARUM, V95, P373, DOI 10.1111/j.1399-3054.1995.tb00851.x; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9535, DOI 10.1073/pnas.92.21.9535; Schmitt D, 1996, PLANT PHYSIOL, V112, P767, DOI 10.1104/pp.112.2.767; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SCHWARTZ A, 1995, PLANT PHYSIOL, V109, P651, DOI 10.1104/pp.109.2.651; VARTANIAN N, 1994, PLANT PHYSIOL, V104, P761, DOI 10.1104/pp.104.2.761; WARD JM, 1995, PLANT CELL, V7, P833, DOI 10.1105/tpc.7.7.833; Yalovsky S, 1997, MOL CELL BIOL, V17, P1986, DOI 10.1128/MCB.17.4.1986; YANG ZB, 1993, PLANT PHYSIOL, V101, P667, DOI 10.1104/pp.101.2.667; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.arplant.39.1.439; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhou DF, 1997, PLANT J, V12, P921, DOI 10.1046/j.1365-313X.1997.12040921.x; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557	43	300	334	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					287	290		10.1126/science.282.5387.287	http://dx.doi.org/10.1126/science.282.5387.287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765153				2022-12-28	WOS:000076370200046
J	Alexander, GC; Sehgal, AR				Alexander, GC; Sehgal, AR			Barriers to cadaveric renal transplantation among blacks, women, and the poor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							KIDNEY-TRANSPLANT; UNITED-STATES; ALLOCATION; IMPACT; ACCESS; RACE; CANDIDATES; DIALYSIS; SEX	Context.-Cadaveric renal transplantation rates differ greatly by race, sex, and income. Previous efforts to lessen these differences have focused on the transplant waiting list. However, the transplantation process involves a series of steps related to medical suitability, interest in transplantation, pretransplant workup, and movement up a waiting list to eventual transplantation. Objective.-To determine the relative importance of each step in explaining differences in cadaveric renal transplantation rates. Design.-Prospective cohort study. Setting and Patients.-A total of 7125 patients beginning long-term dialysis between January 1993 and December 1996 in Indiana, Kentucky, and Ohio. Main Outcome Measures.-Completion of 4 separate steps during each patient-year of follow-up: (A) being medically suitable and possibly interested in transplantation; (B) being definitely interested in transplantation; (C) completing the pretransplant workup; and (D) moving up a waiting list and receiving a transplant. Results.-Compared with whites, blacks were less likely to complete steps B (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.61-0.76), C (OR, 0.56; 95% CI, 0.48-0.65), and D (OR, 0.50; 95% CI, 0.40-0.62) after adjustment for age, sex, cause of renal failure, years receiving dialysis, and median income of patient ZIP code. Compared with men, women were less likely to complete each of the 4 steps, with ORs of 0.90, 0.89, 0.80, and 0.82, respectively. Poor individuals were less likely than wealthy individuals to complete steps A, B, and C, with ORs of 0.67, 0.78, and 0.77, respectively. Conclusions.-Barriers at several steps are responsible for sociodemographic differences in access to cadaveric renal transplantation. Efforts to allocate kidneys equitably must address each step of the transplant process.	Metrohlth Med Ctr, Div Nephrol, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Biomed Eth, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA	MetroHealth System; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Sehgal, AR (corresponding author), Metrohlth Med Ctr, Div Nephrol, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051472] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51472] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTON PL, 1994, TRANSPLANT P, V26, P3685; Bloembergen WE, 1997, AM J KIDNEY DIS, V30, P733, DOI 10.1016/S0272-6386(97)90076-7; BRYK A, 1996, HIERARCHICAL LINEAR; Callender CO, 1996, TRANSPLANT P, V28, P394; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; Eggers P W, 1995, Health Care Financ Rev, V17, P89; EVANS RW, 1988, NEW ENGL J MED, V318, P223; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; Holley JL, 1996, KIDNEY INT, V49, P494, DOI 10.1038/ki.1996.70; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; Koch T, 1996, THEOR MED, V17, P75, DOI 10.1007/BF00489742; Lowe M, 1995, J MED ETHICS, V21, P356, DOI 10.1136/jme.21.6.356; Ozminkowski RJ, 1997, AM J KIDNEY DIS, V30, P749, DOI 10.1016/S0272-6386(97)90078-0; SANFILIPPO FP, 1992, JAMA-J AM MED ASSOC, V267, P247, DOI 10.1001/jama.267.2.247; Sehgal AR, 1997, AM J KIDNEY DIS, V29, P410, DOI 10.1016/S0272-6386(97)90203-1; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; *US REN DAT SYST, 1997, US REN DAT SYST 1997; Zachary AA, 1997, TRANSPLANTATION, V63, P669, DOI 10.1097/00007890-199703150-00010	20	388	392	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1148	1152		10.1001/jama.280.13.1148	http://dx.doi.org/10.1001/jama.280.13.1148			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777814	Bronze			2022-12-28	WOS:000076210800028
J	Gunn, N; White, C; Srinivasan, R				Gunn, N; White, C; Srinivasan, R			Primary care as harm reduction for injection drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY; NEEDLE-EXCHANGE; INFECTIONS; PREVALENCE; PREVENTION; BEHAVIOR; AIDS; SKIN		Univ Calif Davis, Sch Med, Davis, CA 95616 USA	University of California System; University of California Davis	Gunn, N (corresponding author), Univ Calif Davis, Sch Med, Davis, CA 95616 USA.							ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; ASTEMBORSKI J, 1994, AM J PUBLIC HEALTH, V84, P382, DOI 10.2105/AJPH.84.3.382; BOOTH R, 1991, AM J DRUG ALCOHOL AB, V17, P337, DOI 10.3109/00952999109027557; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P1641, DOI 10.1001/jama.271.21.1641; GABRIELLI C, 1994, J INFECTION, V29, P17, DOI 10.1016/S0163-4453(94)94952-2; Garfein RS, 1996, AM J PUBLIC HEALTH, V86, P655, DOI 10.2105/AJPH.86.5.655; HENNINGFIELD JE, 1995, NEW ENGL J MED, V333, P1196, DOI 10.1056/NEJM199511023331807; Hurley SF, 1997, LANCET, V349, P1797, DOI 10.1016/S0140-6736(96)11380-5; KIRBY D, 1991, FAM PLANN PERSPECT, V23, P6, DOI 10.2307/2135395; LAZARE A, 1987, ARCH INTERN MED, V147, P1653, DOI 10.1001/archinte.147.9.1653; LUCIDARME D, 1994, GASTROEN CLIN BIOL, V18, P964; Manoff SB, 1996, EPIDEMIOLOGY, V7, P566, DOI 10.1097/00001648-199611000-00001; Marlatt GA, 1996, ADDICT BEHAV, V21, P779, DOI 10.1016/0306-4603(96)00042-1; Morrison A, 1997, ADDICTION, V92, P1349; NEWMEYER J, 1995, MIDCITY NUMBERS MONT, V8, P4; THOMAS DL, 1995, MEDICINE, V74, P212, DOI 10.1097/00005792-199507000-00005; TRILLA A, 1995, J CHEMOTHERAPY, V7, P37; VLAHOV D, 1992, PUBLIC HEALTH REP, V107, P595; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115	20	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1191	+		10.1001/jama.280.13.1191	http://dx.doi.org/10.1001/jama.280.13.1191			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124YR	9777822				2022-12-28	WOS:000076210800036
J	Tanabe, Y; William, C; Jessell, TM				Tanabe, Y; William, C; Jessell, TM			Specification of motor neuron identity by the MNR2 homeodomain protein	CELL			English	Article							DORSAL SPINAL-CORD; LIM HOMEOBOX GENES; SONIC HEDGEHOG; FLOOR PLATE; TRANSCRIPTION FACTOR; CELL PATTERN; FROG EMBRYOS; EXPRESSION; INDUCTION; TUBE	Sonic hedgehog signaling controls the differentiation of motor neurons in the ventral neural tube, but the intervening steps are poorly understood. A differential screen of a cDNA library derived from a single Shh-induced motor neuron has identified a novel homeobox gene, MNR2, expressed by motor neuron progenitors and transiently by postmitotic motor neurons. The ectopic expression of MNR2 in neural cells initiates a program of somatic motor neuron differentiation characterized by the expression of homeodomain proteins, by neurotransmitter phenotype, and by axonal trajectory. Our results suggest that the Shh-mediated induction of a single transcription factor, MNR2, is sufficient to direct somatic motor neuron differentiation.	Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Jessell, TM (corresponding author), Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Anderson D, 1997, MOL CELLULAR APPROAC, P26; Bang AG, 1996, CURR OPIN NEUROBIOL, V6, P25, DOI 10.1016/S0959-4388(96)80005-5; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BEGLEY CG, 1992, P NATL ACAD SCI USA, V89, P38, DOI 10.1073/pnas.89.1.38; Burke AC, 1996, DEV BIOL, V178, P192, DOI 10.1006/dbio.1996.0210; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Ding Q, 1998, DEVELOPMENT, V125, P2533; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Fedtsova N, 1997, DEV BIOL, V190, P18, DOI 10.1006/dbio.1997.8691; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEBER SM, 1995, J NEUROSCI, V15, P1236; Lee J, 1997, DEVELOPMENT, V124, P2537; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; Lo LC, 1998, DEVELOPMENT, V125, P609; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matise MP, 1998, DEVELOPMENT, V125, P2759; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Osumi N, 1997, DEVELOPMENT, V124, P2961; Pabst O, 1998, MECH DEVELOP, V73, P85, DOI 10.1016/S0925-4773(98)00035-5; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Pfaff S, 1998, CURR OPIN NEUROBIOL, V8, P27, DOI 10.1016/S0959-4388(98)80005-6; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roztocil T, 1997, DEVELOPMENT, V124, P3263; Saha MS, 1997, DEV BIOL, V187, P209, DOI 10.1006/dbio.1997.8625; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VarelaEchavarria A, 1996, MOL CELL NEUROSCI, V8, P242, DOI 10.1006/mcne.1996.0061; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	51	287	293	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					67	80		10.1016/S0092-8674(00)81783-3	http://dx.doi.org/10.1016/S0092-8674(00)81783-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778248	hybrid			2022-12-28	WOS:000076242300011
J	Solomin, L; Johansson, CB; Zetterstrom, RH; Bissonnette, RP; Heyman, RA; Olson, L; Lendahl, U; Frisen, J; Perlmann, T				Solomin, L; Johansson, CB; Zetterstrom, RH; Bissonnette, RP; Heyman, RA; Olson, L; Lendahl, U; Frisen, J; Perlmann, T			Retinoid-X receptor signalling in the developing spinal cord	NATURE			English	Article							ACID RECEPTOR; RESPONSE ELEMENT; NUCLEAR RECEPTORS; MOUSE DEVELOPMENT; FAS LIGAND; NGFI-B; EXPRESSION; GENE; RXR; DEHYDROGENASE	Retinoids regulate gene expression through the action of retinoic acid receptors (RARs) and retinoid-X receptors (RXRs), which both belong to the family of nuclear hormone receptors(1,2). Retinoids are of fundamental importance during development(2), but it has been difficult to assess the distribution of ligand-activated receptors in vivo. This is particularly the case for RXR, which is a critical unliganded auxiliary protein for several nuclear receptors, including RAR(1), but its ligand-activated role in vivo remains uncertain, Here we describe an assay in transgenic mice, based on the expression of an effector fusion protein linking the ligand-binding domain of either RXR or RAR to the yeast Gal4 DNA-binding domain, and the in situ detection of ligand-activated effector proteins by using an inducible transgenic lacZ reporter gene. We detect receptor activation in the spinal cord in a pattern that indicates that the receptor functions in the maturation of limb-innervating motor neurons. Our results reveal a specific activation pattern of Gal4-RXR which indicates that RXR is a critical bona fide receptor in the developing spinal cord.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska Institutet; Ligand Pharmaceuticals	Perlmann, T (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, POB 240, S-17177 Stockholm, Sweden.	thomas.perlmann@licr.ki.se		Lendahl, Urban/0000-0001-9543-8141; Zetterstrom, Rolf/0000-0002-3016-0019				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; Botling J, 1997, J BIOL CHEM, V272, P9443; COLBERT MC, 1993, P NATL ACAD SCI USA, V90, P6572, DOI 10.1073/pnas.90.14.6572; Dupe V, 1997, DEVELOPMENT, V124, P399; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Lu HC, 1997, DEVELOPMENT, V124, P195; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MASCREZ B, IN PRESS DEVELOPMENT; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; NILSSON E, 1993, MOL REPROD DEV, V34, P149, DOI 10.1002/mrd.1080340206; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; REYNOLDS K, 1991, MECH DEVELOP, V36, P15, DOI 10.1016/0925-4773(91)90068-H; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WAGNER M, 1992, DEVELOPMENT, V116, P55; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	31	110	117	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					398	402		10.1038/26515	http://dx.doi.org/10.1038/26515			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759732				2022-12-28	WOS:000076083800058
J	Usrey, WM; Reppas, JB; Reid, RC				Usrey, WM; Reppas, JB; Reid, RC			Paired-spike interactions and synaptic efficacy of retinal inputs to the thalamus	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; NEOCORTICAL PYRAMIDAL NEURONS; PRIMARY VISUAL-CORTEX; GANGLION-CELLS; CAT; PLASTICITY	In many neural systems studied in vitro, the timing of afferent impulses affects the strength of postsynaptic potentials(1,2). The influence of afferent timing on postsynaptic firing in vivo has received less attention. Here we study the importance of afferent spike timing in vivo by recording simultaneously from ganglion cells in the retina and their targets in the lateral geniculate nucleus of the thalamus, When two spikes from a single ganglion-cell axon arrive within 30 milliseconds of each other, the second spike is much more likely than the first to produce a geniculate spike, an effect we call paired-spike enhancement. Furthermore, simultaneous recordings from a ganglion cell and two thalamic targets indicate that paired-spike enhancement increases the frequency of synchronous thalamic activity. We propose that information encoded in the high firing rate of an individual retinal ganglion cell becomes distributed among several geniculate neurons that fire synchronously. Because synchronous geniculate action potentials are highly effective in driving cortical neurons(3), it is likely that information encoded by this strategy is transmitted to the next level of processing.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Reid, RC (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	clay_reid@hms.harvard.edu						Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; Alonso JM, 1996, NATURE, V383, P815, DOI 10.1038/383815a0; Atluri PP, 1996, J NEUROSCI, V16, P5661; BLOOMFIELD SA, 1987, J PHYSIOL-LONDON, V383, P653; CLELAND BG, 1971, J PHYSIOL-LONDON, V217, P473, DOI 10.1113/jphysiol.1971.sp009581; CLELAND BG, 1971, NATURE-NEW BIOL, V231, P191, DOI 10.1038/newbio231191a0; CLELAND BG, 1986, VISUAL NEUROSCI, P111; DAN Y, IN PRESS NATURE NEUR; HAMOS JE, 1987, J COMP NEUROL, V259, P165, DOI 10.1002/cne.902590202; HUBEL DH, 1961, J PHYSIOL-LONDON, V155, P385, DOI 10.1113/jphysiol.1961.sp006635; KAPLAN E, 1987, J PHYSIOL-LONDON, V391, P267, DOI 10.1113/jphysiol.1987.sp016737; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KONIG P, 1996, TRENDS NEUROSCI, V22, P494; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MEISTER M, 1995, SCIENCE, V270, P1207, DOI 10.1126/science.270.5239.1207; MILLER KD, 1994, J NEUROSCI, V14, P409; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; Reid RC, 1997, VISUAL NEUROSCI, V14, P1015, DOI 10.1017/S0952523800011743; Sutter E.E., 1992, NONLINEAR VISION, P171, DOI [10.1201/9781351075060-6, DOI 10.1201/9781351075060-6]; Sutter E.E., 1987, ADV METHODS PHYSIOLO, V1, P303; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; USREY WM, IN PRESS ANN REV PHY; Varela JA, 1997, J NEUROSCI, V17, P7926; Weliky M, 1997, NATURE, V386, P680, DOI 10.1038/386680a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	29	169	171	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					384	387		10.1038/26487	http://dx.doi.org/10.1038/26487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759728				2022-12-28	WOS:000076083800054
J	Barber, JA; Thompson, SG				Barber, JA; Thompson, SG			Analysis and interpretation of cost data in randomised controlled trials: review of published studies	BRITISH MEDICAL JOURNAL			English	Review							ECONOMIC-EVALUATION; CLINICAL-TRIALS; GUIDELINES; PREGNANCY; JOURNALS; AUTHORS; LIFE; CARE	Objective To review critically the statistical methods used for health economic evaluations in randomised controlled trials where an estimate of cost is available for each patient in the study. Design Survey of published randomised trials including an economic evaluation with cost values suitable for statistical analysis; 45 such trials published in 1995 were identified from Medline. Main outcome measures The use of statistical methods for cost data was assessed in terms of the descriptive statistics reported, use of statistical inference, and whether the reported conclusions were justified. Results Although all 45 trials reviewed apparently had cost data for each patient, only 9 (20%) reported adequate measures of variability for these data and only 25 (56%) Save results of statistical tests or a measure of precision for the comparison of costs between the randomised groups. Only 16 (36%) of the articles gave conclusions which were justified on the basis of results presented in the paper No paper reported sample size calculations for costs. Conclusions The analysis and interpretation of cost data from published trials reveal a lack of statistical awareness. Strong and potentially misleading conclusions about the relative costs of alternative therapies have often been reported in the absence of supporting statistical evidence. Improvements in the analysis and reporting of health economic assessments are urgently required. Health economic guidelines need to be revised to incorporate more detailed statistical advice.	Imperial Coll Sch Med, Dept Med Stat & Evaluat, London W12 0NN, England	Imperial College London	Barber, JA (corresponding author), Imperial Coll Sch Med, Dept Med Stat & Evaluat, London W12 0NN, England.			Barber, Julie/0000-0001-5762-762X				ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; Altman D.G., 1991, PRACTICAL STAT MED R; ALTMAN DG, 1994, JAMA-J AM MED ASSOC, V272, P129, DOI 10.1001/jama.272.2.129; ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; ANCONABERK VA, 1981, NEW ENGL J MED, V304, P393; BRIGGS A, 1995, HEALTH ECON, V4, P355, DOI 10.1002/hec.4730040502; Buxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W; Chaudhary MA, 1996, STAT MED, V15, P1447; COTTRELL JJ, 1995, CHEST, V107, P358, DOI 10.1378/chest.107.2.358; Coyle D, 1996, PHARMACOECONOMICS, V9, P506, DOI 10.2165/00019053-199609060-00005; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; DRUMMOND MF, 1984, CONTROL CLIN TRIALS, V5, P115, DOI 10.1016/0197-2456(84)90118-1; Efron B., 1994, MONOGRAPHS STAT APPL; ELIXHAUSER A, 1993, MED CARE S, V31, pS1; Evers SMAA, 1997, HEALTH ECON, V6, P161, DOI 10.1002/(SICI)1099-1050(199703)6:2<161::AID-HEC258>3.0.CO;2-I; Fayers PM, 1997, LANCET, V350, P1025, DOI 10.1016/S0140-6736(97)03053-5; Ganiats T G, 1991, Fam Med, V23, P457; GERARD K, 1992, HEALTH POLICY, V21, P249, DOI 10.1016/0168-8510(92)90022-4; GOEREE R, 1995, CAN MED ASSOC J, V152, P1445; GORE SM, 1992, LANCET, V340, P100, DOI 10.1016/0140-6736(92)90409-V; HILL AB, 1953, NEW ENGL J MED, V248, P995, DOI 10.1056/NEJM195306112482401; HOOTON TM, 1995, JAMA-J AM MED ASSOC, V273, P41; JEFFERSON T, 1994, HEALTH ECON, V3, P25, DOI 10.1002/hec.4730030105; Jefferson T, 1998, JAMA-J AM MED ASSOC, V280, P275, DOI 10.1001/jama.280.3.275; Lambert CM, 1998, BRIT MED J, V316, P965, DOI 10.1136/bmj.316.7136.965; MASON J, 1995, HEALTH ECON, V4, P85, DOI 10.1002/hec.4730040202; OBrien B, 1996, MED CARE, V34, pDS99; ROWLEY MJ, 1995, MED J AUSTRALIA, V163, P289, DOI 10.5694/j.1326-5377.1995.tb124592.x; THOMPSON SG, 1998, JLANCET, V350, P1781; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; Zhou XH, 1997, ANN INTERN MED, V127, P752, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00063; 1996, BMJ, V312, P41	34	191	194	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1195	1200		10.1136/bmj.317.7167.1195	http://dx.doi.org/10.1136/bmj.317.7167.1195			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138GF	9794854	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000076963000021
J	Loudon, I				Loudon, I			Words - Nosocomial	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1242	1242		10.1136/bmj.317.7167.1242	http://dx.doi.org/10.1136/bmj.317.7167.1242			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794872	Green Published			2022-12-28	WOS:000076963000037
J	Dumont, DJ; Jussila, L; Taipale, J; Lymboussaki, A; Mustonen, T; Pajusola, K; Breitman, M; Alitalo, K				Dumont, DJ; Jussila, L; Taipale, J; Lymboussaki, A; Mustonen, T; Pajusola, K; Breitman, M; Alitalo, K			Cardiovascular failure in mouse embryos deficient in VEGF receptor-3	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; BLOOD-VESSEL DEVELOPMENT; TYROSINE KINASE; MICE; FLT-1; VASCULOGENESIS; APOPTOSIS; LACKING; CELLS	Vascular endothelial growth factor (VEGF) is a key regulator of blood vessel development in embryos and angiogenesis in adult tissues. Unlike VEGF, the related VEGF-C stimulates the growth of Lymphatic vessels through its specific Lymphatic endothelial receptor VEGFR-3. Here it is shown that targeted inactivation of the gene encoding VEGFR-3 resulted in defective blood vessel development in early mouse embryos. Vasculogenesis and angiogenesis occurred, but Large vessels became abnormally organized with defective lumens, Leading to fluid accumulation in the pericardial cavity and cardiovascular failure at embryonic day 9.5. Thus, VEGFR-3 has an essential role in the development of the embryonic cardiovascular system before the emergence of the Lymphatic vessels.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Amgen Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Helsinki; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, PL 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Mustonen, Tuija/0000-0002-2429-5064				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Eichmann A, 1998, DEVELOPMENT, V125, P743; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; JUSSILA L, UNPUB; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; LYMBOUSSAKI A, UNPUB; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PARK JE, 1994, J BIOL CHEM, V269, P25646; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; Sabin FR, 1912, ANAT REC, V6, P335; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SURI C, 1997, CELL, V87, P1161; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293	30	629	683	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					946	949		10.1126/science.282.5390.946	http://dx.doi.org/10.1126/science.282.5390.946			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794766				2022-12-28	WOS:000076727300051
J	Annas, GJ				Annas, GJ			Protecting patients from discrimination - The Americans with Disabilities Act and HIV Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH		Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1994, NEW ENGL J MED, V331, P1027, DOI 10.1056/NEJM199410133311521; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; FEIN E, 1998, NY TIMES        0705, pE6; Gin BR, 1997, COLUMBIA LAW REV, V97, P1406, DOI 10.2307/1123439; GLANTZ LH, 1992, MILBANK Q, V70, P43, DOI 10.2307/3350085; HOLMES S, 1991, NY TIMES        1006, P24; TOMKOWICZ SM, 1996, SYRACUSE L RERV, V46, P1051	7	22	22	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1255	1259		10.1056/NEJM199810223391723	http://dx.doi.org/10.1056/NEJM199810223391723			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	130QW	9780348	Green Published			2022-12-28	WOS:000076532400030
J	Bernardi, E; Prandoni, P; Lensing, AWA; Agnelli, G; Guazzaloca, G; Scannapieco, G; Piovella, F; Verlato, F; Tomasi, C; Moia, M; Scarano, L; Girolami, A				Bernardi, E; Prandoni, P; Lensing, AWA; Agnelli, G; Guazzaloca, G; Scannapieco, G; Piovella, F; Verlato, F; Tomasi, C; Moia, M; Scarano, L; Girolami, A		Multictr Italian D-dimer Ultrasound Study In	D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							SYMPTOMATIC OUTPATIENTS; VENOUS THROMBOEMBOLISM; DIAGNOSIS; ACCURACY	Objective To investigate the efficacy of using a rapid plasma D-dimer test as an adjunct to compression ultrasound for diagnosing clinically suspected deep vein thrombosis. Design D-dimer concentrations were determined in all patients with a normal ultrasonogram at presentation. Repeal ultrasonography was performed 1 week later only in patients with abnormal D-dimer test results. Main outcome measure Patients with normal ultrasonograms were not treated with anticoagulants and were followed for 3 months for thromboembolic complications. Setting University research and affiliated centres, Subjects 946 patients with clinically suspected deep vein thrombosis. Results Ultrasonograms were abnormal at presentation in 260 (27.5%) patients. Of the remaining 686 patients tested for D-dimer, 88 (12.8%) had abnormal concentrations. During follow up venous thromboembolic complications occurred in one of the 598 patients who were not treated with anticoagulants and who had an initial normal ultrasonogram and D-dimer concentration, whereas thromboembolic complications occurred in two of the 83 untreated patients who had abnormal D-dimer concentrations but a normal repeat ultrasonogram. The cumulative incidence of venous thromboembolic complications during follow up was 0.4% (95% confidence interval 0% to 0.9%). The rapid plasma D-dimer test used as an adjunct to compression ultrasonography resulted in a reduction in the mean number of repeat ultrasound examinations and additional hospital visits from 0.7 to 0.1 per patient Conclusions Testing for D-dimer as an adjunct to a normal baseline ultrasound examination decreased the number of subsequent ultrasound examinations considerably without any increased risk of venous thromboembolic complications in patients not receiving anticoagulants. The use of ultrasound and testing for D-dimer enabled treatment decisions to be made at the time of presentation in most patients.	Univ Amsterdam, Acad Med Ctr, Ctr Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Padua, Ist Semeiot Med, I-35128 Padua, Italy; Univ Padua, Azienda Osped Padova, Serv Angiol, I-35100 Padua, Italy; Monteluce Policlin, Azienda Osped Perugia, Ist Med Interna & Vasc, I-06122 Perugia, Italy; Azienda Osped S Orsola Malpighi, Div Angiol, I-40138 Bologna, Italy; Osped Civile Venezia, Div Med 1, I-30100 Venice, Italy; Pavia Policlin, Policlin San Matteo, I-27100 Pavia, Italy; Osped Bolzano, I-39100 Bolzano, Italy; Osped Maggiore, I-20122 Milan, Italy; Univ Milan, I-20122 Milan, Italy	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Perugia; Azienda Ospedaliera di Perugia; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Fondazione San Matteo; University of Milan	Lensing, AWA (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Vasc Med, H-2, NL-1105 AZ Amsterdam, Netherlands.		Piovella, Franco/AAM-8305-2020; Moia, Marco/J-2888-2015	Moia, Marco/0000-0002-7041-7755				Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; LE AYY, 1997, CURR OPINION PUBN ME, V3, P275; Legnani C, 1997, BLOOD COAGUL FIBRIN, V8, P296, DOI 10.1097/00001721-199707000-00006; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1993, HEMOSTASIS THROMBOSI, P1297; Scarano L, 1997, THROMB RES, V86, P93, DOI 10.1016/S0049-3848(97)00053-4; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3	15	182	187	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1037	1040						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774286				2022-12-28	WOS:000076577200021
J	Brown, PD; Lerner, SA				Brown, PD; Lerner, SA			Community-acquired pneumonia	LANCET			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; PENICILLIN-RESISTANT; MULTIVARIATE-ANALYSIS; PNEUMOCOCCAL VACCINE; PROGNOSTIC FACTORS; ADULT PATIENTS; UNITED-STATES; MULTICENTER; ETIOLOGY	This seminar reviews the aetiology, clinical presentation, approach to diagnosis, and management of immunocompetent adults with community-acquired pneumonia (CAP). Pneumonia is a common clinical entity, particularly among the elderly. A thorough understanding of the epidemiology and microbiology of CAP is essential for appropriate diagnosis and management. Although the microbiology of CAP has remained relatively stable over the last decade, there Is new information on the Incidence of atypical pathogens, particularly in patients not admitted to hospital, and new information on the Incidence of pathogens In cases of severe CAP and in CAP in the elderly. Recent studies have provided new data on risk factors for mortality in CAP, which can assist the clinician in decisions about the need for hospital admission. The emergence of antimicrobial resistance in Streptococcus pneumoniae, the organism responsible for most cases of CAP, has greatly affected the approach to therapy, especially in those patients who are treated empirically. Guidelines for the therapy of CAP have been published by the American Thoracic Society, the British Thoracic Society, and, most recently, the Infectious Diseases Society of America. These guidelines differ in their emphasis on empirical versus pathogenic-specific management.	Harper Grace Hosp, Div Infect Dis, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Internal Med, Div Infect Dis, Detroit, MI 48201 USA	Wayne State University	Lerner, SA (corresponding author), Harper Grace Hosp, Div Infect Dis, 3990 John R, Detroit, MI 48201 USA.							Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; [Anonymous], MMWR; Aubier M, 1996, J ANTIMICROB CHEMOTH, V37, P73, DOI 10.1093/jac/37.suppl_A.73; AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013; BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; BARTLETT JG, 1997, MANAGEMENT RESP TRAC, P49; BOHTE R, 1995, THORAX, V50, P543, DOI 10.1136/thx.50.5.543; Brueggemann AB, 1997, ANTIMICROB AGENTS CH, V41, P1594, DOI 10.1128/AAC.41.7.1594; Bryant RE, 1996, CLIN INFECT DIS, V22, P747, DOI 10.1093/clinids/22.5.747; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P556; *CDCP, 1997, MMWR-MORBID MORTAL W, V40, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P919; CHALASANI NP, 1995, CHEST, V108, P932, DOI 10.1378/chest.108.4.932; ClavoSanchez AJ, 1997, CLIN INFECT DIS, V24, P1052, DOI 10.1086/513628; COFFEY TJ, 1995, ANTIMICROB AGENTS CH, V39, P1306, DOI 10.1128/AAC.39.6.1306; CreweBrown HH, 1997, CLIN INFECT DIS, V25, P1165, DOI 10.1086/516104; Donowitz GR, 1997, CLIN THER, V19, P936, DOI 10.1016/S0149-2918(97)80047-1; EDELSTEIN PH, 1993, CLIN INFECT DIS, V16, P741, DOI 10.1093/clind/16.6.741; Ely EW, 1997, INFECT MED, V14, P643; Ernst ME, 1997, AM J HEALTH-SYST PH, V54, P2569, DOI 10.1093/ajhp/54.22.2569; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; File TM, 1997, ANTIMICROB AGENTS CH, V41, P1965, DOI 10.1128/AAC.41.9.1965; FINCH R, 1993, BRIT J HOSP MED, V49, P346; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; FINE MJ, 1994, ARCH INTERN MED, V154, P2666, DOI 10.1001/archinte.1994.00420230051007; FINE MJ, 1991, J GEN INTERN MED, V6, P189, DOI 10.1007/BF02598958; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920, DOI 10.1001/archpedi.1992.02160200042023; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GAYDOS CA, 1994, CLIN INFECT DIS, V19, P157, DOI 10.1093/clinids/19.1.157; GLECKMAN R, 1988, J CLIN MICROBIOL, V26, P846, DOI 10.1128/JCM.26.5.846-849.1988; Goldstein FW, 1996, J ANTIMICROB CHEMOTH, V38, P71, DOI 10.1093/jac/38.suppl_A.71; GOODING BB, 1993, ANTIMICROB AGENTS CH, V37, P349, DOI 10.1128/AAC.37.2.349; Guest JF, 1997, EUR RESPIR J, V10, P1530, DOI 10.1183/09031936.97.10071530; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; Koivula I, 1997, AM J MED, V103, P281, DOI 10.1016/S0002-9343(97)00149-6; Krauss J, 1996, MICROB DRUG RESIST, V2, P183, DOI 10.1089/mdr.1996.2.183; Krauss J, 1997, ANTIMICROB AGENTS CH, V41, P936, DOI 10.1128/AAC.41.5.936; LEVY M, 1988, CHEST, V93, P43, DOI 10.1378/chest.93.1.43; Lieberman D, 1996, THORAX, V51, P179, DOI 10.1136/thx.51.2.179; Lieberman D, 1996, EUR RESPIR J, V9, P2630, DOI 10.1183/09031936.96.09122630; LIM I, 1989, MED J AUSTRALIA, V151, P87, DOI 10.5694/j.1326-5377.1989.tb101168.x; LINARES J, 1992, J ANTIMICROB CHEMOTH, V30, P279, DOI 10.1093/jac/30.3.279; Mandell L A, 1995, Can J Infect Dis, V6, P306; MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501, DOI 10.1093/clinids/18.4.501; Marrie TJ, 1996, AM J MED, V101, P508, DOI 10.1016/S0002-9343(96)00255-0; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MARTON A, 1992, CLIN INFECT DIS, V15, P106, DOI 10.1093/clinids/15.1.106; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; MOINE P, 1994, CHEST, V105, P1487, DOI 10.1378/chest.105.5.1487; Moreillon P, 1996, SCHWEIZ MED WSCHR, V126, P255; MUNDY LM, 1995, AM J RESP CRIT CARE, V152, P1309, DOI 10.1164/ajrccm.152.4.7551387; MURRAY PR, 1975, MAYO CLIN PROC, V50, P339; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; ORTQVIST A, 1990, CHEST, V97, P576, DOI 10.1378/chest.97.3.576; Ortqvist A, 1996, CHEST, V110, P1499, DOI 10.1378/chest.110.6.1499; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; Porath A, 1997, J INFECTION, V34, P41, DOI 10.1016/S0163-4453(97)80008-4; RAMIREZ JA, 1995, ARCH INTERN MED, V155, P1273, DOI 10.1001/archinte.155.12.1273; REIN MF, 1978, JAMA-J AM MED ASSOC, V239, P2671, DOI 10.1001/jama.239.25.2671; REINERT RR, 1993, MED KLIN, V88, P357; Riquelme R, 1996, AM J RESP CRIT CARE, V154, P1450, DOI 10.1164/ajrccm.154.5.8912763; SAHN SA, 1993, AM REV RESPIR DIS, V148, P813, DOI 10.1164/ajrccm/148.3.813; Schrock J, 1997, DIAGN MICR INFEC DIS, V28, P221, DOI 10.1016/S0732-8893(97)00043-6; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Simor AE, 1996, ANTIMICROB AGENTS CH, V40, P2190, DOI 10.1128/AAC.40.9.2190; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273; Stout JE, 1997, NEW ENGL J MED, V337, P682, DOI 10.1056/NEJM199709043371006; TAN TQ, 1992, PEDIATRICS, V90, P928; Tarlow MJ, 1997, PEDIATR INFECT DIS J, V16, P457, DOI 10.1097/00006454-199704000-00030; Thomson KS, 1997, ANTIMICROB AGENTS CH, V41, P478, DOI 10.1128/AAC.41.2.478; Topkis S, 1997, CLIN THER, V19, P975, DOI 10.1016/S0149-2918(97)80050-1; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; Wagstaff AJ, 1997, DRUGS, V53, P817, DOI 10.2165/00003495-199753050-00007; WOODHEAD M, 1994, J ANTIMICROB CHEMOTH, V34, P85, DOI 10.1093/jac/34.suppl_A.85; WOODHEAD MA, 1987, LANCET, V1, P671; 1998, MED LETT DRUGS THER, V40, P30; 1997, MED LETT DRUGS THER, V39, P41; 1998, MED LETT DRUGS THER, V40, P17	86	129	131	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1998	352	9136					1295	1302		10.1016/S0140-6736(98)02239-9	http://dx.doi.org/10.1016/S0140-6736(98)02239-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788476				2022-12-28	WOS:000076573800045
J	Hacke, W; Kaste, M; Fieschi, C; von Kummer, R; Davalos, A; Meier, D; Larrue, V; Bluhmki, E; Davis, S; Donnan, G; Schneider, D; Diez-Tejedor, E; Trouillas, P				Hacke, W; Kaste, M; Fieschi, C; von Kummer, R; Davalos, A; Meier, D; Larrue, V; Bluhmki, E; Davis, S; Donnan, G; Schneider, D; Diez-Tejedor, E; Trouillas, P		Second European Australasian Acute Stroke Study	Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)	LANCET			English	Article							ACUTE ISCHEMIC STROKE; TIME	Background Thrombolysis for acute ischaemic stroke has been investigated in several clinical trials, with variable results. We have assessed the safety and efficacy of intravenous thrombolysis with alteplase (0.9 mg/kg bodyweight) within 6 h of stroke onset. Methods This non-angiographic, randomised, double-blind, trial enrolled 800 patients in Europe, Australia, and New Zealand, Computed tomography was used to exclude patients with signs of major infarction. Alteplase (n=409) and placebo (n=391) were randomly assigned with stratification for time since symptom onset (0-3 h or 3-6 h). The primary endpoint was the modified Rankin scale (mRS) at 90 days, dichotomised for favourable (score 0-1) and unfavourable (score 2-6) outcome. Analyses were by intention to treat. Findings 165 (40.3%) alteplase-group patients and 143 (36.6%) placebo-group patients had favourable mRS outcomes (absolute difference 3.7%, p=0.277). In a post-hoc analysis of mRS scores dichotomised far death or dependency, 222 (54.3%) alteplase-group and 180 (46.0%) placebo-group patients had favourable outcomes (score 0-2; absolute difference 8.3%, p=0.024). Treatment differences were similar whether patients were treated within 3 h or 3-6 h, 85 (10.6%) patients died, with no difference between treatment groups at day 90+/-14 days (43 alteplase, 42 placebo). Symptomatic intracranial haemorrhage occurred in 36 (8.8%) alteplase-group patients and 13 (3.4%) placebo-group patients. Interpretation The results do not confirm a statistical benefit for alteplase. However, we believe the trend towards efficacy should be interpreted in the light ui evidence from previous trials. Despite the increased risk of intracranial haemorrhage, thrombolysis with alteplase at a dose of 0.9 mg/kg in selected patients may lead to a clinically relevant improvement in outcome.	Heidelberg Univ, Sch Med, Dept Neurol, D-69120 Heidelberg, Germany; Univ Helsinki, Dept Neurol, FIN-00014 Helsinki, Finland; Univ Rome, Dept Neurol, Rome, Italy; Univ Dresden, Dept Neuroradiol, Dresden, Germany; Univ Hosp Girona, Dept Neurol, Girona, Spain; Boehringer Ingelheim KG, Dept Clin Res, Ingelheim, Germany; Boehringer Ingelheim KG, Dept Stat, Ingelheim, Germany; Univ Toulouse, Dept Neurol, Toulouse, France; Univ Melbourne, Dept Neurol, Parkville, Vic 3052, Australia; Univ Leipzig, Dept Neurol, Leipzig, Germany; Univ Madrid, Dept Neurol, Madrid, Spain; Univ Lyon, Dept Neurol, Lyon, France	Ruprecht Karls University Heidelberg; University of Helsinki; Sapienza University Rome; Technische Universitat Dresden; Boehringer Ingelheim; Boehringer Ingelheim; Universite de Toulouse; University of Melbourne; Leipzig University	Hacke, W (corresponding author), Heidelberg Univ, Sch Med, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	werner_hacke@ukl.unl-heldelberg.de	Hacke, Werner/ABE-8661-2020; DONNAN, GEOFFREY A/A-9947-2008; Davis, Stephen M/L-5260-2013; von Kummer, Rüdiger/AAA-4478-2019	Davis, Stephen M/0000-0003-0962-2300; von Kummer, Rüdiger/0000-0003-0119-4604; Kaste, Markku/0000-0001-6557-6412; Donnan, Geoffrey/0000-0001-6324-3403				Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Azzimondi G, 1997, STROKE, V28, P537, DOI 10.1161/01.STR.28.3.537; BARON JC, 1995, STROKE, V26, P2219, DOI 10.1161/01.STR.26.12.2219; Brott T, 1997, STROKE, V28, P1530, DOI 10.1161/01.STR.28.8.1530; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; Fisher M, 1996, NEUROLOGY, V47, P884, DOI 10.1212/WNL.47.4.884; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HACKE W, IN PRESS STROKE; Hommel M, 1996, NEW ENGL J MED, V335, P145; HORNIG CR, 1986, STROKE, V17, P179, DOI 10.1161/01.STR.17.2.179; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; *MULT AC STROK TRI, 1995, LANCET, V356, P1509; OKADA Y, 1989, STROKE, V20, P598, DOI 10.1161/01.STR.20.5.598; Ronning OM, 1998, STROKE, V29, P586, DOI 10.1161/01.STR.29.3.586; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; Steiner T, 1998, CEREBROVASC DIS, V8, P198, DOI 10.1159/000015851; von Kummer R, 1998, STROKE, V29, P310; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214	19	2527	2649	1	74	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1998	352	9136					1245	1251		10.1016/S0140-6736(98)08020-9	http://dx.doi.org/10.1016/S0140-6736(98)08020-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788453				2022-12-28	WOS:000076573800007
J	Hutchon, DJR; Cooper, S				Hutchon, DJR; Cooper, S			Terminology for early pregnancy loss must be changed	BRITISH MEDICAL JOURNAL			English	Letter							DELAYED MISCARRIAGE; MISSED ABORTION		Mem Hosp, Dept Obstet & Gynaecol, Durham DL3 6HX, England; Clayton Hosp, Miscarriage Assoc, Wakefield WF1 3JS, W Yorkshire, England		Hutchon, DJR (corresponding author), Mem Hosp, Dept Obstet & Gynaecol, Durham DL3 6HX, England.							GRUDZINSKAS J, 1997, PROBLEMS EARLY PREGN; Hutchon DJ, 1997, BRIT J OBSTET GYNAEC, V104, P753, DOI 10.1111/j.1471-0528.1997.tb11994.x; LLEWELLYNJONES D, 1995, FUNDAMENTALS OBSTET, P99; Morgan M, 1997, BRIT J OBSTET GYNAEC, V104, P1099, DOI 10.1111/j.1471-0528.1997.tb12077.x	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1081	1081						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774309				2022-12-28	WOS:000076577200052
J	Roland, R; Torgerson, D				Roland, R; Torgerson, D			Understanding controlled trials - What outcomes should be measured?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMERCIAL DEPUTIZING SERVICES; RANDOMIZED CONTROLLED TRIAL; OWN GENERAL-PRACTITIONERS; CARE		Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Roland, R (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				BOWLING A, 1994, MEASURING DIS REV DI; Cragg DK, 1997, BMJ-BRIT MED J, V314, P187, DOI 10.1136/bmj.314.7075.187; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; McKinley RK, 1997, BMJ-BRIT MED J, V314, P190, DOI 10.1136/bmj.314.7075.190; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; TORGERSON DJ, 1998, IN PRESS BMJ; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; WILKIN D, 1992, MEASURES NEED OUTCOM	10	30	34	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	1998	317	7165					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774302				2022-12-28	WOS:000076577200036
J	Barbaro, G; Di Lorenzo, G; Grisorio, B; Barbarini, G				Barbaro, G; Di Lorenzo, G; Grisorio, B; Barbarini, G		Gruppo Italiano Studio Cardiologico Pazienti Af	RETRACTED: Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients (Retracted Article. See vol 347, pg 140, 2002)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Retracted Publication							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY-SYNDROME; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; LEFT-VENTRICULAR DYSFUNCTION; SYNDROME AIDS; CONGESTIVE CARDIOMYOPATHY; CARDIAC MANIFESTATIONS; VIRUS-INFECTION; HEART	Background Human immunodeficiency virus (HIV) infection is increasingly recognized as an important cause of dilated cardiomyopathy. However, the pathogenesis of the heart-muscle disease in the acquired immunodeficiency syndrome is unclear. Methods We performed a prospective, long-term clinical and echocardiographic follow-up study of 952 asymptomatic HIV-positive patients to assess the incidence of dilated cardiomyopathy and to analyze the clinical variables associated with the development of cardiomyopathy. All patients with an echocardiographic diagnosis of dilated cardiomyopathy underwent endomyocardial biopsy for histologic, immunohistologic, and virologic assessment. Results During a mean (+/-SD) follow-up period of 60+/-5.3 months, an echocardiographic diagnosis of dilated cardiomyopathy was made in 76 patients (8 percent), with a mean annual incidence rate of 15.9 cases per 1000 patients. The incidence of dilated cardiomyopathy was higher in patients with a CD4 count of less than 400 cells per cubic millimeter (as compared with a CD4 count of greater than or equal to 400 cells per cubic millimeter) and in those who received therapy with zidovudine. A histologic diagnosis of myocarditis was made in 63 of the patients with dilated cardiomyopathy (83 percent). Inflammatory infiltrates were predominantly composed of CD3 and CD8 lymphocytes, with staining for major histocompatibility complex class I antigens in 71 percent of the patients. In the myocytes of 58 patients, HIV nucleic acid sequences were detected by in situ hybridization, and active myocarditis was documented in 36 of the 58. Among these 36 patients, 6 were also infected with coxsackievirus group B (17 percent), 2 with cytomegalovirus (6 percent), and 1 with Epstein-Barr virus (3 percent). Conclusions Dilated cardiomyopathy may be related either to a direct action of HIV on the myocardial tissue or to an autoimmune process induced by HIV, possibly in association with other cardiotropic viruses. (N Engl J Med 1998;339:1093-9,) (C) 1998. Massachusetts Medical Society.	Univ Roma La Sapienza, Dept Emergency Med, Rome, Italy; Gen Hosp, Div Infect Dis, Foggia, Italy; Univ Pavia, Policlin San Matteo, Dept Infect & Trop Dis, I-27100 Pavia, Italy	Sapienza University Rome; IRCCS Fondazione San Matteo; University of Pavia	Barbaro, G (corresponding author), Viale Anicio Gallo 63, I-00174 Rome, Italy.							ACIERNO LJ, 1989, J AM COLL CARDIOL, V13, P1144, DOI 10.1016/0735-1097(89)90277-5; ANDERSON DW, 1988, J AM COLL CARDIOL, V11, P792, DOI 10.1016/0735-1097(88)90213-6; Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; Armitage P., 2001, STAT METHODS MED RES; Barbaro G, 1996, AIDS RES HUM RETROV, V12, P1559, DOI 10.1089/aid.1996.12.1559; Barbaro G, 1996, Cardiologia, V41, P1199; BAROLDI G, 1988, J AM COLL CARDIOL, V12, P463, DOI 10.1016/0735-1097(88)90420-2; BESCHORNER WE, 1990, AM J PATHOL, V137, P1365; BESTETTI RB, 1989, INT J CARDIOL, V22, P143, DOI 10.1016/0167-5273(89)90060-0; BYRD BF, 1985, J AM COLL CARDIOL, V6, P1021, DOI 10.1016/S0735-1097(85)80304-1; CALABRESE LH, 1987, ANN INTERN MED, V107, P691, DOI 10.7326/0003-4819-107-5-691; Caves P K, 1973, Ann Thorac Surg, V16, P325; COHEN IS, 1986, NEW ENGL J MED, V315, P628, DOI 10.1056/NEJM198609043151007; DEAN AG, 1994, EPI INFO VERSION 6 M; DOMANSKI MJ, 1995, J PEDIATR-US, V127, P137, DOI 10.1016/S0022-3476(95)70275-X; FACTOR SM, 1989, J AM COLL CARDIOL, V13, P1037, DOI 10.1016/0735-1097(89)90257-X; GRODY WW, 1990, AM J CARDIOL, V66, P203, DOI 10.1016/0002-9149(90)90589-S; HERSKOWITZ A, 1993, CLIN IMMUNOL IMMUNOP, V68, P234, DOI 10.1006/clin.1993.1124; HERSKOWITZ A, 1994, J AM COLL CARDIOL, V24, P1025, DOI 10.1016/0735-1097(94)90865-6; HERSKOWITZ A, 1992, ANN INTERN MED, V116, P311, DOI 10.7326/0003-4819-116-4-311; HIMELMAN RB, 1989, J AM COLL CARDIOL, V13, P1030, DOI 10.1016/0735-1097(89)90256-8; KAUL S, 1991, AM HEART J, V122, P535, DOI 10.1016/0002-8703(91)91013-D; LEVY WS, 1989, AM J CARDIOL, V63, P86, DOI 10.1016/0002-9149(89)91081-3; REILLY JM, 1988, AM J CARDIOL, V62, P789, DOI 10.1016/0002-9149(88)91223-4; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; WAHR DW, 1983, J AM COLL CARDIOL, V1, P863, DOI 10.1016/S0735-1097(83)80200-9; WOODRUFF JF, 1980, AM J PATHOL, V101, P425; WOODS GL, 1987, J VIROL METHODS, V18, P207, DOI 10.1016/0166-0934(87)90082-6; 1987, MMWR MORB MORTAL S1, V36, pS3	29	191	201	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1093	1099		10.1056/NEJM199810153391601	http://dx.doi.org/10.1056/NEJM199810153391601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129DP	9770555				2022-12-28	WOS:000076448200001
J	Guesde, R; Barrou, B; Leblanc, I; Ourahma, S; Goarin, JP; Coriat, P; Riou, B				Guesde, R; Barrou, B; Leblanc, I; Ourahma, S; Goarin, JP; Coriat, P; Riou, B			Administration of desmopressin in brain-dead donors and renal function in kidney recipients	LANCET			English	Article							ORGAN DONORS; TRANSPLANT DONORS; GRAFT FUNCTION; VASOPRESSIN; HYDROXYETHYLSTARCH; SUPPLEMENTATION; DOPAMINE	Background Diabetes insipidus is common among brain-dead donors and may lead to decreased graft function. The use of desmopressin to limit the consequences of diabetes insipidus is controversial. We assessed the effects of desmopressin administered to brain-dead donors on early and long-term graft function in kidney recipients. Methods In a randomised controlled study, 97 brain-dead donors received desmopressin as 1 mu g bolus every 2 h when diuresis was more than 300 mL/h (desmopressin group n=49) or no desmopressin (control group n=48). In 175 kidney recipients (controls n=89, desmopressin group n=86) we measured serum concentrations of creatinine and haemodialysis requirements to assess early renal function in the first 15 days after transplantation. We assessed longterm results of transplantation (median time 45 months) for a homogeneous subgroup of 95 recipients (48 in the desmopressin group). Findings We found no significant differences between the two groups of brain-dead donors, except for final diuresis, which was lower in the desmopressin group than among controls. Haemodialysis requirement in controls and the desmopressin group (20 vs 23%, p=0.63) and serum creatinine concentrations (decrease from 903 mu mol/L to 206 mu mol/L vs 814 mu mol/L to 193 mu mol/L, p=0.14) did not differ significantly in the first 15 days after transplantation. Long-term graft survival was similar in the two groups (88 vs 87%). Interpretation Desmopressin can be given to brain-dead donors to limit the harmful effects of diabetes insipidus without any substantial effects to graft function in recipients.	Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Anesthesiol & Crit Care, F-75651 Paris 13, France; Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Urol, F-75651 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Guesde, R (corresponding author), Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Anesthesiol & Crit Care, 47 Blvd Hop, F-75651 Paris 13, France.			Leblanc, Isabelle/0000-0003-0086-3853				BLAINE EM, 1984, TRANSPLANTATION, V38, P459, DOI 10.1097/00007890-198411000-00003; CECKA JM, 1992, TRANSPLANTATION, V53, P59, DOI 10.1097/00007890-199201000-00011; Cittanova ML, 1996, LANCET, V348, P1620, DOI 10.1016/S0140-6736(96)07588-5; FEIGENBAUM H, 1986, ECHOCARDIOGR-J CARD, P621; FISER DH, 1987, CRIT CARE MED, V15, P551, DOI 10.1097/00003246-198706000-00002; FOLLAND ED, 1979, CIRCULATION, V60, P760, DOI 10.1161/01.CIR.60.4.760; FULGENICO JP, 1995, INTENS CARE MED, V21, P832, DOI 10.1007/BF01700967; GILBERT EM, 1988, J THORAC CARDIOV SUR, V95, P1003; GJERTSON DW, 1992, TRANSPLANTATION, V53, P357, DOI 10.1097/00007890-199202010-00018; Goarin JP, 1996, ANESTH ANALG, V83, P41, DOI 10.1097/00000539-199607000-00008; GOLDSMITH SR, 1987, AM J MED, V82, P1213, DOI 10.1016/0002-9343(87)90228-2; GRAMM HJ, 1992, TRANSPLANTATION, V54, P851, DOI 10.1097/00007890-199211000-00016; GRUNDMANN R, 1981, TRANSPLANTATION, V32, P184, DOI 10.1097/00007890-198109000-00003; GUESDE R, 1993, BRIT J ANAESTH, V70, P41; Hirschl MM, 1996, NEPHROL DIAL TRANSPL, V11, P173; IWAI A, 1989, TRANSPLANTATION, V48, P613; KADIEVA VS, 1993, ANESTH ANALG, V76, P362; Kofke WA., 1993, TXB TRAUMA ANESTHESI, P994; Langeron O, 1996, BRIT J ANAESTH, V76, P783, DOI 10.1093/bja/76.6.783; LEGENDRE C, 1993, LANCET, V342, P248, DOI 10.1016/0140-6736(93)92345-T; LEUNG JM, 1994, ANESTHESIOLOGY, V81, P1102, DOI 10.1097/00000542-199411000-00003; RICHARDSON DW, 1985, ANN INTERN MED, V103, P228, DOI 10.7326/0003-4819-103-2-228; RIOU B, 1995, BRIT J ANAESTH, V74, P424, DOI 10.1093/bja/74.4.424; RIOU B, 1995, CIRCULATION, V92, P409, DOI 10.1161/01.CIR.92.3.409; RIOU B, 1994, SOC FRANCAISE ANESTH, P575; Robertson Kerri M., 1994, P27; SCHNEIDER A, 1983, TRANSPLANTATION, V36, P110; STARZL TE, 1987, SURG GYNECOL OBSTET, V165, P343; Troppmann C, 1996, TRANSPLANTATION, V61, P1331, DOI 10.1097/00007890-199605150-00008	29	53	53	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1178	1181		10.1016/S0140-6736(98)05456-7	http://dx.doi.org/10.1016/S0140-6736(98)05456-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777834				2022-12-28	WOS:000076415400009
J	Santocanale, C; Diffley, JFX				Santocanale, C; Diffley, JFX			A Mec1- and Rad53-dependent checkpoint controls late-firing origins of DNA replication	NATURE			English	Article							S-PHASE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; ARS ELEMENTS; PROTEIN; COMPLEXES; DAMAGE; TIME; PROGRESSION; ACTIVATION	DNA replication in eukaryotic cells initiates from many replication origins(1) which fire throughout the S phase of the cell cycle in a predictable pattern: some origins fire early, others late(2). Little is known about how the initiation of DNA replication and the elongation of newly synthesized DNA strands are coordinated during S phase. Here we show that, in budding yeast, hydroxyurea, which blocks the progression of replication forks from early-firing origins, also inhibits the firing of late origins. These late origins are maintained in the initiation-competent prereplicative state for extended periods. The block to late origin firing is an active process and is defective in yeast with mutations in the rad53 and mec1 checkpoint genes, indicating that regulation of late origin firing may also be an important component of the 'intra-S-phase' checkpoint(3) and may aid cell survival under adverse conditions.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		Diffley, JFX (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.			Santocanale, Corrado/0000-0003-1337-5656; Diffley, John/0000-0001-5184-7680				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, GENETICS, V145, P45; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANTOCANALE C, 1995, J MOL BIOL, V254, P595, DOI 10.1006/jmbi.1995.0641; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	25	516	526	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					615	618		10.1038/27001	http://dx.doi.org/10.1038/27001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783589				2022-12-28	WOS:000076362900052
J	Rojas, MR; Noueiry, AO; Lucas, WJ; Gilbertson, RL				Rojas, MR; Noueiry, AO; Lucas, WJ; Gilbertson, RL			Bean dwarf mosaic geminivirus movement proteins recognize DNA in a form- and size-specific manner	CELL			English	Article							CELL-TO-CELL; COAT PROTEIN; NICOTIANA-BENTHAMIANA; DELETION MUTANTS; VIRAL MOVEMENT; STRANDED-DNA; VIRUS; BL1; PLASMODESMATA; INFECTION	Plant viral movement proteins mediate the cell-to-cell movement of nucleic acids. This involves either a direct interaction between the viral movement protein and the nucleic acid or an indirect interaction involving host factors. The bipartite geminiviruses possess two movement proteins, BV1 and BC1, that coordinate movement of viral DNA across nuclear and plasmodesmal boundaries, respectively. Here, we demonstrate that both BV1 and BC1 interact directly with DNA and, in addition, that they have the unique property to recognize DNA on the basis of form and size rather than sequence. This is a novel feature for plant virus movement proteins and raises the possibility that BV1 and BC1 may be determinants of genome size in the bipartite geminiviruses.	Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA; Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Gilbertson, RL (corresponding author), Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA.							AZZAM O, 1994, VIROLOGY, V204, P289, DOI 10.1006/viro.1994.1533; BROUGH CL, 1988, J GEN VIROL, V69, P503, DOI 10.1099/0022-1317-69-3-503; BROWN KC, 1995, BIOCHEMISTRY-US, V34, P4733, DOI 10.1021/bi00014a030; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; CITOVSKY V, 1990, CELL, V60, P637, DOI 10.1016/0092-8674(90)90667-4; DEOM CM, 1992, CELL, V69, P221, DOI 10.1016/0092-8674(92)90403-Y; DING BA, 1995, VIROLOGY, V207, P345, DOI 10.1006/viro.1995.1093; ELMER S, 1990, NUCLEIC ACIDS RES, V18, P2001, DOI 10.1093/nar/18.8.2001; ETESSAMI P, 1988, NUCLEIC ACIDS RES, V16, P4811, DOI 10.1093/nar/16.11.4811; ETESSAMI P, 1989, J GEN VIROL, V70, P277, DOI 10.1099/0022-1317-70-2-277; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; Ghoshroy Soumitra, 1997, Annu Rev Plant Physiol Plant Mol Biol, V48, P27, DOI 10.1146/annurev.arplant.48.1.27; GIESMANCOOKMEYER D, 1993, PLANT CELL, V5, P973, DOI 10.1105/tpc.5.8.973; Gilbertson RL, 1996, TRENDS PLANT SCI, V1, P260; GILBERTSON RL, 1991, PHYTOPATHOLOGY, V81, P980, DOI 10.1094/Phyto-81-980; HIDAYAT SH, 1993, PHYTOPATHOLOGY, V83, P181, DOI 10.1094/Phyto-83-181; HOEFERT LL, 1987, PHYTOPATHOLOGY, V77, P1596, DOI 10.1094/Phyto-77-1596; Hou YM, 1998, MOL PLANT MICROBE IN, V11, P208, DOI 10.1094/MPMI.1998.11.3.208; INGHAM DJ, 1995, VIROLOGY, V207, P191, DOI 10.1006/viro.1995.1066; KLINKENBERG FA, 1989, J GEN VIROL, V70, P1837, DOI 10.1099/0022-1317-70-7-1837; Li QB, 1996, VIROLOGY, V216, P71, DOI 10.1006/viro.1996.0035; Liu HT, 1997, J GEN VIROL, V78, P1265, DOI 10.1099/0022-1317-78-6-1265; LUCAS WJ, 1994, ANNU REV PHYTOPATHOL, V32, P387, DOI 10.1146/annurev.py.32.090194.002131; Maia IG, 1996, J GEN VIROL, V77, P1335, DOI 10.1099/0022-1317-77-7-1335; McLean BG, 1997, PLANT CELL, V9, P1043, DOI 10.1105/tpc.9.7.1043; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; OSMAN TAM, 1992, J GEN VIROL, V73, P223, DOI 10.1099/0022-1317-73-2-223; PAPLOMATAS EJ, 1994, PHYTOPATHOLOGY, V84, P1215, DOI 10.1094/Phyto-84-1215; PASCAL E, 1994, PLANT CELL, V6, P995, DOI 10.1105/tpc.6.7.995; Qu F, 1997, J VIROL, V71, P1428, DOI 10.1128/JVI.71.2.1428-1435.1997; Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777; ROJAS MR, 1993, PLANT DIS, V77, P340, DOI 10.1094/PD-77-0340; SANDERFOOT AA, 1995, PLANT CELL, V7, P1185, DOI 10.1105/tpc.7.8.1185; Schaffer RL, 1995, VIROLOGY, V214, P330, DOI 10.1006/viro.1995.0042; STANLEY J, 1985, NUCLEIC ACIDS RES, V13, P2189, DOI 10.1093/nar/13.7.2189; Sudarshana MR, 1998, MOL PLANT MICROBE IN, V11, P277, DOI 10.1094/MPMI.1998.11.4.277; TIMMERMANS MCP, 1994, ANNU REV PLANT PHYS, V45, P79, DOI 10.1146/annurev.pp.45.060194.000455; Wang HL, 1996, PHYTOPATHOLOGY, V86, P1204, DOI 10.1094/Phyto-86-1204; Ward BM, 1997, J VIROL, V71, P3726, DOI 10.1128/JVI.71.5.3726-3733.1997	39	91	93	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					105	113		10.1016/S0092-8674(00)81786-9	http://dx.doi.org/10.1016/S0092-8674(00)81786-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778251	Bronze			2022-12-28	WOS:000076242300014
J	Moawad, MR; Blair, SD				Moawad, MR; Blair, SD			Pulsating varicose veins	LANCET			English	Article									Arrowe Pk Hosp, Wirral L49 5PE, Merseyside, England		Moawad, MR (corresponding author), Care of Morgan ERN, 228 Middlewood Rd, Sheffield S6 1TE, S Yorkshire, England.							AbuYousef MM, 1996, AM J ROENTGENOL, V167, P977, DOI 10.2214/ajr.167.4.8819397	1	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1030	1030		10.1016/S0140-6736(98)04471-7	http://dx.doi.org/10.1016/S0140-6736(98)04471-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759747				2022-12-28	WOS:000076121800013
J	Scambler, G				Scambler, G			Stigma and disease: changing paradigms	LANCET			English	Editorial Material									UCL, Sch Med, Dept Psychiat, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Scambler, G (corresponding author), UCL, Sch Med, Dept Psychiat, Gower St, London WC1E 6AU, England.							ALBRECHT GL, 1982, SOC SCI MED, V16, P1319, DOI 10.1016/0277-9536(82)90027-2; Campbell, 1996, DISABILITY POLITICS; Goffman E., 1963, STIGMA MANAGEMENT SP; Parsons T., 1951, SOCIAL SYSTEM; ROBINSON I, 1988, MULTIPLE SCLEROSIS; Scambler G, 1994, Seizure, V3, P287, DOI 10.1016/S1059-1311(05)80176-1; Scambler G., 1989, EPILEPSY; SCHNEIDER JW, 1981, SOC SCI MED-MED SOC, V15, P211, DOI 10.1016/0271-7123(81)90004-3; Shakespeare T., 1995, CRITICAL PUBLIC HLTH, V6, P4, DOI 10.1080/09581599508409047; Sontag S., 1977, ILLNESS METAPHOR	10	165	179	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1054	1055		10.1016/S0140-6736(98)08068-4	http://dx.doi.org/10.1016/S0140-6736(98)08068-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759769				2022-12-28	WOS:000076121800048
J	Brandes, JA; Boctor, NZ; Cody, GD; Cooper, BA; Hazen, RM; Yoder, HS				Brandes, JA; Boctor, NZ; Cody, GD; Cooper, BA; Hazen, RM; Yoder, HS			Abiotic nitrogen reduction on the early Earth	NATURE			English	Article							AMINO-ACIDS; EVOLUTION; NITRATE; IRON; CO2	The production of organic precursors to life depends critically on the form of the reactants, In particular, an environment dominated by N-2 is far less efficient in synthesizing nitrogen-bearing organics than a reducing environment rich in ammonia (refs 1, 2). Relatively reducing lithospheric conditions on the early Earth have been presumed to favour the generation of an ammonia-rich atmosphere. but this hypothesis has not been studied experimentally. Here we demonstrate mineral-catalysed reduction of N-2, NO2- and NO3- to ammonia at temperatures between 300 and 800 degrees C and pressures of 0.1-0.4 GPa-conditions typical of crustal and oceanic hydrothermal systems. We also show that only N-2 is stable above 800 degrees C, thus precluding significant atmospheric ammonia formation during hot accretion, We conclude that mineral-catalysed N-2 reduction might have provided a significant source of ammonia to the Hadean ocean. These results also suggest that, whereas nitrogen in the Earth's early atmosphere was present predominantly as N-2, exchange with oceanic, hydrothermally derived ammonia could have provided a significant amount of the atmospheric ammonia necessary to resolve the early-faint-Sun paradox(3).	Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA	Carnegie Institution for Science	Brandes, JA (corresponding author), Carnegie Inst Washington, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.	brandes@gl.ciw.edu						BADA JL, 1968, SCIENCE, V159, P423, DOI 10.1126/science.159.3813.423; Berndt ME, 1996, GEOLOGY, V24, P351, DOI 10.1130/0091-7613(1996)024<0351:ROCDSO>2.3.CO;2; BLOCHL E, 1992, P NATL ACAD SCI USA, V89, P8117, DOI 10.1073/pnas.89.17.8117; BURESH RJ, 1976, J ENVIRON QUAL, V5, P320, DOI 10.2134/jeq1976.00472425000500030021x; FALKOWSKI PG, 1997, AQUATIC PHOTOSYNTHES, pCH10; FOURNIER RO, 1987, US GS PROF PAP, V1350, P1497; Frost B. R., 1991, REV MINERAL, V25, P469; HENDERSON-SELLERS A, 1980, NATURE, V287, P526, DOI 10.1038/287526a0; Holland HD., 1984, CHEM EVOLUTION ATMOS; JAVOY M, 1991, EARTH PLANET SC LETT, V107, P598, DOI 10.1016/0012-821X(91)90104-P; JOHNSON MC, 1994, REV MINERAL, V30, P281; JONES MN, 1984, WATER RES, V18, P643, DOI 10.1016/0043-1354(84)90215-X; KASTING JF, 1993, J GEOL, V101, P245, DOI 10.1086/648219; KNOWLES R, 1982, MICROBIOL REV, V46, P43, DOI 10.1128/MMBR.46.1.43-70.1982; KULLERUD G, 1959, ECON GEOL, V54, P534; MANCINELI RL, 1990, ORIGINS LIFE EVOL BI, V18, P311; PIZZARELLO S, 1994, GEOCHIM COSMOCHIM AC, V58, P5579, DOI 10.1016/0016-7037(94)90251-8; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217; SCHLESINGER G, 1983, J MOL EVOL, V19, P376, DOI 10.1007/BF02101642; STEVENSON DJ, 1983, EARTHS EARLIEST BIOS, P32; STRIBLING R, 1987, ORIGINS LIFE EVOL B, V17, P261, DOI 10.1007/BF02386466; Strickland J.D.H., 1972, PRACTICAL HDB SEWATE, DOI [10.2307/1979241, DOI 10.2307/1979241]; SUMMERS DP, 1993, NATURE, V365, P630, DOI 10.1038/365630a0; Tamaru K., 1991, CATALYTIC AMMONIA SY, P1; YODER HS, 1962, J PETROL, V3, P342, DOI 10.1093/petrology/3.3.342; YODER HS, 1950, T AM GEOPHYS UNION, V31, P821; ZEIS EG, 1924, NAT GEOL SOC CONT TE, V1; ZHANG YX, 1993, EARTH PLANET SC LETT, V117, P331, DOI 10.1016/0012-821X(93)90088-Q	28	163	166	4	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					365	367		10.1038/26450	http://dx.doi.org/10.1038/26450			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759725				2022-12-28	WOS:000076083800048
J	Godt, D; Tepass, U				Godt, D; Tepass, U			Drosophila oocyte localization is mediated by differential cadherin-based adhesion	NATURE			English	Article							POLARITY GENE ARMADILLO; CELL-ADHESION; ANTERIOR-POSTERIOR; BODY AXES; OOGENESIS; PROTEIN; SPECIFICATION; REARRANGEMENT; MELANOGASTER; POLARIZATION	In a Drosophila follicle the oocyte always occupies a posterior position among a group of sixteen germline cells. Although the importance of this cell arrangement for the subsequent formation of the anterior-posterior axis of the embryo is well documented(1-4), the molecular mechanism responsible for the posterior localization of the oocyte was unknown. Here we show that the homophilic adhesion molecule DE-cadherin(5-7) mediates oocyte positioning. During follicle biogenesis, DE-cadherin is expressed in germline (including oocyte) and surrounding follicle cells, with the highest concentration of DE-cadherin being found at the interface between oocyte and posterior follicle cells. Mosaic analysis shows that DE-cadherin is required in both germline and follicle cells for correct oocyte localization, indicating that germline-soma interactions may be involved in this process. By analysing the behaviour of the oocyte in follicles with a chimaeric follicular epithelium, we find that the position of the oocyte is determined by the position of DE-cadherin-expressing follicle cells, to which the oocyte attaches itself selectively. Among the DE-cadherin positive follicle cells, the oocyte preferentially contacts those cells that express higher levels of DE-cadherin. On the basis of these data, we propose that in wild-type follicles the oocyte competes successfully with its sister germline cells for contact to the posterior follicle cells, a sorting process driven by different concentrations of DE-cadherin. This is, to our knowledge, the first in vivo example of a cell-sorting process that depends on differential adhesion mediated by a cadherin.	Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada	University of Toronto	Godt, D (corresponding author), Univ Toronto, Dept Zool, 25 Harbord St, Toronto, ON M5S 3G5, Canada.	dgodt@zoo.utoronto.ca; utepass@zoo.utoronto.ca						BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CARPENTER ATC, 1994, CIBA F SYMP, V182, P223; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; King R. C., 1970, OVARIAN DEV DROSOPHI; Mach JM, 1997, GENE DEV, V11, P423, DOI 10.1101/gad.11.4.423; MAHOWALD AP, 1970, J CELL BIOL, V45, P306, DOI 10.1083/jcb.45.2.306; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Oda H, 1997, GENES CELLS, V2, P29, DOI 10.1046/j.1365-2443.1997.d01-284.x; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1993, DEVELOPMENT, V118, P1191; RAN B, 1994, DEVELOPMENT, V120, P1233; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; Steinberg MS, 1996, DEV BIOL, V180, P377, DOI 10.1006/dbio.1996.0312; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; XU T, 1994, DROSOPHILA MELANOGAS, P655	30	264	265	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					387	391		10.1038/26493	http://dx.doi.org/10.1038/26493			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759729				2022-12-28	WOS:000076083800055
J	Baker, R				Baker, R			Memorable patients - The milkman of human kindness	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1148	1148						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784461				2022-12-28	WOS:000076755100040
J	Eng, TR; Maxfield, A; Patrick, K; Deering, MJ; Ratzan, SC; Gustafson, DH				Eng, TR; Maxfield, A; Patrick, K; Deering, MJ; Ratzan, SC; Gustafson, DH			Access to health information and support - A public highway or a private road?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LOW-INCOME WOMEN; INTERACTIVE MULTIMEDIA; EDUCATION; RISK; COMPUTERS; EMERGENCY; LITERACY; DELIVERY; INTERNET; SCIENCES	Information and communication technologies may help reduce health disparities through their potential for promoting health, preventing disease, and supporting clinical care for all. Unfortunately, those who have preventable health problems and lack health insurance coverage are the least likely to have access to such technologies. Barriers to access include cost, geographic location, illiteracy, disability, and factors related to the capacity of people to use these technologies appropriately and effectively. A goal of universal access to health information and support is proposed to augment existing initiatives to improve the health of individuals and the public. Both public- and private-sector stakeholders, particularly government agencies and private corporations, will need to collaboratively reduce the gap between the health information "haves" and "have-nots, This will include supporting health information technology access in homes and public places, developing applications for the growing diversity of users, funding research on access-related issues, ensuring the quality of health information and support, enhancing literacy in health and technology, training health information intermediaries, and integrating the concept of universal access to health information and support into health planning processes.	US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA; NIOSH, US Dept HHS, Washington, DC USA; Acad Educ Dev, Washington, DC USA; San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA; Tufts Univ, Sch Med, Dept Family Med, Medford, MA 02155 USA; Univ Wisconsin, Dept Ind Engn, Madison, WI 53706 USA; Univ Wisconsin, Dept Prevent Med, Madison, WI 53706 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); California State University System; San Diego State University; Tufts University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Deering, MJ (corresponding author), US Dept HHS, Off Dis Prevent & Hlth Promot, 200 Independence Ave SW,Room 738G, Washington, DC 20201 USA.		Tao, Youyou/D-2367-2014					Alemi F, 1996, MED CARE, V34, pOS32; Alemi F, 1996, MED CARE, V34, pOS21; Alemi F, 1996, MED CARE, V34, pOS10; Alwitt Linda F., 1996, LOW INCOME CONSUMER; *AM ASS HLTH PLANS, 1998, AAHP MEMB ORG; *AM LIB ASS, 1998, 1997 NAT SURV PUBL L; *AM MED ASS, 1998, LINKS OTH MED SIT; [Anonymous], MAKING POWERFUL CONN; Baker DW, 1996, ARCH FAM MED, V5, P329, DOI 10.1001/archfami.5.6.329; BARRY MJ, 1995, MED CARE, V33, P771, DOI 10.1097/00005650-199508000-00003; BERGMAN R, 1993, HOSPITALS, V67, P52; BIER M, 1996, J RES COMPUT ED, P28; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V278, P1622, DOI 10.1001/jama.278.19.1622; Carroll JM, 1996, J NUTR EDUC, V28, P19, DOI 10.1016/S0022-3182(96)70011-0; *COMP INT, 1997, CI FINDS PC PEN US H; *CYB DIAL INC, 1998, AM INT US SURV FINDS; Deering MJ, 1996, B MED LIBR ASSOC, V84, P209; ELLIS LBM, 1991, J FAM PRACTICE, V33, P390; *FED COMM COMM, 1998, UN SERV; FENNELL ML, 1993, ANNU REV SOCIOL, V19, P89; *FIND SVP INC, 1997, 1997 AM INT US SURV; Foran M, 1995, AAOHN J, V43, P564; Gropper M, 1995, SOC WORK HEALTH CARE, V22, P87; Gustafson David, 1993, Journal of Psychosocial Oncology, V11, P69; GUSTAFSON DH, 1995, HOSP HEALTH SERV ADM, V40, P154; GUSTAFSON DH, 1994, J AM MED INFORM ASSN, P604; GUSTAFSON DH, IN PRESS AM J PREV M; Hallgren MM, 1997, INTERNET ECONOMICS, P455; Hammett TM, 1998, HEALTH EDUC BEHAV, V25, P99, DOI 10.1177/109019819802500108; Hassett M, 1992, Proc Annu Symp Comput Appl Med Care, P151; HENDERSON J, IN PRESS AM J PREV M; Hoffman DL, 1998, SCIENCE, V280, P390, DOI 10.1126/science.280.5362.390; HORNIK RC, 1992, RES ISSUES HUMAN BEH, P201; JIMISON H, IN PRESS AM J PREV M; KAHIN B, 1995, PUBLIC ACCESS INTERN; KINZIE MB, 1993, PATIENT EDUC COUNS, V21, P51, DOI 10.1016/0738-3991(93)90059-6; Kraut R, 1996, COMMUN ACM, V39, P55, DOI 10.1145/240483.240493; Lawrence S, 1998, SCIENCE, V280, P98, DOI 10.1126/science.280.5360.98; Liu TP, 1996, J HEALTH CARE POOR U, V7, P323; MacKieMason JK, 1997, INTERNET ECONOMICS, P27; McCray JC, 1997, B MED LIBR ASSOC, V85, P136; MCTAVISH FM, 1994, J AM MED INFORM ASSN, P599; Milio N, 1996, B MED LIBR ASSOC, V84, P223; *MMWR, 1998, MMWR-MORBID MORTAL W, V47, P170; MOGELONSKY M, 1994, AM DEMOGR, V16, P14; Morris TA, 1997, J AM MED INFORM ASSN, V4, P6, DOI 10.1136/jamia.1997.0040006; Musil C M, 1998, J Gerontol Nurs, V24, P30; PANE GA, 1991, ANN EMERG MED, V20, P730, DOI 10.1016/S0196-0644(05)80832-7; PATRICK K, IN PRESS AM J PREV M; Pingree S, 1996, J BROADCAST ELECTRON, V40, P331, DOI 10.1080/08838159609364357; Powell D R, 1997, AAOHN J, V45, P247; Robinson TN, 1998, JAMA-J AM MED ASSOC, V280, P1264, DOI 10.1001/jama.280.14.1264; SHIMAKAWA T, 1994, PREV MED, V23, P769, DOI 10.1006/pmed.1994.1133; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; SILVERSTEIN SC, 1995, FASEB J, V9, P833, DOI 10.1096/fasebj.9.10.7615152; SKINNER CS, 1993, PATIENT EDUC COUNS, V22, P27, DOI 10.1016/0738-3991(93)90086-C; STERN RS, 1991, JAMA-J AM MED ASSOC, V266, P2238, DOI 10.1001/jama.266.16.2238; STRECHER VJ, 1994, J FAM PRACTICE, V39, P262; *US BUR CENS, 1998, HLTH INS COV STAT TY; *US BUR CENS, 1998, FALL NET, V2; *US BUR CENS, 1995, FALL NET SURV HAV NO; *US BUR CENS, 1998, LEV ACC US COMP 1984; *US DEP HHS, 1995, NETW HLTH INF C MAY; *US DEP HHS, 1997, DIS PREV HLTH PROM D; *US GOV ACC OFF, 1996, CONS HLTH INF EM ISS; WATKINS SA, 1994, J NATL MED ASSOC, V86, P909; Weiss BD, 1998, J FAM PRACTICE, V46, P168; *WHO, 1997, WHODGO981; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166; Yom S S, 1996, JAMA, V275, P735, DOI 10.1001/jama.275.9.735; ZALLEN BG, 1995, LEA COMMUN SER, P21	72	216	217	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1371	1375		10.1001/jama.280.15.1371	http://dx.doi.org/10.1001/jama.280.15.1371			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129PQ	9794322				2022-12-28	WOS:000076472500039
J	Caidahl, K; Kazzam, E; Lidberg, J; Andersen, GN; Nordanstig, J; Dahlwvist, SR; Waldenstrom, A; Wikh, R				Caidahl, K; Kazzam, E; Lidberg, J; Andersen, GN; Nordanstig, J; Dahlwvist, SR; Waldenstrom, A; Wikh, R			New concept in echocardiography: harmonic imaging of tissue without use of contrast agent	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; SYSTEMIC-SCLEROSIS; INJECTION; OPACIFICATION; ULTRASOUND; RESOLUTION; EFFICACY	Background Endocardial border detection is important for echocardiographic assessment of left-ventricular function. Second harmonic imaging of contrast agents enhances this border detection. We discovered that harmonic imaging improves tissue visualisation even before contrast injection. We therefore sought objectively to demonstrate the degree of enhancement of endocardial and myocardial visualisation. Methods An ATL HDI-3000 scanner with software for contrast harmonic imaging was used to record short-axis images of the left ventricle in 27 patients with possible myocardial disease and 22 controls, in the fundamental mode and with harmonic imaging. A computer program measured the relative grey-scale values within six segments of the endocardium and myocardium. An Acuson Sequoia Scanner equipped with software for tissue harmonic imaging was used to investigate the reproducibility of ejection-fraction calculations in 22 patients with ischaemic heart disease. Findings Harmonic imaging produced brighter endocardium within each segment. Relative to the mean grey value of the total imaging sector, the values for harmonic and fundamental imaging were 171.5 vs 85.6% (p<0.0001) in end diastole and 194.1 vs 106.7% (p<0.0001) in end systole. Results for the myocardial segments were also significantly better for harmonic imaging. Structure enhancement of similar magnitude was seen among patients and healthy controls. Use of harmonic imaging reduced the proportion of unacceptable images by 14-46% in different views and improved the reproducibility of biplane ejection-fraction measurements. Interpretation In comparison with fundamental imaging, the relative endocardial and myocardial brightness is enhanced by harmonic imaging.	Sahlgrens Univ Hosp, Dept Clin Physiol, SE-41345 Gothenburg, Sweden; Univ Umea Hosp, Dept Cardiol, S-90185 Umea, Sweden; Univ Umea Hosp, Dept Rheumatol, S-90185 Umea, Sweden	Sahlgrenska University Hospital; Umea University; Umea University	Caidahl, K (corresponding author), Sahlgrens Univ Hosp, Dept Clin Physiol, SE-41345 Gothenburg, Sweden.		Caidahl, Kenneth/AAQ-2645-2021; Silverdal, Jonas/AAY-5269-2021	Silverdal, Jonas/0000-0002-6088-7868; Waldenstrom, Anders/0000-0002-5304-0802; Nordanstig, Joakim/0000-0002-2670-2268				AVERKIOU M, 1997, IEEE ULTR S TOR ONT, P1561; Beppu S, 1997, J AM SOC ECHOCARDIOG, V10, P11, DOI 10.1016/S0894-7317(97)80028-4; BONARJEE VVS, 1993, AM J CARDIOL, V72, P1004, DOI 10.1016/0002-9149(93)90853-5; CAIDAHL K, 1997, EUR HEART J SUPPL, V19, P146; Colon PJ, 1997, J AM SOC ECHOCARDIOG, V10, P602, DOI 10.1016/S0894-7317(97)70022-1; Forsberg F, 1996, J ULTRAS MED, V15, P853, DOI 10.7863/jum.1996.15.12.853; GENY B, 1993, J AM COLL CARDIOL, V22, P1193, DOI 10.1016/0735-1097(93)90437-6; GUSTAFSSON R, 1989, LANCET, V2, P475; Iliceto S, 1996, EUR HEART J, V17, P344; KAZZAM E, 1991, AM J NONINVAS CARD, V5, P343; Krishnan S, 1996, ULTRASONIC IMAGING, V18, P77, DOI 10.1006/uimg.1996.0005; Lindner JR, 1997, AM J CARDIOL, V79, P1657, DOI 10.1016/S0002-9149(97)00217-8; Mulvagh SL, 1996, J AM COLL CARDIOL, V27, P1519, DOI 10.1016/0735-1097(95)00619-2; Porter TR, 1997, J AM COLL CARDIOL, V29, P791, DOI 10.1016/S0735-1097(96)00575-X; PORTER TR, 1994, J AM COLL CARDIOL, V23, P1440, DOI 10.1016/0735-1097(94)90389-1; Schwarz KQ, 1997, J AM SOC ECHOCARDIOG, V10, P1, DOI 10.1016/S0894-7317(97)80027-2; Ward B, 1997, J ACOUST SOC AM, V101, P143, DOI 10.1121/1.417977; Zotz R J, 1996, J Am Soc Echocardiogr, V9, P1, DOI 10.1016/S0894-7317(96)90098-X	19	111	114	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1264	1270		10.1016/S0140-6736(98)02361-7	http://dx.doi.org/10.1016/S0140-6736(98)02361-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788456				2022-12-28	WOS:000076573800010
J	Kirsner, JB				Kirsner, JB			Historical origins of medical and surgical therapy of inflammatory bowel disease	LANCET			English	Article									Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Kirsner, JB (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 2100, Chicago, IL 60637 USA.							BEAN RHD, 1962, MED J AUSTRALIA, V2, P592, DOI 10.5694/j.1326-5377.1962.tb20590.x; BROOKE BN, 1952, LANCET, V263, P102; BROWN JY, 1913, SURG GYNECOL OBSTET, V16, P610; Cesnik H, 1968, Langenbecks Arch Chir, V321, P86, DOI 10.1007/BF01439744; CROHN BB, 1958, REGIONAL ILEITIS; Domagk G, 1935, DEUT MED WOCHENSCHR, V61, P829, DOI 10.1055/s-0028-1129654; FERGUSON LK, 1937, AM J DIG DIS, V4, P487; Fleming A., 1944, BRIT MED BULL, V2, P4, DOI [10.1093/oxfordjournals.bmb.a071032, DOI 10.1093/OXFORDJOURNALS.BMB.A071032]; HAGGARD H, 1937, EARLY MEDIEVAL MED, P33; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; HITCHINGS GH, 1950, ANN NY ACAD SCI, V52, P1318, DOI 10.1111/j.1749-6632.1950.tb54032.x; KARNSH A, 1977, PSYCHOTHERAPY CHRONI; KIRSNER JB, 1951, JAMA-J AM MED ASSOC, V147, P541, DOI 10.1001/jama.1951.03670230007003; Kirsner JB, 1996, INFLAMM BOWEL DIS, V2, P73, DOI 10.1002/ibd.3780020202; KORELITZ BI, 1972, AM J DIG DIS, V17, P111, DOI 10.1007/BF02232730; MARTINI GA, 1976, KLIN WOCHENSCHR, V54, P367, DOI 10.1007/BF01469792; PARKS AG, 1978, BRIT MED J, V2, P85, DOI 10.1136/bmj.2.6130.85; Sands BE, 1997, INFLAMM BOWEL DIS, V3, P95, DOI 10.1002/ibd.3780030206; SANPANER R, 1955, ANN SURG, V141, P367; SCHLITT RJ, 1951, GASTROENTEROLOGY, V19, P812; Schmelkes FC, 1934, J AM CHEM SOC, V56, P1610, DOI 10.1021/ja01322a049; SCHWARTZ R, 1958, P SOC EXP BIOL MED, V99, P164; Svartz N, 1942, ACTA MED SCAND, V110, P577; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041	24	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1998	352	9136					1303	1305		10.1016/S0140-6736(98)11132-7	http://dx.doi.org/10.1016/S0140-6736(98)11132-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788477				2022-12-28	WOS:000076573800046
J	Cernicharo, J; Lefloch, B; Cox, P; Cesarsky, D; Esteban, C; Yusef-Zadeh, F; Mendez, DI; Acosta-Pulido, J; Lopez, RJG; Heras, A				Cernicharo, J; Lefloch, B; Cox, P; Cesarsky, D; Esteban, C; Yusef-Zadeh, F; Mendez, DI; Acosta-Pulido, J; Lopez, RJG; Heras, A			Induced massive star formation in the Trifid nebula?	SCIENCE			English	Article							YOUNG STELLAR OBJECTS; GLOBULES	The Trifid nebula is a young (10(5) years) galactic HII region where several protostellar sources have been detected with the infrared space observatory. The sources are massive (17 to 60 solar masses) and are associated with molecular gas condensations at the edges or inside the nebula. They appear to be in an early evolutionary stage and may represent the most recent generation of stars in the Trifid. These sources range from dense, apparently still inactive cores to more evolved sources, undergoing violent mass ejection episodes, including a source that powers an optical jet. These observations suggest that the protostellar sources may have evolved by induced star formation in the Trifid nebula.	CSIC, Inst Estructura Mat, Dept Fis Mol, E-28006 Madrid, Spain; Domaine Univ Grenoble, Observ Grenoble, F-38406 St Martin Dheres, France; Univ Paris 11, Inst Astrophys Spatiale, F-94500 Orsay, France; Inst Astrofis Canarias, E-38200 Tenerife, Spain; Northwestern Univ, Evanston, IL 60208 USA; European Space Agcy, Div Astrophys, Sci Operat Ctr, Infrared Space Observ, E-28080 Madrid, Spain; Max Planck Inst Aeron, D-69117 Heidelberg, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Instituto de Astrofisica de Canarias; Northwestern University; European Space Agency; Max Planck Society	Cernicharo, J (corresponding author), CSIC, Inst Estructura Mat, Dept Fis Mol, Serrano 123, E-28006 Madrid, Spain.		Acosta-Pulido, Jose A./AAA-4704-2019; Esteban, Cesar/H-1540-2015; Cernicharo, Jose/G-3059-2015	Esteban, Cesar/0000-0002-5247-5943; Cernicharo, Jose/0000-0002-3518-2524				ANDRE P, 1993, ASTROPHYS J, V406, P122, DOI 10.1086/172425; ANDRE P, 1994, ASTROPHYS J, V420, P837, DOI 10.1086/173608; BLAAUW A, 1964, ANNU REV ASTRON ASTR, V2, P213, DOI 10.1146/annurev.aa.02.090164.001241; CERNICHARO J, 1992, ASTRON ASTROPHYS, V261, P589; CERNICHARO J, 1997, HERBIG HARO OBJECTS, P8; Cesarsky CJ, 1996, ASTRON ASTROPHYS, V315, pL32; ELMEGREEN BG, 1977, ASTROPHYS J, V214, P725, DOI 10.1086/155302; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; LADA CJ, 1985, ANNU REV ASTRON ASTR, V23, P267, DOI 10.1146/annurev.aa.23.090185.001411; LEFLOCH B, 1994, ASTRON ASTROPHYS, V289, P559; Lemke D, 1996, ASTRON ASTROPHYS, V315, pL64; LYNDS BT, 1985, ASTROPHYS J, V288, P164, DOI 10.1086/162775; REIPURTH B, GEN CATALOGUE HERBIG; SUGITANI K, 1989, ASTROPHYS J, V342, pL87, DOI 10.1086/185491; WHITWORTH AP, 1994, MON NOT R ASTRON SOC, V268, P291, DOI 10.1093/mnras/268.1.291	15	49	49	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					462	465		10.1126/science.282.5388.462	http://dx.doi.org/10.1126/science.282.5388.462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774270				2022-12-28	WOS:000076479600050
J	Liu, XH; Wang, H; Eberstadt, M; Schnuchel, A; Olejniczak, ET; Meadows, RP; Schkeryantz, JM; Janowick, DA; Harlan, JE; Harris, EAS; Staunton, DE; Fesik, SW				Liu, XH; Wang, H; Eberstadt, M; Schnuchel, A; Olejniczak, ET; Meadows, RP; Schkeryantz, JM; Janowick, DA; Harlan, JE; Harris, EAS; Staunton, DE; Fesik, SW			NMR structure and mutagenesis of the N-terminal Dbl homology domain of the nucleotide exchange factor trio	CELL			English	Article							ISOTOPICALLY ENRICHED PROTEINS; NUCLEAR-MAGNETIC-RESONANCE; BETA-GAMMA-SUBUNITS; EF-TS COMPLEX; CRYSTAL-STRUCTURE; EXPRESSION CLONING; ONCOGENE PRODUCT; BINDING; KINASE; ACTIVATION	Guanine nucleotide exchange factors for the Rho family of GTPases contain a Dbl homology (DH) domain responsible for catalysis and a pleckstrin homology (PH) domain whose function is unknown. Here we describe the solution structure of the N-terminal DH domain of Trio that catalyzes nucleotide exchange for Rac1. The all-alpha-helical protein has a very different structure compared to other exchange factors. Based on site-directed mutagenesis, functionally important residues of the DH domain were identified. They are all highly conserved and reside in close proximity on two alpha helices. In addition, we have discovered a unique capability of the PH domain to enhance nucleotide exchange in DH domain-containing proteins.	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA; ICOS Corp, Bothell, WA 98021 USA	Abbott Laboratories; Icos Corporation	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA.	fesiks@pprd.abbott.com						Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; Gardner KH, 1997, J AM CHEM SOC, V119, P7599, DOI 10.1021/ja9706514; GRZESIEK S, 1993, J BIOMOL NMR, V3, P487; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; WANG H, 1998, IN PRESS J BIOMOL NM; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	52	154	156	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					269	277		10.1016/S0092-8674(00)81757-2	http://dx.doi.org/10.1016/S0092-8674(00)81757-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790533	Bronze			2022-12-28	WOS:000076538300014
J	Wood, WB				Wood, WB			Aging of C-elegans: Mosaics and mechanisms	CELL			English	Review							CAENORHABDITIS-ELEGANS; LIFE; GENE; STRESS; AGE-1		Univ Colorado, Dept MCD Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Wood, WB (corresponding author), Univ Colorado, Dept MCD Biol, Boulder, CO 80309 USA.							Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; ARKING R, 1998, BIOL AGING; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FRIEDMAN DB, 1988, GENETICS, V118, P75; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; Guarente L, 1998, P NATL ACAD SCI USA, V95, P11034, DOI 10.1073/pnas.95.19.11034; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LAKOWSKI B, 1998, IN PRESS P NATL ACAD; Lithgow GJ, 1996, SCIENCE, V273, P80, DOI 10.1126/science.273.5271.80; Malone EA, 1996, GENETICS, V143, P1193; Murakami S, 1996, GENETICS, V143, P1207; Riddle DL, 1997, C ELEGANS, P739; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Shook DR, 1996, GENETICS, V142, P801; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Tissenbaum HA, 1998, GENETICS, V148, P703; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	19	31	36	5	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					147	150		10.1016/S0092-8674(00)81744-4	http://dx.doi.org/10.1016/S0092-8674(00)81744-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790520	Bronze			2022-12-28	WOS:000076538300001
J	Sudlow, M; Thomson, R; Thwaites, B; Rodgers, H; Kenny, RA				Sudlow, M; Thomson, R; Thwaites, B; Rodgers, H; Kenny, RA			Prevalence of atrial fibrillation and eligibility for anticoagulants in the community	LANCET			English	Article							GENERAL-PRACTICE; STROKE; PREVENTION; POPULATION; WARFARIN; RECOMMENDATIONS; PERSPECTIVE	Background: Anticoagulants are effective in the prevention of stroke in atrial fibrillation and flutter (AF). We aimed to find out the prevalence of AF in the UK and to estimate the proportion of patients with AF who might benefit from anticoagulation. Methods We screened with electrocardiography a random sample of 4843 people from the community aged 65 years and older for AF. Participants with AF had further investigations to identify risk factors for stroke and contraindications to anticoagulants. We used three sets of criteria to assess risk and elibility for anticoagulation. Findings 228 (4.7%) participants had AF. According to analyses derived from risk stratifications based on the Stroke Prevention in Atrial Fibrillation (SPAF) study 61% of these patients would have benefited from anticoagulation, 49% according to pooled analysis of trial results, and 41% according to the inclusion criteria for the SPAF 3 study. Anticoagulants were used by 1114 (23%) of all patients and were least used among elderly women, who may be the most likely to benefit. Echocardiography would be useful to assess the need for anticoagulation only in patients younger than 75 years with no contraindications to treatment and no clinical risk factors for stroke. Interpretation: Anticoagulants seem to be underused and misdirected in treatment of AF, according to various criteria. Efforts to promote and support wider and more appropriate use of anticoagulants would seem to be justified, and should decrease the incidence of stroke amongst elderly patients.	Newcastle Univ, Sch Clin Med Sci, Dept Med, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Newcastle Univ, Sch Hlth Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Wansbeck Gen Hosp, Ashington, England	Newcastle University - UK; Newcastle University - UK	Sudlow, M (corresponding author), Newcastle Univ, Sch Clin Med Sci, Dept Med, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.		Rodgers, Helen/K-4358-2012	Kenny, Rose Anne/0000-0002-9336-8124				ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; Blackshear JL, 1996, LANCET, V348, P633; Breeze E, 1994, HLTH SURVEY ENGLAND; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P52; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; Halperin JL, 1997, CIRCULATION, V96, P1562; HILL JD, 1987, J ROY COLL GEN PRACT, V37, P172; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lip GYH, 1997, BRIT J GEN PRACT, V47, P285; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; OMAHONY PG, 1995, STROKE, V26, P1334, DOI 10.1161/01.STR.26.8.1334; PETERSEN P, 1989, LANCET, V1, P175; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Stroke Prevention in Atrial Fibrillation Investigators, 1995, J Stroke Cerebrovasc Dis, V5, P147, DOI 10.1016/S1052-3057(10)80166-1; SUDLOW CM, 1995, BRIT MED J, V311, P558, DOI 10.1136/bmj.311.7004.558; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Thomson R, 1998, BRIT MED J, V316, P509, DOI 10.1136/bmj.316.7130.509; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	29	314	320	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1998	352	9135					1167	1171		10.1016/S0140-6736(98)01401-9	http://dx.doi.org/10.1016/S0140-6736(98)01401-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777832				2022-12-28	WOS:000076415400007
J	Shirahige, K; Hori, Y; Shiraishi, K; Yamashita, M; Takahashi, K; Obuse, C; Tsurimoto, T; Yoshikawa, H				Shirahige, K; Hori, Y; Shiraishi, K; Yamashita, M; Takahashi, K; Obuse, C; Tsurimoto, T; Yoshikawa, H			Regulation of DNA-replication origins during cell-cycle progression	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; S-PHASE; YEAST ORIGIN; DAMAGE; CHECKPOINT	We have shown previously that chromosome VI of Saccharomyces cerevisiae contains nine origins of DNA replication that differ in initiation frequency and replicate sequentially during the S phase of the cell cycle(1,2). Here we show that there are links between activation of these multiple origins and regulation of S-phase progression. We study the effects of a DNA-damaging agent, methyl methane sulphonate (MMS), and of mutations in checkpoint genes such as rad53 (ref. 3) on the activity of origins, measured by two-dimensional gel analysis, and on cell-cycle progression, measured by fluorescence-activated cell sorting. We find that when MMS slows down S-phase progression it also selectively blocks initiation from late origins. A rad53 mutation enhances late and/or inefficient origins and releases the initiation block by MMS. Mutation of rad53 also results in a late origin becoming early replicating, We conclude that rad53 regulates the timing of initiation of replication from late origins during normal cell growth and blocks initiation from late origins in MMS-treated cells. rad53 is, therefore, involved in the cell's surveillance of S-phase progression(4,5). We also find that orc2, which encodes subunit 2 of the origin-recognition complex(6,7), is involved in suppression of late origins.	Nara Inst Sci & Technol, Nara 6300101, Japan; Ajinomoto Co Inc, Kawasaki, Kanagawa 2108680, Japan	Nara Institute of Science & Technology; Ajinomoto Co Inc	Yoshikawa, H (corresponding author), Nara Inst Sci & Technol, 8916-5 Takayama, Nara 6300101, Japan.		Obuse, Chikashi/F-5273-2011	Shirahige, Katsuhiko/0000-0002-7862-1144; Tsurimoto, Toshiki/0000-0001-7597-2216				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; HORIUCHI S, 1996, APPL PHYS S, V6, P7; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, GENETICS, V145, P45; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x	12	352	360	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					618	621		10.1038/27007	http://dx.doi.org/10.1038/27007			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783590				2022-12-28	WOS:000076362900053
J	Kamb, ML; Fishbein, M; Douglas, JM; Rhodes, F; Rogers, J; Bolan, G; Zenilman, J; Hoxworth, T; Malotte, CK; Iatesta, M; Kent, C; Lentz, A; Graziano, S; Byers, RH; Peterman, TA				Kamb, ML; Fishbein, M; Douglas, JM; Rhodes, F; Rogers, J; Bolan, G; Zenilman, J; Hoxworth, T; Malotte, CK; Iatesta, M; Kent, C; Lentz, A; Graziano, S; Byers, RH; Peterman, TA		RESPECT Study Grp	Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEHAVIORAL INTERVENTIONS; HIV; AIDS; INFECTION	Context.-The efficacy of counseling to prevent infection with the human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs) has not been definitively shown. Objective.-To compare the effects of 2 interactive HIV/STD counseling interventions with didactic prevention messages typical of current practice. Design.-Multicenter randomized controlled trial (Project RESPECT), with par ticipants assigned to 1 of 3 individual face-to-face interventions. Setting.-Five public STD clinics (Baltimore, Md; Denver, Cole; Long Beach, Calif; Newark, NJ; and San Francisco, Calif) between July 1993 and September 1996. Participants.-A total of 5758 heterosexual, HIV-negative patients aged 14 years or older who came for STD examinations. Interventions.-Arm 1 received enhanced counseling, 4 interactive theory based sessions. Arm 2 received brief counseling, 2 interactive risk-reduction sessions. Arms 3 and 4 each received 2 brief didactic messages typical of current care. Arms 1, 2, and 3 were actively followed up after enrollment with questionnaires at 3, 6, 9, and 12 months and STD tests at 6 and 12 months. An intent-to-treat analysis was used to compare interventions. Main Outcome Measures.-Self-reported condom use and new diagnoses of STDs (gonorrhea, chlamydia, syphilis, HIV) defined by laboratory tests. Results.-At the 3- and 6-month follow-up visits! self-reported 100% condom use was higher (P<.05) in both the enhanced counseling and brief counseling arms compared with participants in the didactic messages arm. Through the 6-month interval, 30% fewer participants had new STDs in both the enhanced counseling (7.2%; P=.002) and brief counseling (7.3%; P=.005) arms compared with those in the didactic messages arm (10.4%). Through the 12-month study, 20% fewer participants in each counseling intervention had new STDs compared with those in the didactic messages arm (P=.008). Consistently at each of the 5 study sites, STD incidence was lower in the counseling intervention arms than in the didactic messages intervention arm, Reduction of STD was similar for men and women and greater for adolescents and persons with an STD diagnosed at enrollment. Conclusions.-Short counseling interventions using personalized risk reduction plans can increase condom use and prevent new STDs. Effective counseling can be conducted even in busy public clinics.	Ctr Dis Control & Prevent, Off Commun, NCHSTP, Reprint Serv,Div HIV AIDS Prevent, Atlanta, GA 30333 USA; Denver Publ Hlth, Denver, CO USA; Colorado Dept Hlth & Environm, Denver, CO USA; Long Beach Hlth Dept, Long Beach, CA USA; Calif State Univ Long Beach, Long Beach, CA 90840 USA; New Jersey Hlth Dept, Newark STD Clin, Newark, NJ USA; San Francisco Hlth Dept, San Francisco, CA USA; Baltimore City Hlth Dept, Baltimore, MD USA; Johns Hopkins Univ, Baltimore, MD USA	Centers for Disease Control & Prevention - USA; California State University System; California State University Long Beach; New Jersey Department of Health & Senior Services; Johns Hopkins University	Kamb, ML (corresponding author), Ctr Dis Control & Prevent, Off Commun, NCHSTP, Reprint Serv,Div HIV AIDS Prevent, Mailstop E-06,1600 Clifton Rd NE, Atlanta, GA 30333 USA.							Ajzen I., 1980, UNDERSTANDING ATTITU; Allen JP, 1997, J STUD ALCOHOL, V58, P7; ANDREW E, 1994, JAMA-J AM MED ASSOC, V272, P1926, DOI 10.1001/jama.1994.03520240054041; [Anonymous], 1993, MMWR Recomm Rep, V42, P11; *CDCP, 1994, HIV COUNSELING TESTI; *CDCP, 1997, HIV COUNS TEST PUBL; *DCDP, 1997, 46 CDCP, P861; *DCDP, 1996, MMWR-MORBID MORTAL W, V45, P121; DICLEMENTE RJ, 1995, JAMA-J AM MED ASSOC, V274, P1271, DOI 10.1001/jama.274.16.1271; Fishbein M., 1992, FACTORS INFLUENCING; FISHBEIN M, 1991, RES ISSUES HUMAN BEH, P243; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; Holtgrave DR, 1997, J ACQ IMMUN DEF SYND, V16, P54, DOI 10.1097/00042560-199709010-00009; Kamb ML, 1996, PUBLIC HEALTH REP, V111, P99; KELLY JA, 1989, J CONSULT CLIN PSYCH, V57, P60, DOI 10.1037/0022-006X.57.1.60; LAWRENCE J, 1996, 11 INT AIDS JUL 7 12; OAKLEY A, 1995, AIDS, V9, P479, DOI 10.1097/00002030-199509050-00010; PETERMAN TA, 1993, JAMA-J AM MED ASSOC, V269, P2845, DOI 10.1001/jama.1993.03500220031011; RHODES F, 1996, UNDERSTANDING PREVEN, P211; RICHERT CA, 1993, AM J PUBLIC HEALTH, V83, P520, DOI 10.2105/AJPH.83.4.520; ROTHERAMBORUS MJ, 1991, JAMA-J AM MED ASSOC, V266, P1237, DOI 10.1001/jama.266.9.1237; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WEINSTOCK HS, 1995, J ACQ IMMUN DEF SYND, V9, P514; Wolitski RJ, 1997, AIDS EDUC PREV, V9, P52; ZEIGER SL, 1986, BIOMETRICS, V42, P121	30	768	785	0	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1161	1167		10.1001/jama.280.13.1161	http://dx.doi.org/10.1001/jama.280.13.1161			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124YR	9777816	Bronze			2022-12-28	WOS:000076210800030
J	Nightingale, SL				Nightingale, SL			Crohn's disease treatment approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1128	1128		10.1001/jama.280.13.1128	http://dx.doi.org/10.1001/jama.280.13.1128			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777799				2022-12-28	WOS:000076210800004
J	Parente, CA; Blacklock, BJ; Froehlich, WM; Murphy, DB; Devreotes, PN				Parente, CA; Blacklock, BJ; Froehlich, WM; Murphy, DB; Devreotes, PN			G protein signaling events are activated at the leading edge of chemotactic cells	CELL			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ADENYLYL-CYCLASE; CHEMOATTRACTANT RECEPTORS; DICTYOSTELIUM-DISCOIDEUM; MEDIATED ACTIVATION; CYTOSOLIC REGULATOR; FUSION PROTEIN; STIMULATION; DYNAMICS; KINASE	Directional sensing by eukaryotic cells does not require polarization of chemoattractant receptors. The translocation of the PH domain-containing protein CRAC in D. discoideum to binding sites on the inner face of the plasma membrane reflects activation of the G protein-linked signaling system. Increments in chemoattractant elicit a uniform response around the cell periphery. Yet when cells are exposed to a gradient, the activation occurs selectively at the stimulated edge, even in immobilized cells. We propose that such localized activation, transmitted by the recruitment of cytosolic proteins, may be a general mechanism for gradient sensing by G protein-linked chemotactic systems including those involving chemotactic cytokines in leukocytes.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	pnd@welchlink.welch.jhu.edu			NIGMS NIH HHS [GM57874, GM33171] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033171] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa H, 1997, J CELL SCI, V110, P2333; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; Chen MY, 1997, GENE DEV, V11, P3218, DOI 10.1101/gad.11.23.3218; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Gottwald U, 1996, MOL BIOL CELL, V7, P261, DOI 10.1091/mbc.7.2.261; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; HUGHES JE, 1994, MOL CELL BIOL, V14, P6117, DOI 10.1128/MCB.14.9.6117; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KOSHLAND DE, 1977, SCIENCE, V196, P1055, DOI 10.1126/science.870969; KREITMEIER M, 1995, J CELL BIOL, V129, P179, DOI 10.1083/jcb.129.1.179; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; Maeda M, 1996, J BIOL CHEM, V271, P3351; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PARENT CA, 1995, J BIOL CHEM, V270, P22693, DOI 10.1074/jbc.270.39.22693; Parent CA, 1996, J BIOL CHEM, V271, P18333, DOI 10.1074/jbc.271.31.18333; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; Peracino B, 1998, J CELL BIOL, V141, P1529, DOI 10.1083/jcb.141.7.1529; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; ZIGMOND SH, 1981, J CELL BIOL, V89, P585, DOI 10.1083/jcb.89.3.585	46	489	495	3	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					81	91		10.1016/S0092-8674(00)81784-5	http://dx.doi.org/10.1016/S0092-8674(00)81784-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778249	hybrid			2022-12-28	WOS:000076242300012
J	Meng, ID; Manning, BH; Martin, WJ; Fields, HL				Meng, ID; Manning, BH; Martin, WJ; Fields, HL			An analgesia circuit activated by cannabinoids	NATURE			English	Article							ROSTRAL VENTROMEDIAL MEDULLA; RECEPTOR; BRAIN; PAIN; NEURONS; DELTA-9-TETRAHYDROCANNABINOL; ANTINOCICEPTION; MORPHINE; AGONIST	Although many anecdotal reports indicate that marijuana and its active constituent, delta-9-tetrahydrocannabinol (delta-9-THC), may reduce pain sensation(1,2), studies of humans have produced inconsistent results(3-6). In animal studies, the apparent pain-suppressing effects of delta-9-THC and other cannabinoid drugs(7-12) are confounded by motor deficits(13,14). Here we show that a brainstem circuit that contributes to the pain-suppressing effects of morphine(15) is also required for the analgesic effects of cannabinoids. Inactivation of the rostral ventromedial medulla (RVM) prevents the analgesia but not the motor deficits produced by systemically administered cannabinoids, Furthermore, cannabinoids produce analgesia by modulating RVM neuronal activity in a manner similar to, but pharmacologically dissociable from, that of morphine. We also show that endogenous cannabinoids tonically regulate pain thresholds in part through the modulation of RVM neuronal activity. These results show that analgesia produced by cannabinoids and opioids involves similar brainstem circuitry and that cannabinoids are indeed centrally acting analgesics with a new mechanism of action.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Meng, ID (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.		Manning, Barton/AAD-2340-2021; Fields, Howard/ABG-9073-2020; Martin, William J/L-9033-2017	Martin, William J/0000-0002-2749-3365				BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BUXBAUM D, 1969, FED PROC, V28, P735; Cadas H, 1997, J NEUROSCI, V17, P1226; CLARK WC, 1981, J CLIN PHARM S, V21, P299; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dunn M, 1974, Paraplegia, V12, P175; FIELDS HL, 1983, NATURE, V306, P684, DOI 10.1038/306684a0; FIELDS HL, 1995, J NEUROPHYSIOL, V74, P1742, DOI 10.1152/jn.1995.74.4.1742; GOUGH AL, 1977, PSYCHOPHARMACOLOGY, V54, P87, DOI 10.1007/BF00426547; HEINRICHER MM, 1992, NEUROSCIENCE, V48, P533, DOI 10.1016/0306-4522(92)90400-V; Herzberg U, 1997, NEUROSCI LETT, V221, P157, DOI 10.1016/S0304-3940(96)13308-5; Holdcroft A, 1997, ANAESTHESIA, V52, P483, DOI 10.1111/j.1365-2044.1997.139-az0132.x; LIBMAN E, 1985, PERS INDIV DIFFER, V6, P169, DOI 10.1016/0191-8869(85)90106-0; LICHTMAN AH, 1991, BRAIN RES, V559, P309, DOI 10.1016/0006-8993(91)90017-P; Martin WJ, 1996, J NEUROSCI, V16, P6601; Martin WJ, 1998, NEUROSCI LETT, V242, P33, DOI 10.1016/S0304-3940(98)00044-5; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mikuriya Tod H, 1973, MARIJUANA MED PAPERS; Mitchell JM, 1998, NEUROSCIENCE, V87, P123, DOI 10.1016/S0306-4522(98)00119-5; MOSS DE, 1980, EUR J PHARMACOL, V61, P313, DOI 10.1016/0014-2999(80)90134-X; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; Pan ZZ, 1996, NEUROSCIENCE, V74, P855, DOI 10.1016/0306-4522(96)00179-0; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; RICHARDSON JD, 1998, J NEUROSCI, V518; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Roychowdhury SM, 1996, NEUROSCIENCE, V74, P863, DOI 10.1016/0306-4522(96)00180-7; SOFIA RD, 1973, J PHARMACOL EXP THER, V186, P646; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; UEKI S, 1980, TRENDS PHARMACOL SCI, V1, P126	31	298	305	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					381	383		10.1038/26481	http://dx.doi.org/10.1038/26481			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759727				2022-12-28	WOS:000076083800053
J	Cranberg, L				Cranberg, L			Evaluating new treatments	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1261	1261		10.1136/bmj.317.7167.1261	http://dx.doi.org/10.1136/bmj.317.7167.1261			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794890	Green Published			2022-12-28	WOS:000076963000075
J	Williams, AJ				Williams, AJ			ABC of oxygen - Assessing and interpreting arterial blood gases and acid-base balance	BRITISH MEDICAL JOURNAL			English	Article									St Thomass Hosp, Lane Fox Resp Unit, London, England		Williams, AJ (corresponding author), St Thomass Hosp, Lane Fox Resp Unit, London, England.								0	77	87	2	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1213	1216		10.1136/bmj.317.7167.1213	http://dx.doi.org/10.1136/bmj.317.7167.1213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794863	Green Published			2022-12-28	WOS:000076963000026
J	Lin, YJ; Seroude, L; Benzer, S				Lin, YJ; Seroude, L; Benzer, S			Extended life-span and stress resistance in the Drosophila mutant methuselah	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; POSTPONED SENESCENCE; RECEPTOR; PROTEIN; GENE; MELANOGASTER; LONGEVITY; FAMILY; MUTAGENESIS; MUTATIONS	Toward a genetic dissection of the processes involved in aging, a screen for gene mutations that extend life-span in Drosophila melanogaster was perform ed, The mutant Line methuselah (mth) displayed approximately 35 percent increase in average life-span and enhanced resistance to various forms of stress, including starvation, high temperature, and dietary paraquat, a free-radical generator. The mth gene predicted a protein with homology to several guanosine triphosphate-binding protein-coupled seven-transmembrane domain receptors. Thus, the organism may use signal transduction pathways to modulate stress response and life-span.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Benzer, S (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.			Seroude, Laurent/0000-0002-4785-3890	NATIONAL EYE INSTITUTE [R01EY009278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012289] Funding Source: NIH RePORTER; NEI NIH HHS [EY09278] Funding Source: Medline; NIA NIH HHS [AG12289] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARKING R, 1991, DEV GENET, V12, P362, DOI 10.1002/dvg.1020120505; ASHTON FM, 1973, MODE ACTION INSECTIC; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; Burstein ES, 1998, BIOCHEMISTRY-US, V37, P4052, DOI 10.1021/bi972132j; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; FRIEDMAN DB, 1988, GENETICS, V118, P75; GRAVES JL, 1992, PHYSIOL ZOOL, V65, P268, DOI 10.1086/physzool.65.2.30158253; HAMILTON BA, 1994, METHOD CELL BIOL, V44, P81, DOI 10.1016/S0091-679X(08)60907-3; HEKIMI S, 1995, GENETICS, V141, P1351; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HEYDARI AR, 1994, EXPERIENTIA, V50, P1092, DOI 10.1007/BF01923466; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; ROSE M, 1980, NATURE, V287, P141, DOI 10.1038/287141a0; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; Tatar M, 1997, NATURE, V390, P30, DOI 10.1038/36237; Tower J, 1996, BIOESSAYS, V18, P799, DOI 10.1002/bies.950181006; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Vassart G, 1995, ANN NY ACAD SCI, V766, P23, DOI 10.1111/j.1749-6632.1995.tb26645.x; Walker GA, 1998, ANN NY ACAD SCI, V851, P444, DOI 10.1111/j.1749-6632.1998.tb09022.x; Watson S., 1994, G PROTEIN LINKED REC; WONG SKF, 1988, J BIOL CHEM, V263, P7925	34	628	661	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					943	946		10.1126/science.282.5390.943	http://dx.doi.org/10.1126/science.282.5390.943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794765				2022-12-28	WOS:000076727300050
J	Yoon, HS; Golden, JW				Yoon, HS; Golden, JW			Heterocyst pattern formation controlled by a diffusible peptide	SCIENCE			English	Article							SP STRAIN PCC-7120; CELL-CELL COMMUNICATION; GRAM-POSITIVE BACTERIA; PCC 7120; BACILLUS-SUBTILIS; ANABAENA; DIFFERENTIATION; REARRANGEMENT; SUPPRESSION; EXPRESSION	Many filamentous cyanobacteria grow as multicellular organisms that show a developmental pattern of single nitrogen-fixing heterocysts separated by approximately 10 vegetative cells. Overexpression of a 54-base-pair gene, patS, blocked heterocyst differentiation in Anabaena sp. strain PCC 7120. A patS null mutant showed an increased frequency of heterocysts and an abnormal pattern. Expression of a patS-gfp reporter was Localized in developing proheterocysts. The addition of a synthetic peptide corresponding to the Last five amino acids of PatS inhibited heterocyst development. PatS appears to control heterocyst pattern formation through intercellular signaling mechanisms.	Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Golden, JW (corresponding author), Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA.			Golden, James/0000-0001-5463-3207	NIGMS NIH HHS [GM36890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bauer CC, 1997, FEMS MICROBIOL LETT, V151, P23, DOI 10.1111/j.1574-6968.1997.tb10390.x; BLACK TA, 1993, MOL MICROBIOL, V9, P77, DOI 10.1111/j.1365-2958.1993.tb01670.x; BUIKEMA WJ, COMMUNICATION; Cai YP, 1997, J BACTERIOL, V179, P267, DOI 10.1128/jb.179.1.267-271.1997; CARRASCO CD, 1994, GENE DEV, V8, P74, DOI 10.1101/gad.8.1.74; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dunny GM, 1997, ANNU REV MICROBIOL, V51, P527, DOI 10.1146/annurev.micro.51.1.527; ElhaI J, 1997, J BACTERIOL, V179, P1998, DOI 10.1128/jb.179.6.1998-2005.1997; GOLDEN JW, 1991, J BACTERIOL, V173, P7098, DOI 10.1128/jb.173.22.7098-7105.1991; Kaplan HB, 1996, FEMS MICROBIOL LETT, V139, P89, DOI 10.1111/j.1574-6968.1996.tb08185.x; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Khudyakov I, 1997, J BACTERIOL, V179, P6971, DOI 10.1128/jb.179.22.6971-6978.1997; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Lazazzera BA, 1997, CELL, V89, P917, DOI 10.1016/S0092-8674(00)80277-9; Nodwell JR, 1996, MOL MICROBIOL, V22, P881, DOI 10.1046/j.1365-2958.1996.01540.x; Perego M, 1996, P NATL ACAD SCI USA, V93, P1549, DOI 10.1073/pnas.93.4.1549; RAMASUBRAMANIAN TS, 1994, J BACTERIOL, V176, P1214, DOI 10.1128/jb.176.5.1214-1223.1994; Ramaswamy KS, 1997, MOL MICROBIOL, V23, P1241, DOI 10.1046/j.1365-2958.1997.3081671.x; Ramaswamy KS, 1996, J BACTERIOL, V178, P3893, DOI 10.1128/jb.178.13.3893-3898.1996; SCHAEFER MR, 1989, J BACTERIOL, V171, P3973, DOI 10.1128/jb.171.7.3973-3981.1989; SIMPSON P, 1990, DEVELOPMENT, V109, P509; WEI TF, 1994, J BACTERIOL, V176, P4473, DOI 10.1128/JB.176.15.4473-4482.1994; Wolk C. P., 1994, MOL BIOL CYANOBACTER, V1, P769; YOON H, UNPUB	24	292	307	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					935	938		10.1126/science.282.5390.935	http://dx.doi.org/10.1126/science.282.5390.935			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794762				2022-12-28	WOS:000076727300047
J	Gotzsche, PC; Hammarquist, C; Burr, M				Gotzsche, PC; Hammarquist, C; Burr, M			House dust mite control measures in the management of asthma: meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							SENSITIVE ADULT ASTHMA; CONTROLLED TRIAL; DOUBLE-BLIND; ALLERGEN-AVOIDANCE; BRONCHIAL HYPERREACTIVITY; CHILDHOOD ASTHMA; CHILDREN; MATTRESS; EFFICACY	Objective To determine whether patients with asthma who are sensitive to mites benefit from measures designed to reduce their exposure to house dust mite antigen in the home. Design Meta-analysis of randomised trials that investigated the effects on asthma patients of chemical or physical measures to control mites, or both, in comparison with an untreated control group. All trials in any language were eligible for inclusion. Subjects Patients with bronchial asthma as diagnosed by a doctor and sensitisation to mites as determined by skin prick testing bronchial provocation testing or serum assays for specific IgE antibodies. Main outcome measures Number of patients whose allergic symptoms improved, improvement in asthma symptoms, improvement in peak expiratory now rate. Outcomes measured on different scales were combined using the standardised effect size method (the difference in effect was divided by the standard deviation of the measurements). Results 23 studies were included in the meta-analysis; 6 studies used chemical methods to reduce exposure to mites, 13 used physical methods, and 4 used a combination. Altogether, 41/113 patients exposed to treatment interventions improved compared with 38/117 in the control groups (odds ratio 1.20, 95% confidence interval 0.66 to 2.18). The standardised mean difference for improvement in asthma symptoms was - 0.06 (95% confidence interval - 0.54 to 0.41). For peak flow rate measured in the morning the standardised mean difference was - 0.03 (- 0.25 to 0.19). As measured in the original units this difference between the treatment and the control group corresponds to - 3 l/min (95% confidence interval - 25 l/min to 19 l/min). The results were similar in the subgroups of trials that reported successful reduction in exposure to mites or had long follow up times. Conclusion Current chemical and physical methods aimed at reducing exposure to allergens from house dust mites seem to be ineffective and cannot be recommended as prophylactic treatment for asthma patients sensitive to mites.	Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2200 Copenhagen N, Denmark; Municipal Gotland, Unit Publ Hlth, Execut Off, S-62181 Visby, Sweden; Univ Wales Coll Med, Ctr Appl Publ Hlth Med, Cardiff CF1 3NW, S Glam, Wales	Rigshospitalet; Cardiff University	Gotzsche, PC (corresponding author), Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2200 Copenhagen N, Denmark.							ANTONICELLI L, 1991, ALLERGY, V46, P594, DOI 10.1111/j.1398-9995.1991.tb00629.x; Bland JM, 1996, BRIT MED J, V313, P106, DOI 10.1136/bmj.313.7049.106; BURR ML, 1980, THORAX, V35, P513, DOI 10.1136/thx.35.7.513; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; BURR ML, 1976, LANCET, V1, P333; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; *COCHR COLL, 1998, REV MAN VERS 3 1 WIN; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Geller-Bernstein C, 1995, Allerg Immunol (Paris), V27, P147; GILLIES DRN, 1987, CLIN ALLERGY, V17, P105, DOI 10.1111/j.1365-2222.1987.tb02327.x; GOTZSCHE PC, 1990, DAN MED BULL, V37, P329; HAMMARQUIST C, 1998, COCHRANE LIBR; HUSS K, 1992, J ALLERGY CLIN IMMUN, V89, P836, DOI 10.1016/0091-6749(92)90439-9; IHRE E, 1988, CLIN ALLERGY, V18, P557, DOI 10.1111/j.1365-2222.1988.tb02907.x; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; Maesen F P, 1977, Acta Tuberc Pneumol Belg, V68, P133; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; MITCHELL EA, 1980, LANCET, V2, P559; REISER J, 1990, CLIN EXP ALLERGY, V20, P561, DOI 10.1111/j.1365-2222.1990.tb03150.x; SETTE L, 1994, PEDIATR PULM, V18, P218, DOI 10.1002/ppul.1950180405; vanderHeide S, 1997, ALLERGY, V52, P921, DOI 10.1111/j.1398-9995.1997.tb01252.x; VERRALL B, 1988, ANN ALLERGY, V61, P117; WALSHAW MJ, 1986, Q J MED, V58, P199; WARBURTON CJ, 1994, RESP MED, V88, P771, DOI 10.1016/S0954-6111(05)80200-8; WARNER JA, 1993, THORAX, V48, P330, DOI 10.1136/thx.48.4.330; ZWEMER RJ, 1973, ANN ALLERGY, V31, P284	29	151	157	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1105	1110						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784442	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000076755100022
J	McManus, IC				McManus, IC			Factors affecting likelihood of applicants being offered a place in medical schools in the United Kingdom in 1996 and 1997: retrospective study	BRITISH MEDICAL JOURNAL			English	Article							ETHNIC-MINORITY GROUPS; RACIAL-DISCRIMINATION	Objective To assess the relation between a range of measures and the likelihood of applicants to medical schools in the United Kingdom being offered a place overall and at each medical school, with particular emphasis on ethnic minority applicants. Design Data provided by the Universities and Colleges Admissions Service on 92 676 applications to medical schools from 18 943 candidates for admission in 1996 and 1997. Statistical analysis was by multiple logistic regression. Main outcome measures Receipt of a conditional or unconditional offer of a place at medical school. Results Eighteen separate measures were independently associated with the overall likelihood of receiving an offer. Applicants from ethnic minority groups were disadvantaged, as were male applicants, applicants applying late in the selection season, applicants making non-medical (so called insurance) choices, applicants requesting deferred entry (so called gap year), and applicants at further or higher education or sixth form colleges. Analysis at individual medical schools showed different patterns of measures that predicted offers. Not all schools disadvantaged applicants from ethnic minority groups and the effect was stable across the two years, suggesting structural differences in the process of selection. The degree of disadvantage did not relate to the proportion of applicants from ethnic minority groups. Conclusions The data released by the Council of Heads of Medical Schools allow a detailed analysis of the selection process at individual medical schools. The results suggest several areas in which some candidates are disadvantaged, in particular those from ethnic minority groups. Similar data in the future will allow monitoring of changes in selection processes.	UCL, Royal Free & Univ Coll Med Sch, Ctr Hlth Informat & Multiprofess Educ, London N19 5NF, England	University of London; University College London	McManus, IC (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Ctr Hlth Informat & Multiprofess Educ, Whittington Hosp Campus, London N19 5NF, England.	i.mcmanus@ucl.ac.uk		McManus, Ian/0000-0003-3510-4814				ANDERSON J, 1980, BRIT MED J, V1, P1216; COHEN J, 1908, APPL MULTIPLE REGRES; *COMM VIC CHANC PR, 1990, WOULD BE MED STUD NE; Commission for Racial Equality, 1988, MED SCH ADM REP FORM; Esmail A, 1997, BRIT MED J, V314, P618, DOI 10.1136/bmj.314.7081.618; ESMAIL A, 1995, BRIT MED J, V310, P501, DOI 10.1136/bmj.310.6978.501; HORTON RC, 1986, J R SOC MED, V79, P506; LOWRY S, 1988, BRIT MED J, V296, P657, DOI 10.1136/bmj.296.6623.657; MCKENZIE KJ, 1995, BRIT MED J, V310, P478, DOI 10.1136/bmj.310.6978.478; MCMANUS IC, 1984, BRIT MED J, V289, P1201, DOI 10.1136/bmj.289.6453.1201; MCMANUS IC, 1989, BRIT MED J, V298, P723, DOI 10.1136/bmj.298.6675.723; MCMANUS IC, 1995, BRIT MED J, V310, P496, DOI 10.1136/bmj.310.6978.496; MCMANUS IC, 1995, BRIT MED J, V310, P1530, DOI 10.1136/bmj.310.6993.1530b; MCMANUS IC, IN PRESS ADV HLTH SC; MCMANUS IC, 1994, TIMES HIGHER ED 1021, P44; MCMANUS IC, 1908, MED EDUC, V20, P181; MODOOD T, 1994, ETHMIC MINORITIES HI; Poloniecki J, 1998, BRIT MED J, V316, P1734, DOI 10.1136/bmj.316.7146.1734; Rice N, 1996, J Health Serv Res Policy, V1, P154; Solomos J., 1993, RACE RACISM BRITAIN; THOMLINSON L, 1998, BMA NEWS REV     AUG, P16	21	83	83	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1111	1116						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784446				2022-12-28	WOS:000076755100025
J	Richards, P				Richards, P			Professional self respect: rights and responsibilities in the new NHS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERFORMANCE; DOCTORS				Richards, P (corresponding author), Hughes Hall, Cambridge CB1 2EW, England.	prs28@hermes.cam.ac.uk						Berwick DM, 1997, BRIT MED J, V314, P1564, DOI 10.1136/bmj.314.7094.1564; *BRIT MED ASS COR, 1995, COR VAL MED PROF 21; *GEN MED COUNC, 1998, DUT DOCT GOOD MED PR; *GEN MED COUNC, 1998, MAINT GOOD MED PRACT; *GEN MED COUNC, 1997, MAN DOCT PROBL REF G; Horton R, 1998, LANCET, V351, P1900; Irvine D, 1997, BRIT MED J, V314, P1540, DOI 10.1136/bmj.314.7093.1540; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; Johnson JN, 1998, BRIT MED J, V316, P1847; KENNEDY I, 1983, UNMAKSING MED, P104; LAURANCE J, 1998, INDEPENDENT     0728, P13; MCINTOSH K, 1997, HOSPITAL DOCTOR 1113, P20; *NHS CONF ROYAL CO, 1997, TACHL NHS EM ADM POL; RELMAN AS, 1991, NEW ENGL J MED, V325, P854, DOI 10.1056/NEJM199109193251205; Richards P, 1997, BRIT MED J, V314, P1756, DOI 10.1136/bmj.314.7096.1756; Richards T, 1998, BRIT MED J, V316, P246, DOI 10.1136/bmj.316.7127.246; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; SHAW GB, 1937, COMPLETE PLAYS GB SH, P789; SHAW GB, 1946, DOCTORS DILEMMA, P14; Smith R, 1998, BMJ-BRIT MED J, V316, P1917, DOI 10.1136/bmj.316.7149.1917; Smith R, 1998, BRIT MED J, V316, P1622, DOI 10.1136/bmj.316.7145.1622	21	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	1998	317	7166					1146	1148						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784460				2022-12-28	WOS:000076755100039
J	Peacock, AJ				Peacock, AJ			ABC of oxygen - Oxygen at high altitude	BRITISH MEDICAL JOURNAL			English	Article									W Glasgow Hosp Univ NHS Trust, Dept Resp Med, Glasgow, Lanark, Scotland	University of Glasgow	Peacock, AJ (corresponding author), W Glasgow Hosp Univ NHS Trust, Dept Resp Med, Glasgow, Lanark, Scotland.								0	162	169	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1063	1066						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774298				2022-12-28	WOS:000076577200032
J	Fan, S; Gloor, M; Mahlman, J; Pacala, S; Sarmiento, J; Takahashi, T; Tans, P				Fan, S; Gloor, M; Mahlman, J; Pacala, S; Sarmiento, J; Takahashi, T; Tans, P			A large terrestrial carbon sink in North America implied by atmospheric and oceanic carbon dioxide data and models	SCIENCE			English	Article							GENERAL-CIRCULATION MODEL; MISSING CO2 SINK; CLIMATE VARIABILITY; NITROGEN DEPOSITION; DECIDUOUS FOREST; EXCHANGE; BUDGET; BIOSPHERE; SATELLITE; CYCLE	Atmospheric carbon dioxide increased at a rate of 2.8 petagrams of carbon per year (Pg C year(-1)) during 1988 to 1992 (1 Pg = 10(15) grams). Given estimates of fossil carbon dioxide,emissions, and net oceanic uptake, this implies a global terrestrial uptake of 1.0 to 2.2 Pg C year(-1). The spatial distribution of the terrestrial carbon dioxide uptake is estimated by means of the observed spatial patterns of the greatly increased atmospheric carbon dioxide data set available from 1988 onward, together with two atmospheric transport models, two estimates of the sea-air flux, and an estimate of the spatial distribution of fossil carbon dioxide emissions. North America is the best constrained continent, with a mean uptake of 1.7 +/- 0.5 Pg C year(-1), mostly south of 51 degrees north. Eurasia-North Africa is relatively weakly constrained, with a mean uptake of 0.1 +/- 0.6 Pg C year(-1). The rest of the world's land surface is poorly constrained, with a mean source of 0.2 +/- 0.9 Pg C year(-1).	Princeton Univ, Carbon Modeling Consortium, Atmospher & Ocean Sci Program, Princeton, NJ 08544 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08542 USA; Princeton Univ, NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; NOAA, Climate Modeling & Diagnost Lab, Boulder, CO 80303 USA	National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; Princeton University; National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; Columbia University; National Oceanic Atmospheric Admin (NOAA) - USA	Fan, S (corresponding author), Princeton Univ, Carbon Modeling Consortium, Atmospher & Ocean Sci Program, Princeton, NJ 08544 USA.	cmc@princeton.edu	Tans, Pieter/AAG-8273-2019; Fan, Song-Miao/A-8004-2008	Tans, Pieter/0000-0002-9883-0787; Fan, Song-Miao/0000-0001-8352-8035				Andres RJ, 1996, GLOBAL BIOGEOCHEM CY, V10, P419, DOI 10.1029/96GB01523; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; DAI A, 1993, GLOBAL BIOGEOCHEM CY, V7, P599, DOI 10.1029/93GB01165; DENNING AS, 1995, NATURE, V376, P240, DOI 10.1038/376240a0; ENTING IG, 1991, TELLUS B, V43, P156, DOI 10.1034/j.1600-0889.1991.00010.x; Goulden ML, 1998, SCIENCE, V279, P214, DOI 10.1126/science.279.5348.214; Goulden ML, 1996, SCIENCE, V271, P1576, DOI 10.1126/science.271.5255.1576; Greco S, 1996, GLOBAL CHANGE BIOL, V2, P183, DOI 10.1111/j.1365-2486.1996.tb00071.x; Gruber N, 1996, GLOBAL BIOGEOCHEM CY, V10, P809, DOI 10.1029/96GB01608; HAMILTON K, 1995, J ATMOS SCI, V52, P5, DOI 10.1175/1520-0469(1995)052<0005:COTSTG>2.0.CO;2; Holland EA, 1997, J GEOPHYS RES-ATMOS, V102, P15849, DOI 10.1029/96JD03164; HUDSON RJM, 1994, GLOBAL BIOGEOCHEM CY, V8, P307, DOI 10.1029/94GB01044; Keeling CD, 1996, NATURE, V382, P146, DOI 10.1038/382146a0; KEELING CD, 1989, GEOPHYS MONOGR SER, V55, P305, DOI DOI 10.1029/GM055P0305; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Law RM, 1996, GLOBAL BIOGEOCHEM CY, V10, P783, DOI 10.1029/96GB01892; LEVY H, 1982, J GEOPHYS RES-OCEANS, V87, P3061, DOI 10.1029/JC087iC04p03061; MAHLMAN JD, 1978, J ATMOS SCI, V35, P1340, DOI 10.1175/1520-0469(1978)035<1340:TSUAGG>2.0.CO;2; MASARIE KA, 1995, J GEOPHYS RES-ATMOS, V100, P11593, DOI 10.1029/95JD00859; Myneni RB, 1996, GEOPHYS RES LETT, V23, P729, DOI 10.1029/96GL00266; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; NICHOLLS N, 1996, CLIMATE CHANGE 1995, P133; POTTER CS, 1993, GLOBAL BIOGEOCHEM CY, V7, P811, DOI 10.1029/93GB02725; Randerson JT, 1997, GLOBAL BIOGEOCHEM CY, V11, P535, DOI 10.1029/97GB02268; SARMIENTO JL, 1995, PHILOS T R SOC B, V348, P211, DOI 10.1098/rstb.1995.0063; SCHINDLER DW, 1993, GLOBAL BIOGEOCHEM CY, V7, P717, DOI 10.1029/93GB02562; SIEGENTHALER U, 1993, NATURE, V365, P119, DOI 10.1038/365119a0; Stallard RF, 1998, GLOBAL BIOGEOCHEM CY, V12, P231, DOI 10.1029/98GB00741; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431; Townsend AR, 1996, ECOL APPL, V6, P806, DOI 10.2307/2269486; TURNER DP, 1995, ECOL APPL, V5, P421, DOI 10.2307/1942033; WANNINKHOF R, 1992, J GEOPHYS RES-OCEANS, V97, P7373, DOI 10.1029/92JC00188; Wofsy S. C., 1993, Science (Washington D C), V260, P1314, DOI 10.1126/science.260.5112.1314; [No title captured]; [No title captured]; [No title captured]; [No title captured]	37	598	696	14	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					442	446		10.1126/science.282.5388.442	http://dx.doi.org/10.1126/science.282.5388.442			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774264				2022-12-28	WOS:000076479600044
J	Gurdon, JB; Dyson, S				Gurdon, JB; Dyson, S			Cells' perception of position in a concentration gradient	CELL			English	Review							MORPHOGEN GRADIENT; DORSAL GRADIENT; T-CELLS; THRESHOLDS; RECEPTORS; RESPONSES; ACTIVIN; ACTIVATION; MESODERM; SIGNALS		Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Cambridge; University of Cambridge	Gurdon, JB (corresponding author), Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.		St Johnston, Daniel/C-9568-2009	GURDON, JOHN/0000-0002-5621-3799; St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armes NA, 1997, DEVELOPMENT, V124, P3797; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; Huang AM, 1997, GENE DEV, V11, P1963, DOI 10.1101/gad.11.15.1963; Itoh Y, 1997, J EXP MED, V186, P757, DOI 10.1084/jem.186.5.757; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Rothenberg EV, 1996, SCIENCE, V273, P78, DOI 10.1126/science.273.5271.78; Singer MA, 1997, DEVELOPMENT, V124, P79; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Wilson PA, 1997, DEVELOPMENT, V124, P3177; WOLPERT L, 1989, DEVELOPMENT, V107, P3	20	90	92	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					159	162		10.1016/S0092-8674(00)81747-X	http://dx.doi.org/10.1016/S0092-8674(00)81747-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790523	Bronze			2022-12-28	WOS:000076538300004
J	King, TS; Elia, M; Hunter, JO				King, TS; Elia, M; Hunter, JO			Abnormal colonic fermentation in irritable bowel syndrome	LANCET			English	Article							FOOD INTOLERANCE; HUMANS; GAS; MANAGEMENT	Background The cause of irritable bowel syndrome (IBS) is unknown. It may follow gastroenteritis and be associated with an abnormal gut flora and with food intolerance. Our study was designed to assess whether these factors were associated with colonic malfermentation. Methods We carried out a crossover controlled trial of a standard diet and an exclusion diet matched for macronutrients in six female IBS patients and six female controls. During the final 72 h on each diet, faecal excretion of fat, nitrogen, starch, and non-starch polysaccharide NSP was measured, and total excretion of hydrogen and methane collected over 24 h in a purpose-built 1.4 m(3) whole-body calorimeter. Breath hydrogen and methane excretion were then measured for 3 h after 20 g oral lactulose. Findings The maximum rate of gas excretion was significantly greater in patients than in controls (2.4 mL/min IQR 1.7-2.6 vs 0.6, 0.4-1.1). Although total gas production in patients was not greater than in controls (median 527 mL/24 h IQR 387-660 vs 412, 234-507), hydrogen production was higher (332, 318-478 vs 162, 126-217, p=0.009). In patients, the exclusion diet reduced symptoms and produced a fall in maximum gas excretion (0.5 mL/min IQR 0.3-0.7). After lactulose, breath hydrogen was greater on the standard than on the exclusion diet. Interpretation Colonic-gas production, particularly of hydrogen, is greater in patients with IBS than in controls, and both symptoms and gas production are reduced by an exclusion diet. This reduction may be associated with alterations in the activity of hydrogen-consuming bacteria. Fermentation may be an important factor in the pathogenesis of IBS.	Addenbrookes Hosp, Dept Gastroenterol, Cambridge CB2 2QQ, England; MRC, Dunn Clin Nutr Ctr, Cambridge CB2 1QL, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Hunter, JO (corresponding author), Addenbrookes Hosp, Dept Gastroenterol, Cambridge CB2 2QQ, England.							ARGENZIO RA, 1991, DIGEST DIS SCI, V36, P1459, DOI 10.1007/BF01296816; BALSARI A, 1982, MICROBIOLOGICA, V5, P185; CHAMI TN, 1991, AM J GASTROENTEROL, V86, P599; CHRISTL SU, 1993, GASTROENTEROLOGY, V104, P392, DOI 10.1016/0016-5085(93)90406-3; ENGLYST HN, 1994, ANALYST, V119, P1497, DOI 10.1039/an9941901497; FOTHERBY K J, 1987, Alimentary Pharmacology and Therapeutics, V1, P331; Gwee KA, 1996, LANCET, V347, P150, DOI 10.1016/S0140-6736(96)90341-4; HUNTER JO, 1991, LANCET, V338, P495, DOI 10.1016/0140-6736(91)90557-6; JONES VA, 1984, J OBSTET GYNECOL S1, V5, P22; KING TS, 1997, GUT               S1, V40, P64; LASSER RB, 1975, NEW ENGL J MED, V293, P524, DOI 10.1056/NEJM197509112931103; Maxwell PR, 1997, LANCET, V350, P1691, DOI 10.1016/S0140-6736(97)05276-8; MURRAY KE, 1986, GUT, V27, P1173, DOI 10.1136/gut.27.10.1173; NANDA R, 1989, GUT, V30, P1099, DOI 10.1136/gut.30.8.1099; PARKER TJ, 1995, J HUM NUTR DIET, V8, P159, DOI 10.1111/j.1365-277X.1995.tb00308.x; PHILLIPS J, 1995, AM J CLIN NUTR, V62, P121; RAVICH WJ, 1983, GASTROENTEROLOGY, V84, P26; REUSER AJJ, 1994, EUR J CLIN INVEST, V24, P19; SERRA J, 1995, GASTROENTEROLOGY, V109, P1742, DOI 10.1016/0016-5085(95)90739-4; WADE GN, 1986, AM J PHYSIOL, V250, pR845, DOI 10.1152/ajpregu.1986.250.5.R845	20	335	364	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1187	1189		10.1016/S0140-6736(98)02146-1	http://dx.doi.org/10.1016/S0140-6736(98)02146-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777836				2022-12-28	WOS:000076415400011
J	Thomson, B				Thomson, B			Time for reassessment of use of all medical information by UK insurers	LANCET			English	Editorial Material							INSURANCE		Univ Sheffield, Dept Law, Sheffield S10 1FL, S Yorkshire, England	University of Sheffield	Thomson, B (corresponding author), Univ Sheffield, Dept Law, Crookesmoor Bldg, Sheffield S10 1FL, S Yorkshire, England.							ANDREWS L, 1995, AM J HUM GENET, V56, P327; *COUNC EUR, 1961, 35 ETS COUNC EUR; *COUNC EUR, 1996, 164 ETS COUNC EUR; EMERY AEH, 1992, ELEMENTS MED GENETIC, P195; GAULDING J, 1995, CORNELL LAW REV, V80, P1645; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; Harper PS, 1997, J MED GENET, V34, P749, DOI 10.1136/jmg.34.9.749; *HC SCI TECHN COMM, 1995, HUM GEN MIN EV, V41, P38; *HOUS COMM SCI TEC, 1995, HUM GEN SCI ITS CONS, P41; *HUM GEN ADV COMM, 1997, IMPL GEN TEST INS; MacDonald AS, 1997, PHILOS T ROY SOC B, V352, P1067, DOI 10.1098/rstb.1997.0087; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; ONeill O, 1997, PHILOS T ROY SOC B, V352, P1087, DOI 10.1098/rstb.1997.0089; Pokorski RJ, 1997, AM J HUM GENET, V60, P205	14	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1216	1218		10.1016/S0140-6736(97)12515-6	http://dx.doi.org/10.1016/S0140-6736(97)12515-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777856				2022-12-28	WOS:000076415400042
J	Hass, KC; Schneider, WF; Curioni, A; Andreoni, W				Hass, KC; Schneider, WF; Curioni, A; Andreoni, W			The chemistry of water on alumina surfaces: Reaction dynamics from first principles	SCIENCE			English	Article							DENSITY-FUNCTIONAL THEORY; MOLECULAR-DYNAMICS; ELECTRONIC-STRUCTURE; ALPHA-ALUMINA; H2O; SIMULATIONS; ADSORPTION; PLANE	Aluminas and their surface chemistry play a vital role in many areas of modern technology. The behavior of adsorbed water is particularly important and poorly understood, Simulations of hydrated alpha-alumina (0001) surfaces with ab initio molecular dynamics elucidate many aspects of this problem, especially the complex dynamics of water dissociation and related surface reactions. At low water coverage, free energy profiles established that molecularly adsorbed water is metastable and dissociates readily, even in the absence of defects, by a kinetically preferred pathway. Observations at higher water coverage revealed rapid dissociation and unanticipated collective effects, including water-catalyzed dissociation and proton transfer reactions between adsorbed water and hydroxide, The results provide a consistent interpretation of the measured coverage dependence of water heats of adsorption, hydroxyl vibrational spectra, and other experiments.	Ford Res Lab, Dearborn, MI 48121 USA; IBM Corp, Div Res, Zurich Res Lab, CH-8803 Ruschlikon, Switzerland	Ford Motor Company; International Business Machines (IBM)	Andreoni, W (corresponding author), Ford Res Lab, Dearborn, MI 48121 USA.	and@zurich.ibm.com	Schneider, William F./ABH-6170-2020; Schneider, William F/D-4240-2013	Schneider, William F./0000-0003-0664-2138; 				BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Blonski S, 1996, J PHYS CHEM-US, V100, P2201, DOI 10.1021/jp951798p; BLONSKI S, 1993, SURF SCI, V295, P263, DOI 10.1016/0039-6028(93)90202-U; Brown DE, 1998, SCIENCE, V279, P542, DOI 10.1126/science.279.5350.542; CAUSA M, 1989, SURF SCI, V215, P259, DOI 10.1016/0039-6028(89)90713-9; CHEN JG, 1986, J CHEM PHYS, V84, P5906, DOI 10.1063/1.449902; COUSTET V, 1994, SURF SCI, V307, P1161, DOI 10.1016/0039-6028(94)91557-1; Curioni A, 1997, J AM CHEM SOC, V119, P7218, DOI 10.1021/ja970935o; Dai Q, 1997, J PHYS CHEM B, V101, P4940, DOI 10.1021/jp963015l; deSainteClaire P, 1997, J CHEM PHYS, V106, P7331, DOI 10.1063/1.473694; Frank I, 1996, J CHEM PHYS, V104, P8143, DOI 10.1063/1.471490; GAUTIER M, 1994, J AM CERAM SOC, V77, P323, DOI 10.1111/j.1151-2916.1994.tb06999.x; Goniakowski J, 1996, SURF SCI, V350, P145, DOI 10.1016/0039-6028(95)01252-4; HASS KC, UNPUB; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; HUGGINS BA, 1992, J AM CHEM SOC, V114, P2098, DOI 10.1021/ja00032a025; KNOZINGER H, 1978, CATAL REV, V17, P31, DOI 10.1080/03602457808080878; LANGEL W, 1995, J CHEM PHYS, V103, P3240, DOI 10.1063/1.470256; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Lindan PJD, 1996, CHEM PHYS LETT, V261, P246, DOI 10.1016/0009-2614(96)00934-7; Lindan PJD, 1998, PHYS REV LETT, V80, P762, DOI 10.1103/PhysRevLett.80.762; LYGIN VI, 1995, RUSS J PHYS CHEM, V69, P1829; MANASSIDIS I, 1993, SURF SCI, V285, pL517, DOI 10.1016/0039-6028(93)90423-H; McHale JM, 1997, SCIENCE, V277, P788, DOI 10.1126/science.277.5327.788; Misra C, 1987, OXIDES HYDROXIDES AL; MORTERRA C, 1976, J CHEM SOC FARAD T 1, V72, P2722, DOI 10.1039/f19767202722; NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334; Nygren MA, 1997, SURF SCI, V380, P113, DOI 10.1016/S0039-6028(97)01596-3; Puchin VE, 1997, SURF SCI, V370, P190, DOI 10.1016/S0039-6028(96)00971-5; SCHEINER S, 1992, NATO ADV SCI I B-PHY, V291, P29; THIEL PA, 1987, SURF SCI REP, V7, P211, DOI 10.1016/0167-5729(87)90001-X; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993; Tsyganenko AA, 1996, J CHEM SOC FARADAY T, V92, P4843, DOI 10.1039/ft9969204843; Wittbrodt JM, 1998, J PHYS CHEM B, V102, P6539, DOI 10.1021/jp981516w; Zare RN, 1998, SCIENCE, V279, P1875, DOI 10.1126/science.279.5358.1875	36	478	478	7	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1998	282	5387					265	268		10.1126/science.282.5387.265	http://dx.doi.org/10.1126/science.282.5387.265			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765145				2022-12-28	WOS:000076370200038
J	Eisenberger, MA; Blumenstein, BA; Crawford, ED; Miller, G; McLeod, DG; Loehrer, PJ; Wilding, G; Sears, K; Culkin, DJ; Thompson, IM; Bueschen, AJ; Lowe, BA				Eisenberger, MA; Blumenstein, BA; Crawford, ED; Miller, G; McLeod, DG; Loehrer, PJ; Wilding, G; Sears, K; Culkin, DJ; Thompson, IM; Bueschen, AJ; Lowe, BA			Bilateral orchiectomy with or without flutamide for metastatic prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III; PROGNOSTIC FACTORS; CLINICAL-TRIAL; CARCINOMA; DIETHYLSTILBESTROL; CASTRATION; NILUTAMIDE; THERAPY; ACETATE	Background Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. Methods We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. Results Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. Conclusions The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer. (N Engl J Med 1998;339: 1036-42.) (C) 1998, Massachusetts Medical Society.	SW Oncol Grp SWOG 8894, Operat Off, Ctr Stat, San Antonio, TX 78245 USA; Johns Hopkins Hosp, Baltimore, MD 21287 USA; Univ Colorado, Denver, CO 80202 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; Indiana Univ, Med Ctr, Indianapolis, IN USA; Univ Wisconsin, Ctr Clin Canc, Madison, WI USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; Brooke Army Med Ctr, Wilford Hall USAF Med Ctr, San Antonio, TX USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA	Southwest Oncology Group; Johns Hopkins University; Johns Hopkins Medicine; University of Colorado System; University of Colorado Denver; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; University of Wisconsin System; University of Wisconsin Madison; University of Oklahoma System; University of Oklahoma Health Sciences Center; San Antonio Military Medical Center; United States Department of Defense; United States Air Force; United States Army; Oregon Health & Science University	Eisenberger, MA (corresponding author), SW Oncol Grp SWOG 8894, Operat Off, Ctr Stat, 14980 Omicron Dr, San Antonio, TX 78245 USA.				NATIONAL CANCER INSTITUTE [U10CA038926, U10CA032102, U10CA042777] Funding Source: NIH RePORTER; NCI NIH HHS [CA32102, CA42777, CA38926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blumenstein B A, 1995, Urol Oncol, V1, P95, DOI 10.1016/1078-1439(95)00026-E; BLUMENSTEIN BA, 1993, CANCER, V72, P3834, DOI 10.1002/1097-0142(19931215)72:12+<3834::AID-CNCR2820721714>3.0.CO;2-Z; BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C; Caubet JF, 1997, UROLOGY, V49, P71, DOI 10.1016/S0090-4295(96)00325-1; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P1420; DALESIO O, 1995, LANCET, V346, P265; DENIS L, 1993, CANCER, V72, P3888, DOI 10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B; DENIS LJ, 1993, UROLOGY, V42, P119, DOI 10.1016/0090-4295(93)90634-M; EISENBERGER MA, 1994, SEMIN ONCOL, V21, P613; EISENBERGER MA, 1985, J CLIN ONCOL, V3, P827, DOI 10.1200/JCO.1985.3.6.827; EISENBERGER MA, 1986, J CLIN ONCOL, V4, P414, DOI 10.1200/JCO.1986.4.3.414; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; GARNICK MB, 1984, NEW ENGL J MED, V311, P1281; GELLER J, 1981, J CLIN ENDOCR METAB, V52, P576, DOI 10.1210/jcem-52-3-576; Huggins C, 1941, CANCER RES, V1, P293; JANKNEGT RA, 1993, J UROLOGY, V149, P77, DOI 10.1016/S0022-5347(17)36003-2; KUHN JM, 1989, NEW ENGL J MED, V321, P413, DOI 10.1056/NEJM198908173210701; LABRIE F, 1985, J STEROID BIOCHEM, V23, P833, DOI 10.1016/S0022-4731(85)80024-8; LABRIE F, 1988, JNCI-J NATL CANCER I, V80, P1138, DOI 10.1093/jnci/80.14.1138; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Parker SL, 1997, CA-CANCER J CLIN, V47, P68; PEELING WB, 1989, UROLOGY, V33, P45, DOI 10.1016/0090-4295(89)90106-4; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; RUBINSTEIN LV, 1981, J CHRON DIS, V34, P469, DOI 10.1016/0021-9681(81)90007-2	25	690	713	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1036	1042		10.1056/NEJM199810083391504	http://dx.doi.org/10.1056/NEJM199810083391504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761805				2022-12-28	WOS:000076294800004
J	Ferre-D'Amare, AR; Zhou, KH; Doudna, JA				Ferre-D'Amare, AR; Zhou, KH; Doudna, JA			Crystal structure of a hepatitis delta virus ribozyme	NATURE			English	Article							HDV ANTIGENOMIC RIBOZYME; SELF-CLEAVAGE ACTIVITY; INTERFERENCE ANALYSIS; PSEUDOKNOT STRUCTURE; HAMMERHEAD RIBOZYME; RNA SEQUENCES; CLEAVING RNA; SITE; PAIR; CORE	The self-cleaving ribozyme of the hepatitis delta virus (HDV) is the only catalytic RNA known to be required for the viability of a human pathogen. We obtained crystals of a 72-nucleotide, self-cleaved form of the genomic HDV ribozyme that diffract X-rays to 2.3 Angstrom resolution by engineering the RNA to bind a small, basic protein without affecting ribozyme activity. The co-crystal structure shows that the compact catalytic core comprises five helical segments connected as an intricate nested double pseudoknot. The 5'-hydroxyl leaving group resulting from the self-scission reaction is buried deep within an active-site cleft produced by juxtaposition of the helices and five strand-crossovers, and is surrounded by biochemically important backbone and base functional groups in a manner reminiscent of protein enzymes.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University	Doudna, JA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.	doudna@csb.yale.edu						ABRAHAMS JP, 1998, ACTA CRYSTALLOGR D, V54, P905; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Been MD, 1997, EUR J BIOCHEM, V247, P741, DOI 10.1111/j.1432-1033.1997.00741.x; BELINSKY MG, 1993, FASEB J, V7, P130, DOI 10.1096/fasebj.7.1.8422959; Bravo C, 1996, NUCLEIC ACIDS RES, V24, P1351, DOI 10.1093/nar/24.7.1351; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Duhamel J, 1996, NUCLEIC ACIDS RES, V24, P3911, DOI 10.1093/nar/24.20.3911; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; Ferre-D'Amare AR, 1998, J MOL BIOL, V279, P621, DOI 10.1006/jmbi.1998.1789; GLUICK TC, 1994, J MOL BIOL, V241, P246, DOI 10.1006/jmbi.1994.1493; Huang ZS, 1997, FEBS LETT, V413, P299, DOI 10.1016/S0014-5793(97)00902-2; JEOUNG YH, 1994, NUCLEIC ACIDS RES, V22, P3722, DOI 10.1093/nar/22.18.3722; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kolk MH, 1998, SCIENCE, V280, P434, DOI 10.1126/science.280.5362.434; Kolk MH, 1997, EMBO J, V16, P3685, DOI 10.1093/emboj/16.12.3685; KUMAR PKR, 1993, FASEB J, V7, P124, DOI 10.1096/fasebj.7.1.8422958; KUMAR PKR, 1994, BIOCHEMISTRY-US, V33, P583, DOI 10.1021/bi00168a025; KUMAR PKR, 1992, NUCLEIC ACIDS RES, V20, P3919, DOI 10.1093/nar/20.15.3919; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lynch SR, 1998, NUCLEIC ACIDS RES, V26, P980, DOI 10.1093/nar/26.4.980; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishikawa F, 1997, NUCLEIC ACIDS RES, V25, P1605, DOI 10.1093/nar/25.8.1605; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PERROTTA AT, 1990, NUCLEIC ACIDS RES, V18, P6821, DOI 10.1093/nar/18.23.6821; Perrotta AT, 1996, NUCLEIC ACIDS RES, V24, P1314, DOI 10.1093/nar/24.7.1314; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RICHARDS FM, 1971, ENZYMES, V4, P647; ROSENSTEIN SP, 1991, NUCLEIC ACIDS RES, V19, P5409, DOI 10.1093/nar/19.19.5409; Rosenstein SP, 1996, BIOCHEMISTRY-US, V35, P11403, DOI 10.1021/bi9609984; ROSENSTEIN SP, 1990, BIOCHEMISTRY-US, V29, P8011, DOI 10.1021/bi00487a002; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; SUH YA, 1993, NUCLEIC ACIDS RES, V21, P3277, DOI 10.1093/nar/21.14.3277; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; TANNER NK, 1994, CURR BIOL, V4, P488, DOI 10.1016/S0960-9822(00)00109-3; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; THILL G, 1993, BIOCHEMISTRY-US, V32, P4254, DOI 10.1021/bi00067a013; Wadkins TS, 1997, NUCLEIC ACIDS RES, V25, P4085, DOI 10.1093/nar/25.20.4085; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831	49	607	627	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 8	1998	395	6702					567	574		10.1038/26912	http://dx.doi.org/10.1038/26912			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783582				2022-12-28	WOS:000076362900038
J	Kanwisher, N; Downing, P				Kanwisher, N; Downing, P			Neuroscience - Separating the wheat from the chaff	SCIENCE			English	Editorial Material							ATTENTION; MT		MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Kanwisher, N (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.			Downing, Paul/0000-0002-5046-2858				Beauchamp MS, 1997, J NEUROPHYSIOL, V78, P516, DOI 10.1152/jn.1997.78.1.516; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; CULHAM JC, IN PRESS J NEUROPHYS; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DRIVER J, IN PRESS VIS COGN; DUNCAN J, 1984, J EXP PSYCHOL GEN, V113, P501, DOI 10.1037/0096-3445.113.4.501; HELMHOLTZ H, 1850, HDB PHYSL OPTIK; Kastner S, 1998, SCIENCE, V282, P108, DOI 10.1126/science.282.5386.108; OCraven KM, 1997, NEURON, V18, P591, DOI 10.1016/S0896-6273(00)80300-1; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; Pylyshyn Z., 1988, SPATIAL VISION, V3, P1, DOI [DOI 10.1163/156856888X00122, 10.1163/156856888X00122]; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; vonGrunau M, 1995, PERCEPTION, V24, P1297, DOI 10.1068/p241297; Wojciulik E, 1998, J NEUROPHYSIOL, V79, P1574, DOI 10.1152/jn.1998.79.3.1574; WOJCIULIK E, 1998, NEUROIMAGE, V7, pS78	15	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					57	58		10.1126/science.282.5386.57	http://dx.doi.org/10.1126/science.282.5386.57			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	126LM	9786798				2022-12-28	WOS:000076294900034
J	Murphy, VJ; Harrison, LC; Rudert, WA; Luppi, P; Trucco, M; Fierabracci, A; Biro, PA; Bottazzo, GF				Murphy, VJ; Harrison, LC; Rudert, WA; Luppi, P; Trucco, M; Fierabracci, A; Biro, PA; Bottazzo, GF			Retroviral superantigens and type 1 diabetes mellitus	CELL			English	Letter							AUTOIMMUNE		Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Parkville, Vic 3050, Australia; Univ Pittsburgh, Sch Med, Dept Pediat, Div Immunogenet, Pittsburgh, PA 15213 USA; Childrens Hosp, Pittsburgh, PA 15213 USA; St Bartholomews & Royal London Sch Med & Dent, Dept Immunol, London E1 2AD, England; Autoimmune Dis Charitable Trust, London NW3 4AN, England	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of London; Queen Mary University London	Bottazzo, GF (corresponding author), Osped Pediat Bambino Gesu, Inst Sci, Direz Sci, Via Piazza S Onofrio 4, I-00165 Rome, Italy.		Luppi, Pierre-Hervé/C-4333-2014; Fierabracci, Alessandra/K-5930-2016	Luppi, Pierre-Hervé/0000-0002-0503-423X; Fierabracci, Alessandra/0000-0003-3078-9754				Benoist C, 1997, NATURE, V388, P833, DOI 10.1038/42145; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; Nakagawa K, 1996, IMMUNOL REV, V152, P193, DOI 10.1111/j.1600-065X.1996.tb00917.x	4	48	48	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					9	11		10.1016/S0092-8674(00)81775-4	http://dx.doi.org/10.1016/S0092-8674(00)81775-4			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778241	Bronze			2022-12-28	WOS:000076242300003
J	Sayos, J; Wu, C; Morra, M; Wang, N; Zhang, X; Allen, D; van Schaik, S; Notarangelo, L; Geha, R; Roncarolo, MG; Oettgen, H; De Vries, JE; Aversa, G; Terhorst, C				Sayos, J; Wu, C; Morra, M; Wang, N; Zhang, X; Allen, D; van Schaik, S; Notarangelo, L; Geha, R; Roncarolo, MG; Oettgen, H; De Vries, JE; Aversa, G; Terhorst, C			The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM	NATURE			English	Article							LYMPHOCYTIC ACTIVATION MOLECULE; T-CELL ACTIVATION; CONTIG; PROLIFERATION; REGION	In addition to triggering the activation of B- or T-cell antigen receptors, the binding of a ligand to its receptor at the cell surface can sometimes determine the physiological outcome of interactions between antigen-presenting cells, Tend B lymphocytes. The protein SLAM (also known as CDw150), which is present on the surface of B and T cells, forms such a receptor-ligand pair as it is a self-ligand. We now show that a T-cell-specific, SLAM-associated protein (SAP), which contains an SH2 domain end a short tail, acts as an inhibitor by blocking recruitment of the SH2-domain-containing signal-transduction molecule SHP-2 to a docking site in the SLAM cytoplasmic region. The gene encoding SAP maps to the same area of the X chromosome as the locus for X-linked lymphoproliferative disease (XLP) and we found mutations In the SAP gene in three XLP patients. Absence of the Inhibitor SAP In XLP patients affects T/B-cell Interactions Induced by SLAM, leading to an inability to control B-cell proliferation caused by Epstein-Barr virus infections.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Immunol, Boston, MA 02215 USA; Univ Brescia, Dept Pediat, I-25125 Brescia, Italy; Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; Telethon Inst Gene Therapy, Cellular Therapy Lab, I-20132 Milan, Italy; Novartis Forschungsinst Geselsch Mbh, A-1235 Vienna, Austria	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Brescia; Harvard University; Boston Children's Hospital; Harvard Medical School; Fondazione Telethon	Sayos, J (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Immunol, Boston, MA 02215 USA.	jortega@bidmc.harvard.edu; terhorst@bidmc.harvard.edu	van Schaik, Sandrijn M/H-9078-2019; Notarangelo, Luigi D/F-9718-2016; Sayos, Joan/B-6119-2009	Notarangelo, Luigi D/0000-0002-8335-0262; Sayos, Joan/0000-0002-4664-3461; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon [TGT97000, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Aversa G, 1997, J IMMUNOL, V158, P4036; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Carballido JM, 1997, J IMMUNOL, V159, P4316; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; COOPER DN, 1993, HUMAN GENE MUTATIONS; deAos I, 1997, J BIOL CHEM, V272, P25310, DOI 10.1074/jbc.272.40.25310; Ferrante P, 1998, J IMMUNOL, V160, P1514; Isomaki P, 1997, J IMMUNOL, V159, P2986; Lamartine J, 1996, EUR J HUM GENET, V4, P342; Lanyi A, 1997, GENOMICS, V39, P55, DOI 10.1006/geno.1996.4466; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Porta G, 1997, GENOME RES, V7, P27, DOI 10.1101/gr.7.1.27; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; PURTILO DT, 1983, IMMUNOL TODAY, V4, P291, DOI 10.1016/0167-5699(83)90139-1; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; ROUSSET F, 1986, CLIN EXP IMMUNOL, V63, P280; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; Sutkowski N, 1996, J EXP MED, V184, P971, DOI 10.1084/jem.184.3.971; WANG BP, 1995, INT IMMUNOL, V7, P435, DOI 10.1093/intimm/7.3.435	23	736	769	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					462	469		10.1038/26683	http://dx.doi.org/10.1038/26683			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774102				2022-12-28	WOS:000076212200046
J	Jones, AH				Jones, AH			Mental illness made public: ending the stigma?	LANCET			English	Article									Univ Texas, Med Branch, Inst Med Humanities, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Jones, AH (corresponding author), Univ Texas, Med Branch, Inst Med Humanities, 2-210 Ashbel Smith Bldg,301 Univ Blvd, Galveston, TX 77555 USA.		Corbin, Melody/B-8937-2009					Coupland Douglas, 1991, GENERATION 10 TALES; CRONKITE K, 1994, EDGE DARKNESS CONVER; DUKE P, 1992, BRILLIANT MADNESS LI, pR17; Jamison KR., 2015, UNQUIET MIND MEMOIR, V4; STYRON W, 1996, CHICAGO HUMANITIES F, V7; STYRON W, 1990, DARKNESS VISIBLE MEM, P67; WEISSMAN MM, 1992, JAMA-J AM MED ASSOC, V268, P3098, DOI 10.1001/jama.1992.03490210080039; Wurtzel E., 1994, PROZAC NATION YOUNG	8	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1060	1060		10.1016/S0140-6736(98)08418-9	http://dx.doi.org/10.1016/S0140-6736(98)08418-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759772				2022-12-28	WOS:000076121800052
J	Kemp, M				Kemp, M			Gray's greyness	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	3	3	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					333	333		10.1038/26372	http://dx.doi.org/10.1038/26372			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759722				2022-12-28	WOS:000076083800032
J	Roelfsema, PR; Lamme, VAF; Spekreijse, H				Roelfsema, PR; Lamme, VAF; Spekreijse, H			Object-based attention in the primary visual cortex of the macaque monkey	NATURE			English	Article							SELECTIVE ATTENTION; STRIATE CORTEX; FOCAL ATTENTION; AREAS V1; ORGANIZATION; MODULATION; RESPONSES; ALERT; V2; V4	Typical natural visual scenes contain many objects, which need to be segregated from each other and from the background. Present theories subdivide the processes responsible for this segregation into a pre-attentive and attentive system(1,2). The pre-attentive system segregates image regions that 'pop out' rapidly and in parallel across the visual field. In the primary visual cortex, responses to pre-attentively selected image regions are enhanced(3-5). When objects do not segregate automatically from the rest of the image, the time-consuming attentive system is recruited. Here we investigate whether attentive selection is also associated with a modulation of firing rates in area V1 of the brain in monkeys trained to perform a curve-tracing task(6,7). Neuronal responses to the various segments of a target curve were simultaneously enhanced relative to responses evoked by a distracter curve, even if the two curves crossed each other. This indicates that object-based attention is associated with a response enhancement at the earliest level of the visual cortical processing hierarchy.	Grad Sch Neurosci Amsterdam, Lab Med Phys, NL-1100 AC Amsterdam, Netherlands; Netherlands Ophthalm Res Inst, Dept Visual Syst Anal, Acad Med Ctr, NL-1100 AC Amsterdam, Netherlands	University of Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam	Roelfsema, PR (corresponding author), Grad Sch Neurosci Amsterdam, Lab Med Phys, POB 12141, NL-1100 AC Amsterdam, Netherlands.	p.roelfsema@ioi.knaw.nl	Roelfsema, Pieter/J-6903-2013	Roelfsema, Pieter/0000-0002-1625-0034				Bosking WH, 1997, J NEUROSCI, V17, P2112; BOUR LJ, 1984, IEEE T BIO-MED ENG, V31, P419, DOI 10.1109/TBME.1984.325281; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; DUNCAN J, 1984, J EXP PSYCHOL GEN, V113, P501, DOI 10.1037/0096-3445.113.4.501; GATTASS R, 1981, J COMP NEUROL, V201, P519, DOI 10.1002/cne.902010405; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; JOLICOEUR P, 1986, MEM COGNITION, V14, P129, DOI 10.3758/BF03198373; Kanwisher N., 1992, CURR DIR PSYCHOL SCI, V1, P26; KAPADIA MK, 1995, NEURON, V15, P843, DOI 10.1016/0896-6273(95)90175-2; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; KRAMER AF, 1991, PERCEPT PSYCHOPHYS, V50, P267, DOI 10.3758/BF03206750; LAMME VAF, 1995, J NEUROSCI, V15, P1605; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; MAUSELL JHR, 1995, SCIENCE, V270, P764; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; NELSON JI, 1985, EXP BRAIN RES, V61, P54; Polat U, 1998, NATURE, V391, P580, DOI 10.1038/35372; POSNER MI, 1980, J EXP PSYCHOL GEN, V109, P160, DOI 10.1037/0096-3445.109.2.160; POSNER MI, 1987, TRENDS NEUROSCI, V10, P13, DOI 10.1016/0166-2236(87)90116-0; Press W. A., 1997, Society for Neuroscience Abstracts, V23, P1026; PRINGLE R, 1988, J EXP PSYCHOL HUMAN, V14, P716, DOI 10.1037/0096-1523.14.4.716; ROCK I, 1990, SCI AM, V263, P48; Schmidt KE, 1997, EUR J NEUROSCI, V9, P1083, DOI 10.1111/j.1460-9568.1997.tb01459.x; SNODDERLY DM, 1995, J NEUROPHYSIOL, V74, P2100, DOI 10.1152/jn.1995.74.5.2100; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; WURTZ RH, 1976, J NEUROPHYSIOL, V39, P766, DOI 10.1152/jn.1976.39.4.766; Zipser K, 1996, J NEUROSCI, V16, P7376	30	592	596	1	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					376	381		10.1038/26475	http://dx.doi.org/10.1038/26475			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	122QW	9759726				2022-12-28	WOS:000076083800052
J	Havlir, DV; Marschner, IC; Hirsch, MS; Collier, AC; Tebas, P; Bassett, RL; Ioannidis, JPA; Holohan, MK; Leavitt, R; Boone, G; Richman, DD				Havlir, DV; Marschner, IC; Hirsch, MS; Collier, AC; Tebas, P; Bassett, RL; Ioannidis, JPA; Holohan, MK; Leavitt, R; Boone, G; Richman, DD		AIDS Clin Trials Grp Study 343 Team	Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CUBIC MILLIMETER; ZIDOVUDINE; LAMIVUDINE; SUPPRESSION; REPLICATION; RESERVOIR; INDINAVIR; DYNAMICS	Background Combination antiretroviral therapy with indinavir, zidovudine, and lamivudine can suppress the level of human immunodeficiency virus (HIV) RNA in plasma below the threshold of detection for two years or more. We investigated whether a less intensive maintenance regimen could sustain viral suppression after an initial response to combination therapy. Methods HIV-infected subjects who had CD4 cell counts greater than 200 per cubic millimeter, who had been treated with indinavir, lamivudine, and zidovudine, and who had less than 200 copies of HIV RNA per milliliter of plasma after 16, 20, and 24 weeks of induction therapy were randomly assigned to receive either continued triple-drug therapy (106 subjects), indinavir alone (103 subjects), or a combination of zidovudine and lamivudine (107 subjects). The primary end point was loss of viral suppression, which was defined as a plasma level of at least 200 copies of HIV RNA per milliliter on two consecutive measurements during maintenance therapy. Results During maintenance treatment, 23 percent of the subjects receiving indinavir and 23 percent of those receiving zidovudine and lamivudine, but only 4 percent of those receiving all three drugs, had loss of viral suppression (P<0.001 for the comparison between triple-drug therapy and the other two maintenance regimens). Subjects with greater increases in CD4 cell counts during induction therapy, higher viral loads at base line (i.e., at the beginning of induction therapy), and slower rates of viral clearance were at greater risk for loss of viral suppression. The presence of zidovudine-resistance mutations in HIV RNA at base line was strongly predictive of the loss of viral suppression in subjects treated with zidovudine and lamivudine. Conclusions The suppression of plasma HIV RNA after six months of treatment with indinavir, zidovudine, and lamivudine is better sustained by the continuation of these three drugs than by maintenance therapy with either indinavir alone or zidovudine and lamivudine. (N Engl J Med 1998;339:1261-8.) (C)1998, Massachusetts Medical Society.	Univ Calif San Diego, San Diego, CA 92103 USA; San Diego Vet Affairs Med Ctr, San Diego, CA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Sch Med, Seattle, WA USA; Washington Univ, St Louis, MO USA; NIAID, Div Aids, Bethesda, MD 20892 USA; Aids Clin Trials Grp, Operat Ctr, Rockville, MD USA; Merck & Co Inc, W Point, PA USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	University of California System; University of California San Diego; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Merck & Company; GlaxoSmithKline	Havlir, DV (corresponding author), Univ Calif San Diego, 2760 5th Ave,Suite 300, San Diego, CA 92103 USA.		Ioannidis, John P. A./G-9836-2011; Tebas, Pablo/A-7061-2008	Tebas, Pablo/0000-0001-5345-7942; Marschner, Ian/0000-0002-6225-1572	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, P30AI036214, U01AI038858] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38858, AI36214, AI27670] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Cavert W, 1997, SCIENCE, V276, P1321; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHAISSON MA, 1998, 5 C RETR OPP INF CHI, P80; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Collett D, 1994, MODELLING SURVIVAL D; De Boer RJ, 1998, AIDS, V12, P1567, DOI 10.1097/00002030-199813000-00002; DEEKS SG, 1998, 5 C RETR OPP INFE CH, P224; deJong MD, 1996, P NATL ACAD SCI USA, V93, P5501, DOI 10.1073/pnas.93.11.5501; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HICKS C, 1998, 5 C RET OPP INF CHIC, P209; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; LAL R, 1998, 5 C RETR OPP INF CHI, P201; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEAVITT R, 1996, 36 INT C ANT AG CHEM, P206; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; MCLEAN AR, 1991, AIDS, V5, P485, DOI 10.1097/00002030-199105000-00002; OH MD, 1998, 5 C RETR OPP INFE CH, P198; OPRAVIL M, 1997, ANTIVIRAL THER, V2, P62; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; RAFFI F, 1998, 5 C RETR OPP INF CHI, P225; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; Rutschmann OT, 1998, AIDS, V12, pF71, DOI 10.1097/00002030-199808000-00003; STRUYVER L, 1997, ANTIMICROB AGENTS CH, V41, P284; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wein LM, 1998, J THEOR BIOL, V192, P81, DOI 10.1006/jtbi.1997.0622; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	33	262	271	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1261	1268		10.1056/NEJM199810293391801	http://dx.doi.org/10.1056/NEJM199810293391801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132XC	9791141	Bronze			2022-12-28	WOS:000076655300001
J	Pialoux, G; Raffi, F; Brun-Vezinet, F; Meiffredy, V; Flandre, P; Gastaut, JA; Dellamonica, P; Yeni, P; Delfraissy, JF; Aboulker, JP				Pialoux, G; Raffi, F; Brun-Vezinet, F; Meiffredy, V; Flandre, P; Gastaut, JA; Dellamonica, P; Yeni, P; Delfraissy, JF; Aboulker, JP		Trilege Study Team	A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; HIV-1 INFECTION; ANTIRETROVIRAL THERAPY; CUBIC MILLIMETER; VIRAL LOAD; PLASMA; RNA; LYMPHOCYTES; MARKERS; ADULTS	Background The long-term effectiveness of potent three-drug antiretroviral regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection is limited by problems related to compliance and tolerability. We investigated whether two-drug maintenance therapy would suppress viral replication after a three-month period of aggressive triple-drug induction therapy. Methods A total of 378 HIV-1-infected adults who had not received previous antiretroviral treatment received three months of induction therapy consisting of 300 mg of zidovudine every 12 hours, 150 mg of lamivudine every 12 hours, and 800 mg of indinavir every 8 hours. The 279 patients in whom the plasma HIV-1 RNA titer fell below 500 copies per milliliter after two months of triple-drug therapy, and who completed the induction phase, were randomly assigned at month 3 to one of the following three open-label maintenance regimens: zidovudine, lamivudine, and indinavir; zidovudine and lamivudine; or zidovudine and indinavir. The primary end point was an increase in HIV-1 RNA levels to 500 copies or more per milliliter during the maintenance phase. Results The proportion of patients who reached the primary end point was significantly higher among patients receiving zidovudine plus lamivudine (29 of 93 patients, P<0.001) or zidovudine plus indinavir (21 of 94, P=0.01) than among patients receiving continued triple-drug therapy (8 of 92). This higher failure rate in the groups treated with the two-drug maintenance regimens was also observed in the subgroup of patients with maximally suppressed HIV-1 RNA (below 50 copies per milliliter) at the time of randomization to maintenance therapy. Conclusions In HIV-1-infected adults not previously treated with antiretroviral drugs whose plasma HIV-1 RNA levels fell below 500 copies per milliliter after three months of induction therapy with zidovudine, lamivudine, and indinavir, two-drug maintenance therapy was less effective in sustaining a reduced viral load than continued three-drug therapy. (N Engl J Med 1998;339:1269-76.) (C)1998, Massachusetts Medical Society.	Hop Paris, Inst Pasteur & Assistance Publ, Paris, France; Hotel Dieu, Hop Nantes, Nantes, France; INSERM, Serv Commun 10, Villejuif, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; Hop St Marguerite, Marseille, France; Hop Archet, Nice, France; Hop Bicetre, Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Pialoux, G (corresponding author), Hop Rothschild, Serv Malad Infect, 33 Blvd Picpus, F-75012 Paris, France.		Flandre, Philippe/N-6314-2017	Flandre, Philippe/0000-0002-2612-3522				BrunVezinet F, 1997, LANCET, V350, P983, DOI 10.1016/S0140-6736(97)03380-1; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; deJong MD, 1997, AIDS, V11, pF79, DOI 10.1097/00002030-199711000-00002; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Katzenstein DA, 1997, NEW ENGL J MED, V337, P1097; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Mehta S, 1997, AIDS, V11, P1665, DOI 10.1097/00002030-199714000-00002; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, SCIENCE, V275, P14; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Moutouh L, 1996, P NATL ACAD SCI USA, V93, P6106, DOI 10.1073/pnas.93.12.6106	23	184	191	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1269	1276		10.1056/NEJM199810293391802	http://dx.doi.org/10.1056/NEJM199810293391802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132XC	9791142	Bronze			2022-12-28	WOS:000076655300002
J	Berger, A				Berger, A			Science commentary: Hypersensitivity revisited	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1110	1110						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784443	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000076755100023
J	Teng, HH; Dove, PM; Orme, CA; De Yoreo, JJ				Teng, HH; Dove, PM; Orme, CA; De Yoreo, JJ			Thermodynamics of calcite growth: Baseline for understanding biomineral formation	SCIENCE			English	Article							SHELL PROTEINS; CRYSTALLIZATION	The complexity of biomineralized structures suggests the potential of organic constituents for controlling energetic factors during crystal synthesis. Atomic force microscopy was used to investigate the thermodynamic controls on carbonate growth and to measure the dependence of step speed on step Length and the dependence of critical step Length on supersaturation in precisely controlled solutions. These data were used to test the classic Gibbs-Thomson relationship and provided the step edge free energies and free energy barriers to one-dimension nucleation for calcite. Addition of aspartic acid, a common component in biomineralizing systems, dramatically affected growth morphology and altered the magnitude of the surface energy.	Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA; Univ Calif Lawrence Livermore Natl Lab, Dept Chem & Mat Sci, Livermore, CA 94550 USA	University System of Georgia; Georgia Institute of Technology; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Dove, PM (corresponding author), Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA.		Dove, Patricia M/A-7911-2010; Orme, Christine A/A-4109-2009	Orme, Christine A/0000-0003-3652-3367				Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; BERMAN A, 1988, NATURE, V331, P546, DOI 10.1038/331546a0; BURTON WK, 1951, PHILOS T R SOC S-A, V243, P299, DOI 10.1098/rsta.1951.0006; Chernov A.A., 1995, SCI TECHNOLOGY CRYST, P67; Chernov AA, 1998, MATER SCI FORUM, V276-2, P71, DOI 10.4028/www.scientific.net/MSF.276-277.71; Drever J. I., 1988, GEOCHEMISTRY NATURAL; KERN R, 1969, GROWTH CRYSTALS, P3; Land TA, 1997, SURF SCI, V384, P136, DOI 10.1016/S0039-6028(97)00187-8; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MANN S, 1993, SCIENCE, V261, P1286, DOI 10.1126/science.261.5126.1286; MUCCI A, 1983, AM J SCI, V283, P780, DOI 10.2475/ajs.283.7.780; PAQUETTE J, 1995, GEOCHIM COSMOCHIM AC, V59, P735, DOI 10.1016/0016-7037(95)00004-J; Rashkovich L. N., 1991, KDP FAMILY SINGLE CR; SIKES CS, 1991, SURFACE REACTIVE PEP, P30; TENG H, UNPUB; Teng HH, 1997, AM MINERAL, V82, P878; Voronkov V. V., 1973, Soviet Physics - Crystallography, V18, P19; Walters DA, 1997, BIOPHYS J, V72, P1425, DOI 10.1016/S0006-3495(97)78789-7; Winter A., 1994, COCCOLITHOPHORES	19	454	461	7	294	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					724	727		10.1126/science.282.5389.724	http://dx.doi.org/10.1126/science.282.5389.724			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784126				2022-12-28	WOS:000076607500045
J	Grove, AS				Grove, AS			The X Factor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Intel Corp, Santa Clara, CA 95051 USA	Intel Corporation	Grove, AS (corresponding author), Intel Corp, Santa Clara, CA 95051 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1294	1294		10.1001/jama.280.15.1294	http://dx.doi.org/10.1001/jama.280.15.1294			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794293				2022-12-28	WOS:000076472500001
J	Bath, P				Bath, P			Alteplase not yet proven for acute ischaemic stroke	LANCET			English	Editorial Material									Univ Nottingham Hosp, Div Stroke Med, Nottingham NG7 2UH, England	University of Nottingham	Bath, P (corresponding author), Univ Nottingham Hosp, Div Stroke Med, Nottingham NG7 2UH, England.		Bath, Philip/F-9020-2011	Bath, Philip/0000-0003-2734-5132				Bath FJ, 1997, CEREBROVASC DIS, V7, P205, DOI 10.1159/000108192; Bath P, 1997, BRIT MED J, V315, P1167; Brott T, 1998, STROKE, V29, P1504, DOI 10.1161/01.STR.29.8.1504; CANDELISE L, 1995, LANCET, V346, P1509; DONNAN GA, 1996, JAMA-J AM MED ASSOC, V276, P995; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hommel M, 1996, NEW ENGL J MED, V335, P145; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Slyter H, 1998, STROKE, V29, P1725, DOI 10.1161/01.STR.29.8.1725; WARDLAW J, 1998, COCHRANE LIB	10	35	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1238	1239		10.1016/S0140-6736(98)00039-7	http://dx.doi.org/10.1016/S0140-6736(98)00039-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788448				2022-12-28	WOS:000076573800002
J	Mackie, GA				Mackie, GA			Ribonuclease E is a 5 '-end-dependent endonuclease	NATURE			English	Article							RIBOSOMAL-PROTEIN S20; ESCHERICHIA-COLI; MESSENGER-RNA; CLEAVAGE SITES; IN-VITRO; DEGRADATION; INVITRO; ENZYME; INVIVO; OVEREXPRESSION	The selective degradation of messenger RNAs enables cells to regulate the levels of particular mRNAs in response to changes in the environment. Ribonuclease (RNase) E (ref, 1), a single-strand-specific endonuclease(2-4) that is found in a multi-enzyme complex known as the 'degradosome'(5-7), initiates the degradation of many mRNAs in Escherichia coli(3,8,9). Its relative lack of sequence specificity and the presence of many potential cleavage sires in mRNA substrate(2,3) cannot explain why mRNA decay frequently proceeds in a net 5'-to-3' directian(9-11). I have prepared covalently dosed circular derivatives of natural substrates, the rpsT mRNA encoding ribosomal protein S20 (ref. 2) and the 9S precursor to 5S ribosomal RNA(1,12), and find that these derivatives are considerably more resistant to cleavage in vitro by RNase E than are linear molecules. Moreover, antisense oligo-deoxynucleotides complementary to the 5' end of linear substrates significantly reduce the latter's susceptibility to attack by RNase E. Finally, natural substrates with terminal 5'-h triphosphate groups are poorly cleaved by RNase E in vitro, whereas 5' monophosphorylated substrates are strongly preferred (compare with ref, 13). These results show that RNase E has inherent: vectorial properties, with its activity depending on the 5' end of its substrates; this can account for the direction of mRNA decay in E, coli, the phenomenon of 'all or none' mRNA decay, and the stabilization provided by 5' stem-loop structures(14-17).	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Mackie, GA (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	gamackie@unixg.ubc.ca						APIRION D, 1973, MOL GEN GENET, V122, P313, DOI 10.1007/BF00269431; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1998, J MOL BIOL, V279, P1061, DOI 10.1006/jmbi.1998.1842; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; HANSEN MJ, 1994, MOL MICROBIOL, V12, P707, DOI 10.1111/j.1365-2958.1994.tb01058.x; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Kennell D, 1986, MAXIMIZING GENE EXPR, P101; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; Mackie GA, 1997, J BIOL CHEM, V272, P609; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Nierlich DP, 1996, PROG NUCLEIC ACID RE, V52, P153, DOI 10.1016/S0079-6603(08)60967-8; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; STEVENS A, 1978, BIOCHEM BIOPH RES CO, V81, P656, DOI 10.1016/0006-291X(78)91586-3; XU E, 1995, NATURE, V374, P180; ZHU LQ, 1990, J BACTERIOL, V172, P3146, DOI 10.1128/jb.172.6.3146-3151.1990	28	323	328	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					720	723		10.1038/27246	http://dx.doi.org/10.1038/27246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790196				2022-12-28	WOS:000076472600058
J	Mor, E; Kaspa, RT; Sheiner, P; Schwartz, M				Mor, E; Kaspa, RT; Sheiner, P; Schwartz, M			Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Review							PERCUTANEOUS ETHANOL INJECTION; HEPATITIS-C VIRUS; TRANSCATHETER ARTERIAL EMBOLIZATION; SURGICAL RESECTION; RISK-FACTORS; MACROREGENERATIVE NODULES; COMPLICATING CIRRHOSIS; ALCOHOL INJECTION; MESSENGER-RNA; CHEMOEMBOLIZATION	Purpose: To review the treatment of cirrhotic patients with hepatocellular carcinoma in the era of liver transplantation and to determine the most appropriate approach to the treatment of patients at different stages of disease. Data Sources: A MEDLINE search of English-language articles published between 1981 and 1997 and the clinical experience of the Mount Sinai Liver Transplant Program. Study Selection: Selected studies were 1) original articles reporting results of resection and transplantation in the treatment of hepatocellular carcinoma in cirrhotic patients and 2) initial reports from major transplantation centers of multimethod therapies combining chemotherapy with transplantation. Data Extraction: Study designs were assessed with careful attention to methods and aims. Relevant data on patient population, tumor stage distribution, treatment, survival, and rate of recurrent disease were extracted and analyzed. Data Synthesis: Options for the treatment of hepatocellular carcinoma in cirrhotic patients vary according to tumor stage and severity of underlying liver disease. Resection remains an important method primarily in eastern countries, where the screening of high-risk populations has been associated with early detection of small asymptomatic lesions. Long-term survival after resection, how ever, is low. In western countries, liver transplantation is becoming the treatment of choice in patients with advanced cirrhosis and small, unresectable lesions; resection is reserved for cirrhotic patients with small, peripheral lesions and preserved hepatic function. Minimally invasive procedures (such as percutaneous ethanol injection and transarterial chemoembolization) have been developed to treat unresectable tumors. Transarterial chemoembolitation may also be effective in patients with advanced cirrhosis and unresectable lesions who are awaiting transplantation. Conclusions: The efficacy of liver transplantation for hepatocellular carcinoma has been proven mainly in patients with advanced cirrhosis and small lesions. Future studies may clarify the role of approaches combining neoadjuvant chemotherapy with transplantation for large (stage III) tumors.	Rabin Med Ctr, Dept Transplantat, IL-49100 Petah Tiqwa, Israel; CUNY, Mt Sinai Med Ctr, Recanati Miller Transplantat Inst, New York, NY 10029 USA	Rabin Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Mor, E (corresponding author), Rabin Med Ctr, Dept Transplantat, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	eytanmor@mail.netvision.net.il						BELGHITI J, 1991, ANN SURG, V214, P114, DOI 10.1097/00000658-199108000-00004; Bhattacharya S, 1997, HEPATOLOGY, V25, P613, DOI 10.1002/hep.510250320; BISMUTH H, 1992, AM J SURG, V163, P387, DOI 10.1016/0002-9610(92)90039-T; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; BISMUTH H, 1996, TRANSPLANT REV, V10, P13; Bruix J, 1996, GASTROENTEROLOGY, V111, P1018, DOI 10.1016/S0016-5085(96)70070-7; Bruix J, 1997, HEPATOLOGY, V25, P259; CARR BI, 1993, TRANSPLANT P, V25, P1128; CASTELLS A, 1993, HEPATOLOGY, V18, P1121; CASTELLS L, 1993, MED CLIN-BARCELONA, V100, P441; CHERQUI D, 1994, CANCER, V73, P2721, DOI 10.1002/1097-0142(19940601)73:11<2721::AID-CNCR2820731112>3.0.CO;2-K; CHUNG SW, 1994, AM J SURG, V167, P317, DOI 10.1016/0002-9610(94)90208-9; Colella G, 1997, TRANSPL P, V29, P492, DOI 10.1016/S0041-1345(96)00221-7; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; COLOMBO M, 1994, VIRAL HEPATITIS LIVE, P479; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; EBARA M, 1990, J GASTROEN HEPATOL, V5, P616, DOI 10.1111/j.1440-1746.1990.tb01115.x; FARMER DG, 1994, ANN SURG, V219, P236, DOI 10.1097/00000658-199403000-00003; Figueras J, 1997, TRANSPL P, V29, P495, DOI 10.1016/S0041-1345(96)00222-9; GOZZETTI G, 1993, J SURG ONCOL, P59; HAUG CE, 1992, TRANSPLANTATION, V53, P376, DOI 10.1097/00007890-199202010-00021; HILLAIRE S, 1994, GASTROENTEROLOGY, V106, P239, DOI 10.1016/S0016-5085(94)95705-3; HINO O, 1989, CANCER GENET CYTOGEN, V37, P273, DOI 10.1016/0165-4608(89)90059-9; HORIGUCHI Y, 1994, CANCER CHEMOTH PHARM, V33, pS111, DOI 10.1007/BF00686680; HYTIROGLOU P, 1995, HEPATOLOGY, V21, P703, DOI 10.1002/hep.1840210316; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; IKEDA K, 1993, CANCER, V71, P19, DOI 10.1002/1097-0142(19930101)71:1<19::AID-CNCR2820710105>3.0.CO;2-I; ISMAIL T, 1990, BRIT J SURG, V77, P983, DOI 10.1002/bjs.1800770908; IWATSUKI S, 1993, SEMIN SURG ONCOL, V9, P337, DOI 10.1002/ssu.2980090411; IWATSUKI S, 1991, ANN SURG, V214, P221, DOI 10.1097/00000658-199109000-00005; KAKAZU T, 1993, HEPATO-GASTROENTEROL, V40, P337; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; Kang J. Y., 1995, Digestive Surgery, V12, P79, DOI 10.1159/000172320; Kawasaki Seiji, 1995, Digestive Surgery, V12, P40, DOI 10.1159/000172314; Kenji J, 1997, Semin Oncol, V24, pS6; KEW MC, 1994, FEMS MICROBIOL REV, V14, P211, DOI 10.1111/j.1574-6976.1994.tb00091.x; Khakoo SI, 1996, MED CLIN N AM, V80, P1121, DOI 10.1016/S0025-7125(05)70482-X; KINAMI Y, 1986, WORLD J SURG, V10, P294, DOI 10.1007/BF01658148; KOBAYASHI S, 1994, CANCER, V73, P48, DOI 10.1002/1097-0142(19940101)73:1<48::AID-CNCR2820730110>3.0.CO;2-L; LIVRAGHI T, 1986, RADIOLOGY, V161, P309, DOI 10.1148/radiology.161.2.3020612; LIVRAGHI T, 1988, RADIOLOGY, V168, P313, DOI 10.1148/radiology.168.2.2839865; MarcosAlvarez A, 1996, ARCH SURG-CHICAGO, V131, P292; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; MATSUMURA M, 1994, HEPATOLOGY, V20, P1418, DOI 10.1002/hep.1840200607; MAZZAFERRO V, 1994, TRANSPLANT P, V26, P3557; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; MONDEN M, 1992, CANCER CHEMOTH PHARM, V31, pS38, DOI 10.1007/BF00687103; NAGAO T, 1987, ANN SURG, V205, P33, DOI 10.1097/00000658-198701000-00006; Nagashima I, 1996, SURGERY, V119, P40, DOI 10.1016/S0039-6060(96)80211-X; NAGASUE N, 1989, SURGERY, V106, P81; NAGASUE N, 1993, ANN SURG, V217, P375, DOI 10.1097/00000658-199304000-00009; Nakamura S, 1997, SEMIN ONCOL, V24, P46; NERENSTONE S, 1987, GASTROENTEROL CLIN N, V16, P603; OBERTI F, 1995, NEW ENGL J MED, V332, P1256; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OLTHOFF KM, 1990, ARCH SURG-CHICAGO, V125, P1261; OLTHOFF KM, 1995, ANN SURG, V221, P734, DOI 10.1097/00000658-199506000-00012; OTTO G, 1990, EUR J SURG ONCOL, V16, P346; Otto G, 1997, TRANSPL P, V29, P489, DOI 10.1016/S0041-1345(96)00220-5; PATERON D, 1994, J HEPATOL, V20, P65, DOI 10.1016/S0168-8278(05)80468-4; PENN I, 1991, SURGERY, V110, P726; PETERS M, 1994, Z GASTROENTEROL, V32, P146; PICHLMAYR R, 1992, CANCER CHEMOTH PHARM, V31, pS157, DOI 10.1007/BF00687127; PICHLMAYR R, 1994, HEPATOLOGY, V20, pS33, DOI 10.1016/0270-9139(94)90271-2; Que Florencia G., 1995, Digestive Surgery, V12, P45, DOI 10.1159/000172315; RINGE B, 1991, WORLD J SURG, V15, P270, DOI 10.1007/BF01659064; ROMANI F, 1994, J AM COLL SURGEONS, V178, P379; Ruster B, 1996, BIOCHEM BIOPH RES CO, V219, P911, DOI 10.1006/bbrc.1996.0340; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; SCHWARTZ M, 1997, 23 ANN M AM SOC TRAN; SCHWARTZ ME, 1995, J AM COLL SURGEONS, V180, P596; SEGAWA T, 1993, WORLD J SURG, V17, P663, DOI 10.1007/BF01659138; SHIJO H, 1991, CANCER-AM CANCER SOC, V67, P2626, DOI 10.1002/1097-0142(19910515)67:10<2626::AID-CNCR2820671038>3.0.CO;2-4; SPREAFICO C, 1994, RADIOLOGY, V192, P687, DOI 10.1148/radiology.192.3.8058934; STONE MJ, 1993, GASTROENTEROLOGY, V104, P196, DOI 10.1016/0016-5085(93)90852-4; SUENAGA M, 1992, WORLD J SURG, V16, P97, DOI 10.1007/BF02067120; TAKANO S, 1995, HEPATOLOGY, V21, P650; TAKENAKA K, 1990, WORLD J SURG, V14, P123, DOI 10.1007/BF01670561; Takenaka K, 1996, ARCH SURG-CHICAGO, V131, P71; TAKENAKA K, 1995, HEPATOLOGY, V22, P20, DOI 10.1002/hep.1840220104; TANAKA K, 1992, RADIOLOGY, V185, P457, DOI 10.1148/radiology.185.2.1329143; TANG ZY, 1993, SEMIN SURG ONCOL, V9, P293, DOI 10.1002/ssu.2980090403; Tani M, 1997, Semin Oncol, V24, pS6; TERADA T, 1993, CANCER, V72, P1551, DOI 10.1002/1097-0142(19930901)72:5<1551::AID-CNCR2820720511>3.0.CO;2-Q; THEISE ND, 1992, HEPATOLOGY, V16, P949, DOI 10.1002/hep.1840160416; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Tsai JF, 1997, BRIT J CANCER, V76, P968, DOI 10.1038/bjc.1997.493; Tsai Sun-Lung, 1995, Digestive Surgery, V12, P7, DOI 10.1159/000172310; *US DEP HHS, 1997, ANN REP US SCI REG T; Venook A P, 1995, Liver Transpl Surg, V1, P242, DOI 10.1002/lt.500010409; VENOOK AP, 1990, J CLIN ONCOL, V8, P1108, DOI 10.1200/JCO.1990.8.6.1108; YAMADA R, 1983, RADIOLOGY, V148, P397, DOI 10.1148/radiology.148.2.6306721; Yamamoto K, 1997, SEMIN ONCOL, V24, P50; Yamasaki S, 1991, HPB Surg, V3, P235, DOI 10.1155/1991/54751	94	177	187	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					643	653		10.7326/0003-4819-129-8-199810150-00013	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00013			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786813				2022-12-28	WOS:000076431800008
J	Moreno-Reyes, R; Suetens, C; Mathieu, F; Begaux, F; Zhu, D; Rivera, MT; Boelaert, M; Neve, J; Perlmutter, N; Vanderpas, J				Moreno-Reyes, R; Suetens, C; Mathieu, F; Begaux, F; Zhu, D; Rivera, MT; Boelaert, M; Neve, J; Perlmutter, N; Vanderpas, J			Kashin-Beck osteoarthropathy in rural Tibet in relation to selenium and iodine status	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	6th International Thyroid Symposium	MAY 08-11, 1996	GRAZ, AUSTRIA				GLUTATHIONE-PEROXIDASE; ENDEMIC CRETINISM; SERUM SELENIUM; DISEASE; SUPPLEMENTATION; HYPOTHYROIDISM; DEFICIENCY; BLOOD; AREA	Background and Methods Kashin-Beck disease is a degenerative osteoarticular disorder that is endemic to certain areas of Tibet, where selenium deficiency is also endemic; Because selenium is involved in thyroid hormone metabolism, we studied the relation among the serum selenium concentration, thyroid function, and Kashin-Beck disease in 575 subjects 5 to 15 years of age in 12 villages around Lhasa, Tibet, including 1 control village in which no subject had Kashin-Beck disease. Clinical, radiologic, and biochemical data were collected. Results Among the 575 subjects, 280 (49 percent) had Kashin-Beck disease, 267 (46 percent) had goiter, and 7 (1 percent) had cretinism. Of the 557 subjects in whom urinary iodine was measured, 66 per cent had a urinary iodine concentration of less than 2 mu g per deciliter (157 nmol per liter; normal, 5 to 25 mu g per deciliter [394 to 1968 nmol per liter]). The mean urinary iodine concentration was lower in subjects with Kashin-Beck disease than in control subjects (1.2 vs. 1.8 mu g per deciliter [94 vs. 142 nmol per liter], P<0.001) and hypothyroidism was more frequent (23 percent vs. 4 percent, P=0.01). Severe selenium deficiency was documented in all villages; 38 percent of subjects had serum concentrations of less than 5 ng per milliliter (64 nmol per liter; normal, 60 to 105 ng per milliliter [762 to 1334 nmol per liter]). When age and sex were controlled for in a multivariate analysis, low urinary iodine, high serum thyrotrophin, and low serum thyroxine-binding globulin Values were associated with an increased risk of Kashin-Beck disease, but a low serum selenium concentration was not. Conclusions In areas where severe selenium deficiency is endemic, iodine deficiency is a risk factor for Kashin-Beck disease. (N Engl J Med 1998;339: 1112-20.) (C) 1998, Massachusetts Medical Society.	Hop Erasme, Dept Nucl Med, B-1070 Brussels, Belgium; Inst Pharm, Lab Pharmaceut Chem, Brussels, Belgium; Childrens Univ Hosp, Dept Pediat Radiol, Brussels, Belgium; Free Univ Brussels, Sch Publ Hlth, Brussels, Belgium; Med Sans Frontiers, Brussels, Belgium; Ambroise Pare Hosp, Mons, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Moreno-Reyes, R (corresponding author), Hop Erasme, Dept Nucl Med, Route Lennik 808, B-1070 Brussels, Belgium.		Rivera, Maria/GYU-2150-2022; Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Jean, Vanderpas/0000-0003-0623-5612				Alfthan G, 1996, J TRACE ELEM MED BIO, V10, P77, DOI 10.1016/S0946-672X(96)80015-0; ALLANDER E, 1994, SCAND J RHEUMATOL S, V99, P36; [Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; BECK MA, 1994, J MED VIROL, V43, P166, DOI 10.1002/jmv.1890430213; Calomme MR, 1995, EXPERIENTIA, V51, P1208, DOI 10.1007/BF01944738; Chasseur C, 1997, LANCET, V350, P1074, DOI 10.1016/S0140-6736(05)70453-0; CONTEMPRE B, 1991, J CLIN ENDOCR METAB, V73, P213, DOI 10.1210/jcem-73-1-213; DELANGE F, 1972, J CLIN ENDOCR METAB, V34, P1059, DOI 10.1210/jcem-34-6-1059; DIPLOCK AT, 1987, AM J CLIN NUTR, V45, P1313, DOI 10.1093/ajcn/45.5.1313; DIPLOCK AT, 1993, AM J CLIN NUTR, V57, P256, DOI 10.1093/ajcn/57.2.256S; DUNN JT, 1986, SCI PUBLICATION PAHO, V502, P373; Greulich WW., 1959, CALIF MED, V91, P53; LOMBECK I, 1977, EUR J PEDIATR, V125, P81, DOI 10.1007/BF00470608; MA T, 1993, AM J CLIN NUTR, V57, P264; Mathieu F, 1997, INT ORTHOP, V21, P151, DOI 10.1007/s002640050139; MEINHOLD H, 1993, EXP CLIN ENDOCRINOL, V101, P87, DOI 10.1055/s-0029-1211212; Molle L., 1987, TRACE ELEM ANAL CHEM, V4, P349; NEVE J, 1995, J TRACE ELEM MED BIO, V9, P65, DOI 10.1016/S0946-672X(11)80013-1; NEVE J, 1991, J TRACE ELEM ELECT H, V5, P1; NEVE J, 1992, PURE APPL CHEM, V64, P765, DOI 10.1351/pac199264050765; PENG A, 1992, J TOXICOL ENV HEALTH, V35, P79, DOI 10.1080/15287399209531597; SOKOLOFF L, 1989, NEW YORK STATE J MED, V89, P486; SOKOLOFF L, 1989, NEW YORK STATE J MED, V89, P343; SOKOLOFF L, 1990, ANN RHEUM DIS, V49, P262, DOI 10.1136/ard.49.4.262; StGermain DL, 1997, THYROID, V7, P655; Thilly C.H., 1980, EPIDEMIOLOGIC SURVEY, P157; VANDERPAS J, 1984, CLIN ENDOCRINOL, V20, P327, DOI 10.1111/j.1365-2265.1984.tb00089.x; VANDERPAS JB, 1986, NEW ENGL J MED, V315, P791, DOI 10.1056/NEJM198609253151302; VANDERPAS JB, 1990, AM J CLIN NUTR, V52, P1087, DOI 10.1093/ajcn/52.6.1087; Wang YZ, 1996, RADIOLOGY, V201, P265, DOI 10.1148/radiology.201.1.8816556; Wu J, 1987, J Trace Elem Electrolytes Health Dis, V1, P39; Yang G Q, 1988, World Rev Nutr Diet, V55, P98; Yang Guang-Qi, 1995, Biomedical and Environmental Sciences, V8, P187	33	235	257	3	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1112	1120		10.1056/NEJM199810153391604	http://dx.doi.org/10.1056/NEJM199810153391604			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	129DP	9770558	Bronze			2022-12-28	WOS:000076448200004
J	Bonde, JPE; Ernst, E; Jensen, TK; Hjollund, NHI; Kolstad, H; Henriksen, TB; Scheike, T; Giwercman, A; Olsen, J; Skakkebaek, NE				Bonde, JPE; Ernst, E; Jensen, TK; Hjollund, NHI; Kolstad, H; Henriksen, TB; Scheike, T; Giwercman, A; Olsen, J; Skakkebaek, NE			Relation between semen quality and fertility: a population-based study of 430 first-pregnancy planners	LANCET			English	Article							INFERTILE COUPLES; SPERM COUNT; SURVIVAL; VOLUME; TIME; MEN	Background Semen analysis is part of the routine assessment of infertile couples. WHO defines a sperm concentration above 20x10(6) per mt seminal fluid as normal. We studied the association between semen quality and the probability of conception in a single menstrual cycle in Danish couples with no previous reproductive experience. Methods In 1992-94, we invited 52 255 trades-union members aged 20-35 years, who lived with a partner and had no children to take part in the study; 430 couples agreed. The couples discontinued use of contraception, and were followed up for six menstrual cycles or until a pregnancy was verified within this period. Each man was asked to provide a semen sample at enrolment (which was analysed without freezing). Women kept a daily record of vaginal bleeding and sexual activity. The association between semen quality and likelihood of pregnancy was assessed by logistic regression, adjusted for sexual activity and female factors associated with low fertility. Results There were 256 (59.5%) pregnancies among the 430 couples: 165 (65.0%) among those with a sperm concentration of 40x10(6)/mL or more and 84 (51.2%) among those with lower sperm concentrations. The probability of conception increased with increasing sperm concentration up to 40x10(6)/mL, but any higher sperm density was not associated with additional likelihood of pregnancy. The proportion of sperm with normal morphology was strongly related to likelihood of pregnancy independently of sperm concentration. Semen volume and motility were of limited value in pregnancy prediction. Interpretation Our study suggests that the current WHO guidelines for normal semen quality should be used with caution. Some men with sperm counts above the lower limit of the normal range defined by WHO may in fact be subfertile.	Aarhus Univ Hosp, Dept Occupat Med, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Obstet & Gynaecol, Perinatal Epidemiol Res Unit, DK-8000 Aarhus, Denmark; Univ Aarhus, Inst Anat, Reprod Toxicol Unit, DK-8000 Aarhus C, Denmark; Univ Aarhus, Steno Ctr, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark; Natl Hosp, Dept Growth & Reprod, Copenhagen, Denmark; Univ Copenhagen, Dept Biostat, DK-1168 Copenhagen, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Rigshospitalet; University of Copenhagen	Bonde, JPE (corresponding author), Aarhus Univ Hosp, Dept Occupat Med, Norrebrogade 37-39, DK-8000 Aarhus C, Denmark.			Scheike, Thomas/0000-0002-2148-4740; Jensen, Tina Kold/0000-0003-2311-5778; Hjollund, Niels Henrik I/0000-0002-6697-6597				AITKEN RJ, 1984, J ANDROL, V5, P321; Belsey MA, 1980, WHO LAB MANUAL EXAMI; BONDE JP, 1990, BRIT J IND MED, V47, P508; Bonde JPE, 1998, REPROD TOXICOL, V12, P19, DOI 10.1016/S0890-6238(97)00096-8; BOSTOFTE E, 1984, FERTIL STERIL, V41, P95; BOSTOFTE E, 1982, INT J ANDROL, V5, P267, DOI 10.1111/j.1365-2605.1982.tb00255.x; BOSTOFTE E, 1993, FERTIL STERIL, V59, P102; CHAMBERS JM, 1992, STAT MODELS S, P249; COLLINS JA, 1984, AM J OBSTET GYNECOL, V148, P527, DOI 10.1016/0002-9378(84)90741-5; COMHAIRE FH, 1993, REPROD TOXICOL, V7, P39, DOI 10.1016/0890-6238(93)90067-H; DUNPHY BC, 1989, FERTIL STERIL, V51, P324; *EUROMAC, 1992, INT J EPIDEMIOLOG S1, V21, pS1; GLAZENER CMA, 1987, HUM REPROD, V2, P665, DOI 10.1093/oxfordjournals.humrep.a136612; GWATKIN RBL, 1990, FERTIL STERIL, V53, P693; HOSMER DW, 1989, APPL LOGISTIC REGRES; Jelnes J E, 1988, Reprod Toxicol, V2, P209, DOI 10.1016/0890-6238(88)90024-X; MACLEOD J, 1951, FERTIL STERIL, V2, P115; MEISTRICH ML, 1983, FERTIL STERIL, V40, P220; OLSEN J, 1994, J EPIDEMIOL COMMUN H, V48, P171, DOI 10.1136/jech.48.2.171; POLANSKY FF, 1988, FERTIL STERIL, V49, P1059; ROWE PJ, 1993, WHO MANUAL STANDARDI; Scheike TH, 1997, BIOMETRICS, V53, P318, DOI 10.2307/2533117; SCHWARTZ D, 1979, J REPROD FERTIL, V57, P391; WANG C, 1988, J ANDROL, V9, P384; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Zinaman MJ, 1996, FERTIL STERIL, V65, P503, DOI 10.1016/S0015-0282(16)58144-8	26	520	536	1	36	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1172	1177		10.1016/S0140-6736(97)10514-1	http://dx.doi.org/10.1016/S0140-6736(97)10514-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777833				2022-12-28	WOS:000076415400008
J	D'Hondt, S; Donaghay, P; Zachos, JC; Luttenberg, D; Lindinger, M				D'Hondt, S; Donaghay, P; Zachos, JC; Luttenberg, D; Lindinger, M			Organic carbon fluxes and ecological recovery from the Cretaceous-Tertiary mass extinction	SCIENCE			English	Article							STABLE-ISOTOPE; BOUNDARY; FORAMINIFERA; RECORD; MAGNETOSTRATIGRAPHY; SITE-528; CLIMATE; TETHYS; OCEANS	Differences between the carbon isotopic values of carbonates secreted by planktic and benthic organisms did not recover to stable preextinction Levels for more than 3 million years after the Cretaceous-Tertiary mass extinction. These decreased differences may have resulted from a smaller proportion of marine biological production sinking to deep water in the postextinction ocean. Under this hypothesis, marine production may have recovered shortly after the mass extinction, but the structure of the open-ocean ecosystem did not fully recover for more than 3 million years.	Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA	University of Rhode Island; University of California System; University of California Santa Cruz	D'Hondt, S (corresponding author), Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA.		Zachos, James C/A-7674-2008	Zachos, James C/0000-0001-8439-1886				ANGEL MV, 1989, LIFE SCI R, V44, P155; Arthur M.A., 1983, STABLE ISOTOPES SEDI; Barrera E, 1990, PALEOCEANOGRAPHY, V5, P867, DOI 10.1029/PA005i006p00867; BAUD A, 1989, GEOL RUNDSCH, V78, P649, DOI 10.1007/BF01776196; BERGER WH, 1989, PRODUCTIVITY OCEAN P, P49; BLEIL U, 1985, INITIAL REP DEEP SEA, V86, P441, DOI 10.2973/dsdp.proc.86.117.1985; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; Brand Larry E., 1994, P39; BUFFETAUT E, 1990, TECTONOPHYSICS, V171, P337, DOI 10.1016/0040-1951(90)90108-K; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; CHAVE AD, 1984, INITIAL REP DEEP SEA, V74, P525; CORFIELD RM, 1992, TERRA NOVA, V4, P443, DOI 10.1111/j.1365-3121.1992.tb00579.x; CORFIELD RM, 1994, EARTH-SCI REV, V37, P225, DOI 10.1016/0012-8252(94)90030-2; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; D'Hondt Steven, 1996, Geological Society of America Special Paper, V307, P303; DHONDT S, 1994, PALAEOGEOGR PALAEOCL, V112, P363, DOI 10.1016/0031-0182(94)90081-7; DHONDT S, 1994, PALEOBIOLOGY, V20, P391, DOI 10.1017/S0094837300012847; DHONDT S, IN PRESS PALEOBIOLOG; DHONDT S, 1988, LUNAR PLANET I CONBR, V673, P40; DHONDT S, 1995, GEOL SOC AM ABSTR, V27, pA164; FENCHEL T, 1988, ANNU REV ECOL SYST, V19, P19, DOI 10.1146/annurev.es.19.110188.000315; HOLLIS CJ, 1995, GEOLOGY, V23, P835, DOI 10.1130/0091-7613(1995)023<0835:SPBITE>2.3.CO;2; HOLSER WT, 1989, NATURE, V337, P39, DOI 10.1038/337039a0; HSU KJ, 1982, SCIENCE, V216, P249, DOI 10.1126/science.216.4543.249; HSU KJ, 1985, AM GEOPHYS UNION GEO, V32, P251; KELLER G, 1989, PALAEOGEOGR PALAEOCL, V73, P243, DOI 10.1016/0031-0182(89)90007-2; KUMP LR, 1991, GEOLOGY, V19, P299, DOI 10.1130/0091-7613(1991)019<0299:ICIESO>2.3.CO;2; Marshall CR, 1996, SCIENCE, V274, P1360, DOI 10.1126/science.274.5291.1360; MICHAELS AF, 1988, DEEP-SEA RES, V35, P473, DOI 10.1016/0198-0149(88)90126-4; Miller KG, 1987, PALEOCEANOGRAPHY, V2, P741, DOI 10.1029/PA002i006p00741; Paull CK, 1987, PALEOCEANOGRAPHY, V2, P423, DOI 10.1029/PA002i004p00423; Pope KO, 1997, J GEOPHYS RES-PLANET, V102, P21645, DOI 10.1029/97JE01743; Schlesinger WH., 1997, BIOGEOCHEMISTRY; SHACKLETON NJ, 1985, J FORAMIN RES, V15, P321, DOI 10.2113/gsjfr.15.4.321; SHACKLETON NJ, 1983, NATURE, V306, P319, DOI 10.1038/306319a0; SHACKLETON NJ, 1985, INITIAL REP DEEP SEA, V86, P503; SMIT J., 1982, GEOLOGICAL SOC AM SP, V190, P329, DOI DOI 10.1130/SPE190; Spero HJ, 1996, MAR MICROPALEONTOL, V28, P231, DOI 10.1016/0377-8398(96)00003-5; SPERO HJ, 1993, MAR MICROPALEONTOL, V22, P193; Stott L.D., 1990, Proceedings of the Ocean Drilling Program Scientific Results, V113, P829, DOI 10.2973/odp.proc.sr.113.158.1990; STOTT LD, 1989, NATURE, V342, P526, DOI 10.1038/342526a0; Taylor F.J.R., 1987, BIOL DINOFLAGELLATES, P399; Zachos JC, 1986, PALEOCEANOGRAPHY, V1, P5, DOI 10.1029/PA001i001p00005; ZACHOS JC, 1989, NATURE, V337, P61, DOI 10.1038/337061a0; ZACHOS JC, 1992, SCI RESULTS, V120, P961	45	201	209	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					276	279		10.1126/science.282.5387.276	http://dx.doi.org/10.1126/science.282.5387.276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765149				2022-12-28	WOS:000076370200042
J	Levasseur, S; Birck, JL; Allegre, CJ				Levasseur, S; Birck, JL; Allegre, CJ			Direct measurement of femtomoles of osmium and the Os-187/Os-186 ratio in seawater	SCIENCE			English	Article							ISOTOPIC COMPOSITION; MANGANESE NODULES; SEDIMENTS; OCEANS; SEA	Two depth profiles of the osmium concentration and the Os-187/Os-186 isotopic ratio in the Indian Ocean showed that the osmium concentration seems to be unaltered by chemical or biological processes occuring in seawater; accordingly, osmium is conservative. These data were obtained from an experimental method that eliminated the problems related to osmium preconcentration. This method led to a new evaluation of the concentration of osmium in seawater; the mean concentration of osmium and the Os-187/Os-186 ratio are equal to 10.86 +/- 0.07 picograms per kilogram and 8.80 +/- 0.07, respectively. The results suggest the existence of an organocomplex that dominates the speciation of osmium in seawater.	Univ Paris 07, Inst Phys Globe, Lab Geochim & Cosmochim, CNRS,URA 1758, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Levasseur, S (corresponding author), Univ Paris 07, Inst Phys Globe, Lab Geochim & Cosmochim, CNRS,URA 1758, 4 pl Jussieu, F-75252 Paris 05, France.		BIRCK, Jean Louis/A-6127-2011					ALLEGRE CJ, 1980, EARTH PLANET SC LETT, V48, P148, DOI 10.1016/0012-821X(80)90177-6; Anbar AD, 1996, SCIENCE, V273, P1524, DOI 10.1126/science.273.5281.1524; Birck JL, 1997, GEOSTANDARD NEWSLETT, V21, P19, DOI 10.1111/j.1751-908X.1997.tb00528.x; BROOKINS DG, 1988, EH PH DIAGRAMS GEOCH, P92; ESSER BK, 1993, GEOCHIM COSMOCHIM AC, V57, P3093, DOI 10.1016/0016-7037(93)90296-9; ESSER BK, 1988, GEOCHIM COSMOCHIM AC, V52, P1383, DOI 10.1016/0016-7037(88)90209-8; JACINTO GS, 1989, NATURE, V338, P332, DOI 10.1038/338332a0; Koide M, 1996, DEEP-SEA RES PT II, V43, P53, DOI 10.1016/0967-0645(95)00082-8; Krogh A, 1934, BIOL BULL-US, V67, P132, DOI 10.2307/1537488; LUCK JM, 1983, SCIENCE, V222, P613, DOI 10.1126/science.222.4624.613; Nier AO, 1937, PHYS REV, V52, P0885, DOI 10.1103/PhysRev.52.885; PEGRAM WJ, 1992, EARTH PLANET SC LETT, V113, P569, DOI 10.1016/0012-821X(92)90132-F; PEUCKEREHRENBRINK B, 1995, EARTH PLANET SC LETT, V130, P155, DOI 10.1016/0012-821X(95)00003-U; PeuckerEhrenbrink B, 1996, GEOLOGY, V24, P327; RAVIZZA G, 1993, EARTH PLANET SC LETT, V118, P335, DOI 10.1016/0012-821X(93)90177-B; RAVIZZA G, 1993, GEOCHIM COSMOCHIM AC, V57, P4301, DOI 10.1016/0016-7037(93)90324-P; RAVIZZA G, 1992, EARTH PLANET SC LETT, V110, P1, DOI 10.1016/0012-821X(92)90034-S; RICHTER FM, 1993, EARTH PLANET SC LETT, V119, P121, DOI 10.1016/0012-821X(93)90010-7; SACKETT WM, 1978, CHEM OCEANOGR, P127; Sharma M, 1997, GEOCHIM COSMOCHIM AC, V61, P5411, DOI 10.1016/S0016-7037(97)00329-3; Sharma M, 1997, GEOCHIM COSMOCHIM AC, V61, P3287, DOI 10.1016/S0016-7037(97)00210-X	21	163	176	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					272	274		10.1126/science.282.5387.272	http://dx.doi.org/10.1126/science.282.5387.272			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765147				2022-12-28	WOS:000076370200040
J	Makary, MA; Kawachi, I				Makary, MA; Kawachi, I			The International Tobacco Strategy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEVELOPING-COUNTRIES; HEALTH; PROMOTION; INDUSTRY		Georgetown Univ, Med Ctr, Washington, DC 20057 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA	Georgetown University; Harvard University; Harvard T.H. Chan School of Public Health	Makary, MA (corresponding author), Georgetown Univ, Med Ctr, Washington, DC 20057 USA.							BARRY M, 1991, NEW ENGL J MED, V324, P917, DOI 10.1056/NEJM199103283241311; BORLAND R, 1992, JAMA-J AM MED ASSOC, V268, P749, DOI 10.1001/jama.268.6.749; BOYD JW, 1995, LANCET, V346, P64, DOI 10.1016/S0140-6736(95)92104-4; BRUNNEMAN KD, 1988, AM HLTH FDN APR 12; CONNOLLY G, 1989, TOB US AM C HOUST TE, P49; *COUNC SCI AFF, 1990, JAMA-J AM MED ASSOC, V255, P993; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P993; Gilpin EA, 1997, PREV MED, V26, P14, DOI 10.1006/pmed.1996.9980; MACKAY J, 1994, PREV MED, V23, P535, DOI 10.1006/pmed.1994.1074; MASIRONI R, 1987, 6 WORLD C SMOK HLTH; PETO R, 1989, HONG KONG C SMOK JAN; PROFFITT WT, 1991, INVESTOR RESPONSIBIL; SCHELLING T, 1988, NY TIMES MAGAZINE, V62, P16; SIEGEL M, 1996, AM J PREV MED, V12, P2	14	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1194	1195		10.1001/jama.280.13.1194	http://dx.doi.org/10.1001/jama.280.13.1194			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777824				2022-12-28	WOS:000076210800038
J	Lower, R; Tonjes, RR; Boller, K; Denner, J; Kaiser, B; Phelps, RC; Lower, J; Kurth, R; Badenhoop, K; Donner, H; Usadel, KH; Miethke, T; Lapatschek, M; Wagner, H				Lower, R; Tonjes, RR; Boller, K; Denner, J; Kaiser, B; Phelps, RC; Lower, J; Kurth, R; Badenhoop, K; Donner, H; Usadel, KH; Miethke, T; Lapatschek, M; Wagner, H			Development of insulin-dependent diabetes mellitus does not depend on specific expression of the human endogenous retrovirus HERV-K	CELL			English	Letter							LONG TERMINAL REPEAT; REVERSE-TRANSCRIPTASE; HTDV/HERV-K; SEQUENCES; PROTEIN; IDENTIFICATION; SUPERANTIGEN; ANTIBODIES; PARTICLES; CELLS		Paul Ehrlich Inst, D-63225 Langen, Germany; Univ Frankfurt, Dept Med 1, D-60596 Frankfurt, Germany; Tech Univ Munich, Inst Med Microbiol, D-81675 Munich, Germany	Paul Ehrlich Institute; Goethe University Frankfurt; Technical University of Munich	Lower, R (corresponding author), Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.							Boller K, 1997, J VIROL, V71, P4581, DOI 10.1128/JVI.71.6.4581-4588.1997; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; GUNZBURG WH, 1993, NATURE, V364, P154, DOI 10.1038/364154a0; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, VIROLOGY, V192, P501, DOI 10.1006/viro.1993.1066; ONO M, 1986, J VIROL, V58, P937, DOI 10.1128/JVI.58.3.937-944.1986; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; Sauter M, 1996, CANCER RES, V56, P4362; Simpson GR, 1996, VIROLOGY, V222, P451, DOI 10.1006/viro.1996.0443; Tonjes RR, 1996, J ACQ IMMUN DEF SYND, V13, pS261; Tonjes RR, 1997, J VIROL, V71, P2747; VOGETSEDER W, 1993, AIDS RES HUM RETROV, V9, P687, DOI 10.1089/aid.1993.9.687; Weissmahr RN, 1997, J VIROL, V71, P3005, DOI 10.1128/JVI.71.4.3005-3012.1997	14	46	46	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					11	14		10.1016/S0092-8674(00)81776-6	http://dx.doi.org/10.1016/S0092-8674(00)81776-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778242	Bronze			2022-12-28	WOS:000076242300004
J	Marshall, B				Marshall, B			NSAIDs and Helicobacter pylori: therapeutic options	LANCET			English	Editorial Material							INFECTION; DISEASE; TRIAL		Sir Charles Gairdner Hosp, Natl Hlth & Med Res Council, Helicobacter Pylori Res Lab, Nedlands, WA 6009, Australia	University of Western Australia	Marshall, B (corresponding author), Sir Charles Gairdner Hosp, Natl Hlth & Med Res Council, Helicobacter Pylori Res Lab, Nedlands, WA 6009, Australia.			Marshall, Barry/0000-0003-4853-5015				Blaser MJ, 1996, ALIMENT PHARM THER, V10, P73, DOI 10.1046/j.1365-2036.1996.22164008.x; Chan FKL, 1997, LANCET, V350, P975, DOI 10.1016/S0140-6736(97)04523-6; Chey WD, 1996, AM J GASTROENTEROL, V91, P89; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; Hawkey C J, 1998, Am J Med, V104, p96S, DOI 10.1016/S0002-9343(97)00220-9; Jensen DM, 1998, GASTROENTEROLOGY, V114, pA161, DOI 10.1016/S0016-5085(98)80651-3; Konturek JW, 1998, GASTROENTEROLOGY, V114, P245, DOI 10.1016/S0016-5085(98)70474-3; LANZA FL, 1991, AM J GASTROENTEROL, V86, P735; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Pan ZJ, 1997, J CLIN MICROBIOL, V35, P1344, DOI 10.1128/JCM.35.6.1344-1347.1997; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001	11	7	7	2	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1001	1003		10.1016/S0140-6736(05)60069-4	http://dx.doi.org/10.1016/S0140-6736(05)60069-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759737				2022-12-28	WOS:000076121800003
J	Hines, P; Culotta, E				Hines, P; Culotta, E			The evolution of sex	SCIENCE			English	Editorial Material																			0	7	8	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					1979	1979		10.1126/science.281.5385.1979	http://dx.doi.org/10.1126/science.281.5385.1979			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9767048				2022-12-28	WOS:000076161800040
J	Pieters, T				Pieters, T			Marketing medicines through randomised controlled trials: the case of interferon	BRITISH MEDICAL JOURNAL			English	Article									Free Univ Amsterdam, Sch Med, Sect Med Hist, NL-1081 BT Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Pieters, T (corresponding author), Israelslaan 8-iv, NL-3582 HK Utrecht, Netherlands.			Pieters, Toine/0000-0002-8156-8436				Came PE, 1984, INTERFERONS THEIR AP; FENYVESI C, 1981, WASHINGTON POST 0114, P28; FINTER NB, 1985, INTERFERON, V4; Johnson R S, 1981, JAMA, V245, P109, DOI 10.1001/jama.245.2.109; KIRCHNER H, 1986, PROGR ONCOLOGY, P2; KIRCHNER H, 1987, PROGR VIROLOGY, P1; KROWN S, 1981, CANC ACHIEVEMENTS CH, P367; MARKS H, 1997, PROGR EXPT THERAPEUT; NEWMARK P, 1981, NATURE, V291, P105, DOI 10.1038/291105a0; PARKINSON DR, 1994, SEMIN ONCOL, V21, P1; PIETERS T, 1993, MED HIST, V37, P270, DOI 10.1017/S0025727300058452; PIETERS T, 1997, CLIN APPL INTERFERON, P1; PINSKY CM, 1986, SEMIN ONCOL, V13, P131; POWLEDGE TM, 1984, BIO-TECHNOL, V2, P214; SILVER HK, 1986, INTERFERONS CANC TRE; STUARTHARRIS R, 1997, CLIN APPL INTERFERON; SUN M, 1981, SCIENCE, V212, P141, DOI 10.1126/science.6163213; TAUBES G, 1995, SCIENCE, V267, P25, DOI 10.1126/science.7809605; THOMAS HC, 1987, INTERFERONS TODAY TO, P5; 1981, NY TIMES        1121; 1983, NEW SCI         1103	21	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1231	1233		10.1136/bmj.317.7167.1231	http://dx.doi.org/10.1136/bmj.317.7167.1231			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794868	Green Published, Green Submitted			2022-12-28	WOS:000076963000033
J	Wang, MD; Schnitzer, MJ; Yin, H; Landick, R; Gelles, J; Block, SM				Wang, MD; Schnitzer, MJ; Yin, H; Landick, R; Gelles, J; Block, SM			Force and velocity measured for single molecules of RNA polymerase	SCIENCE			English	Article							ESCHERICHIA-COLI; CHAIN ELONGATION; KINESIN MOLECULES; TERMINATION; DNA; TRANSCRIPTION; PAUSE; MECHANICS	RNA polymerase (RNAP) moves along DNA while carrying out transcription, acting as a molecular motor. Transcriptional velocities for single molecules of Escherichia coli RNAP were measured as progressively larger forces were applied by;a feedback-controlled optical trap. The shapes of RNAP force-velocity curves are distinct from those of the motor enzymes myosin or kinesin, and indicate that biochemical steps limiting transcription rates at Low loads do not generate movement. Modeling the data suggests-that high Loads may halt RNAP by promoting a structural change which moves all or part of the enzyme backwards through a comparatively Large distance, corresponding to 5 to 10 base pairs. This contrasts with previous models that assumed force acts directly upon a single-base translocation step.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02254 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Princeton University; Princeton University; Princeton University; Brandeis University; University of Wisconsin System; University of Wisconsin Madison	Block, SM (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	block@princeton.edu						ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BERG HC, 1993, BIOPHYS J, V65, P2201, DOI 10.1016/S0006-3495(93)81278-5; BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169, DOI 10.1016/S0962-8924(00)88982-5; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; CHAN CL, 1994, RAV S MOL C, V3, P297; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Julicher F, 1998, BIOPHYS J, V74, P1169, DOI 10.1016/S0006-3495(98)77833-6; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; Palangat M, 1998, MOL CELL, V1, P1033, DOI 10.1016/S1097-2765(00)80103-3; Press W.H., 1992, NUMERICAL RECIPES, V2, P650; REISBIG RR, 1981, BIOCHEMISTRY-US, V20, P1907, DOI 10.1021/bi00510a029; Saenger W., 1988, PRINCIPLES NUCL ACID; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang HY, 1998, BIOPHYS J, V74, P1186, DOI 10.1016/S0006-3495(98)77834-8; Wang M. D., 1996, Biophysical Journal, V70, pA44; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653	29	697	735	2	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1998	282	5390					902	907		10.1126/science.282.5390.902	http://dx.doi.org/10.1126/science.282.5390.902			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794753				2022-12-28	WOS:000076727300038
J	Wetterau, JR; Gregg, RE; Harrity, TW; Arbeeny, C; Cap, M; Connolly, F; Chu, CH; George, RJ; Gordon, DA; Jamil, H; Jolibois, KG; Kunselman, LK; Lan, SJ; Maccagnan, TJ; Ricci, B; Yan, MJ; Young, D; Chen, Y; Fryszman, OM; Logan, JVH; Musial, CL; Poss, MA; Robl, JA; Simpkins, LM; Slusarchyk, WA; Sulsky, R; Taunk, P; Magnin, DR; Tino, JA; Lawrence, RM; Dickson, JK; Biller, SA				Wetterau, JR; Gregg, RE; Harrity, TW; Arbeeny, C; Cap, M; Connolly, F; Chu, CH; George, RJ; Gordon, DA; Jamil, H; Jolibois, KG; Kunselman, LK; Lan, SJ; Maccagnan, TJ; Ricci, B; Yan, MJ; Young, D; Chen, Y; Fryszman, OM; Logan, JVH; Musial, CL; Poss, MA; Robl, JA; Simpkins, LM; Slusarchyk, WA; Sulsky, R; Taunk, P; Magnin, DR; Tino, JA; Lawrence, RM; Dickson, JK; Biller, SA			An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits	SCIENCE			English	Article							TRIGLYCERIDE-TRANSFER-PROTEIN; DISULFIDE-ISOMERASE; ABETALIPOPROTEINEMIA; SUBUNIT; GENE; COMPLEX; DEFECTS	Patients with abetalipoproteinemia, a disease caused by defects in the microsomal triglyceride transfer protein (MTP), do not produce apolipoprotein B-containing lipoproteins. It was hypothesized that small molecule inhibitors of MTP would prevent the assembly and secretion of these atherogenic lipoproteins. To test this hypothesis, two compounds identified in a high-throughput screen for MTP inhibitors were used to direct the synthesis of a highly potent MTP inhibitor. This molecule (compound 9) inhibited the production of Lipoprotein particles in rodent models and normalized plasma Lipoprotein Levels in Watanabe-heritable hyperlipidemic (WHHL) rabbits, which are a model for human homozygous familiar hypercholesterolemia. These results suggest that compound 9, or derivatives thereof, has potential applications for the therapeutic Lowering of atherogenic Lipoprotein levels in humans.	Bristol Myers Squibb Pharmaceut Res Inst, Dept Metab Dis, Princeton, NJ 08543 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Metab & Pharmacokinet, Princeton, NJ 08543 USA; Bristol Myers Squibb Pharmaceut Res Inst, Div Discovery Chem, Princeton, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb	Wetterau, JR (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Dept Metab Dis, POB 4000, Princeton, NJ 08543 USA.			Musial, Christa/0000-0002-1916-596X				BORENSZTAJN J, 1976, BIOCHEM J, V156, P539, DOI 10.1042/bj1560539; CAIRNS SR, 1983, CLIN SCI, V65, P645, DOI 10.1042/cs0650645; Glueck C J, 1977, Trans Assoc Am Physicians, V90, P184; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; KANE JP, 1995, METABOLIC MOL BASES, P1853; KITA T, 1981, P NATL ACAD SCI-BIOL, V78, P2268, DOI 10.1073/pnas.78.4.2268; Lawrence RM, 1997, SYNTHESIS-STUTTGART, P553; LINTON MF, 1993, J LIPID RES, V34, P521; NARCISI TME, 1995, AM J HUM GENET, V57, P1298; Rehberg EF, 1996, J BIOL CHEM, V271, P29945, DOI 10.1074/jbc.271.47.29945; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6	15	238	262	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					751	754		10.1126/science.282.5389.751	http://dx.doi.org/10.1126/science.282.5389.751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784135				2022-12-28	WOS:000076607500054
J	Spielberg, AR				Spielberg, AR			On call and online - Sociohistorical, legal, and ethical implications of e-mail for the patient-physician relationship	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; INFORMATION	Increased use of e-mail by physicians, patients, and other health care organizations and staff has the potential to reshape the current boundaries of relationships in medical practice. By comparing reception of e-mail technology in medical practice with its historical analogue, reception of the telephone, this article suggests that new expectations, practice standards, and potential liabilities emerge with the introduction of this new communication technology. Physicians using e-mail should be aware of these considerations and construct their e-mail communications accordingly, recognizing that e-mail may be included in the patient's medical record. Likewise, physicians should discuss the ramifications of communicating electronically with patients and obtain documented informed consent before using e-mail. Physicians must keep patient information confidential, which will require taking precautions (including encryption to prevent interception) to preserve patient information, trust, and the integrity of the patient-physician relationship.	Harvard Univ, Sch Med, Div Med Eth, Boston, MA USA	Harvard University; Harvard Medical School	Spielberg, AR (corresponding author), 124 Mt Auburn St,Suite 200 N, Cambridge, MA 02138 USA.							*AM MED ASS, 1997, COD MED ETH CURR OP; BRADHAM DD, 1995, WAKE FOREST LAW REV, V30, P145; Brailer DJ, 1997, HOSP HEALTH NETWORK, V71, P32; Cowan R. S., 1997, SOCIAL HIST AM TECHN; Davies S.G., 1997, TECHNOL 1, P143; Diffie W., 1998, PRIVACY LINE POLITIC; FEIN E, 1997, NY TIMES        1123, pA1; Ferguson T, 1997, FUTURIST, V31, P29; Fischer Claude, 1992, AM CALLING SOCIAL HI; GOSTIN LO, 1995, CORNELL LAW REV, V80, P451; Granade PF, 1997, ND L REV, V73, P65; Green L, 1996, Med Econ, V73, P153; Greene J, 1997, HOSP HEALTH NETWORK, V71, P45; GROS SML, 1966, DOCTORS; GROSSMAN M, 1998, LEGAL TIMES     0202, P31; HARROCH RD, 1998, NATL LAW J      0202, pC7; Institute of Medicine, 1996, TEL GUID ASS TEL HLT; JARVIS PR, 1997, WILLAMETTE LAW REV, V33, P467; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; MATTHEWS WP, 1996, KANS LAW REV, V45, P273; Mitchell P, 1997, LANCET, V349, P1608, DOI 10.1016/S0140-6736(05)61643-1; Peters R, 1997, JAMA-J AM MED ASSOC, V277, P1258, DOI 10.1001/jama.277.15.1258; Reichertz PS, 1997, FOOD DRUG LAW J, V52, P517; Reiser S., 1978, MED REIGN TECHNOLOGY; Rose J., 1997, Rutgers Computer & Technology Law Journal, V23, P179; Rubin R, 1995, US News World Rep, V118, P82; SALTUS R, 1998, BOSTON GLOBE MA 0118, P11; SHEPHERD DC, 1997, MARKETING HLTH SERV, V17, P50; Skolnick AA, 1996, JAMA-J AM MED ASSOC, V275, P669; Starr P, 1997, HEALTH AFFAIR, V16, P91, DOI 10.1377/hlthaff.16.3.91; Starr P, 1982, SOCIAL TRANSFORMATIO; U.S. Department of Commerce. The Department of Health and Human Services National Telecommunications and Information Administration, 1997, TEL REP C; *US DEP HHS, 1997, CONF IND ID HLTH INF; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; 1878, BMJ, V2, P43; 1997, BOSTON U SCI TECHNOL, V3, P24; 1998, COMPLEAT LAWYER  WIN, P63	38	140	140	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1353	1359		10.1001/jama.280.15.1353	http://dx.doi.org/10.1001/jama.280.15.1353			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129PQ	9794317				2022-12-28	WOS:000076472500030
J	Marchetti, K; Nakamura, H; Gibbs, HL				Marchetti, K; Nakamura, H; Gibbs, HL			Host-race formation in the common cuckoo	SCIENCE			English	Article							CUCULUS-CANORUS; PREFERENCE	The exploitation of a new host by a parasite may result in host-race formation or speciation. A brood parasitic bird, the common cuckoo, is divided into host races, each characterized by egg mimicry of different host species. Microsatellite DNA markers were used to examine cuckoo mating patterns and host usage in an area where a new host has been recently colonized. Female cuckoos show strong host preferences, but individual males mate with females that Lay in the nests of different hosts. Female host specialization may Lead to the evolution of sex-linked traits such as egg mimicry, even though gene flow through the male Line prevents completion of the speciation process.	Univ Calif San Diego, Dept Biol 0116, La Jolla, CA 92093 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; Shinshu Univ, Fac Educ, Dept Biol, Nishinagano, Nagano 380, Japan	University of California System; University of California San Diego; McMaster University; Shinshu University	Marchetti, K (corresponding author), Univ Calif San Diego, Dept Biol 0116, La Jolla, CA 92093 USA.	Marchet@biomail.ucsd.edu						BROOKE MD, 1987, J ANIM ECOL, V56, P873, DOI 10.2307/4954; BROOKE MD, 1988, NATURE, V335, P630; Camara MD, 1997, EVOLUTION, V51, P873, DOI 10.1111/j.1558-5646.1997.tb03669.x; Chance EP., 1940, TRUTH CUCKOO; DAVIES NB, 1988, ANIM BEHAV, V36, P262, DOI 10.1016/S0003-3472(88)80269-0; Futuyma D.J., 1983, P207; FUTUYMA DJ, 1988, ANNU REV ECOL SYST, V19, P207, DOI 10.1146/annurev.es.19.110188.001231; Gibbs HL, 1996, P ROY SOC B-BIOL SCI, V263, P89, DOI 10.1098/rspb.1996.0015; Gibbs HL, 1998, MOL ECOL, V7, P1437; Griffiths R, 1998, MOL ECOL, V7, P1071, DOI 10.1046/j.1365-294x.1998.00389.x; JENSEN RAC, 1966, NATURE, V209, P827, DOI 10.1038/209827a0; Jones DA, 1997, IBIS, V139, P560, DOI 10.1111/j.1474-919X.1997.tb04672.x; LOTEM A, COMMUNICATION; Martinez JG, 1998, MOL ECOL, V7, P289, DOI 10.1046/j.1365-294X.1998.00348.x; MOKSNES A, 1995, J ZOOL, V236, P625, DOI 10.1111/j.1469-7998.1995.tb02736.x; NAKAMURA H, 1990, Japanese Journal of Ornithology, V39, P1, DOI 10.3838/jjo.39.1; NAKAMURA H, 1988, PARASITIC BIRDS THEI, P94; Nakamura Hiroshi, 1997, Japanese Journal of Ornithology, V46, P23, DOI 10.3838/jjo.46.23; Payne RB, 1998, ANIM BEHAV, V55, P1537, DOI 10.1006/anbe.1997.0701; ROWAN MK, 1983, DAVES PARROTS LORIES; Wyllie I., 1981, CUCKOO; Yamagishi S., 1986, TORI BULLETIN OF THE ORNITHOLOGICAL SOCIETY OF JAPAN, V34, P91; [No title captured]	23	112	115	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					471	472		10.1126/science.282.5388.471	http://dx.doi.org/10.1126/science.282.5388.471			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774273				2022-12-28	WOS:000076479600053
J	Nakamura, TM; Cooper, JP; Cech, TR				Nakamura, TM; Cooper, JP; Cech, TR			Two modes of survival of fission yeast without telomerase	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE GENOME; I RESTRICTION MAP; SACCHAROMYCES-CEREVISIAE; HOMOLOG; CHROMOSOME; PROTEIN; GENE; DNA; CLONING; REPAIR	Deletion of the telomerase catalytic subunit gene trt1(+) in Schizosaccharomyces pombe results in death for the majority of cells, but a subpopulation survives. Here it is shown that most survivors have circularized all of their chromosomes, whereas a smaller number maintain their telomeres presumably through recombination. When the telomeric DNA-binding gene taz1(+) is also deleted, trt1(-) taz1(-) survivors use the recombinational mode more frequently. Moreover, the massive elongation of telomeres in taz1(-) cells is absent in the double mutant. Thus, Taz1p appears to regulate telomeric recombination as well as telomerase activity in fission yeast.	Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cech, TR (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA.		Nakamura, Toru M/B-2055-2008	Nakamura, Toru M/0000-0001-5752-0814; cooper, julia promisel/0000-0003-2171-2587	NIGMS NIH HHS [GM28039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028039, R37GM028039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C., 1993, EXPT FISSION YEAST; Brun C, 1997, TRENDS CELL BIOL, V7, P317, DOI 10.1016/S0962-8924(97)01092-1; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; COOPER JR, UNPUB; FAN JB, 1992, NUCLEIC ACIDS RES, V20, P5943, DOI 10.1093/nar/20.22.5943; FAN JB, 1991, NUCLEIC ACIDS RES, V19, P6289, DOI 10.1093/nar/19.22.6289; FAN JB, 1989, NUCLEIC ACIDS RES, V17, P2801, DOI 10.1093/nar/17.7.2801; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; JANG YK, 1994, GENE, V142, P207, DOI 10.1016/0378-1119(94)90262-3; KLAR AJS, 1983, MOL CELL BIOL, V3, P803, DOI 10.1128/MCB.3.5.803; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI S, 1995, MOL GEN GENET, V246, P671, DOI 10.1007/BF00290712; Muris DFR, 1996, J CELL SCI, V109, P73; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; NAITOH T, IN PRESS NATURE GENE; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OSTERMANN K, 1993, NUCLEIC ACIDS RES, V21, P5940, DOI 10.1093/nar/21.25.5940; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; Sugawara N, 1989, THESIS HARVARD U CAM	28	229	231	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					493	496		10.1126/science.282.5388.493	http://dx.doi.org/10.1126/science.282.5388.493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774280				2022-12-28	WOS:000076479600060
J	Phillips, OL; Malhi, Y; Higuchi, N; Laurance, WF; Nunez, PV; Vasquez, RM; Laurance, SG; Ferreira, LV; Stern, M; Brown, S; Grace, J				Phillips, OL; Malhi, Y; Higuchi, N; Laurance, WF; Nunez, PV; Vasquez, RM; Laurance, SG; Ferreira, LV; Stern, M; Brown, S; Grace, J			Changes in the carbon balance of tropical forests: Evidence from long-term plots	SCIENCE			English	Article							ATMOSPHERIC CO2 CONCENTRATIONS; BIOMASS ESTIMATION; SPECIES RICHNESS; EL-NINO; ECOSYSTEMS; TURNOVER; SINKS; DYNAMICS; NITROGEN; SOUTH	The role of the world's forests as a "sink" for atmospheric carbon dioxide is the subject of active debate. Long-term monitoring of plots in mature humid tropical forests concentrated in South America revealed that biomass gain by tree growth exceeded Losses from tree death in 38 of 50 Neotropical sites. These forest plots have accumulated 0.71 ton, plus or minus 0.34 ton, of carbon per hectare per year in recent decades. The data suggest that Neotropical forests may be a significant carbon sink, reducing the rate of increase in atmospheric carbon dioxide.	Univ Leeds, Sch Geog, Leeds LS2 9JT, W Yorkshire, England; Univ Edinburgh, Inst Ecol & Resource Management, Edinburgh EH9 3JU, Midlothian, Scotland; Inst Nacl de Pesquisas da Amazonia, Dept Silvicultura Trop, BR-69011970 Manaus, Amazonas, Brazil; Inst Nacl de Pesquisas da Amazonia, Biol Dynam Forest Fragments Project, BR-69011970 Manaus, Amazonas, Brazil; Missouri Bot Garden, Proyecto Flora Peru, Iquitos, Peru; New York Bot Garden, Inst Econ Bot, Bronx, NY 10458 USA; Univ Illinois, Dept Nat Resources and Environm Sci, Urbana, IL 61801 USA	University of Leeds; University of Edinburgh; Institute Nacional de Pesquisas da Amazonia; Institute Nacional de Pesquisas da Amazonia; Missouri Botanical Gardens; New York Botanical Garden; University of Illinois System; University of Illinois Urbana-Champaign	Phillips, OL (corresponding author), Univ Leeds, Sch Geog, Leeds LS2 9JT, W Yorkshire, England.	O.Phillips@geog.Leeds.ac.uk; YMalhi@ed.ac.uk	Grace, John/N-9280-2013; Higuchi, Niro/ABC-9134-2020; Laurance, Susan/G-6021-2011; Higuchi, Niro/ABC-8890-2020; Phillips, Oliver/A-1523-2011; Laurance, William F/B-2709-2012; Higuchi, Niro/J-1287-2016	Higuchi, Niro/0000-0002-1203-4502; Laurance, Susan/0000-0002-2831-2933; Phillips, Oliver/0000-0002-8993-6168; Laurance, William F/0000-0003-4430-9408; Higuchi, Niro/0000-0002-1203-4502				ARAUJO TM, 1996, AN ACAD BRAS CIENC; BECKER M, 1994, ANN SCI FOREST, V51, P477, DOI 10.1051/forest:19940504; BIERREGAARD RO, 1992, BIOSCIENCE, V42, P859, DOI 10.2307/1312085; BROWN IF, 1992, ENVIRON CONSERV, V19, P307, DOI 10.1017/S0376892900031428; BROWN S, 1991, CAN J FOREST RES, V21, P111, DOI 10.1139/x91-015; BROWN S, 1989, FOREST SCI, V35, P881; BROWN S, 1995, IMPACTS ADAPTATIONS, P775; Cairns MA, 1997, OECOLOGIA, V111, P1, DOI 10.1007/s004420050201; CARVALHO JA, 1995, ATMOS ENVIRON, V29, P2301, DOI 10.1016/1352-2310(95)00094-F; Carvalho JA, 1998, J GEOPHYS RES-ATMOS, V103, P13195, DOI 10.1029/98JD00172; Chambers JQ, 1998, NATURE, V391, P135, DOI 10.1038/34325; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; CONDIT R, 1995, ECOL MONOGR, V65, P419, DOI 10.2307/2963497; Condit R, 1997, TRENDS ECOL EVOL, V12, P249, DOI 10.1016/S0169-5347(97)01095-1; CROW TR, 1980, BIOTROPICA, V12, P42, DOI 10.2307/2387772; DENEVAN WM, 1992, ANN ASSOC AM GEOGR, V82, P369, DOI 10.1111/j.1467-8306.1992.tb01965.x; DIXON RK, 1994, SCIENCE, V263, P185, DOI 10.1126/science.263.5144.185; ENTING IG, 1995, TELLUS B, V47, P35, DOI 10.1034/j.1600-0889.47.issue1.5.x; FAO, 1993, FOR RES ASS 1990 TRO; FEARNSIDE PM, 1996, BIOMASS BURNING GLOB, V2, P606; Ferreira LV, 1997, CONSERV BIOL, V11, P797, DOI 10.1046/j.1523-1739.1997.96167.x; GILLESPIE AJR, 1992, FOREST ECOL MANAG, V48, P69, DOI 10.1016/0378-1127(92)90122-P; GRACE J, 1995, GLOBAL CHANGE BIOL, V1, P1, DOI 10.1111/j.1365-2486.1995.tb00001.x; GRACE J, IN PRESS TERRESTRIAL; GRAYBILL DA, 1993, GLOBAL BIOGEOCHEM CY, V7, P81, DOI 10.1029/92GB02533; Hegarty E.E., 1991, BIOL VINES, P313; Higuchi N., 1994, AN SEM EM SEQ CO2 NO; Houghton RA, 1996, TELLUS B, V48, P420, DOI 10.1034/j.1600-0889.1996.t01-3-00002.x; HOUGHTON RA, 1996, NATO ASI SER 1, V40; Hunt ER, 1996, GLOBAL BIOGEOCHEM CY, V10, P431, DOI 10.1029/96GB01691; Kattenberg A, 1995, CLIMATE CHANGE 1995: THE SCIENCE OF CLIMATE CHANGE, P285; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Korner C, 2000, ECOL APPL, V10, P1590, DOI 10.2307/2641226; Laurance WF, 1997, SCIENCE, V278, P1117, DOI 10.1126/science.278.5340.1117; LAURANCE WF, IN PRESS TRENDS ECOL; Lloyd J, 1996, FUNCT ECOL, V10, P4, DOI 10.2307/2390258; Lovejoy T.E., 1985, KEY ENV AMAZONIA, P109; LUGO AE, 1992, FOREST ECOL MANAG, V54, P239, DOI 10.1016/0378-1127(92)90016-3; MALHI Y, IN PRESS J GEOPHYS R; MCKANE RB, 1995, GLOBAL BIOGEOCHEM CY, V9, P329, DOI 10.1029/95GB01736; Nicholson D. I., 1988, Proceedings of the Ecological Society of Australia, V15, P61; PHILLIPS O, 1995, SCIENCE, V268, P894, DOI 10.1126/science.268.5212.894-a; Phillips O, 1997, TRENDS ECOL EVOL, V12, P404, DOI 10.1016/S0169-5347(97)87392-2; Phillips O, 1997, OIKOS, V79, P183, DOI 10.2307/3546105; Phillips OL, 1996, ENVIRON CONSERV, V23, P235, DOI 10.1017/S0376892900038856; PHILLIPS OL, 1994, P NATL ACAD SCI USA, V91, P2805, DOI 10.1073/pnas.91.7.2805; PHILLIPS OL, 1994, SCIENCE, V263, P954, DOI 10.1126/science.263.5149.954; PHILLIPS OL, IN PRESS BIOTROPICA; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; SALATI E, 1991, CLIMATIC CHANGE, V19, P177, DOI 10.1007/BF00142225; Schimel DS, 1996, GLOBAL BIOGEOCHEM CY, V10, P677, DOI 10.1029/96GB01524; SCHIMEL DS, 1995, GLOBAL CHANGE BIOL, V1, P77, DOI 10.1111/j.1365-2486.1995.tb00008.x; SHEIL D, 1995, FOREST ECOL MANAG, V77, P11, DOI 10.1016/0378-1127(95)03583-V; SKOLE D, 1993, SCIENCE, V260, P1905, DOI 10.1126/science.260.5116.1905; Sun DZ, 1997, GEOPHYS RES LETT, V24, P2031, DOI 10.1029/97GL01960; SWAP R, 1992, TELLUS B, V44, P133, DOI 10.1034/j.1600-0889.1992.t01-1-00005.x; TANNER EVJ, 1992, ECOLOGY, V73, P78, DOI 10.2307/1938722; TANNER EVJ, 1991, BIOTROPICA, V23, P513, DOI 10.2307/2388274; TAYLOR JA, 1992, AUST J BOT, V40, P407, DOI 10.1071/BT9920407; TUOMISTO H, 1995, SCIENCE, V269, P63, DOI 10.1126/science.269.5220.63; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431; Whitmore T. C., 1997, P3	62	604	670	10	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					439	442		10.1126/science.282.5388.439	http://dx.doi.org/10.1126/science.282.5388.439			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774263				2022-12-28	WOS:000076479600043
J	Kovtun, Y; Chiu, WL; Zeng, WK; Sheen, J				Kovtun, Y; Chiu, WL; Zeng, WK; Sheen, J			Suppression of auxin signal transduction by a MAPK cascade in higher plants	NATURE			English	Article							PROTEIN-KINASES; ARABIDOPSIS; EXPRESSION; TOBACCO; GENE; PHOSPHATASE; REPORTER; ENCODES; STRESS; CELLS	The plant hormone auxin activates many early response genes that are thought to be responsible for diverse aspects of plant growth and development(1). It has been proposed that auxin signal transduction is mediated by a conserved signalling cascade consisting of three protein kinases: the mitogen-activated protein kinase (MAPK), MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK)(2), Here we show that a specific plant MAPKKK, NPK1 (ref. 3), activates a MAPK cascade that leads to the suppression of early auxin response gene transcription, A mutation in the kinase domain abolishes NPK1 activity, and the presence of the carboxy-terminal domain diminishes the kinase activity, Moreover, the effects of NPK1 on the activation of a MAPK and the repression of early auxin response gene transcription are specifically eliminated by a MAPK phosphatase(4). Transgenic tobacco plants overexpressing the NPK1 kinase domain produced seeds defective in embryo and endosperm development. These results suggest that auxin sensitivity may be balanced by antagonistic signalling pathways that use a distinct MAPK cascade in higher plants.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Sheen, J (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.							Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; BANNO H, 1993, MOL CELL BIOL, V13, P4745, DOI 10.1128/MCB.13.8.4745; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; Guilfoyle TJ, 1998, TRENDS PLANT SCI, V3, P205, DOI 10.1016/S1360-1385(98)01244-8; HAGEN G, 1991, PLANT MOL BIOL, V17, P567, DOI 10.1007/BF00040658; Hirt H, 1997, TRENDS PLANT SCI, V2, P11, DOI 10.1016/S1360-1385(96)10048-0; JANG JC, 1994, PLANT CELL, V6, P1665, DOI 10.1105/tpc.6.11.1665; Jang JC, 1997, PLANT CELL, V9, P5, DOI 10.1105/tpc.9.1.5; John M, 1997, TRENDS PLANT SCI, V2, P111, DOI 10.1016/S1360-1385(97)01005-4; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KLIMCZAK LJ, 1995, PLANT PHYSIOL, V109, P687, DOI 10.1104/pp.109.2.687; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Leyser O, 1998, CURR BIOL, V8, pR305, DOI 10.1016/S0960-9822(98)70193-9; MACHIDA Y, 1998, 40 NIBB C STRESS RES; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; Nakashima M, 1998, PLANT CELL PHYSIOL, V39, P690, DOI 10.1093/oxfordjournals.pcp.a029423; Nishihama R, 1997, PLANT J, V12, P39, DOI 10.1046/j.1365-313X.1997.12010039.x; SHEEN J, 1993, EMBO J, V12, P3497, DOI 10.1002/j.1460-2075.1993.tb06024.x; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Zhang SQ, 1997, PLANT CELL, V9, P809, DOI 10.1105/tpc.9.5.809	29	195	224	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					716	720		10.1038/27240	http://dx.doi.org/10.1038/27240			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790195				2022-12-28	WOS:000076472600057
J	Hutchings, O; Evans, G; Fallowfield, L; Cuzick, J; Howell, A				Hutchings, O; Evans, G; Fallowfield, L; Cuzick, J; Howell, A			Effect of early American results on patients in a tamoxifen prevention trial (IBIS)	LANCET			English	Letter									Christie Hosp, CRC, Dept Med Oncol, Manchester, Lancs, England; Christie Hosp, Dept Med Genet, Manchester, Lancs, England; Imperial Canc Res Fund, Dept Math Stat & Epidemiol, London WC2A 3PX, England; UCL Hosp, Sch Med, CRC, Psychosocial Oncol Grp, London W1P 7PL, England	Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; Cancer Research UK; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School	Hutchings, O (corresponding author), Christie Hosp, CRC, Dept Med Oncol, Manchester, Lancs, England.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784; Howell, Anthony/0000-0002-6233-719X				Bruzzi P, 1998, BRIT MED J, V316, P1181, DOI 10.1136/bmj.316.7139.1181; CUZICK J, 1985, LANCET, V2, P282; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Powles T, 1998, LANCET, V352, P98; Veronesi U, 1998, LANCET, V352, P93	5	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1222	1222		10.1016/S0140-6736(05)60560-0	http://dx.doi.org/10.1016/S0140-6736(05)60560-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777861	Bronze			2022-12-28	WOS:000076415400049
J	Bennett, M; Macdonald, K; Chan, SW; Luzio, JP; Simari, R; Weissberg, P				Bennett, M; Macdonald, K; Chan, SW; Luzio, JP; Simari, R; Weissberg, P			Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; P53; GENE; INDUCTION; RECEPTOR; BINDING; LIGAND; PROLIFERATION; INHIBITION; PATHWAY	p53 acts as a tumor suppressor by inducing both growth arrest and apoptosis. p53-induced apoptosis can occur without new RNA synthesis through an unknown mechanism. In human vascular smooth muscle cells, p53 activation transiently increased surface pas (CD95) expression by transport from the Golgi complex. Golgi disruption blocked both p53-induced surface Fas expression and apoptosis. p53 also induced Fas-FADD binding and transiently sensitized cells to Fas-induced apoptosis. In contrast, lpr and gld fibroblasts were resistant to p53-induced apoptosis. Thus, p53 can mediate apoptosis through pas transport from cytoplasmic stores.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Mayo Clin & Mayo Fdn, Dept Cardiovasc Dis Biochem & Mol Biol, Rochester, MN 55905 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Mayo Clinic	Bennett, M (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England.			Bennett, Martin/0000-0002-2565-1825; Chan, Shiu-Wan/0000-0002-4018-9309	NHLBI NIH HHS [HL34073] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bennett MR, 1997, CIRC RES, V81, P591, DOI 10.1161/01.RES.81.4.591; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YonishRouach E, 1995, ONCOGENE, V11, P2197	25	623	638	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					290	293		10.1126/science.282.5387.290	http://dx.doi.org/10.1126/science.282.5387.290			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765154				2022-12-28	WOS:000076370200047
J	Balon, J; Aker, PD; Crowther, ER; Danielson, C; Cox, PG; O'Shaughnessy, D; Walker, C; Goldsmith, CH; Duku, E; Sears, MR				Balon, J; Aker, PD; Crowther, ER; Danielson, C; Cox, PG; O'Shaughnessy, D; Walker, C; Goldsmith, CH; Duku, E; Sears, MR			A comparison of active and simulated chiropractic manipulation as adjunctive treatment for childhood asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED BETA-AGONIST; LONG-TERM TREATMENT; ALTERNATIVE MEDICINE; BRONCHIAL-ASTHMA; SPINAL MANIPULATION; CHILDREN; RESPONSIVENESS; PREVALENCE; TRIAL	Background Chiropractic spinal manipulation has been reported to be of benefit in nonmusculoskeletal conditions, including asthma, Methods We conducted a randomized, controlled trial of chiropractic spinal manipulation for children with mild or moderate asthma, After a three-week base-line evaluation period, 91 children who had continuing symptoms of asthma despite usual medical therapy were randomly assigned to receive either active or simulated chiropractic manipulation for four months. None had previously received chiropractic care. Each subject was treated by 1 of 11 participating chiropractors, selected by the family according to location. The primary outcome measure was the change from base line in the peak expiratory flow, measured in the morning, before the use of a bronchodilator, at two and four months. Except for the treating chiropractor and one investigator (who was not involved in assessing outcomes), all participants remained fully blinded to treatment assignment throughout the study. Results Eighty children (38 in the active-treatment group and 42 in the simulated-treatment group) had outcome data that could be evaluated. There were small increases (7 to 12 liters per minute) in peak expiratory flow in the morning and the evening in both treatment groups, with no significant differences between the groups in the degree of change from base line (morning peak expiratory flow, P=0.49 at two months and P=0.82 at four months). Symptoms of asthma and use of P-agonists decreased and the quality of life increased in both groups, with no significant differences between the groups. There were no significant changes in spirometric measurements or airway responsiveness. Conclusions In children with mild or moderate asthma, the addition of chiropractic spinal manipulation to usual medical care provided no benefit. (N Engl J Med 1998;339:1013-20.) (C) 1998, Massachusetts Medical Society.	St Josephs Hosp, Firestone Reg Chest & Allergy Unit, Hamilton, ON L8N 4A6, Canada; Canadian Mem Chiropract Coll, Div Grad Studies & Res, Toronto, ON, Canada; Los Angeles Coll Chiropract, Dept Res, Los Angeles, CA USA; McMaster Univ, Dept Med, Hamilton, ON, Canada; St Josephs Hosp, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; St Josephs Hosp, Father Sean OSullivan Res Ctr, Ctr Evaluat Med, Hamilton, ON, Canada	McGill University; McMaster University; McMaster University; McGill University; McMaster University; McGill University; McMaster University	Sears, MR (corresponding author), St Josephs Hosp, Firestone Reg Chest & Allergy Unit, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.		Duku, Eric/C-6552-2008	Duku, Eric/0000-0003-3599-3527				ARBILOFF B, 1969, J CLIN CHIROPRACTIC, V2, P40; Armitage P., 1987, STAT METHODS MED RES; BARNES PJ, 1992, J ASTHMA, V29, P165, DOI 10.3109/02770909209099025; BOE J, 1992, EUR RESPIR J, V5, P1037; CHRISTENSEN PA, 1984, ALLERGY, V39, P379, DOI 10.1111/j.1398-9995.1984.tb01956.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Coulter ID, 1994, TOP CLIN CHIROPRACTI, V1, P40; Dhami MSI, 1992, PRINCIPLES PRACTICE, P115; DONNELLY WJ, 1985, MED J AUSTRALIA, V142, P539, DOI 10.5694/j.1326-5377.1985.tb113486.x; Draper N.R., 1998, APPL REGRESSION ANAL, P79; DRISCOLL DR, 1991, FUNDAMENTALS CHIROPR, P265; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; EWER TC, 1986, BMJ-BRIT MED J, V293, P1129, DOI 10.1136/bmj.293.6555.1129; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; GARDE DC, 1994, CHIROPRACTIC PEDIAT, V1, P9; GATTERMAN MI, 1995, FDN CHIROPRACTIC SUB, P5; GITELMAN R, 1992, PRINCIPLES PRACTICE, P483; GRAHAM RL, 1997, J VERTEBRAL SUBLUXAT, V1, P41; HILL R, 1991, BRIT MED J, V303, P1169, DOI 10.1136/bmj.303.6811.1169; HVIID C, 1978, B EUR CHIROPRACTORS, V26, P14; ISLES AF, 1993, MED J AUSTRALIA, V158, P761, DOI 10.5694/j.1326-5377.1993.tb121958.x; JAMISON JR, 1986, J AUST CHIRO ASS, V16, P137; JANSE J, 1976, J JANSE PRINCIPLES P, P227; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Konig P, 1996, J ALLERGY CLIN IMMUN, V98, P1103, DOI 10.1016/S0091-6749(96)80198-9; KONIG P, 1993, EUR RESPIR REV, V3, P501; LANE DJ, 1994, J ASTHMA, V31, P153, DOI 10.3109/02770909409044821; LANE DJ, 1991, THORAX, V46, P787, DOI 10.1136/thx.46.11.787; Lewith GT, 1996, ALLERGY, V51, P761, DOI 10.1111/j.1398-9995.1996.tb04464.x; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; NAGARATHNA R, 1985, BRIT MED J, V291, P1077, DOI 10.1136/bmj.291.6502.1077; NIELSEN NH, 1995, CLIN EXP ALLERGY, V25, P80, DOI 10.1111/j.1365-2222.1995.tb01006.x; PEAT JK, 1994, J CLIN EPIDEMIOL, V47, P1099, DOI 10.1016/0895-4356(94)90096-5; RENAUD CI, 1990, J CHIROPRACTIC, V27, P25; Roorda RJ, 1996, THORAX, V51, pS7, DOI 10.1136/thx.51.Suppl_1.S7; SEARS MR, 1994, DRUG SAFETY, V11, P259, DOI 10.2165/00002018-199411040-00005; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SEARS MR, 1994, BRIT MED J, V309, P72, DOI 10.1136/bmj.309.6947.72; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; VERHOEF TJ, 1995, CAN FAM PHYSICIAN, V41, P1005; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; WILES MR, 1982, J CAN CHIROPRACTIC A, V26, P65; WOLTHERS OD, 1995, RESP MED, V89, P347, DOI 10.1016/0954-6111(95)90006-3	45	105	106	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1013	1020		10.1056/NEJM199810083391501	http://dx.doi.org/10.1056/NEJM199810083391501			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761802				2022-12-28	WOS:000076294800001
J	Lomeli, J; Quevedo, J; Linares, P; Rudomin, P				Lomeli, J; Quevedo, J; Linares, P; Rudomin, P			Local control of information flow in segmental and ascending collaterals of single afferents	NATURE			English	Article							CAT SPINAL-CORD; I MUSCLE AFFERENTS; PRESYNAPTIC DEPOLARIZATION; CLARKE COLUMN; FIBERS; TRANSMISSION; PATHWAYS; INTERNEURONS; MOTONEURONS; INHIBITION	In the vertebrate spinal cord, the activation of GABA (gamma-aminobutyric acid)-releasing interneurons that synapse with intraspinal terminals of sensory fibres leading into the central nervous system (afferent fibres) produces primary afferent depolarization and presynaptic inhibition(1-3). It is not known to what extent these presynaptic mechanisms allow a selective control of information transmitted through specific sets of intraspinal branches of individual afferents(4-7). Here we study the local nature of the presynaptic control by measuring primary afferent depolarization simultaneously in two intraspinal collaterals of the same muscle spindle afferent. One of these collaterals ends at the L6-L7 segmental level in the intermediate nucleus, and the other ascends to segment L3 within Clarke's column, the site of origin of spinocerebellar neurons(8). Our results indicate that there are central mechanisms that are able to affect independently the synaptic effectiveness of segmental and ascending collaterals of individual muscle spindle afferents. Focal control of presynaptic inhibition thus allows the intraspinal branches of afferent fibres to function as a dynamic assembly that can be fractionated to convey information to selected neuronal targets. This may be a mechanism by which different spinal postsynaptic targets that are coupled by sensory input from a common source could be uncoupled.	Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Physiol Biophys & Neurosci, Mexico City 07000, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Rudomin, P (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Physiol Biophys & Neurosci, Apartado Postal 14-740, Mexico City 07000, DF, Mexico.	rudomin@fisio.cinvestav.mx		Lomeli, Joel/0000-0001-5318-8949				[Anonymous], [No title captured]; CHAN SHH, 1972, BRAIN RES, V45, P101, DOI 10.1016/0006-8993(72)90218-1; CURTIS DR, 1983, BRAIN RES, V258, P328, DOI 10.1016/0006-8993(83)91160-5; CURTIS DR, 1984, BRAIN RES, V295, P372, DOI 10.1016/0006-8993(84)90989-2; Eguibar JR, 1997, EXP BRAIN RES, V113, P411, DOI 10.1007/PL00005595; Enriquez M, 1996, EXP BRAIN RES, V107, P391; GEO JH, 1996, SCIENCE, V272, P545; Gossard JP, 1996, J NEUROPHYSIOL, V76, P4104, DOI 10.1152/jn.1996.76.6.4104; HARRISON PJ, 1984, BRAIN RES, V295, P203, DOI 10.1016/0006-8993(84)90968-5; HULTBORN H, 1987, J PHYSIOL-LONDON, V389, P757, DOI 10.1113/jphysiol.1987.sp016681; Iles JF, 1996, J PHYSIOL-LONDON, V491, P197, DOI 10.1113/jphysiol.1996.sp021207; JANKOWSKA E, 1981, J NEUROPHYSIOL, V46, P506, DOI 10.1152/jn.1981.46.3.506; JANKOWSKA E, 1984, BRAIN RES, V295, P195, DOI 10.1016/0006-8993(84)90967-3; JANKOWSKA E, 1992, PROG NEUROBIOL, V38, P335, DOI 10.1016/0301-0082(92)90024-9; LUSCHER HR, 1998, PRESYNAPTIC INHIBITI, P126; MADRID J, 1979, NEUROSCI LETT, V11, P253, DOI 10.1016/0304-3940(79)90003-X; MANN MD, 1973, BRAIN BEHAV EVOLUT, V7, P34, DOI 10.1159/000124397; Nelson RJ, 1996, CURR OPIN NEUROBIOL, V6, P801, DOI 10.1016/S0959-4388(96)80031-6; NUSBAUM MP, 1997, NEURONS NETWORKS MOT, P237; Quevedo J, 1997, EXP BRAIN RES, V115, P387, DOI 10.1007/PL00005709; QUEVEDO J, 1993, J NEUROPHYSIOL, V70, P1; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; RIDDELL JS, 1993, J PHYSIOL-LONDON, V461, P723, DOI 10.1113/jphysiol.1993.sp019538; RUDOMIN P, 1975, J NEUROPHYSIOL, V38, P267, DOI 10.1152/jn.1975.38.2.267; RUDOMIN P, 1981, J NEUROPHYSIOL, V46, P532, DOI 10.1152/jn.1981.46.3.532; RUDOMIN P, 1974, J NEUROPHYSIOL, V37, P413, DOI 10.1152/jn.1974.37.3.413; RUDOMIN P, 1987, J NEUROPHYSIOL, V57, P1288, DOI 10.1152/jn.1987.57.5.1288; RUDOMIN P, 1983, J NEUROPHYSIOL, V50, P743, DOI 10.1152/jn.1983.50.4.743; RUDOMIN P, 1990, SEGMENTAL MOTOR SYST, P349; WALL PD, 1995, TRENDS NEUROSCI, V18, P99, DOI 10.1016/0166-2236(95)93883-Y	30	76	77	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					600	604		10.1038/26975	http://dx.doi.org/10.1038/26975			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783585				2022-12-28	WOS:000076362900048
J	Makhubu, L				Makhubu, L			Bioprospecting in an African context	SCIENCE			English	Editorial Material									Univ Swaziland, Kwaluseni, Swaziland		Makhubu, L (corresponding author), Univ Swaziland, Private Bag 4, Kwaluseni, Swaziland.							Chadwick D, 1994, CIBA F B, V37, P13; Farnsworth NR, 1985, B WORLD HEALTH ORGAN, V63, P695; MAKHUBU LP, 1978, TRADIONAL HEALER; *OAU, 1997, POL ISS OWN ACC CONS; SOFOWORA A, 1992, MED PLANTS TRADITION, P9; 1985, GOOD NEWS BIBLE EDIT	6	11	12	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					41	42		10.1126/science.282.5386.41	http://dx.doi.org/10.1126/science.282.5386.41			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9786792				2022-12-28	WOS:000076294900016
J	Zhou, YB; Gerchman, SE; Ramakrishnan, V; Travers, A; Muyldermans, S				Zhou, YB; Gerchman, SE; Ramakrishnan, V; Travers, A; Muyldermans, S			Position and orientation of the globular domain of linker histone H5 on the nucleosome	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING-SITE; DNA-SEQUENCE; CHROMATOSOMES; CHROMATIN; IDENTIFICATION; ORGANIZATION; RESOLUTION; LOCATION; PARTICLE	It is essential to identify the exact location of the linker histone within nucleosomes, the fundamental packing units of chromatin, in order to understand how condensed, transcriptionally inactive chromatin forms. Here, using a site-specific protein-DNA photocrosslinking method(1), we map the binding site and the orientation of the globular domain of linker histone H5 on mixed-sequence chicken nucleosomes. We show, in contrast to an earlier model(2), that the globular domain forms a bridge between one terminus of chromatosomal DNA and the DNA in the vicinity of the dyad axis of symmetry of the core particle. Helix III of the globular domain binds in the major groove of the first helical turn of the chromatosomal DNA, whereas the secondary DNA-binding site on the opposite face of the globular domain of histone H5 makes contact with the nucleosomal DNA dose to its midpoint. We also infer that helix I and helix II of the globular domain of histone H5 probably face, respectively, the solvent and the nucleosome. This location places the basic carboxy-terminal region of the globular domain in a position from which it could simultaneously bind the nucleosome-linking DNA strands that exit and enter the nucleosome.	Free Univ Brussels VIB, B-1640 Rhode St Genese, Belgium; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; United States Department of Energy (DOE); Brookhaven National Laboratory; Utah System of Higher Education; University of Utah; MRC Laboratory Molecular Biology	Muyldermans, S (corresponding author), Free Univ Brussels VIB, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	svmuylde@vub.ac.be	Muyldermans, Serge V/C-6418-2016; Muyldermans, Serge/AAC-7374-2019	Muyldermans, Serge V/0000-0002-3678-3575; Muyldermans, Serge/0000-0002-3678-3575; Ramakrishnan, V/0000-0002-4699-2194				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; AN W, IN PRESS NUCL ACIDS; CERF C, 1994, BIOCHEMISTRY-US, V33, P11079, DOI 10.1021/bi00203a004; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CraneRobinson C, 1997, TRENDS BIOCHEM SCI, V22, P75, DOI 10.1016/S0968-0004(97)01013-X; DRWE HR, 1987, J MOL BIOL, V197, P485; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; Hayes JJ, 1996, BIOCHEMISTRY-US, V35, P11931, DOI 10.1021/bi961590+; Howe LW, 1998, MOL CELL BIOL, V18, P1156, DOI 10.1128/MCB.18.3.1156; LAMBERT S, 1991, BIOCHEM BIOPH RES CO, V179, P810, DOI 10.1016/0006-291X(91)91889-K; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUTTER LC, 1979, NUCLEIC ACIDS RES, V6, P41, DOI 10.1093/nar/6.1.41; MIRZABEKOV AD, 1990, J MOL BIOL, V211, P479, DOI 10.1016/0022-2836(90)90366-T; MUYLDERMANS S, 1994, J MOL BIOL, V235, P855, DOI 10.1006/jmbi.1994.1044; PANNETTA G, IN PRESS J MOL BIOL; PEHRSON JR, 1989, P NATL ACAD SCI USA, V86, P9149, DOI 10.1073/pnas.86.23.9149; PENDERGRAST PS, 1992, P NATL ACAD SCI USA, V89, P10287, DOI 10.1073/pnas.89.21.10287; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SEGERS A, 1991, J BIOL CHEM, V266, P1502; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1986, EMBO J, V5, P3531, DOI 10.1002/j.1460-2075.1986.tb04679.x; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; Travers AA, 1996, J MOL BIOL, V257, P486, DOI 10.1006/jmbi.1996.0178	29	167	174	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					402	405		10.1038/26521	http://dx.doi.org/10.1038/26521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759733				2022-12-28	WOS:000076083800059
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Statistics notes - Bayesians and frequentists	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Imperial Canc Res Fund, Med Stat Grp, Ctr Stat Med, Inst Hlth Sci, Oxford OX3 7LF, England	St Georges University London; University of Oxford	Bland, JM (corresponding author), St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.							Breslow N., 1990, STAT SCI, V5, P269; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527	2	85	86	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1151	1151						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784463				2022-12-28	WOS:000076755100042
J	Markham, N				Markham, N			Personal view - When big may not be beautiful	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1165	1165						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784480	Green Published			2022-12-28	WOS:000076755100081
J	Powis, D				Powis, D			How to do it - Select medical students	BRITISH MEDICAL JOURNAL			English	Article									Univ Newcastle, Fac Med & Hlth Sci, Newcastle, NSW 2308, Australia	University of Newcastle	Powis, D (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Newcastle, NSW 2308, Australia.		Powis, David A/C-1956-2008	Singh, Sheena/0000-0001-6448-1737				POWIS DA, 1994, MED EDUC, V28, P443, DOI 10.1111/j.1365-2923.1994.tb02555.x; Powis DA., 1998, NEW S WALES ED HLTH, V11, P15; Powis DA, 1992, TEACH LEARN MED, V4, P25	3	32	32	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1149	1150						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784462				2022-12-28	WOS:000076755100041
J	Collins, FS; Patrinos, A; Jordan, E; Chakravarti, A; Gesteland, R; Walters, L; Fearon, E; Hartwelt, L; Langley, CH; Mathies, RA; Olson, M; Pawson, AJ; Pollard, T; Williamson, A; Wold, B; Buetow, K; Branscomb, E; Capecchi, M; Church, G; Garner, H; Gibbs, RA; Hawkins, T; Hodgson, K; Knotek, M; Meisler, M; Rubin, GM; Smith, LM; Smith, RF; Westerfield, M; Clayton, EW; Fisher, NL; Lerman, CE; McInerney, JD; Nebo, W; Press, N; Valle, D				Collins, FS; Patrinos, A; Jordan, E; Chakravarti, A; Gesteland, R; Walters, L; Fearon, E; Hartwelt, L; Langley, CH; Mathies, RA; Olson, M; Pawson, AJ; Pollard, T; Williamson, A; Wold, B; Buetow, K; Branscomb, E; Capecchi, M; Church, G; Garner, H; Gibbs, RA; Hawkins, T; Hodgson, K; Knotek, M; Meisler, M; Rubin, GM; Smith, LM; Smith, RF; Westerfield, M; Clayton, EW; Fisher, NL; Lerman, CE; McInerney, JD; Nebo, W; Press, N; Valle, D		DOE Grp; NIH Grp	New goals for the US Human Genome Project: 1998-2003	SCIENCE			English	Review								The Human Genome Project has successfully completed all the major goals in its current 5-year plan, covering the period 1993-98. A new plan, for 1998-2003, is presented, in which human DNA sequencing will be the major emphasis. An ambitious schedule has been set to complete the full sequence by the end of 2003, 2 years ahead of previous projections. In the course of completing the sequence, a "working draft" of the human sequence will be produced by the end of 2001. The plan also includes goals for sequencing technology development; for studying human genome sequence variation; for developing technology for functional genomics; for completing the sequence of Caenorhabditis elegans and Drosophila melanogaster and starting the mouse genome; for studying the ethical, Legal, and social implications of genome research; for bioinformatics and computational studies; and for training of genome scientists.	Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA; US DOE, Off Biol & Environm Res, Washington, DC 20585 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); United States Department of Energy (DOE); Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Georgetown University	Collins, FS (corresponding author), Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA.	fc23a@nih.gov	Lerman, Caryn/AHC-5180-2022					Bentley DR, 1996, SCIENCE, V274, P533, DOI 10.1126/science.274.5287.533; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; GREEN P, GENOME RES, V7, P410; Guyer M, 1998, GENOME RES, V8, P413; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Waterston R, 1998, SCIENCE, V282, P53, DOI 10.1126/science.282.5386.53; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WEBER J, GENOME RES, V7, P401	8	632	689	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					682	689		10.1126/science.282.5389.682	http://dx.doi.org/10.1126/science.282.5389.682			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784121				2022-12-28	WOS:000076607500040
J	Meinke, DW; Cherry, JM; Dean, C; Rounsley, SD; Koornneef, M				Meinke, DW; Cherry, JM; Dean, C; Rounsley, SD; Koornneef, M			Arabidopsis thaliana: A model plant for genome analysis	SCIENCE			English	Review							SIGNAL-TRANSDUCTION; GENES; TRANSFORMATION; SEQUENCE; BRASSINOSTEROIDS; IDENTIFICATION; GENETICS; MUTANTS; SYSTEM; MAP	Arabidopsis thaliana is a small plant in the mustard family that has become the model system of choice for research in plant biology. Significant advances in understanding plant growth and development have been made by focusing on the molecular genetics of this simple angiosperm, The 120-megabase genome of Arabidopsis is organized into five chromosomes and contains an estimated 20,000 genes. More than 30 megabases of annotated genomic sequence has already been deposited in GenBank by a consortium of laboratories in Europe, Japan, and the United States. The entire genome is scheduled to be sequenced by the end of the year 2000. Reaching this milestone should enhance the value of Arabidopsis as a model for plant biology and the analysis of complex organisms in general.	Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Oklahoma State Univ, Dept Bot, Stillwater, OK 74078 USA; John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UH, Norfolk, England; Inst Genom Res, Rockville, MD 20850 USA; Wageningen Univ Agr, Genet Lab, NL-6307 HA Wageningen, Netherlands	Stanford University; Oklahoma State University System; Oklahoma State University - Stillwater; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; J. Craig Venter Institute; Wageningen University & Research	Cherry, JM (corresponding author), Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.	cherry@genome.stanford.edu		Koornneef, Maarten/0000-0002-7759-4869; Cherry, J. Michael/0000-0001-9163-5180				AN G, 1986, PLANT PHYSIOL, V81, P301, DOI 10.1104/pp.81.1.301; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; Bevan M, 1998, NATURE, V391, P485, DOI 10.1038/35140; Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; FELDMANN KA, 1987, MOL GEN GENET, V208, P1, DOI 10.1007/BF00330414; Fink GR, 1998, GENETICS, V149, P473; Finnegan EJ, 1998, ANNU REV PLANT PHYS, V49, P223, DOI 10.1146/annurev.arplant.49.1.223; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104; Kempin SA, 1997, NATURE, V389, P802, DOI 10.1038/39770; Koncz C., 1992, METHODS ARABIDOPSIS; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; Krysan PJ, 1996, P NATL ACAD SCI USA, V93, P8145, DOI 10.1073/pnas.93.15.8145; LAIBACH F., 1943, BOT ARCH [LEIPZIG], V44, P439; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LLOYD AM, 1986, SCIENCE, V234, P464, DOI 10.1126/science.234.4775.464; MARTINEZZAPATER JM, 1998, ARABIDOPSIS PROTOCOL, V82; MCKINNEY EC, 1995, PLANT J, V8, P613, DOI 10.1046/j.1365-313X.1995.8040613.x; Meinke D, 1997, PLANT J, V12, P247, DOI 10.1046/j.1365-313X.1997.12020247.x; MEINKE D, 1997, NAT SCI FDN PUBLICAT; MEINKE DW, 1979, DEV BIOL, V72, P50, DOI 10.1016/0012-1606(79)90097-6; MEYEROWITZ EM, 1985, SCIENCE, V229, P1214, DOI 10.1126/science.229.4719.1214; MEYEROWITZ EM, 1994, ARABIDOPSIS; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; NAWRATH C, 1994, P NATL ACAD SCI USA, V91, P12760, DOI 10.1073/pnas.91.26.12760; PREUSS D, 1994, SCIENCE, V264, P1458, DOI 10.1126/science.8197459; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Sato S, 1997, DNA Res, V4, P215, DOI 10.1093/dnares/4.3.215; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; Sundaresan V, 1996, TRENDS PLANT SCI, V1, P184, DOI 10.1016/1360-1385(96)10022-4; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; Xin ZG, 1998, P NATL ACAD SCI USA, V95, P7799, DOI 10.1073/pnas.95.13.7799	45	328	360	8	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					662	+		10.1126/science.282.5389.662	http://dx.doi.org/10.1126/science.282.5389.662			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784120				2022-12-28	WOS:000076607500039
J	Cooper, H; Smaje, C; Arber, S				Cooper, H; Smaje, C; Arber, S			Use of health services by children and young people according to ethnicity and social class: secondary analysis of a national survey	BRITISH MEDICAL JOURNAL			English	Article							EQUITY; CARE; NHS	Objective To assess whether equity is achieved in use of general practitioner, outpatient, and inpatient services by children and young people according to their ethnic group and socioeconomic background. Design Secondary analysis of the British general household survey, 1991-94. Subjects 20 473 children and young people aged between 0 and 19 years. Main outcome measures Consultations with a general practitioner within a two week period, outpatient attendances within a three month period, and inpatient stays during the past year. Results There were no significant class differences in the use of health services by children and young people, and there was little evidence of variation in use of health services according to housing tenure and parental work status. South Asian children and young people used general practitioner services more than any other ethnic group after controlling for socioeconomic background and perceived health status, but the use of hospital outpatient and inpatient services was significantly lower for children and young people from all minority ethnic groups compared with the white population. Conclusions Our results differ from previous studies, which have reported significant class differences in use of health services for other age groups. We found no evidence that children and young people's use of health services varied according to their socioeconomic status, suggesting that equity has been achieved. A child or young person's ethnic origin, however, was clearly associated with use of general practitioner and hospital services, which could imply that children and young people from minority ethnic groups receive a poorer quality of health care than other children and young people.	Univ Surrey, Dept Sociol, Guildford GU2 5XH, Surrey, England	University of Surrey	Cooper, H (corresponding author), Univ Surrey, Dept Sociol, Guildford GU2 5XH, Surrey, England.							BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; BALARAJAN R, 1987, J EPIDEMIOL COMMUN H, V41, P196, DOI 10.1136/jech.41.3.196; Balarajan R, 1991, Health Trends, V23, P90; BENNETT N, 1996, LIVING BRITAIN RESUL; BLAXTER M, 1984, BRIT MED J, V288, P1963, DOI 10.1136/bmj.288.6435.1963; Bryce C., 1995, CHILDREN RISK SAFETY; COLLINS E, 1980, BRIT MED J, V281, P1111, DOI 10.1136/bmj.281.6248.1111; *DEP HLTH SOC SEC, 1982, IN HLTH BLACK REP; ECOB R, 1993, SOC SCI MED, V36, P1017, DOI 10.1016/0277-9536(93)90119-O; FORSTER DP, 1976, HLTH TRENDS, V8, P29; FOSTER K, 1995, GEN HOUSEHOLD SURVEY; JOHNSON MRD, 1983, POSTGRAD MED J, V59, P664, DOI 10.1136/pgmj.59.696.664; LEGRAND J, 1978, ECONOMICA, V45, P125, DOI 10.2307/2553499; Lundberg O, 1996, SCAND J SOC MED, V24, P218, DOI 10.1177/140349489602400314; MACINTYRE S, 1989, SOC SCI MED, V29, P1243, DOI 10.1016/0277-9536(89)90063-4; MACLURE A, 1984, LANCET, V2, P682; Modood T., 1997, ETHNIC MINORITIES BR; NORUSIS MJ, 1993, BASE SYSTEM USERS GU; ODONNELL O, 1991, J HEALTH ECON, V10, P1, DOI 10.1016/0167-6296(91)90014-E; *OFF POP CENS SURV, 1994, 1991 CENS CHILDR YOU; Roberts I, 1996, BRIT MED J, V313, P784; Rudat K., 1994, BLACK MINORITY ETHNI; Smaje C, 1997, SOC SCI MED, V45, P485, DOI 10.1016/S0277-9536(96)00380-2; Smaje C, 1998, SOC POLICY ADMIN, V32, P116, DOI 10.1111/1467-9515.00092; SMAJE C, 1995, HLTH RACE ETHNICITY	25	94	94	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1047	1051						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131LH	9774288				2022-12-28	WOS:000076577200024
J	Kuster, H; Weiss, M; Willeitner, AE; Detlefsen, S; Jeremias, I; Zbojan, J; Geiger, R; Lipowsky, G; Simbruner, G				Kuster, H; Weiss, M; Willeitner, AE; Detlefsen, S; Jeremias, I; Zbojan, J; Geiger, R; Lipowsky, G; Simbruner, G			Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; C-REACTIVE PROTEIN; EXPERIMENTAL ENDOTOXEMIA; BACTERIAL-INFECTION; CIRCULATING ICAM-1; PREDICTIVE VALUE; PLASMA-LEVELS; FACTOR-ALPHA; DISORDERS; DISEASE	Background Neonatal sepsis is a common and life-threatening disorder, particularly among preterm infants. Early initiation of antibiotic therapy is frequently delayed because the first clinical signs of sepsis are non-specific and there are no reliable early laboratory indicators. We investigated the time course of expression and the prognostic power of the early inflammatory mediators interleukin-1 receptor antagonist (IL-1ra), interleukin-6 (IL-6), and circulating intercellular adhesion molecule-1 (cICAM-1) before clinical diagnosis of sepsis. Methods In a prospective multicentre study, we monitored 182 very-low-birthweight infants in six intensive-care units for occurrence of sepsis. During routine or clinically indicated blood sampling, an additional sample was collected for measurement of IL-1ra, IL-6, cICAM-1, and C-reactive protein (CRP). Infants were grouped into those with proven sepsis, no infection, or unclassified. The mean study duration was 34 days. Whenever sepsis occurred, a study period of 10 days was defined: day 0 was the day of clinical diagnosis of sepsis; days -4 to -1 were the 4 days before diagnosis; days +1 to +5 were the 5 days after. We compared the concentrations of the immune mediators during the 10-day study period with group-specific baseline values from before day -4. Findings 101 infants were included in the analysis: 21 with proven sepsis, 20 with no infection, and 60 unclassified. We excluded 57 because of incomplete datasets and 24 who had early-onset sepsis. IL-1ra and IL-6 increased significantly 2 days before diagnosis of sepsis; maximum median increases within the study period were 15-fold for IL-1ra and 12-fold for IL-6. The diagnostic sensitivities of IL-1ra, IL-6, and CRP concentrations on day 0 of diagnosis were 93%, 86%, and 43%, respectively; corresponding values on day -1 were 64%, 57%, and 18%. The specificities of IL-1ra, IL-6, and CRP concentrations were 92%, 83%, and 93%. cICAM-1 had a specificity of only 64%. Interpretation IL-1ra and IL-6 are superior to cICAM-1 and CRP as predictors of sepsis 1 or more days before clinical diagnosis. Ad-hoc measurement of these cytokines could allow earlier initiation of antibiotic therapy with corresponding improvement in outcome in very-low-birthweight infants with sepsis.	Univ Munich, Childrens Hosp, Kinderpoliklin, D-80336 Munich, Germany; Univ Munich, Dr Von Haunersches Kinderspital, D-80337 Munich, Germany; T Roosevelt Hosp, Dept Neonatol, Banska Bystrica, Slovakia; Univ Innsbruck Hosp, Dept Paediat, Innsbruck, Austria	University of Munich; University of Munich; Medical University of Innsbruck	Kuster, H (corresponding author), Univ Munich, Childrens Hosp, Kinderpoliklin, D-80336 Munich, Germany.		Jeremias, Irmela/Q-5934-2019; Jeremias, Irmela/C-6090-2015	Jeremias, Irmela/0000-0003-1773-7677; 				[Anonymous], 1989, Ann N Y Acad Sci, V557, P1; BUCK C, 1994, PEDIATRICS, V93, P54; DASILVA O, 1995, PEDIATR INFECT DIS J, V14, P362; DEBONT ESJM, 1995, PEDIATR RES, V37, P626, DOI 10.1203/00006450-199505000-00012; DEBONT ESJM, 1994, ACTA PAEDIATR, V83, P696; DEBONT ESJM, 1993, PEDIATR RES, V33, P380; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DUSTIN ML, 1986, J IMMUNOL, V137, P245; EDGAR JDM, 1994, CLIN SCI, V87, P165, DOI 10.1042/cs0870165; FISCHER E, 1992, BLOOD, V79, P2196; Geiger R, 1996, EUR J PEDIATR, V155, P811; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; Hachey W E, 1992, J Perinatol, V12, P240; HARRIS MC, 1994, J PEDIATR-US, V124, P105, DOI 10.1016/S0022-3476(94)70264-0; Klein JO, 1995, INFECT DIS FETUS NEW, P835; KREDIET T, 1992, J PERINAT MED, V20, P479, DOI 10.1515/jpme.1992.20.6.479; KUSTER H, 1993, LANCET, V341, P506, DOI 10.1016/0140-6736(93)90272-I; MATHERS NJ, 1987, EUR J PEDIATR, V146, P147, DOI 10.1007/BF02343221; Messer J, 1996, J PEDIATR-US, V129, P574, DOI 10.1016/S0022-3476(96)70123-3; Nakae H, 1996, SURG TODAY, V26, P225, DOI 10.1007/BF00311579; Panero A, 1997, PEDIATR INFECT DIS J, V16, P370, DOI 10.1097/00006454-199704000-00007; POURCYROUS M, 1993, PEDIATRICS, V92, P431; RODWELL RL, 1988, J PEDIATR-US, V112, P761, DOI 10.1016/S0022-3476(88)80699-1; SALZER HR, 1993, EUR J CLIN MICROBIOL, V12, P553, DOI 10.1007/BF01970964; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; SQUIRE E, 1979, PEDIATRICS, V64, P60; TSAKA T, 1990, CLIN CHIM ACTA, V193, P103, DOI 10.1016/0009-8981(90)90241-J; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; *VERM OXF NEON NET, 1996, VERM OXF NETW 1995 D; WEINSTEIN MV, 1980, CLIN DECISION ANAL, P79	30	185	202	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1271	1277		10.1016/S0140-6736(98)08148-3	http://dx.doi.org/10.1016/S0140-6736(98)08148-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788457				2022-12-28	WOS:000076573800011
J	Burns, MA; Johnson, BN; Brahmasandra, SN; Handique, K; Webster, JR; Krishnan, M; Sammarco, TS; Man, PM; Jones, D; Heldsinger, D; Mastrangelo, CH; Burke, DT				Burns, MA; Johnson, BN; Brahmasandra, SN; Handique, K; Webster, JR; Krishnan, M; Sammarco, TS; Man, PM; Jones, D; Heldsinger, D; Mastrangelo, CH; Burke, DT			An integrated nanoliter DNA analysis device	SCIENCE			English	Article							STRAND DISPLACEMENT AMPLIFICATION; CAPILLARY ELECTROPHORESIS; CHIPS; SEPARATIONS; PCR	A device was developed that uses microfabricated fluidic channels, heaters, temperature sensors, and fluorescence detectors to analyze nanoliter-size DNA samples. The device is capable of measuring aqueous reagent and DNA-containing solutions, mixing the solutions together, amplifying or digesting the DNA to form discrete products, and separating and defecting those products. No external Lenses, heaters, or mechanical pumps are necessary for complete sample processing and analysis. Because all of the components are made using conventional photolithographic production techniques, they operate as a single closed system. The components have the potential for assembly into complex, low-power, integrated analysis systems at Low unit cost, The availability of portable, reliable instruments may facilitate the use of DNA analysis in applications such as rapid medical diagnostics and point-of-use agricultural testing.	Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Engn & Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Burns, MA (corresponding author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.		Krishnan, Madhavi/J-4217-2015	Krishnan, Madhavi/0000-0003-1274-7155; Burke, David/0000-0002-2564-7949	NHGRI NIH HHS [R01-HG01044, R01-HG01406] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001044, R01HG001406] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Arlinghaus HF, 1997, ANAL CHEM, V69, P3747, DOI 10.1021/ac970267p; Boysen C, 1997, BIOTECHNIQUES, V23, P978, DOI 10.2144/97236bm01; Burke DT, 1997, GENOME RES, V7, P189, DOI 10.1101/gr.7.3.189; Burns MA, 1996, P NATL ACAD SCI USA, V93, P5556, DOI 10.1073/pnas.93.11.5556; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; EFFENHAUSER CS, 1994, ANAL CHEM, V66, P2949, DOI 10.1021/ac00090a024; Effenhauser CS, 1997, ANAL CHEM, V69, P3451, DOI 10.1021/ac9703919; GIBBS RA, 1995, NAT GENET, V11, P121, DOI 10.1038/ng1095-121; Hadd AG, 1997, ANAL CHEM, V69, P3407, DOI 10.1021/ac970192p; Handique K, 1997, P SOC PHOTO-OPT INS, V3224, P185, DOI 10.1117/12.284515; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; JACOBSON SC, 1994, ANAL CHEM, V66, P3472, DOI 10.1021/ac00092a027; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; McCormick RM, 1997, ANAL CHEM, V69, P2626, DOI 10.1021/ac9701997; MEASROS JM, 1993, ANAL CHEM, V65, P3313; OLSON MV, 1995, SCIENCE, V270, P394, DOI 10.1126/science.270.5235.394; Shoffner MA, 1996, NUCLEIC ACIDS RES, V24, P375, DOI 10.1093/nar/24.2.375; Simpson PC, 1998, P NATL ACAD SCI USA, V95, P2256, DOI 10.1073/pnas.95.5.2256; Sosnowski RG, 1997, P NATL ACAD SCI USA, V94, P1119, DOI 10.1073/pnas.94.4.1119; Spargo CA, 1996, MOL CELL PROBE, V10, P247, DOI 10.1006/mcpr.1996.0034; WALKER GT, 1992, NUCLEIC ACIDS RES, V20, P1691, DOI 10.1093/nar/20.7.1691; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Wilson RK, 1997, GENOME ANAL, V1, P301; Woolley AT, 1996, ANAL CHEM, V68, P4081, DOI 10.1021/ac960718q; Woolley AT, 1998, ANAL CHEM, V70, P684, DOI 10.1021/ac971135z; WOOLLEY AT, 1995, ANAL CHEM, V67, P3676, DOI 10.1021/ac00116a010; WOOLLEY AT, 1994, P NATL ACAD SCI USA, V91, P11348, DOI 10.1073/pnas.91.24.11348	27	1129	1392	2	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					484	487		10.1126/science.282.5388.484	http://dx.doi.org/10.1126/science.282.5388.484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774277				2022-12-28	WOS:000076479600057
J	Hanna, Z; Kay, DG; Rebai, N; Guimond, A; Jothy, S; Jolicoeur, P				Hanna, Z; Kay, DG; Rebai, N; Guimond, A; Jothy, S; Jolicoeur, P			Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice	CELL			English	Article							DOWN-REGULATION; TAT PROTEIN; INFECTION; GENE; CD4; PROLIFERATION; MACROPHAGES; LYMPHOCYTES; EXPRESSION; APOPTOSIS	Transgenic (Tg) mice expressing the complete coding sequences of HIV-1 in CD4(+) T cells and in cells of the macrophage/dendritic lineages develop severe AIDS-like pathologies: failure to thrive/weight loss, diarrhea, wasting, premature death, thymus atrophy, loss of CD4(+) T cells, interstitial pneumonitis, and tubulo-interstitial nephritis. The generation of Tg mice expressing selected HIV-1 gene(s) revealed that nef harbors a major disease determinant. The latency and progression (fast/slow) of the disease were strongly correlated with the levels of Tg expression. Nef-expressing Tg thymocytes were activated and alpha-CD3 hyperresponsive with respect to tyrosine phosphorylation of several substrates, including LAT and MAPK. The similarity of this mouse model to human AIDS, particularly pediatric AIDS, suggests that Nef may play a critical role in human AIDS, independently of its role in virus replication.	Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Pathol, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5G 1L5, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University; University of Toronto	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada.							BRADY HJM, 1993, EMBO J, V12, P4923, DOI 10.1002/j.1460-2075.1993.tb06186.x; CALVELLI T A, 1990, Immunodeficiency Reviews, V2, P83; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; COODLEY GO, 1994, J ACQ IMMUN DEF SYND, V7, P681; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P343, DOI 10.1089/aid.1994.10.343; Goudreau G, 1996, NAT MED, V2, P655, DOI 10.1038/nm0696-655; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; Hanna Z, 1998, J VIROL, V72, P121, DOI 10.1128/JVI.72.1.121-132.1998; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; Harris M, 1996, J GEN VIROL, V77, P2379, DOI 10.1099/0022-1317-77-10-2379; Herskowitz A, 1996, CURR OPIN CARDIOL, V11, P325, DOI 10.1097/00001573-199605000-00013; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; HUANG M, 1991, J VIROL, V65, P6562, DOI 10.1128/JVI.65.12.6562-6571.1991; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLOTMAN PE, 1995, AIDS, V9, P313, DOI 10.1097/00002030-199509040-00001; KROEMER G, 1995, ADV IMMUNOL, V58, P211, DOI 10.1016/S0065-2776(08)60621-5; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LINDEMANN D, 1994, J EXP MED, V179, P797, DOI 10.1084/jem.179.3.797; McSherry G D, 1996, Semin Respir Infect, V11, P173; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; Price RW, 1996, LANCET, V348, P445, DOI 10.1016/S0140-6736(95)11035-6; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SENEY FD, 1990, AM J KIDNEY DIS, V16, P1; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS TW, 1992, MOL BIOTHER, V4, P66; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	35	395	400	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					163	175		10.1016/S0092-8674(00)81748-1	http://dx.doi.org/10.1016/S0092-8674(00)81748-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790524	Bronze			2022-12-28	WOS:000076538300005
J	Olds, D; Henderson, CR; Cole, R; Eckenrode, J; Kitzman, H; Luckey, D; Pettitt, L; Sidora, K; Morris, P; Powers, J				Olds, D; Henderson, CR; Cole, R; Eckenrode, J; Kitzman, H; Luckey, D; Pettitt, L; Sidora, K; Morris, P; Powers, J			Long-term effects of nurse home visitation on children's criminal and antisocial behavior - 15-year follow-up of a randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTELLECTUAL IMPAIRMENT; CONDUCT DISORDER; SMOKE CIGARETTES; LIFE-COURSE; PREGNANCY; OUTCOMES; ABUSE; WOMEN; NEUROPSYCHOLOGY; AGGRESSION	Context.-A program of home visitation by nurses has been shown to affect the rates of maternal welfare dependence, criminality, problems due to use of substances, and child abuse and neglect. However, the long-term effects of this program on children's antisocial behavior have not been examined. Objective.-To examine the long-term effects of a program of prenatal and early childhood home visitation by nurses on children's antisocial behavior. Design.-Fifteen-year follow-up of a randomized trial. Interviews were conducted with the adolescents and their biological mothers or custodial parents. Setting.-Semirural community in New York. Participants.-Between April 1978 and September 1980, 500 consecutive pregnant women with no previous live births were recruited, and 400 were enrolled. A total of 315 adolescent offspring participated in a follow-up study when they were 15 years old; 280 (89%) were born to white mothers, 195 (62%) to unmarried mothers, 151 (48%) to mothers younger than 19 years, and 186 (59%) to mothers from households of low socioeconomic status at the time of registration during pregnancy. Intervention.-families in the groups that received home visits had an average of 9 (range, 0-16) home visits during pregnancy and 23 (range, 0-59) home visits from birth through the child's second birthday. The control groups received standard prenatal and well-child care in a clinic. Main Outcome Measures.-Children's self-reports of running away, arrests, convictions, being sentenced to youth corrections, initiation of sexual intercourse, number of sex partners, and use of illegal substances; school records of suspensions; teachers' reports of children's disruptive behavior in school; and parents' reports of the children's arrests and behavioral problems related to the children's use of alcohol and other drugs. Results.-Adolescents born to women who received nurse visits during pregnancy and postnatally and who were unmarried and from households of low socioeconomic status (risk factors for antisocial behavior), in contrast with those in the comparison groups, reported fewer instances (incidence) of running away (0.24 vs 0.60; P = .003), fewer arrests (0.20 vs 0.45; P = .03), fewer convictions and violations of probation (0.09 vs 0.47; P<.001), fewer lifetime sex partners (0.92 vs 2.48; P = .003), fewer cigarettes smoked per day (1.50 vs 2.50; P = .10), and fewer days having consumed alcohol in the last 6 months (1.09 vs 2.49; P = .03). Parents of nurse-visited children reported that their children had fewer behavioral problems related to use of alcohol and other drugs (0.15 vs 0.34; P = .08). There were no program effects on other behavioral problems. Conclusions.-This program of prenatal and early childhood home visitation by nurses can reduce reported serious antisocial behavior and emergent use of substances on the part of adolescents born into high-risk families.	Univ Colorado, Hlth Sci Ctr, Res Ctr Family & Child Hlth, Denver, CO 80218 USA; Cornell Univ, Ithaca, NY USA; Univ Rochester, Rochester, NY USA; Univ Denver, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Cornell University; University of Rochester; University of Denver	Olds, D (corresponding author), Univ Colorado, Hlth Sci Ctr, Res Ctr Family & Child Hlth, 1825 Marion St, Denver, CO 80218 USA.			Kitzman, Harriet/0000-0001-9470-7979	NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001382, R01MH049381] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH49381, 1-K05-MH01382-01] Funding Source: Medline; PHS HHS [96ASPE278A] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHENBACH TM, 1981, MONOGR SOC RES CHILD, V46, P188; BAKER P, 1989, NLSY YOUTH HDB 1989; BROOKSGUNN J, 1992, PEDIATRICS, V89, P1209; CLARKE AS, 1996, INFANT BEHAV DEV, V19, P453; ELLIOTT DS, 1997, BLUEPRINTS VIOLENCE; GRANT B, 1998, NATL J SUBST ABUSE, V9, P103; HAWKINS JD, 1991, J AM ACAD CHILD PSY, V30, P208, DOI 10.1097/00004583-199103000-00008; HENDERSON CR, 1982, BIOMETRICS, V38, P623, DOI 10.2307/2530044; HIGHTOWER AD, 1986, SCH PSYCHOL REV; HIGLEY JD, 1991, P NATL ACAD SCI USA, V88, P7261, DOI 10.1073/pnas.88.16.7261; Higley JD, 1996, NEUROPSYCHOPHARMACOL, V14, P67, DOI 10.1016/S0893-133X(96)80060-1; HUIZINGA D, 1991, NEUROPSYCHOLOGY AGGR; Jessor R., 1992, HLTH BEHAV QUESTIONN; JOFFE GP, 1992, SEX TRANSM DIS, V19, P22; Karoly L. A., 1998, INVESTING OUR CHILDR; Kessler Ronald C., 1994, International Review of Psychiatry, V6, P365, DOI 10.3109/09540269409023274; Kitzman H, 1997, JAMA-J AM MED ASSOC, V278, P644, DOI 10.1001/jama.278.8.644; MOFFITT TE, 1993, DEV PSYCHOPATHOL, V5, P135, DOI 10.1017/S0954579400004302; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Olds D, 1997, MENT RETARD DEV D R, V3, P257, DOI 10.1002/(SICI)1098-2779(1997)3:3<257::AID-MRDD6>3.0.CO;2-M; Olds D, 1997, J COMMUNITY PSYCHOL, V25, P9; Olds D, 1998, J COMMUNITY PSYCHOL, V26, P65; OLDS D, 1997, J COMMUNITY PSYCHOL, V1, P25; OLDS DL, 1994, PEDIATRICS, V93, P228; OLDS DL, 1986, PEDIATRICS, V77, P16; OLDS DL, 1986, PEDIATRICS, V78, P65; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; OLDS DL, 1994, PEDIATRICS, V93, P221; PATTERSON GR, 1989, AM PSYCHOL, V44, P329, DOI 10.1037/0003-066X.44.2.329; PENNINGTON BF, 1993, DEV PSYCHOPATHOL, V5, P153, DOI 10.1017/S0954579400004314; RAINE A, 1994, ARCH GEN PSYCHIAT, V51, P984; SCHNEIDER ML, 1993, J DEV BEHAV PEDIATR, V14, P81; SHAFER MA, 1993, SEX TRANSM DIS, V20, P307, DOI 10.1097/00007435-199320060-00002; SNYDER H, 1997, OFFICE JUVENILE JUST	34	682	687	2	78	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1238	1244		10.1001/jama.280.14.1238	http://dx.doi.org/10.1001/jama.280.14.1238			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127NR	9786373	Bronze			2022-12-28	WOS:000076357900029
J	Donaldson, GC; Ermakov, SP; Komarov, YM; McDonald, CP; Keatinge, WR				Donaldson, GC; Ermakov, SP; Komarov, YM; McDonald, CP; Keatinge, WR			Cold related mortalities and protection against cold in Yakutsk, eastern Siberia: observation and interview study	BRITISH MEDICAL JOURNAL			English	Article							PLASMA-FIBRINOGEN; BODY-TEMPERATURE; DISEASE; WINTER; DEATH; INCREASES; PRESSURE; CORONARY; AIR	Objective To assess how effectively measures adopted in extreme cold in Yakutsk control winter mortality. Design interviews to assess outdoor clothing and measure indoor temperatures; regressions of these and of delayed cause-specific mortalities on temperature. Setting Yakutsk, east Siberia, Russia Subjects: AU people aged 50-59 and 65-74 years living within 400 km of Yakutsk during 1989-95 and sample of 1002 men and women who agreed to be interviewed. Main outcome measures Daily mortality from all causes and from ischaemic heart, cerebrovascular, and respiratory disease. Results Mean temperature for October-March 1989-95 was - 26.6 degrees C. At 10.2 degrees C people wore 3.30 (95% confidence interval 3.08 to 3.53) layers ofclothing outdoors, increasing to 4.39 (4.13 to 4.66; P < 0.0001) layers at - 20 degrees C. Thick coats, often of fur, replaced anoraks as temperature fell to - 48.2 degrees C, 82% of people went out each day when temperatures were 10.2 degrees C to - 20 degrees C, but below - 20 degrees C the proportion fell steadily to 44% (35% to 53%) at -48.2 degrees C (P < 0.001), and overall shivering outdoors did not increase. Living room temperature was 17.9 (17.2 to 18.5)degrees C at 10.2 degrees C outdoors, 19.6 (18.8 to 20.4)degrees C at - 20 degrees C, and 19.1 (18.6 to 19.6)degrees C at -48.2 degrees C. Mortality from all causes and from ischaemic heart and respiratory disease was unaffected by the fall in temperature. Mortality from respiratory disease (daily deaths per million) rose from 4.7 (4.3 to 5.1) to 5.1 (4.4 to 5.7) (P = 0.03), but this was offset by a fall in deaths from injury Conclusions People in Yakutsk wore very warm clothing, and in extremely cold weather stayed indoors in warm housing preventing the increases in mortality seen in winter in milder regions of the world. Only respiratory mortality rose, perhaps because of breathing cold air.	Univ London Queen Mary & Westfield Coll, Dept Physiol, London E1 4NS, England; Minist Publ Hlth Russia, Publ Hlth Res Inst, Moscow 127254, Russia; Peckwater, Res, Surrey GU15 2LY, England	University of London; Queen Mary University London	Keatinge, WR (corresponding author), Univ London Queen Mary & Westfield Coll, Dept Physiol, Mile End Rd, London E1 4NS, England.	wr.keatinge@qmw.ac.uk	Ermakov, Sergey/G-1709-2016; Donaldson, Gavin/M-7992-2017	Ermakov, Sergey/0000-0003-1072-1162; Donaldson, Gavin/0000-0002-5538-4190	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; COLLINS KJ, 1985, CLIN SCI, V69, P465, DOI 10.1042/cs0690465; Donaldson GC, 1997, J EPIDEMIOL COMMUN H, V51, P643, DOI 10.1136/jech.51.6.643; Donaldson GC, 1998, BRIT MED J, V316, P514, DOI 10.1136/bmj.316.7130.514; ESCHENBACHER WL, 1992, LUNG, V170, P51, DOI 10.1007/BF00164755; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; FROST DB, 1992, INT J BIOMETEOROL, V36, P14, DOI 10.1007/BF01208729; GIESBRECHT GG, 1995, AVIAT SPACE ENVIR MD, V66, P890; GRAY PG, 1950, J ROY STAT SOC A STA, V113, P150, DOI 10.2307/2981039; HAYWARD MG, 1981, J PHYSIOL-LONDON, V320, P229, DOI 10.1113/jphysiol.1981.sp013946; HEUNIS JC, 1995, S AFR MED J, V85, P1016; HILL L, 1928, LANCET, V1, P802; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; Koskela H, 1995, EUR RESPIR J, V8, P2088, DOI 10.1183/09031936.95.08122088; LEWIS C, 1970, OXFORD ATLAS, P11; LOVETT AA, 1986, SOC SCI MED, V23, P935, DOI 10.1016/0277-9536(86)90251-0; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; NEILD PJ, 1994, CLIN SCI, V86, P43, DOI 10.1042/cs0860043; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; YOSHIHARA S, 1995, AM J RESP CRIT CARE, V151, P1011	21	65	67	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					978	982		10.1136/bmj.317.7164.978	http://dx.doi.org/10.1136/bmj.317.7164.978			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765165	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000076449300022
J	Pethica, BD; Penrose, A; MacKenzie, D; Hall, J; Beasle, R; Tilyard, M				Pethica, BD; Penrose, A; MacKenzie, D; Hall, J; Beasle, R; Tilyard, M			Comparison of potency of inhaled beclomethasone and budesonide in New Zealand: retrospective study of computerised general practice records	BRITISH MEDICAL JOURNAL			English	Article							ASTHMA; DIPROPIONATE; GLUCOCORTICOIDS; CORTICOSTEROIDS; DEATH; RISK	Objective To determine whether inhaled budesonide and beclomethasone are equipotent in the treatment of asthma in primary care. Design Retrospective study of computerised clinical records from 28 general practices in New Zealand, Subjects 5930 patients who received 16 725 prescriptions for inhaled budesonide or beclomethasone from 1 July 1991 to 30 June 1995, Setting General practices on the database of the Royal New Zealand College of General Practitioners Research Unit Linked information from secondary care was available for a subset of the practices. Main outcome measure Mean prescribed daily inhaled corticosteroid dose. Results The daily prescribed dose was higher for patients receiving inhaled budesonide (mean 979 mu g) than beclomethasone (mean 635 mu g), a difference of 344 mu g (95% confidence interval 313 to 376 mu g). This difference was consistent in all age bands and with different types of inhalation device. Evidence of systematic prescribing of higher doses of budesonide to patients with mole severe asthma was not found. Conclusions In primary care in New Zealand evidence suggests that budesonide is less potent than beclomethasone, Consideration of validated, established, and other possible markers of asthma severity did not support confounding by severity as a reason for the higher prescribed doses of budesonide. Pending further epidemiological evaluation, international asthma guidelines may need to be modified on the equivalence of inhaled corticosteroid doses. Furthermore, the comparative potency of newly developed inhaled steroids in clinical trials will need to be confirmed in appropriately designed epidemiological studies based in general practice.	Univ Otago, Wellington Sch Med, Wellington Asthma Res Grp, Wellington S, New Zealand; Univ Otago, Dunedin Sch Med, Dept Gen Practice, Royal New Zealand Coll Gen Practitioners,Res Unit, Dunedin, New Zealand	University of Otago; University of Otago	Pethica, BD (corresponding author), Univ Otago, Wellington Sch Med, Wellington Asthma Res Grp, POB 7343, Wellington S, New Zealand.			Beasley, Richard/0000-0003-0337-406X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Birkebaek NH, 1995, ARCH DIS CHILD, V73, P524, DOI 10.1136/adc.73.6.524; Clark DJ, 1997, CLIN PHARMACOKINET, V32, P58, DOI 10.2165/00003088-199732010-00003; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; CRANE J, 1991, ADULT ASTHMA MANAGEM; DAVIES B, 1993, BRIT J CLIN PRACT, V47, P87; Dovey SM, 1996, BRIT J GEN PRACT, V46, P749; Kamada AK, 1997, J ALLERGY CLIN IMMUN, V99, P735, DOI 10.1016/S0091-6749(97)80004-8; LIPWORTH BJ, 1993, PHARMACOL THERAPEUT, V58, P173, DOI 10.1016/0163-7258(93)90049-J; *NAT HEART LUNG BL, 1992, INT CONS REP DIAGN T; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; ROHDEWALD P, 1990, ATEMWEG LUNGENKRANK, V16, P79; RYAN G, 1991, AUST NZ J MED, V21, P681, DOI 10.1111/j.1445-5994.1991.tb01370.x; SVENDSEN UG, 1992, ALLERGY, V47, P174, DOI 10.1111/j.1398-9995.1992.tb00960.x; TILYARD MW, 1995, NEW ZEAL MED J, V108, P118; TJWA MKT, 1995, ANN ALLERG ASTHMA IM, V75, P107; TOWN I, 1992, NZ DOCTOR       0305, P27	17	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					986	990		10.1136/bmj.317.7164.986	http://dx.doi.org/10.1136/bmj.317.7164.986			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765169	Green Published			2022-12-28	WOS:000076449300025
J	Plana, M; Garcia, F; Gallart, T; Miro, JM; Gatell, JM				Plana, M; Garcia, F; Gallart, T; Miro, JM; Gatell, JM		Spanish EARTH-1 Study	Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease	LANCET			English	Article									Hosp Clin Barcelona, Servei Malaties Infeccioses, Barcelona, Spain; Hosp Clin Barcelona, Servei Immunol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Gatell, JM (corresponding author), Hosp Clin Barcelona, Servei Malaties Infeccioses, Villarroel 170, Barcelona, Spain.	gatell@medicina.ub.es	Plana, Montserrat/AAA-5124-2020; , Felipe/F-4242-2014; Gatell, Jose M/ABC-3607-2020	, Felipe/0000-0001-7658-5832; 				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Carlesimo M, 1997, CLIN EXP IMMUNOL, V109, P406, DOI 10.1046/j.1365-2249.1997.4721370.x; DAVIGNON JL, 1995, SCAND J IMMUNOL, V41, P247, DOI 10.1111/j.1365-3083.1995.tb03560.x; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338	5	95	95	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1998	352	9135					1194	1195		10.1016/S0140-6736(05)60532-6	http://dx.doi.org/10.1016/S0140-6736(05)60532-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777842				2022-12-28	WOS:000076415400017
J	Hoekstra, EJ; LeBaron, CW; Megaloeconomou, Y; Guerrero, H; Byers, C; Johnson-Partlow, T; Lyons, B; Mihalek, E; Devier, J; Mize, J				Hoekstra, EJ; LeBaron, CW; Megaloeconomou, Y; Guerrero, H; Byers, C; Johnson-Partlow, T; Lyons, B; Mihalek, E; Devier, J; Mize, J			Impact of a large-scale immunization initiative in the special supplemental nutrition program for women, infants, and children (WIC)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESCHOOL-CHILDREN; UNITED-STATES; MEASLES; EPIDEMIC; RATES	Context.-Inner-city immunization rates have lagged behind those in other areas of the country. Objective.-To evaluate the impact of an initiative linking immunization with distribution of food vouchers in the inner city, Design.-Retrospective analysis of immunization data gathered in 1996 and 1997, Setting.-Nineteen Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) sites serving 30% of the Chicago, III, birth cohort, Participants.-A total of 16581 children 24 months old or younger. Interventions.-voucher incentives (varying frequency of food voucher issuance based on immunization status) and assessment of immunization status and referral to immunization provider. Main Outcome Measures.-Age-appropriate immunization rates and WIC enrollment rates. Results.-During the 15-month period of evaluation, immunization rates increased from 56% to 89% at sites performing voucher incentives. The proportion of children needing voucher incentives declined from 51% to 12%, Sites performing assessment and referral, but not providing voucher incentives, showed no evidence of improvement in immunization coverage. No difference was observed in enrollment rates between sites performing voucher incentives and those that did not, Conclusion.-Applied in a large-scale, programmatic fashion, voucher incentives in WIC can rapidly increase and sustain high childhood immunization rates in an inner-city population.	Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA; Catholic Charities, Chicago, IL USA; Chicago Dept Publ Hlth, Chicago Immunizat Program, Chicago, IL USA; Special Supplemental Nutr Program Women Infants &, Chicago, IL USA	Centers for Disease Control & Prevention - USA; Chicago Department of Public Health	LeBaron, CW (corresponding author), Ctr Dis Control & Prevent, Natl Immunizat Program, MS E-61, Atlanta, GA 30333 USA.			Lyons, Bridget/0000-0003-1152-9439				BIRKHEAD GS, 1995, JAMA-J AM MED ASSOC, V274, P312, DOI 10.1001/jama.274.4.312; *CDC, 1990, MMWR-MORBID MORTAL W, V40, P317; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P369; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P176; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P613; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P217; Flatt K, 1996, 124 ANN M EXP AM PUB; GINDLER JS, 1992, PEDIATR INFECT DIS J, V11, P841, DOI 10.1097/00006454-199210000-00007; Goldstein KP, 1996, JAMA-J AM MED ASSOC, V276, P56, DOI 10.1001/jama.276.1.56; Hutchins S, 1996, PEDIATR INFECT DIS J, V15, P31, DOI 10.1097/00006454-199601000-00007; HUTCHINS SS, 1993, AM J PUBLIC HEALTH, V83, P862, DOI 10.2105/AJPH.83.6.862; HUTCHINS SS, 1995, P 28 NAT IMM C ATL G, P1; Kenyon TA, 1998, PEDIATRICS, V101, P612, DOI 10.1542/peds.101.4.612; LeBaron CW, 1997, JAMA-J AM MED ASSOC, V277, P631, DOI 10.1001/jama.277.8.631; LeBaron CW, 1996, AM J PUBLIC HEALTH, V86, P1551, DOI 10.2105/AJPH.86.11.1551; SCHLENKER TL, 1992, JAMA-J AM MED ASSOC, V267, P823, DOI 10.1001/jama.267.6.823; Shefer A, 1996, J Public Health Manag Pract, V2, P34; Shefer A, 1998, ARCH PEDIAT ADOL MED, V152, P65; WOOD DL, 1997, 37 ANN AM AMB PED AS	19	45	45	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1143	1147		10.1001/jama.280.13.1143	http://dx.doi.org/10.1001/jama.280.13.1143			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777813	Bronze			2022-12-28	WOS:000076210800027
J	Hurt, RD; Robertson, CR				Hurt, RD; Robertson, CR			Prying open the door to the tobacco industry's secrets about nicotine - The Minnesota Tobacco Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WILLIAMSON DOCUMENTS; LAWYER CONTROL; ADDICTION	In 1994 the state of Minnesota filed suit against the tobacco industry, This trial is now history, but its legacy will carry on into the 21st century because of the revelations contained in the millions of pages of previously secret internal tobacco industry documents made public in the trial. In this article, we review representative documents relating to nicotine addiction, low-tar, low-nicotine cigarettes, and cigarette design and nicotine manipulation in cigarette manufacture. These documents reveal that for decades, the industry knew and internally acknowledged that nicotine is an addictive drug and cigarettes are the ultimate nicotine delivery device; that nicotine addiction can be perpetuated and even enhanced through cigarette design alterations and manipulations; and that "health-conscious" smokers could be captured by low-tar, low-nicotine products, all the while ensuring the marketplace viability of their products. Appreciation of tobacco industry strategies over the past decades is essential to formulate an appropriate legislative and public policy response. We propose key elements for such legislation and urge no legal or financial immunity for the tobacco industry.	Mayo Clin & Mayo Fdn, Nicotine Dependence Ctr, Rochester, MN 55905 USA; Stanford Univ, Sch Engn, Dept Chem Engn, Stanford, CA 94305 USA	Mayo Clinic; Stanford University	Hurt, RD (corresponding author), Mayo Clin & Mayo Fdn, Nicotine Dependence Ctr, 200 1st St SW, Rochester, MN 55905 USA.							[Anonymous], 1971, COMMUNICATION; AYRES CI, 1984, P SMOK BEH MARK C 3; BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENTLEY HR, 1958, BAT             0417; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; BLACKHURST JD, 1966, WORK EXTRACTABLE NIC; BROOKS GO, 1982, COMMUNICATION   0407; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1043; CHEN L, 1976, PH SMOKE REV; COLBY FG, 1981, COMMUNICATION   1209; COLBY FG, 1973, COMMUNICATION   1204; CREIGHTON DE, 1988, SIGNIFICANCE PH TOBA; CREIGHTON DE, 1978, COMPENSATION CHANGED; CRELLIN RA, 1980, BRAINSTORMING, V2; *DEP HLTH UK, 1998, REP SCI COMM TOB HLT, P9; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DUKES CA, 1974, COMMUNICATION   0930; Dunn W.L., 1972, MOTIVES INCENTIVES C; DUNN WL, 1980, COMMUNICATION   0324; DUNN WL, 1980, COMMUNICATION   0321; DUNN WL, 1969, COMMUNICATION   0219; ELLIS C, 1962, BAT             0213; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; Goodman B., 1975, MARLBORO MARLBORO LI; GREEN SJ, 1976, PRODUCT EARLY 1980S; GREGORY CF, 1980, OBSERVATIONS FREE NI; GREIG CC, STRUCTURED CREATIVIT; GRIFFITH RB, 1963, COMMUNICATION   0918; GUESS HE, 1980, COMMUNICATION   0205; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HANNERS D, 1998, ST PAUL PIONEER 0215, pA12; HANNERS D, 1998, ST PAUL PIONEER 0215, pA1; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; HIND JF, 1975, COMMUNICATION   0123; HIRJI T, 1987, COMMUNICATION   0723; IHRIG AM, 1973, COMMUNICATION   0208; JOHNSON RL, 1973, COMMUNICATION   0221; JOHNSON RR, 1989, AMM TECHN C MIN LOUI; KNOPICK P, 1980, COMMUNICATION   0909; Koop CE, 1998, JAMA-J AM MED ASSOC, V279, P550, DOI 10.1001/jama.279.7.550; Kozlowski L T, 1996, Tob Control, V5, P265, DOI 10.1136/tc.5.4.265; LAURENE AH, 1971, COMMUNICATION   0524; LONG GH, 1980, COMMUNICATION   0722; MACKENZIE JL, 1976, COMMUNICATION   0921; MCCORMICK AD, 1974, SMOKNG HLTH; MELLMAN AJ, 1983, COMMUNICATION   0325; *NOWL ORG INC, 1976, SHF CIG MARK OPP SEA; OLDMAN M, 1991, PRODUCTS CONSUMER IN; OLDMAN M, 1979, CIGARETTE SMOKING HL; OSDENE TS, 1980, COMMUNICATION   0812; OSDENE TS, 1978, COMMUNICATION   0110; *P MORR, 1994, EFF CIG SMOK PH NIC; PANZER F, 1972, COMMUNICATION   0501; PEPLES E, 1977, COMMUNICATION; RIEHL T, 1984, PROJECT SHIP REV PRO; *RJR, 1992, RJR BIOS GEN JOINT R; ROBERTS DL, 1983, COMMUNICATION   1013; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P411, DOI 10.1007/BF02247414; ROBINSON JH, 1983, COMMUNICATION   0725; RODGMAN A, 1980, COMMUNICATION   0908; Schori TR, 1979, FREE NICOTINE ITS IM; SCHUMACHER S, 1977, NICOTINE SMOKER SATI; SENKUS M, 1969, COMMUNICATION; SHAFFER D, 1998, EXTOBACCO RES TAKES; SHORT A, 1971, NEW PRODUCT; SHORT PL, 1977, COMMUNICATION   0414; SHORT PL, 1977, COMMUNICATION   0428; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; SLAVEN RW, 1982, PROGR REPORT NICOTIN; SMITH RE, 1980, COMMUNICATION   0213; STANFORD JE, 1993, COMMUNICATION   1202; STEELE HD, 1978, COMMUNICATION   0824; TEAGUE CE, 1972, COMMUNICATION   0414; TEAGUE CE, 1973, IMPLICATIONS ACTIVIT; *TOB IND RES COMM, 1954, TOC IND RES COMM M J; TODD JS, 1995, JAMA-J AM MED ASSOC, V274, P256, DOI 10.1001/jama.274.3.256; *US DEP HHS, 1988, PUBL CDC; *US DHHS, 1996, NIH PUBL US DEP HLTH; WILLIAMS RK, 1971, DEV CIGARETTE INCREA; WOOD DJ, 1977, SMOKING PRODUCTS RES; Woods J.D., 1973, HIST REV SMOKE PH DA; WOODS JD, 1975, 4 RDM; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; WYNDER EL, 1953, CANCER RES, V13, P855; 1984, P SMOK BEH MARK C JU	87	156	185	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1173	1181		10.1001/jama.280.13.1173	http://dx.doi.org/10.1001/jama.280.13.1173			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777818				2022-12-28	WOS:000076210800032
J	Klement, IA; Skinner, PJ; Kaytor, MD; Yi, H; Hersch, SM; Clark, HB; Zoghbi, HY; Orr, HT				Klement, IA; Skinner, PJ; Kaytor, MD; Yi, H; Hersch, SM; Clark, HB; Zoghbi, HY; Orr, HT			Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice	CELL			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; PALLIDOLUYSIAN ATROPHY DRPLA; MACHADO-JOSEPH DISEASE; CAG REPEAT; EXPANDED POLYGLUTAMINE; NEUROLOGICAL PHENOTYPE; TRINUCLEOTIDE REPEAT; PROTEIN; GENE; EXPANSION	Transgenic mice carrying the spinocerebellar ataxia type 1 (SCA1) gene, a polyglutamine neurodegenerative disorder, develop ataxia with ataxin-l localized to aggregates within cerebellar Purkinje cells nuclei. To examine the importance of nuclear localization and aggregation in pathogenesis, mice expressing ataxin-1[82] with a mutated NLS were established. These mice did not develop disease, demonstrating that nuclear localization is critical for pathogenesis. In a second series of transgenic mice, ataxin-1[77] containing a deletion within the self-association region was expressed within Purkinje cells nuclei. These mice developed ataxia and Purkinje cell pathology similar to the original SCA1 mice. However, no evidence of nuclear ataxin-l aggregates was found. Thus, although nuclear localization of ataxin-1 is necessary, nuclear aggregation of ataxin-l is not required to initiate pathogenesis in transgenic mice.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Emory University; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Howard Hughes Medical Institute	Orr, HT (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.	harry@lenti.med.umn.edu		Skinner, Pamela/0000-0003-3388-1687; Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027699, R37NS022920, R01NS022920, R01NS035255] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27699, NS22920, NS35255] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Becher MW, 1997, MOVEMENT DISORD, V12, P519, DOI 10.1002/mds.870120408; BISOTTO S, 1995, J CELL SCI, V108, P1873; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Burright EN, 1997, HUM MOL GENET, V6, P513, DOI 10.1093/hmg/6.4.513; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark HB, 1997, J NEUROSCI, V17, P7385; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davies SW, 1998, LANCET, V351, P131, DOI 10.1016/S0140-6736(97)08360-8; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; FRANGIONI JV, 1993, J CELL SCI, V105, P481; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Koob MD, 1998, NAT GENET, V18, P72, DOI 10.1038/ng0198-72; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; LA SA, 1991, NATURE, V352, P77; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MATILLA A, 1998, IN PRESS J NEUROSCI; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Orr HT, 1996, COLD SPRING HARB SYM, V61, P649; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; QUINLAN MP, 1984, CELL, V36, P857, DOI 10.1016/0092-8674(84)90035-7; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; YI H, 1997, RECEPTOR LOCALIZATIO, P107	49	820	849	2	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1998	95	1					41	53		10.1016/S0092-8674(00)81781-X	http://dx.doi.org/10.1016/S0092-8674(00)81781-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778246	Bronze			2022-12-28	WOS:000076242300009
J	Yamashita, A; Watanabe, Y; Nukina, N; Yamamoto, M				Yamashita, A; Watanabe, Y; Nukina, N; Yamamoto, M			RNA-assisted nuclear transport of the meiotic regulator Mei2p in fission yeast	CELL			English	Article							PREMEIOTIC DNA-SYNTHESIS; SCHIZOSACCHAROMYCES-POMBE; MEIOSIS; PROTEIN; GENE; TELOMERES; PROPHASE; IDENTIFICATION; TRANSCRIPTION; CENTROMERES	Fission yeast Mei2p is an RNA-binding protein required for both premeiotic DNA synthesis and meiosis I. Mei2p binds to a polyadenylated RNA molecule, meiRNA, loss of which blocks meiosis I. Mei2p forms a dot in meiotic prophase nuclei. Here, we show that meiRNA is required for the nuclear localization of Mei2p and is detectable in the dot. However, Mei2p carrying a nuclear localization signal can produce a nuclear dot and promote meiosis I in the absence of meiRNA. Mei2p expressed in cultured mammalian cells stays in the cytoplasm, but it accumulates in the nucleolus if meiRNA is coexpressed. These results indicate that meiRNA contributes to the promotion of meiosis I exclusively as a cofactor that assists nuclear transport of Mei2p.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Wako, Saitama 3510198, Japan	University of Tokyo; RIKEN	Yamamoto, M (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan.	myamamot@ims.u-tokyo.ac.jp	Nukina, Nobuyuki/GPP-6265-2022; Yamashita, Akira/A-5278-2015	Yamashita, Akira/0000-0002-1805-1434; Watanabe, Yoshinori/0000-0002-5488-4812				ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bass HW, 1997, J CELL BIOL, V137, P5, DOI 10.1083/jcb.137.1.5; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; EGEL R, 1974, EXP CELL RES, V88, P127, DOI 10.1016/0014-4827(74)90626-0; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; FUSSELL C P, 1987, P275; Gebauer F, 1997, BIOESSAYS, V19, P23, DOI 10.1002/bies.950190106; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gutz H., 1974, HDB GENETICS, V1, P395; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HAGAN IM, 1988, J CELL SCI, V89, P343; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HELM R, 1995, NATURE, V373, P663; IINO Y, 1995, GENETICS, V140, P1235; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOHLI J, 1994, EXPERIENTIA, V50, P295, DOI 10.1007/BF01924013; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kupiec M., 1997, MOL CELLULAR BIOL YE, P889; Li P, 1996, CELL, V87, P869, DOI 10.1016/S0092-8674(00)81994-7; LIN Y, 1992, GENETICS, V132, P75; MCLEOD M, 1988, NATURE, V332, P509, DOI 10.1038/332509a0; MOLNAR M, 1995, GENETICS, V141, P61; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; ROBINOW CF, 1977, GENETICS, V87, P491; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Sherman F., 1986, METHODS YEAST GENETI; SHIMODA C, 1987, J BACTERIOL, V169, P93, DOI 10.1128/jb.169.1.93-96.1987; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; SVOBODA A, 1995, CHROMOSOMA, V104, P203, DOI 10.1007/s004120050109; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; UZAWA S, 1992, J CELL SCI, V101, P267; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x; Watanabe Y, 1997, NATURE, V386, P187, DOI 10.1038/386187a0; Yamamoto M., 1997, MATING SPORULATION S, P1037; Yamashita A, 1997, GENES CELLS, V2, P155, DOI 10.1046/j.1365-2443.1997.1100307.x	44	95	98	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1998	95	1					115	123		10.1016/S0092-8674(00)81787-0	http://dx.doi.org/10.1016/S0092-8674(00)81787-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778252	Bronze			2022-12-28	WOS:000076242300015
J	Zeng, Y; Forbes, KC; Wu, ZQ; Moreno, S; Piwnica-Worms, H; Enoch, T				Zeng, Y; Forbes, KC; Wu, ZQ; Moreno, S; Piwnica-Worms, H; Enoch, T			Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1	NATURE			English	Article							DNA-DAMAGE CHECKPOINT; FISSION YEAST; MITOTIC INDUCER; PROTEIN-KINASE; S-PHASE; MITOSIS; SERINE-216; THIAMINE; PATHWAY; GENE	Checkpoints maintain the order and fidelity of events of the cell cycle by blocking mitosis in response to unreplicated or damaged DNA(1). In most species this is accomplished by preventing activation of the cell-division kinase Cdc2, which regulates entry into mitosis(2-5). The Chk1 kinase, an effector of the DNA-damage checkpoint, phosphorylates Cdc25, an activator of Cdc2 (refs 6-11), Phosphorylation of Cdc25 promotes its binding, to 14-3-3 proteins, preventing it from activating: Cdc2 (ref. 8). Here we propose that a similar pathway is required for mitotic arrest in the presence of unreplicated DNA (that is, in the replication checkpoint) in fission yeast. We show by mutagenesis that Chk1 functions redundantly with the kinase Cds1 at the replication checkpoint and that both kinases phosphorylate Cdc25 on the same sites, which include serine residues at positions 99, 192 and 359, Mutation of these residues reduces binding of 14-3-3 proteins to Cdc25 in vitro and disrupts the replication checkpoint in vivo. We conclude that both Cds1 and Chk1 regulate the binding of Cdc25 to 14-3-3 proteins as part of the checkpoint response to unreplicated DNA.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Salamanca, CSIC, Dept Genet & Microbiol, Inst Microbiol Bioquim, Salamanca, Spain	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Harvard University; Harvard Medical School; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	hpiwnica@cellbio.wustl.edu	Moreno, Sergio/K-3671-2014; Piwnica-Worms, Helen/C-5214-2012	Moreno, Sergio/0000-0002-8039-1413; 				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FORBES KC, IN PRESS GENETICS; Francesconi S, 1997, EMBO J, V16, P1332, DOI 10.1093/emboj/16.6.1332; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kostrub CF, 1997, MOL GEN GENET, V254, P389, DOI 10.1007/PL00008606; LEE MS, 1994, J BIOL CHEM, V269, P30530; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; Uchiyama M, 1997, MOL CELL BIOL, V17, P3103, DOI 10.1128/MCB.17.6.3103; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	304	313	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					507	510		10.1038/26766	http://dx.doi.org/10.1038/26766			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774107				2022-12-28	WOS:000076212200058
J	Fujisawa, T; Oosterkamp, TH; van der Wiel, WG; Broer, BW; Aguado, R; Tarucha, S; Kouwenhoven, LP				Fujisawa, T; Oosterkamp, TH; van der Wiel, WG; Broer, BW; Aguado, R; Tarucha, S; Kouwenhoven, LP			Spontaneous emission spectrum in double quantum dot devices	SCIENCE			English	Article							STATES; SYSTEM	A double quantum dot device is a tunable two-level system for electronic energy states. A de electron current was used to directly measure the rates for elastic and inelastic transitions between the two levels. For inelastic transitions, energy is exchanged with bosonic degrees of freedom in the environment. The inelastic transition rates are well described by the Einstein coefficients, relating absorption with stimulated and spontaneous emission. The most effectively coupled bosons in the specific environment of the semiconductor device used here were acoustic phonons. The experiments demonstrate the importance of vacuum fluctuations in the environment for quantum dot devices and potential design constraints for their use for preparing long-lived quantum states.	Delft Univ Technol, Dept Appl Phys, NL-2600 GA Delft, Netherlands; Delft Univ Technol, DIMES, NL-2600 GA Delft, Netherlands; Nippon Telegraph & Tel Corp, Basic Res Labs, Atsugi, Kanagawa 2430198, Japan; Univ Tokyo, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan	Delft University of Technology; Delft University of Technology; Nippon Telegraph & Telephone Corporation; University of Tokyo	Kouwenhoven, LP (corresponding author), Delft Univ Technol, Dept Appl Phys, NL-2600 GA Delft, Netherlands.	leo@qt.tn.tudelft.nl	van der Wiel, Wilfred/F-8812-2014; Fujisawa, Toshimasa/M-2428-2013; Aguado, Ramon/B-5516-2008; TARUCHA, SEIGO/I-7030-2012	van der Wiel, Wilfred/0000-0002-3479-8853; Fujisawa, Toshimasa/0000-0002-0451-6579; Aguado, Ramon/0000-0002-7464-7363; 				Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; AVERIN DV, 1992, NATO ADV SCI I B-PHY, V294, P217; BOCKELMANN U, 1994, PHYS REV B, V50, P17271, DOI 10.1103/PhysRevB.50.17271; Cleland AN, 1998, NATURE, V392, P160, DOI 10.1038/32373; Fujisawa T, 1997, SUPERLATTICE MICROST, V21, P247, DOI 10.1006/spmi.1996.0191; Fujisawa T, 1997, JPN J APPL PHYS 1, V36, P4000, DOI 10.1143/JJAP.36.4000; GLAZMAN LI, 1988, ZH EKSP TEOR FIZ, V67, P1276; GRABERT H, 1992, SINGLE CHARGE TUNN B, V294; HOLST T, 1994, PHYS REV LETT, V73, P3455, DOI 10.1103/PhysRevLett.73.3455; IMAMOGLU A, 1992, PHYS REV B, V46, P15982, DOI 10.1103/PhysRevB.46.15982; Kouwenhoven L, 1998, PHYS WORLD, V11, P35; Kouwenhoven LP, 1997, NATO ADV SCI I E-APP, V345, P105; LEGGETT AJ, 1987, REV MOD PHYS, V59, P1, DOI 10.1103/RevModPhys.59.1; McEuen PL, 1998, NATURE, V393, P15, DOI 10.1038/29874; Milonni P. W., 1994, QUANTUM VACUUM INTRO; MIZUTA H, 1995, PHYSICS APPL RESONAN; Nakamura Y, 1997, PHYS REV LETT, V79, P2328, DOI 10.1103/PhysRevLett.79.2328; NAZAROV YV, 1993, PHYSICA B, V189, P57, DOI 10.1016/0921-4526(93)90146-W; OOSTERKAMP TH, IN PRESS NATURE; Shilton JM, 1996, J PHYS-CONDENS MAT, V8, pL531, DOI 10.1088/0953-8984/8/38/001; Stoof TH, 1996, PHYS REV B, V53, P1050, DOI 10.1103/PhysRevB.53.1050; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; VANDERVAART NC, 1995, PHYS REV LETT, V74, P4702, DOI 10.1103/PhysRevLett.74.4702; WEINSTOCK H, 1992, P NATO ADV STUDY I E, V251	25	361	366	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1998	282	5390					932	935		10.1126/science.282.5390.932	http://dx.doi.org/10.1126/science.282.5390.932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794761	Green Submitted			2022-12-28	WOS:000076727300046
J	Beyerle, U; Purtschert, R; Aeschbach-Hertig, W; Imboden, DM; Loosli, HH; Wieler, R; Kipfer, R				Beyerle, U; Purtschert, R; Aeschbach-Hertig, W; Imboden, DM; Loosli, HH; Wieler, R; Kipfer, R			Climate and groundwater recharge during the last glaciation in an ice-covered region	SCIENCE			English	Article							NOBLE-GASES; PALEOTEMPERATURES; TEMPERATURE; PLAIN	A multitracer study of a small aquifer in northern Switzerland indicates that the atmosphere in central Europe cooled by at Least 5 degrees C during the Last glacial period. The relation between oxygen isotope ratios (delta(18)O) and recharge temperatures reconstructed for this period is similar to the present-day one if a shift in the delta(18)O value of the oceans during the ice age is taken into account. This similarity suggests that the present-day delta(18)O-temperature relation can be used to reconstruct paleoclimate conditions in northern Switzerland. A gap in calculated groundwater age between about 17,000 and 25,000 years before the present indicates that during the Last glacial maximum, local groundwater recharge was prevented by overlying glaciers.	Swiss Fed Inst Technol, Dept Environm Phys, Zurich, Switzerland; Swiss Fed Inst Environm Sci & Technol, CH-8600 Dubendorf, Switzerland; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Swiss Fed Inst Technol, Dept Earth Sci, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); University of Bern; Swiss Federal Institutes of Technology Domain; ETH Zurich	Beyerle, U (corresponding author), Swiss Fed Inst Technol, Dept Environm Phys, Zurich, Switzerland.	beyerle@eawag.ch	Purtschert, Roland J/N-7108-2016; Aeschbach, Werner/C-1026-2008; Wieler, Rainer/A-1355-2010; Beyerle, Urs/M-9490-2017	Purtschert, Roland J/0000-0002-4734-7664; Aeschbach, Werner/0000-0003-0917-1239; Wieler, Rainer/0000-0001-5666-7494; Beyerle, Urs/0000-0002-6464-0838				AESCHBACHHERTIG W, 1971, J CHEM ENG DATA, V16, P235; AESCHBACHHERTIG W, 1970, DEEP-SEA RES, V17, P721; Andrews J., 1992, ISOTOPES NOBLE GASES, P87; ANDREWS JN, 1994, WATER RESOUR RES, V30, P45, DOI 10.1029/93WR02226; ANDREWS JN, 1984, ISOTOPE HYDROLOGY 19, P535; [Anonymous], 1964, RECENT RES FIELDS HY, P263; BATH AH, 1979, ISOTOPE HYDROLOGY, V2, P545; BOULTON GS, 1995, QUATERNARY SCI REV, V14, P545, DOI 10.1016/0277-3791(95)00039-R; CLEVER HL, 1979, KRYPTON XENON RADON, P1; CLIMAP Project Members, 1976, Science, V191, P1131; DEGENS ET, 1962, GEOL RUNDSCH, V52, P625; FONTES JC, 1979, WATER RESOUR RES, V15, P399, DOI 10.1029/WR015i002p00399; FRENZEL B, 1980, KLIMA ANAL MODELLE G, P45; GELHAR LW, 1992, WATER RESOUR RES, V28, P1955, DOI 10.1029/92WR00607; HEATON THE, 1981, J HYDROL, V50, P201, DOI 10.1016/0022-1694(81)90070-6; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; Kullin M., 1991, APPL ISOTOPE HYDROGE, V43, P65; LOOSLI HH, 1991, APPL ISOTOPE HYDROGE, P153; MAZOR E, 1972, GEOCHIM COSMOCHIM AC, V36, P1321, DOI 10.1016/0016-7037(72)90065-8; MAZOR M, 1997, CHEM ISOTOPIC GROUND, pCH9; MUNNICH KO, 1962, GEOL RUNDSCH, V52, P611; RUDOLPH J, 1984, ISOTOPE HYDROLOGY, P467; SCHLUECHTER C, 1987, Vierteljahrsschrift der Naturforschenden Gesellschaft in Zuerich, V132, P135; SCHUEPP M, 1981, ATLAS SCHWEIZ, P11; SIEGENTHALER U, 1980, NATURE, V285, P314, DOI 10.1038/285314a0; SOWERS T, 1993, PALEOCEANOGRAPHY, V8, P737, DOI 10.1029/93PA02328; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; STUTE M, 1992, SCIENCE, V256, P1000, DOI 10.1126/science.256.5059.1000; STUTE M, 1995, QUATERNARY RES, V43, P209, DOI 10.1006/qres.1995.1021; STUTE M, 1992, GEOCHIM COSMOCHIM AC, V56, P2051, DOI 10.1016/0016-7037(92)90329-H; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; Stute M., 1993, PROTEOM, P89, DOI [DOI 10.1016/J.CBD.2016.06.005, DOI 10.1029/GM078P0089]; WYSSLING L, 1988, 8846 CANT ZUR DEP WA; Yurtsever Y., 1981, STABLE ISOTOPE HYDRO, V210, P103; ZUBER A, 1986, J HYDROL, V86, P45, DOI 10.1016/0022-1694(86)90005-3	35	84	85	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					731	734		10.1126/science.282.5389.731	http://dx.doi.org/10.1126/science.282.5389.731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784128				2022-12-28	WOS:000076607500047
J	Furusawa, A; Sorensen, JL; Braunstein, SL; Fuchs, CA; Kimble, HJ; Polzik, ES				Furusawa, A; Sorensen, JL; Braunstein, SL; Fuchs, CA; Kimble, HJ; Polzik, ES			Unconditional quantum teleportation	SCIENCE			English	Article							PODOLSKY-ROSEN PARADOX; SUB-POISSONIAN LIGHT; CONTINUOUS-VARIABLES; ATOMIC-STATE; REALIZATION; CONVERSION; CAVITY	Quantum teleportation of optical coherent states was demonstrated experimentally using squeezed-state entanglement. The quantum nature of the achieved teleportation was verified by the experimentally determined fidelity F-exp = 0.58 +/- 0.02, which describes the match between input and output states. A fidelity greater than 0.5 is not possible for coherent states without the use of entanglement. This is the first realization of unconditional quantum teleportation where every state entering the device is actually teleported.	CALTECH, Norman Bridge Lab Phys, Pasadena, CA 91125 USA; Aarhus Univ, Inst Phys & Astron, DK-8000 Aarhus, Denmark; Univ Wales, Sch Elect Engn & Comp Sci, Bangor LL57 1UT, Gwynedd, Wales	California Institute of Technology; Aarhus University; Bangor University	Kimble, HJ (corresponding author), CALTECH, Norman Bridge Lab Phys, Pasadena, CA 91125 USA.	hjkimble@cco.caltech.edu	Braunstein, Samuel L/A-5501-2009; Furusawa, Akira/P-5787-2014	Furusawa, Akira/0000-0002-6176-6742				ARTHURS E, 1965, AT&T TECH J, V44, P725, DOI 10.1002/j.1538-7305.1965.tb01684.x; Barnum H. N., 1998, THESIS U NEW MEXICO; Bell J. S., 1988, SPEAKABLE UNSPEAKABL, P196; BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Boschi D, 1998, PHYS REV LETT, V80, P1121, DOI 10.1103/PhysRevLett.80.1121; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Braunstein SI, 1998, NATURE, V394, P840, DOI 10.1038/29674; BRAUNSTEIN SL, 1990, PHYS REV A, V42, P474, DOI 10.1103/PhysRevA.42.474; Braunstein SL, 1996, PHYS REV A, V53, P630, DOI 10.1103/PhysRevA.53.630.2; Braunstein SL, 1998, NATURE, V394, P47, DOI 10.1038/27850; Braunstein SL, 1998, PHYS REV LETT, V80, P869, DOI 10.1103/PhysRevLett.80.869; CIRAC JI, 1994, PHYS REV A, V50, pR4441, DOI 10.1103/PhysRevA.50.R4441; DAVIDOVICH L, 1994, PHYS REV A, V50, pR895, DOI 10.1103/PhysRevA.50.R895; Einstein A, 1935, PHYS REV, V47, P0777, DOI 10.1103/PhysRev.47.777; Fuchs CA, 1996, PHYS REV A, V53, P2038, DOI 10.1103/PhysRevA.53.2038; KIMBLE HJ, 1992, FUNDAMENTAL SYSTEMS, P549; MERTZ J, 1990, PHYS REV LETT, V64, P2897, DOI 10.1103/PhysRevLett.64.2897; OU ZY, 1992, PHYS REV LETT, V68, P3663, DOI 10.1103/PhysRevLett.68.3663; OU ZY, 1992, APPL PHYS B-PHOTO, V55, P265, DOI 10.1007/BF00325015; POLZIK ES, 1992, PHYS REV LETT, V68, P3020, DOI 10.1103/PhysRevLett.68.3020; POLZIK ES, 1991, OPT LETT, V16, P1400, DOI 10.1364/OL.16.001400; REID MD, 1988, PHYS REV LETT, V60, P2731, DOI 10.1103/PhysRevLett.60.2731; SLEATOR T, 1995, ANN NY ACAD SCI, V755, P715, DOI 10.1111/j.1749-6632.1995.tb39013.x; TAPSTER PR, 1988, PHYS REV A, V37, P2963, DOI 10.1103/PhysRevA.37.2963; VAIDMAN L, 1994, PHYS REV A, V49, P1473, DOI 10.1103/PhysRevA.49.1473; VANLOOCK P, UNPUB; WU LA, 1986, PHYS REV LETT, V57, P2520, DOI 10.1103/PhysRevLett.57.2520; YUEN HP, 1980, IEEE T INFORM THEORY, V26, P78, DOI 10.1109/TIT.1980.1056132; YURKE B, 1986, PHYS REV A, V33, P4033, DOI 10.1103/PhysRevA.33.4033; [No title captured]	30	2378	2487	12	197	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					706	709		10.1126/science.282.5389.706	http://dx.doi.org/10.1126/science.282.5389.706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784123				2022-12-28	WOS:000076607500042
J	Wyatt, JC; Paterson-Brown, S; Johanson, R; Altman, DG; Bradburn, MJ; Fisk, NM				Wyatt, JC; Paterson-Brown, S; Johanson, R; Altman, DG; Bradburn, MJ; Fisk, NM			Randomised trial of educational visits to enhance use of systematic reviews in 25 obstetric units	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; PHYSICIAN PERFORMANCE; EFFECTIVE CARE; OVERVIEWS; KNOWLEDGE; DELIVERY	Objective To evaluate the effectiveness of an educational visit to help obstetricians and midwives select and use evidence from a Cochrane database containing 600 systematic reviews. Design Randomised single blind controlled trial with obstetric units allocated to an educational visit or control group. Setting 25 of the 26 district general obstetric units in two former NHS regions. Subjects The senior obstetrician and midwife from each intervention unit participated in educational visits. Clinical practices of all staff were assessed in 4508 pregnancies. Intervention Single informal educational visit by a respected obstetrician including discussion of evidence based obstetrics, guidance on implementation and donation of Cochrane database and other materials. Main outcome measures Rates of perineal suturing with polyglycolic acid, ventouse delivery, prophylactic antibiotics in caesarean section, and steroids in preterm delivery, before and 9 months after visits, and concordance of guidelines with review evidence for same marker practices before and after visits. Results Rates varied greatly, but the overall baseline mean of 43% (986/2312) increased to 54% (1189/2196) 9 months later. Rates of ventouse delivery increased significantly in intervention units but not in control units; there was no difference between the two types of units in uptake of other practices. Pooling rates from all 25 units, use of antibiotics in caesarean section and use of polyglycolic acid sutures increased significantly over the period, but use of steroids in preterm delivery was unchanged. Labour ward guidelines seldom agreed with evidence at baseline; this hardly improved after visits. Educational visits cost pound 860 each (at 1995 prices). Conclusions There was considerable uptake of evidence into practice in both control and intervention units between 1994 and 1995, Our educational visits added little to this, despite the informal setting, targeting of senior staff from two disciplines, and donation of educational materials. Further work is needed to define cost effective methods to enhance the uptake of evidence from systematic reviews and to clarify leadership and roles of senior obstetric staff in implementing the evidence.	Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Fund, Med Stat Grp, Oxford OX3 7LF, England; Queen Charlottes & Chelsea Hosp, Imperial Coll, Sch Med, Inst Obstet & Gynaecol, London W6 0XG, England; City Gen Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England	University of Oxford; Imperial College London	Wyatt, JC (corresponding author), UCL, Sch Publ Policy, Hlth Knowledge Management Programme, London WC1E 7HN, England.	jeremy.wyatt@ucl.ac.uk	Wyatt, Jeremy/F-8160-2010; Bradburn, Mike/A-2272-2010; Fisk, Nicholas M/B-2126-2009	Wyatt, Jeremy/0000-0001-7008-1473; Fisk, Nicholas M/0000-0003-0031-7975; Bradburn, Mike/0000-0002-3783-9761				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BATH PMW, 1993, BRIT MED J, V307, P1045, DOI 10.1136/bmj.307.6911.1045; BENBOW A, 1997, EFFECTIVE PROCEDURE; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; *CLIN STAND ADV GR, 1995, WOM NORM LAB; Davis David A., 1995, JAMA (Journal of the American Medical Association), V274, P700, DOI 10.1001/jama.274.9.700; DEBURGH S, 1995, AUST J PUBLIC HEALTH, V19, P142; DONALDSON LJ, 1992, BRIT MED J, V305, P1280, DOI 10.1136/bmj.305.6864.1280; ENKIN MW, 1995, COCHRANE COLLABORATI; EVANS C E, 1986, Journal of the American Medical Association, V255, P501, DOI 10.1001/jama.255.4.501; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; Hodnett ED, 1996, RES NURS HEALTH, V19, P13, DOI 10.1002/(SICI)1098-240X(199602)19:1<13::AID-NUR2>3.0.CO;2-O; *HOUS COMM HLTH CO, 1992, MAT SERV; JOHANSON R, 1994, PROMOTING EFFECTIVE; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1994, DISSEMINATING NEW KN; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PATERSONBROWN S, 1993, BMJ-BRIT MED J, V307, P1464, DOI 10.1136/bmj.307.6917.1464; PATERSONBROWN S, 1995, BRIT J OBSTET GYNAEC, V102, P297, DOI 10.1111/j.1471-0528.1995.tb09135.x; PENN ZJ, 1991, BRIT J OBSTET GYNAEC, V98, P531, DOI 10.1111/j.1471-0528.1991.tb10365.x; PETO R, 1993, ANN NY ACAD SCI, V703, P314, DOI 10.1111/j.1749-6632.1993.tb26369.x; Rogers EM., 1983, DIFFUSION INNOVATION; *ROYAL COLL OBST G, 1994, MIN STAND CAR LAB RE; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; STEER P, 1993, BRIT MED J, V307, P697, DOI 10.1136/bmj.307.6906.697; STREINER DL, 1993, HLTH MEASUREMENT SCA, P80; STROSS JK, 1989, JAMA-J AM MED ASSOC, V262, P2721, DOI 10.1001/jama.262.19.2721; THOMSON MA, 1997, COLLABORATION EFFECT; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W	34	71	72	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	1998	317	7165					1041	1046						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131LH	9774287				2022-12-28	WOS:000076577200022
J	Stamm, C; Marty, F; Vaterlaus, A; Weich, V; Egger, S; Maier, U; Ramsperger, U; Fuhrmann, H; Pescia, D				Stamm, C; Marty, F; Vaterlaus, A; Weich, V; Egger, S; Maier, U; Ramsperger, U; Fuhrmann, H; Pescia, D			Two-dimensional magnetic particles	SCIENCE			English	Article							MESOSCOPIC MAGNETS; DOMAINS; ARRAYS; MICROSCOPE; NANOWIRES; DYNAMICS; CU(001); FILMS	Single two-dimensional (2D) atomically thick magnetic particles of cobalt and iron with variable size and shape were fabricated by combining a mask technique with standard molecular beam epitaxy. Reduction of the Lateral size of in-plane magnetized 2D cobalt films down to about 100 nanometers did not essentially modify their magnetic properties; although the separation of boundaries decreased greatly, neither domain penetrated the particle, nor was any sizable shape anisotropy observed. The mutual interaction of 2D cobalt particles was negligible, and the magnetic state of a single particle could be switched without modifying the state of the neighbors. Perpendicularly magnetized iron particles did not exhibit such responses. These results suggest that only a few atoms forming a 2D in-plane magnetized dot may provide a stable elementary bit for nanorecording.	Swiss Fed Inst Technol, Festkorperphys Lab, CH-8093 Zurich, Switzerland; Natl Res Inst Met, Tsukuba, Ibaraki 305, Japan; Swiss Fed Inst Technol, Inst Teilchenphys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; National Institute for Materials Science; Swiss Federal Institutes of Technology Domain; ETH Zurich	Pescia, D (corresponding author), Swiss Fed Inst Technol, Festkorperphys Lab, CH-8093 Zurich, Switzerland.		Stamm, Christian/G-4814-2013	Stamm, Christian/0000-0001-5611-9084				ALLENSPACH R, 1994, J MAGN MAGN MATER, V129, P160, DOI 10.1016/0304-8853(94)90108-2; AWSCHALOM DD, 1995, PHYS TODAY, V48, P43, DOI 10.1063/1.881448; Beeli C, 1997, ULTRAMICROSCOPY, V67, P143, DOI 10.1016/S0304-3991(96)00101-5; CZECH R, 1989, J PHYS-CONDENS MAT, V1, P619, DOI 10.1088/0953-8984/1/3/013; DURR W, 1990, INT J MOD PHYS B, V4, P410; Ebels U, 1997, J APPL PHYS, V81, P4724, DOI 10.1063/1.364748; Gu E, 1997, PHYS REV LETT, V78, P1158, DOI 10.1103/PhysRevLett.78.1158; Hehn M, 1996, SCIENCE, V272, P1782, DOI 10.1126/science.272.5269.1782; KENT AD, 1994, J APPL PHYS, V76, P6656, DOI 10.1063/1.358160; KITTEL C, 1946, PHYS REV, V70, P965, DOI 10.1103/PhysRev.70.965; KOIKE K, 1987, SCANNING MICROSCOPY, P241; KRAMS P, 1992, PHYS REV LETT, V69, P3674, DOI 10.1103/PhysRevLett.69.3674; LEDERMAN M, 1994, PHYS REV LETT, V73, P1986, DOI 10.1103/PhysRevLett.73.1986; MAXWELL JC, 1954, TREATISE ELECT MAGNE, V2; NEEL L, 1953, REV MOD PHYS, V25, P293, DOI 10.1103/RevModPhys.25.293; OEPEN HP, 1991, J MAGN MAGN MATER, V93, P116, DOI 10.1016/0304-8853(91)90314-Z; Politi P, 1998, EUR PHYS J B, V2, P475, DOI 10.1007/s100510050270; QIU ZQ, 1992, PHYS REV B, V46, P8659, DOI 10.1103/PhysRevB.46.8659; Ramsperger U, 1996, PHYS REV B, V53, P8001, DOI 10.1103/PhysRevB.53.8001; SCHEINFEIN MR, 1990, REV SCI INSTRUM, V61, P2501, DOI 10.1063/1.1141908; SMYTH JF, 1991, J APPL PHYS, V69, P5262, DOI 10.1063/1.348071; STONER EC, 1945, PHILOS MAG, V36, P803, DOI DOI 10.1080/14786444508521510; Vaterlaus A, 1997, REV SCI INSTRUM, V68, P2800, DOI 10.1063/1.1148198; WEI MS, 1994, J APPL PHYS, V76, P6679, DOI 10.1063/1.358166; Wernsdorfer W, 1997, PHYS REV B, V55, P11552, DOI 10.1103/PhysRevB.55.11552; Wu RQ, 1998, J MAGN MAGN MATER, V177, P1216, DOI 10.1016/S0304-8853(97)00382-X; YAFET Y, 1988, PHYS REV B, V38, P9145, DOI 10.1103/PhysRevB.38.9145	27	139	139	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					449	451		10.1126/science.282.5388.449	http://dx.doi.org/10.1126/science.282.5388.449			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774266				2022-12-28	WOS:000076479600046
J	Wingham, DJ; Ridout, AJ; Scharroo, R; Arthern, RJ; Shum, CK				Wingham, DJ; Ridout, AJ; Scharroo, R; Arthern, RJ; Shum, CK			Antarctic elevation change from 1992 to 1996	SCIENCE			English	Article							GLOBAL SEA-LEVEL; SNOW ACCUMULATION; MOTION; EARTH	Satellite radar altimeter measurements show that the average elevation of the Antarctic Ice Sheet interior fell by 0.9 +/- 0.5 centimeters per year from 1992 to 1996. If the variability of snowfall observed in Antarctic ice cores is allowed for, the mass imbalance of the interior this century is only -0.06 +/- 0.08 of the mean mass accumulation rate.	UCL, Dept Space & Climate Phys, London WC1H 0AH, England; Delft Univ Technol, Delft Inst Earth Oriented Space Res, NL-2629 HS Delft, Netherlands; Ohio State Univ, Dept Civil & Engn Sci & Geodet Sci, Columbus, OH 43210 USA	University of London; University College London; Delft University of Technology; University System of Ohio; Ohio State University	Wingham, DJ (corresponding author), UCL, Dept Space & Climate Phys, 17-19 Gordon St, London WC1H 0AH, England.		Scharroo, Remko/F-5623-2010	Shum, C K/0000-0001-9378-4067; Scharroo, Remko/0000-0002-2118-131X				ARTHERN RJ, 1997, THESIS U LONDON; ARTHERN RJ, IN PRESS CLIM CHANGE; Bamber J.L., 1996, ANN GLACIOL, V23, P364; BAMBER JL, 1994, INT J REMOTE SENS, V15, P925, DOI 10.1080/01431169408954125; BENTLEY CR, 1991, P INT C ROL POL REG, P481; Cameron R.L., 1964, ANTARCT RES SER, V2, P1; CHAO BF, 1988, J GEOPHYS RES-SOLID, V93, P13811, DOI 10.1029/JB093iB11p13811; CUDLIP W, 1994, INT J REMOTE SENS, V14, P889; ENOMOTO H, 1991, CLIMATIC CHANGE, V18, P67, DOI 10.1007/BF00142505; *EUR SPAC AG, 1993, ESA PUBL; FU LL, 1994, J GEOPHYS RES-OCEANS, V99, P24369, DOI 10.1029/94JC01761; GORNITZ V, 1995, EARTH SURF PROC LAND, V20, P7, DOI 10.1002/esp.3290200103; GOW A, 1961, 78 US ARM COLD REG R; HUGHES TJ, 1981, J GLACIOL, V27, P518, DOI 10.3189/S002214300001159X; Isaksson E, 1996, J GEOPHYS RES-ATMOS, V101, P7085, DOI 10.1029/95JD03232; JACOBS SS, 1992, NATURE, V360, P29, DOI 10.1038/360029a0; KOERNER RM, 1971, ANTARCT RES SER, V16, P225; MEIER MF, 1984, SCIENCE, V226, P1418, DOI 10.1126/science.226.4681.1418; MORGAN VI, 1991, NATURE, V354, P58, DOI 10.1038/354058a0; MOSELYTHOMPSON E, 1991, J GLACIOL, V37, P11; PELTIER WR, 1988, SCIENCE, V240, P895, DOI 10.1126/science.240.4854.895; PETIT JR, 1982, J GEOPHYS RES-OCEANS, V87, P4301, DOI 10.1029/JC087iC06p04301; Raymond C, 1996, J GLACIOL, V42, P510, DOI 10.3189/S002214300000349X; REEH N, 1985, GLACIERS ICE SHEETS, P155; Scharroo R, 1998, J GEOPHYS RES-OCEANS, V103, P8113, DOI 10.1029/97JC03179; SHUM CK, 1994, ESA PUBLICATION, V361; VAUGHAN DG, IN PRESS J CLIM; WAHR J, 1995, GEOPHYS RES LETT, V22, P977, DOI 10.1029/94GL02840; [No title captured]; [No title captured]	30	258	266	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					456	458		10.1126/science.282.5388.456	http://dx.doi.org/10.1126/science.282.5388.456			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774268				2022-12-28	WOS:000076479600048
J	Parr, BA; McMahon, AP				Parr, BA; McMahon, AP			Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a	NATURE			English	Article							MULLERIAN-INHIBITING SUBSTANCE; ESTROGEN-RECEPTOR GENE; DUCT SYNDROME; VERTEBRATE LIMB; II RECEPTOR; EXPRESSION; HORMONE; DISRUPTION; CLONING; CELLS	An important feature of mammalian development is the generation of sexually dimorphic reproductive tracts from the Mullerian and Wolffian ducts. In females, Mullerian ducts develop into the oviduct, uterus, cervix and upper vagina, whereas Wolffian ducts regress. In males, testosterone promotes differentiation of Wolffian ducts into the epididymis, vas deferens and seminal vesicle. The Sertoli cells of the testes produce Mullerian-inhibiting substance, which stimulates Mullerian duct regression in males(1-4) The receptor for Mullerian-inhibiting substance is expressed by mesenchymal cells underlying the Mullerian duct that are thought to mediate regression of the duct(5-7). Mutations that inactivate either Mullerian-inhibiting substance or its receptor allow development of the female reproductive tract in males(8-12). These pseudohermaphrodites are frequently infertile because sperm passage is blocked by the presence of the female reproductive system(9,10,12). Here we show that male mice lacking the signalling molecule Wnt-7a fail to undergo regression of the Mullerian duct as a result of the absence of the receptor for Mullerian-inhibiting substance. Wnt7a-deficient females are infertile because of abnormal development of the oviduct and uterus, both of which are Mullerian duct derivatives. Therefore, we propose that signalling by Wnt-7a allows sexually dimorphic development of the Mullerian ducts.	Harvard Univ, Dept Mol & Cellular Biol, Biolabs, Cambridge, MA 02138 USA	Harvard University	McMahon, AP (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Biolabs, 16 Divin Ave, Cambridge, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020					BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; Cygan JA, 1997, DEVELOPMENT, V124, P5021; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Imbeaud S, 1996, HUM MOL GENET, V5, P1269, DOI 10.1093/hmg/5.9.1269; Josso N, 1997, CLIN ENDOCRINOL, V47, P137, DOI 10.1046/j.1365-2265.1997.2411044.x; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KNEBELMANN B, 1991, P NATL ACAD SCI USA, V88, P3767, DOI 10.1073/pnas.88.9.3767; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Miller C, 1998, DEVELOPMENT, V125, P3201; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; VAINIO S, UNPUB NATURE; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0	24	248	262	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					707	710		10.1038/27221	http://dx.doi.org/10.1038/27221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790192				2022-12-28	WOS:000076472600054
J	Emery, AEH				Emery, AEH			Fortnightly review - The muscular dystrophies	BRITISH MEDICAL JOURNAL			English	Review							X-CHROMOSOME; MUTATIONS; DEFICIENCY; DIAGNOSIS; GENETICS; MYOPATHY; CLONING; LINKAGE; MICE; DNA		Royal Devon & Exeter Hosp, Dept Neurol, Res Unit, Exeter EX2 5DW, Devon, England	University of Exeter	Emery, AEH (corresponding author), 2 Ingleside,Upper W Terrace, Budleigh Salterton EX9 6NZ, Devon, England.							BAKKER E, 1987, NATURE, V329, P554, DOI 10.1038/329554a0; Beckmann JS, 1996, CURR OPIN NEUROL, V9, P389, DOI 10.1097/00019052-199610000-00013; Bouchard J-P., 1997, NEUROMUSCULAR DISORD, V7, pS1; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; Brown Susan C., 1997, P163; Bushby K, 1996, NEUROMUSCULAR DISORD, V6, P439, DOI 10.1016/S0960-8966(96)00392-6; Cartegni L, 1997, HUM MOL GENET, V6, P2257, DOI 10.1093/hmg/6.13.2257; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Dubowitz V, 1997, NEUROMUSCULAR DISORD, V7, P539; Dubowitz V, 1997, NEUROMUSCULAR DISORD, V7, P261; Duggan DJ, 1997, NEW ENGL J MED, V336, P618, DOI 10.1056/NEJM199702273360904; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; EMERY AEH, 1996, MUSCULAR DYSTROPHY F; Guicheney P, 1997, NEUROMUSCULAR DISORD, V7, P180, DOI 10.1016/S0960-8966(97)00460-4; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOLDING C, 1993, J MED GENET, V30, P903, DOI 10.1136/jmg.30.11.903; HOWELL JM, 1997, NEUROMUSCULAR DISORD, V7, P273; KUNKEL LM, 1985, P NATL ACAD SCI USA, V82, P4778, DOI 10.1073/pnas.82.14.4778; LAING NG, 1995, AM J HUM GENET, V56, P422; Metzinger L, 1997, HUM MOL GENET, V6, P1185, DOI 10.1093/hmg/6.7.1185; MURRAY JM, 1982, NATURE, V300, P69, DOI 10.1038/300069a0; PADBERG GW, 1997, DIAGNOSTIC CRITERIA, P9; RAY PN, 1985, NATURE, V318, P672, DOI 10.1038/318672a0; SOMER H, 1998, NEUROMUSCULAR DISORD, P181; SUGITA H, 1988, P JPN ACAD B-PHYS, V64, P37, DOI 10.2183/pjab.64.37; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; TOME FMS, 1998, NEUROMUSCULAR DISORD, P21; WALTON JN, 1964, BRIT MED J, V1, P1271, DOI 10.1136/bmj.1.5393.1271; WALTON JN, 1954, BRAIN, V77, P169, DOI 10.1093/brain/77.2.169; WALTON JN, 1964, BMJ-BRIT MED J, V1, P1344; Welander L, 1951, ACTA MED SCAND, V141, P1; Wijmenga C, 1990, LANCET, V336, P651, DOI 10.1016/0140-6736(90)92148-B; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	34	84	88	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					991	995		10.1136/bmj.317.7164.991	http://dx.doi.org/10.1136/bmj.317.7164.991			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765171	Green Published			2022-12-28	WOS:000076449300026
J	Wang, SS; Esplin, ED; Li, JL; Huang, LY; Gazdar, A; Minna, J; Evans, GA				Wang, SS; Esplin, ED; Li, JL; Huang, LY; Gazdar, A; Minna, J; Evans, GA			Alterations of the PPP2R1B gene in human lung and colon cancer	SCIENCE			English	Article							PROTEIN PHOSPHATASE 2A; SERINE THREONINE PHOSPHATASES; MEDIATED CHROMOSOME TRANSFER; TUMORIGENIC EXPRESSION; CELLS; SUBUNIT; BREAST; SUPPRESSION; ANTIGENS; BRAIN	The PPP2R1B gene, which encodes the beta isoform of the A subunit of the serine/threonine protein phosphatase ZA (PP2A), was identified as a putative human tumor suppressor gene. Sequencing of the PPP2R1B gene, located on human chromosome 11q22-24, revealed somatic alterations in 15% (5 out of 33) of primary lung tumors, 6% (4 out of 70) of lung tumor-derived cell lines, and 15% (2 out of 13) of primary colon tumors. One deletion mutation generated a truncated PP2A-A beta protein that was unable to bind to the catalytic subunit of the PP2A holoenzyme. The PP2R1B gene product may suppress tumor development through its role in cell cycle regulation and cellular growth control.	Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Evans, GA (corresponding author), Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Esplin, Ed/AAL-2226-2021	Esplin, Edward/0000-0001-9205-3756				Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; Evans Glen A., 1996, American Journal of Human Genetics, V59, pA66; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kawai T, 1997, KOREA POLYM J, V5, P1; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; McCright B, 1996, GENOMICS, V36, P168, DOI 10.1006/geno.1996.0438; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NEGRINI M, 1994, CANCER RES, V54, P1331; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang S, 1997, AM J HUM GENET, V61, pA87; WANG SG, UNPUB; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	25	325	332	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					284	287		10.1126/science.282.5387.284	http://dx.doi.org/10.1126/science.282.5387.284			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765152				2022-12-28	WOS:000076370200045
J	Lang, AE; Lozano, AM				Lang, AE; Lozano, AM			Parkinson's disease - First of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSITRON EMISSION TOMOGRAPHY; MAGNETIC-RESONANCE SPECTROSCOPY; PROGRESSIVE SUPRANUCLEAR PALSY; OPIOID RECEPTOR-BINDING; MULTIPLE SYSTEM ATROPHY; SUBSTANTIA-NIGRA; LEWY BODY; ALPHA-SYNUCLEIN; DIFFERENTIAL-DIAGNOSIS; GENETIC COMPLEXITY		Toronto Hosp, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Med, Div Neurol, Toronto, ON, Canada; Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; Toronto Hosp, Morton & Gloria Shulman Movement Disorders Ctr, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Lang, AE (corresponding author), Toronto Hosp, 399 Bathurst St,MP 11, Toronto, ON M5T 2S8, Canada.		Lang, Anthony/ABF-8114-2021; Lozano, Andres M/A-5058-2012	Lang, Anthony/0000-0003-1229-3667; Lozano, Andres M./0000-0001-8257-3694				Aarsland D, 1996, ARCH NEUROL-CHICAGO, V53, P538, DOI 10.1001/archneur.1996.00550060082020; Antonini A, 1997, MOVEMENT DISORD, V12, P33, DOI 10.1002/mds.870120107; Bandmann O, 1998, MOVEMENT DISORD, V13, P203, DOI 10.1002/mds.870130203; Bandmann O, 1997, LANCET, V350, P1136, DOI 10.1016/S0140-6736(97)03495-8; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; BenShlomo Y, 1996, J NEUROL NEUROSUR PS, V61, P4, DOI 10.1136/jnnp.61.1.4; Bergeron C, 1996, AM J PATHOL, V148, P267; BRAAK H, 1994, ACTA NEUROPATHOL, V88, P493, DOI 10.1007/BF00296485; BROOKS DJ, 1993, NEUROLOGY, V43, P6; Brucke T, 1997, J NEURAL TRANSM-SUPP, P9; Burke RE, 1998, MOVEMENT DISORD, V13, P17; BURN DJ, 1995, BRAIN, V118, P951, DOI 10.1093/brain/118.4.951; Calne DB, 1997, J NEURAL TRANSM-SUPP, P47; CALNE DB, 1994, NEUROLOGY, V44, P5; Chase TN, 1997, ARCH NEUROL-CHICAGO, V54, P1156, DOI 10.1001/archneur.1997.00550210084017; Churchyard A, 1997, NEUROLOGY, V49, P1570, DOI 10.1212/WNL.49.6.1570; DAVIE CA, 1995, J NEUROL NEUROSUR PS, V58, P688, DOI 10.1136/jnnp.58.6.688; DAVIE CA, 1995, ANN NEUROL, V37, P204, DOI 10.1002/ana.410370211; deRijk MC, 1997, J NEUROL NEUROSUR PS, V62, P10, DOI 10.1136/jnnp.62.1.10; deRijk MC, 1997, ARCH NEUROL-CHICAGO, V54, P762, DOI 10.1001/archneur.1997.00550180070015; EIDELBERG D, 1995, NEUROLOGY, V45, P1995, DOI 10.1212/WNL.45.11.1995; Ellis CM, 1997, NEUROLOGY, V49, P438, DOI 10.1212/WNL.49.2.438; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Gai WP, 1995, BRAIN, V118, P1447, DOI 10.1093/brain/118.6.1447; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Gasser T, 1997, SCIENCE, V277, P388; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; Ghika J, 1997, ARCH NEUROL-CHICAGO, V54, P1104, DOI 10.1001/archneur.1997.00550210038010; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; GIBB WRG, 1991, J NEUROL NEUROSUR PS, V54, P388, DOI 10.1136/jnnp.54.5.388; GILADI N, 1990, NEUROLOGY, V40, P1731, DOI 10.1212/WNL.40.11.1731; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604; Hellenbrand W, 1997, INT J EPIDEMIOL, V26, P328, DOI 10.1093/ije/26.2.328; Hirsch E. C., 1992, Neurodegeneration, V1, P83; Hirsch EC, 1998, MOVEMENT DISORD, V13, P39; HUGHES AJ, 1993, ARCH NEUROL-CHICAGO, V50, P140, DOI 10.1001/archneur.1993.00540020018011; JENDROSKA K, 1994, LANCET, V344, P882, DOI 10.1016/S0140-6736(94)92854-1; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jenner P, 1998, MOVEMENT DISORD, V13, P24; KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; KOLLER WC, 1991, NEUROLOGY, V41, P8, DOI 10.1212/WNL.41.5_Suppl_2.8; Kosel S, 1997, ACTA NEUROPATHOL, V93, P105, DOI 10.1007/s004010050590; KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LANG AE, 1995, CAN J NEUROL SCI, V22, P73; Lang AE, 1994, NEURODEGENER DIS, P877; Lapchak PA, 1996, NEURODEGENERATION, V5, P197, DOI 10.1006/neur.1996.0027; LILIENFELD DE, 1993, NEUROEPIDEMIOLOGY, V12, P219, DOI 10.1159/000110320; Louis ED, 1997, ARCH NEUROL-CHICAGO, V54, P260, DOI 10.1001/archneur.1997.00550150024011; MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333; MANYAM BV, 1990, MOVEMENT DISORD, V5, P47, DOI 10.1002/mds.870050112; Marek KL, 1996, NEUROLOGY, V46, P231, DOI 10.1212/WNL.46.1.231; MAYEUX R, 1990, NEUROLOGY, V40, P1513, DOI 10.1212/WNL.40.10.1513; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MOGHAL S, 1994, NEUROEPIDEMIOLOGY, V13, P175, DOI 10.1159/000110376; Morens DM, 1996, NEUROLOGY, V46, P1044, DOI 10.1212/WNL.46.4.1044; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; Morrish PK, 1996, BRAIN, V119, P585, DOI 10.1093/brain/119.2.585; OLANOW CW, 1997, DOPAMINE AGONISTS EA, P00037; Piccini P, 1997, ANN NEUROL, V42, P720, DOI 10.1002/ana.410420508; Pizzolato G, 1995, J NEURAL TRANSM-SUPP, P113; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; RAJPUT AH, 1991, CAN J NEUROL SCI, V18, P275, DOI 10.1017/S0317167100031814; Rajput AH, 1997, MOVEMENT DISORD, V12, P634, DOI 10.1002/mds.870120503; Riedl AG, 1998, MOVEMENT DISORD, V13, P212, DOI 10.1002/mds.870130204; SCHAPIRA A, 1995, J MED GENET, V32, P411, DOI 10.1136/jmg.32.6.411; Scott WK, 1997, SCIENCE, V277, P387, DOI 10.1126/science.277.5324.387; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; Tandberg E, 1996, ARCH NEUROL-CHICAGO, V53, P175, DOI 10.1001/archneur.1996.00550020087019; Tedeschi G, 1997, BRAIN, V120, P1541, DOI 10.1093/brain/120.9.1541; TROJANOWSKI JQ, 1994, ANN NY ACAD SCI, V747, P92; TURJANSKI N, 1993, NEUROLOGY, V43, P1563, DOI 10.1212/WNL.43.8.1563; Tzourio C, 1997, NEUROLOGY, V49, P1267, DOI 10.1212/WNL.49.5.1267; UHL GR, 1994, ANN NEUROL, V35, P494, DOI 10.1002/ana.410350421; VINGERHOETS FJG, 1994, ANN NEUROL, V36, P765, DOI 10.1002/ana.410360513; WARD CD, 1983, NEUROLOGY, V33, P815, DOI 10.1212/WNL.33.7.815; WENNING GK, 1994, BRAIN, V117, P835, DOI 10.1093/brain/117.4.835; WOLTERS EC, 1989, ANN NEUROL, V26, P647, DOI 10.1002/ana.410260510; Wood N, 1997, J NEUROL NEUROSUR PS, V62, P305, DOI 10.1136/jnnp.62.4.305; Wooten GF, 1997, ANN NEUROL, V41, P265, DOI 10.1002/ana.410410218; ZHANG ZX, 1993, NEUROEPIDEMIOLOGY, V12, P195, DOI 10.1159/000110318; [No title captured]; [No title captured]	93	1589	1641	1	172	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1044	1053		10.1056/NEJM199810083391506	http://dx.doi.org/10.1056/NEJM199810083391506			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761807				2022-12-28	WOS:000076294800006
J	Lin, HM; Kauffman, HM; McBride, MA; Davies, DB; Rosendale, JD; Smith, CM; Edwards, EB; Daily, OP; Kirklin, J; Shield, CF; Hunsicker, LG				Lin, HM; Kauffman, HM; McBride, MA; Davies, DB; Rosendale, JD; Smith, CM; Edwards, EB; Daily, OP; Kirklin, J; Shield, CF; Hunsicker, LG			Center-specific graft and patient survival rates - 1997 United Network for Organ Sharing (UNOS) Report	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; TRANSPLANT SURVIVAL; RISK ADJUSTMENT; SURGICAL RISK; MORTALITY; SURGERY; VOLUME; IMPROVE; QUALITY; CARE	Context.-Multiple comprehensive, risk-adjusted studies evaluating short-term surgical mortality have been reported previously. This report analyzes short-term and long-term outcomes, both nationally and at each individual transplant program, for all solid organ transplantations performed in the United States. Objectives.-To report graft and patient survival rates for all solid organ transplantations, both nationally and at each specific transplant program in the United States, and to compare the expected survival rate with the actual survival rate of each individual program. Design and Setting.-Multivariate regression analysis of donor and recipient factors affecting graft and patient survival of all kidney, liver, pancreas, heart, lung, and heart-lung transplants reported to the United Network for Organ Sharing from 742 separate transplant programs. Patients.-A cohort of 97 587 solid organ transplantations performed on 92 966 recipients in the United States from January 1988 through April 1994, Main Outcome Measures,-Short-term and conditional 3-year national and individual transplant program graft and patient survival rates overall and from 2 separate eras (era 1, January 1988-April 1992; era 2, May 1992-April 1994); comparison of actual center-specific performance with risk-adjusted expected performance and identification of centers with better-than-expected or worse-than-expected survival rates. Results.-One-year graft follow-up exceeded 98% and conditional 3-year followup exceeded 91% for all organs. Graft and patient survival improved significantly in era 2 compared with era 1 for all cadaver organs except heart, which remained the same. One-year cadaveric graft survival ranged from 81.5% for heart to 61.9% for heart-lung and 3-year conditional graft survival ranged from 91.3% for pancreas to 74.7% for lung. The percentage of programs whose actual 1-year graft survival was not different from or was better than their risk-adjusted expected survival ranged from 98.3% for heart-lung to 75.7% for liver. Most kidney, liver, and heart programs whose actual survival was significantly less than expected performed small numbers (less than the national average) of transplantations per year. Conclusions.-Graft and patient survival for solid organ transplantations showed improvement over time. Conditional 3-year graft and patient survival rates were approximately 90% for all organs except for lung and heart-lung. The conditional 3-year survival rates were better than 1-year survival rates, indicating the major risk after transplantation occurs in the first year. The majority of transplant programs achieved actual survival rates not significantly different from their expected survival rates. Center effects were most significant within the first year after transplantation and had much less influence on long-term survival outcomes.	United Network Organ Sharing, Richmond, VA 23220 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Hlth Evaulat Sci, Hershey, PA 17033 USA; Univ Alabama Hosp, Div Cardiac Surg, Birmingham, AL USA; Via Christi Reg Med Ctr, Dept Surg, Wichita, KS USA; Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA	United Network for Organ Sharing; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Alabama System; University of Alabama Birmingham; University of Iowa	Kauffman, HM (corresponding author), United Network Organ Sharing, 1100 Boulders Pkwy,Suite 500, Richmond, VA 23220 USA.							Burdick J, 1997, TRANSPL P, V29, P1495, DOI 10.1016/S0041-1345(96)00701-4; BUTKUS DE, 1992, NEW ENGL J MED, V327, P840, DOI 10.1056/NEJM199209173271203; CECKA JM, 1993, TRANSPLANT P, V25, P548; CHO YW, 1993, CLIN KIDNEY TRANSPLA, P363; CHO YW, 1997, CLIN KIDNEY TRANSPLA, P427; CICCIARELLI J, 1986, CLIN KIDNEY TRANSPLA, P93; COPELAND GP, 1991, BRIT J SURG, V78, P356; EDWARDS E, 1994, 1994 CTR SPECIFIC GR; Edwards E., 1992, 1991 CTR SPECIFIC GR; EDWARDS FH, 1994, ANN THORAC SURG, V57, P12, DOI 10.1016/0003-4975(94)90358-1; GROVER FL, 1990, ANN THORAC SURG, V50, P12, DOI 10.1016/0003-4975(90)90073-F; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HOSENPUD JD, 1994, JAMA-J AM MED ASSOC, V271, P1844, DOI 10.1001/jama.271.23.1844; KATZNELSON S, 1997, CLIN TRANSPLANTS 199, P361; KAUFFMAN HM, 1997, TRANSPLANT REV, V11, P165; Khuri SF, 1997, J AM COLL SURGEONS, V185, P315, DOI 10.1016/S1072-7515(01)00938-3; KHURI SF, 1995, J AM COLL SURGEONS, V180, P519; Klintmalm G., 1994, TRANSPLANT REV, V8, P53, DOI [10.1016/S0955-470X(05)80015-1, DOI 10.1016/S0955-470X(05)80015-1]; LE A, 1994, AM J KIDNEY DIS, V24, P65, DOI 10.1016/S0272-6386(12)80161-2; LIN HM, 1997, 1997 CTR SPECIFIC GR; Mickey M R, 1989, Clin Transpl, P435; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; OPELZ G, 1975, TRANSPLANTATION, V19, P226, DOI 10.1097/00007890-197503000-00005; Shield CF, 1997, TRANSPLANTATION, V63, P1257, DOI 10.1097/00007890-199705150-00011; SMITH CM, 1996, ANN REPORT US SCI RE; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706	28	64	64	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1153	1160		10.1001/jama.280.13.1153	http://dx.doi.org/10.1001/jama.280.13.1153			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777815				2022-12-28	WOS:000076210800029
J	Nguyen, QE; Foster, CS				Nguyen, QE; Foster, CS			Saving the vision of children with juvenile rheumatoid arthritis-associated uveitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							THERAPY; IRIDOCYCLITIS; METHOTREXATE		Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Immunol & Uveitis Serv, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Foster, CS (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Immunol & Uveitis Serv, 243 Charles St, Boston, MA 02114 USA.							Chalom EC, 1997, J RHEUMATOL, V24, P2031; CHYLACK LT, 1975, AM J OPHTHALMOL, V79, P1026, DOI 10.1016/0002-9394(75)90689-3; Dana MR, 1997, OPHTHALMOLOGY, V104, P236, DOI 10.1016/S0161-6420(97)30329-7; FOSTER CS, 1993, OPHTHALMOLOGY, V100, P809; GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602; HEMADY RK, 1992, INT OPHTHALMOL CLIN, V32, P241, DOI 10.1097/00004397-199203210-00018; KANSKI J J, 1988, Eye (London), V2, P641; LANE L, 1995, OPHTHALMOLOGY, V102, P1530; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; MAKELA AL, 1977, SCAND J RHEUMATOL, V6, P193; MORGAN SL, 1990, ARTHRITIS RHEUM-US, V33, P9, DOI 10.1002/art.1780330102; OBRIEN JM, 1994, PRINCIPLES PRACTICE, P2873; OLSON NY, 1988, AM J DIS CHILD, V142, P1289, DOI 10.1001/archpedi.1988.02150120043036; Peterson LS, 1996, ARTHRITIS RHEUM, V39, P1385, DOI 10.1002/art.1780390817; RAMADAN A, 1997, OPHTHALMOL CLIN N AM, V10, P377; Sibilia J, 1998, REV RHUM, V65, P267; SMITH RE, 1989, UVEITIS CLIN APPROAC, P113; Vitale AT, 1996, OPHTHALMOLOGY, V103, P365; WOLF MD, 1987, OPHTHALMOLOGY, V94, P1242; YANCEY C, 1993, PEDIATRICS, V92, P295	20	23	26	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1133	1134		10.1001/jama.280.13.1133	http://dx.doi.org/10.1001/jama.280.13.1133			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777803				2022-12-28	WOS:000076210800011
J	Hosfield, DJ; Mol, CD; Shen, BH; Tainer, JA				Hosfield, DJ; Mol, CD; Shen, BH; Tainer, JA			Structure of the DNA repair and replication endonuclease and exonuclease FEN-1: Coupling DNA and PCNA binding to FEN-1 activity	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; HUMAN FLAP ENDONUCLEASE-1; MAMMALIAN 5'-EXONUCLEASE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURES; PURIFIED PROTEINS; ESCHERICHIA-COLI; POLYMERASE-I; RNASE-H	Flap endonuclease (FEN-1) removes 5' overhanging flaps in DNA repair and processes the 5' ends of Okazaki fragments in lagging strand DNA synthesis. The crystal structure of Pyrococcus furiosos FEN-1, active-site metal ions, and mutational information indicate interactions for the single- and double-stranded portions of the flap DNA substrate and identify an unusual DNA-binding motif. The enzyme's active-site structure suggests that DNA binding induces FEN-1 to clamp onto the cleavage junction to form the productive complex. The conserved FEN-1 C terminus binds proliferating cell nuclear antigen (PCNA) and positions FEN-1 to act primarily as an exonuclease in DNA replication, in contrast to its endonuclease activity in DNA repair. FEN-1 mutations altering PCNA binding should reduce activity during replication, likely causing DNA repeat expansions as seen in some cancers and genetic diseases.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA	Scripps Research Institute; Scripps Research Institute; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Tainer, JA (corresponding author), Scripps Res Inst, Dept Biol Mol, MB4,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jat@scripps.edu	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Shen, Binghui/0000-0002-4408-407X	NCI NIH HHS [CA57348] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; BORGES KM, 1996, GENOME SCI TECHNOL, V1, P37; Brunger A. T., 1992, X PLOR SYSTEM X RAY; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HOSFIELD DJ, 1998, IN PRESS J BIOL CHEM; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kim CY, 1998, BIOPHYS J, V74, pA63; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; UYEMURA D, 1976, J BIOL CHEM, V251, P4078; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	61	216	238	23	169	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1998	95	1					135	146		10.1016/S0092-8674(00)81789-4	http://dx.doi.org/10.1016/S0092-8674(00)81789-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778254	Bronze			2022-12-28	WOS:000076242300017
J	Sisodia, SS				Sisodia, SS			Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial?	CELL			English	Review							NEURONAL INTRANUCLEAR INCLUSIONS; HUNTINGTIN; EXPANSION; ATAXIN-1; BRAIN; MICE		Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA	University of Chicago	Sisodia, SS (corresponding author), Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA.							BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; Matilla A, 1998, J NEUROSCI, V18, P5508, DOI 10.1523/JNEUROSCI.18-14-05508.1998; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SITTLER A, 1998, IN PRESS MOL CELL; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3	21	201	204	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					1	4		10.1016/S0092-8674(00)81743-2	http://dx.doi.org/10.1016/S0092-8674(00)81743-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778239	Bronze			2022-12-28	WOS:000076242300001
J	Edwards, SJL; Lilford, RJ; Hewison, J				Edwards, SJL; Lilford, RJ; Hewison, J			The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals	BRITISH MEDICAL JOURNAL			English	Review							BLIND CONTROLLED EXPERIMENT; CLINICAL-TRIALS; INFORMED CONSENT; PHASE-I; PHYSICIAN PARTICIPATION; INDIVIDUAL AUTONOMY; CANCER; VOLUNTEERS; ATTITUDES; PERCEPTIONS		Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Univ Leeds, Dept Psychol, Leeds LS2 9JT, W Yorkshire, England	University of Birmingham; University of Leeds	Edwards, SJL (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.	S.J.Edwards@bham.ac.uk	Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				ALDERSON P, 1994, WOMENS KNOWLEDGE EXP; AUTRET E, 1993, DEV PHARMACOL THERAP, V20, P64, DOI 10.1159/000457542; Barofsky I., 1979, AM J CLIN ONCOL-CANC, V2, P237; BENSON AB, 1991, J CLIN ONCOL, V9, P2067, DOI 10.1200/JCO.1991.9.11.2067; BEVAN EG, 1993, BRIT J CLIN PHARMACO, V35, P204, DOI 10.1111/j.1365-2125.1993.tb05687.x; BLUM AL, 1987, J INT MED RES, V15, P2, DOI 10.1177/030006058701500102; CASSILETH BR, 1982, JAMA-J AM MED ASSOC, V248, P968, DOI 10.1001/jama.248.8.968; DALRE R, 1990, EUR J CLIN PHARMACOL, V38, P319, DOI 10.1007/BF00315568; DALRE R, 1992, J INTERN MED, V231, P375, DOI 10.1111/j.1365-2796.1992.tb00947.x; DALRE R, 1993, MED CLIN-BARCELONA, V100, P423; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; EDWARDS SJL, IN PRESS HLTH TECHNO; Flanery M, 1978, S D J Med, V31, P33; HARTH SC, 1995, SOC SCI MED, V40, P1573, DOI 10.1016/0277-9536(94)00412-M; HARTH SC, 1990, BRIT MED J, V300, P1372, DOI 10.1136/bmj.300.6736.1372; HASSAR M, 1976, CLIN PHARMACOL THER, V20, P379; HENZLOVA MJ, 1994, CONTROL CLIN TRIALS, V15, P284, DOI 10.1016/0197-2456(94)90044-2; JENSEN AB, 1993, EUR J CANCER, V29A, P2235, DOI 10.1016/0959-8049(93)90213-Y; KEMP N, 1984, CLIN ONCOL, V10, P155; KING J, 1986, I MED ETHICS B   DEC; KODISH E, 1992, J CLIN ONCOL, V10, P1810, DOI 10.1200/JCO.1992.10.11.1810; LILFORD R, 1994, BMJ-BRIT MED J, V308, P111, DOI 10.1136/bmj.308.6921.111; Lilford RJ, 1995, J ROY SOC MED, V88, P552; LOGUE G, 1995, J MED PHILOS, V20, P57, DOI 10.1093/jmp/20.1.57; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; MATTSON ME, 1985, CONTROL CLIN TRIALS, V6, P156, DOI 10.1016/0197-2456(85)90121-7; MEISEL A, 1983, ARIZ LAW REV, V25, P246; MILLONUNDERWOOD S, 1993, CANCER NURS, V16, P25; MINOGUE BP, 1995, J MED PHILOS, V20, P43, DOI 10.1093/jmp/20.1.43; PENMAN DT, 1984, J CLIN ONCOL, V2, P849, DOI 10.1200/JCO.1984.2.7.849; RODENHUIS S, 1984, EUR J CANCER CLIN ON, V20, P457, DOI 10.1016/0277-5379(84)90229-3; SCHAIN WS, 1994, CANCER, V74, P2666, DOI 10.1002/1097-0142(19941101)74:9+<2666::AID-CNCR2820741814>3.0.CO;2-P; SIMES RJ, 1986, BRIT MED J, V293, P1065, DOI 10.1136/bmj.293.6554.1065; SLEVIN M, 1995, BRIT J CANCER, V71, P1270, DOI 10.1038/bjc.1995.245; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; Spaight S J, 1984, Prog Clin Biol Res, V156, P49; TAYLOR KM, 1992, SOC SCI MED, V35, P217, DOI 10.1016/0277-9536(92)90169-Q; TAYLOR KM, 1987, J HEALTH SOC BEHAV, V28, P389, DOI 10.2307/2136792; TAYLOR KM, 1987, SOC SCI MED, V24, P135, DOI 10.1016/0277-9536(87)90246-2; TAYLOR KM, 1984, NEW ENGL J MED, V310, P1363, DOI 10.1056/NEJM198405243102106; TINDALL B, 1994, PATIENT EDUC COUNS, V24, P261, DOI 10.1016/0738-3991(94)90069-8; TOBIAS JS, 1993, BRIT MED J, V307, P1199, DOI 10.1136/bmj.307.6913.1199; Twomey J G Jr, 1994, West J Nurs Res, V16, P404, DOI 10.1177/019394599401600405; Ubel PA, 1997, J INVEST MED, V45, P561; VOGT TM, 1986, CONTROL CLIN TRIALS, V7, P118, DOI 10.1016/0197-2456(86)90028-0; Wilcox M, 1994, J Vasc Nurs, V12, P112; WILLIAMS CJ, 1994, EUR J CANCER, V30A, P907, DOI 10.1016/0959-8049(94)90111-2	47	124	126	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1209	1212		10.1136/bmj.317.7167.1209	http://dx.doi.org/10.1136/bmj.317.7167.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138GF	9794861	Green Published			2022-12-28	WOS:000076963000025
J	Holme, C				Holme, C			Tuberculosis: story of medical failure	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1260	1260		10.1136/bmj.317.7167.1260	http://dx.doi.org/10.1136/bmj.317.7167.1260			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794889	Green Published			2022-12-28	WOS:000076963000073
J	Fairhurst, K; Huby, G				Fairhurst, K; Huby, G			From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BEHAVIOR	Objectives To explore how general practitioners have accessed and evaluated evidence from trials on the use of statin lipid lowering drugs and incorporated this evidence into their practice. To draw out the practical implications of this study for strategies to integrate clinical evidence into general medical practice. Design Qualitative analysis of semistructured interviews. Setting General practices in Lothian, Subjects 24 general practitioners selected to obtain a heterogeneous sample. Results Respondents were generally aware of the evidence relating to the use of statins in secondary prevention of coronary heart disease, but they were less clear about the evidence in primary prevention, The benefits of statins in secondary prevention were clearer to them and the social and economic issues less complex than was the case for use in primary prevention, Respondents rarely said they appraised the methods and content of trials, rather they judged the trustworthiness of the source of trial evidence and interpreted it within the context of the economic and social factors which impinge on their practice Moreover, trial data become relevant for routine practice only when underpinned by a consensus an these issues. Conclusion Strategies to promote incorporation of evidence from clinical trials into everyday practice are likely to be effective if they tap into and build on the process of local consensus building. Strategies such as teaching critical appraisal skills and guideline development may have little effect if they are separated from this process.	Univ Edinburgh, Dept Community Hlth Sci Gen Practice, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Fairhurst, K (corresponding author), Univ Edinburgh, Dept Community Hlth Sci Gen Practice, Levinson House, Edinburgh EH8 9DX, Midlothian, Scotland.	Karen.Fairhurst@ed.ac.uk						Allery LA, 1997, BMJ-BRIT MED J, V314, P870; [Anonymous], 1979, STRUCTURE SCI REVOLU; Armstrong D, 1996, BRIT MED J, V312, P949; Caro J, 1997, BRIT MED J, V315, P1577, DOI 10.1136/bmj.315.7122.1577; *DEP HLTH, 1997, CMND3807; Freemantle N, 1997, BMJ-BRIT MED J, V315, P826, DOI 10.1136/bmj.315.7112.826; Gill P, 1996, BRIT MED J, V312, P819; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; Maxwell M, 1998, BRIT J GEN PRACT, V48, P1467; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; PEDERSEN TR, 1994, LANCET, V344, P1383; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SECR STAT SCOTL S, 1997, DIS CAR NAT HLTH SER; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; *STAND MED ADV COM, 1997, US STAT; Sullivan FM, 1996, LANCET, V348, P941, DOI 10.1016/S0140-6736(96)05219-1; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W	19	104	106	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	1998	317	7166					1130	1134						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784451				2022-12-28	WOS:000076755100033
J	Flahault, A; Dias-Ferrao, V; Chaberty, P; Esteves, K; Valleron, AJ; Lavanchy, D				Flahault, A; Dias-Ferrao, V; Chaberty, P; Esteves, K; Valleron, AJ; Lavanchy, D			FluNet as a tool for global monitoring of influenza on the web	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In collaboration with the Institut National de la Sante et de la Recherche Medicale, the World Health Organization (WHO) has developed an Internet application linking the global WHO network of influenza centers (FluNet; http:// oms.b3e.jussieu.fr/flunet/). During 1997, 22 pilot centers entered data on influenza activity and viral laboratory results directly into FluNet via secured access. In addition, 54 centers sent data to WHO for entry. Four countries (the Russian Federation, Romania, Sweden, and the United Kingdom) reported widespread outbreaks of at least 4 weeks' duration. The FluNet server ran 24 hours a day without interruption. To improve management and enhance standardization of reporting, this early-alert system for the global monitoring of influenza provides international and national authorities, the public, and the media with full access to real-time epidemiological and virological information.	INSERM, U444, Unite Epidemiol & Sci Informat, F-75571 Paris 12, France; WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); World Health Organization	Flahault, A (corresponding author), INSERM, U444, Unite Epidemiol & Sci Informat, 27 Rue Challigny, F-75571 Paris 12, France.							COSTAGLIOLA D, 1991, AM J PUBLIC HEALTH, V81, P97, DOI 10.2105/AJPH.81.1.97; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Hampson Alan W., 1997, Journal of Infectious Diseases, V176, pS8, DOI 10.1086/514184; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; PENNISI E, 1995, SCIENCE, V270, P1916, DOI 10.1126/science.270.5244.1916; 1997, J INFECT DIS S1, V176, pS73	6	46	47	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1330	1332		10.1001/jama.280.15.1330	http://dx.doi.org/10.1001/jama.280.15.1330			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794312				2022-12-28	WOS:000076472500025
J	Hunt, DL; Haynes, RB; Hanna, SE; Smith, K				Hunt, DL; Haynes, RB; Hanna, SE; Smith, K			Effects of computer-based clinical decision support systems on physician performance and patient outcomes - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED TRIAL; PROMOTING SCREENING MAMMOGRAPHY; PRIMARY-CARE PHYSICIANS; INNER-CITY SETTINGS; PREVENTIVE CARE; WARFARIN THERAPY; HEALTH-CARE; INFLUENZA VACCINATION; ORAL ANTICOAGULATION; CRITICAL-APPRAISAL	Context.-Many computer software developers and vendors claim that their systems can directly improve clinical decisions. As for other health care interventions, such claims should be based on careful trials that assess their effects on clinical performance and, preferably, patient outcomes. Objective.-To systematically review controlled clinical trials assessing the effects of computer-based clinical decision support systems (CDSSs) on physician performance and patient outcomes. Data Sources.-We updated earlier reviews covering 1974 to 1992 by searching the MEDLINE, EMBASE, INSPEC, SCISEARCH, and the Cochrane Library bibliographic databases from 1992 to March 1998. Reference lists and conference proceedings were reviewed and evaluators of CDSSs were contacted. Study Selection.-Studies were included if they involved the use of a CDSS in a clinical setting by a health care practitioner and assessed the effects of the system prospectively with a concurrent control. Data Extraction.-The validity of each relevant study (scored from 0-10) was evaluated in duplicate. Data on setting, subjects, computer systems, and outcomes were abstracted and a power analysis was done on studies with negative findings. Data Synthesis.-A total of 68 controlled trials met our criteria, 40 of which were published since 1992, Quality scores ranged from 2 to 10, with more recent trials rating higher (mean, 7.7) than earlier studies (mean, 6.4) (P<.001), Effects on physician performance were assessed in 65 studies and 43 found a benefit (66%). These included 9 of 15 studies on drug dosing systems, 1 of 5 studies on diagnostic aids, 14 of 19 preventive care systems, and 19 of 26 studies evaluating CDSSs for other medical care. Six of 14 studies assessing patient outcomes found a benefit. Of the remaining 8 studies, only 3 had a power of greater than 80% to detect a clinically important effect. Conclusions.-Published studies of CDSSs are increasing rapidly, and their quality is improving. The CDSSs can enhance clinical performance for drug dosing, preventive care, and other aspects of medical care, but not convincingly for diagnosis. The effects of CDSSs on patient outcomes have been insufficiently studied.	McMaster Univ, Med Ctr, Fac Hlth Sci,Dept Clin Epidemiol & Biostat, Hlth Informat Res Unit, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON, Canada; McMaster Univ, Fac Hlth Sci, Grad Program Hlth Res Methodol, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University	Haynes, RB (corresponding author), McMaster Univ, Med Ctr, Fac Hlth Sci,Dept Clin Epidemiol & Biostat, Hlth Informat Res Unit, Room 3H7,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	bhaynes@fhs.mcmaster.ca		Haynes, Robert Brian/0000-0002-1453-3196; Hanna, Steven/0000-0003-3120-9600				ABBRECHT PH, 1982, CLIN PHARMACOL THER, V32, P129, DOI 10.1038/clpt.1982.136; AUSTIN SM, 1994, J AM MED INFORM ASSN, P121; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; BATES DW, 1995, P ANN S COMPUT APPL, P935; BEGG EJ, 1989, BRIT J CLIN PHARMACO, V28, P137, DOI 10.1111/j.1365-2125.1989.tb05405.x; BROWNBRIDGE G, 1986, J ROY COLL GEN PRACT, V36, P198; BURACK RC, 1994, MED CARE, V32, P609, DOI 10.1097/00005650-199406000-00006; Burack RC, 1996, CANCER, V78, P1708, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1708::AID-CNCR11>3.3.CO;2-9; Burack RC, 1997, MED CARE, V35, P921, DOI 10.1097/00005650-199709000-00005; CARTER BL, 1987, CLIN PHARMACY, V6, P37; CASNER PR, 1993, CLIN PHARMACOL THER, V53, P684, DOI 10.1038/clpt.1993.90; Chambers C V, 1991, J Am Board Fam Pract, V4, P19; CHASE CR, 1983, MED CARE, V21, P410, DOI 10.1097/00005650-198304000-00004; CLAYTON PD, 1995, INT J BIOMED COMPUT, V39, P59, DOI 10.1016/0020-7101(94)01080-K; *COCHR LIB, 1998, UPD SOFTW; COE FL, 1977, J CHRON DIS, V30, P81, DOI 10.1016/0021-9681(77)90077-7; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; DASTA JF, 1992, ANN PHARMACOTHER, V26, P109, DOI 10.1177/106002809202600120; DESTACHE CJ, 1990, THER DRUG MONIT, V12, P419, DOI 10.1097/00007691-199009000-00003; Dexter PR, 1998, ANN INTERN MED, V128, P102, DOI 10.7326/0003-4819-128-2-199801150-00005; FIHN SD, 1994, J GEN INTERN MED, V9, P131, DOI 10.1007/BF02600026; Fitzmaurice DA, 1996, BRIT J GEN PRACT, V46, P533; Frame P S, 1994, Arch Fam Med, V3, P581, DOI 10.1001/archfami.3.7.581; GONZALEZ ER, 1989, AM J EMERG MED, V7, P395, DOI 10.1016/0735-6757(89)90046-6; Hales J W, 1995, Proc Annu Symp Comput Appl Med Care, P728; HAYNES RB, 1987, ARCH INTERN MED, V147, P1297, DOI 10.1001/archinte.147.7.1297; HICKLING K, 1989, INTENS CARE MED, V15, P233, DOI 10.1007/BF00271057; Hobbs FDR, 1996, FAM PRACT, V13, P133, DOI 10.1093/fampra/13.2.133; HURLEY SF, 1986, AM REV RESPIR DIS, V134, P1219; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KELLER LS, 1991, P ANN S COMPUT APPL, V15, P38; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; Lobach D F, 1996, Proc AMIA Annu Fall Symp, P493; LOBACH DF, 1994, J AM MED INFORM ASSN, P787; MAZZUCA SA, 1990, AM EDUC RES J, V27, P473, DOI 10.3102/00028312027003473; MCALISTER NH, 1986, BRIT MED J, V293, P670, DOI 10.1136/bmj.293.6548.670; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1994, ANN INTERN MED, V121, P469, DOI 10.7326/0003-4819-121-6-199409150-00017; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MCPHEE SJ, 1993, CANCER, V72, P1100, DOI 10.1002/1097-0142(19930801)72:3+<1100::AID-CNCR2820721327>3.0.CO;2-N; MILLER RA, 1994, J AM MED INFORM ASSN, V1, P8, DOI 10.1136/jamia.1994.95236141; MUNGALL DR, 1994, CLIN PHARMACOL THER, V55, P591, DOI 10.1038/clpt.1994.73; Nilasena D S, 1995, Proc Annu Symp Comput Appl Med Care, P640; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Overhage JM, 1996, ARCH INTERN MED, V156, P1551, DOI 10.1001/archinte.156.14.1551; PETRUCCI K, 1991, P ANN S COMPUT APPL, V15, P43; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PRINGLE M, 1990, BMJ-BRIT MED J, V290, P1709; RODMAN JH, 1984, ARCH INTERN MED, V144, P703, DOI 10.1001/archinte.144.4.703; Rogers J L, 1984, QRB Qual Rev Bull, V10, P65; ROGERS JL, 1979, MED CARE, V17, P618, DOI 10.1097/00005650-197906000-00006; ROGERS JL, 1982, MED CARE, V20, P63, DOI 10.1097/00005650-198201000-00005; ROSSER WW, 1992, CAN MED ASSOC J, V146, P911; ROSSER WW, 1991, CAN MED ASSOC J, V145, P807; Rossi RA, 1997, J GEN INTERN MED, V12, P672, DOI 10.1046/j.1525-1497.1997.07140.x; Rotman BL, 1996, J AM MED INFORM ASSN, V3, P340, DOI 10.1136/jamia.1996.97035025; RUBENSTEIN LV, 1995, J GEN INTERN MED, V10, P607, DOI 10.1007/BF02602744; RYFFDELECHE A, 1992, DIABETES RES CLIN EX, V19, P97; SAFRAN C, 1995, LANCET, V346, P341, DOI 10.1016/S0140-6736(95)92226-1; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; SHEA S, 1995, J AM MED INFORM ASSN, V2, P58, DOI 10.1136/jamia.1995.95202549; SHEINER LB, 1975, ANN INTERN MED, V82, P619, DOI 10.7326/0003-4819-82-5-619; TAPE TG, 1993, AM J MED, V94, P619, DOI 10.1016/0002-9343(93)90214-A; Thomas J C, 1983, J Med Syst, V7, P307, DOI 10.1007/BF00993294; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; TURNER BJ, 1989, J GEN INTERN MED, V4, P403, DOI 10.1007/BF02599691; TURNER RC, 1994, ARCH INTERN MED, V154, P1957, DOI 10.1001/archinte.154.17.1957; Vadher B, 1997, BMJ-BRIT MED J, V314, P1252, DOI 10.1136/bmj.314.7089.1252; Vadher BD, 1997, CLIN LAB HAEMATOL, V19, P203; VERNER D, 1992, EUR J CLIN PHARMACOL, V43, P29, DOI 10.1007/BF02280750; WELLWOOD J, 1992, ANN ROY COLL SURG, V74, P40; WEXLER JR, 1975, AM J DIS CHILD, V129, P203, DOI 10.1001/archpedi.1975.02120390037008; WHITE KS, 1984, J AM COLL CARDIOL, V4, P571, DOI 10.1016/S0735-1097(84)80104-7; WHITE RH, 1987, J GEN INTERN MED, V2, P141, DOI 10.1007/BF02596140; WHITE RH, 1991, THER DRUG MONIT, V13, P46, DOI 10.1097/00007691-199101000-00006; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; WYATT J, 1989, P 6 WORLD C MED INF, P111; YOUNG DW, 1981, MED INFORM, V6, P13, DOI 10.3109/14639238109017764	91	1072	1090	4	82	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1339	1346		10.1001/jama.280.15.1339	http://dx.doi.org/10.1001/jama.280.15.1339			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129PQ	9794315				2022-12-28	WOS:000076472500028
J	Kleinert, S				Kleinert, S			Rationing of health care - how should it be done?	LANCET			English	Editorial Material									Lancet, London, England		Kleinert, S (corresponding author), Lancet, London, England.							Chinitz D, 1998, BRIT MED J, V317, P1005; MACLEOD SM, 1998, CMAJ, V58, P213; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5	3	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1244	1244		10.1016/S0140-6736(05)70485-2	http://dx.doi.org/10.1016/S0140-6736(05)70485-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788452				2022-12-28	WOS:000076573800006
J	Martines, J; Underwood, B; Arthur, P; Bahl, R; Bhan, MK; Kirkwood, BR; Martines, J; Moulton, LH; Penny, ME; Ram, M; Underwood, B; Moulton, LH; Ram, M; Kholhede, CL; Propper, L; Arthur, GP; Kirkwood, BR; Morris, S; Etego, SA; Zandoh, C; Boahen, O; Bhandari, N; Bahl, R; Bhan, MK; Wahed, MA; Penny, ME; Lanata, CF; Butron, B; Huapaya, AR; Rivera, KB				Martines, J; Underwood, B; Arthur, P; Bahl, R; Bhan, MK; Kirkwood, BR; Martines, J; Moulton, LH; Penny, ME; Ram, M; Underwood, B; Moulton, LH; Ram, M; Kholhede, CL; Propper, L; Arthur, GP; Kirkwood, BR; Morris, S; Etego, SA; Zandoh, C; Boahen, O; Bhandari, N; Bahl, R; Bhan, MK; Wahed, MA; Penny, ME; Lanata, CF; Butron, B; Huapaya, AR; Rivera, KB		WHO CHD Immunisat-Linked Vitamin A Suppl	Randomised trial to assess benefits and safety of vitamin A supplementation linked to immunisation in early infancy	LANCET			English	Article							A SUPPLEMENTATION; 9-MONTH-OLD INFANTS; MEASLES-VACCINE; GUINEA-BISSAU; DIARRHEA; FONTANELLE; INFECTIONS; TOLERANCE; MORTALITY; CHILDREN	Background The benefits and safety of vitamin A supplementation linked to immunisation in infancy need to be assessed before it can be widely recommended. We assessed the safety and benefits of maternal postpartum and infant vitamin A supplementation administered with each of the three diphtheria-tetanus-pertussis (DPT) and poliomyelitis immunisations and with a fourth dose with measles immunisation. Methods From January, 1995, we enrolled 9424 mother-infant pairs from Ghana, India, and Peru in this randomised, double-blind, placebo-controlled trial. 4716 mothers of infants in the vitamin A group received 200 000 IU vitamin A, and their infants were given 25 000 IU vitamin A with each of the first three doses of DPT/poliomyelitis immunisation at 6, 10, and 14 weeks. In the control group, 4708 mothers and their infants received placebo at the same times. At 9 months, with measles immunisation, infants in the vitamin A group were given a further dose of 25 000 IU and those in the control group received 100 000 IU vitamin A. Infants were followed up to age 12 months. The primary outcome measures were vitamin A status, signs of acute toxic effects, anthropometric indicators, and severe morbidity. Analysis was by intention to treat. Findings 3933 (93%) of the eligible 4212 infants on vitamin A and 3938 (93%) of the eligible 4227 controls received all four study doses. At the g-month follow-up, there was a small decrease in vitamin A deficiency in the vitamin A group compared with controls (serum retinol less than or equal to 0.70 mu mol/L 101 [29.9%] vs 122 [37.1%; 95% CI of the difference -14.3% to -0.2%1]). This effect was no longer apparent at 9 and 12 months, There were no significant between-group differences in mortality throughout the study. The rate ratio to compare all deaths up to age 9 months in the two groups was 0.96 (95% CI 0.73 to 1.27), Fewer than 1% of the infants had bulging fontanelle. The intervention had no effect on anthropometric status, or on overall or severe morbidity. Interpretation The trial confirmed the safety of the intervention, but shows no sustained benefits in terms of vitamin A status beyond age 6 months or infant morbidity.	WHO, Div Child Hlth & Dev, CH-1211 Geneva 27, Switzerland; Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD USA; Kintampo Hlth Res Ctr, Kintampo, Ghana; London Sch Hyg & Trop Med, London WC1, England; All India Inst Med Sci, New Delhi 110029, India; Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; Inst Invest Nutr, Lima, Peru	World Health Organization; Johns Hopkins University; Kintampo Health Research Centre; University of London; London School of Hygiene & Tropical Medicine; All India Institute of Medical Sciences (AIIMS) New Delhi; International Centre for Diarrhoeal Disease Research (ICDDR)	Martines, J (corresponding author), WHO, Div Child Hlth & Dev, CH-1211 Geneva 27, Switzerland.	martinesJ@who.ch	Penny, Mary/J-2286-2017; Martines, Jose Carlos/ABE-4082-2020	Penny, Mary/0000-0001-5501-9399; Kirkwood, Betty/0000-0001-5274-6072; Moulton, Lawrence/0000-0001-7041-7387				BAQUI AH, 1995, ACTA PAEDIATR, V84, P863, DOI 10.1111/j.1651-2227.1995.tb13781.x; BARRETO ML, 1994, LANCET, V344, P228, DOI 10.1016/S0140-6736(94)92998-X; BEATON GH, 1993, 13 UN ADM COMM COORD; BENDICH A, 1989, AM J CLIN NUTR, V49, P358, DOI 10.1093/ajcn/49.2.358; Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5; deFrancisco A, 1996, T ROY SOC TROP MED H, V90, P441, DOI 10.1016/S0035-9203(96)90540-4; DEFRANCISCO A, 1993, LANCET, V342, P526, DOI 10.1016/0140-6736(93)91648-6; Dibley MJ, 1996, J NUTR, V126, P434, DOI 10.1093/jn/126.2.434; FLORENTINO RF, 1990, AM J CLIN NUTR, V52, P694, DOI 10.1093/ajcn/52.4.694; Ghana VAST study Team, 1993, LANCET, V342, P7; Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1; JELIFFE DB, 1996, MONOGRAPH SERIES WHO, V53; LUCAS A, 1978, BRIT MED J, V1, P1018, DOI 10.1136/bmj.1.6119.1018; MARIE J, 1953, AM J DIS CHILD, V87, P731; PEREIRA SM, 1969, AM J CLIN NUTR, V22, P858; RAHMAN MM, 1997, 18 M INT VIT A CONS; RICE AL, 1997, 18 M INT VIT A CONS; Rothman K, 1986, MODERN EPIDEMIOLOGY; Semba RD, 1997, PUBLIC HEALTH, V111, P245, DOI 10.1016/S0033-3506(97)00042-5; Sommer A, 1995, B WORLD HEALTH ORGAN, V73, P609; STABELL C, 1995, EUR J CLIN NUTR, V49, P73; STANSFIELD SK, 1993, LANCET, V342, P578, DOI 10.1016/0140-6736(93)91410-N; STOLTZFUS RJ, 1993, J NUTR, V123, P666, DOI 10.1093/jn/123.4.666; vanDillen J, 1996, LANCET, V347, P1705, DOI 10.1016/S0140-6736(96)91541-X; WEST KP, 1995, AM J CLIN NUTR, V62, P143, DOI 10.1093/ajcn/62.1.143; WEST KP, 1992, B WORLD HEALTH ORGAN, V70, P733; *WHO, 1993, WHONUTEPI931; WHO, 1996, WHONUT9610; WHO, 1995, WHONUT953, P3	29	143	145	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1257	1263						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788455				2022-12-28	WOS:000076573800009
J	Kramer, RH; Karpen, JW				Kramer, RH; Karpen, JW			Spanning binding sites on allosteric proteins with polymer-linked ligand dimers	NATURE			English	Article							NUCLEOTIDE-GATED CHANNELS; CYCLIC-GMP; ROD PHOTORECEPTOR; FUNCTIONAL EXPRESSION; DIVERSE FUNCTIONS; CATION CHANNEL; CGMP ANALOGS; SUBUNIT; KINASE; CAMP	One approach to drug design involves determination of the structure of binding sites on target proteins to provide templates for ligand construction. Alternatively, random combinations of chemical groups can be used to generate diverse molecules for screening in the search for effective compounds'. Here we report a strategy for developing potent ligands for proteins with multiple binding sites, which combines elements of both approaches: 'polymer-linked ligand dimers: in which two ligands are joined by a polymer chain of variable length. We find that polymer-linked ligand dimers containing two cyclic GMP moieties are up to a thousand times more potent than cyclic GMP in activating cyclic-nucleotide-gated channels and cGMP-dependent protein kinase. Each target protein responds optimally to a polymer-linked ligand dimer with a different average polymer length, even though their cyclic-nucleotide-binding sites are conserved. The tuning of polymer-linked ligand dimers indicates that each protein has a unique spacing of binding sites and provides an estimate of the distance between these sires. As optimal ligands are selected empirically, the: polymer-linked Ligand dimer strategy enables potent and selective agents to be identified without requiring previous structural information about the target proteins.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Univ Colorado, Sch Med, Dept Physiol & Biophys, Denver, CO 80262 USA	University of Miami; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kramer, RH (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA.							BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; BROWN RL, 1993, BIOCHEMISTRY-US, V32, P10089, DOI 10.1021/bi00089a026; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; BUTTS NK, 1994, J STRENGTH COND RES, V8, P265; CARTETTA A, 1985, EUR J BIOCHEM, V153, P49; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; FLOREY PJ, 1953, PRINCIPLES POLYM CHE; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KNOLL D, 1983, J BIOL CHEM, V258, P5710; KOCH KW, 1985, J BIOL CHEM, V260, P6788; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; Kramer RH, 1996, J NEUROSCI, V16, P1285; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TANAKA JC, 1989, BIOCHEMISTRY-US, V28, P2776, DOI 10.1021/bi00433a006; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Wei JY, 1996, BIOCHEMISTRY-US, V35, P16815, DOI 10.1021/bi961763v; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	28	226	240	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					710	713		10.1038/27227	http://dx.doi.org/10.1038/27227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790193				2022-12-28	WOS:000076472600055
J	Robinson, TN; Patrick, K; Eng, TR; Gustafson, D				Robinson, TN; Patrick, K; Eng, TR; Gustafson, D		Sci Panel Interactive Commun Hlth	An evidence-based approach to interactive health communication - A challenge to medicine in the information age	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED TRIALS; WORLD-WIDE-WEB; SMOKING-CESSATION; COMPUTER NETWORK; CARE; INTERNET; QUALITY; TECHNOLOGY; AUTHORSHIP; ABSTRACTS	Objective.-To examine the current status of interactive health communication (IHC) and propose evidence-based approaches to improve the quality of such applications. Participants.-The Science Panel on Interactive Communication and Health, a 14-member, nonfederal panel with expertise in clinical medicine and nursing, public health, media and instructional design, health systems engineering, decision sciences, computer and communication technologies, and health communication, convened by the Office of Disease Prevention and Health Promotion, US Department of Health and Human Services. Evidence.-Published studies, online resources, expert panel opinions, and opinions from outside experts in fields related to IHC. Consensus Process.-The panel met 9 times during more than 2 years. Government agencies and private-sector experts provided review and feedback on the panel's work. Conclusions.-Interactive health communication applications have great potential to improve health, but they may also cause harm. To date, few applications have been adequately evaluated. Physicians and other health professionals should promote and participate in an evidence-based approach to the development and diffusion of IHC applications and endorse efforts to rigorously evaluate the safety, quality, and utility of these resources. A standardized reporting template is proposed to help developers and evaluators of IHC applications conduct evaluations and disclose their results and to help clinicians, purchasers, and consumers judge the quality of IHC applications.	US Dept HHS, Off Dis Prevent & Hlth Promot, 200 Independence Ave SW,Room 738G, Washington, DC 20201 USA; Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Stanford, CA 94305 USA; San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA; Univ Wisconsin, Madison, WI USA	Stanford University; California State University System; San Diego State University; University of Wisconsin System; University of Wisconsin Madison	Eng, TR (corresponding author), US Dept HHS, Off Dis Prevent & Hlth Promot, 200 Independence Ave SW,Room 738G, Washington, DC 20201 USA.	teng@osophs.dhhs.gov						Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; Balas EA, 1997, JAMA-J AM MED ASSOC, V278, P152, DOI 10.1001/jama.278.2.152; BARRY MJ, 1995, MED CARE, V33, P771, DOI 10.1097/00005650-199508000-00003; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V278, P1622, DOI 10.1001/jama.278.19.1622; Bluming A, 1996, B MED LIBR ASSOC, V84, P217; Bower H, 1996, BRIT MED J, V313, P381; BRENNAN PF, 1995, NURS RES, V44, P166; BUHLE EL, 1994, P ANN S COMPUT APPL, V20, P103; BULKELEY WM, 1995, WALL STREET J   0227, pA1; CAMPBELL MK, 1994, AM J PUBLIC HEALTH, V84, P783, DOI 10.2105/AJPH.84.5.783; Coiera E, 1996, BMJ-BRIT MED J, V312, P3, DOI 10.1136/bmj.312.7022.3; *CONS UN, 1997, CONSUM REP, V62, P27; *COUNC COMP, 1996, HLGHW HLTH TRANSF US; ENG TR, IN PRESS JAMA; Feenberg AL, 1996, J NEUROL SCI, V139, P129, DOI 10.1016/0022-510X(96)00093-7; Ferguson S., 2020, J ED ONLINE; Ferguson T, 1997, FUTURIST, V31, P29; Fernsler J I, 1997, Cancer Pract, V5, P46; Field MJ, 1996, TELEMEDICINE GUIDE A; Firshein J, 1997, LANCET, V349, P1155, DOI 10.1016/S0140-6736(05)63038-3; FLAY BR, 1987, AM J PUBLIC HEALTH, V77, P153, DOI 10.2105/AJPH.77.2.153; FLORA JA, 1995, ASSESSING SOCIAL BEH, P129; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; GLEASON NA, 1995, J AM COLL HEALTH, V44, P78, DOI 10.1080/07448481.1995.9937517; GOLDWEIN JW, 1995, ANN INTERN MED, V123, P152, DOI 10.7326/0003-4819-123-2-199507150-00012; GRAY D, 1998, NY TIMES        0423, pE1; GRAY D, 1998, NY TIMES        0423, pE7; Gustafson D H, 1992, Proc Annu Symp Comput Appl Med Care, P161; Gustafson David, 1993, Journal of Psychosocial Oncology, V11, P69; GUSTAFSON DH, 1994, J AM MED INFORM ASSN, P604; GUSTAFSON DH, IN PRESS AM J PREV M; HARRIS LM, 1995, HLTH NEWS MEDIA TECH; HAWKINS RP, 1987, J COMMUN, V37, P8, DOI 10.1111/j.1460-2466.1987.tb00980.x; HAYNES RB, 1990, ANN INTERN MED, V113, P69, DOI 10.7326/0003-4819-113-1-69; HENDERSON J, IN PRESS AM J PREV M; *HLTH COMM I, 1994, SHAR DEC MAK NEW INF; *HLTH INF TECHN I, 1998, CRIT ASS QUAL HLTH I; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; JIMISON H, IN PRESS AM J PREV M; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; Keoun B, 1996, J NATL CANCER I, V88, P1263, DOI 10.1093/jnci/88.18.1263; KIESCHNICK T, 1996, 1996 HLTH INFORMATIO; Krishna S, 1997, J FAM PRACTICE, V45, P25; LOCKE SE, 1992, JAMA-J AM MED ASSOC, V268, P1301, DOI 10.1001/jama.268.10.1301; Meyer H, 1996, HOSP HEALTH NETWORK, V70, P37; MULLICH J, 1997, HEALTHCARE INFOR JUL, P27; MURRAY PJ, 1998, WEB SITE REV EVALUAT; *OFF TECHN ASS, 1995, OTAITC624; PATRICK K, IN PRESS AM J PREV M; PEREDNIA DA, 1995, JAMA-J AM MED ASSOC, V273, P483, DOI 10.1001/jama.273.6.483; Peters R, 1997, JAMA-J AM MED ASSOC, V277, P1258, DOI 10.1001/jama.277.15.1258; Pingree S, 1996, J BROADCAST ELECTRON, V40, P331, DOI 10.1080/08838159609364357; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; Rennie D, 1996, JAMA-J AM MED ASSOC, V276, P649, DOI 10.1001/jama.276.8.649; ROBINSON TN, 1989, COMPUT METH PROG BIO, V30, P137, DOI 10.1016/0169-2607(89)90065-5; Saksena S, 1995, PACE, V18, P2216, DOI 10.1111/j.1540-8159.1995.tb04649.x; Scolamiero SJ, 1997, M D COMPUT, V14, P12; SHIFFMAN S, 1997, 10 WORLD C TOB HLTH; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; SKINNER CS, 1993, PATIENT EDUC COUNS, V22, P27, DOI 10.1016/0738-3991(93)90086-C; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V278, P1723; Sonnenberg FA, 1997, ARCH INTERN MED, V157, P151, DOI 10.1001/archinte.157.2.151; STRECHER VJ, 1994, J FAM PRACTICE, V39, P262; Susser M, 1997, AM J PUBLIC HEALTH, V87, P1091, DOI 10.2105/AJPH.87.7.1091; TADDIO A, 1994, CAN MED ASSOC J, V150, P1611; TAYLOR E, 1994, J NATL CANCER I, V86, P1272, DOI 10.1093/jnci/86.17.1272-a; THOMAS JR, 1996, MOL MED, V98, P742; *US GEN ACC OFF, 1996, GAOAIMD9686; *US PREV SERV TASK, 1989, NEW ENGL J MED, V321, P1405; VICKERY DM, 1995, LEA COMMUN SER, P45; Weinberg N, 1996, HEALTH SOC WORK, V21, P24, DOI 10.1093/hsw/21.1.24; Weisbord SD, 1997, NEW ENGL J MED, V337, P825, DOI 10.1056/NEJM199709183371205; WENNBERG J, 1995, LEA COMMUN SER, P109; WINGERSON L, 1997, PATIENT RESOURCES IN; Wyatt JC, 1997, BRIT MED J, V314, P1879, DOI 10.1136/bmj.314.7098.1879; 1997, LANCET, V349, P1781	78	220	221	0	48	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1264	1269		10.1001/jama.280.14.1264	http://dx.doi.org/10.1001/jama.280.14.1264			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127NR	9786378				2022-12-28	WOS:000076357900034
J	Kemp, M				Kemp, M			Haeckel's hierarchies	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	4	4	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1998	395	6701					447	447		10.1038/26642	http://dx.doi.org/10.1038/26642			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774098	Bronze			2022-12-28	WOS:000076212200034
J	Sereno, AB; Maunsell, JHR				Sereno, AB; Maunsell, JHR			Shape selectivity in primate lateral intraparietal cortex	NATURE			English	Article							POSTERIOR PARIETAL CORTEX; PREFRONTAL CORTEX; VISUAL GUIDANCE; MONKEY; MECHANISMS; NEURONS; CONNECTIONS; PERCEPTION; PREHENSION; PATHWAYS	The extrastriate visual cortex can be divided into functionally distinct temporal and parietal regions, which have been implicated in feature-related ('what') and spatial ('where') vision, respectively(1). Neuropsychological studies of patients with damage to either the temporal or the parietal regions provide support for this functional distinction(2-4). Given the prevailing modular theoretical framework and the fact that prefrontal cortex receives inputs from both temporal and parietal streams(5,6), recent studies have focused on the role of prefrontal cortex in understanding where and how information about object identity is integrated with (or remains segregated from) information about object location(7-10). Here we show that many neurons in primate posterior parietal cortex (the 'where' pathway) show sensory shape selectivities to simple, two-dimensional geometric shapes while the animal performs a simple fixation task. In a delayed match-to-sample paradigm, many neuronal units also show significant differences in delay-period activity, and these differences depend on the shape of the sample. These results indicate that units in posterior parietal cortex contribute to attending to and remembering shape features in a way that is independent of eye movements, reaching, or object manipulation. These units show shape selectivity equivalent to any shown in the ventral pathway.	Baylor Coll Med, Div Neurosci S603, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Rutgers State University Newark; Rutgers State University New Brunswick	Sereno, AB (corresponding author), Baylor Coll Med, Div Neurosci S603, Houston, TX 77030 USA.	sereno@cmbn.rutgers.edu	Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439	NEI NIH HHS [R01 EY005911] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN RA, 1990, J COMP NEUROL, V296, P65, DOI 10.1002/cne.902960106; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Colby CL, 1998, NEURON, V20, P15, DOI 10.1016/S0896-6273(00)80429-8; Courtney SM, 1998, SCIENCE, V279, P1347, DOI 10.1126/science.279.5355.1347; FARAH MJ, 1990, VISUAL AGNOSIA; GALLESE V, 1994, NEUROREPORT, V5, P1525, DOI 10.1097/00001756-199407000-00029; Goldberg M. E., 1997, Society for Neuroscience Abstracts, V23, P17; GOODALE MA, 1994, CURR BIOL, V4, P604, DOI 10.1016/S0960-9822(00)00132-9; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; JEANNEROD M, 1986, BEHAV BRAIN RES, V19, P99, DOI 10.1016/0166-4328(86)90008-2; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; Murata A, 1996, J NEUROPHYSIOL, V75, P2180, DOI 10.1152/jn.1996.75.5.2180; OScalaidhe SP, 1997, SCIENCE, V278, P1135, DOI 10.1126/science.278.5340.1135; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; SAKATA H, 1995, CEREB CORTEX, V5, P429, DOI 10.1093/cercor/5.5.429; Shadlen M, 1997, NATURE, V386, P122, DOI 10.1038/386122a0; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; TAIRA M, 1990, EXP BRAIN RES, V83, P29; Troscianko T, 1996, CURR BIOL, V6, P200, DOI 10.1016/S0960-9822(02)00453-0; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	26	310	312	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1998	395	6701					500	503		10.1038/26752	http://dx.doi.org/10.1038/26752			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774105				2022-12-28	WOS:000076212200056
J	Sartorius, N				Sartorius, N			Stigma: what can psychiatrists do about it?	LANCET			English	Article									Hop Univ Geneve, Dept Psychiat, World Psychiat Assoc, Off President, CH-1205 Geneva, Switzerland	University of Geneva	Sartorius, N (corresponding author), Hop Univ Geneve, Dept Psychiat, World Psychiat Assoc, Off President, 16-18 Blvd St Georges, CH-1205 Geneva, Switzerland.							ALEM A, 1997, MENTAL HLTH RURAL ET; [Anonymous], 1992, STIGMA MENTAL ILLNES; Freeman H.L., 1985, MENTAL HLTH SERVICES; MURRAY CJL, 1996, GLOBAL BURDEN DS; SARTORIUS N, 1993, MENTAL DISORDERS REV; SCHARFSTEIN SS, 1995, SOC PSYCHIAT PSYCHIA, V30, P236; *WORLD BANK, 1993, WORLD DEV REP 1993 I	7	111	120	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1058	1059		10.1016/S0140-6736(98)08008-8	http://dx.doi.org/10.1016/S0140-6736(98)08008-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759771				2022-12-28	WOS:000076121800051
J	Dollow, S				Dollow, S			Safety of patients participating in drug trials - Use of placebo in trials of drugs for mental illness should be debated - Reply	BRITISH MEDICAL JOURNAL			English	Letter									Glaxo Wellcome UK, Uxbridge UB11 1BT, Middx, England	GlaxoSmithKline	Dollow, S (corresponding author), Glaxo Wellcome UK, Uxbridge UB11 1BT, Middx, England.							Baldessarini RJ, 1997, AM J PSYCHIAT, V154, P551	1	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					818	818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9786684				2022-12-28	WOS:000076084200070
J	Kleyn, PW; Vesell, ES				Kleyn, PW; Vesell, ES			Genetic variation as a guide to drug development	SCIENCE			English	Article							ALZHEIMERS-DISEASE; POLYMORPHISM; PREDICTOR; ALLELE; CDNA		Millennium Predict Med Inc, Cambridge, MA 02139 USA; Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kleyn, PW (corresponding author), Millennium Predict Med Inc, 640 Mem Dr, Cambridge, MA 02139 USA.	kleyn@mpi.com						Arranz MJ, 1996, NEUROSCI LETT, V217, P177, DOI 10.1016/S0304-3940(96)13094-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; de Maat MPM, 1998, ARTERIOSCL THROM VAS, V18, P265, DOI 10.1161/01.ATV.18.2.265; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; IDLE JR, 1979, DRUG METAB REV, V9, P301, DOI 10.3109/03602537908993896; Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913; Kornmann M, 1997, CANCER LETT, V118, P29, DOI 10.1016/S0304-3835(97)00220-6; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Persidis A, 1998, NAT BIOTECHNOL, V16, P393, DOI 10.1038/nbt0498-393; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; TRENT JM, 1984, J CLIN ONCOL, V2, P8, DOI 10.1200/JCO.1984.2.1.8; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; Wilkins M. R., 1997, PROTEOME RES NEW FRO; Zubenko GS, 1998, GENOMICS, V50, P121, DOI 10.1006/geno.1998.5306	20	92	99	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1998	281	5384					1820	1821		10.1126/science.281.5384.1820	http://dx.doi.org/10.1126/science.281.5384.1820			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9776686				2022-12-28	WOS:000076007100040
J	Wahlestedt, C				Wahlestedt, C			Neuropharmacology - Reward for persistence in substance P research	SCIENCE			English	Editorial Material							K RECEPTOR; CDNA; ANTAGONIST; EXPRESSION; PRECURSOR; NEURONS; CLONING; SYSTEM; GENE		Karolinska Inst, Ctr Genom Res, S-17177 Stockholm, Sweden	Karolinska Institutet	Wahlestedt, C (corresponding author), Karolinska Inst, Ctr Genom Res, S-17177 Stockholm, Sweden.	Claes.Wahlestedt@cgr.ki.se	Wahlestedt, Claes/A-7039-2009					CHANG MM, 1971, NATURE-NEW BIOL, V232, P86, DOI 10.1038/newbio232086a0; CULMAN J, 1995, CAN J PHYSIOL PHARM, V73, P885, DOI 10.1139/y95-122; File SE, 1997, PHARMACOL BIOCHEM BE, V58, P747, DOI 10.1016/S0091-3057(97)90002-2; HAKANSON R, 1985, TACHYKININ ANTAGONIS; HOKFELT T, 1975, SCIENCE, V190, P889, DOI 10.1126/science.242075; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; LEE CM, 1982, N-S ARCH PHARMACOL, V318, P281, DOI 10.1007/BF00501166; LEMBECK F, 1953, N-S ARCH EX PATH PH, V219, P197; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OTSUKA M, 1975, FED PROC, V34, P1922; PERNOW B, 1953, Acta Physiol Scand Suppl, V29, P1; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763; Wood P L, 1998, Curr Opin Drug Discov Devel, V1, P34; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	20	14	19	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1624	1625		10.1126/science.281.5383.1624	http://dx.doi.org/10.1126/science.281.5383.1624			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9767028				2022-12-28	WOS:000075856500033
J	Holway, DA; Suarez, AV; Case, TJ				Holway, DA; Suarez, AV; Case, TJ			Loss of intraspecific aggression in the success of a widespread invasive social insect	SCIENCE			English	Article							ARGENTINE ANT; FIRE ANTS; INTERFERENCE COMPETITION; TERRITORIAL BEHAVIOR; IRIDOMYRMEX-HUMILIS; HYMENOPTERA; FORMICIDAE; EVOLUTION; HABITATS; FAUNA	Despite the innumerable ecological problems and large economic costs associated with biological invasions, the proximate causes of invasion success are often poorly understood. Here, evidence is provided that reduced intraspecific aggression and the concomitant abandonment of territorial behavior unique to introduced populations of the Argentine ant contribute to the elevated population densities directly responsible for its widespread success as an invader. In the Laboratory, nonaggressive pairs of colonies experienced lower mortality and greater foraging activity relative to aggressive pairs. These differences translated into higher rates of resource retrieval, greater brood production, and Larger worker populations.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Holway, DA (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dholway@biomail.ucsd.edu						BROWN JL, 1969, WILSON BULL, V81, P293; Cammell ME, 1996, INSECT SOC, V43, P37, DOI 10.1007/BF01253954; CARPENTER FL, 1987, AM ZOOL, V27, P223; CASE TJ, 1974, P NATL ACAD SCI USA, V71, P3073, DOI 10.1073/pnas.71.8.3073; COLE FR, 1992, ECOLOGY, V73, P1313, DOI 10.2307/1940678; Davies N. B., 1984, BEHAV ECOLOGY EVOLUT, P148; DIAMOND J, 1986, COMMUNITY ECOLOGY, P64; Drake, 1986, ECOLOGY BIOL INVASIO; Drake JA, 1989, BIOL INVASIONS GLOBA; Elton C. S., 1958, ECOLOGY INVASIONS AN; ERICKSON J M, 1971, Psyche (Cambridge), V78, P257, DOI 10.1155/1971/34713; FEENER DH, 1981, SCIENCE, V214, P815, DOI 10.1126/science.214.4522.815; Feener DH, 1997, ANNU REV ENTOMOL, V42, P73, DOI 10.1146/annurev.ento.42.1.73; HOLLDOBLER B, 1977, NATURWISSENSCHAFTEN, V64, P8, DOI 10.1007/BF00439886; HOLLDOBLER B, 1980, SCIENCE, V210, P732, DOI 10.1126/science.210.4471.732; Holldobler B., 1990, pi; HOLLDOBLER B, 1982, OECOLOGIA, V52, P208, DOI 10.1007/BF00363838; Holway DA, 1998, OECOLOGIA, V116, P252, DOI 10.1007/s004420050586; HOLWAY DA, IN PRESS ECOLOGY; Human KG, 1996, OECOLOGIA, V105, P405, DOI 10.1007/BF00328744; Kareiva P, 1996, ECOLOGY, V77, P1651, DOI 10.2307/2265766; LODGE DM, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P367; LYNCH JF, 1980, ECOL ENTOMOL, V5, P353, DOI 10.1111/j.1365-2311.1980.tb01160.x; MAJER JD, 1994, WESTV STUD, P163; MARKIN G P, 1968, Journal of the Kansas Entomological Society, V41, P511; MARKIN GP, 1970, ANN ENTOMOL SOC AM, V63, P1238, DOI 10.1093/aesa/63.5.1238; NEWELL W, 1913, USDA BUR ENTOMOL B, V122; ORR MR, 1995, NATURE, V373, P292, DOI 10.1038/373292a0; PASSERA L, 1994, WESTV STUD, P23; PATTERSON IJ, 1980, ARDEA, V68, P53; PETREN K, 1993, SCIENCE, V259, P354, DOI 10.1126/science.259.5093.354; Pimm SL, 1991, BALANCE NATURE ECOLO; PORTER SD, 1990, ECOLOGY, V71, P2095, DOI 10.2307/1938623; Porter SD, 1997, ENVIRON ENTOMOL, V26, P373, DOI 10.1093/ee/26.2.373; Ross KG, 1996, P NATL ACAD SCI USA, V93, P3021, DOI 10.1073/pnas.93.7.3021; Shelton TG, 1997, ENVIRON ENTOMOL, V26, P632, DOI 10.1093/ee/26.3.632; STAMPS J, 1994, ADV STUD BEHAV, V23, P173, DOI 10.1016/S0065-3454(08)60354-X; Suarez AV, 1998, ECOLOGY, V79, P2041, DOI 10.1890/0012-9658(1998)079[2041:EOFAIO]2.0.CO;2; SUAREZ AV, IN PRESS BIOL INVASI; TREMPER BS, 1976, THESIS U CALIFORNIA; VANDERMEER RK, 1990, APPL MYRMECOLOGY WOR; Vermeij GJ, 1996, BIOL CONSERV, V78, P3, DOI 10.1016/0006-3207(96)00013-4; VINSON BS, 1986, EC IMPACT CONTROL SO; Vitousek PM, 1996, AM SCI, V84, P468; WARD PS, 1987, HILGARDIA, V55, P1; WATSON A, 1980, ARDEA, V68, P103; WATSON A, 1967, NATURE, V215, P1274, DOI 10.1038/2151274a0; WAY MJ, 1963, ANNU REV ENTOMOL, V8, P307, DOI 10.1146/annurev.en.08.010163.001515; Williams DF, 1994, EXOTIC ANTS BIOL IMP; WINSTON ML, 1991, KILLER BEES AFRICAN	50	253	264	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1998	282	5390					949	952		10.1126/science.282.5390.949	http://dx.doi.org/10.1126/science.282.5390.949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794767				2022-12-28	WOS:000076727300052
J	Zakhidov, AA; Baughman, RH; Iqbal, Z; Cui, CX; Khayrullin, I; Dantas, SO; Marti, I; Ralchenko, VG				Zakhidov, AA; Baughman, RH; Iqbal, Z; Cui, CX; Khayrullin, I; Dantas, SO; Marti, I; Ralchenko, VG			Carbon structures with three-dimensional periodicity at optical wavelengths	SCIENCE			English	Article							COLLOIDAL CRYSTALLIZATION; LOCALIZATION; CRYSTALS; DIAMOND; FILMS; LIGHT; OPALS	Porous carbons that are three-dimensionally periodic on the scale of optical wavelengths were made by a synthesis route resembling the geological formation of natural opal, Porous silica opal crystals were sintered to form an intersphere interface through which the silica was removed after infiltration with carbon or a carbon precursor. The resulting porous carbons had different structures depending on synthesis conditions. Both diamond and glassy carbon inverse opals resulted from volume filling. Graphite inverse opals, comprising 40-angstrom-thick Layers of graphite sheets tiled on spherical surfaces, were produced by surface templating, The carbon inverse opals provide examples of both dielectric and metallic optical photonic crystals, They strongly diffract Light and may provide a route toward photonic band-gap materials.	Allied Signal Inc, Res & Technol, Morristown, NJ 07962 USA; Uzbek Acad Sci, Dept Thermal Phys, Tashkent 700135, Uzbekistan; Univ Fed Juiz de Fara, Dept Fis, BR-36036330 Juiz De Fora, MG, Brazil; Russian Acad Sci, Inst Gen Phys, Moscow 117942, Russia	Academy of Sciences of Uzbekistan; Russian Academy of Sciences; Prokhorov General Physics Institute of the Russian Academy of Sciences	Zakhidov, AA (corresponding author), Allied Signal Inc, Res & Technol, Morristown, NJ 07962 USA.	anvar.zakhidov@alliedsignal.com; ray.baughman@alliedsignal.com	Ralchenko, Victor Grigorevich/V-1290-2017	Ralchenko, Victor Grigorevich/0000-0002-2213-4224				ASKER EG, 1977, Patent No. 4049781; BOGOMOLOV VN, 1993, PHYSICA C, V208, P371, DOI 10.1016/0921-4534(93)90211-8; Busch K, 1998, PHYS REV E, V58, P3896, DOI 10.1103/PhysRevE.58.3896; DARRAGH PJ, 1976, SCI AM, V234, P84, DOI 10.1038/scientificamerican0476-84; DENISKINA ND, 1988, GEM QUALITY OPALS TH; GASKIN AJ, 1970, Patent No. 3497367; Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538; Holtz JH, 1997, NATURE, V389, P829, DOI 10.1038/39834; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; JOHN S, 1991, PHYS TODAY, V44, P32, DOI 10.1063/1.881300; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; LENOSKY T, 1992, NATURE, V355, P333, DOI 10.1038/355333a0; Lopez C, 1997, SUPERLATTICE MICROST, V22, P399, DOI 10.1006/spmi.1996.0313; MACKAY AL, 1991, NATURE, V352, P762, DOI 10.1038/352762a0; Miguez H, 1997, APPL PHYS LETT, V71, P1148, DOI 10.1063/1.119849; NEMANICH RJ, 1988, J VAC SCI TECHNOL A, V6, P1783, DOI 10.1116/1.575297; Nistor LC, 1997, DIAM RELAT MATER, V6, P159, DOI 10.1016/S0925-9635(96)00743-1; Obraztsova ED, 1998, CARBON, V36, P821, DOI 10.1016/S0008-6223(98)00014-1; PHILIPSE AP, 1989, J MATER SCI LETT, V8, P1371, DOI 10.1007/BF00720190; Romanov SG, 1996, J CRYST GROWTH, V159, P857, DOI 10.1016/0022-0248(95)00679-6; Sievenpiper DF, 1996, PHYS REV LETT, V76, P2480, DOI 10.1103/PhysRevLett.76.2480; Tsunekawa S, 1997, MICROPOROUS MATER, V8, P275, DOI 10.1016/S0927-6513(96)00089-2; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; VANDERBILT D, 1992, PHYS REV LETT, V68, P511, DOI 10.1103/PhysRevLett.68.511; Velev OD, 1997, NATURE, V389, P447, DOI 10.1038/38921; Vlasov YA, 1997, PHYS REV B, V55, P13357, DOI 10.1103/PhysRevB.55.R13357; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; YABLONOVITCH E, 1998, NATURE, V391, P667; Yoshino K, 1997, JPN J APPL PHYS 2, V36, pL714, DOI 10.1143/JJAP.36.L714	31	1009	1116	9	365	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					897	901		10.1126/science.282.5390.897	http://dx.doi.org/10.1126/science.282.5390.897			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794752				2022-12-28	WOS:000076727300037
J	Brannon, EM; Terrace, HS				Brannon, EM; Terrace, HS			Ordering of the numerosities 1 to 9 by monkeys	SCIENCE			English	Article							SQUIRREL-MONKEYS; RHESUS-MONKEYS; SERIAL; CHIMPANZEE; DISCRIMINATION; JUDGMENTS; STIMULI; PIGEONS; SYMBOLS; RATS	A fundamental question in cognitive science is whether animals can represent numerosity (a property of a stimulus that is defined by the number of discriminable elements it contains) and use numerical representations computationally. Here, it was shown that rhesus monkeys represent the numerosity of visual stimuli and detect their ordinal disparity. Two monkeys were first trained to respond to exemplars of the numerosities 1 to 4 in an ascending numerical order (1 --> 2 --> 3 --> 4). As a control for non-numerical cues, exemplars were varied with respect to size, shape, and color, The monkeys were later tested, without reward, on their ability to order stimulus pairs composed of the novel numerosities 5 to 9. Both monkeys responded in an ascending order to the novel numerosities, These results show that rhesus monkeys represent the numerosities 1 to 9 on an ordinal scale.	Columbia Univ, Dept Psychol, New York, NY 10027 USA; Columbia Univ, Dept Psychiat, New York, NY 10027 USA	Columbia University; Columbia University	Brannon, EM (corresponding author), Columbia Univ, Dept Psychol, New York, NY 10027 USA.				NIMH NIH HHS [MH406462] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BOYSEN ST, 1989, J COMP PSYCHOL, V103, P23, DOI 10.1037/0735-7036.103.1.23; Breukelaar JWC, 1998, J EXP PSYCHOL ANIM B, V24, P84, DOI 10.1037/0097-7403.24.1.84; BUCKLEY PB, 1974, J EXP PSYCHOL, V103, P1131, DOI 10.1037/h0037361; CAPALDI EJ, 1988, J EXP PSYCHOL ANIM B, V14, P3, DOI 10.1037/0097-7403.14.1.3; Chen SF, 1997, PSYCHOL SCI, V8, P80, DOI 10.1111/j.1467-9280.1997.tb00687.x; Dantzig T., 1930, NUMBER LANGUAGE SCI; DAVIS H, 1988, BEHAV BRAIN SCI, V11, P602, DOI 10.1017/S0140525X00053693; DAVIS H, 1986, ANIM LEARN BEHAV, V14, P57, DOI 10.3758/BF03200037; Dehaene S, 1998, TRENDS NEUROSCI, V21, P355, DOI 10.1016/S0166-2236(98)01263-6; Emmerton J, 1997, ANIM LEARN BEHAV, V25, P234, DOI 10.3758/BF03199062; GALLISTEL CR, 1992, COGNITION, V44, P43, DOI 10.1016/0010-0277(92)90050-R; Gelman R., 1978, CHILDS UNDERSTANDING; HARLOW HF, 1949, PSYCHOL REV, V56, P51, DOI 10.1037/h0062474; Hauser MD, 1996, P NATL ACAD SCI USA, V93, P1514, DOI 10.1073/pnas.93.4.1514; Hiestand L, 1996, MATH COGNIT, V2, P171; HONIG WK, 1989, ANIM LEARN BEHAV, V17, P134, DOI 10.3758/BF03207628; HULSE SH, 1977, LEARN MOTIV, V8, P488, DOI 10.1016/0023-9690(77)90047-9; MATSUZAWA T, 1985, NATURE, V315, P57, DOI 10.1038/315057a0; MCGONIGLE BO, 1977, NATURE, V267, P694, DOI 10.1038/267694a0; MCGONIGLE BO, 1986, REASONING DISCOURSE, P141; MECK WH, 1983, J EXP PSYCHOL ANIM B, V9, P320, DOI 10.1037/0097-7403.9.3.320; MITCHELL RW, 1985, J COMP PSYCHOL, V99, P218, DOI 10.1037/0735-7036.99.2.218; MOYER RS, 1967, NATURE, V215, P1519, DOI 10.1038/2151519a0; Ohshiba N, 1997, JPN PSYCHOL RES, V39, P236, DOI 10.1111/1468-5884.00057; Olthof A, 1997, J EXP PSYCHOL ANIM B, V23, P325, DOI 10.1037/0097-7403.23.3.325; PEPPERBREG I, 1987, ETHLOGY, V75, P137; SWARTZ KB, 1991, J EXP PSYCHOL ANIM B, V17, P396, DOI 10.1037/0097-7403.17.4.396; TERRACE HS, 1984, QUANTITATIVE ANAL BE, P115; THOMAS RK, 1980, AM J PSYCHOL, V93, P247, DOI 10.2307/1422230; THOMAS RK, 1993, DEV NUMERICAL COMPET, P127; WASHBURN DA, 1991, PSYCHOL SCI, V2, P190, DOI 10.1111/j.1467-9280.1991.tb00130.x	31	381	390	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					746	749		10.1126/science.282.5389.746	http://dx.doi.org/10.1126/science.282.5389.746			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	132AM	9784133				2022-12-28	WOS:000076607500052
J	Eysenbach, G; Diepgen, TL				Eysenbach, G; Diepgen, TL			Responses to unsolicited patient e-mail requests for medical advice on the World Wide Web	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ZOSTER VIRUS-INFECTION; IMMUNOCOMPROMISED PATIENTS; HEALTH-CARE; ACYCLOVIR; INFORMATION	Context.-The Internet is increasingly used by consumers to seek health and medical information, but online medical advice has not been explored systematically. Objective.-To explore the attitude of physicians and other providers of medical information on the Internet toward unsolicited e-mail from patients and their reaction to a fictitious acute medical problem described in such an e-mail. Design.-E-mail in December 1997 and January 1998 to Web sites from a fictitious patient describing an acute dermatological problem. Follow-up questionnaire survey to the same sites. Setting.-World Wide Web. Subjects.-Fifty-eight physicians and Web masters. Main Outcome Measures.-Response rate and types of responses. Results.-Twenty-nine (50%) responded to the fictitious patient request; 9 respondents (31%) refused to give advice without having seen the lesion, 27 (93%) recommended that the patient see a physician, and 17 (59%) explicitly mentioned the correct "diagnosis" in their reply. In response to the questionnaire, 8 (28%) of the 29 respondents said that they tended not to answer any patient e-mail, 7 (24%) said they usually reply with a standard e-mail message, and 7 (24%) said they answer each request individually. Conclusions.-Responses of physicians and Web masters to e-mail requests for medical advice vary as do approaches to handling unsolicited e-mail. Standards for physician response to unsolicited patient e-mail are needed.	Univ Hosp Erlangen, Dept Dermatol, Unit Med Informat Epidemiol & Publ Hlth, D-91052 Erlangen, Germany	University of Erlangen Nuremberg	Eysenbach, G (corresponding author), Univ Hosp Erlangen, Dept Dermatol, Unit Med Informat Epidemiol & Publ Hlth, Hartmannstr 14, D-91052 Erlangen, Germany.	ey@yi.com	Eysenbach, Gunther/AAJ-7158-2020	Eysenbach, Gunther/0000-0001-6479-5330				BALFOUR HH, 1983, NEW ENGL J MED, V308, P1448, DOI 10.1056/NEJM198306163082404; BALFOUR HH, 1993, J MED VIROL, P74; Coiera E, 1996, BMJ-BRIT MED J, V312, P3, DOI 10.1136/bmj.312.7022.3; Deering CM, 1995, ANN TROP MED PARASIT, V89, P579, DOI 10.1080/00034983.1995.11812992; EYSENBACH G, IN PRESS ARCH DERMAT; FRIDSMA DB, 1994, J AM MED INFORM ASSN, P15; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; MEYERS JD, 1984, TRANSPLANTATION, V37, P571, DOI 10.1097/00007890-198406000-00009; Neill R A, 1994, Arch Fam Med, V3, P268, DOI 10.1001/archfami.3.3.268; Sellu D, 1996, BRIT MED J, V312, P49, DOI 10.1136/bmj.312.7022.49a; SHEPP DH, 1986, NEW ENGL J MED, V314, P208, DOI 10.1056/NEJM198601233140404; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209	12	93	94	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1333	1335		10.1001/jama.280.15.1333	http://dx.doi.org/10.1001/jama.280.15.1333			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794313				2022-12-28	WOS:000076472500026
J	Harman, KE; Lockwood, DNJ; Black, MM				Harman, KE; Lockwood, DNJ; Black, MM			Never take things at face value	LANCET			English	Article							LEPROSY		St Thomas Hosp, St Johns Inst Dermatol, London SE1 7EH, England; UCL Hosp, Hosp Trop Dis, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University College London	Harman, KE (corresponding author), St Thomas Hosp, St Johns Inst Dermatol, London SE1 7EH, England.							KIRAN KU, 1985, LEPROSY REV, V56, P127; LOCKWOOD DNJ, 1993, INT J LEPROSY, V61, P8; MISHRA B, 1993, LEPROSY REV, V64, P255; Noordeen SK, 1996, MANSONS TROPICAL DIS, P1016; VANBEERS SM, 1994, INT J LEPROSY, V62, P1	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1190	1190		10.1016/S0140-6736(98)08152-5	http://dx.doi.org/10.1016/S0140-6736(98)08152-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777837				2022-12-28	WOS:000076415400012
J	Szasz, T				Szasz, T			Parity for mental illness, disparity for the mental patient	LANCET			English	Article									SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Szasz, T (corresponding author), SUNY Hlth Sci Ctr, 750 E Adams St, Syracuse, NY 13210 USA.							COLLINS J, 1997, TIME            0707, P29; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HAUSMAN K, 1997, PSYCHIAT NEWS, V32, P1; Kasper JA, 1997, AM J PSYCHIAT, V154, P483; SZASZ T, 1996, MEANING MIND LANGUAG, P115; SZASZ TS, 1982, AM PSYCHOL, V37, P762, DOI 10.1037/0003-066X.37.7.762; WINICK BJ, 1997, RIGHT REFUSE MENTAL, P398; 1997, NY TIMES        0624, pB11; 1997, Q NAMI REV, V1, P2; 1996, ARIZONA REPUBLI 1214, pA9; 1991, JAMA, V266, P410	11	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1213	1215		10.1016/S0140-6736(98)04344-X	http://dx.doi.org/10.1016/S0140-6736(98)04344-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128PQ	9777855				2022-12-28	WOS:000076415400041
J	[Anonymous]				[Anonymous]			Junior doctors advised on self regulation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 10	1998	317	7164					1021	1021						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765188				2022-12-28	WOS:000076449300072
J	Kratz, A; Lewandrowski, KB				Kratz, A; Lewandrowski, KB			Normal reference laboratory values	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	141	146	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1063	1072		10.1056/NEJM199810083391508	http://dx.doi.org/10.1056/NEJM199810083391508			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761809				2022-12-28	WOS:000076294800008
J	Qureshi, F; Pestian, J; Davis, P; Zaritsky, A				Qureshi, F; Pestian, J; Davis, P; Zaritsky, A			Effect of nebulized ipratropium on the hospitalization rates of children with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD ASTHMA; BROMIDE; SALBUTAMOL; EFFICACY; ALBUTEROL; BRONCHOSPASM; INHALATION	Background Anticholinergic medications such as ipratropium improve the pulmonary function of patients with acute exacerbations of asthma, but their effect on hospitalization rates is uncertain. Methods We conducted a randomized, double-blind, placebo-controlled study of 434 children (2 to 18 years old) who had acute exacerbations of moderate or severe asthma treated in the emergency department. All the children received a nebulized solution of albuterol (2.5 or 5 mg per dose, depending on body weight) every 20 minutes for three doses and then as needed, A corticosteroid (2 mg of prednisone or prednisolone per kilogram of body weight) was given orally with the second dose of albuterol. Children in the treatment group received 500 mu g (2.5 mi) of ipratropium bromide with the second and third doses of albuterol; children in the control group received 2.5 mi of normal saline at these times. Results Overall, the rate of hospitalization was lower in the ipratropium group (59 of 215 children [27.4 percent]) than in the control group (80 of 219 [36.5 percent], P=0.05). For patients with moderate asthma (indicated by a peak expiratory flow rate of 50 to 70 percent of the predicted value or an asthma score of 8 to 11 on a 15-point scale), hospitalization rates were similar in the two groups (ipratropium: 8 of 79 children [10.1 percent]; control: 9 of 84 [10.7 percent]). For patients with severe asthma (defined as a peak expiratory flow rate of <50 percent of the predicted value or an asthma score of 12 to 15), the addition of ipratropium significantly reduced the need for hospitalization (51 of 136 children [37.5 percent], as compared with 71 of 135 [52.6 percent] in the control group; P=0.02). Conclusions Among children with a severe exacerbation of asthma, the addition of ipratropium bromide to albuterol and corticosteroid therapy significantly decreases the hospitalization rate. (N Engl J Med 1998;339:1030-5.) (C) 1998, Massachusetts Medical Society.	Eastern Virginia Med Sch, Childrens Hosp Kings Daughters, Div Pediat Emergency Med, Norfolk, VA 23507 USA; Eastern Virginia Med Sch, Childrens Hosp Kings Daughters, Dept Clin Outcomes, Norfolk, VA 23507 USA; Eastern Virginia Med Sch, Childrens Hosp Kings Daughters, Dept Pediat, Norfolk, VA 23507 USA	Eastern Virginia Medical School; Eastern Virginia Medical School; Eastern Virginia Medical School	Qureshi, F (corresponding author), Eastern Virginia Med Sch, Childrens Hosp Kings Daughters, Div Pediat Emergency Med, 601 Childrens Lane, Norfolk, VA 23507 USA.							BECK R, 1985, J PEDIATR-US, V107, P605, DOI 10.1016/S0022-3476(85)80033-0; BONER AL, 1987, ANN ALLERGY, V58, P54; Dawson-Saunders B., 1994, BASIC CLIN BIOSTATIS; DESTEFANO G, 1990, ANN ALLERGY, V65, P260; FitzGerald JM, 1997, CHEST, V111, P311, DOI 10.1378/chest.111.2.311; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; Karpel JP, 1996, CHEST, V110, P611, DOI 10.1378/chest.110.3.611; *NAT HEART LUNG BL, 1991, NIH PUBL; *NAT HEART LUNG BL, 1997, NIH PUBL; ODRISCOLL BR, 1989, LANCET, V1, P1418; OSMOND MH, 1995, ACAD EMERG MED, V2, P651, DOI 10.1111/j.1553-2712.1995.tb03607.x; Qureshi F, 1997, ANN EMERG MED, V29, P205, DOI 10.1016/S0196-0644(97)70269-5; RAYNER RJ, 1987, ARCH DIS CHILD, V62, P840, DOI 10.1136/adc.62.8.840; REBUCK AS, 1987, AM J MED, V82, P59, DOI 10.1016/0002-9343(87)90378-0; REISMAN J, 1988, J ALLERGY CLIN IMMUN, V81, P16, DOI 10.1016/0091-6749(88)90214-X; SACKETT DL, 1997, EVIDENCE BASED MED P, P157; SCHUH S, 1995, J PEDIATR-US, V126, P639, DOI 10.1016/S0022-3476(95)70368-3; STORR J, 1986, ARCH DIS CHILD, V61, P602, DOI 10.1136/adc.61.6.602; WARD MJ, 1981, BRIT MED J, V282, P598, DOI 10.1136/bmj.282.6264.598; WATSON WTA, 1988, J ALLERGY CLIN IMMUN, V82, P1012, DOI 10.1016/0091-6749(88)90138-8	20	190	201	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1030	1035		10.1056/NEJM199810083391503	http://dx.doi.org/10.1056/NEJM199810083391503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761804				2022-12-28	WOS:000076294800003
J	Preston, RA; Materson, BJ; Reda, DJ; Williams, DW; Hamburger, RJ; Cushman, WC; Anderson, RJ				Preston, RA; Materson, BJ; Reda, DJ; Williams, DW; Hamburger, RJ; Cushman, WC; Anderson, RJ		Dept Vet Affairs Cooperative Study Grp	Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SINGLE-DRUG THERAPY; MYOCARDIAL-INFARCTION; ALDOSTERONE SYSTEM; PLASMA-RENIN; HYPERTENSION; ANGIOTENSIN; STROKE; RISK	Context.-Renin profiling and age-race subgroup may help select single-drug therapy for stage 1 and stage 2 hypertension. Objective.-To compare the plasma renin profiling and age-race subgroup methods as predictors of response to single-drug therapy in men with stage 1 and 2 hypertension as defined by the Joint National Committee an Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Design.-The Veterans Affairs Cooperative Study on Single-Drug Therapy of Hypertension, a randomized controlled trial. Setting.-Fifteen Veterans Affairs hypertension centers. Patients.-A total of 1105 ambulatory men with entry diastolic blood pressure (DBP) of 95 to 109 mm Hg, of whom 1031 had valid plasma and urine samples for renin profiling. Interverations.-Randomization to 1 of 6 antihypertensive drugs: hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem (sustained release), or prazosin, Main Outcome Measure.-Treatment response as assessed by percentage achieving goal DBP (<90 mm Hg) in response to a single drug that corresponded to patients' renin profile vs a single drug that corresponded to patients' age-race subgroup. Results.-Clonidine and diltiazem had consistent response rates regardless of renin profile (76%, 67%, and 80% for low, medium, and high renin, respectively, for clonidine and 83%, 82%, and 83%, respectively for diltiazem for patients with baseline DBP of 95-99 mm Hg). Hydrochlorothiazide and prazosin were best in low- and medium-renin profiles; captopril was best in medium- and high-renin profiles (low-, medium-, and high-renin response rates were 82%, 78%, and 14%, respectively, for hyorochlorothiazide; 88%, 67%, and 40%, respectively, for prazosin; and 51%, 83%, and 100%, respectively, for captopril for patients with baseline DBP of 95-99 mm Hg). Response rates for patients with baseline DBP of 95 to 99 mm Hg by age-race subgroup ranged from 70% for clonidine to 90% for prazosin for younger black men, from 50% for captopril to 97% for diltiazem for older black men, from 70% for hydrochlorothiazide to 92% for atenolol for younger white men, and from 84% for hydrochlorothiazide to 95% for diltiazem for older white men. Patients with a correct treatment for their renin profile but incorrect for age-race subgroup had a response rate of 58.7%; patients with an incorrect treatment for their renin profile but correct for age-race subgroup had a response rate of 63.1% (P=.30). After controlling for DBP and interactions with treatment group, age-race subgroup (P<.001) significantly predicted response to single-drug therapy, whereas renin profile was of borderline significance (P=.05). Conclusions.-In these men with stage 1 and stage 2 hypertension, therapeutic responses were consistent with baseline renin profile, but age-race subgroup was a better predictor of response.	Univ Miami, Sch Med, Dept Med, Div Clin Pharmacol, Miami, FL 33136 USA; Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program, Hines, IL USA; Vet Affairs Med Ctr, Prevent Med Sect, Memphis, TN USA	University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Preston, RA (corresponding author), Univ Miami, Sch Med, Dept Med, Div Clin Pharmacol, 1500 NW 12th Ave,15th Floor,W Tower, Miami, FL 33136 USA.			, Domenic/0000-0003-1831-4270				ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; Black HR, 1997, ARCH INTERN MED, V157, P2413; Blumenfeld Jon D., 1995, P1897; CASE DB, 1977, NEW ENGL J MED, V296, P641, DOI 10.1056/NEJM197703242961201; GRIZZLE JE, 1969, BIOMETRICS, V25, P489, DOI 10.2307/2528901; HABER E, 1969, J CLIN ENDOCR METAB, V29, P1349, DOI 10.1210/jcem-29-10-1349; HAMBURGER RJ, 1982, RENOVASCULAR HYPERTE, P1; HOSMER DW, 1989, APPL LOGISTIC REGRES; LARAGH JH, 1972, AM J MED, V52, P633, DOI 10.1016/0002-9343(72)90054-X; LARAGH JH, 1973, AM J MED, V55, P261, DOI 10.1016/0002-9343(73)90128-9; LARAGH JH, 1992, HYPERTENSION, V20, P267, DOI 10.1161/01.HYP.20.3.267; LARAGH JH, 1993, KIDNEY INT, V44, P1163, DOI 10.1038/ki.1993.363; LARAGH JH, 1995, J HUM HYPERTENS, V9, P385; Laragh John H., 1995, P1813; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MATERSON BJ, 1994, NEW ENGL J MED, V330, P1689, DOI 10.1056/NEJM199406093302316; MATERSON BJ, 1995, AM J HYPERTENS, V8, P189, DOI 10.1016/0895-7061(94)00196-I; SAS Institute Inc, 1989, SAS STAT US GUID VER; SEALEY J E, 1975, Seminars in Nuclear Medicine, V5, P189, DOI 10.1016/S0001-2998(75)80033-X; SEALEY JE, 1977, CARDIOVASC MED, V2, P1079; Taylor J., 1977, CIRC RES S1, V40, pI106; TOBIAN L, 1994, AM J HYPERTENS, V7, P859, DOI 10.1093/ajh/7.10.859; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; Woolson RF, 1987, STAT METHODS ANAL BI	24	137	139	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1168	1172		10.1001/jama.280.13.1168	http://dx.doi.org/10.1001/jama.280.13.1168			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777817	Bronze			2022-12-28	WOS:000076210800031
J	Armstrong, JA; Bieker, JJ; Emerson, BM				Armstrong, JA; Bieker, JJ; Emerson, BM			A SWI/SNF-related chromatin remodeling complex, E-RC1, is required for tissue-specific transcriptional regulation by EKLF in vitro	CELL			English	Article							KRUPPEL-LIKE FACTOR; HUMAN GAMMA-GLOBIN; SWI-SNF COMPLEX; BETA-THALASSEMIA; DNA INTERACTIONS; NUCLEOSOMAL DNA; BINDING PROTEIN; IN-VITRO; GENE; ACTIVATION	Erythroid Kruppel-like factor (EKLF) is necessary for stage-specific expression of the human beta-globin gene. We show that EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro. E-RC1 contains BRG1, BAF170, BAF155, and INI1 (BAF47) homologs of yeast SWI/SNF subunits, as well as a subunit unique to higher eukaryotes, BAF57, which is critical for chromatin remodeling and transcription with EKLF. E-RC1 displays functional selectivity toward transcription factors, since it cannot activate expression of chromatin-assembled HIV-1 templates with the E box-binding protein TFE-3. Thus, a member of the SWI/SNF family acts directly in transcriptional activation and may regulate subsets of genes by selectively interacting with specific DNA-binding proteins.	Salk Inst Biol Studies, Regulatory Biol Lab, La Jolla, CA 92037 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA	Salk Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Emerson, BM (corresponding author), Salk Inst Biol Studies, Regulatory Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM 38760] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038760] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Baron MH, 1997, BBA-GENE STRUCT EXPR, V1351, P51, DOI 10.1016/S0167-4781(96)00195-9; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Bulger M., 1994, METH MOL G, V5, P241; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; FENG WC, 1994, J BIOL CHEM, V269, P1493; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KULOZIK AE, 1991, BLOOD, V77, P2054; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PAPOULAS O, 1998, IN PRESS DEVELOPMENT; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PERKINS AC, 1995, NATURE, V375, P318; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	48	268	277	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					93	104		10.1016/S0092-8674(00)81785-7	http://dx.doi.org/10.1016/S0092-8674(00)81785-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778250	Bronze			2022-12-28	WOS:000076242300013
J	Lerner, BH; Gulick, PM; Dubler, NN				Lerner, BH; Gulick, PM; Dubler, NN			Rethinking nonadherence: Historical perspectives on triple-drug therapy for HIV disease	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; IMPROVING MEDICATION COMPLIANCE; PROTEASE INHIBITORS; TUBERCULOSIS TREATMENT; ZIDOVUDINE THERAPY; PATIENT COMPLIANCE; CLINICAL-TRIALS; CARE; ADHERENCE	The advent of triple-drug therapy for HIV disease has raised the concern that disadvantaged patients with multiple social problems may be nonadherent to treatment. Fearing that partial adherence will lead to drug resistance, some clinicians are withholding these powerful new drugs from such patients. The historical record demonstrates that labeling patients as nonadherent may be both stigmatizing and inaccurate. Since 1900, such adjectives as ignorant, vicious, and recalcitrant have been used to describe patients who do not follow medical advice. Less judgmental terms, such as nonadherent and noncompliant, are now used, but these terms still imply that patients should obey physician-imposed regimens. Studies of nonadherence have consistently shown that the problem is widespread among all persons and cannot reliably be predicted on the basis of patient characteristics. This paper argues that physicians should deemphasize the standard approach of predicting and correcting nonadherent behavior in certain patients. Rather, clinicians should encourage all HIV-positive patients to devise individualized treatment plans that can facilitate reliable ingestion of medication. Although the potential development of resistance to triple-drug therapy remains an important public health issue, concern about this possibility must be balanced with respect for patients' rights. Encouraging the active participation of HIV-positive persons in their own treatment will help avoid judgmental and inaccurate assessments of patient behavior and may help patients take medications more successfully.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Cornell Univ, Sch Med, Cornell Clin Trials Unit, New York, NY 10011 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA	Columbia University; Cornell University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Lerner, BH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St,Box 11, New York, NY 10032 USA.	bh15@columbia.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027665] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR0096] Funding Source: Medline; NIAID NIH HHS [U01 AI27665] Funding Source: Medline; CSAP SAMHSA HHS [SP30 AI27742] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CSAP SAMHSA HHS		ALTMAN LK, 1998, NY TIMES        1124, pF7; Bangsberg D, 1997, JAMA-J AM MED ASSOC, V278, P63, DOI 10.1001/jama.278.1.63; BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002; BERGMAN AB, 1963, NEW ENGL J MED, V268, P1334, DOI 10.1056/NEJM196306132682404; BIGGS HM, 1904, MED NEWS, V84, P337; Blackwell B, 1996, NETH J MED, V48, P140; BOND WS, 1991, AM J HOSP PHARM, V48, P1978, DOI 10.1093/ajhp/48.9.1978; BRIDGE E, 1949, B NATL TUBERCULOSIS, V35, P119; BROERS B, 1994, ARCH INTERN MED, V154, P1121, DOI 10.1001/archinte.154.10.1121; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1994, IMPR PAT ADH TUB TRE, P19; CHARNEY E, 1967, PEDIATRICS, V40, P188; CHESNEY MA, 1997, HIV NEWSLINE, V3, P67; COWAN FM, 1989, J INFECTION, V18, P59, DOI 10.1016/S0163-4453(89)80081-7; Crespo-Fierro M, 1997, J Assoc Nurses AIDS Care, V8, P43, DOI 10.1016/S1055-3290(97)80012-X; CURTIS R, 1994, PUBLIC HEALTH REP, V109, P319; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DAVIES R, 1954, B NATL TUBERCULOSIS, V40, P121; DAVIS MS, 1967, J HEALTH SOC BEHAV, V8, P265, DOI 10.2307/2948420; DAVIS MS, 1963, J HEALTH HUM BEHAV, V4, P240, DOI 10.2307/2948830; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DiMatteo M R, 1994, JAMA, V271, P83, DOI 10.1001/jama.271.1.79; DONOVAN JL, 1995, INT J TECHNOL ASSESS, V11, P443, DOI 10.1017/S0266462300008667; ELDRED L, 1997, 4 C RETR OPP INF 22; ELDRED L, 1998, NW U REPORTS HIV AID, V2, P7; ELDRED L, 1998, NW U REPORTS HIV AID, V2, P1; ElSadr W, 1996, AM J PUBLIC HEALTH, V86, P1146, DOI 10.2105/AJPH.86.8_Pt_1.1146; Epstein Steven., 1996, IMPURE SCI; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; FOSTER JPC, 1905, T NATL ASS STUDY PRE, V1, P333; FRANK E, 1995, J CLIN PSYCHIAT, V56, P11; Freeman RC, 1996, AIDS EDUC PREV, V8, P58; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HAYNES RB, 1987, PATIENT EDUC COUNS, V10, P155, DOI 10.1016/0738-3991(87)90095-4; Haynes RB, 1996, LANCET, V348, P383; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; HUDSON LD, 1973, JAMA-J AM MED ASSOC, V223, P139, DOI 10.1001/jama.223.2.139; HUGHES JR, 1993, CONTROL CLIN TRIALS, V14, P176, DOI 10.1016/0197-2456(93)90019-A; Ickovics JR, 1997, J CLIN EPIDEMIOL, V50, P385, DOI 10.1016/S0895-4356(97)00041-3; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; KAHN MA, 1977, NEW ENGL J MED, V297, P1294; Kyngas H, 1996, J ADV NURS, V24, P997, DOI 10.1111/j.1365-2648.1996.tb02936.x; LERNER B, 1998, CONTAGION CONFINEMEN; Lerner BH, 1996, AM J PUBLIC HEALTH, V86, P257, DOI 10.2105/AJPH.86.2.257; Lerner BH, 1997, SOC SCI MED, V45, P1423, DOI 10.1016/S0277-9536(97)00067-1; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; McDonald CK, 1997, ARCH INTERN MED, V157, P951, DOI 10.1001/archinte.157.9.951; Mehta S, 1997, AIDS, V11, P1665, DOI 10.1097/00002030-199714000-00002; MELLORS J, 1997, 4 C RETR OPP INF 22; *MERR WEBS, 1981, WEBST 3 NEW INT DICT; Milch R A, 1996, Am J Hosp Palliat Care, V13, P46, DOI 10.1177/104990919601300314; Miller NH, 1997, CIRCULATION, V95, P1085; MITCHELL RS, 1967, NEW ENGL J MED, V276, P905, DOI 10.1056/NEJM196704202761606; MOHLER DN, 1955, NEW ENGL J MED, V252, P1116, DOI 10.1056/NEJM195506302522604; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MONTOUH L, 1996, P NATL ACAD SCI USA, V93, P6106; MUSHLIN AI, 1977, ARCH INTERN MED, V137, P318, DOI 10.1001/archinte.137.3.318; *NEW YORK STAT DEP, 1998, TREATM ADH PEOPL HIV; NORELL SE, 1981, SOC SCI MED-MED PSYC, V15, P57, DOI 10.1016/0271-5384(81)90063-6; NORTHROP C, 1952, PUBLIC HEALTH REP, V67, P894, DOI 10.2307/4588233; PablosMendez A, 1997, AM J MED, V102, P164, DOI 10.1016/S0002-9343(96)00402-0; Pilote L, 1996, ARCH INTERN MED, V156, P161, DOI 10.1001/archinte.156.2.161; PRAGOFF H, 1962, PUBLIC HEALTH REP, V77, P671, DOI 10.2307/4591596; PROBSTFIELD JL, 1991, PATIENT COMPLIANCE M, P323; ROSENSTOCK IM, 1975, JAMA-J AM MED ASSOC, V234, P402, DOI 10.1001/jama.234.4.402; Roter D L, 1994, JAMA, V271, P80, DOI 10.1001/jama.271.1.80; Rothman S M, 1993, J Law Med Ethics, V21, P289, DOI 10.1111/j.1748-720X.1993.tb01253.x; RUBEL AJ, 1992, PUBLIC HEALTH REP, V107, P626; RUDD P, 1989, CLIN PHARMACOL THER, V46, P169, DOI 10.1038/clpt.1989.122; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SACKETT DL, 1975, LANCET, V1, P1205; Sackett DL, 1976, COMPLIANCE THERAPEUT; SAMET JH, 1992, AM J MED, V92, P495, DOI 10.1016/0002-9343(92)90746-X; SAMUELS JE, 1990, J ACQ IMMUN DEF SYND, V3, P877; Sbarbaro J A, 1994, Semin Respir Infect, V9, P120; Senak M, 1997, J Int Assoc Physicians AIDS Care, V3, P45; SLUTKIN G, 1986, PUBLIC HEALTH REP, V101, P481; Sontag Deborah, 1997, N Y Times Web, pB6; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; TELLER ME, 1988, TUBERCULOSIS MOVEMEN, P93; TROSTLE JA, 1988, SOC SCI MED, V27, P1299, DOI 10.1016/0277-9536(88)90194-3; URQUHART J, 1992, POSTGRAD MED J, V68, pS49; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; Voelker R, 1996, JAMA-J AM MED ASSOC, V275, P743, DOI 10.1001/jama.275.10.743; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; WILLIFORD SL, 1995, MIL MED, V160, P561, DOI 10.1093/milmed/160.11.561; WINSLOW CE, 1929, PHYSICIAN STATESMAN, P131; 1997, HIV NEWSLINE, V3, P65	93	102	103	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					573	578		10.7326/0003-4819-129-7-199810010-00012	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123KN	9758579				2022-12-28	WOS:000076124500010
J	Littlewood, R				Littlewood, R			Cultural variation in the stigmatisation of mental illness	LANCET			English	Editorial Material							SCHIZOPHRENIA		Univ London Univ Coll, Dept Anthropol, London WC1E 6BT, England; Univ London Univ Coll, Dept Psychiat, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Littlewood, R (corresponding author), Univ London Univ Coll, Dept Anthropol, Gower St, London WC1E 6BT, England.							Askenasy A, 1974, ATTITUDES MENTAL PAT; Ben-Tovim David, 1987, DEV PSYCHIAT MENTAL; COHEN A, 1992, CULT MED PSYCHIAT, V16, P53, DOI 10.1007/BF00054439; COOPER J, 1977, BRIT J PSYCHIAT, V130, P50, DOI 10.1192/bjp.130.1.50; EDGERTON RB, 1966, AM ANTHROPOL, V66, P408; ELISLAM MF, 1979, BRIT J PSYCHIAT, V135, P343, DOI 10.1192/bjp.135.4.343; Horwitz AV., 1982, SOCIAL CONTROL MENTA; HUNT SM, 1991, CROSS CULTURAL MEASU; LEFLEY HP, 1990, HOSP COMMUNITY PSYCH, V41, P277; LI CM, 1981, INSANITY IMPERIAL CH; LITTLEWOOD R, 1988, SOC SCI MED, V27, P129, DOI 10.1016/0277-9536(88)90322-X; McDaniel June, 1989, MADNESS SAINTS ECSTA; MURPHY HBM, 1976, TRANSCULT PSYCHIAT, V13, P49; Scheper-Hughes N., 1979, SAINTS SCHOLARS SCHI; SCHEPERHUGHES N, 1987, CULT MED PSYCHIAT, V11, P53, DOI 10.1007/BF00055009; TOWNSEND J M, 1979, Culture Medicine and Psychiatry, V3, P205, DOI 10.1007/BF00114611; Warner R., 1994, RECOVERY SCHIZOPHREN; WAXLER NE, 1976, CULTURE BOUND SYNDRO; WIG NN, 1980, ACTA PSYCHIAT SCAND, V61, P111, DOI 10.1111/j.1600-0447.1980.tb00571.x	19	41	44	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1056	1057		10.1016/S0140-6736(98)07471-6	http://dx.doi.org/10.1016/S0140-6736(98)07471-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759770				2022-12-28	WOS:000076121800049
J	Rahman, A; Mubbashar, MH; Gater, R; Goldberg, D				Rahman, A; Mubbashar, MH; Gater, R; Goldberg, D			Randomised trial of impact of school mental-health programme in rural Rawalpindi, Pakistan	LANCET			English	Article								Background A school mental-health programme has been developed as a component of the community mental-health programme in Rawalpindi, Pakistan. It has the objective of improving the understanding of disorders of mental health in the rural community. We aimed to assess the impact of a school mental-health programme on the awareness of schoolchildren, their parents, friends who were not attending school, and neighbours. Methods We chose two secondary schools for boys and two for girls that were similar in terms of size, staff-pupil ratio, and dropout rates. 100 children aged 12-16 years (25 girls and 25 boys in each of the study and control groups), 100 parents tone for each child), 100 friends who did not attend school tone for each child), and 100 neighbours tone for each child) were given a 19-item questionnaire before and after the study group had had a 4-month programme of mental-health education. The maximum score for the questionnaire was 16 points. Findings Before the school mental-health programme the awareness of mental-health issues was poor (mean score 5.7-7.6) in the four groups of participants. In the study group there was a significant improvement iri the mean scores after the school programme in the schoolchildren (mean improvement 7.6 [95% CI 6.7-8.5], p<0.01), their parents (5.3 [4.5-6.1], p<0.01), friends (5.1 [4.1-6.1], p<0.01), and neighbours (3.4 [2.6-4.2], p<0.01). In the control group the difference in awareness was significant only in schoolchildren (1.5 [0.5-2.3], p=0.01) and their friends (0.8 [0.3-1.3], p<0.01). Interpretation The school programme succeeded in improving awareness of mental health in schoolchildren and the community. The schoolchildren were receptive to the programme, and shared their new understanding with family, friends, and neighbours. Mental-health planners who wish to improve community awareness of mental health, particularly in areas with low literacy rates, should consider setting up school mental-health programmes.	Rawalpindi Med Coll, Inst Psychiat, WHO, Collaborating Ctr Mental Hlth Res & Training, Rawalpindi, Pakistan; Univ Manchester, Manchester Royal Infirm, Sch Psychiat & Behav Sci, Manchester M13 9WL, Lancs, England; Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England; Inst Psychiat, London, England	National University of Sciences & Technology - Pakistan; Rawalpindi Medical College; World Health Organization; University of Manchester; Royal Manchester Children's Hospital; University of London; King's College London	Mubbashar, MH (corresponding author), Rawalpindi Med Coll, Inst Psychiat, WHO, Collaborating Ctr Mental Hlth Res & Training, Rawalpindi, Pakistan.							ELDIN AS, 1991, E MED HLTH SERVICES, V11, P24; GOLDBERG D, 1989, LANCET, V2, P1445; GOLDBERG D, 1987, LANCET, V1, P736; GOLDBERG D, 1992, LANCET, V39, P114; Good B, 1994, MED RATIONALITY EXPE; KNIGHT L, 1985, CHILD CARE HLTH DEV, V11, P81; LANDERS C, 1991, YB EARLY CHILDHOOD E, V2; Lynagh M, 1997, HEALTH PROMOT INT, V12, P43, DOI 10.1093/heapro/12.1.43; Mubbashar M. H., 1986, E MED HLTH SERVICES, V1, P14; MUBBASHAR MH, 1989, E MEDITERR HEALTH J, V6, P14; *PLANN COMM SUBW G, 1987, 7 5 YEAR PLAN 1988 9; ROHDE JE, 1980, LANCET, V1, P1350; *WHO, 1975, WHO TECHN REP SER, V564; *WHO, 1997, WHO TECHN REP SER, V0870; Yoder PS, 1997, MED ANTHROPOL Q, V11, P131, DOI 10.1525/maq.1997.11.2.131	15	95	95	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1022	1025		10.1016/S0140-6736(98)02381-2	http://dx.doi.org/10.1016/S0140-6736(98)02381-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759745				2022-12-28	WOS:000076121800011
J	Kunz, R; Oxman, AD				Kunz, R; Oxman, AD			The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials	BRITISH MEDICAL JOURNAL			English	Article							DESIGN AFFECTS OUTCOMES; HISTORICAL CONTROLS; PUBLICATION BIAS; METAANALYSIS; THERAPY; QUALITY; ASSIGNMENT; PREVENTION; MORTALITY; EFFICACY	Objective To summarise comparisons of randomised clinical trials and non-randomised clinical trials, trials with adequately concealed random allocation versus inadequately concealed random allocation, and high quality trials versus low quality trials where the effect of randomisation could not be separated from the effects of other methodological manoeuvres. Design Systematic review Selection criteria Cohorts or meta-analyses of clinical trials that included an empirical assessment of the relation between randomisation and estimates of effect Data sources Cochrane Review Methodology Database, Medline, SciSearch, bibliographies, hand searching of journals, personal communication with methodologists, and the reference lists of relevant articles. Main outcome measures Relation between randomisation and estimates of effect Results Eleven studies that compared randomised controlled trials with non-randomised controlled trials (eight for evaluations of the same intervention and three across different interventions), two studies that compared trials with adequately concealed random allocation and inadequately concealed random allocation, and five studies that assessed the relation between quality scores and estimates of treatment effects, were identified. Failure to use random allocation and concealment of allocation were associated with relative increases in estimates of effects of 150% or more, relative decreases of up to 90%, inversion of the estimated effect and, in some cases, no difference. On average, failure to use randomisation or adequate concealment of allocation resulted in larger estimates of effect due to a poorer prognosis in non-randomly selected control groups compared with randomly selected control groups. Conclusions Failure to use adequately concealed random allocation can distort the apparent effects of care in either direction, causing the effects to seem either larger or smaller than they really are. The size of these distortions can be as large as or larger than the size of the effects that are to be detected.	Natl Inst Publ Hlth, Hlth Serv Res Unit, Oslo, Norway; Charite, Dept Nephrol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Oxman, AD (corresponding author), Natl Inst Publ Hlth, Hlth Serv Res Unit, Oslo, Norway.	andrew.oxman@labmed.uio.no	Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061				AOKI K, 1994, AM J REPROD IMMUNOL, V32, P55; Black N, 1996, BRIT MED J, V312, P1215; Carroll D, 1996, BRIT J ANAESTH, V77, P798, DOI 10.1093/bja/77.6.798; Chalmers I, 1997, J ROY SOC MED, V90, P379; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; CLARKE M, 1998, COCHRANE LIBRARY; *COCHR EMP METH ST, 1998, COCHR LIBR; *COCHR METH WORK G, 1998, COCHR LIBR; Cochrane A.L., 1972, EFFECTIVENESS EFFICI, P20; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; *COMM EV MED TECHN, 1985, ASS MED TECHN, P76; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; DICKSERSIN K, 1993, ONLINE J CURR CLIN T; DIEHL LF, 1986, J CLIN ONCOL, V4, P1114, DOI 10.1200/JCO.1986.4.7.1114; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; Forgie MA, 1998, ARCH INTERN MED, V158, P610, DOI 10.1001/archinte.158.6.610; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; IAONNIDIS JPA, 1998, JAMA-J AM MED ASSOC, V279, P281; IMPERIALE TF, 1990, ANN INTERN MED, V113, P299, DOI 10.7326/0003-4819-113-4-299; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; Kleijnen J, 1997, NONRANDOM REFLECTION, P93; MILLER JN, 1989, STAT MED, V8, P455, DOI 10.1002/sim.4780080409; *NHS CTR REV DISS, 1998, COCHR LIBR; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; Ortiz Z, 1998, J RHEUMATOL, V25, P36; OTTENBACHER K, 1992, CONTROL CLIN TRIALS, V13, P50, DOI 10.1016/0197-2456(92)90029-Y; Oxman A. D., 1998, EVIDENCE BASED PRACT, P91; PYORALA S, 1995, J CLIN ENDOCR METAB, V80, P2795, DOI 10.1210/jc.80.9.2795; REIMOLD SC, 1992, AM HEART J, V124, P924, DOI 10.1016/0002-8703(92)90974-Z; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; STIEB DM, 1990, CAN MED ASSOC J, V142, P719; US Congress Office of Technology Assessment, 1994, OTATCT600, P41; WATSON A, 1994, FERTIL STERIL, V61, P470; Weiss CH., 1998, METHODS STUDYING PRO, V2nd, P229	42	491	501	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1185	1190		10.1136/bmj.317.7167.1185	http://dx.doi.org/10.1136/bmj.317.7167.1185			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794851	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000076963000018
J	Aversa, F; Tabilio, A; Velardi, A; Cunningham, I; Terenzi, A; Falzetti, F; Ruggeri, L; Barbabietola, G; Aristei, C; Latini, P; Reisner, Y; Martelli, MF				Aversa, F; Tabilio, A; Velardi, A; Cunningham, I; Terenzi, A; Falzetti, F; Ruggeri, L; Barbabietola, G; Aristei, C; Latini, P; Reisner, Y; Martelli, MF			Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SEVERE COMBINED IMMUNODEFICIENCY; VERSUS-HOST DISEASE; ALLOGENEIC MARROW; UNRELATED DONORS; GRAFT-REJECTION; ENGRAFTMENT; IRRADIATION; ENHANCEMENT; RECIPIENTS	Background In this study we tried to achieve successful transplantation in patients with acute leukemia with the use of hematopoietic stem cells from donors who shared only one HLA haplotype with the recipient (a "full-haplotype mismatch"). To prevent graft failure, large doses of T-cell-depleted hematopoietic stem cells were transplanted after a conditioning regimen of enhanced myeloablation and immunosuppression was administered to the recipient. Methods Forty-three patients with high-risk acute leukemia who were scheduled for transplantation received total-body irradiation, thiotepa, fludarabine, and antithymocyte globulin. The graft consisted of peripheral-blood progenitor cells that had been mobilized in the donor with recombinant granulocyte colony-stimulating factor and also, in 28 cases, bone marrow. Bone marrow from the donor was depleted of T lymphocytes by processing with soybean agglutinin and E-rosetting. T-cell depletion of peripheral-blood mononuclear cells was achieved by E-rosetting followed by positive selection of CD34+ cells. No post-transplantation prophylaxis against graft-versus-host disease (GVHD) was administered, Results In all the patients, full donor-type engraftment was achieved. In none of the patients who could be evaluated did acute or chronic GVHD develop. Regimen-related toxicity was minimal. Eleven of the 23 patients with acute lymphoblastic leukemia had a relapse, as did 2 of the 20 patients with acute myeloid leukemia. Transplantation-related mortality was 40 percent. After a median follow-up of 18 months (range, 8 to 30), 12 of the 43 patients were alive and free of disease. All surviving patients had a good quality of life. Conclusions The main limitations of transplantation of bone marrow from donors who are matched with the recipient for only one HLA haplotype GVHD and graft failure - can be overcome. Since most patients have a relative with one haplotype mismatch, advances in this method will increase the availability of hematopoietic-cell transplantation as curative therapy for acute leukemia. (N Engl J Med 1998;339:1186-93.) (C) 1998, Massachusetts Medical Society.	Univ Perugia, Dept Internal & Expt Med, Hematopoiet Stem Cell Transplant Program, I-06100 Perugia, Italy; Univ Perugia, Dept Radiotherapy, I-06100 Perugia, Italy; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	University of Perugia; University of Perugia; Weizmann Institute of Science	Aversa, F (corresponding author), Univ Perugia, Monteluce Policlin, Ist Ematol, Via Brunamonti, I-06100 Perugia, Italy.		Reisner, Yair/AAA-4772-2019	Reisner, Yair/0000-0002-3354-6945; Aversa, Franco/0000-0002-8871-6817				ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; ANASETTI C, 1995, ANNU REV MED, V46, P169; AVERSA F, 1994, BLOOD, V84, P3948, DOI 10.1182/blood.V84.11.3948.bloodjournal84113948; BACHARLUSTIG E, 1995, NAT MED, V1, P1268, DOI 10.1038/nm1295-1268; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BEATTY PG, 1995, TRANSPLANTATION, V60, P778, DOI 10.1097/00007890-199510270-00003; BERENSON RJ, 1990, PROG CLIN BIOL RES, V333, P403; CHAMPLIN R, 1993, BONE MARROW TRANSPL, V11, P74; Ciccone E, 1996, IMMUNOL TODAY, V17, P450, DOI 10.1016/0167-5699(96)30054-V; CLIFT RA, 1990, BLOOD, V76, P1867; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; COTTLERFOX M, 1995, EXP HEMATOL, V23, P320; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; GALE RP, 1986, LANCET, V1, P1468; Gerritsen EJA, 1996, BONE MARROW TRANSPL, V18, P377; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KAUFMAN CL, 1994, BLOOD, V84, P2436; KERNAN NA, 1987, TRANSPLANTATION, V43, P842, DOI 10.1097/00007890-198743060-00014; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Lamparelli T, 1997, BONE MARROW TRANSPL, V20, P1057, DOI 10.1038/sj.bmt.1701031; LAPIDOT T, 1990, P NATL ACAD SCI USA, V87, P4595, DOI 10.1073/pnas.87.12.4595; LAPIDOT T, 1992, BLOOD, V80, P2406; LUBIN I, 1995, TRANSPLANTATION, V60, P740, DOI 10.1097/00007890-199510150-00022; MARMONT AM, 1991, BLOOD, V78, P2120, DOI 10.1182/blood.V78.8.2120.bloodjournal7882120; MARTIN PJ, 1990, BONE MARROW TRANSPL, V6, P283; O'Reilly R J, 1996, Important Adv Oncol, P149; PETERSEN FB, 1994, BONE MARROW TRANSPL, P79; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Rachamim N, 1998, TRANSPLANTATION, V65, P1386, DOI 10.1097/00007890-199805270-00017; REISNER Y, 1983, BLOOD, V61, P341; REISNER Y, 1986, P NATL ACAD SCI USA, V83, P4012, DOI 10.1073/pnas.83.11.4012; REISNER Y, 1995, IMMUNOL TODAY, V16, P437, DOI 10.1016/0167-5699(95)80021-2; REISNER Y, 1986, TRANSPLANTATION, V42, P312; Reisner Y., 1997, Blood, V90, p563A; REISNER Y, 1988, SERONO S REV, V13, P37; Rothberg PG, 1997, CLIN LAB MED, V17, P109, DOI 10.1016/S0272-2712(18)30235-X; SCHMIDT J, 1994, IMMUNOPHARMACOLOGY, V27, P173, DOI 10.1016/0162-3109(94)90013-2; SIENA S, 1991, BLOOD, V77, P400; Sierra J, 1997, BLOOD, V89, P4226, DOI 10.1182/blood.V89.11.4226; SOIFFER RJ, 1991, BONE MARROW TRANSPL, V7, P23; STROBER S, 1987, J IMMUNOL, V138, P699; Tabilio A, 1997, J HEMATOTHER, V6, P227, DOI 10.1089/scd.1.1997.6.227; TERENZI A, 1990, TRANSPLANTATION, V50, P717; TERENZI A, 1996, BONE MARROW TRANS S1, V17, pS11; THOMAS ED, 1983, J CLIN ONCOL, V1, P517, DOI 10.1200/JCO.1983.1.9.517; THOMAS JM, 1995, TRANSPLANTATION, V59, P245, DOI 10.1097/00007890-199501270-00017; Uchida N, 1998, J CLIN INVEST, V101, P961, DOI 10.1172/JCI1681; UrbanoIspizua A, 1997, BLOOD, V89, P3967, DOI 10.1182/blood.V89.11.3967; VELARDI A, 1990, BLOOD, V75, P1364; Velardi A., 1996, Blood, V88, p267A; WOODS WG, 1990, BONE MARROW TRANSPL, V6, P9	53	917	980	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1186	1193		10.1056/NEJM199810223391702	http://dx.doi.org/10.1056/NEJM199810223391702			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780338				2022-12-28	WOS:000076532400002
J	Lattimer, V; George, S; Thompson, F; Thomas, E; Mullee, M; Turnbull, J; Smith, H; Moore, M; Bond, H; Glasper, A				Lattimer, V; George, S; Thompson, F; Thomas, E; Mullee, M; Turnbull, J; Smith, H; Moore, M; Bond, H; Glasper, A		S Wiltshire Out Hours Project Grp	Safety and effectiveness of nurse telephone consultation in out of hours primary care: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY MEDICAL-CARE; EMERGENCY; ADVICE; ACCIDENT; CALLS	Objective To determine the safety and effectiveness of nurse telephone consultation in out of hours primary care by investigating adverse events and the management of calls. Design Block randomised controlled trial over a year of 156 matched pairs of days and weekends in 26 blocks. One of each matched pair was randomised to receive the intervention. Setting One 55 member general practice cooperative serving 97 000 registered patients in Wiltshire. Subjects All patients contacting the out of hours service or about whom contact was made during specified times over the trial year. Intervention A nurse telephone consultation service integrated within a general practice cooperative. The out of hours period was 6 15 pm to 11 15 pm from Monday to Friday, 11 00 am to 11 15 pm on Saturday, and 8 00 am to 11 15 pm on Sunday. Experienced and specially trained nurses received, assessed, and managed calls from patients or their carers. Management options included telephone advice; referral to the general practitioner on duty (for telephone advice, an appointment at a primary care centre, or a home visit); referral to the emergency service or advice to attend accident and emergency. Calls were managed with the help of decision support software. Main outcome measures Deaths within seven days of a contact with the out of hours service; emergency hospital admissions within 24 hours and within three days of contact; attendance at accident and emergency within three days of a contact; number and management of calls in each arm of the trial. Results 14 492 calls were received during the specified times in the trial pear (7308 in the control,, and 7184 in the intervention arm) concerning 10 134 patients (10.4% of the registered population). There were no substantial differences in the age and sex of patients in the intervention and control groups, though male patients were underrepresented overall. Reasons for calling the service were consistent with previous studies. Nurses managed 49.8% of calls during intervention periods without referral to a general practitioner. A 69% reduction in telephone advice from a general practitioner, together with a 38% reduction in patient attendance at primary care centres and a 23% reduction in home visits was observed during intervention periods. Statistical equivalence was observed in the number of deaths within seven days, in the number of emergency hospital admissions, and in the number of attendances at accident and emergency departments, Conclusions Nurse telephone consultation produced substantial changes in call management, reducing overall workload of general practitioners by 50% while allowing callers faster access to health information and advice. It was not associated with an increase in the number of adverse events. This model of out of hours primary care is safe and effective.	Univ Southampton, Sch Med, Southampton SO16 6YD, Hants, England; Univ Southampton, Wessex Inst Hlth Res & Dev, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	George, S (corresponding author), Univ Southampton, Southampton Gen Hosp, Hlth Care Res Unit, Mailpoint 805,Level B,S Acad Block, Southampton SO16 6YD, Hants, England.	pluto@soton.ac.uk	Smith, Helen E/M-2449-2016; Moore, Michael/C-3447-2011	Smith, Helen E/0000-0003-1883-6124; Moore, Michael/0000-0002-5127-4509; Turnbull, Joanne/0000-0002-5006-4438				[Anonymous], 1993, SPSS WINDOWS BASE SY; BEECHAM L, 1993, BRIT MED J, V307, P1375; BRADLEY SB, 1974, J PEDIATR, V84, P117; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; *CENTR STAT OFF, 1995, SOC TRENDS, V25; Christensen MB, 1998, BMJ-BRIT MED J, V316, P1502, DOI 10.1136/bmj.316.7143.1502; *COLL HLTH, 1998, DEV NHS DIR; CROUCH R, 1996, RINGING CHANGES DEV; *DEP HLTH, 1998, CM3807; EVANS RJ, 1993, ARCH EMERG MED, V10, P216; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GREITZER L, 1976, J PEDIATR-US, V88, P880, DOI 10.1016/S0022-3476(76)81137-7; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; ISAACMAN DJ, 1992, PEDIATRICS, V89, P35; JAMES MR, 1989, ARCH EMERG MED, V6, P241; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Lattimer V, 1996, BRIT MED J, V312, P352; Lattimer V, 1997, BRIT MED J, V314, P198; Lattimer V, 1996, PRIMARY CARE MANAGEM, V6, P3; LEPROHON J, 1995, MED DECIS MAKING, V15, P240, DOI 10.1177/0272989X9501500307; MARKLUND B, 1989, FAM PRACT, V6, P42, DOI 10.1093/fampra/6.1.42; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; *NAT HLTH SERV EX, 1996, DEV EM SERV COMM, V1; *NAT HLTH SERV EX, 1996, DEV EM SERV COMM, V2; *OFF NAT STAT, 1998, PUBL HLTH MORT FIL 1; OTT JE, 1974, J MED EDUC, V49, P596; PERRIN EC, 1978, NEW ENGL J MED, V298, P130, DOI 10.1056/NEJM197801192980304; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SINGH G, 1991, J ROY SOC MED, V84, P345, DOI 10.1177/014107689108400613; SOMAN M, 1984, J FAM PRACTICE, V19, P329; WHEELER S, 1993, TELEPHONE TRIAGE THE; WILKINS VC, 1993, J NURS ADMIN, V23, P26, DOI 10.1097/00005110-199303000-00008; YANOVSKI SZ, 1992, PEDIATRICS, V89, P701	33	199	202	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	1998	317	7165					1054	1059						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774295				2022-12-28	WOS:000076577200029
J	Moynihan, C				Moynihan, C			Theories in health care and research - Theories of masculinity	BRITISH MEDICAL JOURNAL			English	Article							GENDER DIFFERENCES; SEX-DIFFERENCES; FEMININITY		Inst Canc Res, Sutton SM2 5PT, Surrey, England; Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Moynihan, C (corresponding author), Inst Canc Res, Sutton SM2 5PT, Surrey, England.							Allison KR, 1997, CAN J PUBLIC HEALTH, V88, P177, DOI 10.1007/BF03403883; ANNANDALE E, 1990, SOCIOL HEALTH ILL, V12, P24, DOI 10.1111/1467-9566.ep10844865; BEM SL, 1974, J CONSULT CLIN PSYCH, V42, P155, DOI 10.1037/h0036215; Docherty Thomas, 1993, POSTMODERNISM READER; Edley N., 1995, MEN PERSPECTIVE PRAC; HEARN J, 1994, AUST NZ J SOCIOL, V30, P47; KAPLAN MS, 1995, SOCIOL HEALTH ILL, V17, P206, DOI 10.1111/1467-9566.ep10933391; Kilmartin C.T, 1994, THE MASCULINE SELF; KING D, 1996, BLENDING GENDERS SOC, P79; KORZENNY F, 1988, AIDS COMUNICATION BE; MacIntyre S, 1996, SOC SCI MED, V42, P617, DOI 10.1016/0277-9536(95)00335-5; MECHANIC D, 1978, SOC SCI MED-MED ANTH, V12, P207, DOI 10.1016/0160-7987(78)90034-0; MITCHELL CL, 1987, SEX ROLES, V16, P151, DOI 10.1007/BF00289646; Moynihan C, 1998, BMJ-BRIT MED J, V316, P429, DOI 10.1136/bmj.316.7129.429; MOYNIHAN C, 1987, CANCER SURV, V6, P477; Ramirez AJ, 1996, LANCET, V347, P724, DOI 10.1016/S0140-6736(96)90077-X; Seidler V., 1994, UNREASONABLE MEN; SEIDLER VJ, 1995, MAPPING SUBJECT GEOG, P170; SINNOT JD, 1986, SEX ROLES AGING THEO; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Stoltenberg J, 1989, REFUSING BE MAN ESSA; Thompson N., 1997, DEATH GENDER ETHNICI, P76; VERBRUGGE L, 1985, J HEALTH SOC BEHAV, V26, P1156	23	137	139	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1072	1075						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131LH	9774301				2022-12-28	WOS:000076577200035
J	Lau, AY; Scharer, OD; Samson, L; Verdine, GL; Ellenberger, E				Lau, AY; Scharer, OD; Samson, L; Verdine, GL; Ellenberger, E			Crystal structure of a human alkylbase-DNA repair enzyme complexed to DNA: Mechanisms for nucleotide flipping and base excision	CELL			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; 3-METHYLADENINE-DNA GLYCOSYLASE; ENDONUCLEASE-III; ALKA GENE; OGG1 GENE; PROTEIN; CLONING; 1,N-6-ETHENOADENINE; SEQUENCE	DNA N-glycosylases are base excision-repair proteins that locate and cleave damaged bases from DNA as the first step in restoring the genetic blueprint. The human enzyme 3-methyladenine DNA glycosylase removes a diverse group of damaged bases from DNA, including cytotoxic and mutagenic alkylation adducts of purines. We report the crystal structure of human 3-methyladenine DNA glycosylase complexed to a mechanism-based pyrrolidine inhibitor. The enzyme has intercalated into the minor groove of DNA, causing the abasic pyrrolidine nucleotide to flip into the enzyme active site, where a bound water is poised for nucleophilic attack. The structure shows an elegant means of exposing a nucleotide for base excision as well as a network of residues that could catalyze the in-line displacement of a damaged base from the phosphodeoxyribose backbone.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Harvard Univ, Grad Program Biophys, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Erasmus University Rotterdam; Harvard University	Ellenberger, E (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	tome@jeckle.med.harvard.edu	Schärer, Orlando D./AAF-8613-2021; Scharer, Orlando/B-8908-2008	Scharer, Orlando/0000-0003-2425-2715; Lau, Albert/0000-0002-0967-7558				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1998, IN PRESS ACTA CRYST; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; CLARKE ND, 1984, MOL GEN GENET, V197, P368, DOI 10.1007/BF00329931; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Ezaz-Nikpay K, 1994, Chem Biol, V1, P235, DOI 10.1016/1074-5521(94)90016-7; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; FRIEDBERG EC, 1995, DNA REPAIR MUTAGNESI; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Hang B, 1996, CARCINOGENESIS, V17, P155, DOI 10.1093/carcin/17.1.155; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; Jones T. A., 1992, MANUAL; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Krokan HE, 1997, BIOCHEM J, V325, P1; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEONARD GA, 1994, BIOCHEMISTRY-US, V33, P4755, DOI 10.1021/bi00182a002; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Mattes WB, 1996, CARCINOGENESIS, V17, P643, DOI 10.1093/carcin/17.4.643; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Memisoglu A, 1996, GENE, V177, P229, DOI 10.1016/0378-1119(96)00308-3; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SANTERRE A, 1994, P NATL ACAD SCI USA, V91, P2240, DOI 10.1073/pnas.91.6.2240; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; SCHRAMM VL, 1994, J BIOL CHEM, V269, P18259; Singer B., 1983, MOL BIOL MUTAGENS CA; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Taverna P, 1996, J BACTERIOL, V178, P5105, DOI 10.1128/jb.178.17.5105-5111.1996; TERWILLIGER TC, 1997, SOLVE; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; WEIBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842; XUAN JC, 1992, NUCLEIC ACIDS RES, V20, P5457, DOI 10.1093/nar/20.20.5457; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6	86	262	268	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					249	258		10.1016/S0092-8674(00)81755-9	http://dx.doi.org/10.1016/S0092-8674(00)81755-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790531	Bronze			2022-12-28	WOS:000076538300012
J	Viard, I; Wehrli, P; Bullani, R; Schneider, P; Holler, N; Salomon, D; Hunziker, T; Saurat, JH; Tschopp, J; French, LE				Viard, I; Wehrli, P; Bullani, R; Schneider, P; Holler, N; Salomon, D; Hunziker, T; Saurat, JH; Tschopp, J; French, LE			Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin	SCIENCE			English	Article							STEVENS-JOHNSON SYNDROME; FAS LIGAND; CULTURED KERATINOCYTES; IMMUNE GLOBULIN; APOPTOSIS; EXPRESSION; CELLS; ANTIGEN; INVOLVEMENT; MULTIFORME	Toxic epidermal necrolysis (TEN, Lyell's syndrome) is a severe adverse drug reaction in which keratinocytes die and Large sections of epidermis separate from the dermis. Keratinocytes normally express the death receptor Fas (CD95); those from TEN patients were found ro express lytically active Fas ligand (FasL). Antibodies present in pooled human intravenous immunoglobulins (IVIG) blocked Fas-mediated keratinocyte death in vitro. In a pilot study, 10 consecutive individuals with clinically and histologically confirmed TEN were treated with IVIG; disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIG may be an effective treatment.	Univ Geneva, Sch Med, Dept Dermatol, CH-1211 Geneva 4, Switzerland; Univ Lausanne, BIL Res Ctr, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Bern, Sch Med, Dept Dermatol, CH-3010 Bern, Switzerland	University of Geneva; University of Lausanne; University of Bern	French, LE (corresponding author), Univ Geneva, Sch Med, Dept Dermatol, CH-1211 Geneva 4, Switzerland.	french@cmu.unige.ch	French, Lars/AAL-5977-2020	French, Lars/0000-0002-4629-1486; Schneider, Pascal/0000-0003-0677-9409				Andersson J, 1996, CLIN EXP IMMUNOL, V104, P10, DOI 10.1111/cei.1996.104.s1.10; Baker MB, 1996, J EXP MED, V183, P2645, DOI 10.1084/jem.183.6.2645; Berthou C, 1997, J IMMUNOL, V159, P5293; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; BUECHNER SA, 1997, NAT MED, V100, P2691; CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43; CHAN HL, 1995, ARCH DERMATOL, V131, P1212, DOI 10.1001/archderm.131.10.1212; DWYER JM, 1992, NEW ENGL J MED, V326, P107; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Jolles S, 1998, ARCH DERMATOL, V134, P80, DOI 10.1001/archderm.134.1.80; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LEITHAUSER F, 1993, LAB INVEST, V69, P415; MATSUE H, 1995, ARCH DERMATOL RES, V287, P315, DOI 10.1007/BF01105085; OISHI M, 1994, ARCH DERMATOL RES, V286, P396, DOI 10.1007/BF00371800; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; ROUJEAU JC, 1990, ARCH DERMATOL, V126, P37, DOI 10.1001/archderm.126.1.37; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; Rzany B, 1996, J CLIN EPIDEMIOL, V49, P769, DOI 10.1016/0895-4356(96)00035-2; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; SCHOPF E, 1991, ARCH DERMATOL, V127, P839, DOI 10.1001/archderm.127.6.839; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STROM BL, 1991, ARCH DERMATOL, V127, P831, DOI 10.1001/archderm.127.6.831; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Terskikh AV, 1997, P NATL ACAD SCI USA, V94, P1663, DOI 10.1073/pnas.94.5.1663; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; VIARD I, UNPUB	34	777	825	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					490	493		10.1126/science.282.5388.490	http://dx.doi.org/10.1126/science.282.5388.490			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774279				2022-12-28	WOS:000076479600059
J	Daviglus, ML; Liu, KA; Greenland, P; Dyer, AR; Garside, DB; Manheim, L; Lowe, LP; Rodin, M; Lubitz, J; Stamler, J				Daviglus, ML; Liu, KA; Greenland, P; Dyer, AR; Garside, DB; Manheim, L; Lowe, LP; Rodin, M; Lubitz, J; Stamler, J			Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; CARE; MORTALITY; PATTERNS; ACCURACY; WOMEN; DEATH; MEN	Background People without major risk factors for cardiovascular disease in middle age live longer than those with unfavorable risk-factor profiles. it is not known whether such low-risk status also results in lower expenditures for medical care at older ages. We used data from the Chicago Heart Association Detection Project in Industry to assess the relation of a low risk of cardiovascular disease in middle age to Medicare expenditures later in life. Methods We studied 7039 men and 6757 women who were 40 to 64 years of age when surveyed between 1967 and 1973 and who survived to have at least two years of Medicare coverage in 1984 through 1994. Men and women classified as being at low risk for cardiovascular disease were those who had the following characteristics at the time they were initially surveyed: serum cholesterol level, <200 mg per deciliter (5.2 mmol per liter); blood pressure, less than or equal to 120/80 mm Hg; no current smoking; an absence of electrocardiographic abnormalities; no history of diabetes; and no history of myocardial infarction. We compared Medicare costs for the 279 men (4.0 percent) and 298 women (4.4 percent) who had this low-risk profile with those for the rest of the study group, who were not at low risk. Health Care Financing Administration charges for services to Medicare beneficiaries were used to estimate average annual health care costs (total costs, those for cardiovascular diseases, and those for cancer). Results Average annual health care charges were much lower for persons at low risk - the total charges for the men at low risk were less than two thirds of the charges for the men not at low risk($1,615 less); for the women at low risk, the charges were less than one half of those far the women not at low risk ($1,885 less). Charges related to cardiovascular disease were lower for the low-risk groups of men and women than for those nor at low risk (by $979 and $556, respectively), and charges related to cancer were also lower (by $134 and $189). Conclusions People with favorable cardiovascular risk profiles in middle age had lower average annual Medicare charges in older age. Having optimal status with respect to major cardiovascular risk factors may result nor only in greater longevity but also in lower health care costs. (N Engl J Med 1998;339: 1122-9.) (C) 1998, Massachusetts Medical Society.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Div Geriatr, Chicago, IL 60611 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Evanston, IL USA; Hlth Care Financing Adm, Off Res & Demonstrat, Baltimore, MD USA	Northwestern University; Northwestern University; Northwestern University	Daviglus, ML (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.		Greenland, Philip/ABD-5528-2021		NHLBI NIH HHS [HL03387, HL21010] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K14HL003387, R01HL021010] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BERTERA RL, 1991, J OCCUP ENVIRON MED, V33, P1119, DOI 10.1097/00043764-199111000-00006; BLAUM CS, 1994, J AM GERIATR SOC, V42, P1087, DOI 10.1111/j.1532-5415.1994.tb06214.x; *BUR CENS, 1996, STAT ABSTR US 1996, P486; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Committee on Diet and Health, 1989, DIET HLTH IMPL RED C; COX DR, 1972, J R STAT SOC B, V34, P187; *DEPT HLTH HUM SER, 1980, DHHS PUBL; Dyer A R, 1992, Ann Epidemiol, V2, P51, DOI 10.1016/1047-2797(92)90037-Q; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; GREENE VL, 1990, J GERONTOL, V45, P250; HLATKY MA, 1990, CIRCULATION, V82, P208; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; HULKA BS, 1985, MED CARE, V23, P438, DOI 10.1097/00005650-198505000-00009; Inter-Society Commission for Heart Disease Resources Atherosclerosis Study Group and Epidemiology Study Group, 1970, CIRCULATION, V42, pA55; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2538, DOI 10.1001/jama.258.18.2538; LEIGH JP, 1992, INQUIRY-J HEALTH CAR, V29, P44; LEVINE JB, 1964, CLIN CHIM ACTA, V10, P381, DOI 10.1016/0009-8981(64)90073-7; Levit KR, 1996, HEALTH CARE FINANC R, V18, P175; LIU K, 1978, J CHRON DIS, V31, P399, DOI 10.1016/0021-9681(78)90004-8; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; *MILL ROB, 1987, HLTH RISKS BEH IMP M; *NAT HEART LUNG BL, 1994, TASK FORC RES EP PRE; NATHANSON CA, 1977, SOC SCI MED, V11, P13, DOI 10.1016/0037-7856(77)90141-X; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; PRINEAS RJ, 1983, HYPERTENSION, V5, P160; SCHAUFFLER HH, 1993, AM J PREV MED, V9, P146, DOI 10.1016/S0749-3797(18)30730-X; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; STAMLER J, 1991, CARDIOLOGY ILLUSTRAT, V2; Stamler J, 1992, CORONARY HEART DIS E, P35; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; WOLINSKY FD, 1992, J GERONTOL, V47, pS173, DOI 10.1093/geronj/47.4.S173; Yen L T, 1991, Am J Health Promot, V6, P46; [No title captured]	37	135	138	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1122	1129		10.1056/NEJM199810153391606	http://dx.doi.org/10.1056/NEJM199810153391606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129DP	9770560	Bronze			2022-12-28	WOS:000076448200006
J	DahlJensen, D; Mosegaard, K; Gundestrup, N; Clow, GD; Johnsen, SJ; Hansen, AW; Balling, N				DahlJensen, D; Mosegaard, K; Gundestrup, N; Clow, GD; Johnsen, SJ; Hansen, AW; Balling, N			Past temperatures directly from the Greenland Ice Sheet	SCIENCE			English	Article							BORE-HOLE SURVEY; SOUTH GREENLAND; HEAT-FLOW; CLIMATE; TRANSITION; SIGNAL; DOME	A Monte Carlo inverse method has been used on the temperature profiles measured down through the Greenland Ice Core Project (GRIP) borehole, at the summit of the Greenland Ice Sheet, and the Dye 3 borehole 865 kilometers farther south. The result is a 50,000-year-long temperature history at GRIP and a 7000-year history at Dye 3. The Last Glacial Maximum, the Climatic Optimum, the Medieval Warmth, the Little Ice Age, and a warm period at 1930 A.D. are resolved from the GRIP reconstruction with the amplitudes -23 Kelvin, +2.5 Kelvin, +1 Kelvin, -1 Kelvin, and +0.5 Kelvin, respectively. The Dye 3 temperature is similar to the GRIP history but has an amplitude 1.5 times larger, indicating higher climatic variability there. The calculated terrestrial heat flow density from the GRIP inversion is 51.3 milliwatts per square meter.	Niels Bohr Inst Astron Phys & Geophys, Dept Geophys, DK-2100 Copenhagen OE, Denmark; US Geol Survey, Denver Fed Ctr, Climate Program, Denver, CO 80225 USA; Univ Aarhus, Dept Earth Sci, Geophys Lab, DK-8200 Aarhus N, Denmark	University of Copenhagen; Niels Bohr Institute; United States Department of the Interior; United States Geological Survey; Aarhus University	DahlJensen, D (corresponding author), Niels Bohr Inst Astron Phys & Geophys, Dept Geophys, Juliane Marles Vej 30, DK-2100 Copenhagen OE, Denmark.	ddj@gfy.ku.dk	Dahl-Jensen, Dorthe/N-4401-2016; Dahl-Jensen, Dorthe/AAO-6951-2020; Balling, Niels/A-5292-2012	Dahl-Jensen, Dorthe/0000-0002-1474-1948; Dahl-Jensen, Dorthe/0000-0002-1474-1948; Mosegaard, Klaus/0000-0001-5292-5249				ANKLIN M, 1993, NATURE, V364, P203, DOI 10.1038/364203a0; Barlow LK, 1997, J GEOPHYS RES-OCEANS, V102, P26333, DOI 10.1029/96JC02401; Barry R. G., 1992, ATMOSPHERE WEATHER C; BRINK NWT, 1974, QUATERNARY RES, V4, P429; Clauser C, 1997, J GEOPHYS RES-SOL EA, V102, P18417, DOI 10.1029/96JB03443; CLOW GD, 1992, GLOBAL PLANET CHANGE, V98, P81; Clow GD, 1996, J GLACIOL, V42, P576, DOI 10.3189/S0022143000003555; Cuffey KM, 1997, J GEOPHYS RES-OCEANS, V102, P26383, DOI 10.1029/96JC03981; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; DahlJensen D, 1997, J GLACIOL, V43, P300, DOI 10.3189/S0022143000003245; DAHLJENSEN D, 1986, NATURE, V320, P250, DOI 10.1038/320250a0; DAHLJENSEN D, 1993, P INT INV WORKSH 2 C, P11; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; FIRESTONE J, 1995, J GLACIOL, V41, P39, DOI 10.3189/S0022143000017743; Fisher DA, 1996, NATO ASI SER, V1, P297, DOI DOI 10.1007/978-3-642-61113-1_15; FRICH P, 1996, 961 DMI; Guillou-Frottier L, 1998, J GEOPHYS RES-SOL EA, V103, P7385, DOI 10.1029/98JB00021; GUNDESTRUP NS, 1984, J GLACIOL, V30, P282, DOI 10.3189/S0022143000006109; GUNDESTRUP NS, 1993, COLD REG SCI TECHNOL, V21, P399, DOI 10.1016/0165-232X(93)90015-Z; HAMMER CU, IN PRESS REPORT STRA; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; JOHNSEN SJ, 1992, NATO ASI SER 1, V2, P13; JOHNSEN SJ, 1977, IAHS-AISH PUBL, V118, P388; KEEN RA, 1980, 34 U COL I ARCT ALP; Lamb H.H., 1995, CLIMATE HIST MODERN, P211; Mosegaard K, 1998, INVERSE PROBL, V14, P405, DOI 10.1088/0266-5611/14/3/004; MOSEGAARD K, 1995, J GEOPHYS RES-SOL EA, V100, P12431, DOI 10.1029/94JB03097; Overpeck J, 1997, SCIENCE, V278, P1251, DOI 10.1126/science.278.5341.1251; POLLACK HN, 1993, REV GEOPHYS, V31, P267, DOI 10.1029/93RG01249; Powell W.G., 1988, HDB TERRESTRIAL HEAT, P167, DOI DOI 10.1007/978-94-009-2847-3_5; REX F, 1969, WORLD SURV CLIMATOL, V4, P1; SASS JH, 1972, J GEOPHYS RES, V77, P6435, DOI 10.1029/JB077i032p06435; SHUBERT S, 1990, 100762 NASA; White JWC, 1997, J GEOPHYS RES-OCEANS, V102, P26425, DOI 10.1029/97JC00162	35	689	730	1	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1998	282	5387					268	271		10.1126/science.282.5387.268	http://dx.doi.org/10.1126/science.282.5387.268			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765146				2022-12-28	WOS:000076370200039
J	Werstuck, G; Green, MR				Werstuck, G; Green, MR			Controlling gene expression in living cells through small molecule-RNA interactions	SCIENCE			English	Article							MAMMALIAN-CELLS; TRANSLATION; LIGANDS	Short RNA aptamers that specifically bind to a wide variety of Ligands in vitro can be isolated from randomized pools of RNA. Here it is shown that small molecule aptamers also bound their ligand in vivo, enabling development of a method for controlling gene expression in living cells. Insertion of a small molecule aptamer into the 5' untranslated region of a messenger RNA allowed its translation to be repressible by ligand addition in vitro as well as in mammalian cells. The ability of small molecules to control expression of specific genes could facilitate studies in many areas of biology and medicine.	Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Program Mol Med, 373 Plantat St,Suite 309, Worcester, MA 01605 USA.							ELSTEIN KH, 1994, EXP CELL RES, V211, P322, DOI 10.1006/excr.1994.1094; Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Liu C, 1996, P NATL ACAD SCI USA, V93, P940, DOI 10.1073/pnas.93.2.940; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Paraskeva E, 1998, P NATL ACAD SCI USA, V95, P951, DOI 10.1073/pnas.95.3.951; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SINGH R, 1995, SCIENCE, V268, P173; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Uphoff KW, 1996, CURR OPIN STRUC BIOL, V6, P281, DOI 10.1016/S0959-440X(96)80045-5	14	328	379	3	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					296	298		10.1126/science.282.5387.296	http://dx.doi.org/10.1126/science.282.5387.296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765156				2022-12-28	WOS:000076370200049
J	Dehaene, S; Naccache, L; Le Clec'H, G; Koechlin, E; Mueller, M; Dehaene-Lambertz, G; van de Moortele, PF; Le Bihan, D				Dehaene, S; Naccache, L; Le Clec'H, G; Koechlin, E; Mueller, M; Dehaene-Lambertz, G; van de Moortele, PF; Le Bihan, D			Imaging unconscious semantic priming	NATURE			English	Article							VISUAL MASKING; AWARENESS; ACTIVATION; PERCEPTION	Visual words that are masked and presented so briefly that they cannot be seen may nevertheless facilitate the subsequent processing of related words, a phenomenon called masked priming(1,2). It has been debated whether masked primes can activate cognitive processes without gaining access to consciousness(3-5). Here we use a combination of behavioural and brain-imaging techniques to estimate the depth of processing of masked numerical primes. Our results indicate that masked stimuli have a measurable influence on electrical and haemodynamic measures of brain activity, When subjects engage in an overt semantic comparison task with a clearly visible target numeral, measures of covert motor activity indicate that they also unconsciously apply the task instructions to an unseen masked numeral. A stream of perceptual, semantic and motor processes can therefore occur without awareness.	Serv Hosp Frederic Joliot, INSERM, U334, CEA,DRM,DSV, F-91401 Orsay, France; CNRS, EHESS, Lab Sci Cognit & Psycholinguist, F-75270 Paris 06, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Dehaene, S (corresponding author), Serv Hosp Frederic Joliot, INSERM, U334, CEA,DRM,DSV, 4 Pl Gen Leclerc, F-91401 Orsay, France.		Dehaene, Ghislaine/O-3633-2017; Van de Moortele, Pierre-François/H-5087-2011; Koechlin, Etienne/AAF-5717-2021; Koechlin, Etienne/E-5061-2016	Dehaene, Ghislaine/0000-0003-2221-9081; Van de Moortele, Pierre-François/0000-0002-6941-5947; Koechlin, Etienne/0000-0002-6514-9311; Koechlin, Etienne/0000-0002-6514-9311; naccache, lionel/0000-0002-2874-1009				Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P14878, DOI 10.1073/pnas.93.25.14878; CHEESMAN J, 1984, PERCEPT PSYCHOPHYS, V36, P387, DOI 10.3758/BF03202793; COLES MGH, 1988, BIOL PSYCHOL, V26, P69, DOI 10.1016/0301-0511(88)90014-2; DEHAENE S, 1995, J EXP PSYCHOL LEARN, V21, P314, DOI 10.1037/0278-7393.21.2.314; FORSTER KI, 1984, J EXP PSYCHOL LEARN, V10, P680, DOI 10.1037/0278-7393.10.4.680; HOLENDER D, 1986, BEHAV BRAIN SCI, V9, P1, DOI 10.1017/S0140525X00021269; MARCEL AJ, 1983, COGNITIVE PSYCHOL, V15, P197, DOI 10.1016/0010-0285(83)90009-9; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; MERIKLE PM, 1992, AM PSYCHOL, V47, P792, DOI 10.1037/0003-066X.47.6.792; MILLER J, 1992, J EXP PSYCHOL GEN, V121, P195, DOI 10.1037/0096-3445.121.2.195; Morris JS, 1998, NATURE, V393, P467, DOI 10.1038/30976; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Sahraie A, 1997, P NATL ACAD SCI USA, V94, P9406, DOI 10.1073/pnas.94.17.9406; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B; van Turennout M, 1998, SCIENCE, V280, P572, DOI 10.1126/science.280.5363.572; Whalen PJ, 1998, J NEUROSCI, V18, P411	17	743	763	2	143	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					597	600		10.1038/26967	http://dx.doi.org/10.1038/26967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	127QW	9783584				2022-12-28	WOS:000076362900047
J	Ubel, PA; Caplan, AL				Ubel, PA; Caplan, AL			Geographic favoritism in liver transplantation - Unfortunate or unfair?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES; HEALTH-CARE; RETRANSPLANTATION; PROCUREMENT; EXPERIENCE; EQUITY; ORGAN; ALLOCATION; ATTITUDES; DONATION		Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania	Ubel, PA (corresponding author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.							[Anonymous], 1998, LANCET, V352, P79; Belle S H, 1995, Clin Transpl, P19; Bryce CL, 1998, HEALTH AFFAIR, V17, P213, DOI 10.1377/hlthaff.17.1.213; CAPLAN A, 1998, AM I MY BROTHERS KEE; CRIPPIN J, 1994, TRANSPLANTATION, V57, P823, DOI 10.1097/00007890-199403270-00009; DALESSANDRO AM, 1993, TRANSPLANTATION, V55, P1083, DOI 10.1097/00007890-199305000-00028; GRIFFITH D, 1998, SCARAMENTO BEE  0327, pB1; Hauptman PJ, 1997, NEW ENGL J MED, V336, P422, DOI 10.1056/NEJM199702063360607; Kilner J., 1990, WHO LIVES WHO DIES E; Klassen AC, 1998, MED CARE, V36, P281, DOI 10.1097/00005650-199803000-00006; MECKLER L, 1998, SEVERAL STATES OPPOS; NORD E, 1993, HEALTH POLICY, V24, P227, DOI 10.1016/0168-8510(93)90042-N; NOVELLO AC, 1991, SURG GEN WORKSHOP IN; PACKERTURSMAN J, 1998, PITTSBURGH POST 0618, pA5; POWELSON JA, 1993, TRANSPLANTATION, V55, P802, DOI 10.1097/00007890-199304000-00023; Rawls J., 1971, THEORY JUSTICE; Rovner J, 1998, LANCET, V351, P1041, DOI 10.1016/S0140-6736(05)79016-4; SIMINOFF LA, 1995, J TRAUMA, V39, P553; Siminoff LA, 1996, TRANSPLANT P, V28, P3632; SIMINOFF LA, 1995, ANN INTERN MED, V123, P10, DOI 10.7326/0003-4819-123-1-199507010-00037; SIMMONS RG, 1987, GIFT LIFE; SOUTHARD JH, 1995, ANNU REV MED, V46, P235; Steinbrook R, 1997, NEW ENGL J MED, V336, P436, DOI 10.1056/NEJM199702063360610; STEWARD A, 1998, STAR LEDGER     0505, P28; UBEL PA, 1995, HEALTH POLICY, V34, P145, DOI 10.1016/0168-8510(95)00714-4; Ubel PA, 1996, SOC SCI MED, V42, P1049, DOI 10.1016/0277-9536(95)00216-2; UBEL PA, 1993, JAMA-J AM MED ASSOC, V270, P2469, DOI 10.1001/jama.270.20.2469; Ubel PA, 1996, MED DECIS MAKING, V16, P108, DOI 10.1177/0272989X9601600202; Ubel PA, 1996, MED DECIS MAKING, V16, P234, DOI 10.1177/0272989X9601600307; Ubel PA, 1998, MED DECIS MAKING, V18, P141, DOI 10.1177/0272989X9801800202; Ubel PA, 1996, TRANSPLANT P, V28, P2997; Vix J, 1996, Liver Transpl Surg, V2, P105, DOI 10.1002/lt.500020204; WIKLER D, 1989, TRANSPLANT P, V21, P3437; 1998, SAN FRANCISCO C 0405, P6	34	59	60	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1322	1325		10.1056/NEJM199810293391811	http://dx.doi.org/10.1056/NEJM199810293391811			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	132XC	9791151				2022-12-28	WOS:000076655300011
J	Hirsch, J				Hirsch, J			Fortnightly review - Magic bullet for obesity	BRITISH MEDICAL JOURNAL			English	Review									Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Hirsch, J (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	Hirsch@raockvax.rockefeller.edu						Hirsch J, 1998, AM J CLIN NUTR, V67, P2, DOI 10.1093/ajcn/67.1.2; HIRSCH J, 1994, AM J CLIN NUTR, V60, P658, DOI 10.1093/ajcn/60.5.658; Kassirer JP, 1998, NEW ENGL J MED, V338, P52, DOI 10.1056/NEJM199801013380109; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P615, DOI 10.1038/clpt.1992.73	8	8	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1136	1138						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784455				2022-12-28	WOS:000076755100035
J	Goldberg, J				Goldberg, J			Structural basis for activation of ARF GTPase: Mechanisms of guanine nucleotide exchange and GTP-myristoyl switching	CELL			English	Article							ADP-RIBOSYLATION FACTOR-1; AMINO-ACID-RESIDUES; EF-TS COMPLEX; MEMBRANE PHOSPHOLIPIDS; CRYSTAL-STRUCTURE; RAS; GDP; TU; PROTEINS; PROGRAM	Ras-related GTPases are positively regulated by guanine nucleotide exchange factors (GEFs) that promote the exchange of GDP for GTP. The crystal structure of the Sec7 domain GEF bound to nucleotide-free ARF1 GTPase has been determined at 2.8 Angstrom resolution and the structure of ARF1 in the GTP-analog form determined at 1.6 Angstrom resolution. The Sec7 domain binds to the switch regions of ARF1 and inserts residues directly into the GTPase active site. The interaction leaves the purine-binding site intact but perturbs the Mg2+ and phosphate groups to promote the dissociation of guanine nucleotides. The structure of ARF1 in the GTP-analog form closely resembles Pas, revealing a substantial rearrangement from the GDP conformation. The transition controls the exposure of the myristoylated N terminus, explaining how ARF GTPases couple the GDP-GTP conformational switch to membrane binding.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	jonathan@ximpact4.ski.mskcc.org						Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOUME HR, 1991, NATURE, V349, P117; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI SHY, 1993, COMPUT IND ENG, V25, P13, DOI 10.1016/0360-8352(93)90209-G; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	35	425	428	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					237	248		10.1016/S0092-8674(00)81754-7	http://dx.doi.org/10.1016/S0092-8674(00)81754-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790530	Bronze			2022-12-28	WOS:000076538300011
J	Ding, JX; Yang, L; Yan, YT; Chen, A; Desai, N; Wynshaw-Boris, A; Shen, MM				Ding, JX; Yang, L; Yan, YT; Chen, A; Desai, N; Wynshaw-Boris, A; Shen, MM			Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo	NATURE			English	Article							NEURAL PLATE; PRIMITIVE ENDODERM; GENE; EXPRESSION; MESODERM; GASTRULATION; FAMILY; GROWTH; BRAIN; CELLS	The anterior-posterior axis of the mouse embryo is established by two distinct organizing centres in the anterior visceral endoderm and the distal primitive streak(1-7). These organizers induce and pattern the head and trunk respectively, and have been proposed to be localized through coordinate cell movements that rotate a pre-existing pre-existing proximal-distal axis(6,8). Here we show that correct localization of both head- and trunk-organizing centres requires Cripto(9,10), a putative signalling molecule that is a member of the EGF-CFC gene family(11,12), Before gastrulation, Cripto is asymmetrically expressed in a proximal-distal gradient in the epiblast, and subsequently is expressed in the primitive streak and newly formed embryonic mesoderm. A Cripto null mutation generated by targeted gene disruption results in homozygous Cripto(-/-) embryos that mostly consist of anterior neuroectoderm and lack posterior structures, thus resembling a head without a trunk, Notably, markers of the head organizer are located at the distal end of the embryo, whereas markers of the primitive streak are absent or localized to the proximal side. Our results indicate that Cripto signalling is essential for the conversion of a pro;proximal-distal asymmetry into an orthogonal anterior-posterior axis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Piscataway, NJ 08854 USA; Natl Human Genome Res Inst, Lab Genet Dis Res, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Shen, MM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.	mshen@cabm.rutgers.edu	Shen, Michael M/C-7546-2009; Yan, Yu-Ting/Q-3065-2018	Shen, Michael M/0000-0002-4042-1657; Yan, Yu-Ting/0000-0002-9559-706X				ANG SL, 1994, DEVELOPMENT, V120, P2979; Ang SL, 1996, DEVELOPMENT, V122, P243; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DONO R, 1993, DEVELOPMENT, V118, P1157; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; Hermesz E, 1996, DEVELOPMENT, V122, P41; JOHNSON SE, 1994, DEV DYNAM, V201, P216, DOI 10.1002/aja.1002010305; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Liguori G, 1996, MAMM GENOME, V7, P344, DOI 10.1007/s003359900100; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; Rhinn M, 1998, DEVELOPMENT, V125, P845; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Shen MM, 1997, DEVELOPMENT, V124, P429; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Thomas PQ, 1998, DEVELOPMENT, V125, P85; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Varlet I, 1997, DEVELOPMENT, V124, P1033; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	30	383	389	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					702	707		10.1038/27215	http://dx.doi.org/10.1038/27215			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790191				2022-12-28	WOS:000076472600053
J	Durso, SC				Durso, SC			The season's end	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA	Johns Hopkins University	Durso, SC (corresponding author), 8800 Walther Blvd, Parkville, MD 21234 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					658	660		10.7326/0003-4819-129-8-199810150-00017	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00017			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786816				2022-12-28	WOS:000076431800011
J	Lang, AE; Lozano, AM				Lang, AE; Lozano, AM			Parkinson's disease - Second of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEVODOPA-INDUCED DYSKINESIAS; GLOBUS-PALLIDUS NEURONS; SUPPLEMENTARY MOTOR AREA; MOVEMENT-DISORDERS; BASAL GANGLIA; DOPAMINOMIMETIC PSYCHOSIS; RESPONSE FLUCTUATIONS; GLUTAMATE ANTAGONIST; SUBTHALAMIC NUCLEUS; FUNCTIONAL-ANATOMY		Univ Toronto, Dept Med, Div Neurol, Toronto, ON, Canada; Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada; Toronto Hosp, Morton & Gloria Shulman Movement Disorders Ctr, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Lang, AE (corresponding author), Toronto Hosp, 399 Bathurst St,MP 11, Toronto, ON M5T 2S8, Canada.		Lozano, Andres M/A-5058-2012; Lang, Anthony/ABF-8114-2021	Lozano, Andres M./0000-0001-8257-3694; Lang, Anthony/0000-0003-1229-3667				Adler, 1997, NEUROLOGY, V49, P1484; Agid Y, 1998, NEUROLOGY, V50, P858, DOI 10.1212/WNL.50.4.858; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; [Anonymous], 1996, Ann Neurol, V39, P29; [Anonymous], 1996, Ann Neurol, V39, P37; [Anonymous], 1996, Ann Neurol, V40, P99; [Anonymous], 1997, Ann Neurol, V42, P747; Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; BELLUZZI JD, 1994, MOVEMENT DISORD, V9, P147, DOI 10.1002/mds.870090204; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BENNETT JP, 1994, MOVEMENT DISORD, V9, P409, DOI 10.1002/mds.870090406; BLANCHET PJ, 1995, FUND CLIN PHARMACOL, V9, P434, DOI 10.1111/j.1472-8206.1995.tb00518.x; Block G, 1997, EUR NEUROL, V37, P23, DOI 10.1159/000117399; BONIFATI V, 1994, CLIN NEUROPHARMACOL, V17, P73, DOI 10.1097/00002826-199402000-00008; BONNET AM, 1987, NEUROLOGY, V37, P1539, DOI 10.1212/WNL.37.9.1539; Carpentier AF, 1996, NEUROLOGY, V46, P1548, DOI 10.1212/WNL.46.6.1548; Chase TN, 1996, ADV NEUROL, V69, P497; CHASE TN, 1994, NEUROLOGY, V44, pS15; Chesselet MF, 1996, TRENDS NEUROSCI, V19, P417; Colosimo C, 1996, J NEUROL NEUROSUR PS, V60, P634, DOI 10.1136/jnnp.60.6.634; Davis KD, 1997, NAT MED, V3, P671, DOI 10.1038/nm0697-671; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Dewey RB, 1996, CLIN NEUROPHARMACOL, V19, P193, DOI 10.1097/00002826-199619030-00001; Djaldetti R, 1996, ANN NEUROL, V39, P400, DOI 10.1002/ana.410390321; DJALDETTI R, 1995, MOVEMENT DISORD, V10, P81, DOI 10.1002/mds.870100113; Djaldetti R, 1996, NEUROLOGY, V46, P1051, DOI 10.1212/WNL.46.4.1051; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Durif F, 1997, NEUROLOGY, V48, P658, DOI 10.1212/WNL.48.3.658; DURIF F, 1995, NEUROLOGY, V45, P1855, DOI 10.1212/WNL.45.10.1855; EVATT ML, 1996, MOVEMENT DISORD, V11, P595; Factor SA, 1997, MOVEMENT DISORD, V12, P483, DOI 10.1002/mds.870120403; Fahn S, 1996, NEUROLOGY, V47, pS184, DOI 10.1212/WNL.47.6_Suppl_3.184S; FILION M, 1991, BRAIN RES, V547, P142; FILION M, 1988, BRAIN RES, V444, P165, DOI 10.1016/0006-8993(88)90924-9; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; Friedman JH, 1997, NEUROLOGY, V48, P1077, DOI 10.1212/WNL.48.4.1077; Gill SS, 1997, LANCET, V350, P1224, DOI 10.1016/S0140-6736(05)63455-1; GOETZ CG, 1993, NEUROLOGY, V43, P2227, DOI 10.1212/WNL.43.11.2227; GOETZ CG, 1995, NEUROLOGY, V45, P669, DOI 10.1212/WNL.45.4.669; GOLBE LI, 1991, NEUROLOGY, V41, P168, DOI 10.1212/WNL.41.2_Part_1.168; Greenamyre JT, 1996, ANN NEUROL, V39, P557, DOI 10.1002/ana.410390502; GREENAMYRE JT, 1994, ANN NEUROL, V35, P655, DOI 10.1002/ana.410350605; HELY MA, 1994, J NEUROL NEUROSUR PS, V57, P903, DOI 10.1136/jnnp.57.8.903; HOROWSKI R, 1995, THERAPY PARKINSONS D, P219; HUGHES AJ, 1993, MOVEMENT DISORD, V8, P165, DOI 10.1002/mds.870080208; Hughes NR, 1998, MOVEMENT DISORD, V13, P228, DOI 10.1002/mds.870130206; HURWITZ TA, 1988, CAN J NEUROL SCI, V15, P32, DOI 10.1017/S0317167100027141; Hutchison WD, 1997, ANN NEUROL, V42, P767, DOI 10.1002/ana.410420513; HUTCHISON WD, 1994, NEUROREPORT, V5, P1533, DOI 10.1097/00001756-199407000-00031; JANKOVIC J, 1995, NEUROSURGERY, V37, P680, DOI 10.1227/00006123-199510000-00011; JENKINS IH, 1992, ANN NEUROL, V32, P749, DOI 10.1002/ana.410320608; Kang UJ, 1998, MOVEMENT DISORD, V13, P59; Kishore A, 1997, BRAIN, V120, P729, DOI 10.1093/brain/120.5.729; Koller W, 1997, ANN NEUROL, V42, P292, DOI 10.1002/ana.410420304; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Krack P, 1998, BRAIN, V121, P451, DOI 10.1093/brain/121.3.451; Kuno S, 1997, EUR NEUROL, V38, P56, DOI 10.1159/000113484; Kurth MC, 1997, NEUROLOGY, V48, P81, DOI 10.1212/WNL.48.1.81; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; Lees AJ, 1995, BRIT MED J, V311, P1602, DOI 10.1136/bmj.311.7020.1602; Limousin P, 1997, ANN NEUROL, V42, P283, DOI 10.1002/ana.410420303; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; Lindvall O, 1997, NEUROREPORT, V8, pR3, DOI 10.1097/00001756-199709290-00036; LUQUIN MR, 1992, MOVEMENT DISORD, V7, P117, DOI 10.1002/mds.870070204; MakiIkola O, 1996, BRIT MED J, V312, P702; MARCONI R, 1994, MOVEMENT DISORD, V9, P2, DOI 10.1002/mds.870090103; MAYEUX R, 1985, NEW ENGL J MED, V313, P724, DOI 10.1056/NEJM198509193131204; Metman LV, 1998, NEUROLOGY, V50, P1323, DOI 10.1212/WNL.50.5.1323; Metman LV, 1997, NEUROLOGY, V49, P711, DOI 10.1212/WNL.49.3.711; Metman LV, 1997, NEUROLOGY, V48, P369, DOI 10.1212/WNL.48.2.369; Miyawaki E, 1997, CLIN NEUROPHARMACOL, V20, P300, DOI 10.1097/00002826-199708000-00002; Miyawaki E, 1997, CLIN NEUROPHARMACOL, V20, P523, DOI 10.1097/00002826-199712000-00004; Miyoshi Y, 1996, EXP NEUROL, V138, P169, DOI 10.1006/exnr.1996.0055; MOURADIAN MM, 1988, ANN NEUROL, V24, P372, DOI 10.1002/ana.410240304; Mytilineou C, 1997, J NEUROCHEM, V68, P434; NUTT JG, 1990, NEUROLOGY, V40, P340; Nutt JG, 1996, ANN NEUROL, V39, P561, DOI 10.1002/ana.410390504; OLANOW CW, 1990, ARCH NEUROL-CHICAGO, V47, P1286, DOI 10.1001/archneur.1990.00530120030006; Olanow CW, 1996, ANN NEUROL, V40, P841, DOI 10.1002/ana.410400605; OLANOW CW, 1995, ANN NEUROL, V38, P771, DOI 10.1002/ana.410380512; Pahwa R, 1997, NEUROLOGY, V49, P249, DOI 10.1212/WNL.49.1.249; Papa SM, 1996, ANN NEUROL, V39, P574, DOI 10.1002/ana.410390505; Pappert EJ, 1996, NEUROLOGY, V47, P1493, DOI 10.1212/WNL.47.6.1493; PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D; Rajput A H, 1997, Parkinsonism Relat Disord, V3, P159, DOI 10.1016/S1353-8020(97)00030-8; Rascol O., 1997, Neurology, V48, pA269; Richard IH, 1997, NEUROLOGY, V48, P1070, DOI 10.1212/WNL.48.4.1070; Richardson PJ, 1997, TRENDS PHARMACOL SCI, V18, P338, DOI 10.1016/S0165-6147(97)01096-1; RILEY DE, 1993, NEUROLOGY, V43, P1459, DOI 10.1212/WNL.43.8.1459; Rinne UK, 1997, NEUROLOGY, V48, P363, DOI 10.1212/WNL.48.2.363; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; SAGE JI, 1990, ADV NEUROL, V53, P383; Samuel M, 1997, BRAIN, V120, P1301, DOI 10.1093/brain/120.8.1301; Schenck CH, 1996, NEUROLOGY, V46, P388, DOI 10.1212/WNL.46.2.388; Schuurman PR, 1997, MOVEMENT DISORD, V12, P752, DOI 10.1002/mds.870120521; Shannon, 1998, NEUROLOGY, V50, P838; Shannon KM, 1997, NEUROLOGY, V49, P724, DOI 10.1212/WNL.49.3.724; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Shoulson I, 1998, ANN NEUROL, V43, P318; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Tariot PN, 1997, POSTGRAD MED, V101, P73, DOI 10.3810/pgm.1997.06.224; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Williams M, 1997, TRENDS PHARMACOL SCI, V18, P307, DOI 10.1016/S0165-6147(97)90650-7; Wolters EC, 1996, NEUROLOGY, V47, P1085, DOI 10.1212/WNL.47.4.1085; Zoldan J, 1996, ADV NEUROL, V69, P541	107	965	1002	0	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1130	1143		10.1056/NEJM199810153391607	http://dx.doi.org/10.1056/NEJM199810153391607			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129DP	9770561				2022-12-28	WOS:000076448200007
J	Limousin, P; Krack, P; Pollak, P; Benazzouz, A; Ardouin, C; Hoffmann, D; Benabid, AL				Limousin, P; Krack, P; Pollak, P; Benazzouz, A; Ardouin, C; Hoffmann, D; Benabid, AL			Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-FREQUENCY STIMULATION; GLOBUS-PALLIDUS; NEURONAL-ACTIVITY; GPI PALLIDOTOMY; MPTP MODEL; PRIMATE; REVERSAL; SYMPTOMS; MONKEYS	Background In many patients with idiopathic Parkinson's disease, treatment with levodopa is complicated by fluctuations between an "off" period (also referred to as "off medication"), when the medication is not working and the motor symptoms of parkinsonism are present, and an "on" period, when the medication is causing improved mobility (also referred to as "on medication"), often accompanied by debilitating dyskinesias. In animal models of Parkinson's disease, there is overactivity in the subthalamic nucleus, and electrical stimulation of the subthalamic nucleus improves parkinsonism. We therefore sought to determine the efficacy and safety of electrical stimulation of the subthalamic nucleus in patients with Parkinson's disease. Methods We studied 24 patients with idiopathic Parkinson's disease in whom electrodes were implanted bilaterally in the subthalamic nucleus under stereotactic guidance with imaging and electrophysiologic testing of the location. Twenty were followed for at least 12 months. Clinical evaluations included the Unified Parkinson's Disease Rating Scale, a dyskinesia scale, and timed tests conducted before and after surgery, when patients were off and on medications. Results After one year of electrical stimulation of the subthalamic nucleus, the patients' scores for activities of daily living and motor examination scores (Unified Parkinson's Disease Rating Scale parts II and III, respectively) off medication improved by 60 percent (P<0.001). The subscores improved for limb akinesia, rigidity, tremor, and gait. In the testing done on medication, the scores on part III improved by 10 percent (P<0.005). The mean dose of dopaminergic drugs was reduced by half. The cognitive-performance scores remained unchanged, but one patient had paralysis and aphasia after an intracerebral hematoma during the implantation procedure. Conclusions Electrical stimulation of the subthalamic nucleus is an effective treatment for advanced Parkinson's disease. The severity of symptoms off medication decreases, and the dose of levodopa can be reduced, with a consequent reduction in dyskinesias. (N Engl J Med 1998;339:1105-11.) (C) 1998, Massachusetts Medical Society.	Univ Grenoble 1, Dept Clin & Biol Neurosci, F-38043 Grenoble 9, France; MRC, Human Movement & Balance Unit, London, England; Univ Kiel, Dept Neurol, D-2300 Kiel, Germany	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Kiel	Pollak, P (corresponding author), Univ Grenoble 1, Dept Clin & Biol Neurosci, BP 217, F-38043 Grenoble 9, France.		Benabid, Alim L/Q-3506-2017; Benazzouz, Abdelhamid/E-5050-2016	Krack, Paul/0000-0002-3508-7295				AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BENABID AL, 1991, LANCET, V337, P401; BENAZZOUZ A, 1995, NEUROSCI LETT, V189, P77, DOI 10.1016/0304-3940(95)11455-6; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BROWN RG, 1990, TRENDS NEUROSCI, V13, P21, DOI 10.1016/0166-2236(90)90058-I; COOPER IS, 1958, PATHOGENESIS TREATME, P325; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GALVEZJIMENEZ N, 1996, MOVEMENT DISORD, V11, P242; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Golbe LI, 1998, LANCET, V351, P998, DOI 10.1016/S0140-6736(98)22014-9; Gross C, 1997, J NEUROSURG, V87, P491, DOI 10.3171/jns.1997.87.4.0491; GUIOT G, 1953, REV NEUROL, V89, P578; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; Hassler R, 1954, NERVENARZT, V25, P441; Karusu T.B., 1976, GERIATRIC PSYCHIAT, P77; Krack P, 1997, LANCET, V350, P1675, DOI 10.1016/S0140-6736(97)24049-3; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LANGSTON JW, 1984, BRAIN RES, V292, P390; LEPORE FE, 1985, NEUROLOGY, V35, P423, DOI 10.1212/WNL.35.3.423; Limousin P, 1997, ANN NEUROL, V42, P283, DOI 10.1002/ana.410420303; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Limousin P, 1996, MOVEMENT DISORD, V11, P231, DOI 10.1002/mds.870110303; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; LOZANO AM, 1996, LANCET, V348, P1108; Meyers R, 1942, N ST J MED, V42, P317; MILLER WC, 1987, ADV BEHAV BIOL, V32, P415; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Obeso JA, 1997, J NEUROL NEUROSUR PS, V62, P2, DOI 10.1136/jnnp.62.1.2; Pahwa R, 1997, NEUROLOGY, V49, P249, DOI 10.1212/WNL.49.1.249; Penney JB, 1996, ANN NEUROL, V39, P37; PILLON B, 1986, NEUROLOGY, V36, P1179, DOI 10.1212/WNL.36.9.1179; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; Tronnier VM, 1997, J NEUROSURG, V87, P700, DOI 10.3171/jns.1997.87.5.0700; WICHMANN T, 1994, J NEUROPHYSIOL, V72, P521, DOI 10.1152/jn.1994.72.2.521	43	1363	1432	1	219	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1105	1111		10.1056/NEJM199810153391603	http://dx.doi.org/10.1056/NEJM199810153391603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129DP	9770557				2022-12-28	WOS:000076448200003
J	Shwayder, TA				Shwayder, TA			Call of the loon	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1221	1222		10.1001/jama.280.14.1221	http://dx.doi.org/10.1001/jama.280.14.1221			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786364				2022-12-28	WOS:000076357900012
J	Horton, R				Horton, R			UH medicine: what are we to do?	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							Horton R, 1998, LANCET, V351, P1900; JACKSON B, 1998, B R COLL SURG ENGL, P199; Laurence J., 1998, INDEPENDENT SUN 1004, P23	3	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1166	1166		10.1016/S0140-6736(05)60528-4	http://dx.doi.org/10.1016/S0140-6736(05)60528-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777831				2022-12-28	WOS:000076415400006
J	Plotnick, LH; Ducharme, FM				Plotnick, LH; Ducharme, FM			Should inhaled anticholinergics be added to beta(2) agonists for treating acute childhood and adolescent asthma? A systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IPRATROPIUM BROMIDE; NEBULIZED IPRATROPIUM; PEDIATRIC ASTHMA; CONTROLLED TRIAL; CHILDREN; METAANALYSIS; MANAGEMENT; CONSENSUS; EFFICACY; THERAPY	Objectives To estimate the therapeutic and adverse effects of addition of inhaled anticholinergics to beta(2) agonists in acute asthma in children and adolescents. Design Systematic review of randomised controlled trials of children and adolescents taking beta(2) agonists for acute asthma with or without the addition of inhaled anticholinergics. Main outcome measures Hospital admission, pulmonary function tests, number of nebulised treatments, relapse, and adverse effects. Results Of 37 identified trials, 10 were relevant and six of these were of high quality. The addition of a single dose of anticholinergic to beta(2) agonist did not reduce hospital admission (relative risk 0.93, 95% confidence interval 0.65 to 1.32). However, significant group differences in lung function supporting the combination treatment were observed 60 minutes (standardised mean difference - 0.57, - 0.93 to - 0.21) and 120 minutes (- 0.53, - 0.90 to - 0.17) after the dose of anticholinergic. In contrast, the addition of multiple doses of anticholinergics to beta(2) agonists, mainly in children and adolescents with severe exacerbations, reduced the risk of hospital admission by 30% (relative risk 0.72, 0.53 to 0.99). Eleven (95% confidence interval 5 to 250) children would need to be treated to avoid one admission. A parallel improvement in lung function (standardised mean difference - 0.66, - 0.95 to - 0.37) was noted 60 minutes after the last combined inhalation. In the single study where anticholinergics were systematically added to every beta(2) agonist inhalation, irrespective of asthma severity, no group differences were observed for the few available outcomes. There was no increase in the amount of nausea, vomiting, or tremor in patients treated with anticholinergics. Conclusions Adding multiple doses of anticholinergics to beta(2) agonists seems safe, improves lung function, and may avoid hospital admission in 1 of 11 such treated patients. Although multiple doses should be preferred to single doses of anticholinergics, the available evidence only supports their use in school aged children and adolescents with severe asthma exacerbation.	McGill Univ, Montreal Childrens Hosp, Dept Pediat, Div Pediat Emergency Med, Montreal, PQ H3H 1P3, Canada	McGill University	Ducharme, FM (corresponding author), McGill Univ, Montreal Childrens Hosp, Dept Pediat, Div Pediat Emergency Med, Montreal, PQ H3H 1P3, Canada.	fduccpr@mch.mcgill.ca	Ducharme, Francine/N-8332-2013	Ducharme, Francine/0000-0001-5096-0614				[Anonymous], 1993, THORAX, V48, pS1; BECK R, 1985, J PEDIATR-US, V107, P605, DOI 10.1016/S0022-3476(85)80033-0; Chapman KR, 1996, AM J MED, V100, pS2, DOI 10.1016/S0002-9343(96)80013-1; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; COOK JJ, 1985, PHARMATHERAPEUTICA, V4, P383; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUCHARME FM, 1995, PEDIATR RES, V37, pA136; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ernst P, 1996, CAN RESPIR J, V3, P89; Greenhalgh T, 1997, BRIT MED J, V315, P672, DOI 10.1136/bmj.315.7109.672; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GROSS NJ, 1988, NEW ENGL J MED, V319, P486; GUILL MF, 1987, ANN ALLERGY, V59, P367; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; Homer CJ, 1996, PEDIATRICS, V98, P18; Jadad AR, 1995, CONTROL CLIN TRIALS, V134, P1; Khan KS, 1996, ARCH INTERN MED, V156, P661, DOI 10.1001/archinte.156.6.661; MITCHELL EA, 1992, NEW ZEAL MED J, V105, P353; OLKIN I, 1995, J CLIN EPIDEMIOL, V48, P133, DOI 10.1016/0895-4356(94)00136-E; OSMOND MH, 1995, ACAD EMERG MED, V2, P651, DOI 10.1111/j.1553-2712.1995.tb03607.x; PAYNE SMC, 1995, ARCH PEDIAT ADOL MED, V149, P162, DOI 10.1001/archpedi.1995.02170140044006; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; PHANICHYAKARN P, 1990, ASIAN PAC J ALLERGY, V8, P45; Qureshi F, 1997, ANN EMERG MED, V29, P205, DOI 10.1016/S0196-0644(97)70269-5; RACHELEFSKY GS, 1993, PEDIATR PULM, V15, P125, DOI 10.1002/ppul.1950150211; REISMAN J, 1988, J ALLERGY CLIN IMMUN, V81, P16, DOI 10.1016/0091-6749(88)90214-X; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; SACKETT DL, 1995, J CLIN EPIDEMIOL, V48, P61, DOI 10.1016/0895-4356(94)00085-5; SCARFONE RJ, 1993, PEDIATRICS, V92, P513; SCHUH S, 1995, J PEDIATR-US, V126, P639, DOI 10.1016/S0022-3476(95)70368-3; SEARS MR, 1992, PRACTICAL ALLERGY IM, V7, P98; SILVERMAN M, 1990, LUNG, V168, P304, DOI 10.1007/BF02718146; Sim I, 1996, BRIT MED J, V313, P702; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; SVEDMYR N, 1985, PHARMACOTHERAPY, V5, P109; TAL A, 1990, PEDIATRICS, V86, P350; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; WATSON WTA, 1988, J ALLERGY CLIN IMMUN, V82, P1012, DOI 10.1016/0091-6749(88)90138-8	39	61	66	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 10	1998	317	7164					971	977		10.1136/bmj.317.7164.971	http://dx.doi.org/10.1136/bmj.317.7164.971			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765164	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000076449300021
J	Forman, BM; Tzameli, I; Choi, HS; Chen, L; Simha, D; Seol, W; Evans, RM; Moore, DD				Forman, BM; Tzameli, I; Choi, HS; Chen, L; Simha, D; Seol, W; Evans, RM; Moore, DD			Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta	NATURE			English	Article							THYROID-HORMONE RECEPTOR; FATTY-ACIDS; INVERSE AGONISTS; RETINOIC ACID; LXR-ALPHA; EICOSANOIDS; ACTIVATION; IDENTIFICATION; 16-ANDROSTENES; COACTIVATOR	The orphan receptor CAR-beta (ref. 1) binds DNA as a heterodimer with the retinoid-X receptor and activates gene transcription in a constitutive manner. Here we show that, in contrast to the classical nuclear receptors, the constitutive activity of CAR-beta results from a ligand-independent recruitment of transcriptional co-activators. While searching for potential ligands of CAR-beta, we found that the steroids androstanol and androstenol inhibit the constitutive activity of CAR-beta. This effect is stereospecific: only 3 alpha-hydroxy, 5 alpha-reduced androstanes are active. These androstanes do not interfere with heterodimerization or DNA binding of CAR-beta; instead, they promote co-activator release from the ligand-binding domain. These androstane ligands are examples of naturally occurring inverse agonists(2,3) that reverse transcriptional activation by nuclear receptors. CAR-beta (constitutive androstane receptor-beta), therefore, defines an unanticipated steroidal signalling pathway that functions in a manner opposite to that of the conventional nuclear receptor pathways.	City Hope Natl Med Ctr, Duarte, CA 91010 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77401 USA; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Dana Farber Canc Inst, Div Neoplast Dis Mechanisms, Boston, MA 02115 USA	City of Hope; Howard Hughes Medical Institute; Salk Institute; Baylor College of Medicine; Chonnam National University; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute	Forman, BM (corresponding author), City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BICKNELL DC, 1976, J STEROID BIOCHEM, V7, P451, DOI 10.1016/0022-4731(76)90111-4; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GOWER DB, 1994, J STEROID BIOCHEM, V48, P409, DOI 10.1016/0960-0760(94)90082-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LOUVEAU I, 1991, ACTA ENDOCRINOL-COP, V125, P526, DOI 10.1530/acta.0.1250526; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SEOL W, 1996, SCIENCE, V272, P1136; SINGER AG, 1991, J STEROID BIOCHEM, V39, P627, DOI 10.1016/0960-0760(91)90261-3; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEUSTEN JJAM, 1989, J STEROID BIOCHEM, V32, P689, DOI 10.1016/0022-4731(89)90513-X	26	412	432	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					612	615		10.1038/26996	http://dx.doi.org/10.1038/26996			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783588				2022-12-28	WOS:000076362900051
J	Mangus, RS; Hawkins, CE; Miller, MJ				Mangus, RS; Hawkins, CE; Miller, MJ			Tobacco and alcohol use among 1996 medical school graduates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUBSTANCE USE; DRINKING PATTERNS; PHYSICIANS; STUDENTS; SMOKING; ADVICE; ABUSE		Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA	Oregon Health & Science University	Mangus, RS (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA.		Mangus, Richard S/M-1446-2018	Mangus, Richard S/0000-0003-4300-2594				*ASS AM MED COLL, 1996, ASS AM MED COLL 1996; BALDWIN DC, 1991, JAMA-J AM MED ASSOC, V265, P2074, DOI 10.1001/jama.265.16.2074; BREWSTER JM, 1986, JAMA-J AM MED ASSOC, V255, P1913, DOI 10.1001/jama.255.14.1913; BREWSTER JM, 1991, JAMA-J AM MED ASSOC, V255, P1913; Clark D C, 1990, J Subst Abuse, V2, P15; CLARK DC, 1987, JAMA-J AM MED ASSOC, V257, P2921, DOI 10.1001/jama.257.21.2921; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; ELDERS MJ, 1994, AM J PUBLIC HEALTH, V84, P543, DOI 10.2105/AJPH.84.4.543; FLAHERTY JA, 1993, PSYCHIAT CLIN N AM, V16, P189; FLAHERTY JA, 1991, ANN M AM PSYCH ASS N; FORNEY MA, 1988, INT J ADDICT, V23, P767, DOI 10.3109/10826088809058838; HILTON ME, 1987, J STUD ALCOHOL, V48, P515, DOI 10.15288/jsa.1987.48.515; HILTON ME, 1989, BRIT J ADDICT, V84, P1085; JAMROZIK K, 1994, BRIT MED J, V288, P1499; KUZEL AJ, 1991, SOUTH MED J, V84, P9, DOI 10.1097/00007611-199101000-00004; McAuliffe W E, 1984, Adv Alcohol Subst Abuse, V4, P67; MCAULIFFE WE, 1991, AM J PUBLIC HEALTH, V81, P177, DOI 10.2105/AJPH.81.2.177; MIDANIK LT, 1989, BRIT J ADDICT, V84, P1419; MOORE RD, 1990, AM J MED, V88, P332, DOI 10.1016/0002-9343(90)90485-V; NAJEM GR, 1995, J CLIN EPIDEMIOL, V48, P841, DOI 10.1016/0895-4356(94)00193-T; PEDERSON LL, 1982, PREV MED, V11, P71, DOI 10.1016/0091-7435(82)90006-8; RICHMAN JA, 1992, ALCOHOL CLIN EXP RES, V16, P166, DOI 10.1111/j.1530-0277.1992.tb01360.x; STEWART PJ, 1982, CAN MED ASSOC J, V126, P1051; THOMAS RB, 1977, DIS NERV SYST, V38, P41; *US DHEW, 1979, US DHEW PUBL; WYSHAK G, 1980, NEW ENGL J MED, V303, P104, DOI 10.1056/NEJM198007103030210	26	38	39	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1192	+		10.1001/jama.280.13.1192	http://dx.doi.org/10.1001/jama.280.13.1192			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124YR	9777823	hybrid			2022-12-28	WOS:000076210800037
J	van Leyen, K; Duvoisin, RM; Engelhardt, H; Wiedmann, M				van Leyen, K; Duvoisin, RM; Engelhardt, H; Wiedmann, M			A function for lipoxygenase in programmed organelle degradation	NATURE			English	Article							RETICULOCYTE LIPOXYGENASE; MESSENGER-RNA; 15-LIPOXYGENASE; PROTEINS; TRANSLATION; MEMBRANES; CELLS; LENS	Membrane-enclosed organelles, a defining characteristic of eukaryotic cells, are lost during differentiation of specific cell types such as reticulocytes (an intermediate in differentiation of erythrocytes), central fibre cells of the eye lens, and keratinocytes(1). The degradation of these organelles must be tightly regulated with respect to both the time of activation and the specificity of membrane degradation. The expression of 15-lipoxygenase (15-LOX) peaks in reticulocytes immediately before organelle degradation(2). Here we show that 15-LOX integrates into the membranes of various organelles, allowing release of proteins from the organelle lumen and access of proteases to both lumenal and integral membrane proteins. In addition, by sparing the plasma membrane, 15-LOX shows the required specificity for organellar membranes. Thus, the action of 15-LOX provides a mechanism by which the natural degradation process can be explained. This conclusion is supported by our finding that lipoxygenase expression in the eye lens is restricted to the region at which organelle degradation occurs.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Dyson Vis Res Inst, Coll Med, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany	Memorial Sloan Kettering Cancer Center; Cornell University; Dyson; Cornell University; Max Planck Society	Wiedmann, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.							ALBERTS B, 1994, MOL BIOL CELL, P1158; Arora JK, 1996, INVEST OPHTH VIS SCI, V37, P1411; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; HUNT T, 1989, TRENDS BIOCHEM SCI, V14, P393, DOI 10.1016/0968-0004(89)90280-6; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JAIN MK, 1980, INTRO BIOL MEMBRANES; KUHN H, 1990, J BIOL CHEM, V265, P18351; Kuhn H, 1997, CURR OPIN LIPIDOL, V8, P111; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEW RRC, 1990, LIPOSOMES PRACTICAL, P37; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; PAUL A, 1992, BIOPHYS J, V61, P172, DOI 10.1016/S0006-3495(92)81825-8; RAPOPORT SM, 1979, EUR J BIOCHEM, V96, P545, DOI 10.1111/j.1432-1033.1979.tb13068.x; SAMUELSSON B, 1991, ANN NY ACAD SCI, V629, P89; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; Steck T L, 1974, Methods Enzymol, V31, P172; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WATSON A, 1994, BIOCHEM J, V298, P377, DOI 10.1042/bj2980377	26	246	247	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					392	395		10.1038/26500	http://dx.doi.org/10.1038/26500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759730				2022-12-28	WOS:000076083800056
J	Presgraves, DC; Orr, HA				Presgraves, DC; Orr, HA			Haldane's rule in taxa lacking a hemizygous X	SCIENCE			English	Article							DROSOPHILA-SIMULANS; REPRODUCTIVE ISOLATION; LINKAGE MAP; CHROMOSOME	Haldane's rule states that species hybrids of the XY sex are preferentially sterile or inviable. In all taxa known to obey this rule, the Y is inert and X-Linked genes show full expression in XY individuals. Until recently, all theories of Haldane's rule depended on this hemizygosity. A test of Haldane's rule in animals Lacking a hemizygous sex-mosquitoes having two functional sex chromosomes in both sexes-reveals that these species show Haldane's rule for sterility but not inviability, A related group having a "normal" hemizygous X obeys Haldane's rule for both sterility and inviability. These results support the faster male and dominance theories of Haldane's rule.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Presgraves, DC (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.							[Anonymous], 1967, GENETICS INSECT VECT; BHALLA SC, 1970, CAN J GENET CYTOL, V12, P425, DOI 10.1139/g70-061; COULTHART MB, 1988, MOL BIOL EVOL, V5, P182; Coyne J.A., 1989, P180; Eberhard W.G., 1985, SEXUAL SELECTION ANI; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; Hollocher H, 1996, GENETICS, V143, P1243; KITZMILLER JB, 1976, ADV GENET, V18, P315, DOI 10.1016/S0065-2660(08)60441-1; KUITZMILLER JB, 1967, GENETICS INSECT VECT, P151; Laurie CC, 1997, GENETICS, V147, P937; Muller HJ, 1942, BIOL S, V6, P71; MUNSTERMANN LE, 1990, GENETIC MAPS LOCUS M, P179; ORR HA, 1993, EVOLUTION, V47, P1606, DOI [10.2307/2410171, 10.1111/j.1558-5646.1993.tb02179.x]; ORR HA, 1992, GENET RES, V59, P73, DOI 10.1017/S0016672300030275; ORR HA, 1993, NATURE, V361, P532, DOI 10.1038/361532a0; Orr HA, 1997, ANNU REV ECOL SYST, V28, P195, DOI 10.1146/annurev.ecolsys.28.1.195; QUINN TC, 1971, J HERED, V62, P2, DOI 10.1093/oxfordjournals.jhered.a108114; SEVERSON DW, 1993, J HERED, V84, P241, DOI 10.1093/oxfordjournals.jhered.a111333; TADANO T, 1984, JPN J GENET, V59, P165, DOI 10.1266/jjg.59.165; True JR, 1996, GENETICS, V142, P819; Turelli M, 1997, GENETICS, V147, P1799; WU CI, 1993, AM NAT, V142, P187, DOI 10.1086/285534; WU CI, 1996, TRENDS ECOL EVOL, V11, P411; ZHENG LB, 1993, SCIENCE, V261, P605, DOI 10.1126/science.8342025	24	109	109	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1998	282	5390					952	954		10.1126/science.282.5390.952	http://dx.doi.org/10.1126/science.282.5390.952			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794768				2022-12-28	WOS:000076727300053
J	Rasmussen, PE; Goulding, KWT; Brown, JR; Grace, PR; Janzen, HH; Korschens, M				Rasmussen, PE; Goulding, KWT; Brown, JR; Grace, PR; Janzen, HH; Korschens, M			Agroecosystem - Long-term agroecosystem experiments: Assessing agricultural sustainability and global change	SCIENCE			English	Review							SOIL ACIDIFICATION; GRASSLAND; TILLAGE; CARBON	Long-term agroecosystem experiments can be defined as large-scale field experiments more than 20 years old that study crop production, nutrient cycling, and environmental impacts of agriculture. They provide a resource for evaluating biological, biogeochemical, and environmental dimensions of agricultural sustainability; for predicting future global changes; and for validating model competence and performance. A systematic assessment is needed to determine the merits of all known experiments and to identify any that may exist in tropical and subtropical environments. The establishment of an international network to coordinate data collection and link sites would facilitate more precise prediction of agroecosystem sustainability and future global change.	Agr Res Serv, USDA, Columbia Plateau Conservat Res Ctr, Pendleton, OR 97801 USA; AFRC, Inst Arable Crops Res, Harpenden AL5 2JQ, Herts, England; Univ Missouri, Dept Soil & Atmospher Sci, Columbia, MO 65211 USA; CIMMYT, Int Maize & Wheat Improvement Ctr, Mexico City 06600, DF, Mexico; UFZ Helmholtz Ctr Environm Res, D-06246 Bad Lauchstadt, Germany; Agr & Agri Food Canada, Lethbridge, AB T1J 4B1, Canada	United States Department of Agriculture (USDA); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; University of Missouri System; University of Missouri Columbia; CGIAR; International Maize & Wheat Improvement Center (CIMMYT); Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Agriculture & Agri Food Canada	Rasmussen, PE (corresponding author), Agr Res Serv, USDA, Columbia Plateau Conservat Res Ctr, Pendleton, OR 97801 USA.	paul.rasmussen@orst.edu	Grace, Peter R/F-3743-2012; Goulding, Keith WT/B-2635-2012; Zhong, Hong Lin/C-2633-2012	Goulding, Keith WT/0000-0002-6465-1465; Grace, Peter/0000-0003-4136-4129				BARNETT V, 1994, LONG-TERM EXPERIMENTS IN AGRICULTURAL AND ECOLOGICAL SCIENCES, P165; BARNETT V, 1995, AGR SUSTAINABILITY E; Batjes NH, 1998, BIOL FERT SOILS, V27, P230, DOI 10.1007/s003740050425; BROWN JR, 1993, PUBLICATION MX, V390; Brummer EC, 1998, AGRON J, V90, P1, DOI 10.2134/agronj1998.00021962009000010001x; Buyanovsky GA, 1998, BIOL FERT SOILS, V27, P242, DOI 10.1007/s003740050427; Buyanovsky GA, 1998, GLOBAL CHANGE BIOL, V4, P131, DOI 10.1046/j.1365-2486.1998.00130.x; Calderini DF, 1998, FIELD CROP RES, V57, P335, DOI 10.1016/S0378-4290(98)00080-X; Campbell C.A., 1997, SOIL ORGANIC MATTER, P317; Christensen BT, 1997, DEV SOIL SCI, V25, P399; Conway G., 1990, GREEN REVOLUTION SUS; ELLIOTT ET, 1996, EVALUATION SOIL ORGA, P27; ESSER G, 1990, SOILS AND THE GREENHOUSE EFFECT, P247; FAETH P, 1993, AGR POLICY SUSTAINAB; Falloon PD, 1998, BIOL FERT SOILS, V27, P236, DOI 10.1007/s003740050426; Fischer G, 1997, PHILOS T ROY SOC B, V352, P869, DOI 10.1098/rstb.1997.0067; FLACH KW, 1997, SOIL ORGANIC MATTER, P3, DOI DOI 10.1017/S0889189300008456; Gennadiyev A, 1998, ADV SOIL S, P103; Goulding KWT, 1998, NEW PHYTOL, V139, P49, DOI 10.1046/j.1469-8137.1998.00182.x; GRACE P, 1994, LONG-TERM EXPERIMENTS IN AGRICULTURAL AND ECOLOGICAL SCIENCES, P53; Grace PR, 1995, AUST J EXP AGR, V35, P857, DOI 10.1071/EA9950857; GREELAND DJ, 1994, LONG-TERM EXPERIMENTS IN AGRICULTURAL AND ECOLOGICAL SCIENCES, P187; Greenland DJ, 1997, SOIL USE MANAGE, V13, P169, DOI 10.1111/j.1475-2743.1997.tb00581.x; HOLMBERG J, 1991, DEFENDING FUTURE, P13; INGRAM J, 1996, 12 GCTE NAT ENV RES; Johnson PA, 1997, SOIL USE MANAGE, V13, P17, DOI 10.1111/j.1475-2743.1997.tb00551.x; Johnston A. E., 1992, Phosphate fertilizers and the environment., P255; JOHNSTON AE, 1986, SOIL USE MANAGE, V2, P3, DOI 10.1111/j.1475-2743.1986.tb00669.x; JOHNSTON AE, 1994, LONG-TERM EXPERIMENTS IN AGRICULTURAL AND ECOLOGICAL SCIENCES, P9; Johnston AE, 1997, ADV AGRON, V59, P291, DOI 10.1016/S0065-2113(08)60057-7; JONES KC, 1987, SCI TOTAL ENVIRON, V61, P131, DOI 10.1016/0048-9697(87)90363-9; JONES KC, 1994, LONG-TERM EXPERIMENTS IN AGRICULTURAL AND ECOLOGICAL SCIENCES, P147; JONES KC, 1989, SCI TOTAL ENVIRON, V78, P117, DOI 10.1016/0048-9697(89)90026-0; KORSCHENS M, 1994, STAT DUNGUNGSVERSUCH; Korschens M., 1996, NATO ASI SERIES 1, V38, P69; Lal R, 1998, ADV SOIL SCI-SER, P1; Lal R, 1998, ADV SOIL SCI-SER, P1; Lal R, 1998, MANAGEMENT CARBON SE; Lal R., 1998, SOIL PROCESSES CARBO; LARSON WE, 1983, SCIENCE, V219, P458, DOI 10.1126/science.219.4584.458; LEIGHT RA, 1994, LONG TERM EXPT AGR E; MORTVEDT JJ, 1987, J ENVIRON QUAL, V16, P137, DOI 10.2134/jeq1987.00472425001600020008x; NYANGUMBO I, 1998, CONSERVATION TILLAGE; Paul E.A., 1997, SOIL ORGANIC MATTER; POST WM, 1990, AM SCI, V78, P310; Powlson D.S., 1996, GLOBAL ENVIRON CHANG, V38, DOI [10.1007/978-3-642-61094-3, DOI 10.1007/978-3-642-61094-3]; POWLSON DS, 1994, SOIL RESILIENCE AND SUSTAINABLE LAND USE, P367; RASMUSSEN PE, 1989, SOIL SCI SOC AM J, V53, P119, DOI 10.2136/sssaj1989.03615995005300010022x; Rasmussen PE, 1998, ADV SOIL S, P209; RASMUSSEN PE, 1991, ADV AGRON, V45, P93; RUNNELS CN, 1995, SCI AM, V272, P96, DOI 10.1038/scientificamerican0395-96; RUTTAN VN, 1991, 91 CREDIT U NOTT; Smith P, 1997, GEODERMA, V81, P153, DOI 10.1016/S0016-7061(97)00087-6; Smith P, 1996, NATURE, V381, P15, DOI 10.1038/381015a0; Steiner R., 1995, AGR SUSTAINABILITY E; STEINER RA, 1995, DIRECTORY LONG TERM; SWIFT MJ, 1995, AGR SUSTAINABILITY E, P229; THURSTON JM, 1976, ANN AGRON, V27, P1043; TINKER PB, 1994, LONG-TERM EXPERIMENTS IN AGRICULTURAL AND ECOLOGICAL SCIENCES, P407; [No title captured]	60	267	300	6	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1998	282	5390					893	896		10.1126/science.282.5390.893	http://dx.doi.org/10.1126/science.282.5390.893			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794751				2022-12-28	WOS:000076727300036
J	Takayama, T; Katsuki, S; Takahashi, Y; Ohi, M; Nojiri, S; Sakamaki, S; Kato, J; Kogawa, K; Miyake, H; Niitsu, Y				Takayama, T; Katsuki, S; Takahashi, Y; Ohi, M; Nojiri, S; Sakamaki, S; Kato, J; Kogawa, K; Miyake, H; Niitsu, Y			Aberrant crypt foci of the colon as precursors of adenoma and cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							K-RAS MUTATIONS; PUTATIVE PRENEOPLASTIC LESIONS; CARCINOGENESIS; AZOXYMETHANE; SULINDAC; ASPIRIN; POLYPS; RISK; QUANTIFICATION; MICROADENOMAS	Background Aberrant crypt foci of the colon are possible precursors of adenoma and cancer, but these lesions have been studied mainly in surgical specimens from patients who already had colon cancer. Methods Using magnifying endoscopy, we studied the prevalence, number, size, and dysplastic features of aberrant crypt foci and their distribution according to age in 171 normal subjects, 131 patients with adenoma, and 48 patients with colorectal cancer. We also prospectively examined the prevalence of aberrant crypt foci in 11 subjects (4 normal subjects, 6 with adenoma, and 1 with cancer) before and after the administration of 100 mg of sulindac three times a day for 8 to 12 months and compared the results with those in 9 untreated subjects (4 normal subjects and 5 with adenoma). All 20 subjects had aberrant crypt foci at base line. Results We identified 3155 aberrant crypt foci, 161 of which were dysplastic; the prevalence and number increased with age. There were significant (P<0.001) correlations between the number of aberrant crypt foci, the presence of dysplastic foci, the size of the foci, and the number of adenomas. After sulindac therapy, the number of foci decreased, disappearing in 7 of 11 subjects. In the untreated control group, the number of foci was unchanged in eight subjects and slightly increased in one (P<0.001 for the difference between the groups). Conclusions Aberrant crypt foci, particularly those that are large and have dysplastic features, may be precursors of adenoma and cancer. (N Engl J Med 1998;339:1277-84.) (C)1998, Massachusetts Medical Society.	Sapporo Med Univ, Dept Internal Med 4, Chuo Ku, Sapporo, Hokkaido, Japan; Sapporo Med Univ, Dept Publ Hlth, Chuo Ku, Sapporo, Hokkaido, Japan; Muroran Shinnittetsu Hosp, Muroran, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University	Niitsu, Y (corresponding author), Sapporo Med Univ, Dept Internal Med 4, Chuo Ku, South-1,West-16, Sapporo, Hokkaido, Japan.							Altman DG, 1991, PRACTICAL STAT MED R; BERNSTEIN MA, 1985, RADIOLOGY, V155, P35, DOI 10.1148/radiology.155.1.3975415; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; Cox DR., 1970, ANAL BINARY DATA; DiGregori C, 1997, HISTOPATHOLOGY, V30, P328, DOI 10.1046/j.1365-2559.1997.d01-626.x; DiGregorio C, 1997, HISTOPATHOLOGY, V31, P491; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; HEATH CW, 1993, JNCI-J NATL CANCER I, V85, P258, DOI 10.1093/jnci/85.4.258; HELWIG EB, 1943, SURG GYNECOL OBSTET, V76, P419; JEN J, 1994, CANCER RES, V54, P5523; KIM HG, 1994, AM J PATHOL, V145, P148; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LADENHEIM J, 1995, GASTROENTEROLOGY, V108, P1083, DOI 10.1016/0016-5085(95)90206-6; LEVI S, 1991, CANCER RES, V51, P3497; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; MCLELLAN EA, 1991, CANCER RES, V51, P5270; MERETO E, 1994, CANCER LETT, V76, P5, DOI 10.1016/0304-3835(94)90127-9; PRETLOW TP, 1991, CANCER RES, V51, P1564; PRETLOW TP, 1993, J NATL CANCER I, V85, P2004, DOI 10.1093/jnci/85.24.2004; PRETLOW TP, 1995, GASTROENTEROLOGY, V108, P600, DOI 10.1016/0016-5085(95)90092-6; PRETLOW TP, 1992, J CELL BIOCHEM, P55; RONCUCCI L, 1991, HUM PATHOL, V22, P287, DOI 10.1016/0046-8177(91)90163-J; RONCUCCI L, 1991, CANCER EPIDEM BIOMAR, V1, P57; RONCUCCI L, 1992, ITAL J GASTROENTEROL, V24, P498; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SHIVAPURKAR N, 1994, CARCINOGENESIS, V15, P775, DOI 10.1093/carcin/15.4.775; STOPERA SA, 1992, CARCINOGENESIS, V13, P573, DOI 10.1093/carcin/13.4.573; SUTHERLAND LAM, 1994, CANCER LETT, V76, P101, DOI 10.1016/0304-3835(94)90384-0; TACHINO N, 1995, MOL CARCINOGEN, V12, P187, DOI 10.1002/mc.2940120402; TAKAHASHI M, 1994, CANCER LETT, V83, P177, DOI 10.1016/0304-3835(94)90316-6; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777; YAMASHITA N, 1995, CANCER, V75, P1527, DOI 10.1002/1097-0142(19950315)75:6+<1527::AID-CNCR2820751524>3.0.CO;2-Y; YAMASHITA N, 1995, GASTROENTEROLOGY, V108, P434, DOI 10.1016/0016-5085(95)90071-3	35	472	490	2	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1277	1284		10.1056/NEJM199810293391803	http://dx.doi.org/10.1056/NEJM199810293391803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132XC	9791143				2022-12-28	WOS:000076655300003
J	Dunn, PM				Dunn, PM			The Wisheart affair: paediatric cardiological services in Bristol, 1990-5	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Southmead Hosp, Bristol BS10 5NB, Avon, England	Southmead Hospital; University of Bristol	Dunn, PM (corresponding author), Univ Bristol, Southmead Hosp, Bristol BS10 5NB, Avon, England.								0	19	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1144	1145						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784459				2022-12-28	WOS:000076755100038
J	Leach, RM; Rees, PJ; Wilmshurst, P				Leach, RM; Rees, PJ; Wilmshurst, P			ABC of oxygen - Hyperbaric oxygen therapy	BRITISH MEDICAL JOURNAL			English	Article									Royal Shrewsbury Hosp, Shrewsbury, England; Guys & St Thomass Hosp Trust, Dept Intens Care, London, England; Guys & St Thomass Hosp Trust, Dept Resp Med, London, England	Guy's & St Thomas' NHS Foundation Trust	Leach, RM (corresponding author), Guys & St Thomass Hosp Trust, Dept Intens Care, London, England.								0	248	255	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1140	1143						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784458				2022-12-28	WOS:000076755100037
J	Mathew, MO; Ramamohan, N; Bennet, GC				Mathew, MO; Ramamohan, N; Bennet, GC			Importance of bruising associated with paediatric fractures: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article									Royal Hosp Sick Children, Dept Orthopaed, Glasgow G3 8SJ, Lanark, Scotland	University of Glasgow	Bennet, GC (corresponding author), Royal Hosp Sick Children, Dept Orthopaed, Glasgow G3 8SJ, Lanark, Scotland.							PATERSON CR, 1987, BRIT MED J, V295, P213, DOI 10.1136/bmj.295.6591.213-a; TAITZ LS, 1991, BRIT MED J, V302, P1244, DOI 10.1136/bmj.302.6787.1244; TAITZ LS, 1991, HOSPITAL UPDATE  MAY, P400	3	34	34	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1117	1118						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784447				2022-12-28	WOS:000076755100028
J	Hokama, A; Kinjo, F				Hokama, A; Kinjo, F			Biliary sludge extruding into the duodenum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Ryukyus, Okinawa 90301, Japan	University of the Ryukyus	Hokama, A (corresponding author), Univ Ryukyus, Okinawa 90301, Japan.		, Hokama/AAE-1946-2021	, Hokama/0000-0002-8310-9989					0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1210	1210		10.1056/NEJM199810223391705	http://dx.doi.org/10.1056/NEJM199810223391705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780341				2022-12-28	WOS:000076532400005
J	Yetman, AT; McCrindle, BW; MacDonald, C; Freedom, RM; Gow, R				Yetman, AT; McCrindle, BW; MacDonald, C; Freedom, RM; Gow, R			Myocardial bridging in children with hypertrophic cardiomyopathy - A risk factor for sudden death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DESCENDING CORONARY-ARTERY; BLOOD-PRESSURE RESPONSE; QT DISPERSION; CARDIAC-ARREST; EXERCISE CAPACITY; ISCHEMIA; SCINTIGRAPHY; INTERVAL; OBSTRUCTION; ARRHYTHMIA	Background Myocardial bridging may cause compression of a coronary artery, and it has been suggested that myocardial ischemia may result. The clinical significance and prognostic value of myocardial bridging of the left anterior descending coronary artery in children with hypertrophic cardiomyopathy are unknown. We sought to determine the prevalence and clinical effects of myocardial bridging in children with hypertrophic cardiomyopathy who underwent cardiac catheterization. Methods Angiograms from 36 children with hypertrophic cardiomyopathy were reviewed to determine whether myocardial bridging was present and, if so, to assess the characteristics of systolic narrowing of the left anterior descending coronary artery caused by myocardial bridging and the duration of residual diastolic compression. We also reviewed clinical data on these patients. Results Myocardial bridging was present in 10 (28 percent) of the patients. Compression of the left anterior descending coronary artery persisted for a mean (+/-SD) of 50+/-17 percent of diastole. As compared with patients without bridging, patients with bridging had a greater incidence of chest pain (60 percent vs. 19 percent, P=0.04), cardiac arrest with subsequent resuscitation (50 percent vs. 4 percent, P=0.004), and ventricular tachycardia (80 percent vs. 8 percent, P<0.001). On average, the patients with bridging had a reduction in systolic blood pressure with exercise of 17+/-27 mm Hg, as compared with an elevation of 43+/-31 mm Hg in those without bridging (P<0.001). The patients with bridging also had greater ST-segment depression with exercise (median, 5 vs. 0 mm, P=0.004) and a shorter duration of exercise (mean, 6.6+/-2.4 vs. 9.1+/-1.4 minutes, P=0.008). The degree of dispersion of the OT interval corrected for heart rate on the electrocardiogram was greater in patients with bridging than in those without bridging (104+/-46 vs. 48+/-31 msec, P=0.002). Kaplan-Meier estimates of the proportions of patients who had not died or had cardiac arrest with subsequent resuscitation five years after the diagnosis of hypertrophic cardiomyopathy were 67 percent among patients with bridging and 94 percent among those without bridging (P=0.004). Conclusions Myocardial bridging is associated with a poor outcome in children with hypertrophic cardiomyopathy. Our observations suggest that bridging is associated with myocardial ischemia. (N Engl J Med 1998;339:1201-9.) (C) 1998, Massachusetts Medical Society.	Univ Toronto, Hosp Sick Children, Fac Med, Dept Pediat,Div Cardiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Gow, R (corresponding author), Childrens Hosp Eastern Ontario, 401 Smythe Rd, Ottawa, ON K1H 8L1, Canada.							ACHRAFI H, 1992, INT J CARDIOL, V37, P111, DOI 10.1016/0167-5273(92)90138-S; ANGELINI P, 1983, PROG CARDIOVASC DIS, V26, P75, DOI 10.1016/0033-0620(83)90019-1; BORVINICK EH, 1993, J AM COLL CARDIOL, V22, P805; BRAUNWALD E, 1997, HEART DIS TXB CARDIO, P1169; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; CANNON RO, 1985, CIRCULATION, V71, P234, DOI 10.1161/01.CIR.71.2.234; Colleran JA, 1996, AM HEART J, V131, P196, DOI 10.1016/S0002-8703(96)90071-X; COUNIHAN PJ, 1991, CIRCULATION, V84, P686, DOI 10.1161/01.CIR.84.2.686; COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; CUMMING GR, 1978, AM J CARDIOL, V41, P69, DOI 10.1016/0002-9149(78)90134-0; DAY CP, 1990, BRIT HEART J, V63, P342; DAY CP, 1992, BRIT HEART J, V67, P39; DILSIZIAN V, 1993, J AM COLL CARDIOL, V22, P796, DOI 10.1016/0735-1097(93)90193-5; EDWARDS JC, 1956, CIRCULATION, V13, P235, DOI 10.1161/01.CIR.13.2.235; FANANAPAZIR L, 1991, AM J CARDIOL, V67, P280, DOI 10.1016/0002-9149(91)90560-8; FELD H, 1991, CHEST, V99, P1295, DOI 10.1378/chest.99.5.1295; FRENNEAUX MP, 1990, CIRCULATION, V82, P1995, DOI 10.1161/01.CIR.82.6.1995; GARDIN LL, 1994, CAN J CARDIOL, V10, P548; GE JB, 1994, CIRCULATION, V89, P1725, DOI 10.1161/01.CIR.89.4.1725; GEIRINGER E, 1951, AM HEART J, V41, P359, DOI 10.1016/0002-8703(51)90036-1; GREENSPAN M, 1980, CATHETER CARDIO DIAG, V6, P173, DOI 10.1002/ccd.1810060207; ILLERA JP, 1985, INT J CARDIOL, V8, P327, DOI 10.1016/0167-5273(85)90224-4; IRVIN RG, 1982, CHEST, V81, P198, DOI 10.1378/chest.81.2.198; ISHIMORI T, 1977, CATHETER CARDIO DIAG, V3, P59, DOI 10.1002/ccd.1810030107; IVERSEN S, 1992, SCAND J THORAC CARD, V26, P107, DOI 10.3109/14017439209099063; JUILLIERE Y, 1995, AM HEART J, V129, P663, DOI 10.1016/0002-8703(95)90312-7; KITAZUME H, 1983, AM HEART J, V106, P131, DOI 10.1016/0002-8703(83)90450-7; KRAMER JR, 1982, AM HEART J, V103, P283, DOI 10.1016/0002-8703(82)90500-2; Lazzeroni E, 1997, CIRCULATION, V96, P4268; LELE SS, 1995, CIRCULATION, V92, P2886, DOI 10.1161/01.CIR.92.10.2886; MARON BJ, 1979, AM J CARDIOL, V43, P1086, DOI 10.1016/0002-9149(79)90139-5; MCKENNA WJ, 1988, J AM COLL CARDIOL, V11, P147, DOI 10.1016/0735-1097(88)90181-7; MCKENNA WJ, 1984, ARCH DIS CHILD, V59, P971, DOI 10.1136/adc.59.10.971; MIORELLI M, 1994, INT J CARDIOL, V45, P121, DOI 10.1016/0167-5273(94)90267-4; MORALES AR, 1980, CIRCULATION, V62, P230, DOI 10.1161/01.CIR.62.2.230; NAIR C K, 1986, Canadian Journal of Cardiology, V2, P218; NAVARROLOPEZ F, 1986, INT J CARDIOL, V12, P309, DOI 10.1016/0167-5273(86)90267-6; Nezuo S, 1996, J Cardiol, V27, P65; NIHOYANNOPOULOS P, 1992, J AM COLL CARDIOL, V19, P536, DOI 10.1016/S0735-1097(10)80268-2; NOBLE J, 1976, AM J CARDIOL, V37, P993, DOI 10.1016/0002-9149(76)90414-8; NOBLE J, 1977, AM J CARDIOL, V39, P267; PERKIOMAKI JS, 1995, J AM COLL CARDIOL, V26, P174, DOI 10.1016/0735-1097(95)00122-G; Portsmann W., 1960, ROFO FORTSCHR RONTG, V92, P129, DOI 10.1055/s-0029-1226492; REIG J, 1990, PEDIATR CARDIOL, V11, P186, DOI 10.1007/BF02238364; Sadoul N, 1997, CIRCULATION, V96, P2987, DOI 10.1161/01.CIR.96.9.2987; Schwarz ER, 1996, J AM COLL CARDIOL, V27, P1637, DOI 10.1016/0735-1097(96)00062-9; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; Stoletniy LN, 1997, CIRCULATION, V96, P904; VISSCHER DW, 1983, CATHETER CARDIO DIAG, V9, P493, DOI 10.1002/ccd.1810090508; VOELKER W, 1989, INT J CARDIOL, V23, P258, DOI 10.1016/0167-5273(89)90257-X; Vogt PR, 1996, CIRCULATION, V93, P614, DOI 10.1161/01.CIR.93.3.614; VONDOHLEN TW, 1989, AM J CARDIOL, V64, P498, DOI 10.1016/0002-9149(89)90428-1; Vongpatanasin W, 1997, AM HEART J, V133, P463, DOI 10.1016/S0002-8703(97)70190-X; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680	54	183	201	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1201	1209		10.1056/NEJM199810223391704	http://dx.doi.org/10.1056/NEJM199810223391704			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780340				2022-12-28	WOS:000076532400004
J	Deane, M; Crick, D				Deane, M; Crick, D			Outcome of low back pain in general practice - Evidence based practice can improve outcome	BRITISH MEDICAL JOURNAL			English	Letter									Tees Hlth Author, Middlesbrough TS7 0NJ, Cleveland, England		Deane, M (corresponding author), Tees Hlth Author, Middlesbrough TS7 0NJ, Cleveland, England.							BURTON K, 1996, BACK BOOK; CROFT PA, 1998, BRIT MED J, V16, P1356; Deyo RA, 1996, BRIT MED J, V313, P1343, DOI 10.1136/bmj.313.7069.1343; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; *ROYAL COLL GEN PR, 1996, CLIN GUID MAN AC LOW	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1083	1083						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774311				2022-12-28	WOS:000076577200057
J	Suri, C; McClain, J; Thurston, G; McDonald, DM; Zhou, H; Oldmixon, EH; Sato, TN; Yancopoulos, GD				Suri, C; McClain, J; Thurston, G; McDonald, DM; Zhou, H; Oldmixon, EH; Sato, TN; Yancopoulos, GD			Increased vascularization in mice overexpressing angiopoietin-1	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TRANSGENIC MICE; TIE2 RECEPTOR; EXPRESSION; ANGIOGENESIS; NEOVASCULARIZATION; VASCULOGENESIS; LETHALITY; VESSELS; LIGAND	The angiopoietins and members of the vascular endothelial growth factor (VEGF) family are the only growth factors thought to be largely specific for vascular endothelial cells. Targeted gene inactivation studies in mice have shown that VEGF is necessary for the early stages of vascular development and that angiopoietin-1 is required for the later stages of vascular remodeling. Here it is shown that transgenic overexpression of angiopoietin-1 in the skin of mice produces larger, more numerous, and more highly branched vessels. These results raise the possibility that angiopoietins can be used, alone or in combination with VEGF, to promote therapeutic angiogenesis.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Rogers Imaging, Needham, MA 02192 USA; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	Regeneron; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yancopoulos, GD (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.			Thurston, Gavin/0000-0002-4105-5919	NHLBI NIH HHS [HL-24136, HL-59157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136, R01HL059157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAGY JA, 1995, CANCER RES, V55, P360; Okamoto N, 1997, AM J PATHOL, V151, P281; OLDMIXON E, 1994, FASEB J, V8, pA691; OLDMIXON EH, 1989, J APPL PHYSIOL, V67, P1930, DOI 10.1152/jappl.1989.67.5.1930; RISAU W, 1997, NATURE, V386, P631; Robinson GS, 1998, INT OPHTHALMOL CLIN, V38, P89, DOI 10.1097/00004397-199838020-00007; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; Rosenstein JM, 1998, P NATL ACAD SCI USA, V95, P7086, DOI 10.1073/pnas.95.12.7086; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Viac J, 1997, ARCH DERMATOL RES, V289, P158, DOI 10.1007/s004030050172; WEIBEL E, 1979, STEREOLOGICAL METHOD, V1, P143	28	643	714	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					468	471		10.1126/science.282.5388.468	http://dx.doi.org/10.1126/science.282.5388.468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774272				2022-12-28	WOS:000076479600052
J	Burton, EC; Troxclair, DA; Newman, WP				Burton, EC; Troxclair, DA; Newman, WP			Autopsy diagnoses of malignant neoplasms - How often are clinical diagnoses incorrect?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; ACCURACY	Context.-Autopsy often reveals new diagnoses of malignant neoplasms, but as technological advances to improve diagnosis during life have improved, autopsy rates have declined dramatically. Objective.-To determine if there is still a high discordance rate between clinical and autopsy diagnoses of malignant neoplasms despite increasing technological advances in diagnostic methods. Design and Setting.-A 10-year retrospective study (1986-1995) of all autopsies performed at the Medical Center of Louisiana at New Orleans. Participants.-All patients autopsied, excluding preterm fetuses, at the Medical Center of Louisiana at New Orleans, by both Tulane and Louisiana State University Schools of Medicine in which consent was obtained or authorization given from the Orleans Parish Coroner's Office. Main Outcome Measures.-Discordance between clinical and autopsy diagnoses of malignant neoplasms. Results.-A total of 1625 cases were reviewed of which 520 preterm fetuses were excluded. Of the remaining 1105 cases, 654 were male and 451 were female. The mean age was 48.3 years (range, 1-98 years). A total of 433 neoplasms were diagnosed, 250 of which were malignant. One hundred eleven malignant neoplasms in 100 patients had been either undiagnosed or misdiagnosed, and in 57 patients, the immediate cause of death could be attributed to the malignant neoplasm. The discordance between clinical and autopsy diagnoses of malignant neoplasms in this study is 44%, which is similar to previously reported studies. Conclusion.-The discordance rate between clinical and autopsy diagnoses of malignant neoplasms is large and confirms the importance of the postmortem examination.	Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA	Louisiana State University System	Burton, EC (corresponding author), Louisiana State Univ, Med Ctr, Dept Pathol, P5-1,1901 Perdido St, New Orleans, LA 70112 USA.							BAUER FW, 1972, J AMER MED ASSOC, V221, P1471, DOI 10.1001/jama.221.13.1471; BRITTON M, 1974, ACTA MED SCAND, V196, P211; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; GOBBATO F, 1982, HUM PATHOL, V13, P1036, DOI 10.1016/S0046-8177(82)80096-8; KAJIWARA JK, 1993, J INTERN MED, V234, P181, DOI 10.1111/j.1365-2796.1993.tb00728.x; MANZINI VD, 1995, HUM PATHOL, V26, P280, DOI 10.1016/0046-8177(95)90058-6; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P1889, DOI 10.1001/jama.273.24.1889; ROTHWELL DJ, 1993, SNOMED INT MICROGLOS; SARODE VR, 1993, HUM PATHOL, V24, P194, DOI 10.1016/0046-8177(93)90300-6; *SAS I INC, 1990, SAS US GUID STAT VER; STEVANOVIC G, 1986, HUM PATHOL, V17, P1225, DOI 10.1016/S0046-8177(86)80564-0; SUEN KC, 1974, CANCER-AM CANCER SOC, V33, P1164, DOI 10.1002/1097-0142(197404)33:4<1164::AID-CNCR2820330440>3.0.CO;2-O; Wells HG, 1923, J AMER MED ASSOC, V80, P0737, DOI 10.1001/jama.1923.02640380001001	14	115	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1245	1248		10.1001/jama.280.14.1245	http://dx.doi.org/10.1001/jama.280.14.1245			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786374	Bronze			2022-12-28	WOS:000076357900030
J	Crawford, MJ; Wessely, S				Crawford, MJ; Wessely, S			Does initial management affect the rate of repetition of deliberate self harm? Cohort study	BRITISH MEDICAL JOURNAL			English	Article							TRENDS; OXFORD		Inst Psychiat, Sect Epidemiol & Gen Practice, London SE5 8AZ, England; Univ London Kings Coll Hosp, Dept Psychol Med, London SE5 9RS, England	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Crawford, MJ (corresponding author), Inst Psychiat, Sect Epidemiol & Gen Practice, London SE5 8AZ, England.		Wessely, Simon C/A-8713-2008	Crawford, Mike/0000-0003-3137-5772; Wessely, Simon Charles/0000-0002-6743-9929				Crawford MJ, 1998, J ACCID EMERG MED, V15, P18; HAWTON K, 1992, BRIT MED J, V304, P1409, DOI 10.1136/bmj.304.6839.1409; OWENS D, 1994, BRIT J PSYCHIAT, V165, P797, DOI 10.1192/bjp.165.6.797; PLATT S, 1988, PSYCHOL MED, V18, P405, DOI 10.1017/S0033291700007959; Scott J, 1997, BRIT J MED PSYCHOL, V70, P387, DOI 10.1111/j.2044-8341.1997.tb01914.x	5	52	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					985	985		10.1136/bmj.317.7164.985	http://dx.doi.org/10.1136/bmj.317.7164.985			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129EA	9765167	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000076449300024
J	Mead, PS; Griffin, PM				Mead, PS; Griffin, PM			Escherichia coli O157 : H7	LANCET			English	Article							HEMOLYTIC-UREMIC-SYNDROME; SHIGA-LIKE TOXINS; HEMORRHAGIC COLITIS; BLOODY DIARRHEA; SEVERE OUTBREAK; RISK FACTOR; INFECTION; EPIDEMIOLOGY; CHILDREN; MINNESOTA	Escherichia coli O157 was first identified as a human pathogen in 1982. One of several Shiga toxin-producing serotypes known to cause human illness, the organism probably evolved through horizontal acquisition of genes for Shiga toxins and other virulence factors. E coli O157 is found regularly in the faeces of healthy cattle, and is transmitted to humans through contaminated food, water, and direct contact with infected people or animals. Human infection is associated with a wide range of clinical illness, including asymptomatic shedding, non-bloody diarrhoea, haemorrhagic colitis, haemolytic uraemic syndrome, and death. Since laboratory practices vary, physicians need to know whether laboratories in their area routinely test for E coli O157 in stool specimens. Treatment with antimicrobial agents remains controversial: some studies suggest that treatment may precipitate haemolytic uraemic syndrome, and other studies suggest no effect or even a protective effect. Physicians can help to prevent E coli O157 infections by counselling patients about the hazards of consuming undercooked ground meat or unpasteurised milk products and juices, and about the importance of handwashing to prevent the spread of diarrhoeal illness, and by informing public health authorities when they see unusual numbers of cases of bloody diarrhoea or haemolytic uraemic syndrome.	Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Mead, PS (corresponding author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, MS A-38,1600 Clifton Rd, Atlanta, GA 30333 USA.	pfmO@cdc.gov						*ADV COMM MICR SAF, 1995, ESCH COL; Ahmed A., 1998, ESCHERICHIA COLI O15, P59; AKASHI S, 1994, EUR J PEDIATR, V153, P650, DOI 10.1007/s004310050206; ARMSTRONG GD, 1995, J INFECT DIS, V171, P1042, DOI 10.1093/infdis/171.4.1042; BARRETT TJ, 1991, CURR MICROBIOL, V23, P189, DOI 10.1007/BF02092278; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; Bell BP, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.1.e12; BELL BP, 1994, JAMA-J AM MED ASSOC, V272, P1349, DOI 10.1001/jama.272.17.1349; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; Bender JB, 1997, NEW ENGL J MED, V337, P388, DOI 10.1056/NEJM199708073370604; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; Birch M, 1996, EUR J CLIN MICROBIOL, V15, P297, DOI 10.1007/BF01695661; BITZAN M, 1993, EPIDEMIOL INFECT, V110, P183, DOI 10.1017/S0950268800068102; BITZAN M, 1992, IMMUN INFEKT, V20, P168; BRANDT JR, 1994, J PEDIATR-US, V125, P519, DOI 10.1016/S0022-3476(94)70002-8; Calderwood SB, 1996, ASM NEWS, V62, P118; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; CDC, 1997, MMWR-MORBID MORTAL W, V46, P741; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P777; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P4; Chapman PA, 1997, EPIDEMIOL INFECT, V119, P245, DOI 10.1017/S0950268897007826; Chapman PA, 1996, J MED MICROBIOL, V44, P267, DOI 10.1099/00222615-44-4-267; CHART H, 1991, LANCET, V337, P138, DOI 10.1016/0140-6736(91)90801-U; CIMOLAI N, 1994, CLIN NEPHROL, V42, P85; Cransberg K, 1996, CLIN NEPHROL, V46, P45; Germani Y, 1997, LANCET, V349, P1670, DOI 10.1016/S0140-6736(05)62636-0; GIANANTONIO CA, 1964, J PEDIATR-US, V64, P478, DOI 10.1016/S0022-3476(64)80337-1; Griffin Patricia M., 1995, P739; GRIFFIN PM, 1990, GASTROENTEROLOGY, V99, P142, DOI 10.1016/0016-5085(90)91241-W; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; GUNZER F, 1992, J CLIN MICROBIOL, V30, P1807, DOI 10.1128/JCM.30.7.1807-1810.1992; Hancock DD, 1998, PREV VET MED, V35, P11, DOI 10.1016/S0167-5877(98)00050-6; JOHNSON WM, 1983, LANCET, V1, P76; KARCH H, 1995, J CLIN MICROBIOL, V33, P1602, DOI 10.1128/JCM.33.6.1602-1605.1995; Karch H, 1996, EUR J CLIN MICROBIOL, V15, P276, DOI 10.1007/BF01695657; KARMALI MA, 1988, LANCET, V1, P526; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; Keene WE, 1997, JAMA-J AM MED ASSOC, V277, P1229, DOI 10.1001/jama.277.15.1229; KEENE WE, 1994, NEW ENGL J MED, V331, P579, DOI 10.1056/NEJM199409013310904; Kernland KH, 1997, SCHWEIZ MED WSCHR, V127, P1229; LAW D, 1995, INFECT IMMUN, V63, P700, DOI 10.1128/IAI.63.2.700-702.1995; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LESAUX N, 1993, J INFECT DIS, V167, P500, DOI 10.1093/infdis/167.2.500; Lissner R, 1996, INFECTION, V24, P378, DOI 10.1007/BF01716084; LOPEZ EL, 1989, J INFECT DIS, V160, P469, DOI 10.1093/infdis/160.3.469; MacDonald IAR, 1996, EPIDEMIOL INFECT, V116, P279, DOI 10.1017/S0950268800052584; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; MILFORD DV, 1990, ARCH DIS CHILD, V65, P713, DOI 10.1136/adc.65.7.713; MOAKE JL, 1994, LANCET, V343, P393, DOI 10.1016/S0140-6736(94)91227-0; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; NEILD GH, 1994, LANCET, V343, P398, DOI 10.1016/S0140-6736(94)91228-9; *NIH, 1996, INFECT AGENTS SURVEI, V17, P1; *NIH INF DIS CONTR, 1997, INFECT AGENTS SURVEI, V18, P153; OBRIEN AD, 1992, CURR TOP MICROBIOL, V180, P65; Osterholm MT, 1997, EMERG INFECT DIS, V3, P575, DOI 10.3201/eid0304.970424; PAI CH, 1988, J INFECT DIS, V157, P1054, DOI 10.1093/infdis/157.5.1054; Parry SM, 1998, LANCET, V351, P1019, DOI 10.1016/S0140-6736(97)08376-1; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; Pennington Group, 1997, REP CIRC LEAD 1996 O; PIEL CF, 1966, PEDIATR CLIN N AM, V13, P295; PIERARD D, 1992, ACTA CLIN BELG, V47, P387, DOI 10.1080/17843286.1992.11718260; PROULX F, 1992, J PEDIATR-US, V121, P299, DOI 10.1016/S0022-3476(05)81209-0; Rao GG, 1996, J HOSP INFECT, V33, P228, DOI 10.1016/S0195-6701(96)90008-0; REILLY WJ, 1997, SCOTTISH CTR INFEC S, V1, P4; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Rivas M, 1998, MEDICINA-BUENOS AIRE, V58, P1; RODRIGUE DC, 1995, J INFECT DIS, V172, P1122, DOI 10.1093/infdis/172.4.1122; ROWE PC, 1991, J PEDIATR-US, V119, P218, DOI 10.1016/S0022-3476(05)80730-9; ROWE PC, 1994, J PEDIATR-US, V124, P21, DOI 10.1016/S0022-3476(94)70249-7; SAMADPOUR M, 1995, J CLIN MICROBIOL, V33, P2150, DOI 10.1128/JCM.33.8.2150-2154.1995; SCHLIEPER A, 1992, ARCH DIS CHILD, V67, P930, DOI 10.1136/adc.67.7.930; Schmidt H, 1996, MICROBIOL-UK, V142, P907, DOI 10.1099/00221287-142-4-907; Siegler RL, 1995, PEDIATR CLIN N AM, V42, P1505; Slutsker L, 1997, ANN INTERN MED, V126, P505, DOI 10.7326/0003-4819-126-7-199704010-00002; Swerdlow DL, 1997, LANCET, V349, P745, DOI 10.1016/S0140-6736(05)60196-1; Takeda T, 1998, ESCHERICHIA COLI O15, P385; TAPPER D, 1995, J PEDIATR SURG, V30, P158, DOI 10.1016/0022-3468(95)90554-5; Tarr PI, 1996, J INFECT DIS, V174, P1136, DOI 10.1093/infdis/174.5.1136; TARR PI, 1995, CLIN INFECT DIS, V20, P1, DOI 10.1093/clinids/20.1.1; TARR PI, 1989, AM J EPIDEMIOL, V129, P582, DOI 10.1093/oxfordjournals.aje.a115170; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; Thomas A, 1996, EPIDEMIOL INFECT, V117, P1, DOI 10.1017/S0950268800001060; Tilden J, 1996, AM J PUBLIC HEALTH, V86, P1142, DOI 10.2105/AJPH.86.8_Pt_1.1142; VANWIERINGEN PM, 1974, ARCH DIS CHILD, V49, P432, DOI 10.1136/adc.49.6.432; Wall P G, 1996, Commun Dis Rep CDR Rev, V6, pR26; WATERS JR, 1994, CLIN INFECT DIS, V19, P834, DOI 10.1093/clinids/19.5.834; WHITTAM TS, 1993, INFECT IMMUN, V61, P1619, DOI 10.1128/IAI.61.5.1619-1629.1993	88	493	521	1	95	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1998	352	9135					1207	1212		10.1016/S0140-6736(98)01267-7	http://dx.doi.org/10.1016/S0140-6736(98)01267-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777854	Green Submitted			2022-12-28	WOS:000076415400040
J	Koop, CE				Koop, CE			Protecting medicine in the 21st century	SCIENCE			English	Editorial Material									Dartmouth Coll, Sch Med, Hanover, NH 03755 USA; Dartmouth Coll, C Everett Koop Inst, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Koop, CE (corresponding author), Dartmouth Coll, Sch Med, Hanover, NH 03755 USA.								0	4	4	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					1952	1953		10.1126/science.281.5385.1952	http://dx.doi.org/10.1126/science.281.5385.1952			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9767037				2022-12-28	WOS:000076161800019
J	Lanphear, BP				Lanphear, BP			Environmental health - The paradox of lead poisoning prevention	SCIENCE			English	Article							PAINT HAZARD REMEDIATION; CONTAMINATED HOUSE-DUST; COGNITIVE FUNCTION; EXPOSURE; CHILDREN; CHILDHOOD; ABATEMENT; INTELLIGENCE; IMPACT		Univ Cincinnati, Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Lanphear, BP (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA.	bruce.lanphear@chmcc.org						AMITAI Y, 1991, PEDIATRICS, V88, P893; Aschengrau A, 1997, AM J PUBLIC HEALTH, V87, P1698, DOI 10.2105/AJPH.87.10.1698; BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; BELLINGER D, 1994, PEDIATR ANN, V23, P600, DOI 10.3928/0090-4481-19941101-08; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P141; *CDC, 1997, SCREEN YOUNG CHILDRE; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; CHARNEY E, 1983, NEW ENGL J MED, V309, P1089, DOI 10.1056/NEJM198311033091804; CHISOLM JJ, 1986, AM J PUBLIC HEALTH, V26, P236; CLARK CS, 1985, ENVIRON RES, V38, P46, DOI 10.1016/0013-9351(85)90071-4; DIETRICH KN, 1993, PEDIATRICS, V91, P301; FARFEL MR, 1994, ENVIRON RES, V66, P217, DOI 10.1006/enrs.1994.1057; FARFEL MR, 1990, AM J PUBLIC HEALTH, V80, P1240, DOI 10.2105/AJPH.80.10.1240; HARVEY B, 1994, PEDIATRICS, V93, P201; HAYES EB, 1994, PEDIATRICS, V93, P195; Lanphear BP, 1998, PEDIATRICS, V101, P264, DOI 10.1542/peds.101.2.264; LANPHEAR BP, 1995, ENVIRON RES, V68, P114, DOI 10.1006/enrs.1995.1015; Lanphear BP, 1997, ENVIRON RES, V74, P67, DOI 10.1006/enrs.1997.3726; Lanphear BP, 1996, AM J PUBLIC HEALTH, V86, P1460, DOI 10.2105/AJPH.86.10.1460; Lanphear BP, 1996, AM J PUBLIC HEALTH, V86, P1416, DOI 10.2105/AJPH.86.10.1416; LANPHEAR BP, IN PRESS ENV RES; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; RABINOWITZ M, 1985, ENVIRON RES, V38, P96, DOI 10.1016/0013-9351(85)90075-1; REYALVAREZ S, 1987, PEDIATRICS, V79, P214; ROSNER D, 1985, AM J PUBLIC HEALTH, V75, P344, DOI 10.2105/AJPH.75.4.344; SARGENT JD, 1995, AM J PUBLIC HEALTH, V85, P528, DOI 10.2105/AJPH.85.4.528; SHANNON MW, 1992, PEDIATRICS, V89, P87; STAES C, 1994, AM J EPIDEMIOL, V139, P1016, DOI 10.1093/oxfordjournals.aje.a116941; SWINDELL SL, 1994, CLIN PEDIATR, V33, P536, DOI 10.1177/000992289403300905; THACKER SB, 1992, ARCH ENVIRON HEALTH, V47, P336, DOI 10.1080/00039896.1992.9938372; *US DEP HOUS URB D, 1995, GUID CONTR LEAD BAS; *US EPA, 1996, 747R95009 US EPA	36	83	84	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1617	1618		10.1126/science.281.5383.1617	http://dx.doi.org/10.1126/science.281.5383.1617			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	118TR	9767027				2022-12-28	WOS:000075856500029
J	Doll, R				Doll, R			Controlled trials: the 1948 watershed	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Oxford, Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Doll, R (corresponding author), Univ Oxford, Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1934, BRIT MED J, V1934, P241; [Anonymous], 1951, BMJ-BRIT MED J, V1, P1463; [Anonymous], J MINISTRY AGR; [Anonymous], 1948, BMJ-BRIT MED J, V2, P769; Armitage P, 1982, Stat Med, V1, P345, DOI 10.1002/sim.4780010412; Bradford Hill A., 1937, PRINCIPLES MED STAT; Burns Amberson J., 1931, AM REV TUBERC, V24, P401; COLLINS R, 1992, INTRO NEW TREATMENTS; DOLL R, 1964, Scott Med J, V9, P183; Fibiger J, 1898, HOSPITALSTIDENDE, V6, P309; HILL AB, 1963, BMJ-BRIT MED J, P1043, DOI 10.1136/bmj.1.5337.1043; HILL AB, 1990, CONTROL CLIN TRIALS, V11, P77; LEWIS T, 1934, CLIN SCI ILLUSTRATED, P178; *MRC GREAT BRIT SU, 1955, BMJ-BRIT MED J, V1, P555; *MRC PAT CLIN TRIA, 1944, LANCET, V2, P373; *MRC WORK PART LEU, 1985, LANCET, V1, P408; WILSON C, 1946, LANCET, V250, P881	18	85	90	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	1998	317	7167					1217	1220		10.1136/bmj.317.7167.1217	http://dx.doi.org/10.1136/bmj.317.7167.1217			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794864	Green Published			2022-12-28	WOS:000076963000027
J	Lund, JN; Buckley, D; Bennett, D; Maxwell-Armstrong, C; Smith, A; Tierney, G; Scholefield, J				Lund, JN; Buckley, D; Bennett, D; Maxwell-Armstrong, C; Smith, A; Tierney, G; Scholefield, J			A randomised trial of hospital versus home administered enemas for flexible sigmoidoscopy	BRITISH MEDICAL JOURNAL			English	Article							OUTPATIENT BOWEL PREPARATION		Univ Nottingham Hosp, Dept Surg, Nottingham NG7 2UH, England	University of Nottingham	Lund, JN (corresponding author), Univ Nottingham Hosp, Dept Surg, Nottingham NG7 2UH, England.		Lund, Jonathan/K-6631-2019	Lund, Jonathan/0000-0001-5195-2181; Tierney, Gillian/0000-0001-8222-0258				Heymann TD, 1996, BRIT MED J, V313, P727; Le TH, 1997, SOUTHERN MED J, V90, P526, DOI 10.1097/00007611-199705000-00013; Lee EC, 1996, DIS COLON RECTUM, V39, P369, DOI 10.1007/BF02054048	3	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1201	1201		10.1136/bmj.317.7167.1201	http://dx.doi.org/10.1136/bmj.317.7167.1201			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794856	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000076963000023
J	Beecham, L				Beecham, L			GPs welcome NHS information strategy	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1161	1161						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784475				2022-12-28	WOS:000076755100079
J	Trauner, M; Meier, PJ; Boyer, JL				Trauner, M; Meier, PJ; Boyer, JL			Mechanisms of disease - Molecular pathogenesis of cholestasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL INTRAHEPATIC CHOLESTASIS; PRIMARY BILIARY-CIRRHOSIS; CONJUGATE EXPORT PUMP; BILE-DUCT LIGATION; PLASMA-MEMBRANE PROTEINS; ISOLATED RAT HEPATOCYTES; RESISTANCE GENE-PRODUCT; DUBIN-JOHNSON SYNDROME; MDR2 P-GLYCOPROTEIN; URSODEOXYCHOLIC ACID		Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Liver, New Haven, CT 06510 USA; Karl Franzens Univ Graz, Dept Med, Div Gastroenterol & Hepatol, A-8010 Graz, Austria; Univ Zurich Hosp, Dept Med, Div Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland	Yale University; Yale University; University of Graz; University of Zurich; University Zurich Hospital	Boyer, JL (corresponding author), Yale Univ, Sch Med, Dept Med, POB 208109, New Haven, CT 06520 USA.			Trauner, Michael/0000-0002-1275-6425				ALPINI G, 1994, AM J PHYSIOL, V266, pG922, DOI 10.1152/ajpgi.1994.266.5.G922; ANDERSON JM, 1989, AM J PATHOL, V134, P1055; Anderson JM, 1996, GASTROENTEROLOGY, V110, P1662, DOI 10.1053/gast.1996.v110.agast961662; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; Beuers U, 1996, GASTROENTEROLOGY, V110, P1553, DOI 10.1053/gast.1996.v110.pm8613063; BEUERS U, 1993, GASTROENTEROLOGY, V104, P604, DOI 10.1016/0016-5085(93)90433-D; BEUERS U, 1993, J CLIN INVEST, V92, P2984, DOI 10.1172/JCI116921; BOHME M, 1994, GASTROENTEROLOGY, V107, P255; Bolder U, 1997, GASTROENTEROLOGY, V112, P214, DOI 10.1016/S0016-5085(97)70238-5; BOSSARD R, 1993, J CLIN INVEST, V91, P2714, DOI 10.1172/JCI116511; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; Boyer JL, 1996, AM J PHYSIOL-GASTR L, V270, pG1, DOI 10.1152/ajpgi.1996.270.1.G1; Buchler M, 1996, J BIOL CHEM, V271, P15091; Bull LN, 1997, HEPATOLOGY, V26, P155; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; CALMUS Y, 1990, HEPATOLOGY, V11, P12, DOI 10.1002/hep.1840110104; CARLTON VEH, 1995, HUM MOL GENET, V4, P1049, DOI 10.1093/hmg/4.6.1049; CHANG AGY, 1994, GASTROENTEROLOGY, V106, P1076, DOI 10.1016/0016-5085(94)90771-4; Che MX, 1997, FASEB J, V11, P101, DOI 10.1096/fasebj.11.2.9039951; CHILDS S, 1995, CANCER RES, V55, P2029; Chojkier M, 1995, Prog Liver Dis, V13, P37; COHN JA, 1993, GASTROENTEROLOGY, V105, P1857, DOI 10.1016/0016-5085(93)91085-V; COLOMBO C, 1994, SEMIN LIVER DIS, V14, P259, DOI 10.1055/s-2007-1007316; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Deleuze JF, 1996, HEPATOLOGY, V23, P904, DOI 10.1002/hep.510230435; DIXON BS, 1993, AM J PHYSIOL, V265, pG686, DOI 10.1152/ajpgi.1993.265.4.G686; Dumont M, 1997, J HEPATOL, V27, P1051, DOI 10.1016/S0168-8278(97)80149-3; Dumoulin FL, 1997, J HEPATOL, V26, P852, DOI 10.1016/S0168-8278(97)80252-8; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; Elferink RPJO, 1997, FASEB J, V11, P19, DOI 10.1096/fasebj.11.1.9034162; FALLON MB, 1995, AM J PHYSIOL-CELL PH, V269, pC1057, DOI 10.1152/ajpcell.1995.269.4.C1057; FALLON MB, 1993, AM J PHYSIOL, V264, pC1439, DOI 10.1152/ajpcell.1993.264.6.C1439; FALLON MB, 1995, AM J PHYSIOL-CELL PH, V268, pC1186, DOI 10.1152/ajpcell.1995.268.5.C1186; Gartung C, 1997, HEPATOLOGY, V25, P284; Gartung C, 1996, GASTROENTEROLOGY, V110, P199, DOI 10.1053/gast.1996.v110.pm8536857; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Green RM, 1996, GASTROENTEROLOGY, V111, P193, DOI 10.1053/gast.1996.v111.pm8698199; GRUBMAN SA, 1995, GASTROENTEROLOGY, V108, P584, DOI 10.1016/0016-5085(95)90089-6; GULDUTUNA S, 1993, GASTROENTEROLOGY, V104, P1736; Hagenbuch B, 1996, SEMIN LIVER DIS, V16, P129, DOI 10.1055/s-2007-1007226; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; HILLAIRE S, 1994, GASTROENTEROLOGY, V107, P781, DOI 10.1016/0016-5085(94)90127-9; HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380; JAZRAWI RP, 1994, GASTROENTEROLOGY, V106, P134, DOI 10.1016/S0016-5085(94)94899-2; JONES AL, 1976, GASTROENTEROLOGY, V71, P1050; KADMON M, 1993, GASTROENTEROLOGY, V104, P1507, DOI 10.1016/0016-5085(93)90363-H; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Keppler D, 1996, Prog Liver Dis, V14, P55; Keppler D, 1997, FASEB J, V11, P509, DOI 10.1096/fasebj.11.7.9212074; KullakUblick GA, 1997, HEPATOLOGY, V26, P991, DOI 10.1002/hep.510260429; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; LARKIN JM, 1991, J CELL SCI, V98, P205; Lindor KD, 1997, NEW ENGL J MED, V336, P691, DOI 10.1056/NEJM199703063361003; MARKS DL, 1995, GASTROENTEROLOGY, V108, P824, DOI 10.1016/0016-5085(95)90457-3; MARTINEZANSO E, 1994, HEPATOLOGY, V19, P1400, DOI 10.1002/hep.1840190613; Medina JF, 1997, HEPATOLOGY, V25, P12, DOI 10.1053/jhep.1997.v25.pm0008985258; Moseley RH, 1997, GASTROENTEROLOGY, V112, P302, DOI 10.1016/S0016-5085(97)70250-6; Moseley RH, 1996, AM J PHYSIOL-GASTR L, V271, pG137, DOI 10.1152/ajpgi.1996.271.1.G137; Muller M., 1996, Hepatology, V24, p368A; Nathanson M H, 1996, Prog Liver Dis, V14, P1; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; Nozawa S, 1997, GASTROENTEROLOGY, V112, pA1349; Ortiz DF, 1997, J BIOL CHEM, V272, P15358, DOI 10.1074/jbc.272.24.15358; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PHILLIPS MJ, 1986, LAB INVEST, V54, P593; POUPON R, 1995, PHARMACOL THERAPEUT, V66, P1, DOI 10.1016/0163-7258(94)00073-C; Poupon RE, 1997, GASTROENTEROLOGY, V113, P884, DOI 10.1016/S0016-5085(97)70183-5; Preisegger KH, 1996, HEPATOLOGY, V24, P248, DOI 10.1002/hep.510240139; PRIETO J, 1993, GASTROENTEROLOGY, V105, P572, DOI 10.1016/0016-5085(93)90735-U; Rahner C, 1996, GASTROENTEROLOGY, V110, P1564, DOI 10.1053/gast.1996.v110.pm8613064; Reichen Juerg, 1994, P1291; RODRIGUEZHENCHE N, 1994, HEPATOLOGY, V20, P1041, DOI 10.1002/hep.1840200437; SCHRENK D, 1993, HEPATOLOGY, V17, P854, DOI 10.1016/0270-9139(93)90162-G; SelaHerman S, 1996, BIOCHEM MOL MED, V59, P98, DOI 10.1006/bmme.1996.0073; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; SHIMOKURA GH, 1995, GASTROENTEROLOGY, V109, P965, DOI 10.1016/0016-5085(95)90407-7; Shneider BL, 1997, HEPATOLOGY, V25, P1176, DOI 10.1002/hep.510250521; Simon FR, 1996, AM J PHYSIOL-GASTR L, V271, pG1043, DOI 10.1152/ajpgi.1996.271.6.G1043; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; Stieger B, 1996, J HEPATOL, V24, P128; STIEGER B, 1994, HEPATOLOGY, V20, P201, DOI 10.1016/0270-9139(94)90154-6; STIEGER B, 1994, HEPATOLOGY, V20, P772; Strautnieks SS, 1997, AM J HUM GENET, V61, P630, DOI 10.1086/515501; Strazzabosco M, 1996, J HEPATOL, V24, P631, DOI 10.1016/S0168-8278(96)80153-X; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Trauner M, 1997, GASTROENTEROLOGY, V113, P255, DOI 10.1016/S0016-5085(97)70103-3; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; vanNieuwkerk CMJ, 1996, GASTROENTEROLOGY, V111, P165, DOI 10.1053/gast.1996.v111.pm8698195; VAZQUEZ JJ, 1995, AM J PATHOL, V146, P1422; WEBER AM, 1981, GASTROENTEROLOGY, V81, P653; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1993, P NATL ACAD SCI USA, V90, P4601, DOI 10.1073/pnas.90.10.4601; YOSHIKAWA M, 1992, HEPATOLOGY, V16, P358, DOI 10.1002/hep.1840160213	96	585	604	0	47	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1217	1227		10.1056/NEJM199810223391707	http://dx.doi.org/10.1056/NEJM199810223391707			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780343				2022-12-28	WOS:000076532400007
J	Bates, DW; Leape, LL; Cullen, DJ; Laird, N; Petersen, LA; Teich, JM; Burdick, E; Hickey, M; Kleefield, S; Shea, B; Vander Vliet, M; Seger, DL				Bates, DW; Leape, LL; Cullen, DJ; Laird, N; Petersen, LA; Teich, JM; Burdick, E; Hickey, M; Kleefield, S; Shea, B; Vander Vliet, M; Seger, DL			Effect of computerized physician order entry and a team intervention on prevention of serious medication errors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; HOSPITALIZED-PATIENTS; PREVENTABILITY; PHARMACISTS; MORTALITY; SYSTEMS; IMPACT	Context.-Adverse drug events (ADEs) are a significant and costly cause of injury during hospitalization. Objectives.-To evaluate the efficacy of 2 interventions for preventing nonintercepted serious medication errors, defined as those that either resulted in or had potential to result in an ADE and were not intercepted before reaching the patient. Design.-Before-after comparison between phase 1 (baseline) and phase 2 (after intervention was implemented) and, within phase 2, a randomized comparison between physican computer order entry (POE) and the combination of POE plus a team intervention. Setting.-Large tertiary care hospital. Participants.-For the comparison of phase 1 and 2, all patients admitted to a stratified random sample of 6 medical and surgical units in a tertiary care hospital over a 6-month period, and for the randomized comparison during phase 2, all patients admitted to the same units and 2 randomly selected additional units over a subsequent 9-month period. Interventions.-A physician computer order entry system (POE) for all units and a team-based intervention that included changing the role of pharmacists, implemented for half the units. Main Outcome Measure.-Nonintercepted serious medication errors. Results.-Comparing identical units between phases 1 and 2, nonintercepted serious medication errors decreased 55%, from 10.7 events per 1000 patient-days to 4.86 events per 1000 (P=.01). The decline occurred for all stages of the medication-use process. Preventable ADEs declined 17% from 4.69 to 3.88 (P=.37), while nonintercepted potential ADEs declined 84% from 5.99 to 0.98 per 1000 patient-days (P=.002). When POE-only was compared with the POE plus team intervention combined, the team intervention conferred no additonal benefit over POE. Conclusions.-Physician computer order entry decreased the rate of nonintercepted serious medication errors by more than half, although this decrease was larger for potential ADEs than for errors that actually resulted in an ADE.	Brigham & Womens Hosp, Div Gen Med & Primary Care, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Qual Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pharm, Boston, MA 02115 USA; Partners Healthcare Syst, Ctr Appl Med Informat Syst Res, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; St Elizabeths Med Ctr, Dept Anesthesiol, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brockton W Roxbury Vet Affairs Med Ctr, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; St. Elizabeth's Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, Dept Med, 75 Francis St, Boston, MA 02115 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BROWN G, 1991, AM J HOSP PHARM, V48, P2644, DOI 10.1093/ajhp/48.12.2644; BROWN GC, 1979, HOSPITALS, V53, P61; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; FOLLI HL, 1987, PEDIATRICS, V79, P718; GLASER J, 1996, 1996 HEALTHC INF MAN, P1; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; KUPERMAN GJ, 1994, P ANN S COMPUT APPL, V18, P836; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MASSARO TA, 1993, ACAD MED, V68, P20, DOI 10.1097/00001888-199301000-00003; PATERNO M, 1996, P AMIA ANN FALL S, V20, P872; Perrow C, 1984, NORMAL ACCIDENTS; *SAS I INC, 1992, SAS VERS 6 11; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; TEICH JM, 1993, P ANN S COMPUT APPL, V17, P316; TEICH JM, 1992, P ANN S COMPUT APPL, V16, P99; TEICH JM, 1996, 2 NE DAV CPR REC S M, P3; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379	29	1382	1405	0	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1311	1316		10.1001/jama.280.15.1311	http://dx.doi.org/10.1001/jama.280.15.1311			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794308				2022-12-28	WOS:000076472500021
J	Hope, T; Hicks, N; Reynolds, DJM; Crisp, R; Griffiths, S				Hope, T; Hicks, N; Reynolds, DJM; Crisp, R; Griffiths, S			Rationing and the health authority	BRITISH MEDICAL JOURNAL			English	Article							PRIORITY CRITERIA PROJECT		Inst Hlth Sci, Div Publ Hlth & Primary Care, Oxford OX3 7LF, England; Oxfordshire Hlth Author, Directorate Publ Hlth & Hlth Policy, Oxford OX3 7LG, England; John Radcliffe Hosp, Dept Clin Pharmacol, Oxford OX3 9DU, England; Univ Oxford St Annes Coll, Oxford OX2 6HS, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford	Hope, T (corresponding author), Inst Hlth Sci, Div Publ Hlth & Primary Care, Oxford OX3 7LF, England.			Hicks, Nicholas/0000-0002-7214-9678				*GOV COMM CHOIC HL, 1992, REP GOV COMM CHOIC H; GRAY A, IN PRESS J NEUROL SC; Hadorn DC, 1997, BRIT MED J, V314, P131, DOI 10.1136/bmj.314.7074.131; Hadorn DC, 1997, BRIT MED J, V314, P135, DOI 10.1136/bmj.314.7074.135; HARRIS J, 1997, BRIT MED J, V314, P663; New B, 1996, BRIT MED J, V312, P1593, DOI 10.1136/bmj.312.7046.1593; Newton JN, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000246014	7	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1067	1069						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774299				2022-12-28	WOS:000076577200033
J	Appenzeller, C; Stocker, TF; Anklin, M				Appenzeller, C; Stocker, TF; Anklin, M			North Atlantic oscillation dynamics recorded in Greenland ice cores	SCIENCE			English	Article							CLIMATE-CHANGE; WAVELET ANALYSIS; TEMPERATURE; HEMISPHERE; WINTER; OCEAN; TELECONNECTIONS; PREDICTABILITY; CIRCULATION; TRENDS	Carefully selected ice core data from Greenland can be used to reconstruct an annual proxy North Atlantic oscillation (NAO) index. This index for the past 350 years indicates that the NAO is an intermittent climate oscillation with temporally active (coherent) and passive (incoherent) phases. No indication for a single, ;persistent, multiannual NAO frequency is found. In active phases, most of the energy is located in the frequency band with periods less than about 15 years. In addition, variability on time scales of 80 to 90 years has been observed since the mid-19th century.	Univ Bern, CH-3012 Bern, Switzerland; Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA	University of Bern; University of Arizona	Appenzeller, C (corresponding author), Univ Bern, Sidlerstr 5, CH-3012 Bern, Switzerland.	christof.appenzeller@climate.unibe.ch	Stocker, Thomas/B-1273-2013; Appenzeller, Christof/AAA-8989-2022; Appenzeller, Christof/B-3015-2013	Appenzeller, Christof/0000-0002-9939-9845; Appenzeller, Christof/0000-0002-9939-9845				ANKLIN M, IN PRESS J GEOPHYS R; Appenzeller C, 1998, GEOPHYS RES LETT, V25, P1939, DOI 10.1029/98GL01227; Baliunas S, 1997, GEOPHYS RES LETT, V24, P1351, DOI 10.1029/97GL01184; BARLOW LK, 1993, GEOPHYS RES LETT, V20, P2901, DOI 10.1029/93GL03305; Cook ER, 1998, HOLOCENE, V8, P9, DOI 10.1191/095968398677793725; COOK ER, 1994, Q SCI REV, V12, P431; DARRIGO RD, 1993, QUATERNARY SCI REV, V12, P431, DOI 10.1016/S0277-3791(05)80007-1; DELWORTH T, 1993, J CLIMATE, V6, P1993, DOI 10.1175/1520-0442(1993)006<1993:IVOTTC>2.0.CO;2; DESER C, 1993, J CLIMATE, V6, P1743, DOI 10.1175/1520-0442(1993)006<1743:SCVOTN>2.0.CO;2; FISHER DA, 1996, CLIMATE VARIATIONS F, V41, P297; FOLLAND CK, 1990, SCI ASSESSMENT CLIMA, P195; GIBSON JK, 1997, ERA DESCRIPTION, V1; GRASSL H, 1997, CLIVAR RES PROGRAM C; Griffies SM, 1997, SCIENCE, V275, P181, DOI 10.1126/science.275.5297.181; Hurrell JW, 1996, GEOPHYS RES LETT, V23, P665, DOI 10.1029/96GL00459; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Hurrell JW, 1997, CLIMATIC CHANGE, V36, P301, DOI 10.1023/A:1005314315270; Jones PD, 1997, INT J CLIMATOL, V17, P1433, DOI 10.1002/(SICI)1097-0088(19971115)17:13<1433::AID-JOC203>3.0.CO;2-P; Kumar P, 1997, REV GEOPHYS, V35, P385, DOI 10.1029/97RG00427; Latif M, 1998, J CLIMATE, V11, P602, DOI 10.1175/1520-0442(1998)011<0602:DOIVIC>2.0.CO;2; Mahasenan N, 1997, GEOPHYS RES LETT, V24, P563, DOI 10.1029/97GL00319; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; McCartney M, 1997, NATURE, V388, P521, DOI 10.1038/41438; MEESE DA, 1994, SCIENCE, V266, P1680, DOI 10.1126/science.266.5191.1680; PERLWITZ J, 1995, J CLIMATE, V8, P2281, DOI 10.1175/1520-0442(1995)008<2281:TSCBTA>2.0.CO;2; ROGERS JC, 1984, MON WEATHER REV, V112, P1999, DOI 10.1175/1520-0493(1984)112<1999:TABTNA>2.0.CO;2; STOCKER TF, 1992, CLIMATIC CHANGE, V20, P227, DOI 10.1007/BF00139840; Sutton RT, 1997, NATURE, V388, P563, DOI 10.1038/41523; Thompson DWJ, 1998, GEOPHYS RES LETT, V25, P1297, DOI 10.1029/98GL00950; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; VANLOON H, 1978, MON WEATHER REV, V106, P296, DOI 10.1175/1520-0493(1978)106<0296:TSIWTB>2.0.CO;2; Walker G T, 1932, MEM R METEOROL SOC, V4, P53; WALLACE JM, 1981, MON WEATHER REV, V109, P784, DOI 10.1175/1520-0493(1981)109<0784:TITGHF>2.0.CO;2; White JWC, 1997, J GEOPHYS RES-OCEANS, V102, P26425, DOI 10.1029/97JC00162; WHITE JWC, 1996, CLIMATE VARIATIONS F, V41, P193; [No title captured]	36	244	249	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					446	449		10.1126/science.282.5388.446	http://dx.doi.org/10.1126/science.282.5388.446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774265				2022-12-28	WOS:000076479600045
J	McKenna, WJ; Coccolo, F; Elliott, PM				McKenna, WJ; Coccolo, F; Elliott, PM			Genes and disease expression in hypertrophic cardiomyopathy	LANCET			English	Editorial Material							CARDIAC TROPONIN-T; ALPHA-TROPOMYOSIN; MUTATIONS; MYOSIN; SITE		St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England	St Georges University London	McKenna, WJ (corresponding author), St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England.		McKenna, William J/C-3243-2008; Elliott, Perry/AAR-3430-2020	McKenna, William J/0000-0001-7994-2460; Elliott, Perry/0000-0003-3383-3984				BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; Charron P, 1998, CIRCULATION, V97, P2230, DOI 10.1161/01.CIR.97.22.2230; DUFOUR C, 1994, J MOL CELL CARDIOL, V26, P1241, DOI 10.1006/jmcc.1994.1142; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; KARAM R, 1989, J AM COLL CARDIOL, V13, P580, DOI 10.1016/0735-1097(89)90596-2; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; LECHIN M, 1995, CIRCULATION, V92, P1808, DOI 10.1161/01.CIR.92.7.1808; LEWIS JF, 1994, AM J CARDIOL, V73, P1105, DOI 10.1016/0002-9149(94)90291-7; MACRAE CA, 1995, J CLIN INVEST, V96, P1216, DOI 10.1172/JCI118154; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603	16	17	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1162	1163		10.1016/S0140-6736(98)00033-6	http://dx.doi.org/10.1016/S0140-6736(98)00033-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777827				2022-12-28	WOS:000076415400002
J	[Anonymous]				[Anonymous]			The second phase of priority setting	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 10	1998	317	7164					1000	1000						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765174				2022-12-28	WOS:000076449300029
J	Waltzer, L; Bienz, M				Waltzer, L; Bienz, M			Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling	NATURE			English	Article							BETA-CATENIN; HISTONE ACETYLTRANSFERASES; ENDODERM INDUCTION; GENE-EXPRESSION; TARGET GENE; ACTIVATION; ARMADILLO; COACTIVATOR; ACETYLATION; COMPLEX	T-cell factor (TCF), a high-mobility-group domain protein, is the transcription factor activated by Wnt/Wingless signalling(1-4). When signalling occurs, TCF binds to its coactivator, beta-catenin/Armadillo, and stimulates the transcription of the target genes of Wnt/Wingless by binding to TCF-responsive enhancers(1,5). Inappropriate activation of TCF in the colon epithelium and other cells leads to cancer(6-8). It is therefore desirable for unstimulated cells to have a negative control mechanism to keep TCF inactive. Here we report that Drosophila CREB-binding protein (dCBP)(9,10) binds to dTCF. dCBP mutants show mild Wingless overactivation phenotypes in various tissues. Consistent with this, dCBP loss-of-function suppresses the effects of armadillo mutation. Moreover, our data show that dCBP acetylates a conserved lysine in the Armadillo-binding domain of dTCF, and that this acetylation lowers the affinity of Armadillo binding to dTCF. Although CBP is a coactivator of other transcription factors(11,12), our data show that CBP represses TCF.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bienz, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Waltzer, Lucas/0000-0002-5361-727X				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CHIVRIA JC, 1993, NATURE, V365, P855; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PEIFER M, 1994, DEVELOPMENT, V120, P369; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Riese J, 1997, DEVELOPMENT, V124, P3353; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Szuts D, 1997, DEVELOPMENT, V124, P3209; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yu X, 1996, DEVELOPMENT, V122, P849	29	314	318	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1998	395	6701					521	525		10.1038/26785	http://dx.doi.org/10.1038/26785			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774110				2022-12-28	WOS:000076212200061
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Metastasis in eggs	SCIENCE			English	Article																		KIM J, 1998, CELL, V353	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1823	1823		10.1126/science.281.5384.1823	http://dx.doi.org/10.1126/science.281.5384.1823			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9776688				2022-12-28	WOS:000076007100043
J	Dewar, HA				Dewar, HA			A patient to remember - A surfeit of experts	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1200	1200		10.1136/bmj.317.7167.1200	http://dx.doi.org/10.1136/bmj.317.7167.1200			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794855	Green Published			2022-12-28	WOS:000076963000022
J	Herminghaus, S; Jacobs, K; Mecke, K; Bischof, J; Fery, A; Ibn-Elhaj, M; Schlagowski, S				Herminghaus, S; Jacobs, K; Mecke, K; Bischof, J; Fery, A; Ibn-Elhaj, M; Schlagowski, S			Spinodal dewetting in liquid crystal and liquid metal films	SCIENCE			English	Article							THIN POLYMER-FILMS; SURFACES; NUCLEATION; RUPTURE; GROWTH; FLUID	Theory predicts that dewetting of a homogeneous liquid film from a solid surface may proceed via unstable surface waves on the Liquid. This phenomenon, usually termed spinodal dewetting, has been sought after in many systems. Observations in liquid crystal and Liquid metal films showed that, as expected, the emerging structures were similar to those found for spinodal decomposition in mixtures. Certain differences, however, could be attributed to peculiarities of the wetting forces in these two dissimilar systems, thereby demonstrating the role of nonlinearities inherent in the wetting forces.	Max Planck Inst Colloid & Interface Sci, D-12489 Berlin, Germany; Berg Univ Wuppertal, Fac Phys, D-42097 Wuppertal, Germany; Univ Konstanz, Fac Phys, D-78434 Constance, Germany	Max Planck Society; University of Wuppertal; University of Konstanz	Herminghaus, S (corresponding author), Max Planck Inst Colloid & Interface Sci, Rodower Chaussee 5, D-12489 Berlin, Germany.	heninghaus@mpikg.fta-berlin.de	Fery, Andreas/E-3673-2014; Jacobs, Karin/E-7377-2012; Herminghaus, Stephan/D-1904-2009; Mecke, Klaus R/C-5562-2013	Fery, Andreas/0000-0001-6692-3762; Jacobs, Karin/0000-0002-2963-2533; 				Bischof J, 1996, PHYS REV LETT, V77, P1536, DOI 10.1103/PhysRevLett.77.1536; BROCHARDWYART F, 1994, LANGMUIR, V10, P1566, DOI 10.1021/la00017a040; CAHN JW, 1965, J CHEM PHYS, V42, P93, DOI 10.1063/1.1695731; DEGENNES PG, 1990, LANGMUIR, V6, P1448, DOI 10.1021/la00099a003; Dietrich S., 1988, PHASE TRANSITIONS CR, V12, P1; ELBAUM M, 1994, PHYS REV LETT, V72, P3562, DOI 10.1103/PhysRevLett.72.3562; GODBOLE MJ, 1992, MATER RES SOC SYMP P, V235, P583; Henn G, 1996, MACROMOLECULES, V29, P4305, DOI 10.1021/ma9500392; Herminghaus S, 1997, ULTRAMICROSCOPY, V69, P211, DOI 10.1016/S0304-3991(97)00049-1; Ibn-Elhaj M, 1998, LANGMUIR, V14, P504, DOI 10.1021/la970761o; IIDA T, 1987, PHYSICAL PROPERTIES; Jacobs K, 1998, LANGMUIR, V14, P965, DOI 10.1021/la970954b; Khanna R, 1997, J COLLOID INTERF SCI, V195, P42, DOI 10.1006/jcis.1997.5134; MECKE KR, 1994, ASTRON ASTROPHYS, V288, P697; MITLIN VS, 1993, J COLLOID INTERF SCI, V156, P491, DOI 10.1006/jcis.1993.1142; OCKO BM, 1986, PHYS REV LETT, V57, P94, DOI 10.1103/PhysRevLett.57.94; Ragil K, 1996, PHYS REV LETT, V77, P1532, DOI 10.1103/PhysRevLett.77.1532; REITER G, 1992, PHYS REV LETT, V68, P75, DOI 10.1103/PhysRevLett.68.75; RIEGLER H, 1991, BER BUNSEN PHYS CHEM, V95, P1424, DOI 10.1002/bbpc.19910951121; RUCKENSTEIN E, 1974, J CHEM SOC FARAD T 2, V70, P132, DOI 10.1039/f29747000132; SCHICK M, 1989, HOUCH SESS 48 1988, P415; SHARMA A, 1993, J COLLOID INTERF SCI, V161, P190, DOI 10.1006/jcis.1993.1458; SROLOVITZ DJ, 1995, JOM-J MIN MET MAT S, V47, P31, DOI 10.1007/BF03221433; Stange TG, 1997, LANGMUIR, V13, P4459, DOI 10.1021/la962090k; VRIJ A, 1966, DISCUSS FARADAY SOC, P23; WYART FB, 1990, CAN J PHYS, V68, P1084, DOI 10.1139/p90-151; Xie R, 1998, PHYS REV LETT, V81, P1251, DOI 10.1103/PhysRevLett.81.1251	27	518	524	6	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1998	282	5390					916	919		10.1126/science.282.5390.916	http://dx.doi.org/10.1126/science.282.5390.916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794755				2022-12-28	WOS:000076727300040
J	Wootton, RJ; Kukalova-Peck, J; Newman, DJS; Muzon, J				Wootton, RJ; Kukalova-Peck, J; Newman, DJS; Muzon, J			Smart engineering in the mid-Carboniferous: How well could Palaeozoic dragonflies fly?	SCIENCE			English	Article							INSECT WINGS; ODONATA; FLIGHT	The wings of archaic Odonatoidea from the mid-Carboniferous of Argentina show features analogous to "smart" mechanisms in modern dragonflies that are associated with the agile, versatile flight necessary to catch prey in flight. These mechanisms act automatically in flight to depress the trailing edge and to facilitate wing twisting, in response to aerodynamic Loading. The presence of similar features suggests that the earliest known, odonatoids were already becoming adapted for high-performance flight in association with a predatory habit.	Univ Exeter, Dept Biol Sci, Exeter EX4 4PS, Devon, England; Carleton Univ, Dept Geol, Ottawa, ON K1S 5B6, Canada; Limnol Inst, La Plata, Argentina	University of Exeter; Carleton University	Wootton, RJ (corresponding author), Univ Exeter, Dept Biol Sci, Exeter EX4 4PS, Devon, England.		Muzon, Javier/AAW-2159-2020	Muzon, Javier/0000-0002-3956-1986				Brackenbury J, 1992, INSECTS FLIGHT; BRAUCKMANN C, 1989, DEUT ENTOMOL Z, V36, P177; Dalton S., 1975, BORNE WIND; NEWMAN DJS, 1989, J EXP BIOL, V142, P87; NORBERG RA, 1972, J COMP PHYSIOL, V81, P9; RIEK EF, 1984, CAN J ZOOL, V62, P1150, DOI 10.1139/z84-166; RUPPELL G, 1989, J EXP BIOL, V144, P13; Wakeling JM, 1997, J EXP BIOL, V200, P557; Wakeling JM, 1997, J EXP BIOL, V200, P583; Wootton R.J., 1991, Advances in Odonatology, V5, P153; WOOTTON RJ, 1993, J EXP BIOL, V180, P105; WOOTTON RJ, 1981, J ZOOL, V193, P447	12	46	53	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					749	751		10.1126/science.282.5389.749	http://dx.doi.org/10.1126/science.282.5389.749			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784134				2022-12-28	WOS:000076607500053
J	Troger, U; Meyer, FP				Troger, U; Meyer, FP			Personal paper - Validity of advertising claims for multivitamin preparation Vitacor 20/90 on the internet	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; VITAMIN-E CONSUMPTION; BETA-CAROTENE; CARDIOVASCULAR-DISEASE; PLASMA-CONCENTRATIONS; ALPHA-TOCOPHEROL; RISK; DEATH; MEN; ANTIOXIDANT		Univ Magdeburg, Univ Hosp, Inst Clin Pharmacol, D-39120 Magdeburg, Germany	Otto von Guericke University; University Hospital Magdeburg	Troger, U (corresponding author), Univ Magdeburg, Univ Hosp, Inst Clin Pharmacol, Leipziger Str 44, D-39120 Magdeburg, Germany.	uwe.troeger@medizin.uni-magdeburg.de						Bower H, 1996, BRIT MED J, V313, P381; Decsi T, 1997, J PEDIATR-US, V130, P653, DOI 10.1016/S0022-3476(97)70253-1; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Pandey DK, 1995, AM J EPIDEMIOL, V142, P1269, DOI 10.1093/oxfordjournals.aje.a117594; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Rath Matthias, 1996, Journal of Applied Nutrition, V48, P67; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601	16	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	1998	317	7165					1069	1071						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774300	Green Published			2022-12-28	WOS:000076577200034
J	Farell, B				Farell, B			Two-dimensional matches from one-dimensional stimulus components in human stereopsis	NATURE			English	Article							CAT VISUAL-CORTEX; DEPTH; DISPARITY; MECHANISMS	Three-dimensional visual scenes project onto the retina of the eye as two-dimensional images. The third dimension, depth, is projected as subtle differences between left and right retinal images. As early as the 1830s, stereoscopic depth perception was shown to depend on horizontal disparities between these images(1) To detect disparity, the visual system must match corresponding parts of the two retinal images. To identify the stimulus elements used in stereo matching, I applied a disparity-adaptation technique to visual patterns whose one-dimensional components and two-dimensional features have very different disparities. Surprisingly, the adaptors that are effective in altering depth perception appear widely separated in depth from the patterns they adapt. I conclude that stereo matching occurs in all directions of two-dimensional space and that one-dimensional components are the stimulus primitives, the fundamental elements of stereo matching. This is a reversal of the classical view of stereo correspondence as a one-dimensional (horizontal) matching of monocular two-dimensional features(2-4).	Syracuse Univ, Inst Sensory Res, Syracuse, NY 13244 USA; SUNY Hlth Sci Ctr, Ctr Vis Res, Syracuse, NY 13210 USA	Syracuse University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Farell, B (corresponding author), Syracuse Univ, Inst Sensory Res, Syracuse, NY 13244 USA.	bart_farell@isr.syr.edu		Farell, Bart/0000-0003-0902-5290				ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; Anzai A, 1997, P NATL ACAD SCI USA, V94, P5438, DOI 10.1073/pnas.94.10.5438; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; BISHOP PO, 1970, NEUROSCIENCES RES ST; BLAKEMORE C, 1972, J PHYSIOL-LONDON, V225, P437, DOI 10.1113/jphysiol.1972.sp009948; DEANGELIS GC, 1991, NATURE, V352, P156, DOI 10.1038/352156a0; FARELL B, 1996, INVEST OPHTHALMOL  S, V37, P284; FARELL B, 1997, INVEST OPHTHALMOL  S, V38, P904; FERSTER D, 1981, J PHYSIOL-LONDON, V311, P623, DOI 10.1113/jphysiol.1981.sp013608; GILLAM B, 1988, PERCEPT PSYCHOPHYS, V44, P473, DOI 10.3758/BF03210433; Hibbard PB, 1998, VISION RES, V38, P1073, DOI 10.1016/S0042-6989(97)00275-7; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Julesz B., 1971, FDN CYCLOPEAN PERCEP; LEVAY S, 1988, VISUAL NEUROSCI, V1, P395, DOI 10.1017/S0952523800004168; MAYHEW JEW, 1978, PERCEPTION, V7, P431, DOI 10.1068/p070431; Morgan MJ, 1997, VISION RES, V37, P2737, DOI 10.1016/S0042-6989(97)00074-6; NIKARA T, 1968, EXP BRAIN RES, V6, P353; Ogle K. N., 1950, RES BINOCULAR VISION; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; RAMACHANDRAN VS, 1985, NATURE, V317, P527, DOI 10.1038/317527a0; ROGERS BJ, 1993, NATURE, V361, P253, DOI 10.1038/361253a0; SCHUMER RA, 1979, J OPT SOC AM, V69, P1479; Stevenson SB, 1997, VISION RES, V37, P2717, DOI 10.1016/S0042-6989(97)00097-7; von Helmholtz H., 1925, TREATISE PHYSL OPTIC, V3; Wallach H., 1976, PERCEPTION; WHEATSTONE C, 1838, PHILOS T R SOC LON B, V2, P371; ZEKI SM, 1979, PROC R SOC SER B-BIO, V204, P379, DOI 10.1098/rspb.1979.0034	27	48	48	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					689	693		10.1038/27192	http://dx.doi.org/10.1038/27192			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790188				2022-12-28	WOS:000076472600050
J	Griffith, CA; Owen, T; Miller, GA; Geballe, T				Griffith, CA; Owen, T; Miller, GA; Geballe, T			Transient clouds in Titan's lower atmosphere	NATURE			English	Article							VOYAGER-1 RADIO-OCCULTATION; MU-M; SURFACE; METHANE; TROPOSPHERE; REANALYSIS; SPECTRUM; AEROSOLS; IMAGES; ALBEDO	The 1980 encounter by the Voyager I spacecraft with Titan, Saturn's largest moon, revealed(1,2) the presence of a thick atmosphere containing nitrogen and methane (1.4 and similar to 0.05 bar, respectively). Methane was found to be nearly saturated at Titan's tropopause, which, with other considerations, led to the hypothesis that Titan might experience a methane analogue of Earth's vigorous hydrological cycle, with clouds, rain and seas(3-7). Yet recent analyses of Voyager data indicate large areas of supersaturated methane, more indicative of dry and stagnant conditions(8,9), A resolution to this apparent contradiction requires observations of Titan's lower atmosphere, which was hidden from the Voyager cameras by the photochemical haze (or smog) in Titan's stratosphere. Here we report near-infrared spectroscopic observations of Titan within four narrow spectral windows where the moon's atmosphere is ostensibly transparent. We detect pronounced flux enhancements that indicate the presence of reflective methane condensation clouds in the troposphere, These clouds occur at a relatively low altitude (15 +/- 10 km), at low latitudes, and appear to cover similar to 9 per cent of Titan's disk.	No Arizona Univ, Dept Phys & Astron, Flagstaff, AZ 86001 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Joint Astron Ctr, Hilo, HI 96720 USA	Northern Arizona University; University of Hawaii System	Griffith, CA (corresponding author), No Arizona Univ, Dept Phys & Astron, POB 6010, Flagstaff, AZ 86001 USA.							CALVIN WM, 1991, ICARUS, V89, P305, DOI 10.1016/0019-1035(91)90180-2; Combes M, 1997, ICARUS, V129, P482, DOI 10.1006/icar.1997.5772; COURTIN R, 1995, ICARUS, V114, P144, DOI 10.1006/icar.1995.1050; COUSTENIS A, 1995, ICARUS, V118, P87, DOI 10.1006/icar.1995.1179; ESHLEMAN VR, 1983, SCIENCE, V221, P55; FLASAR FM, 1983, SCIENCE, V221, P55, DOI 10.1126/science.221.4605.55; GRIFFITH CA, 1993, NATURE, V364, P511, DOI 10.1038/364511a0; GRIFFITH CA, 1991, ICARUS, V93, P362, DOI 10.1016/0019-1035(91)90219-J; Hunten D.M, 1984, SATURN, P671; HUSSON N, 1991, 163 LMD; KHARE BN, 1984, ICARUS, V60, P127, DOI 10.1016/0019-1035(84)90142-8; LELLOUCH E, 1989, ICARUS, V79, P328, DOI 10.1016/0019-1035(89)90081-X; LEMMON MT, 1995, ICARUS, V113, P27, DOI 10.1006/icar.1995.1003; LEMMON MT, 1993, ICARUS, V103, P329, DOI 10.1006/icar.1993.1074; LINDAL GF, 1983, ICARUS, V53, P348, DOI 10.1016/0019-1035(83)90155-0; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; Noll KS, 1996, ICARUS, V124, P625, DOI 10.1006/icar.1996.0236; RAGES K, 1983, J GEOPHYS RES-SPACE, V88, P8721, DOI 10.1029/JA088iA11p08721; Samuelson RE, 1997, PLANET SPACE SCI, V45, P959, DOI 10.1016/S0032-0633(97)00090-1; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023; STRONG K, 1993, J QUANT SPECTROSC RA, V50, P363, DOI 10.1016/0022-4073(93)90072-P; TOON OB, 1988, ICARUS, V75, P255, DOI 10.1016/0019-1035(88)90005-X; TOON OB, 1992, ICARUS, V95, P24, DOI 10.1016/0019-1035(92)90188-D	25	168	168	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					575	578		10.1038/26920	http://dx.doi.org/10.1038/26920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783583				2022-12-28	WOS:000076362900039
J	Syed, RS; Reid, SW; Li, CW; Cheetham, JC; Aoki, KH; Liu, BS; Zhan, HJ; Osslund, TD; Chirino, AJ; Zhang, JD; Finer-Moore, J; Elliott, S; Sitney, K; Katz, BA; Matthews, DJ; Wendoloski, JJ; Egrie, J; Stroud, RM				Syed, RS; Reid, SW; Li, CW; Cheetham, JC; Aoki, KH; Liu, BS; Zhan, HJ; Osslund, TD; Chirino, AJ; Zhang, JD; Finer-Moore, J; Elliott, S; Sitney, K; Katz, BA; Matthews, DJ; Wendoloski, JJ; Egrie, J; Stroud, RM			Efficiency of signalling through cytokine receptors depends critically on receptor orientation	NATURE			English	Article							HUMAN ERYTHROPOIETIN RECEPTOR; EXTRACELLULAR DOMAIN; DIFFRACTION DATA; PROTEIN HORMONE; GROWTH-HORMONE; LIGAND-BINDING; EPO RECEPTOR; MUTAGENESIS; ACTIVATION; MOTIF	Human erythropoietin is a haematopoietic cytokine required for the differentiation and proliferation of precursor cells into red blood cells(1). It activates cells by binding and orientating two cell-surface erythropoietin receptors (EPORs) which trigger an intracellular phosphorylation cascade(2). The half-maximal response in a cellular proliferation assay is evoked at an erythropoietin concentration of 10 pM (ref. 3), 10(-2) of its K-d value for erythropoietin-EPOR binding site 1 (K-d approximate to 1 nM), and 10(-5) of the K-d for erythropoietin-EPOR binding site 2 (K-d approximate to 1 mu M)(4). Overall half-maximal binding (IC50) of cell-surface receptors is produced with similar to 0.18 nM erythropoietin, indicating that only similar to 6% of the receptors would be bound in the presence of 10 pM erythropoietin. Other effective erythropoietin-mimetic ligands that dimerize receptors can evoke the same cellular responses(5,6) but much less efficiently, requiring concentrations close to their K-d values (similar to 0.1 mu M). The crystal structure of erythropoietin complexed to the extracellular ligand-binding domains of the erythropoietin receptor, determined at 1.9 Angstrom from two crystal forms, shows that erythropoietin imposes a unique 120 degrees angular relationship and orientation that is responsible for optimal signalling through intracellular kinase pathways.	Amgen Inc, Thousand Oaks, CA 91320 USA; Axys Pharmaceut Inc, San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Amgen; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Syed, RS (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	rsyed@amgen.com; stroud@msg.ucsf.edu	Stroud, Rhonda M./C-5503-2008	Stroud, Rhonda M./0000-0001-5242-8015				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbone FP, 1997, J BIOL CHEM, V272, P4985, DOI 10.1074/jbc.272.8.4985; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHEETHAM JC, IN PRESS NATURE STRU; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Damen JE, 1996, EXP HEMATOL, V24, P1455; DERBY P, 1996, TECHNIQUES PROTEIN C, V7, P109; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elliott S, 1997, BLOOD, V89, P493, DOI 10.1182/blood.V89.2.493; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GRABER SE, 1978, ANNU REV MED, V29, P51, DOI 10.1146/annurev.me.29.020178.000411; GRODBERG J, 1993, EUR J BIOCHEM, V218, P597, DOI 10.1111/j.1432-1033.1993.tb18413.x; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; Johnson DL, 1998, BIOCHEMISTRY-US, V37, P3699, DOI 10.1021/bi971956y; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; NARHI LO, 1991, J BIOL CHEM, V266, P23022; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEN DY, 1994, J BIOL CHEM, V269, P22839; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619	29	440	483	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					511	516		10.1038/26773	http://dx.doi.org/10.1038/26773			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774108				2022-12-28	WOS:000076212200059
J	Chart, H				Chart, H			Are all infections with Escherichia coli O157 associated with cattle?	LANCET			English	Editorial Material							HEMOLYTIC-UREMIC SYNDROME; HEMORRHAGIC COLITIS; OUTBREAK; DIARRHEA; DEATH		Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England	Public Health England	Chart, H (corresponding author), Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England.							Ackers ML, 1998, J INFECT DIS, V177, P1588, DOI 10.1086/515323; Ackman D, 1997, EPIDEMIOL INFECT, V119, P1, DOI 10.1017/S095026889700770X; Chalmers RM, 1997, LANCET, V349, P1816, DOI 10.1016/S0140-6736(05)61697-2; Chapman PA, 1996, VET REC, V138, P23; Clark A, 1997, Commun Dis Rep CDR Rev, V7, pR206; From the centers for disease control and prevention, 1996, JAMA-J AM MED ASSOC, V276, P1865, DOI [10.1001/jama.1996.03540230015010, DOI 10.1001/JAMA.1996.03540230015010]; Germani Y, 1997, LANCET, V349, P1670, DOI 10.1016/S0140-6736(05)62636-0; Itoh Y, 1998, APPL ENVIRON MICROB, V64, P1532; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; Keene WE, 1997, JAMA-J AM MED ASSOC, V277, P1229, DOI 10.1001/jama.277.15.1229; MORGAN GM, 1988, EPIDEMIOL INFECT, V101, P83, DOI 10.1017/S0950268800029241; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; Shefer AM, 1996, WESTERN J MED, V165, P15; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; TAYLOR CM, 1986, BRIT MED J, V292, P1513, DOI 10.1136/bmj.292.6534.1513; Wallace JS, 1997, J APPL MICROBIOL, V82, P399, DOI 10.1046/j.1365-2672.1997.00378.x; WILLSHAW GA, 1994, LETT APPL MICROBIOL, V19, P304, DOI 10.1111/j.1472-765X.1994.tb00461.x	18	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1005	1005		10.1016/S0140-6736(05)60072-4	http://dx.doi.org/10.1016/S0140-6736(05)60072-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759740				2022-12-28	WOS:000076121800006
J	Shore, D				Shore, D			Perspectives: Cell biology - Telomeres - Unsticky ends	SCIENCE			English	Editorial Material							DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; YEAST TELOMERE; REPAIR; ARREST; MAINTENANCE; HOMOLOG		Univ Geneva, Dept Biol Mol, CH-1211 Geneva, Switzerland	University of Geneva	Shore, D (corresponding author), Univ Geneva, Dept Biol Mol, CH-1211 Geneva, Switzerland.		Shore, David/F-6240-2015	Shore, David/0000-0002-9859-143X				Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WILEY EA, 1995, GENETICS, V139, P67	21	46	49	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1818	1819		10.1126/science.281.5384.1818	http://dx.doi.org/10.1126/science.281.5384.1818			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9776685				2022-12-28	WOS:000076007100039
J	Wells, J				Wells, J			Mammography and the politics of randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER DETECTION; WOMEN AGED 40; SCREENING MAMMOGRAPHY; DEATH RATES; MORTALITY; GUIDELINES; RANDOMIZATION; METAANALYSIS; BENEFIT		Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Hlth Serv Res Unit, Oxford OX3 7LF, England	University of Oxford	Wells, J (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Hlth Serv Res Unit, Oxford OX3 7LF, England.	jwells@server.dphpc.ox.ac.uk						ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Bailar JC, 1997, CAN MED ASSOC J, V156, P193; Bjurstam N, 1997, CANCER, V80, P2091, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2091::AID-CNCR8>3.0.CO;2-#; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; BOYD R, 1997, CHICAGO TRIBUNE 0124, P1; CIMONS M, 1997, LOS ANGELES T A 0124, P1; DODD GD, 1993, CANCER, V72, P1429, DOI 10.1002/1097-0142(19930815)72:4+<1429::AID-CNCR2820721403>3.0.CO;2-N; Elwood JM, 1993, ONLINE J CURR CLIN T; Ernster VL, 1997, AM J PUBLIC HEALTH, V87, P1103, DOI 10.2105/AJPH.87.7.1103; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; *FOR PAN, 1992, J GERONTOL, P47; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; GLASZIOU PP, 1995, MED J AUSTRALIA, V162, P625, DOI 10.5694/j.1326-5377.1995.tb126047.x; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; HAMBLIN JE, 1991, J FAM PRACTICE, V32, P472; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; NAPOLI M, 1997, NIH CONS DEV C BREAS; *NIH, 1997, NIH CONS DEV C BREAS; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OKIE S, 1997, WASHINGTON PO Z 0218, P12; PERRY S, 1978, J NATL CANCER I, V60, P1519; ROBERTS MM, 1990, LANCET, V335, P241; Shapiro S, 1988, PERIODIC SCREENING B; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; Slanetz PJ, 1997, RADIOLOGY, V203, P335, DOI 10.1148/radiology.203.2.9114084; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; SNOWE O, 1997, WASHINGTON PO A 0211, P21; Tabar L, 1996, INT J CANCER, V68, P693; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; TARONE RE, 1995, CANCER, V75, P997, DOI 10.1002/1097-0142(19950215)75:4<997::AID-CNCR2820750415>3.0.CO;2-M; Taubes G, 1997, SCIENCE, V275, P1056, DOI 10.1126/science.275.5303.1056; *US PREV SERV TASK, 1996, GUID CLIN SERV; VERBEEK ALM, 1984, LANCET, V1, P1222; WALD NJ, 1994, BRIT J RADIOL, V67, P925, DOI 10.1259/0007-1285-67-802-925; 1995, MMWR MORB MORTAL WKL, V45, P57	37	19	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1224	1229		10.1136/bmj.317.7167.1224	http://dx.doi.org/10.1136/bmj.317.7167.1224			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794866	Green Published			2022-12-28	WOS:000076963000029
J	Song, XD; Helmberger, DV				Song, XD; Helmberger, DV			Seismic evidence for an inner core transition zone	SCIENCE			English	Article							TRAVEL-TIMES; ANISOTROPY; ROTATION; EARTH; MODEL; MANTLE; PKIKP	Seismic waves that traverse Earth's inner core along north-south paths produce unusually broad pulse shapes at long periods (compared with waves along east-west paths) and reflections from below;the inner core boundary at short periods. The observations provide compelling evidence for a seismic velocity discontinuity along north-south paths about 200 kilometers below the inner core boundary separating an isotropic upper inner core from an anisotropic Lower inner core. The triplication associated with such a structure might be responsible for reported waveform complexity of short-period inner core arrivals along north-south paths and, if the depth of the boundary is laterally variable, their Large travel-time variation.	Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Dept Earth & Evnironm Sci, New York, NY 10027 USA; CALTECH, Seismol Lab, Pasadena, CA 91125 USA	Columbia University; Columbia University; California Institute of Technology	Song, XD (corresponding author), Lamont Doherty Earth Observ, Palisades, NY 10964 USA.			Song, Xiaodong/0000-0002-5932-6916				Aurnou JM, 1996, GEOPHYS RES LETT, V23, P3401, DOI 10.1029/96GL03258; Braginsky SI, 1963, DOKL AKAD NAUK SSSR, V149, P8; BURDICK LJ, 1978, J GEOPHYS RES, V83, P1699, DOI 10.1029/JB083iB04p01699; CHOY GL, 1983, GEOPHYS J ROY ASTR S, V72, P1, DOI 10.1111/j.1365-246X.1983.tb02801.x; CREAGER KC, 1992, NATURE, V356, P309, DOI 10.1038/356309a0; Creager KC, 1997, SCIENCE, V278, P1284, DOI 10.1126/science.278.5341.1284; CREAGER KC, 1996, 1996 FALL M AM GEOPH; DOORNBOS DJ, 1974, GEOPHYS J ROY ASTR S, V38, P397, DOI 10.1111/j.1365-246X.1974.tb04131.x; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; EAKINS J, 1997, 1997 FALL M AM GEOPH; GLATZMAIER GA, 1995, PHYS EARTH PLANET IN, V91, P63, DOI 10.1016/0031-9201(95)03049-3; GUBBINS D, 1981, J GEOPHYS RES, V86, P1695, DOI 10.1029/JB086iB12p11695; HELMBERGER DV, 1983, EARTHQUAKES OBSERVAT, P174; JACOBS JA, 1953, NATURE, V172, P297, DOI 10.1038/172297a0; Kuang WL, 1997, NATURE, V389, P371, DOI 10.1038/38712; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; Lehmann I., 1936, BUR CENT SEISMOL INT, V14, P3; MASTERS TG, 1993, NATURE, V366, P629, DOI 10.1038/366629a0; MORELLI A, 1986, GEOPHYS RES LETT, V13, P154; RICHARDS PG, 1985, VELA PROGRAM 25 YEAR, P183; SAXENA SK, 1995, SCIENCE, V269, P1703, DOI 10.1126/science.269.5231.1703; SHEARER PM, 1994, J GEOPHYS RES-SOL EA, V99, P19647, DOI 10.1029/94JB01470; SONG XD, 1995, J GEOPHYS RES-SOL EA, V100, P9805, DOI 10.1029/95JB00244; SONG XD, 1995, J GEOPHYS RES-SOL EA, V100, P9817, DOI 10.1029/94JB03135; Song XD, 1997, REV GEOPHYS, V35, P297, DOI 10.1029/97RG01285; SONG XD, 1993, GEOPHYS RES LETT, V20, P2591, DOI 10.1029/93GL02812; Song XD, 1996, NATURE, V382, P221, DOI 10.1038/382221a0; Souriau A, 1996, GEOPHYS RES LETT, V23, P1, DOI 10.1029/95GL03583; SOURIAU A, 1989, GEOPHYS J INT, V98, P39, DOI 10.1111/j.1365-246X.1989.tb05512.x; SU WJ, 1995, J GEOPHYS RES-SOL EA, V100, P9831, DOI 10.1029/95JB00746; Su WJ, 1996, SCIENCE, V274, P1883, DOI 10.1126/science.274.5294.1883; Tanaka S, 1997, J GEOPHYS RES-SOL EA, V102, P2925, DOI 10.1029/96JB03187; VINNIK L, 1994, GEOPHYS RES LETT, V21, P1671, DOI 10.1029/94GL01600; WOODHOUSE JH, 1986, GEOPHYS RES LETT, V13, P1549, DOI 10.1029/GL013i013p01549	34	106	110	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					924	927		10.1126/science.282.5390.924	http://dx.doi.org/10.1126/science.282.5390.924			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794758				2022-12-28	WOS:000076727300043
J	Verbiest, T; Van Elshocht, S; Kauranen, M; Hellemans, L; Snauwaert, J; Nuckolls, C; Katz, TJ; Persoons, A				Verbiest, T; Van Elshocht, S; Kauranen, M; Hellemans, L; Snauwaert, J; Nuckolls, C; Katz, TJ; Persoons, A			Strong enhancement of nonlinear optical properties through supramolecular chirality	SCIENCE			English	Article							2ND HARMONIC-GENERATION; 2ND-HARMONIC GENERATION; MOLECULES; DESIGN; FILMS	A new approach to second-order nonlinear optical (NLO) materials is reported, in which chirality and supramolecular organization play key roles. Langmuir-Blodgett films of a chiral helicene are composed of supramolecular arrays of the molecules. The chiral supramolecular organization makes the second-order NLO susceptibility about 30 times larger for the nonracemic material than for the racemic material with the same chemical structure. The susceptibility of the nonracemic films is a respectable 50 picometers per volt, even though the helicene structure lacks features commonly associated with high nonlinearity. Susceptibility components that are allowed only by chirality dominate the second-order NLO response.	Katholieke Univ Leuven, Lab Chem & Biol dynam, B-3001 Heverlee, Belgium; Columbia Univ, Dept Chem, New York, NY 10027 USA	KU Leuven; Columbia University	Verbiest, T (corresponding author), Katholieke Univ Leuven, Lab Chem & Biol dynam, Celestijnenlaan 200 D, B-3001 Heverlee, Belgium.	thierry@lcbdiris.fys.kuleuven.ac.be	Kauranen, Martti O/G-4221-2014; Verbiest, Thierry/A-4393-2019	Verbiest, Thierry/0000-0002-0822-176X; Kauranen, Martti/0000-0001-8784-4780				ASHWELL GJ, 1992, NATURE, V357, P393, DOI 10.1038/357393a0; Barron L. D., 1982, MOL LIGHT SCATTERING; Bosshard C., 1995, ORGANIC NONLINEAR OP; Boyd R. W., 2003, NONLINEAR OPTICS; BURLAND DM, 1994, CHEM REV, V94, P31, DOI 10.1021/cr00025a002; Chemla D.S., 1987, NONLINEAR OPTICAL PR, V1; FEJER MM, 1992, IEEE J QUANTUM ELECT, V28, P2631, DOI 10.1109/3.161322; GIORDMAINE JA, 1965, PHYS REV, V138, P1599; Kauranen M, 1998, J MOD OPTIC, V45, P403, DOI 10.1080/09500349808231697; KAURANEN M, 1995, ADV MATER, V7, P641, DOI 10.1002/adma.19950070707; Kauranen M, 1997, PHYS REV B, V55, pR1985, DOI 10.1103/PhysRevB.55.R1985; Lovinger AJ, 1998, J AM CHEM SOC, V120, P264, DOI 10.1021/ja973366t; MAKI JJ, 1995, PHYS REV B, V51, P1425, DOI 10.1103/PhysRevB.51.1425; MARDER SR, 1991, SCIENCE, V252, P103, DOI 10.1126/science.252.5002.103; MARKS TJ, 1995, ANGEW CHEM INT EDIT, V34, P155, DOI 10.1002/anie.199501551; NASSOY P, 1995, PHYS REV LETT, V75, P457, DOI 10.1103/PhysRevLett.75.457; Nuckolls C, 1998, J AM CHEM SOC, V120, P8656, DOI 10.1021/ja981757h; Nuckolls C, 1996, J AM CHEM SOC, V118, P3767, DOI 10.1021/ja960145z; NUCKOLLS C, UNPUB; PETRALLIMALLOW T, 1993, J PHYS CHEM-US, V97, P1383, DOI 10.1021/j100109a022; Prasad P.N., 1991, INTRO NONLINEAR OPTI; ROBERTS DA, 1992, IEEE J QUANTUM ELECT, V28, P2057, DOI 10.1109/3.159516; ROBERTS GG, 1990, LANGMUIRBLODGETT FIL; Verbiest T, 1996, PHYS REV LETT, V77, P1456, DOI 10.1103/PhysRevLett.77.1456; Verbiest T, 1997, J MATER CHEM, V7, P2175, DOI 10.1039/a703434b; VERBIEST T, 1996, ADV MATER, V8, P757; ZHUANG X, 1995, PHYS REV LETT, V75, P2144, DOI 10.1103/PhysRevLett.75.2144	28	648	659	8	256	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1998	282	5390					913	915		10.1126/science.282.5390.913	http://dx.doi.org/10.1126/science.282.5390.913			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794754				2022-12-28	WOS:000076727300039
J	Aboulafia, DM; Bundow, D				Aboulafia, DM; Bundow, D			Buffalo hump in a patient with the acquired immunodeficiency syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Virginia Mason Clin, Seattle, WA 98111 USA	Virginia Mason Medical Center	Aboulafia, DM (corresponding author), Virginia Mason Clin, Seattle, WA 98111 USA.								0	19	19	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1297	1297		10.1056/NEJM199810293391807	http://dx.doi.org/10.1056/NEJM199810293391807			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132XC	9791147				2022-12-28	WOS:000076655300007
J	Beecham, L				Beecham, L			Consultants reach agreement on working time directive	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1161	1161						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784475				2022-12-28	WOS:000076755100078
J	Andrault, D; Fiquet, G; Guyot, F; Hanfland, M				Andrault, D; Fiquet, G; Guyot, F; Hanfland, M			Pressure-induced Landau-type transition in stishovite	SCIENCE			English	Article							TEMPERATURE HEAT-CAPACITY; X-RAY-DIFFRACTION; PHASE-TRANSITIONS; RUTILE-TYPE; SILICA; TRANSFORMATIONS; PEROVSKITE; DIOXIDES; MANTLE; SIO2	A Rietveld structural analysis of stishovite, with angle-dispersive x-ray diffraction synchrotron source at the European Synchrotron Radiation Facility, confirmed a CaCl2 form of stishovite distortion at 54 +/- 1 gigapascals but confirmed no further phase transformation up to 120 gigapascals. The deviatoric stress that is usually encountered at such pressures was relaxed after yttrium-aluminum-garnet-laser heating. A single Birch-Murnaghan equation of state fits volumes of stishovite and a CaCl2 form, showing that the tetragonal distortion occurs without a substantial change in volume. At the 54-gigapascal transition, the pressure-induced Lattice modifications were similar to those found in a Landau-type temperature-induced transition. It is proposed that, above the transition pressure, the critical temperature increases above 300 kelvin, so that the Lower entropy form becomes stable.	Inst Phys Globe, Dept Geomat, F-75252 Paris, France; Ecole Normale Super Lyon, Geol Lab, F-69364 Lyon, France; Univ Paris 07, Lab Mineral Cristallog, F-75252 Paris, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France	UDICE-French Research Universities; Universite Paris Cite; Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Paris Cite; European Synchrotron Radiation Facility (ESRF)	Andrault, D (corresponding author), Inst Phys Globe, Dept Geomat, 4 Pl Jussieu, F-75252 Paris, France.		GUYOT, François J/C-3824-2016; ANDRAULT, Denis/N-8843-2016; Fiquet, Guillaume/O-7077-2019; Fiquet, Guillaume/M-6934-2014; Fiquet, Guillaume M/H-1219-2011	GUYOT, François J/0000-0003-4622-2218; ANDRAULT, Denis/0000-0002-9921-4572; Fiquet, Guillaume/0000-0001-8961-3281; 				Andrault D, 1997, SCIENCE, V278, P831, DOI 10.1126/science.278.5339.831; COHEN RE, 1991, AM MINERAL, V76, P733; COHEN RE, 1992, GEOPHYS MONOGR SER, V67, P425; deLigny D, 1996, PHYS REV B, V53, P3013, DOI 10.1103/PhysRevB.53.3013; El Goresy A, 1998, METEORIT PLANET SCI, V33, pA45; Fiquet G, 1996, PHYS EARTH PLANET IN, V95, P1, DOI 10.1016/0031-9201(95)03109-X; Fiquet G, 1998, PHYS EARTH PLANET IN, V105, P21, DOI 10.1016/S0031-9201(97)00077-0; GUYOT F, 1993, PHYS CHEM MINER, V20, P141; Haines J, 1996, SCIENCE, V271, P629, DOI 10.1126/science.271.5249.629; Haines J, 1996, J PHYS-CONDENS MAT, V8, P1631, DOI 10.1088/0953-8984/8/11/009; HAINES J, 1995, J PHYS CHEM SOLIDS, V56, P965, DOI 10.1016/0022-3697(95)00037-2; HAMMERSLEY J, 1996, PUBLICATION ESRF; HEMLEY RJ, 1994, SILICA PHYSICAL BEHA, P41; JAMIESON JC, 1982, HIGH PRESSURE RES GE, P425; Karki BB, 1997, PHYS REV B, V55, P3465, DOI 10.1103/PhysRevB.55.3465; KINGMA KJ, 1995, NATURE, V374, P243, DOI 10.1038/374243a0; Kingma KJ, 1996, HIGH PRESSURE RES, V14, P363, DOI 10.1080/08957959608201422; LACKS DJ, 1993, J GEOPHYS RES-SOL EA, V98, P22147, DOI 10.1029/93JB02448; Larson A. C., 1994, GEN STRUCTURE ANAL S, P86; LEBAIL A, 1992, ACCURACY POWDER DIFF, P213; LIU LG, 1980, EARTH PLANET SC LETT, V49, P166, DOI 10.1016/0012-821X(80)90158-2; ROSS NL, 1990, AM MINERAL, V75, P739; Salje E. K. H., 1990, PHASE TRANSITIONS FE; Saxena SK, 1996, SCIENCE, V274, P1357, DOI 10.1126/science.274.5291.1357; TSE JS, 1992, PHYS REV LETT, V69, P3647, DOI 10.1103/PhysRevLett.69.3647; TSUCHIDA Y, 1989, NATURE, V340, P217, DOI 10.1038/340217a0; WEIDNER DJ, 1982, J GEOPHYS RES, V87, P4740, DOI 10.1029/JB087iB06p04740	27	185	191	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					720	724		10.1126/science.282.5389.720	http://dx.doi.org/10.1126/science.282.5389.720			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784125				2022-12-28	WOS:000076607500044
J	Deloukas, P; Schuler, GD; Gyapay, G; Beasley, EM; Soderlund, C; Rodriguez-Tome, P; Hui, L; Matise, TC; McKusick, KB; Beckmann, JS; Bentolila, S; Bihoreau, MT; Birren, BB; Browne, J; Butler, A; Castle, AB; Chiannilkulchai, N; Clee, C; Day, PJR; Dehejia, A; Dibling, T; Drouot, N; Duprat, S; Fizames, C; Fox, S; Gelling, S; Green, L; Harrison, P; Hocking, R; Holloway, E; Hunt, S; Keil, S; Lijnzaad, P; Louis-Dit-Sully, C; Ma, J; Mendis, A; Miller, J; Morissette, J; Muselet, D; Nusbaum, HC; Peck, A; Rozen, S; Simon, D; Slonim, DK; Staples, R; Stein, LD; Stewart, EA; Suchard, MA; Thangarajah, T; Vega-Czarny, N; Webber, C; Wu, X; Hudson, J; Auffray, C; Nomura, N; Sikela, JM; Polymeropoulos, MH; James, MR; Lander, ES; Hudson, TJ; Myers, RM; Cox, DR; Weissenbach, J; Boguski, MS; Bentley, DR				Deloukas, P; Schuler, GD; Gyapay, G; Beasley, EM; Soderlund, C; Rodriguez-Tome, P; Hui, L; Matise, TC; McKusick, KB; Beckmann, JS; Bentolila, S; Bihoreau, MT; Birren, BB; Browne, J; Butler, A; Castle, AB; Chiannilkulchai, N; Clee, C; Day, PJR; Dehejia, A; Dibling, T; Drouot, N; Duprat, S; Fizames, C; Fox, S; Gelling, S; Green, L; Harrison, P; Hocking, R; Holloway, E; Hunt, S; Keil, S; Lijnzaad, P; Louis-Dit-Sully, C; Ma, J; Mendis, A; Miller, J; Morissette, J; Muselet, D; Nusbaum, HC; Peck, A; Rozen, S; Simon, D; Slonim, DK; Staples, R; Stein, LD; Stewart, EA; Suchard, MA; Thangarajah, T; Vega-Czarny, N; Webber, C; Wu, X; Hudson, J; Auffray, C; Nomura, N; Sikela, JM; Polymeropoulos, MH; James, MR; Lander, ES; Hudson, TJ; Myers, RM; Cox, DR; Weissenbach, J; Boguski, MS; Bentley, DR			A physical map of 30,000 human genes	SCIENCE			English	Article							EXPRESSED SEQUENCE TAGS; RADIATION HYBRID MAP; OPEN-ANGLE GLAUCOMA; HOLT-ORAM SYNDROME; HUMAN GENOME; POSITIONAL CLONING; MUTATIONS; HOMOLOGY; IDENTIFICATION; PROTEIN	A map of 30,181 human gene-based markers was assembled and integrated with the current genetic map by radiation hybrid mapping. The new gene map contains nearly twice as many genes as the previous release, includes most genes that encode proteins of known function, and is twofold to threefold more accurate than the previous version. A redesigned, more informative and functional World Wide Web site (www.ncbi.nlm.nih.gov/genemap) provides the mapping information and associated data and annotations. This resource constitutes an important infrastructure and tool for the study of complex genetic traits, the positional cloning of disease genes, the cross-referencing of mammalian genomes, and validated human transcribed sequences for Large-scale studies of gene expression.	Sanger Ctr, Cambridge CB10 1SA, England; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; CNRS, URA 1922, F-91000 Evry, France; Stanford Univ, Sch Med, Stanford Human Genome Ctr, Dept Genet, Stanford, CA 94305 USA; European Bioinformat Inst, European Mol Biol Lab Outstn, Cambridge CB10 1SD, England; MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; Genethon, CNRS, URA 1922, F-91000 Evry, France; Univ Oxford, Nuffield Dept Clin Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; NIH, Lab Genet Dis Res, Natl Ctr Human Genome Res, Bethesda, MD 20892 USA; CHU Laval, Ctr Rech, Quebec City, PQ G1V 4G2, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; Res Genet, Huntsville, AL 35801 USA; CNRS, UPR 420, F-94801 Villejuif, France; Kazusa DNA Res Inst, Chiba 292, Japan; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada	Wellcome Trust Sanger Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Centre National de la Recherche Scientifique (CNRS); Stanford University; European Molecular Biology Laboratory (EMBL); Massachusetts Institute of Technology (MIT); Whitehead Institute; Rockefeller University; Centre National de la Recherche Scientifique (CNRS); University of Oxford; Wellcome Centre for Human Genetics; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Laval University; Cold Spring Harbor Laboratory; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Centre National de la Recherche Scientifique (CNRS); Kazusa DNA Research Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Massachusetts Institute of Technology (MIT); McGill University	Deloukas, P (corresponding author), Sanger Ctr, Hixton Hall, Cambridge CB10 1SA, England.		Deloukas, Panos/B-2922-2013; Beckmann, Jacques S/A-9772-2008; Lijnzaad, Philip/ABE-4205-2021; Suchard, Marc A/A-9703-2008; Rozen, Steven G./J-5939-2013	Deloukas, Panos/0000-0001-9251-070X; Beckmann, Jacques S/0000-0002-9741-1900; Lijnzaad, Philip/0000-0002-7535-583X; Webber, Caleb/0000-0001-8063-7674; Hunt, Sarah/0000-0002-8350-1235; Fizames, Cecile/0000-0002-0551-8250; Slonim, Donna/0000-0003-3357-437X; Rozen, Steven G./0000-0002-4288-0056; Hudson, Thomas/0000-0002-1376-4849	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS MD, 1995, NATURE, V377, P3; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Camper SA, 1997, MAMM GENOME, V8, P461, DOI 10.1007/s003359900476; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; DAHL C, 1998, COMPREHENSIVE TRANSC; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eckman BA, 1998, BIOINFORMATICS, V14, P2, DOI 10.1093/bioinformatics/14.1.2; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; EVERETT LA, 1997, NAT GENET, V17, P399; EVERETT LA, 1997, CELL, V90, P797; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; James MR, 1997, TRENDS GENET, V13, P171, DOI 10.1016/S0168-9525(97)01130-X; Kenmochi N, 1998, GENOME RES, V8, P509, DOI 10.1101/gr.8.5.509; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Li QY, 1997, NAT GENET, V15, P21; LYNCH ED, 1997, SCIENCE, V278, P115; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Ortego J, 1997, FEBS LETT, V413, P349, DOI 10.1016/S0014-5793(97)00934-4; Ouellette BFF, 1997, GENOME RES, V7, P952, DOI 10.1101/gr.7.10.952; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; PICKERAL O, UNPUB; Pruitt KD, 1997, GENOME RES, V7, P1038, DOI 10.1101/gr.7.11.1038; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; WILLIAMSON AR, 1995, J NIH RES, V7, P63	45	565	584	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					744	746		10.1126/science.282.5389.744	http://dx.doi.org/10.1126/science.282.5389.744			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784132				2022-12-28	WOS:000076607500051
J	Richardson, H; Smaill, F				Richardson, H; Smaill, F			Recent advances - Medical microbiology	BRITISH MEDICAL JOURNAL			English	Review							CLINICAL MICROBIOLOGY; SUSCEPTIBILITY; RESISTANCE; DIAGNOSIS; INFECTION; SYSTEMS		McMaster Univ, Med Ctr, Fac Hlth Sci, Dept Pathol,Div Med Microbiol, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Med Ctr, Fac Hlth Sci, Dept Pathol,Div Infect Dis, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Med Ctr, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Richardson, H (corresponding author), McMaster Univ, Med Ctr, Fac Hlth Sci, Dept Pathol,Div Med Microbiol, Room 2N30, Hamilton, ON L8N 3Z5, Canada.							BARTLETT RC, 1994, CLIN MICROBIOL REV, V7, P55, DOI 10.1128/CMR.7.1.55-88.1994; DAMATO RF, 1995, J CLIN MICROBIOL, V33, P1832, DOI 10.1128/JCM.33.7.1832-1834.1995; Farrell DJ, 1996, PATHOLOGY, V28, P74, DOI 10.1080/00313029600169583; Ferraro Mary Jane, 1995, P1379; GarciadeLomas J, 1997, PEDIATR INFECT DIS J, V16, pS43, DOI 10.1097/00006454-199703001-00004; Ieven M, 1997, CLIN MICROBIOL REV, V10, P242, DOI 10.1128/CMR.10.2.242; KRISHER KK, 1994, J CLIN MICROBIOL, V32, P2242, DOI 10.1128/JCM.32.9.2242-2245.1994; LASCOLEA L J JR, 1988, Clinical Microbiology Newsletter, V10, P21, DOI 10.1016/0196-4399(88)90021-9; Leong Diane U., 1993, P300; Low D E, 1995, New Horiz, V3, P161; NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003; PERKINS MD, 1995, J CLIN MICROBIOL, V33, P1486, DOI 10.1128/JCM.33.6.1486-1491.1995; PERSING D, 1996, PCR PROTOCOLS EMERGI; Persing D.H., 1993, DIAGNOSTIC MOL MICRO; Pfaller MA, 1997, CLIN INFECT DIS, V25, P858, DOI 10.1086/515557; Relman David A., 1996, P3; SHULMAN ST, 1994, PEDIATR INFECT DIS J, V13, P567, DOI 10.1097/00006454-199406000-00034; SKULNICK M, 1992, J CLIN MICROBIOL, V30, P1985, DOI 10.1128/JCM.30.8.1985-1988.1992; STAGER CE, 1992, CLIN MICROBIOL REV, V5, P302, DOI 10.1128/CMR.5.3.302-327.1992; STEED LL, 1993, J CLIN MICROBIOL, V31, P2996, DOI 10.1128/JCM.31.11.2996-3000.1993; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P1524, DOI 10.1128/JCM.33.6.1524-1527.1995	21	5	5	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1060	1062						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774296				2022-12-28	WOS:000076577200030
J	Ruggenenti, P; Perna, A; Gherardi, G; Gaspari, F; Benini, R; Remuzzi, G				Ruggenenti, P; Perna, A; Gherardi, G; Gaspari, F; Benini, R; Remuzzi, G		GISEN	Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial	LANCET			English	Article							CONVERTING-ENZYME-INHIBITOR; DIABETIC NEPHROPATHY; PROGRESSION; DISEASE	Background The Ramipril Efficacy In Nephropathy (REIN) study found that in patients with chronic nephropathies and proteinuria of 3 g or more per 24 h, ramipril safely reduced the rate of decline of the glomerular filtration rate (GFR) and halved the combined risk of doubling of serum creatinine or end-stage renal failure (ESRF), as compared with placebo plus conventional antihypertensive drugs at the same level of blood pressure control. At the end of the core study patients continued on or shifted to ramipril and were formally enrolled into the REIN follow-up study. Methods 97 patients entered the follow-up study. Patients originally randomised to ramipril continued with the same daily dose (n=51), whereas those originally on placebo plus conventional antihypertensive drugs switched to ramipril after the first visit of the follow-up study (n=46). Ramipril (1.25 to 5.00 mg/day) and conventional antihypertensive therapy were targeted at achieving diastolic blood pressure under 90 mm Hg. The main efficacy variables were GFR decline and ESRF (need for dialysis). Analysis was by intention to treat. Findings During the follow-up study the mean rate of GFR decline per month decreased from 0.44 (SD 0.54) mL/min per 1.73 m(2) in the core study to 0.10 (0.50) mL/min per 1.73 m(2) in patients originally randomised to ramipril (p=0.017), and from 0.81 (1.12) to 0.14 (0.87) mL/min per 1.73 m(2) in those originally randomised to placebo plus conventional antihypertensive therapy (p=0.017). At the final visit, mean absolute GFR values were 12 mL/min per 1.73 m(2) higher (33% better) in patients randomised to ramipril than in those assigned placebo (n=26 and 17, respectively: 35.5 [19.0] vs 23.8 [9.4] mL/min per 1.73 m(2), p=0.01). 19 of the patients originally on ramipril versus 35 switched from placebo to ramipril progressed to ESRF (p=0.027) during the whole observation period; of these, six (8%) versus 14 (16%) reached that endpoint during the follow-up study; and the risk ratios were 1.86 (95% Cl 1.07-3.26) over the whole observation period and 2.95 (1.13-7.68) during follow-up. Beyond follow-up at month 36, the incidence of ESRF was zero in patients originally randomised to ramipril but 30% in patients on placebo plus conventional antihypertensive therapy. Interpretation In patients with chronic nephropathy and high risk of rapid progression to ESRF, ramipril reversed the tendency of GFR to decline with time. Moreover, a treatment period of sufficient duration (greater than or equal to 36 months) eliminated the need for dialysis. Even patients previously treated with antihypertensive drugs other than angiotensin-converting-enzyme inhibitors benefited shifting to ramipril.	Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24125 Bergamo, Italy; Osped Riuniti Bergamo, Div Nephrol, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Ruggenenti, P (corresponding author), Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis Aldo & Cele Dacco, Via Gavazzeni 11,Villa Camozzi, I-24125 Bergamo, Italy.		Perna, Annalisa/AAC-1323-2020; Remuzzi, Giuseppe/V-9766-2017	Perna, Annalisa/0000-0002-9257-0283; Manno, Carlo/0000-0002-7840-9426; Remuzzi, Giuseppe/0000-0002-6194-3446				GASPARI F, 1995, J AM SOC NEPHROL, V6, P1; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; *GRUPP IT STUD EP, 1991, J NEPHROL, V3, P193; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PERICO N, 1994, J AM SOC NEPHROL, V5, P1139; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1998, BRIT MED J, V316, P504, DOI 10.1136/bmj.316.7130.504; RUGGENENTI P, 1997, KIDNEY INT S63, V52, pS54; SHAPIRO SS, 1965, BIOMETRIKA, V52, P519	13	443	471	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1252	1256		10.1016/S0140-6736(98)04433-X	http://dx.doi.org/10.1016/S0140-6736(98)04433-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788454				2022-12-28	WOS:000076573800008
J	Blendon, RJ; Young, JT				Blendon, RJ; Young, JT			The public and the comprehensive tobacco bill	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Blendon, RJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.							GOLDBERG J, 1998, NY TIMES MAGAZI 0621, P58; GOLDBERG J, 1998, NY TIMES MAGAZI 0621, P62; GOLDBERG J, 1998, NY TIMES MAGAZI 0621, P60; GOLDBERG J, 1998, NY TIMES MAGAZI 0621, P36; KOCK W, 1998, US TODAY        0618, P1; MITCHELL A, 1998, NY TIMES        1107, pA1; TAYLOR J, 1998, WALL STREET J   0625, pA23; TORRY S, 1998, WASHINGTON POST 0720, pA	8	19	19	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1279	1284		10.1001/jama.280.14.1279	http://dx.doi.org/10.1001/jama.280.14.1279			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786382				2022-12-28	WOS:000076357900038
J	Stanley, SL				Stanley, SL			Malaria vaccines: are seven antigens better than one?	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM MALARIA		Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Stanley, SL (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.							BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Tine JA, 1996, INFECT IMMUN, V64, P3833, DOI 10.1128/IAI.64.9.3833-3844.1996	7	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1998	352	9135					1163	1164		10.1016/S0140-6736(05)60525-9	http://dx.doi.org/10.1016/S0140-6736(05)60525-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777828				2022-12-28	WOS:000076415400003
J	Bewley, T; Lock, S				Bewley, T; Lock, S			Philip Henry Connell - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1255	1255		10.1136/bmj.317.7167.1255	http://dx.doi.org/10.1136/bmj.317.7167.1255			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794883	Green Published			2022-12-28	WOS:000076963000061
J	Yoshioka, A				Yoshioka, A			Use of randomisation in the Medical Research Council's clinical trial of streptomycin in pulmonary tuberculosis in the 1940s	BRITISH MEDICAL JOURNAL			English	Article									Imperial Coll, Ctr Hist Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Yoshioka, A (corresponding author), POB 166, Pictou, NS B0K 1H0, Canada.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGNEW C, 1947, COMMUNICATION   0619; [Anonymous], 1948, BMJ-BRIT MED J, V2, P769; [Anonymous], MIRACLE CURE STORY P; Armitage P, 1982, Stat Med, V1, P345, DOI 10.1002/sim.4780010412; Bryder Lynn, 1988, MAGIC MOUNTAIN SOCIA; Burns Amberson J., 1931, AM REV TUBERC, V24, P401; DAVENPORTHINES RPT, 1993, GLAXO HIST 1962; DOLL R, 1991, J BIOSOC SCI, V23, P365, DOI 10.1017/S002193200001943X; FELDMAN WH, 1945, AM REV TUBERC PULM, V52, P269; HART PD, 1946, BMJ-BRIT MED J, V2, P849, DOI 10.1136/bmj.2.4483.849; HART PD, 1946, BRIT MED J, V2, P805, DOI 10.1136/bmj.2.4482.805; HILL AB, 1990, CONTROL CLIN TRIALS, V11, P77; HILL AB, 1937, LANCET, V1, P41; Hinshaw H.C., 1944, AM REV TUBERC, V50, P202; HOLME CI, 1997, P R SOC COLL PHYS S4, V27; Marks H., 1997, PROGR EXPT SCI THERA; *MRC PAT CLIN TRIA, 1944, LANCET, V2, P373; PORTER RW, 1946, CHEM ENG         OCT; RYAN F, 1992, GREATEST STORY NEVER; Waksman, 1964, CONQUEST TUBERCULOSI; WILSON C, 1948, BRIT MED J, V2, P552, DOI 10.1136/bmj.2.4576.552; 1948, BMJ, V2, P791	22	53	55	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1220	1223		10.1136/bmj.317.7167.1220	http://dx.doi.org/10.1136/bmj.317.7167.1220			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794865	Green Published			2022-12-28	WOS:000076963000028
J	Berthet, FX; Lagranderie, M; Gounon, P; Laurent-Winter, C; Ensergueix, D; Chavarot, P; Thouron, F; Maranghi, E; Pelicic, V; Portnoi, D; Marchal, G; Gicquel, B				Berthet, FX; Lagranderie, M; Gounon, P; Laurent-Winter, C; Ensergueix, D; Chavarot, P; Thouron, F; Maranghi, E; Pelicic, V; Portnoi, D; Marchal, G; Gicquel, B			Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene	SCIENCE			English	Article							CULTURED MACROPHAGES; EARLY ENDOSOMES; PHAGOSOME; MATURATION; PROTEIN; FUSION; AVIUM	The virulence of the mycobacteria that cause tuberculosis depends on their ability to multiply in mammalian hosts. Disruption of the bacterial erp gene, which encodes the exported repetitive protein, impaired multiplication of M. tuberculosis and M, bovis Bacille Calmette-Guerin in cultured macrophages and mice. Reintroduction of erp into the mutants restored their ability to multiply. These results indicate that erp contributes to the virulence of M. tuberculosis.	Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France; Inst Pasteur, Lab BCG, F-75724 Paris, France; Inst Pasteur, Stn Cent Microscopie Elect, F-75724 Paris 15, France; Inst Pasteur, Lab Electrophorese Bidimens, F-75724 Paris 15, France; Inst Pasteur, Unite Physiopathol Infect, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Gicquel, B (corresponding author), Inst Pasteur, Unite Genet Mycobacterienne, 25 Rue Dr Roux, F-75724 Paris 15, France.	bgicquel@pasteur.fr	Pelicic, Vladimir/N-3755-2017; Pelicic, Vladimir/ABD-3102-2021	Pelicic, Vladimir/0000-0002-9456-4995; Pelicic, Vladimir/0000-0002-9456-4995	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035207] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35207] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; BERTHET FX, 1995, MICROBIOL-UK, V141, P2123, DOI 10.1099/13500872-141-9-2123; BIGI F, 1995, INFECT IMMUN, V63, P2581, DOI 10.1128/IAI.63.7.2581-2586.1995; CHERAYIL BJ, 1988, J IMMUNOL, V141, P4370; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Clemens DL, 1996, TRENDS MICROBIOL, V4, P113, DOI 10.1016/0966-842X(96)81528-9; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DECHASTELLIER C, 1995, EUR J CELL BIOL, V68, P167; DUBOS RJ, 1956, AM REV TUBERC PULM, V74, P699; DUBOS RJ, 1956, AM REV TUBERC PULM, V74, P655; Lagranderie MRR, 1996, INFECT IMMUN, V64, P1; LIM EM, 1995, J BACTERIOL, V177, P59, DOI 10.1128/jb.177.1.59-65.1995; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; PELICIC V, 1996, FEMS MICROBIOL LETT, V144, P61; PIERCE CH, 1956, AM REV TUBERC PULM, V74, P667; PIERCE CH, 1956, AM REV TUBERC PULM, V74, P683; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; *WHO, 1997, GLOB TUB CONTR	22	170	193	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					759	762		10.1126/science.282.5389.759	http://dx.doi.org/10.1126/science.282.5389.759			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784137				2022-12-28	WOS:000076607500056
J	Bittner, B				Bittner, B			John Bruce Bittiner - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1085	1085						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774314				2022-12-28	WOS:000076577200063
J	Reid, I				Reid, I			Patients' preference for male or female breast surgeons: questionnaire study	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN; SEX		Univ Glasgow, Glasgow G42 9TY, Lanark, Scotland; Victoria Infirm, Glasgow G42 9TY, Lanark, Scotland	University of Glasgow	Reid, I (corresponding author), Univ Glasgow, Glasgow G42 9TY, Lanark, Scotland.							FENNEMA K, 1990, J FAM PRACTICE, V30, P441; HAAR E, 1975, MED CARE, V13, P782, DOI 10.1097/00005650-197509000-00008; Kerssens JJ, 1997, SOC SCI MED, V44, P1531, DOI 10.1016/S0277-9536(96)00272-9; WEYRAUCH KF, 1990, J FAM PRACTICE, V30, P559	4	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1051	1051						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774289				2022-12-28	WOS:000076577200025
J	Sprang, SR; Coleman, DE				Sprang, SR; Coleman, DE			Invasion of the nucleotide snatchers: Structural insights into the mechanism of G protein GEFs	CELL			English	Review							EF-TS COMPLEX; CRYSTAL-STRUCTURE		Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650	20	60	62	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					155	158		10.1016/S0092-8674(00)81746-8	http://dx.doi.org/10.1016/S0092-8674(00)81746-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790522	Bronze			2022-12-28	WOS:000076538300003
J	Best, PJ; Tajik, AJ; Gibbons, RJ; Pellikka, PA				Best, PJ; Tajik, AJ; Gibbons, RJ; Pellikka, PA			The safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY DISEASE; CARDIAC RISK; VASCULAR-SURGERY; ECHOCARDIOGRAPHY; DOBUTAMINE; COMPLICATIONS	Background: Exercise stress testing in patients with abdominal aortic aneurysms may cause enlargement or rupture of aneurysms. Objective: To evaluate the safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms. Design: Retrospective descriptive study. Setting: Tertiary care center. Patients: 262 patients who had abdominal aortic aneurysms more than 4 cm in diameter and underwent treadmill exercise stress testing. Measurements: Pain after stress testing, rupture of the aneurysm or death, aneurysm size, and exercise stress test results. Results: The average aneurysm diameter was 5.5 +/- 1.1 cm. One patient with a 6.1-cm aneurysm was found to have a contained rupture 12 hours after stress testing. The event rate for aneurysm rupture was 0.4% (95% CI, 0.0% to 2.1%). No deaths or other negative outcomes were documented. Conclusion: Despite theoretical concerns, exercise stress testing of patients with abdominal aortic aneurysms seems to be safe and is associated with a low incidence of acute adverse events.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Pellikka, PA (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, W16A,200 1st St SW, Rochester, MN 55905 USA.		Pellikka, Patricia A/N-5387-2014	Pellikka, Patricia A/0000-0001-6800-3521				BELESLIN BD, 1994, CIRCULATION, V90, P1168, DOI 10.1161/01.CIR.90.3.1168; BELLER GA, 1989, J AM COLL CARDIOL, V14, P1642, DOI 10.1016/0735-1097(89)90009-0; Daida H, 1996, MAYO CLIN PROC, V71, P445, DOI 10.4065/71.5.445; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; ELMORE JR, 1993, MAYO CLIN PROC, V68, P637, DOI 10.1016/S0025-6196(12)60598-9; FELDMAN AY, 1994, J CARDIOVASC SURG, V35, P541; Fleisher L A, 1993, J Cardiothorac Vasc Anesth, V7, P650, DOI 10.1016/1053-0770(93)90047-O; FLEMING RM, 1995, ANGIOLOGY, V46, P547, DOI 10.1177/000331979504600701; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; MCPHAIL N, 1988, J VASC SURG, V7, P60, DOI 10.1067/mva.1988.avs0070060; Pellikka PA, 1996, AM J CARDIOL, V77, P413, DOI 10.1016/S0002-9149(97)89374-5; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; Pollock ML, 1990, EXERCISE HLTH DIS EV; PREVITALI M, 1993, AM J CARDIOL, V72, P865, DOI 10.1016/0002-9149(93)91097-2; Roger VL, 1997, CIRCULATION, V95, P405; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3	20	15	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					628	631		10.7326/0003-4819-129-8-199810150-00008	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786810				2022-12-28	WOS:000076431800005
J	Rahal, JJ; Urban, C; Horn, D; Freeman, K; Segal-Maurer, S; Maurer, J; Mariano, N; Marks, S; Burns, JM; Dominick, D; Lim, M				Rahal, JJ; Urban, C; Horn, D; Freeman, K; Segal-Maurer, S; Maurer, J; Mariano, N; Marks, S; Burns, JM; Dominick, D; Lim, M			Glass restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRAM-NEGATIVE BACILLI; ANTIMICROBIAL-RESISTANCE; INFECTIOUS-DISEASES; BETA-LACTAMASE; PNEUMONIAE; OUTBREAK; EPIDEMIOLOGY; AGENTS	Context.-Resistance to most or all cephalosporin antibiotics in Klebsiella species has developed in many European and North American hospitals during the past 2 decades. Objective.-To determine if restriction of use of the cephalosporin class of antibiotics would reduce the incidence of patient infection or colonization by cephalosporin-resistant Klebsiella. Design.-A before-after comparative 2-year trial. Setting.-A 500-bed, university-affiliate community hospital in Queens, NY. Patients.-All adult medical and surgical hospital inpatients. Intervention.-A new antibiotic guideline excluded the use of cephalosporins except for pediatric infection, single-dose surgical prophylaxis, acute bacterial meningitis, spontaneous bacterial peritonitis, and outpatient gonococcal infection, All other cephalosporin use required prior approval by the infectious disease section. Main Outcome Measure.-Incidence of patient infection or colonization by ceftazidime-resistant Klebsiella during 1995 (control period) compared with 1996 (intervention period). Results.-An 80.1% reduction in hospital-wide cephalosporin use occurred in 1996 compared with 1995. This was accompanied by a 44.0% reduction in the incidence of ceftazidime-resistant Klebsiella infection and colonization throughout the medical center (P<.01), a 70.9% reduction within all intensive care units (P<.001), and an 87.5% reduction within the surgical intensive care unit (P<.001). A concomitant 68.7% increase in the incidence of imipenem-resistant Pseudomonas aeruginosa occurred throughout the medical center (P<.01). All such isolates except one were susceptible to other antibiotics. Conclusion.-Extensive cephalosporin class restriction significantly reduced nosocomial, plasmid-mediated, cephalosporin-resistant Klebsiella infection and colonization. This occurred at the price of increased imipenem resistance in P aeruginosa, which remained susceptible to other agents. Thus, an overall reduction in multiply-resistant pathogens was achieved within 1 year.	New York Hosp, Queens Med Ctr, Dept Surg, New York, NY 10021 USA; New York Hosp, Queens Med Ctr, Dept Med, Infect Dis Sect, New York, NY 10021 USA; New York Hosp, Queens Med Ctr, Dept Pharm, New York, NY 10021 USA; Cornell Univ Med Coll, New York, NY USA; Montefiore Med Ctr, Dept Biostat, New York, NY USA; Albert Einstein Coll Med, New York, NY USA; New York Hosp, Queens Med Ctr, Dept Nursing, New York, NY 10021 USA; Merck & Co Inc, W Point, PA USA	NewYork-Presbyterian Hospital; NewYork-Presbyterian Hospital; NewYork-Presbyterian Hospital; Cornell University; Montefiore Medical Center; Yeshiva University; NewYork-Presbyterian Hospital; Merck & Company	Rahal, JJ (corresponding author), New York Hosp, Queens Med Ctr, Infect Dis Sect, Dept Med, 56-45 Main St, Flushing, NY 11355 USA.							Bradford PA, 1997, ANTIMICROB AGENTS CH, V41, P563, DOI 10.1128/AAC.41.3.563; BRICELAND LL, 1996, 36 INT C ANT AG CHEM; Duncan RA, 1997, INFECT CONT HOSP EP, V18, P260; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GO ES, 1994, LANCET, V344, P1329, DOI 10.1016/S0140-6736(94)90694-7; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Jarvis WR, 1996, INFECT CONT HOSP EP, V17, P490, DOI 10.1086/647348; LIVINGSTONE D, 1995, J ANTIMICROB CHEMOTH, V35, P1, DOI 10.1093/jac/35.1.1; LUCET JC, 1996, 36 INT C ANT AG CHEM; MA MY, 1983, ANTIMICROB AGENTS CH, V24, P347, DOI 10.1128/AAC.24.3.347; MartinezMartinez L, 1996, ANTIMICROB AGENTS CH, V40, P342, DOI 10.1128/AAC.40.2.342; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; PENA C, 1996, 36 INT C ANT AG CHEM; Pitout JDD, 1997, AM J MED, V103, P51, DOI 10.1016/S0002-9343(97)00044-2; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; Rice LB, 1996, CLIN INFECT DIS, V23, P118, DOI 10.1093/clinids/23.1.118; Schiappa DA, 1996, J INFECT DIS, V174, P529, DOI 10.1093/infdis/174.3.529; Shlaes DM, 1997, INFECT CONT HOSP EP, V18, P275; Tenover FC, 1996, JAMA-J AM MED ASSOC, V275, P300, DOI 10.1001/jama.275.4.300; TOLTZIS P, 1996, 34 ANN M INF DIS SOC; URBAN C, 1994, ANTIMICROB AGENTS CH, V38, P392, DOI 10.1128/AAC.38.2.392; *US C, 1995, OTAH629, P2	22	498	527	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1233	1237		10.1001/jama.280.14.1233	http://dx.doi.org/10.1001/jama.280.14.1233			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786372	Bronze			2022-12-28	WOS:000076357900028
J	Prives, C				Prives, C			Signaling to p53: Breaking the MDM2-p53 circuit	CELL			English	Review							DNA		Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.							Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; GROSSMAN SR, 1998, IN PRESS MOL CELL; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SAKAGUOHI K, 1998, IN PRESS GENES DEV; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	27	610	623	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					5	8		10.1016/S0092-8674(00)81774-2	http://dx.doi.org/10.1016/S0092-8674(00)81774-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778240	hybrid			2022-12-28	WOS:000076242300002
J	Schatz, G				Schatz, G			Policy forum: Biotechnology - The Swiss vote on gene technology	SCIENCE			English	Editorial Material									Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Schatz, G (corresponding author), Univ Basel, Biozentrum, CH-4056 Basel, Switzerland.							CUENI T, COMMUNICATION; *GES SOZ RES I, 1998, REP GENSCH IN; LAYMANN P, 1998, CHEM ENG NEWS   0713, P33; LONGCHAMP C, 1997, BAROMETER CONCERNS; LONGCHAMP C, COMMUNICATION; LONGCHAMP C, 1998, VOX ANAL 7 JUNE 1998; May RM, 1997, SCIENCE, V275, P793, DOI 10.1126/science.275.5301.793	7	9	9	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1810	1811		10.1126/science.281.5384.1810	http://dx.doi.org/10.1126/science.281.5384.1810			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9776684				2022-12-28	WOS:000076007100033
J	Maiti, A; Maki, G; Johnson, P				Maiti, A; Maki, G; Johnson, P			TNF-alpha induction of CD44-mediated leukocyte adhesion by sulfation	SCIENCE			English	Article							CD44; SELECTIN; EXTRAVASATION; LYMPHOCYTES; REQUIREMENT; HYALURONATE; LIGAND; MATRIX; CELLS	Regulation of cell adhesion is important for immune system function. CD44 is a tightly regulated cell adhesion molecule present on Leukocytes and implicated in their attachment to endothelium during an inflammatory immune response. The proinflammatory cytokine tumor necrosis factor-alpha, but not interferon-gamma, was found to convert CD44 from its inactive, nonbinding form to its active form by inducing the sulfation of CD44. This posttranslational modification was required for CD44-mediated binding to the extracellular matrix component hyaluronan and to vascular endothelial cells. Sulfation is thus a potential means of regulating CD44-mediated Leukocyte adhesion at inflammatory sites.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University of British Columbia	Johnson, P (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653				BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; Clark RA, 1996, J CELL BIOL, V134, P1075, DOI 10.1083/jcb.134.4.1075; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; Esford LE, 1998, J CELL SCI, V111, P1021; IMAI Y, 1993, NATURE, V361, P555; JALKANEN S, 1988, J IMMUNOL, V141, P1615; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; KLINGEMANN HG, 1994, LEUKEMIA LYMPHOMA, V12, P463, DOI 10.3109/10428199409073789; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Levesque MC, 1997, J IMMUNOL, V159, P6184; MAITI A, UNPUB; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1995, CELL, V83, P333; Sleeman JP, 1998, EUR J BIOCHEM, V255, P74, DOI 10.1046/j.1432-1327.1998.2550074.x; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takahashi K, 1996, J BIOL CHEM, V271, P9490, DOI 10.1074/jbc.271.16.9490; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390	26	117	125	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					941	943		10.1126/science.282.5390.941	http://dx.doi.org/10.1126/science.282.5390.941			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794764				2022-12-28	WOS:000076727300049
J	Pileri, P; Uematsu, Y; Campagnoli, S; Galli, G; Falugi, F; Petracca, R; Weiner, AJ; Houghton, M; Rosa, D; Grandi, G; Abrignani, S				Pileri, P; Uematsu, Y; Campagnoli, S; Galli, G; Falugi, F; Petracca, R; Weiner, AJ; Houghton, M; Rosa, D; Grandi, G; Abrignani, S			Binding of hepatitis C virus to CD81	SCIENCE			English	Article							INFECTION; CELLS; CRYOGLOBULINEMIA; ANTIBODIES; PROTEINS; TAPA-1; TARGET; GENE	Chronic hepatitis C virus (HCV) infection occurs in about 3 percent of the world's population and is a major cause of liver disease. HCV infection is also associated with cryoglobulinemia, a B Lymphocyte proliferative disorder. Virus tropism is controversial, and the mechanisms of cell entry remain unknown. The HCV envelope protein E2 binds human CD81,a tetraspanin expressed on various cell types including hepatocytes and B Lymphocytes. Binding of E2 was mapped to the major extracellular Loop of CD81. Recombinant molecules containing this loop bound HCV and antibodies that neutralize HCV infection in vivo inhibited virus binding to CD81 in vitro.	Chiron Corp, IRIS, I-53100 Siena, Italy; Chiron Corp, Emeryville, CA 94608 USA	Novartis; Novartis	Abrignani, S (corresponding author), Chiron Corp, IRIS, I-53100 Siena, Italy.	abrignani@iris02.biocine.it	Pileri, Piero/N-6227-2016; Cheng, Yushao/E-6256-2011	Pileri, Piero/0000-0002-2888-8748; Abrignani, Sergio/0000-0002-0794-3285; Houghton, Michael/0000-0003-3762-6771; Grandi, Guido/0000-0001-9724-2185				ABRIGNANI S, UNPUB; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ANDRIA ML, 1991, J IMMUNOL, V147, P1030; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BLIGHT K, 1994, HEPATOLOGY, V20, P553, DOI 10.1016/0270-9139(94)90087-6; BOUFFARD P, 1992, J INFECT DIS, V166, P1276, DOI 10.1093/infdis/166.6.1276; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; COOPER NR, 1988, ANNU REV IMMUNOL, V6, P85; DAILEY L, 1985, J VIROL, V54, P739, DOI 10.1128/JVI.54.3.739-749.1985; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P95; Geisert EE, 1996, J NEUROSCI, V16, P5478; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; HOUGHTON M, 1996, VIROLOGY, P1035; Ivanovski M, 1998, BLOOD, V91, P2433, DOI 10.1182/blood.V91.7.2433.2433_2433_2442; LEYV S, 1998, ANNU REV IMMUNOL, V16, P89; Mannion BA, 1996, J IMMUNOL, V157, P2039; PILERI P, UNPUB; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Silvestri F, 1996, BLOOD, V87, P4296, DOI 10.1182/blood.V87.10.4296.bloodjournal87104296; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P65; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X	27	1622	1727	1	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					938	941		10.1126/science.282.5390.938	http://dx.doi.org/10.1126/science.282.5390.938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794763				2022-12-28	WOS:000076727300048
J	Gainer, JV; Morrow, JD; Loveland, A; King, DJ; Brown, NJ				Gainer, JV; Morrow, JD; Loveland, A; King, DJ; Brown, NJ			Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOSARTAN POTASSIUM; RENAL RESPONSES; BLOOD-PRESSURE; RENIN RELEASE; SODIUM-INTAKE; CAPTOPRIL; ANTAGONIST; KALLIKREIN; HUMANS; SINGLE	Background Angiotensin-converting-enzyme (ACE) inhibitors not only decrease the production of angiotensin II but also decrease the degradation of bradykinin. In this study, a specific bradykinin-receptor antagonist, icatibant acetate (HOE 140), was used to determine the contribution of bradykinin to the short-term effects of ACE inhibition on blood pressure and plasma renin activity in both normotensive and hypertensive subjects. Methods We compared the hemodynamic, renal, and endocrine effects of captopril alone (25 mg), captopril plus icatibant (100 mu g per kilogram of body weight), the angiotensin ii subtype 1-receptor antagonist losartan (75 mg), and placebo in 20 subjects with normal blood pressure and 7 subjects with hypertension. The subjects were studied while they were salt depleted (i.e., in balance on a diet in which they were allowed 10 mmol of sodium per day). The drugs were administered on four separate study days in a single-blind, randomized fashion. Results The coadministration of icatibant significantly attenuated the hypotensive effect of captopril (maximal decrease in mean [+/-SE] arterial pressure for all subjects combined, 10.5+/-1.0 mm Hg, as com pared with 14.0+/-1.0 mm Hg for captopril alone; P = 0.001), in such a way that the decrease in blood pressure after the administration of captopril plus icatibant was similar to that after the administration of losartan (maximal decrease in mean arterial pressure, 11.0+/-1.7 mm Hg). Icatibant did not alter the renal hemodynamic response to captopril, but it significantly altered the change in plasma renin activity in response to ACE inhibition (-0.4+/-0.4 ng of angiotensin I per milliliter per hour, as compared with 2.0+/-0.7 ng per milliliter per hour for captopril alone; P = 0.007). The magnitude of these effects was similar in both the normotensive and the hypertensive subjects, as well as in both the black subjects and the white subjects. Conclusions These data confirm that bradykinin contributes to the short-term effects of ACE inhibition on blood pressure in normotensive and hypertensive persons and suggest that bradykinin also contributes to the short-term effects of ACE inhibition on the renin-angiotensin system. (N Engl J Med 1998;339:1285-92.) (C)1998, Massachusetts Medical Society.	Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Brown, NJ (corresponding author), Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, 560 MRB-1, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056963] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00095] Funding Source: Medline; NHLBI NIH HHS [HL56963] Funding Source: Medline; NIGMS NIH HHS [GM07569] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1980, JPN CIRC J, V44, P422, DOI 10.1253/jcj.44.422; AZIZI M, 1995, CIRCULATION, V92, P825, DOI 10.1161/01.CIR.92.4.825; Barbe F, 1996, AM J PHYSIOL-HEART C, V270, pH1985, DOI 10.1152/ajpheart.1996.270.6.H1985; BEIERWALTES WH, 1987, AM J PHYSIOL, V252, pF794, DOI 10.1152/ajprenal.1987.252.5.F794; BOUAZIZ H, 1994, BRIT J PHARMACOL, V113, P717, DOI 10.1111/j.1476-5381.1994.tb17052.x; Brown NJ, 1996, J PHARMACOL EXP THER, V279, P703; BURNIER M, 1995, HYPERTENSION, V25, P602, DOI 10.1161/01.HYP.25.4.602; CARRETERO OA, 1981, HYPERTENSION, V3, P18, DOI 10.1161/01.HYP.3.1.18; COCKCROFT JR, 1994, BRIT J CLIN PHARMACO, V38, P317, DOI 10.1111/j.1365-2125.1994.tb04360.x; DANIEL VC, 1994, J CHROMATOGR B, V653, P117, DOI 10.1016/0378-4347(93)E0432-P; DOIG JK, 1995, J CARDIOVASC PHARM, V25, P511, DOI 10.1097/00005344-199504000-00001; ERDOS EG, 1977, FED PROC, V36, P1760; FISHER NDL, 1994, HYPERTENSION, V23, P44, DOI 10.1161/01.HYP.23.1.44; GAVRAS H, 1978, NEW ENGL J MED, V298, P991, DOI 10.1056/NEJM197805042981803; GERBER JG, 1978, PROSTAG OTH LIPID M, V15, P81, DOI 10.1016/S0090-6980(78)80006-9; GOLDBERG A, 1995, CAN J CARDIOL, V11, pF27; GOLDBERG MR, 1995, HYPERTENSION, V25, P37, DOI 10.1161/01.HYP.25.1.37; GRADMAN AH, 1995, HYPERTENSION, V25, P1345, DOI 10.1161/01.HYP.25.6.1345; HOLLENBERG NK, 1981, KIDNEY INT, V20, P240, DOI 10.1038/ki.1981.126; Hornig B, 1997, CIRCULATION, V95, P1115; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; Iimura O, 1984, J Hypertens Suppl, V2, pS297; JOHNSTON CI, 1979, LANCET, V2, P493; JUILLERAT L, 1990, HYPERTENSION, V16, P564, DOI 10.1161/01.HYP.16.5.564; KON V, 1993, KIDNEY INT, V44, P545, DOI 10.1038/ki.1993.279; LEVY SB, 1977, J CLIN INVEST, V60, P129, DOI 10.1172/JCI108749; LINZ W, 1992, BRIT J PHARMACOL, V105, P771, DOI 10.1111/j.1476-5381.1992.tb09054.x; MADEDDU P, 1987, J HYPERTENS, V5, P645, DOI 10.1097/00004872-198712000-00002; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MATERSON BJ, 1994, NEW ENGL J MED, V330, P1689, DOI 10.1056/NEJM199406093302316; MIMRAN A, 1979, CLIN SCI, V57, pS421, DOI 10.1042/cs057421s; MUNAFO A, 1992, CLIN PHARMACOL THER, V51, P513, DOI 10.1038/clpt.1992.56; NAVIS G, 1985, Journal of Clinical Hypertension, V1, P228; OHTAWA M, 1993, BRIT J CLIN PHARMACO, V35, P290, DOI 10.1111/j.1365-2125.1993.tb05696.x; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; SHOBACK DM, 1983, J CLIN INVEST, V72, P2115, DOI 10.1172/JCI111176; SWARTZ SL, 1980, J CLIN INVEST, V65, P1257, DOI 10.1172/JCI109788; VANDER AJ, 1965, P SOC EXP BIOL MED, V120, P399; VANHOUTTE PM, 1989, HYPERTENSION, V13, P658, DOI 10.1161/01.HYP.13.6.658; WIRTH K, 1991, BRIT J PHARMACOL, V102, P774, DOI 10.1111/j.1476-5381.1991.tb12249.x; WONG PY, 1975, J CLIN INVEST, V55, P691, DOI 10.1172/JCI107978; WORKMAN RJ, 1979, J LAB CLIN MED, V93, P847; 1982, BR J CLIN PHARM S2, V14, pS97	43	356	363	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1285	1292		10.1056/NEJM199810293391804	http://dx.doi.org/10.1056/NEJM199810293391804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132XC	9791144				2022-12-28	WOS:000076655300004
J	Rodeck, C; Deans, A; Jauniaux, E				Rodeck, C; Deans, A; Jauniaux, E			Thermocoagulation for the early treatment of pregnancy with an acardiac twin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UMBILICAL-CORD LIGATION; ACEPHALIC TWIN; TRAP SEQUENCE; COAGULATION; GESTATION; ARTERY		UCL, Sch Med, Dept Obstet & Gynaecol, Fetal Med Unit, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Rodeck, C (corresponding author), UCL, Sch Med, Dept Obstet & Gynaecol, Fetal Med Unit, 86-96 Chenies Mews, London WC1E 6HX, England.							ASH K, 1990, OBSTET GYNECOL, V76, P960; FOLEY MR, 1995, AM J OBSTET GYNECOL, V172, P212, DOI 10.1016/0002-9378(95)90117-5; Hecher K, 1997, ULTRASOUND OBST GYN, V10, P130, DOI 10.1046/j.1469-0705.1997.10020130.x; JAMES WH, 1977, TERATOLOGY, V16, P211, DOI 10.1002/tera.1420160216; LEMERY DJ, 1994, ULTRASOUND OBST GYN, V4, P399, DOI 10.1046/j.1469-0705.1994.04050399.x; MCCURDY CM, 1993, OBSTET GYNECOL, V82, P708; MOORE TR, 1990, AM J OBSTET GYNECOL, V163, P907, DOI 10.1016/0002-9378(90)91094-S; PLATT LD, 1983, AM J OBSTET GYNECOL, V146, P857, DOI 10.1016/0002-9378(83)91090-6; PORRECO RP, 1991, LANCET, V337, P326, DOI 10.1016/0140-6736(91)90946-M; QUINTERO RA, 1994, NEW ENGL J MED, V330, P469, DOI 10.1056/NEJM199402173300705; ROBIE GF, 1989, NEW ENGL J MED, V320, P512, DOI 10.1056/NEJM198902233200808; SEPULVEDA W, 1995, OBSTET GYNECOL, V86, P680, DOI 10.1016/0029-7844(95)00171-M; SIMPSON PC, 1983, AM J OBSTET GYNECOL, V147, P842, DOI 10.1016/0002-9378(83)90056-X; VANALLEN MI, 1983, SEMIN PERINATOL, V7, P285; VILLE Y, 1994, ULTRASOUND OBST GYN, V4, P396, DOI 10.1046/j.1469-0705.1994.04050396.x	15	72	77	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1293	1295		10.1056/NEJM199810293391805	http://dx.doi.org/10.1056/NEJM199810293391805			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132XC	9791145				2022-12-28	WOS:000076655300005
J	Wharton, MR				Wharton, MR			Donald Barrie Case - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1159	1159						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784474				2022-12-28	WOS:000076755100065
J	Sadiq, ST; Copas, AJ; Johnson, AM				Sadiq, ST; Copas, AJ; Johnson, AM			Factors associated with gonorrhoea in men aware of being positive for HIV infection: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEXUALLY-TRANSMITTED DISEASES; TRANSMISSION; ENGLAND; WALES; SEMEN		Camden & Islington Community NHS Trust, Mortimer Market Ctr, London WC1E 6AU, England; UCL, Sch Med, Dept Sexually Transmitted Dis, Div Pathol & Infect Dis, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Sadiq, ST (corresponding author), Camden & Islington Community NHS Trust, Mortimer Market Ctr, London WC1E 6AU, England.	tsadi@msn.com		Copas, Andrew/0000-0001-8968-5963; Johnson, Anne/0000-0003-1330-7100; Sadiq, S Tariq/0000-0002-0608-3818				Catchpole MA, 1996, BRIT MED J, V312, P539, DOI 10.1136/bmj.312.7030.539; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; EVANS BG, 1993, BRIT MED J, V306, P426, DOI 10.1136/bmj.306.6875.426; *EXP GROUP, 1996, COMMUNICAB DIS REP, V6, P1; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006	5	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	1998	317	7165					1052	1053						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774290				2022-12-28	WOS:000076577200026
J	Goldfarb, S; Henrich, WL				Goldfarb, S; Henrich, WL			Update in nephrology	ANNALS OF INTERNAL MEDICINE			English	Article							TREATED HYPERTENSIVE MEN; DIABETES-MELLITUS; MICROALBUMINURIA; MORTALITY; RISK		Med Coll Ohio, Dept Internal Med, Toledo, OH 43614 USA; Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Goldfarb, S (corresponding author), Hosp Univ Penn, Dept Med, 100 Centrex,3400 Spruce St, Philadelphia, PA 19104 USA.	sgoldfar@mail.med.upenn.edu						Agewall S, 1997, AM J CARDIOL, V80, P164, DOI 10.1016/S0002-9149(97)00312-3; Agewall S, 1996, ANGIOLOGY, V47, P963, DOI 10.1177/000331979604701005; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; Grossman E, 1997, J HUM HYPERTENS, V11, P789, DOI 10.1038/sj.jhh.1000471; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; Pickering TG, 1997, JAMA-J AM MED ASSOC, V278, P1110, DOI 10.1001/jama.278.13.1110; WARRAM JH, 1991, ARCH INTERN MED, V151, P1350, DOI 10.1001/archinte.151.7.1350; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186	10	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					636	642		10.7326/0003-4819-129-8-199810150-00012	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786812				2022-12-28	WOS:000076431800007
J	Iacono, G; Cavataio, F; Montalto, G; Florena, A; Tumminello, M; Soresi, M; Notarbartolo, A; Carroccio, A				Iacono, G; Cavataio, F; Montalto, G; Florena, A; Tumminello, M; Soresi, M; Notarbartolo, A; Carroccio, A			Intolerance of cow's milk and chronic constipation in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ABNORMAL DEFECATION DYNAMICS; GASTROESOPHAGEAL REFLUX; ENCOPRESIS; ALLERGY; CHILDHOOD; SECONDARY	Background Chronic diarrhea is the most common gastrointestinal symptom of intolerance of cow's milk among children. On the basis of a prior open study, we hypothesized that intolerance of cow's milk can also cause severe perianal lesions with pain on defecation and consequent constipation in young children. Methods We performed a double-blind, crossover study comparing cow's milk with soy milk in 65 children (age range, 11 to 72 months) with chronic constipation (defined as having one bower movement every 3 to 15 days). All had been referred to a pediatric gastroenterology clinic and had previously been treated with laxatives without success; 49 had anal fissures and perianal erythema or edema. After 15 days of observation, the patients received cow's milk or soy milk for 2 weeks. After a one-week washout period, the feedings were reversed. A response was defined as eight or more bower movements during a treatment period. Results Forty-four of the 65 children (68 percent) had a response while receiving soy milk. Anal fissures and pain with defecation resolved. None of the children who received cow's milk had a response. In all 44 children with a response, the response was confirmed with a double-blind challenge with cow's milk. Children with a response had a higher frequency of coexistent rhinitis, dermatitis, or bronchospasm than those with no response (11 of 44 children vs. 1 of 27, P=0.05); they were also more likely to have anal fissures and erythema or edema at base line (40 of 44 vs. 9 of 21, P<0.001), evidence of inflammation of the rectal mucosa on biopsy (26 of 44 vs. 5 of 21, P=0.008), and signs of hypersensitivity, such as specific IgE antibodies to cow's-milk antigens (31 of 44 vs. 4 of 21, P<0.001). Conclusions In young children, chronic constipation can be a manifestation of intolerance of cow's milk. (N Engl J Med 1998;339:1100-4.) (C) 1998, Massachusetts Medical Society.	Univ Palermo, Osped G Di Cristina, Div Pediat, Palermo, Italy; Univ Palermo, Cattedra Med Interna, Palermo, Italy; Univ Palermo, Ist Anat Patol, Palermo, Italy	University of Palermo; University of Palermo; University of Palermo	Carroccio, A (corresponding author), Via A Coffaro 25, I-90124 Palermo, Italy.		Carroccio, Antonio/K-4484-2016; Soresi, Maurizio/AAY-2045-2020	Carroccio, Antonio/0000-0001-8913-7916; Soresi, Maurizio/0000-0001-7850-555X; MONTALTO, Giuseppe/0000-0002-8731-8577				ABRAHAMIAN FP, 1984, J PEDIATR GASTR NUTR, V3, P460, DOI 10.1097/00005176-198406000-00027; Cavataio F, 1996, ARCH DIS CHILD, V75, P51, DOI 10.1136/adc.75.1.51; CHIN KC, 1983, BRIT MED J, V287, P1593, DOI 10.1136/bmj.287.6405.1593; CLAYDEN GS, 1976, ARCH DIS CHILD, V51, P918, DOI 10.1136/adc.51.12.918; COLTON T, 1977, STAT MED; CORAZZIARI E, 1985, J PEDIATR-US, V106, P379, DOI 10.1016/S0022-3476(85)80660-0; GOLDMAN H, 1986, AM J SURG PATHOL, V10, P75, DOI 10.1097/00000478-198602000-00001; HATCH TF, 1988, PEDIATR CLIN N AM, V35, P257; IACONO G, 1995, J PEDIATR-US, V126, P34, DOI 10.1016/S0022-3476(95)70496-5; Iacono G, 1996, J ALLERGY CLIN IMMUN, V97, P822, DOI 10.1016/S0091-6749(96)80160-6; IYNGKARAN N, 1989, ARCH DIS CHILD, V64, P1256, DOI 10.1136/adc.64.9.1256; KeuzenkampJansen CW, 1996, ARCH DIS CHILD, V75, P36, DOI 10.1136/adc.75.1.36; LEVINE MD, 1976, PEDIATRICS, V58, P845; LOENINGBAUCKE V, 1990, J PEDIATR-US, V116, P214, DOI 10.1016/S0022-3476(05)82877-X; LOENINGBAUCKE VA, 1986, J PEDIATR-US, V108, P562, DOI 10.1016/S0022-3476(86)80834-4; LOWERY SP, 1985, J PEDIATR GASTR NUTR, V4, P397, DOI 10.1097/00005176-198506000-00013; MCGRATH J, 1984, BRIT MED J, V288, P236, DOI 10.1136/bmj.288.6412.236-a; OLATAWUR.MO, 1973, ACTA PAEDIATR SCAND, V62, P358, DOI 10.1111/j.1651-2227.1973.tb08120.x; PINKERTON P, 1957, ARCH DIS CHILD, V24, P371; STAIANO A, 1991, DIGEST DIS SCI, V36, P733, DOI 10.1007/BF01311229; SURAWICZ CM, 1994, GASTROENTEROLOGY, V107, P755, DOI 10.1016/0016-5085(94)90124-4; YOUNOSZAI MK, 1989, TXB GASTROENTEROLOGY, P1311	22	214	230	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1100	1104		10.1056/NEJM199810153391602	http://dx.doi.org/10.1056/NEJM199810153391602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129DP	9770556	Bronze			2022-12-28	WOS:000076448200002
J	Barreto, ML				Barreto, ML			Questionnaire approach to diagnosis in developing countries	LANCET			English	Editorial Material							SCHISTOSOMIASIS; EPIDEMIOLOGY; MANSONI; RISK		Univ Fed Bahia, Inst Saude Colet, BR-40110170 Salvador, BA, Brazil	Universidade Federal da Bahia	Barreto, ML (corresponding author), Univ Fed Bahia, Inst Saude Colet, BR-40110170 Salvador, BA, Brazil.		Barreto, Mauricio L/B-1752-2008	Barreto, Mauricio L/0000-0002-0215-4930				BARRETO ML, 1993, AM J TROP MED HYG, V48, P742, DOI 10.4269/ajtmh.1993.48.742; BIBEAU G, 1981, SOC SCI MED-MED SOC, V15, P357, DOI 10.1016/0271-7123(81)90066-3; CHANDRAMOHAN D, 1994, INT J EPIDEMIOL, V23, P213, DOI 10.1093/ije/23.2.213; GRAY HR, 1990, 10 J HOPK U SCH HYG; Hammad TA, 1996, T ROY SOC TROP MED H, V90, P372, DOI 10.1016/S0035-9203(96)90509-X; KROEGER A, 1983, INT J EPIDEMIOL, V12, P465, DOI 10.1093/ije/12.4.465; LENGELER C, 1991, INT J EPIDEMIOL, V20, P796, DOI 10.1093/ije/20.3.796; MEZZICH JE, 1994, ACTA PSYCHIAT SCAND, V90, P61, DOI 10.1111/j.1600-0447.1994.tb05915.x; Reeves BC, 1997, INT J EPIDEMIOL, V26, P1080, DOI 10.1093/ije/26.5.1080; STREINER DL, 1989, HLTH MEASUREMENTS SC; Zhou H, 1998, T ROY SOC TROP MED H, V92, P245, DOI 10.1016/S0035-9203(98)90997-X	11	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1164	1165		10.1016/S0140-6736(05)60526-0	http://dx.doi.org/10.1016/S0140-6736(05)60526-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128PQ	9777829				2022-12-28	WOS:000076415400004
J	Fairbank, J				Fairbank, J			Trials and tribulations in cervical spondylosis	LANCET			English	Editorial Material									Nuffield Orthopaed Ctr, Oxford OX3 7LD, England	Nuffield Orthopaedic Centre	Fairbank, J (corresponding author), Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.		Fairbank, Jeremy/AAA-3411-2019					Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FROST H, 1997, PHYSIOTHERAPY, V83, P645; ROWLAND LP, 1992, NEUROLOGY, V42, P5, DOI 10.1212/WNL.42.1.5; Savolainen S, 1998, NEUROSURGERY, V43, P51, DOI 10.1097/00006123-199807000-00032; STIRRAT GM, 1992, ANN ROY COLL SURG, V74, P80	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1165	1166		10.1016/S0140-6736(05)60527-2	http://dx.doi.org/10.1016/S0140-6736(05)60527-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777830				2022-12-28	WOS:000076415400005
J	Greenhalg, T				Greenhalg, T			Soundings - Retraction	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					1022	1022		10.1136/bmj.317.7164.1022	http://dx.doi.org/10.1136/bmj.317.7164.1022			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765189	Green Published			2022-12-28	WOS:000076449300074
J	Ifudu, O				Ifudu, O			Care of patients undergoing hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							STAGE RENAL-DISEASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; IMPROVED SEXUAL FUNCTION; MAINTENANCE HEMODIALYSIS; DIALYSIS PATIENTS; VASCULAR ACCESS; LIPID PROFILE; SHORT-TERM; FAILURE; THERAPY		SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Ifudu, O (corresponding author), SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, 450 Clarkson Ave,Box 52, Brooklyn, NY 11203 USA.							ALAKAILA K, 1987, SCAND J GASTROENTERO, V22, P372, DOI 10.3109/00365528709078607; AlHomrany M, 1997, AM J NEPHROL, V17, P32, DOI 10.1159/000169068; Barth R. H., 1996, Journal of the American Society of Nephrology, V7, P1439; BAZZI C, 1991, CLIN NEPHROL, V35, P176; BEAMISH MR, 1971, BRIT J HAEMATOL, V21, P617, DOI 10.1111/j.1365-2141.1971.tb02724.x; BLANKESTIJN PJ, 1995, J AM SOC NEPHROL, V5, P1703; BODDY K, 1972, BMJ-BRIT MED J, V1, P771, DOI 10.1136/bmj.1.5803.771; BOMMER J, 1979, LANCET, V2, P496; BORAH MF, 1978, KIDNEY INT, V14, P491, DOI 10.1038/ki.1978.154; CHARRA B, 1983, NEPHRON, V33, P96, DOI 10.1159/000182920; CHEIGH JS, 1992, AM J KIDNEY DIS, V19, P453, DOI 10.1016/S0272-6386(12)80954-1; CLAUSEN T, 1989, KIDNEY INT, V35, P1, DOI 10.1038/ki.1989.1; deLemos JA, 1996, J AM SOC NEPHROL, V7, P2044; DELMEZ JA, 1991, J CLIN ENDOCR METAB, V72, P735, DOI 10.1210/jcem-72-4-735; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; FAIRBANKS VF, 1995, WILLIAMS HEMATOLOGY, P490; FARIAS MAG, 1994, AM J KIDNEY DIS, V23, P382; Feldman HI, 1996, J AM SOC NEPHROL, V7, P523; FENVES AZ, 1986, AM J KIDNEY DIS, V7, P130, DOI 10.1016/S0272-6386(86)80133-0; Fishbane S, 1997, AM J KIDNEY DIS, V29, P319, DOI 10.1016/S0272-6386(97)90192-X; GARCIALEONI ME, 1990, EUR J CLIN MICROBIOL, V9, P283, DOI 10.1007/BF01968062; GEERLINGS W, 1993, NEPHROL DIAL TRANSPL, V8, P585; GOLDBLUM SE, 1980, ANN INTERN MED, V93, P597, DOI 10.7326/0003-4819-93-4-597; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; HOU SH, 1994, AM J KIDNEY DIS, V23, P60, DOI 10.1016/S0272-6386(12)80813-4; HOY WE, 1978, NEPHRON, V20, P182, DOI 10.1159/000181220; Ifudu O, 1996, AM J NEPHROL, V16, P118, DOI 10.1159/000168982; IFUDU O, 1994, AM J KIDNEY DIS, V23, P394, DOI 10.1016/S0272-6386(12)81002-X; Ifudu O, 1996, INT J ARTIF ORGANS, V19, P384, DOI 10.1177/039139889601900702; Ifudu O, 1996, NEW ENGL J MED, V334, P420, DOI 10.1056/NEJM199602153340702; Ifudu O, 1997, J Assoc Acad Minor Phys, V8, P49; Ifudu O, 1997, AM J KIDNEY DIS, V29, P549, DOI 10.1016/S0272-6386(97)90336-X; IFUDU O, 1995, DIALYSIS TRANSPLANT, V24, P292; ISHIKAWA I, 1991, NEPHRON, V58, P257, DOI 10.1159/000186434; KAHN JK, 1990, AM HEART J, V119, P484, DOI 10.1016/S0002-8703(05)80268-6; KANG JY, 1988, DIGEST DIS SCI, V33, P774, DOI 10.1007/BF01550962; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; LINAS SL, 1991, KIDNEY INT, V39, P771, DOI 10.1038/ki.1991.95; LIVIO M, 1986, NEW ENGL J MED, V315, P731, DOI 10.1056/NEJM198609183151204; Lundin AP., 1990, SEMIN DIALYSIS, V3, P5, DOI DOI 10.1111/J.1525-139X.1990.TB00003.X; Madore F, 1997, J AM SOC NEPHROL, V8, P1921; MALLUCHE HH, 1992, KIDNEY INT, V42, pS62; MANNUCCI PM, 1983, NEW ENGL J MED, V308, P8, DOI 10.1056/NEJM198301063080102; MCMAHON LP, 1990, AM J NEPHROL, V10, P404, DOI 10.1159/000168156; OH MS, 1975, NEPHRON, V14, P421, DOI 10.1159/000180476; OWEN CH, 1994, ANN THORAC SURG, V58, P1729, DOI 10.1016/0003-4975(94)91671-3; Pastan S, 1998, NEW ENGL J MED, V338, P1428, DOI 10.1056/NEJM199805143382006; POLLOCK CA, 1994, KIDNEY INT, V45, P897, DOI 10.1038/ki.1994.118; PORT FK, 1989, AM J KIDNEY DIS, V14, P119, DOI 10.1016/S0272-6386(89)80187-8; RAO TKS, 1987, NEW ENGL J MED, V316, P1062, DOI 10.1056/NEJM198704233161705; REMUZZI G, 1978, NEPHRON, V22, P347, DOI 10.1159/000181474; RUIZ P, 1990, NEW ENGL J MED, V322, P717, DOI 10.1056/NEJM199003153221102; SANDLE GI, 1987, CLIN SCI, V73, P247, DOI 10.1042/cs0730247; SCHAEFER RM, 1989, CLIN NEPHROL, V31, P1; SCHLESSINGER SD, 1994, AM J KIDNEY DIS, V23, P655, DOI 10.1016/S0272-6386(12)70275-5; The USRDS Dialysis Morbidity and Mortality Study (Wave 1), 1996, REN DAT SYST USRDS 1, P45; TISHER CC, 1994, ANN INTERN MED, V121, P62; Tzamaloukas A H, 1988, J Diabet Complications, V2, P75, DOI 10.1016/0891-6632(88)90007-4; VALJI K, 1991, RADIOLOGY, V178, P243, DOI 10.1148/radiology.178.1.1824582; VANGEELEN JA, 1987, NEPHRON, V45, P216, DOI 10.1159/000184120; WEIZMAN R, 1983, PSYCHOSOM MED, V45, P259, DOI 10.1097/00006842-198306000-00008	62	55	57	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1054	1062		10.1056/NEJM199810083391507	http://dx.doi.org/10.1056/NEJM199810083391507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761808				2022-12-28	WOS:000076294800007
J	Watanabe, D; Inokawa, H; Hashimoto, K; Suzuki, N; Kano, M; Shigemoto, R; Hirano, T; Toyama, K; Kaneko, S; Yokoi, M; Moriyoshi, K; Suzuki, M; Kobayashi, K; Nagatsu, T; Kreitman, RJ; Pastan, I; Nakanishi, S				Watanabe, D; Inokawa, H; Hashimoto, K; Suzuki, N; Kano, M; Shigemoto, R; Hirano, T; Toyama, K; Kaneko, S; Yokoi, M; Moriyoshi, K; Suzuki, M; Kobayashi, K; Nagatsu, T; Kreitman, RJ; Pastan, I; Nakanishi, S			Ablation of cerebellar Golgi cells disrupts synaptic integration involving GABA inhibition and NMDA receptor activation in motor coordination	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; GRANULE CELLS; TRANSGENIC MICE; NERVOUS-SYSTEM; MUTANT MICE; TOXIN GENE; RAT; MGLUR2; EXPRESSION; CURRENTS	The role of inhibitory Golgi cells in cerebellar function was investigated by selectively ablating Golgi cells expressing human interleukin-2 receptor alpha subunit in transgenic mice, using the immunotoxin-mediated cell targeting technique. Golgi cell disruption caused severe acute motor disorders. These mice showed gradual recovery but retained a continuing inability to perform compound movements. Optical and electrical recordings combined with immunocytological analysis indicated that elimination of Golgi cells not only reduces GABA-mediated inhibition but also attenuates functional NMDA receptors in granule cells. These results demonstrate that synaptic integration involving both GABA inhibition and NMDA receptor activation is essential for compound motor coordination. Furthermore, this integration can adapt after Golgi cell elimination so as not to evoke overexcitation by the reduction of NMDA receptors.	Kyoto Univ, Fac Med, Dept Sci Biol, Kyoto 6068501, Japan; Kyoto Prefectural Univ Med, Dept Physiol, Kyoto 6020841, Japan; Kanazawa Univ, Sch Med, Dept Physiol, Kanazawa, Ishikawa 9208640, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Kumamoto Univ, Sch Med, Lab Transgen Technol, Inst Mol Embryol & Genet, Kumamoto 8600976, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Ikoma 6300101, Japan; Fujita Hlth Univ, Sch Med, Inst Comprehens Med Sci, Toyoake, Aichi 4701192, Japan; NCI, Mol Biol Lab, Div Basic Sci, Bethesda, MD 20892 USA	Kyoto University; Kyoto Prefectural University of Medicine; Kanazawa University; Kyoto University; Kumamoto University; Nara Institute of Science & Technology; Fujita Health University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nakanishi, S (corresponding author), Kyoto Univ, Fac Med, Dept Sci Biol, Kyoto 6068501, Japan.		Shigemoto, Ryuichi/E-3628-2013; pastan, ira/P-9319-2019	Shigemoto, Ryuichi/0000-0001-8761-9444; pastan, ira/0000-0002-9223-0270; Hashimoto, Kouichi/0000-0002-3884-8213; Kobayashi, Kazuto/0000-0002-7617-2939; Kano, Masanobu/0000-0002-0725-3292				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P1138, DOI 10.1152/jn.1964.27.6.1138; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; BUONOMANO DV, 1994, NEURAL COMPUT, V6, P38, DOI 10.1162/neco.1994.6.1.38; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; DANGELO E, 1994, EUR J NEUROSCI, V6, P640, DOI 10.1111/j.1460-9568.1994.tb00309.x; DANGELO E, 1995, J PHYSIOL-LONDON, V484, P397, DOI 10.1113/jphysiol.1995.sp020673; ECCLES J, 1964, NATURE, V204, P1265, DOI 10.1038/2041265a0; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; Flourens P, 1824, RECHERCHES EXPT PROP; FUJITA M, 1982, BIOL CYBERN, V45, P195, DOI 10.1007/BF00336192; GABBIANI F, 1994, J NEUROPHYSIOL, V72, P999, DOI 10.1152/jn.1994.72.2.999; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Ito M, 1984, CEREBELLUM NEURAL CO; Kadotani H, 1996, J NEUROSCI, V16, P7859; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; KASE M, 1980, J PHYSIOL-LONDON, V300, P539, DOI 10.1113/jphysiol.1980.sp013178; KOBAYASHI K, 1995, P NATL ACAD SCI USA, V92, P1132, DOI 10.1073/pnas.92.4.1132; KONNERTH A, 1987, J PHYSIOL-LONDON, V393, P681, DOI 10.1113/jphysiol.1987.sp016848; Lujan R, 1997, J CHEM NEUROANAT, V13, P219, DOI 10.1016/S0891-0618(97)00051-3; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAPPER RMA, 1988, J COMP NEUROL, V274, P168, DOI 10.1002/cne.902740204; Neki A, 1996, NEUROSCIENCE, V75, P815, DOI 10.1016/0306-4522(96)00316-8; NIRENBERG S, 1993, J NEUROSCI, V13, P3238, DOI 10.1523/jneurosci.13-08-03238.1993; NUSSER Z, 1995, J NEUROSCI, V15, P2948; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PUIA G, 1994, NEURON, V12, P117, DOI 10.1016/0896-6273(94)90157-0; Ramon y Cajal S, 1995, HIST NERVOUS SYSTEM; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; Singer W, 1996, CURR BIOL, V6, P395, DOI 10.1016/S0960-9822(02)00505-5; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANIFUJI M, 1994, SCIENCE, V266, P1057, DOI 10.1126/science.7973662; Ueda Y, 1997, J NEUROSCI, V17, P3014; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645	44	172	176	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					17	27		10.1016/S0092-8674(00)81779-1	http://dx.doi.org/10.1016/S0092-8674(00)81779-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778244	Green Submitted, Bronze			2022-12-28	WOS:000076242300007
J	Lucassen, A				Lucassen, A			Ethical issues in genetics of mental disorders	LANCET			English	Editorial Material									Churchill Hosp, Dept Clin Genet, Oxford OX3 7LJ, England	University of Oxford	Lucassen, A (corresponding author), Churchill Hosp, Dept Clin Genet, Oxford OX3 7LJ, England.		Lucassen, Anneke/D-7764-2017	Lucassen, Anneke/0000-0003-3324-4338				CLARKE A, 1991, LANCET, V338, P998, DOI 10.1016/0140-6736(91)91849-P; Holtzman NA, 1998, BMJ-BRIT MED J, V316, P852, DOI 10.1136/bmj.316.7134.852; McConnell LM, 1998, NAT MED, V4, P757, DOI 10.1038/nm0798-757; Nuffield Council on Bioethics, 1998, MENT DIS GEN ETH CON; SESHADRI S, 1995, ARCH NEUROL-CHICAGO, V52, P1074, DOI 10.1001/archneur.1995.00540350068018; SHORT N, 1993, NATURE, V362, P783, DOI 10.1038/362783a0; WERTZ DC, 1993, CLIN GENET, V44, P37; Wilcke JTR, 1998, BRIT MED J, V317, P744, DOI 10.1136/bmj.317.7160.744	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1004	1005		10.1016/S0140-6736(05)60071-2	http://dx.doi.org/10.1016/S0140-6736(05)60071-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759739				2022-12-28	WOS:000076121800005
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Two-hybridzyme	SCIENCE			English	Article																		Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1822	1823						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9776687				2022-12-28	WOS:000076007100042
J	Gale, MD; Devos, KM				Gale, MD; Devos, KM			Plant comparative genetics after 10 years	SCIENCE			English	Editorial Material							FLOWERING TIME; GENES; ARABIDOPSIS; BRASSICA; REGIONS; RICE; CONSERVATION; GENOMES; SORGHUM; TOMATO	The past 10 years have seen the discovery of unexpected Levels of conservation of gene content and gene orders over millions of years of evolution within grasses, crucifers, Legumes, some trees, and Solanaceae crops, Within the grasses, which include the three 500-million-ton-plus-per-year crops (wheat, maize, and rice), and the crucifers, which include all the Brassica crops, colinearity Looks good enough to do most map-based cloning only in the small genome model species, rice and Arabidopsis. Elsewhere, knowledge gained in a few major crops is being pooled and applied across the board. The extrapolation of information from the well-studied species to orphan crops, which include many tropical species, is providing a solid base for their improvement. Genome rearrangements are giving new insights into evolution. In fact, comparative genetics is the key that will unlock the secrets of crop plants with genomes Larger than that of humans.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Gale, MD (corresponding author), John Innes Ctr Plant Sci Res, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.		Devos, Katrien M/B-1380-2014					BAILEY PC, IN PRESS THEOR APPL; Barakat A, 1997, P NATL ACAD SCI USA, V94, P6857, DOI 10.1073/pnas.94.13.6857; BENNETZEN JL, COMMUNICATION; BONIERBALE MW, 1988, GENETICS, V120, P1095; Cartinhour SW, 1997, PLANT MOL BIOL, V35, P241, DOI 10.1023/A:1005797203035; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; Cavell AC, 1998, GENOME, V41, P62, DOI 10.1139/gen-41-1-62; Chao S., 1988, Proceedings of the seventh international wheat genetics symposium held at Cambridge, UK, 13-19 July 1988., P493; Chen M, 1997, P NATL ACAD SCI USA, V94, P3431, DOI 10.1073/pnas.94.7.3431; DEVOS KM, 1993, THEOR APPL GENET, V85, P673, DOI 10.1007/BF00225004; DEVOS KM, UNPUB; Foote T, 1997, GENETICS, V147, P801; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; GALE MD, 1998, BBSRC USDA BIL PLANT; HARBERD NP, COMMUNICATION; Kilian A, 1997, PLANT MOL BIOL, V35, P187, DOI 10.1023/A:1005768222615; King G., COMMUNICATION; KLEINHOFS A, COMMUNICATION; Lagercrantz U, 1996, PLANT J, V9, P13, DOI 10.1046/j.1365-313X.1996.09010013.x; Lagercrantz U, 1996, GENETICS, V144, P1903; Leister D, 1998, P NATL ACAD SCI USA, V95, P370, DOI 10.1073/pnas.95.1.370; MARTIENSSEN RA, COMMUNICATION; MENANCIOHAUTEA D, 1993, THEOR APPL GENET, V86, P797, DOI 10.1007/BF00212605; MULLER J, 1981, BOT REV, V47, P1, DOI 10.1007/BF02860537; NEALE D, COMMUNICATION; OSBORN T, COMMUNICATION; Osborn TC, 1997, GENETICS, V146, P1123; Panstruga R, 1998, NUCLEIC ACIDS RES, V26, P1056, DOI 10.1093/nar/26.4.1056; Paterson AH, 1996, NAT GENET, V14, P380, DOI 10.1038/ng1296-380; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; PEREIRA MG, 1995, THEOR APPL GENET, V90, P380, DOI 10.1007/BF00221980; Schmidt Randy L, COMMUNICATION; SCHULZELEFERT P, COMMUNICATION; TANKSLEY SD, 1988, P NATL ACAD SCI USA, V85, P6419, DOI 10.1073/pnas.85.17.6419; TARCHINI R, COMMUNICATION; WEEDEN NF, 1992, J HERED, V83, P123, DOI 10.1093/oxfordjournals.jhered.a111171; ZHANG H, 1998, P NATL ACAD SCI USA, V96, P69	37	276	315	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					656	659		10.1126/science.282.5389.656	http://dx.doi.org/10.1126/science.282.5389.656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784118				2022-12-28	WOS:000076607500037
J	Gelbart, WM				Gelbart, WM			Databases in genomic research	SCIENCE			English	Editorial Material								Genome-related databases have already become an invaluable part of the scientific Landscape. The role played by these databases will only increase as the volume and complexity of relevant biology data rapidly expand. We are far enough into the genome project and into the development of these databases to assess their attributes and to reexamine some of the conceptual organizations and approaches they are taking. It is clear that there are needs for both highly detailed and simplified database views, the Latter being especially needed to make expert domain data more accessible to nonspecialists.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Gelbart, WM (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.								0	54	65	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					659	661		10.1126/science.282.5389.659	http://dx.doi.org/10.1126/science.282.5389.659			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784119				2022-12-28	WOS:000076607500038
J	Lange, P; Parner, J; Vestbo, J; Schnohr, P; Jensen, G				Lange, P; Parner, J; Vestbo, J; Schnohr, P; Jensen, G			A 15-year follow-up study of ventilatory function in adults with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; PULMONARY-FUNCTION; BRONCHIAL-ASTHMA; MUCUS HYPERSECRETION; AIRWAYS OBSTRUCTION; DECLINE; MORTALITY; HYPERRESPONSIVENESS; BUDESONIDE	Background Although the prevalence of asthma and morbidity related to asthma are increasing, little is known about the natural history of lung function in adults with this disease. Methods We used data from a longitudinal epidemiologic study of the general population in a Danish city, the Copenhagen City Heart Study, to analyze changes over time in the forced expiratory volume in one second (FEV1) in adults with self-reported asthma and adults without asthma. The study was conducted between 1976 and 1994; for each patient, three measurements of lung function were obtained over a 15-year period. The final data set consisted of measurements from 17,506 subjects (8136 men and 9370 women), of whom 1095 had asthma. Results Among subjects who participated in all three evaluations, the unadjusted decline in FEV1 among subjects with asthma was 38 mi per year, as compared with 22 mi per year in those without asthma. The decline in FEV1 normalized for height (FEV1 divided by the square of the height in meters) was greater among the subjects with asthma than among those without the disease (P<0.001). Among both men and women, and among both smokers and nonsmokers, subjects with asthma had greater declines in FEV1 over time than those without asthma (P<0.001). At the age of 60 years, a 175-cm-tall nonsmoking man without asthma had an average FEV1 of 3.05 liters, as compared with 1.99 liters for a man of similar age and height who smoked and had asthma. Conclusions In a sample of the general population, people who identified themselves as having asthma had substantially greater declines in FEV1 over time than those who did not, (N Engl J Med 1998;339:1194-200.) (C) 1998, Massachusetts Medical Society.	Bispebjerg Univ Hosp, Epidemiol Res Unit, Copenhagen City Heart Study, DK-2400 Copenhagen NV, Denmark; Hvidovre Hosp, Dept Resp Med 129, Copenhagen, Denmark; Univ Copenhagen, Dept Biostat, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; University of Copenhagen	Lange, P (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Resp Med 129, DK-2650 Hvidovre, Denmark.		Vestbo, Jorgen/Y-2912-2019; Pistelli, Francesco/Y-8270-2019	Pistelli, Francesco/0000-0001-5612-6364; Vestbo, Jorgen/0000-0001-6355-6362				ALMIND M, 1992, DAN MED BULL, V39, P561; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; APPLEYARD M, 1989, SCAND J SOC MED S, V41, P1; Backman KS, 1997, CHEST, V112, P1234, DOI 10.1378/chest.112.5.1234; BOULET LP, 1994, CHEST, V105, P1024, DOI 10.1378/chest.105.4.1024; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; BURROWS B, 1990, MED CLIN N AM, V74, P547, DOI 10.1016/S0025-7125(16)30539-9; CONNOLLY CK, 1988, POSTGRAD MED J, V64, P422, DOI 10.1136/pgmj.64.752.422; Connolly CK, 1997, CHEST, V112, P994, DOI 10.1378/chest.112.4.994; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; FINUCANE KE, 1985, MED J AUSTRALIA, V142, P602, DOI 10.5694/j.1326-5377.1985.tb113530.x; FLETCHER C, 1976, NATURAL HIST CHORNIC; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Huovinen E, 1997, THORAX, V52, P49, DOI 10.1136/thx.52.1.49; JENSEN G, 1984, ACTA MED SCAND S, V602, P1; Lange P, 1996, LANCET, V347, P1285, DOI 10.1016/S0140-6736(96)90937-X; LANGE P, 1988, AM REV RESPIR DIS, V137, P1119, DOI 10.1164/ajrccm/137.5.1119; MULLEN JBM, 1987, THORAX, V42, P843, DOI 10.1136/thx.42.11.843; OPENSHAW PJM, 1989, RESP MED, V83, P25, DOI 10.1016/S0954-6111(89)80056-3; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; PANHUYSEN CIM, 1997, AM J RESP CRIT CARE, V156, P674; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Rijcken B, 1996, AM J RESP CRIT CARE, V154, pS246, DOI 10.1164/ajrccm/154.6_Pt_2.S246; ROCHE WR, 1989, LANCET, V1, P520; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; SLUITER HJ, 1991, EUR RESPIR J, V4, P479; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; Vestbo J, 1996, AM J RESP CRIT CARE, V153, P1530, DOI 10.1164/ajrccm.153.5.8630597; VONESH EF, 1992, BIOMETRICS, V48, P1, DOI 10.2307/2532734; WILSON JW, 1993, AM REV RESPIR DIS, V148, P806, DOI 10.1164/ajrccm/148.3.806	34	922	944	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1194	1200		10.1056/NEJM199810223391703	http://dx.doi.org/10.1056/NEJM199810223391703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780339	Bronze			2022-12-28	WOS:000076532400003
J	Frankignoulle, M; Abril, G; Borges, A; Bourge, I; Canon, C; DeLille, B; Libert, E; Theate, JM				Frankignoulle, M; Abril, G; Borges, A; Bourge, I; Canon, C; DeLille, B; Libert, E; Theate, JM			Carbon dioxide emission from European estuaries	SCIENCE			English	Article							ORGANIC-CARBON; METABOLISM; CYCLE	The partial pressure of carbon dioxide (pCO(2)) in surface waters and related atmospheric exchanges were measured in nine European estuaries. Averaged fluxes over the entire estuaries are usually in the range of 0.1 to 0.5 mole of CO2 per square meter per day, For wide estuaries, net daily fluxes to the atmosphere amount to several hundred tons of carbon (up to 790 tons of carbon per day in the Scheldt estuary). European estuaries emit between 30 and 60 million tons of carbon per year to the atmosphere, representing 5 to 10% of present anthropogenic CO2 emissions for Western Europe.	Univ Liege, Inst Phys B5, Unite Oceanog Chim, B-4000 Liege, Belgium	University of Liege	Frankignoulle, M (corresponding author), Univ Liege, Inst Phys B5, Unite Oceanog Chim, B-4000 Liege, Belgium.	Michel.Frankignoulle@ulg.acl.be	Delille, Bruno/C-3486-2008; Borges, Alberto Vieira/C-4989-2008; Abril, Gwenaël/C-7835-2011	Delille, Bruno/0000-0003-0502-8101; Borges, Alberto Vieira/0000-0002-5434-2247; Abril, Gwenaël/0000-0002-4914-086X				BENNET JP, 1972, 737 US GEOL SURV; BILLEN G, 1975, ESTUAR COAST MAR SCI, V3, P79, DOI 10.1016/0302-3524(75)90007-9; BORGES AV, IN PRESS J MAR SYST; Cai WJ, 1998, LIMNOL OCEANOGR, V43, P657, DOI 10.4319/lo.1998.43.4.0657; ETCHEBER H, 1986, THESIS U BORDEAUX; FRANKIGNOULLE M, 1988, LIMNOL OCEANOGR, V33, P313, DOI 10.4319/lo.1988.33.3.0313; Frankignoulle M, 1996, LIMNOL OCEANOGR, V41, P365, DOI 10.4319/lo.1996.41.2.0365; Gattuso JP, 1998, ANNU REV ECOL SYST, V29, P405, DOI 10.1146/annurev.ecolsys.29.1.405; Heip CHR, 1995, OCEANOGR MAR BIOL, V33, P1; JORDAN F, 1994, TELLUS B, V46, P274; KEMPE S, 1984, J GEOPHYS RES-ATMOS, V89, P4657, DOI 10.1029/JD089iD03p04657; KEMPER HCG, 1995, HKP SPORT S, V6, P1; KERNPE S, 1982, MITT GEOL PALAEONTOL, V52, P719; Liss P.S., 1986, ROLE AIR SEA EXCHANG, P113, DOI [10.1007/978-94-009-4738-2_5, DOI 10.1007/978-94-009-4738-2_5]; MANTOURA RFC, 1983, GEOCHIM COSMOCHIM AC, V47, P1293, DOI 10.1016/0016-7037(83)90069-8; MARLAND G, 1997, 5 INT CARB DIOX C CA, P4; MARTINS O, 1991, BIOGEOCHEMISTRY MAJO, P127; PARK PK, 1969, SCIENCE, V166, P867, DOI 10.1126/science.166.3907.867; Raymond PA, 1997, ESTUARIES, V20, P381, DOI 10.2307/1352351; Riched, 1991, BIOGEOCHEMISTRY MAJO, P57; Schlesinger WH., 1997, BIOGEOCHEMISTRY; Smith SV, 1997, ECOL MONOGR, V67, P509, DOI 10.1890/0012-9615(1997)067[0509:ACAIVO]2.0.CO;2; SMITH SV, 1993, REV GEOPHYS, V31, P75, DOI 10.1029/92RG02584; WANNINKHOF R, 1992, J GEOPHYS RES-OCEANS, V97, P7373, DOI 10.1029/92JC00188; Wollast R., 1988, POLLUTION N SEA ASSE, P185; WOODWELL PM, 1973, CARBON BIOPSHERE, P221	26	422	443	5	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					434	436		10.1126/science.282.5388.434	http://dx.doi.org/10.1126/science.282.5388.434			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774261	Green Submitted			2022-12-28	WOS:000076479600041
J	Soisson, SM; Nimnual, AS; Uy, M; Bar-Sagi, D; Kuriyan, J				Soisson, SM; Nimnual, AS; Uy, M; Bar-Sagi, D; Kuriyan, J			Crystal structure of the Dbl and pleckstrin homology domains from the human Son of Sevenless protein	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EF-TS COMPLEX; ONCOGENE PRODUCT; DIFFRACTION DATA; KINASE-C; ASSOCIATION; ACTIVATION; BINDING; FAMILY; RHO	Proteins containing Dbl homology (DH) domains activate Rho-family GTPases by functioning as specific guanine nucleotide exchange factors. All known DH domains have associated C-terminal pleckstrin homology (PH) domains that are implicated in targeting and regulatory functions. The crystal structure of a fragment of the human Son of sevenless protein containing the DH and PH domains has been determined at 2.3 Angstrom resolution. The entirely alpha-helical DH domain is unrelated in architecture to other nucleotide exchange factors. The active site of the DH domain, identified on the basis of sequence conservation and structural features, lies near the interface between the DH and PH domains. The structure suggests that ligation of the PH domain will be coupled structurally to the GTPase binding site.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; Rockefeller University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kuriyan, J (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	kuriyan@rockvax.rockefeller.edu		Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [P01CA028146, R01CA055360, R37CA055360] Funding Source: NIH RePORTER; NCI NIH HHS [CA55360, CA09176, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Freshney NW, 1997, FEBS LETT, V407, P111, DOI 10.1016/S0014-5793(97)00309-8; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Raabe T, 1998, CURR TOP MICROBIOL, V228, P343; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; RON D, 1991, NEW BIOL, V3, P372; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	58	184	188	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					259	268		10.1016/S0092-8674(00)81756-0	http://dx.doi.org/10.1016/S0092-8674(00)81756-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790532	Bronze			2022-12-28	WOS:000076538300013
J	Lustman, PJ; Griffith, LS; Freedland, KE; Kissel, SS; Clouse, RE				Lustman, PJ; Griffith, LS; Freedland, KE; Kissel, SS; Clouse, RE			Cognitive behavior therapy for depression in type 2 diabetes mellitus - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus, non-insulin-dependent; cognitive therapy; behavior therapy; outcome and process assessment (health care); blood glucose	MAJOR DEPRESSION; GLYCEMIC CONTROL; PSYCHIATRIC-DISORDERS; MEDICATION COMPLIANCE; ADULTS; PREVALENCE; HEMOGLOBIN; EFFICACY; PHARMACOTHERAPY; SYMPTOMATOLOGY	Background: Psychotherapy is the principal nonpharmacologic method for the management of depression, but its usefulness for depressed patients with diabetes remains unknown. Objective: To assess the efficacy of cognitive behavior therapy (CBT) for depression in patients with diabetes. Design: Randomized, controlled trial. Setting: Referral-based academic medical center. Patients: 51 patients with type 2 diabetes and major depression. Intervention: Patients were assigned either to a group that received 10 weeks of individual CBT or to a control group that received no specific antidepressant treatment. All patients participated in a diabetes education program to control for the effects of supportive attention and the possible influence of enhanced diabetes control on mood. Measurements: Degree of depression was measured by using the Beck Depression Inventory; glycemic control was measured by using glycosylated hemoglobin levels. Outcomes were assessed immediately after treatment and 6 months after treatment. Results: The percentage of patients achieving remission of depression (Beck Depression Inventory score less than or equal to 9) was greater in the CBT group than in the control group: posttreatment, 85.0% of patients in the CBT group (17 of 20) compared with 27.3% of controls (6 of 22) achieved remission (difference, 57.7 percentage points [95% CI, 33 to 82 percentage points]) (P < 0.001); at follow-up, 70.0% of patients in the CBT group (14 of 20) compared with 33.3% of controls (7 of 21) achieved remission (difference, 36.7 percentage points [CI, 9 to 65 percentage. points]) (P = 0.03). Post-treatment glycosylated hemoglobin levels were not different in the two groups, but follow-up mean glycosylated hemoglobin levels were significantly better in the CBT group than in the control group (9.5% compared with 10.9%; P = 0.03). Conclusions: The combination of CBT and supportive diabetes education is an effective nonpharmacologic treatment for major depression in patients with type 2 diabetes. It may also be associated with improved glycemic control.	Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Vet Affairs Med Ctr, St Louis, MO USA	Washington University (WUSTL); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lustman, PJ (corresponding author), Washington Univ, Sch Med, Dept Psychiat, 4940 Childrens Pl, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH052629] Funding Source: NIH RePORTER; NIMH NIH HHS [R21 MH 52629] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AHCPR, 1997, AHCPR PUBL; American Diabetes Association, 1998, DIABETES CARE S1, V12, pS20, DOI DOI 10.2337/DIACARE.21.1.S20; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BAYNES JW, 1984, DIABETES CARE, V7, P602, DOI 10.2337/diacare.7.6.602; Beck A T, 1974, Mod Probl Pharmacopsychiatry, V7, P151; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BRAITMAN LE, 1991, ANN INTERN MED, V114, P515, DOI 10.7326/0003-4819-114-6-515; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; DEGROOT M, 1994, PSYCHOSOM MED, V56, P176; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; FRANK E, 1993, PSYCHOPHARMACOL BULL, V29, P457; FRIIS R, 1986, SOC SCI MED, V23, P471, DOI 10.1016/0277-9536(86)90006-7; GAVARD JA, 1993, DIABETES CARE, V16, P1167, DOI 10.2337/diacare.16.8.1167; GOLDSTEIN DE, 1995, DIABETES CARE, V18, P896, DOI 10.2337/diacare.18.6.896; GOLDSTEIN DE, 1986, CLIN CHEM, V32, P864; HOLLON SD, 1992, ARCH GEN PSYCHIAT, V49, P774; HOLLON SD, 1993, J CONSULT CLIN PSYCH, V61, P270, DOI 10.1037/0022-006X.61.2.270; JACOBSON AM, 1985, PSYCHOSOM MED, V47, P372, DOI 10.1097/00006842-198507000-00007; KOVACS M, 1995, DIABETES CARE, V18, P1592, DOI 10.2337/diacare.18.12.1592; Kovacs M, 1997, DIABETES CARE, V20, P45, DOI 10.2337/diacare.20.1.45; LADENSON JH, 1985, CLIN CHEM, V31, P1060; LITTLEFIELD CH, 1992, DIABETES CARE, V15, P90, DOI 10.2337/diacare.15.1.90; LLOYD C, 1997, DIABETES, V46, pA13; Lustman, 1998, Semin Clin Neuropsychiatry, V3, P102; LUSTMAN PJ, 1988, DIABETES CARE, V11, P605, DOI 10.2337/diacare.11.8.605; Lustman PJ, 1997, GEN HOSP PSYCHIAT, V19, P138, DOI 10.1016/S0163-8343(96)00170-3; LUSTMAN PJ, 1986, J NERV MENT DIS, V174, P743, DOI 10.1097/00005053-198612000-00006; Lustman PJ, 1997, PSYCHOSOM MED, V59, P241, DOI 10.1097/00006842-199705000-00007; LUSTMAN PJ, 1992, PSYCHOSOM MED, V54, P602, DOI 10.1097/00006842-199209000-00007; LUSTMAN PJ, 1986, J NERV MENT DIS, V174, P736, DOI 10.1097/00005053-198612000-00005; LUSTMAN PJ, 1987, COMPR PSYCHIAT, V28, P22, DOI 10.1016/0010-440X(87)90040-X; MARCUS MD, 1992, DIABETES CARE, V15, P253, DOI 10.2337/diacare.15.2.253; Matsui DM, 1997, PEDIATR CLIN N AM, V44, P1, DOI 10.1016/S0031-3955(05)70459-4; MAZZE RS, 1984, DIABETES CARE, V7, P360, DOI 10.2337/diacare.7.4.360; McGill JB, 1992, DIABETES, V41, pA84; MCKNIGHT DL, 1992, BEHAV THER, V23, P99, DOI 10.1016/S0005-7894(05)80311-9; MURPHY GE, 1984, ARCH GEN PSYCHIAT, V41, P33; MURRELL SA, 1983, AM J EPIDEMIOL, V117, P173, DOI 10.1093/oxfordjournals.aje.a113528; Peyrot M, 1997, DIABETES CARE, V20, P585, DOI 10.2337/diacare.20.4.585; POPKIN MK, 1988, ARCH GEN PSYCHIAT, V45, P64; POPKIN MK, 1985, ARCH GEN PSYCHIAT, V42, P1160; PRESKORN SH, 1996, J PRACTICAL PSYCHIAT, V2, P231; Robins L.N., 1991, PSYCHIAT DISORDERS A; Robins L.N., 1989, DIAGNOSTIC INTERVIEW; Robins LN, 1981, NIMH DIAGNOSTIC INTE; Rush A. J., 1977, COGNITIVE THERAPY RE, V1, P17, DOI DOI 10.1007/BF01173502; RUSH AJ, 1995, PSYCHOPHARMACOL BULL, V31, P7; SACHS G, 1991, PSYCHOTHER PSYCH MED, V41, P306; SANTIAGO JV, 1978, J CLIN ENDOCR METAB, V47, P578, DOI 10.1210/jcem-47-3-578; SAS Institute, 1990, SAS PROC GUID VERS 6; SHOPE JT, 1981, PEDIATR CLIN N AM, V28, P5; Tun P A, 1990, Clin Geriatr Med, V6, P731; VanderDoes FEE, 1996, DIABETES CARE, V19, P204, DOI 10.2337/diacare.19.3.204; WELLS KB, 1989, GEN HOSP PSYCHIAT, V11, P320, DOI 10.1016/0163-8343(89)90119-9; WEYERER S, 1989, J PSYCHOSOM RES, V33, P633, DOI 10.1016/0022-3999(89)90070-6; WING RR, 1990, DIABETES CARE, V13, P170, DOI 10.2337/diacare.13.2.170	57	379	389	4	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					613	+		10.7326/0003-4819-129-8-199810150-00005	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128WR	9786808				2022-12-28	WOS:000076431800003
J	O'Brien, J; Ames, D; Chiu, E; Schweitzer, I; Desmond, P; Tress, B				O'Brien, J; Ames, D; Chiu, E; Schweitzer, I; Desmond, P; Tress, B			Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPERINTENSITIES; DEMENTIA	Objective To determine the difference in outcome among elderly people with major depression who do and do not have severe white matter lesions on magnetic resonance imaging. Design Follow up study. Setting Two psychiatric and two general hospitals in Melbourne, Australia. Subjects 60 depressed subjects aged over 55 referred to hospital psychiatric services with major depressive disorder meeting American Psychiatric Association (DSM-IIIR) criteria. Main outcome measure Proportion with good outcome as determined by full recover) from initial illness and no evidence of depressive relapse or cognitive decline during follow up among those with and without lesions. Results Mean (SD) follow up was 31.9 (9.9) months. Survival analysis showed a significant effect of severe lesions on time to poor outcome (P = 0.04), with median survival 136 days in those with severe lesions compared with 315 days in those without Conclusion Severe white matter change on magnetic resonance imaging is associated with poor outcome in elderly depressed subjects.	Newcastle Univ, Newcastle Gen Hosp, Dept Psychiat, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Univ, Newcastle Gen Hosp, Inst Hlth Elderly, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Melbourne, Royal Melbourne Hosp, Dept Psychiat, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Dept Radiol, Melbourne, Vic, Australia	Newcastle General Hospital; Newcastle University - UK; Newcastle General Hospital; Newcastle University - UK; Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital	O'Brien, J (corresponding author), Newcastle Univ, Newcastle Gen Hosp, Dept Psychiat, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	j.to'brien@ncl.ac.uk	; Desmond, Patricia/D-1966-2014	O'Brien, John/0000-0002-0837-5080; Desmond, Patricia/0000-0002-4803-6323				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; AMES D, 1991, INT J GERIATR PSYCH, V6, P477, DOI 10.1002/gps.930060702; CHIMOWITZ MI, 1992, ARCH NEUROL-CHICAGO, V49, P747, DOI 10.1001/archneur.1992.00530310095018; FAZEKAS F, 1993, NEUROLOGY, V43, P1683, DOI 10.1212/WNL.43.9.1683; FAZEKAS F, 1987, AM J NEURORADIOL, V8, P421; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; HICKIE I, 1995, BIOL PSYCHIAT, V37, P151, DOI 10.1016/0006-3223(94)00174-2; JACOBY RJ, 1981, BRIT J PSYCHIAT, V139, P288, DOI 10.1192/bjp.139.4.288; OBrien J, 1996, BRIT J PSYCHIAT, V168, P477, DOI 10.1192/bjp.168.4.477; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Simpson S W, 1997, Int Psychogeriatr, V9, P257, DOI 10.1017/S1041610297004432	11	181	181	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 10	1998	317	7164					982	984		10.1136/bmj.317.7164.982	http://dx.doi.org/10.1136/bmj.317.7164.982			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129EA	9765166	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000076449300023
J	Nightingale, SL				Nightingale, SL			Questions raised regarding benefit of albumin or PPF for seriously ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1128	1128		10.1001/jama.280.13.1128	http://dx.doi.org/10.1001/jama.280.13.1128			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777799				2022-12-28	WOS:000076210800006
J	Sinai, MJ; Ooi, TL; He, ZJ				Sinai, MJ; Ooi, TL; He, ZJ			Terrain influences the accurate judgement of distance	NATURE			English	Article							VISUAL-PERCEPTION; LOCOMOTION; LOCATION; GUIDANCE	Mathematically, three-dimensional space can be represented differently by the cartesian, polar, and other coordinate systems. However, in physical sciences, the choice of representation system is restricted by the need to simplify a machine's computation while enhancing its efficiency(1). Does the brain, for the same reasons, 'select' the most cost-efficient way to represent the three-dimensional location of objects? As we frequently interact with objects on the common ground surface, it might be beneficial for the visual system to code an object's location using a ground-surface-based reference frame(2). More precisely, the brain could use a quasi-two-dimensional coordinate system (x(s), y(s)) with respect, to the ground surface (s), rather than a strictly three-dimensional coordinate system (x, y, z), thus reducing coding redundancy and simplifying computations(2-5). Here we provide support for this view by studying human psychophysical performance in perceiving absolute distance and in visually directed action tasks(6-11). For example, when an object was seen on a continuous, homogeneous texture ground surface, the observer judged the distance to the object accurately. However, when similar surface information was unavailable, for example, when the object was seen across a gap in the ground, or across distinct texture regions, distance judgement was impaired.	Univ Louisville, Dept Psychol, Louisville, KY 40292 USA; So Coll Optometry, Dept Biomed Sci, Memphis, TN 38104 USA	University of Louisville	He, ZJ (corresponding author), Univ Louisville, Dept Psychol, Louisville, KY 40292 USA.	zOhe0002@ulkyvm.louisville.edu						ATTNEAVE F, 1954, PSYCHOL REV, V61, P183, DOI 10.1037/h0054663; Barlow H. B., 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; Cutting J.E., 1995, PERCEPTION SPACE MOT, P69, DOI 10.1016/B978-012240530-3/50005-5; ELLIOT D, 1987, J EXP PSYCHOL HUMAN, V12, P388; Gibson JJ, 1950, PERCEPTION VISUAL WO; HE JZ, 1994, NATURE, V367, P173; JIANG Y, 1994, PERCEPT PSYCHOPHYS, V56, P691, DOI 10.3758/BF03208362; LOOMIS JM, 1992, J EXP PSYCHOL HUMAN, V18, P906, DOI 10.1037/0096-1523.18.4.906; Loomis JM, 1996, CURR DIR PSYCHOL SCI, V5, P72, DOI 10.1111/1467-8721.ep10772783; Mark L. S., 1987, J EXPT PSYCHOL HUMAN, V13, P360; Philbeck JW, 1997, J EXP PSYCHOL HUMAN, V23, P72, DOI 10.1037/0096-1523.23.1.72; RIESER JJ, 1990, PERCEPTION, V19, P675, DOI 10.1068/p190675; Sedgwick H.A., 1983, HUMAN MACHINE VISION, P425, DOI [10.1016/b978-0-12-084320-6.50020-7, DOI 10.1016/B978-0-12-084320-6.50020-7]; Sedgwick H.A., 1989, SPIE P, V1198, P447; Shannon C. E., 1949, MATH THEORY COMMUNIC; STEENHUIS RE, 1988, J MOTOR BEHAV, V20, P399; THOMSON JA, 1983, J EXP PSYCHOL HUMAN, V9, P427, DOI 10.1037/0096-1523.9.3.427; WARREN WH, 1987, J EXP PSYCHOL HUMAN, V13, P371, DOI 10.1037/0096-1523.13.3.371	18	161	165	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					497	500		10.1038/26747	http://dx.doi.org/10.1038/26747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	124ZG	9774104				2022-12-28	WOS:000076212200055
J	James, A				James, A			Stigma of mental illness - Foreword	LANCET			English	News Item									The Lancet, London, England		James, A (corresponding author), The Lancet, London, England.							DURCAN P, 1993, MADMAN HIS COLLECTIO; PLATH S, 1966, BELL JAR, P163	2	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1048	1048						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759764				2022-12-28	WOS:000076121800043
J	Ikomi, A; Gupta, N				Ikomi, A; Gupta, N			Randomised controlled trial exists of levonorgestrel intrauterine system for menorrhagia	BRITISH MEDICAL JOURNAL			English	Letter							ENDOMETRIAL		St Peters Hosp, Dept Obstet & Gynaecol, Surrey KT16 0PZ, England		Ikomi, A (corresponding author), St Peters Hosp, Dept Obstet & Gynaecol, Surrey KT16 0PZ, England.							Crosignani PG, 1997, OBSTET GYNECOL, V90, P257, DOI 10.1016/S0029-7844(97)00226-3; Lahteenmaki P, 1998, BMJ-BRIT MED J, V316, P1122, DOI 10.1136/bmj.316.7138.1122; SINGER A, 1994, OBSTET GYNECOL, V83, P732	3	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1250	1250		10.1136/bmj.317.7167.1250	http://dx.doi.org/10.1136/bmj.317.7167.1250			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794876	Green Published			2022-12-28	WOS:000076963000045
J	Assion, A; Baumert, T; Bergt, M; Brixner, T; Kiefer, B; Seyfried, V; Strehle, M; Gerber, G				Assion, A; Baumert, T; Bergt, M; Brixner, T; Kiefer, B; Seyfried, V; Strehle, M; Gerber, G			Control of chemical reactions by feedback-optimized phase-shaped femtosecond laser pulses	SCIENCE			English	Article							UNIMOLECULAR REACTIONS; QUANTUM-SYSTEMS; MOLECULES; TRANSITIONS; SELECTIVITY; EXCITATION; DYNAMICS; LIGHT; NA2	Tailored femtosecond laser pulses from a computer-controlled pulse shaper were used to optimize the branching ratios of different organometallic photodissociation reaction channels. The optimization procedure is based on the feedback from reaction product quantities in a Learning evolutionary algorithm that iteratively improves the phase of the applied femtosecond Laser pulse. In the case of CpFe(CO)(2)Cl, it is shown that two different bond-cleaving reactions can be selected, resulting in chemically different products. At Least in this case, the method works automatically and finds optimal solutions without previous knowledge of the molecular system and the experimental environment.	Univ Wurzburg, Inst Phys, D-97074 Wurzburg, Germany	University of Wurzburg	Assion, A (corresponding author), Univ Wurzburg, Inst Phys, Hubland, D-97074 Wurzburg, Germany.		Brixner, Tobias/S-1451-2016; Baumert, Thomas/D-3962-2009	Brixner, Tobias/0000-0002-6529-704X; Baumert, Thomas/0000-0003-1760-7493				AMBARTZUMIAN RV, 1977, CHEM BIOCH APPLICATI, V3, pCH2; AMSTRUP B, 1995, J PHYS CHEM-US, V99, P5206, DOI 10.1021/j100014a048; AMSTRUP B, 1993, PHYS REV A, V48, P3830, DOI 10.1103/PhysRevA.48.3830; Banares L, 1998, J CHEM PHYS, V108, P5799, DOI 10.1063/1.475991; Bardeen CJ, 1997, CHEM PHYS LETT, V280, P151, DOI 10.1016/S0009-2614(97)01081-6; BAUMERT T, 1991, PHYS REV LETT, V67, P3753, DOI 10.1103/PhysRevLett.67.3753; Baumert T, 1997, APPL PHYS B-LASERS O, V65, P779, DOI 10.1007/s003400050346; BAUMERT T, 1994, ISRAEL J CHEM, V34, P103; BLOEMBERGEN N, 1978, PHYS TODAY, V31, P23, DOI 10.1063/1.2995035; BRUMER P, 1989, CHEM PHYS, V139, P221, DOI 10.1016/0301-0104(89)90013-X; BRUMER P, 1986, CHEM PHYS LETT, V126, P541, DOI 10.1016/S0009-2614(86)80171-3; CHEN C, 1990, PHYS REV LETT, V64, P507, DOI 10.1103/PhysRevLett.64.507; GASPARD P, 1997, CHEM REACTIONS THEIR; GOLDBERG DE, 1993, GENETIC ALGORITHMS S; Gordon RJ, 1997, ANNU REV PHYS CHEM, V48, P601, DOI 10.1146/annurev.physchem.48.1.601; HEREK JL, 1994, CHEM PHYS LETT, V228, P15, DOI 10.1016/0009-2614(94)00910-4; JACKSON RL, 1989, LASER MICROFABRICATI, P385; JAKUBETZ W, 1990, CHEM PHYS LETT, V165, P100, DOI 10.1016/0009-2614(90)87018-M; JORTNER J, 1981, ADV CHEM PHYSICS, V47; JUDSON RS, 1992, PHYS REV LETT, V68, P1500, DOI 10.1103/PhysRevLett.68.1500; KOSLOFF R, 1989, CHEM PHYS, V139, P201, DOI 10.1016/0301-0104(89)90012-8; LETOKHOV VS, 1977, PHYS TODAY, V30, P23, DOI 10.1063/1.3037543; MAMYRIN BA, 1994, INT J MASS SPECTROM, V131, P1, DOI 10.1016/0168-1176(93)03891-O; Manz J., 1995, FEMTOSECOND CHEM; MARTINEZ OE, 1988, IEEE J QUANTUM ELECT, V24, P2530, DOI 10.1109/3.14385; PEIRCE AP, 1988, PHYS REV A, V37, P4950, DOI 10.1103/PhysRevA.37.4950; POTTER ED, 1992, NATURE, V355, P66, DOI 10.1038/355066a0; Schwefel H. -P., 1995, EVOLUTION OPTIMUM SE; SHAPIRO M, 1988, CHEM PHYS LETT, V149, P451, DOI 10.1016/0009-2614(88)80362-2; SHI SH, 1988, J CHEM PHYS, V88, P6870, DOI 10.1063/1.454384; TANNOR DJ, 1986, J CHEM PHYS, V85, P5805, DOI 10.1063/1.451542; WARREN WS, 1993, SCIENCE, V262, P1008, DOI 10.1126/science.262.5136.1008; WARREN WS, 1993, SCIENCE, V259, P1581, DOI 10.1126/science.259.5101.1581; WEINER AM, 1992, IEEE J QUANTUM ELECT, V28, P908, DOI 10.1109/3.135209; WENDER I, 1977, ORGANIC SYNTHESIS ME, V1; WENDER I, 1977, ORGANIC SYMTHESIS VI, V2; Yelin D, 1997, OPT LETT, V22, P1793, DOI 10.1364/OL.22.001793; Zare RN, 1998, SCIENCE, V279, P1875, DOI 10.1126/science.279.5358.1875; ZEWAIL AH, 1980, PHYS TODAY, V33, P27, DOI 10.1063/1.2913821	39	1445	1477	3	270	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					919	922		10.1126/science.282.5390.919	http://dx.doi.org/10.1126/science.282.5390.919			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794756				2022-12-28	WOS:000076727300041
J	Stephens, RS; Kalman, S; Lammel, C; Fan, J; Marathe, R; Aravind, L; Mitchell, W; Olinger, L; Tatusov, RL; Zhao, QX; Koonin, EV; Davis, RW				Stephens, RS; Kalman, S; Lammel, C; Fan, J; Marathe, R; Aravind, L; Mitchell, W; Olinger, L; Tatusov, RL; Zhao, QX; Koonin, EV; Davis, RW			Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis	SCIENCE			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; HAEMOPHILUS-INFLUENZAE; PHOSPHOLIPID SYNTHASES; PROTEIN SEQUENCES; PSITTACI; GENE; CELLS; IDENTIFICATION; SYNTHETASE	Analysis of the 1,042,519-base pair Chlamydia trachomatis genome revealed unexpected features related to the complex biology of chlamydiae. Although chlamydiae lack many biosynthetic capabilities, they retain functions for performing key steps and interconversions of metabolites obtained from their mammalian host cells. Numerous potential virulence-associated proteins also were characterized. Several eukaryotic chromatin-associated domain proteins were identified, suggesting a eukaryotic-like mechanism for chlamydial nucleoid condensation and decondensation. The phylogenetic mosaic of chlamydial genes, including a Large number of genes with phylogenetic origins from eukaryotes, implies a complex evolution for adaptation to obligate intracellular parasitism.	Univ Calif Berkeley, Program Infect Dis, Berkeley, CA 94720 USA; Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Stanford Univ, DNA Sequencing & Technol Ctr, Stanford, CA 94305 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Stanford University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Stephens, RS (corresponding author), Univ Calif Berkeley, Program Infect Dis, Berkeley, CA 94720 USA.	ctgenome@socrates.berkeley.edu	Mitchell, Wayne P/C-5219-2008	Aravind, L/0000-0003-0771-253X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 39258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amann R, 1997, APPL ENVIRON MICROB, V63, P115, DOI 10.1128/AEM.63.1.115-121.1997; [Anonymous], 1984, BACTERIOL; BARRY CE, 1992, SCIENCE, V256, P377, DOI 10.1126/science.256.5055.377; BEATTY WL, 1994, INFECT IMMUN, V62, P3705, DOI 10.1128/IAI.62.9.3705-3711.1994; BRENNER SE, 1995, NATURE, V378, P140, DOI 10.1038/378140a0; COSTERTON JW, 1976, CAN J MICROBIOL, V22, P16, DOI 10.1139/m76-003; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DUFOUR A, 1994, J BACTERIOL, V176, P1813, DOI 10.1128/jb.176.7.1813-1820.1994; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FOX A, 1990, INFECT IMMUN, V58, P835, DOI 10.1128/IAI.58.3.835-837.1990; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; HACKSTADT T, 1995, P NATL ACAD SCI USA, V92, P4877, DOI 10.1073/pnas.92.11.4877; HACKSTADT T, 1991, P NATL ACAD SCI USA, V88, P3937, DOI 10.1073/pnas.88.9.3937; Hatch GM, 1998, INFECT IMMUN, V66, P3727, DOI 10.1128/IAI.66.8.3727-3735.1998; HATCH TP, 1982, J BACTERIOL, V150, P662, DOI 10.1128/JB.150.2.662-670.1982; HATCH TP, 1986, J BACTERIOL, V165, P379, DOI 10.1128/jb.165.2.379-385.1986; HATCH TP, 1976, J BACTERIOL, V125, P706, DOI 10.1128/JB.125.2.706-712.1976; Hayashi M, 1996, FEBS LETT, V381, P174, DOI 10.1016/0014-5793(96)00114-7; Heinzen RA, 1997, INFECT IMMUN, V65, P1088, DOI 10.1128/IAI.65.3.1088-1094.1997; Hsia RC, 1997, MOL MICROBIOL, V25, P351, DOI 10.1046/j.1365-2958.1997.4701834.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; KOONIN EV, UNPUB; LAGA M, 1991, AIDS, V5, pS55; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; Longbottom D, 1996, FEMS MICROBIOL LETT, V142, P277; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; MOULDER JW, 1988, MICROBIOLOGY CHLAMYD, P3; NEWHALL WJ, 1983, J BACTERIOL, V154, P998, DOI 10.1128/JB.154.2.998-1001.1983; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Ponting CP, 1996, PROTEIN SCI, V5, P914; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; Rockey DD, 1997, MOL MICROBIOL, V24, P217, DOI 10.1046/j.1365-2958.1997.3371700.x; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOLBRIG MV, 1990, MOL MICROBIOL, V4, P1535, DOI 10.1111/j.1365-2958.1990.tb02064.x; STEPHENS RS, 1992, INFECT AGENT DIS, V1, P279; Su H, 1985, KEXUE TONGBAO, V30, P695; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; VOELKER U, 1995, J BACTERIOL, V177, P114, DOI 10.1128/jb.177.1.114-122.1995; WAGAR EA, 1995, J BACTERIOL, V177, P5179, DOI 10.1128/jb.177.17.5179-5185.1995; WAGAR EA, 1988, INFECT IMMUN, V56, P1678, DOI 10.1128/IAI.56.7.1678-1684.1988; WAGAR EA, 1992, FEMS MICROBIOL LETT, V98, P161; WALKER DR, 1997, INTELL SYST MOL BIOL, V5, P333; WEBSTER A, 1993, J GEN VIROL, V74, P1415, DOI 10.1099/0022-1317-74-7-1415; WEISBURG WG, 1986, J BACTERIOL, V167, P570, DOI 10.1128/jb.167.2.570-574.1986; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; 1997, MORB MORTAL WKLY REP, V46, P193	53	1227	1743	1	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					754	759		10.1126/science.282.5389.754	http://dx.doi.org/10.1126/science.282.5389.754			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784136				2022-12-28	WOS:000076607500055
J	Wicks, C; Thatcher, W; Dzurisin, D				Wicks, C; Thatcher, W; Dzurisin, D			Migration of fluids beneath Yellowstone caldera inferred from satellite radar interferometry	SCIENCE			English	Article							CRUSTAL DEFORMATION; SUBSIDENCE; UPLIFT	Satellite Interferometric synthetic aperture radar is uniquely suited to monitoring year-to-year deformation of the entire Yellowstone caldera (about 3000 square kilometers). Sequential interferograms indicate that subsidence within the caldera migrated from one resurgent dome to the other between August. 1992 and August 1995. Between August 1995 and September 1996, the caldera region near the northeast dome began to inflate, and accompanying surface uplift migrated to the southwest dome between September 1996 and June 1997. These deformation data are consistent with hydrothermal or magmatic fluid migration into and out of two sill-like bodies that are about 8 kilometers directly beneath the caldera.	US Geol Survey, Menlo Park, CA 94025 USA; USGS, Cascades Volcano Observ, Vancouver, WA 98661 USA	United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey	Wicks, C (corresponding author), US Geol Survey, MS 977, Menlo Park, CA 94025 USA.							AMET F, 1997, GEOPHYS RES LETT, V24, P2741; Christiansen R. L., 1984, EXPLOWIVE VOLCANISM, P84, DOI 10.17226/18602; DZURISIN D, 1994, B VOLCANOL, V56, P261, DOI 10.1007/BF00302079; DZURISIN D, 1990, B VOLCANOL, V52, P247, DOI 10.1007/BF00304098; DZURISIN D, 1987, J GEOPHYS RES-SOLID, V92, P13753, DOI 10.1029/JB092iB13p13753; FEIGL K, IN PRESS COMP GEOSCI; FOURNIER RO, 1991, EOS, V72, P441; LOCKE WW, 1994, J GEOPHYS RES-SOL EA, V99, P20079, DOI 10.1029/94JB00243; MASSONNET D, 1993, IEEE T GEOSCI REMOTE, V31, P455, DOI 10.1109/36.214922; MEERTENS CM, 1991, GEOPHYS RES LETT, V18, P1763, DOI 10.1029/91GL01470; MILLER DC, UNPUB; PELTON JR, 1979, SCIENCE, V206, P1179, DOI 10.1126/science.206.4423.1179; PIERCE KI, 1997, EOS, V78, P802; SMITH RB, 1994, J VOLCANOL GEOTH RES, V61, P121, DOI 10.1016/0377-0273(94)90002-7; Tarayre H, 1996, GEOPHYS RES LETT, V23, P989, DOI 10.1029/96GL00622; TURCOTTE DL, 1982, GEODYNAMICS APPL CON, P240; VASCO DW, 1990, J GEOPHYS RES-SOLID, V95, P19839, DOI 10.1029/JB095iB12p19839; Zebker HA, 1997, J GEOPHYS RES-SOL EA, V102, P7547, DOI 10.1029/96JB03804; ZEBKER HA, 1992, IEEE T GEOSCI REMOTE, V30, P950, DOI 10.1109/36.175330; [No title captured]	21	129	129	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					458	462		10.1126/science.282.5388.458	http://dx.doi.org/10.1126/science.282.5388.458			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774269				2022-12-28	WOS:000076479600049
J	Iezzoni, LI				Iezzoni, LI			What should I say? communication around disability	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Iezzoni, LI (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, E Campus LY-326,330 Brookline Ave, Boston, MA 02215 USA.	liezzoni@bidmc.harvard.edu							0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					661	665		10.7326/0003-4819-129-8-199810150-00018	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00018			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786817				2022-12-28	WOS:000076431800012
J	Inzucchi, SE; Brunet, CM				Inzucchi, SE; Brunet, CM			Mediastinal goiter	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Inzucchi, SE (corresponding author), Yale Univ, Sch Med, New Haven, CT 06520 USA.		Inzucchi, Silvio/ABF-4121-2021						0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1121	1121		10.1056/NEJM199810153391605	http://dx.doi.org/10.1056/NEJM199810153391605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129DP	9770559				2022-12-28	WOS:000076448200005
J	Mackay, F				Mackay, F			Observing patients - The chair sign	BRITISH MEDICAL JOURNAL			English	Article													Mackay, Fabienne/B-7440-2008	Mackay, Fabienne/0000-0002-6074-2693					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					995	995		10.1136/bmj.317.7164.995	http://dx.doi.org/10.1136/bmj.317.7164.995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765172	Green Published			2022-12-28	WOS:000076449300027
J	Bondeva, T; Pirola, L; Bulgarelli-Leva, G; Rubio, I; Wetzker, R; Wymann, MP				Bondeva, T; Pirola, L; Bulgarelli-Leva, G; Rubio, I; Wetzker, R; Wymann, MP			Bifurcation of lipid and protein kinase signals of PI3K gamma to the protein kinases PKB and MAPK	SCIENCE			English	Article							PHOSPHOINOSITIDE 3-KINASE-GAMMA; WORTMANNIN; ACTIVATION; PRODUCT; BETA; AKT	Phosphoinositide 3-kinases (PI3Ks) activate protein kinase PKB (also termed Akt), and PI3K gamma activated by heterotrimeric guanosine triphosphate-binding protein can stimulate mitogen-activated protein kinase (MAPK). Exchange of a putative Lipid substrate-binding site generated PI3K gamma proteins with altered or aborted Lipid but retained protein kinase activity. Transiently expressed, PI3K gamma hybrids exhibited wortmannin-sensitive activation of MAPK, whereas a catalytically inactive PI3K gamma did not. Membrane-targeted PI3K gamma constitutively produced phosphatidylinositol 3,4,5-trisphosphate and activated PKB but not MAPK. Moreover, stimulation of MAPK in response to Lysophosphatidic acid was blocked by catalytically inactive PI3K gamma but not by hybrid PI3K gamma s. Thus, two major signals emerge from PI3K gamma: phosphoinositides that target PKB and protein phosphorylation that activates MAPK.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Univ Jena, Res Unit Mol Cell Biol, D-07747 Jena, Germany	University of Fribourg; Friedrich Schiller University of Jena	Wymann, MP (corresponding author), Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland.		Pirola, Luciano/I-5250-2018; Wetzker, Reinhard/AAD-8713-2019; Wymann, Matthias P/C-3227-2008	Wymann, Matthias P/0000-0003-3349-4281; Pirola, Luciano/0000-0001-6539-5435				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; PIROLA L, UNPUB; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	19	296	305	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					293	296		10.1126/science.282.5387.293	http://dx.doi.org/10.1126/science.282.5387.293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765155				2022-12-28	WOS:000076370200048
J	Kennedy, AK; Guhathakurta, A; Kleckner, N; Haniford, DB				Kennedy, AK; Guhathakurta, A; Kleckner, N; Haniford, DB			Tn10 transposition via a DNA hairpin intermediate	CELL			English	Article							ACTIVE-SITE; INTRAMOLECULAR TRANSPOSITION; TN7 TRANSPOSITION; IDENTIFICATION; RECOMBINATION; COMPLEX; PROTEINS; RESIDUES; CLEAVAGE; MUTANTS	We present evidence that excision of the nonreplicative transposon Tn10 involves three distinct chemical steps, first-strand nicking, hairpin formation, and hairpin resolution. This three-step mechanism makes it possible for a single protein-active site to cleave two DNA strands of opposite polarity, as appears to be the case in this reaction. We infer the existence of alternating bifunctionality within the active site with suitable modulation of substrate components between steps. DNA double-strand breaks are also made by a "hairpin mechanism" in V(D)J recombination, possibly reflecting the same basic constraints faced in the Tn10 system. Similarities in the basic chemical steps in Tn10 transposition and V(D)J recombination suggest that the V(D)J mechanism may have evolved from a bacterial transposition system.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Western University (University of Western Ontario); Harvard University	Haniford, DB (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	dhanifor@julian.uwo.ca			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM25326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; Bao TH, 1997, EMBO J, V16, P3357, DOI 10.1093/emboj/16.11.3357; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg DE, 1989, MOBILE DNA; BOLLAND S, 1995, P NATL ACAD SCI USA, V92, P7814, DOI 10.1073/pnas.92.17.7814; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Chalmers R, 1998, CELL, V93, P897, DOI 10.1016/S0092-8674(00)81449-X; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; COEN ES, 1989, MOBILE DNA, P413; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Junop MS, 1997, EMBO J, V16, P2646, DOI 10.1093/emboj/16.10.2646; KABOTYANSKI EB, 1995, NUCLEIC ACIDS RES, V23, P3872, DOI 10.1093/nar/23.19.3872; Kennedy AK, 1996, J MOL BIOL, V256, P533, DOI 10.1006/jmbi.1996.0106; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; Lewis LA, 1997, MOL MICROBIOL, V25, P517, DOI 10.1046/j.1365-2958.1997.4871848.x; May EW, 1996, SCIENCE, V272, P401, DOI 10.1126/science.272.5260.401; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; Namgoong SY, 1998, EMBO J, V17, P3775, DOI 10.1093/emboj/17.13.3775; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; POLARD P, 1992, EMBO J, V11, P5079, DOI 10.1002/j.1460-2075.1992.tb05615.x; SAEDLER H, 1996, CURR TOP MICROBIOL I, V204, P27; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMOVSKY RJ, 1996, EMBO J, V15, P6348; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x	34	159	161	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1998	95	1					125	134		10.1016/S0092-8674(00)81788-2	http://dx.doi.org/10.1016/S0092-8674(00)81788-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778253	Bronze			2022-12-28	WOS:000076242300016
J	Grimes, JM; Burroughs, JN; Gouet, P; Diprose, JM; Malby, R; Zientara, S; Mertens, PPC; Stuart, DI				Grimes, JM; Burroughs, JN; Gouet, P; Diprose, JM; Malby, R; Zientara, S; Mertens, PPC; Stuart, DI			The atomic structure of the bluetongue virus core	NATURE			English	Article							INFECTIOUS SUBVIRAL PARTICLES; PROTEIN SECONDARY STRUCTURE; DOUBLE-STRANDED-RNA; PATTERN-RECOGNITION; VP7; CRYSTALLOGRAPHY; PURIFICATION; INTERFACES; ORBIVIRUS; INCLUSION	The structure of the core particle of bluetongue virus has been determined by X-ray crystallography at a resolution approaching 3.5 Angstrom. This transcriptionally active compartment, 700 Angstrom in diameter, represents the largest molecular structure determined in such detail. The atomic structure Indicates how approximately 1,000 protein components self-assemble, using both the classical mechanism of quasi-equivalent contacts, which are achieved through triangulation, and a different method, which we term geometrical quasi-equivalence.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; AFRC, Inst Anim Hlth, Pirbright Lab, Woking GU24 0NF, Surrey, England; CNEVA Alfort, Lab Cent Rech Vet, F-94703 Maisons Alfort, France; Oxford Ctr Mol Sci, Oxford OX1 3QT, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; Ecole Nationale Veterinaire d'Alfort (ENVA); University of Oxford	Stuart, DI (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.	dave@biop.ox.ac.uk	Zientara, Stephan/A-5336-2016; Zientara, Stephan/AAA-7661-2021	Zientara, Stephan/0000-0003-0089-8175; Zientara, Stephan/0000-0002-6733-8503; Mertens, Peter/0000-0002-3438-3738; Stuart, David/0000-0002-3426-4210; Grimes, Jonathan Mark/0000-0001-9698-0389; gouet, patrice/0000-0001-9485-6157				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Basak AK, 1997, STRUCTURE, V5, P871, DOI 10.1016/S0969-2126(97)00242-6; BROOKES SM, 1993, J GEN VIROL, V74, P525, DOI 10.1099/0022-1317-74-3-525; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURROUGHS JN, 1994, J GEN VIROL, V75, P1849, DOI 10.1099/0022-1317-75-8-1849; Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; CALISHER CH, IN PRESS ARCH VIRO S, V13; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Caston JR, 1997, J CELL BIOL, V138, P975, DOI 10.1083/jcb.138.5.975; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FILMAN DJ, 1989, EMBO J, V8, P1567, DOI 10.1002/j.1460-2075.1989.tb03541.x; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; FU H, IN PRESS J GEN VIROL; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; GRIMES J, 1995, NATURE, V373, P167, DOI 10.1038/373167a0; Grimes JM, 1997, STRUCTURE, V5, P885, DOI 10.1016/S0969-2126(97)00243-8; HARRISON SC, 1980, BIOPHYS J, V32, P139, DOI 10.1016/S0006-3495(80)84930-7; HEWAT EA, 1992, VIROLOGY, V189, P10, DOI 10.1016/0042-6822(92)90676-G; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; Holmes IHEA, 1998, VIRUS TAXONOMY CLASS, P208; HUISMANS H, 1987, VIROLOGY, V157, P180, DOI 10.1016/0042-6822(87)90327-8; Johnson JE, 1997, J MOL BIOL, V269, P665, DOI 10.1006/jmbi.1997.1068; JONES TA, 1985, DIFFRACTION METHOD B, P157; JUUTI JT, 1997, 6 INT S DSRNA VIR, pA1; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEBLOIS H, 1993, J VIROL, V67, P353, DOI 10.1128/JVI.67.1.353-359.1993; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LOUDON PT, 1991, VIROLOGY, V180, P798, DOI 10.1016/0042-6822(91)90094-R; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mertens PPC, 1996, VIROLOGY, V217, P582, DOI 10.1006/viro.1996.0153; MERTENS PPC, 1987, VIROLOGY, V157, P375, DOI 10.1016/0042-6822(87)90280-7; MOSS SR, 1994, VIRUS RES, V32, P401, DOI 10.1016/0168-1702(94)90088-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Zhu YF, 1997, J VIROL, V71, P8899, DOI 10.1128/JVI.71.11.8899-8901.1997	40	456	480	4	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					470	478		10.1038/26694	http://dx.doi.org/10.1038/26694			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774103				2022-12-28	WOS:000076212200047
J	Keen, H				Keen, H			Impact of new criteria for diabetes on pattern of disease	LANCET			English	Editorial Material							HEALTH		Guys Hosp, Div Med, London SE1 9RT, England; Kings Coll Hosp London, London SE1 9RT, England; St Thomas Hosp, Sch Med & Dent, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; King's College Hospital NHS Foundation Trust; King's College Hospital; Guy's & St Thomas' NHS Foundation Trust	Keen, H (corresponding author), Guys Hosp, Div Med, Guys Campus, London SE1 9RT, England.							Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Borch-Johnsen K, 1998, BMJ-BRIT MED J, V317, P371; Burke JP, 1998, DIABETES CARE, V21, P1266, DOI 10.2337/diacare.21.8.1266; Dinneen SF, 1998, DIABETES CARE, V21, P1408, DOI 10.2337/diacare.21.9.1408; Gavin JR, 1997, DIABETES CARE, V20, P1183; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; Harris MI, 1997, DIABETES CARE, V20, P1859, DOI 10.2337/diacare.20.12.1859; Keen H, 1998, DIABETES METAB REV, V14, pS5, DOI 10.1002/(SICI)1099-0895(199809)14:1+<S5::AID-DMR228>3.3.CO;2-C; Larsson H, 1998, DIABETOLOGIA, V41, P1124; Mannucci E, 1998, DIABETES CARE, V21, P468, DOI 10.2337/diacare.21.3.468; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tanaka Y, 1998, DIABETES CARE, V21, P1133, DOI 10.2337/diacare.21.7.1133; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Unwin N, 1998, DIABETIC MED, V15, P554, DOI 10.1002/(SICI)1096-9136(199807)15:7<554::AID-DIA626>3.0.CO;2-E; *WHO, 1985, WHO TECH REP SER, V727; *WHO EXP COMM DIAB, 1980, WHO TECH REP SER, V646	19	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 26	1998	352	9133					1000	1001		10.1016/S0140-6736(98)00021-X	http://dx.doi.org/10.1016/S0140-6736(98)00021-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759736				2022-12-28	WOS:000076121800002
J	King, MA; Newton, MR; Jackson, GD; Fitt, GJ; Mitchell, LA; Silvapulle, MJ; Berkovic, SF				King, MA; Newton, MR; Jackson, GD; Fitt, GJ; Mitchell, LA; Silvapulle, MJ; Berkovic, SF			Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients	LANCET			English	Article							1ST UNPROVOKED SEIZURE; EXTENDED FOLLOW-UP; ADULT LIFE; RECURRENCE; EPILEPSY; RISK; CHILDHOOD	Background Prognosis and treatment of the first seizure depends on identification of a specific epilepsy syndrome, yet patients with first seizures are generally regarded as a homogeneous group. We studied whether it is possible to diagnose specific epilepsy syndromes promptly by use of standard clinical methods, electroencephalography (EEG) and magnetic resonance imaging (MRI). Methods 300 consecutive adults and children presented with unexplained seizures, We systematically collected clinical data from patients and witnesses. and attempted to obtain an EEG within 24 h of the seizure. Where the EEG was negative, a sleep-deprived EEG was done. MRI was done electively. Findings A generalised or partial epilepsy syndrome was clinically diagnosed in 141 (47%) patients. Subsequent analysis showed that only three of these clinical diagnoses were incorrect, Addition of the EEG data enabled us to diagnose an epilepsy syndrome in 232 (77%) patients. EEG within 24 h was more useful in diagnosis of epileptiform abnormalities than later EEG (51 vs 34%). Neuroimaging showed 38 epileptogenic lesions, including 17 tumours. There were no lesions in patients for whom generalised epilepsy was confirmed by EEG. Our final diagnoses were: generalised epilepsy (23% of patients); partial epilepsy (58%); and unclassified (19%). Interpretation An epilepsy syndrome can be diagnosed in most first-seizure patients. Ideally, an EEG should be obtained within 24 h of the seizure followed by a sleep deprived EEG if necessary. MRI aids diagnosis and should be done for ail patients except for those with idiopathic generalised epilepsies and for children with benign rolandic epilepsy.	Austin & Repatriat Med Ctr, Dept Neurol, Melbourne, Vic 3084, Australia; Univ Melbourne, Dept Med, Melbourne, Vic, Australia; Austin & Repatriat Med Ctr, Dept Radiol, Melbourne, Vic 3084, Australia; La Trobe Univ, Dept Stat Sci, Bundoora, Vic, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University	Berkovic, SF (corresponding author), Austin & Repatriat Med Ctr, Dept Neurol, Melbourne, Vic 3084, Australia.	sberko@austin.unimelb.edu.au	Jackson, Graeme D/A-9064-2013; Jackson, Graeme/AAD-9070-2019; jiang, yu/HGU-0029-2022	Jackson, Graeme D/0000-0002-7917-5326; Jackson, Graeme/0000-0002-7917-5326; Berkovic, Samuel/0000-0003-4580-841X				ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; Brodie MJ, 1996, NEW ENGL J MED, V334, P168, DOI 10.1056/NEJM199601183340308; Brown W., 1987, SURGICAL TREATMENT E, P511; CAMFIELD PR, 1985, NEUROLOGY, V35, P1657, DOI 10.1212/WNL.35.11.1657; CLELAND PG, 1981, BRIT MED J, V283, P1364, DOI 10.1136/bmj.283.6303.1364; DELGADOESCUETA AV, 1984, NEUROLOGY, V34, P285, DOI 10.1212/WNL.34.3.285; Forsgren L, 1996, EPILEPSIA, V37, P224, DOI 10.1111/j.1528-1157.1996.tb00017.x; Gilad R, 1996, ARCH NEUROL-CHICAGO, V53, P1149, DOI 10.1001/archneur.1996.00550110089017; GOTMAN J, 1985, ANN NEUROL, V17, P597, DOI 10.1002/ana.410170612; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; HOPKINS A, 1988, LANCET, V1, P721; JACKSON GD, 1993, AM J NEURORADIOL, V14, P753; Kuzniecky R., 1995, MAGNETIC RESONANCE E; Kuzniecky Ruben I., 1993, P197; Lerman Pinchas, 1992, P189; MARSAN CA, 1970, EPILEPSIA, V11, P361, DOI 10.1111/j.1528-1157.1970.tb03903.x; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MUSICCO M, 1993, NEUROLOGY, V43, P478; SHINNAR S, 1994, EPILEPSIA, V35, P471, DOI 10.1111/j.1528-1157.1994.tb02464.x; SHINNAR S, 1990, PEDIATRICS, V85, P1076; Shinnar S, 1996, PEDIATRICS, V98, P216; VANDONSELAAR CA, 1991, BMJ-BRIT MED J, V302, P620, DOI 10.1136/bmj.302.6777.620	28	390	395	2	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 26	1998	352	9133					1007	1011		10.1016/S0140-6736(98)03543-0	http://dx.doi.org/10.1016/S0140-6736(98)03543-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759742				2022-12-28	WOS:000076121800008
J	Raschke, RA; Gollihare, B; Wunderlich, TA; Guidry, JR; Leibowitz, AI; Peirce, JC; Lemelson, L; Heisler, MA; Susong, C				Raschke, RA; Gollihare, B; Wunderlich, TA; Guidry, JR; Leibowitz, AI; Peirce, JC; Lemelson, L; Heisler, MA; Susong, C			A computer alert system to prevent injury from adverse drug events - Development and evaluation in a community teaching hospital	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREATININE CLEARANCE; INFORMATION-SYSTEM; MEDICAL INPATIENTS; SURVEILLANCE; ERRORS; COSTS	Context.-Adverse drug events (ADEs) are the most common type of iatrogenic injury occurring in hospitalized patients. Errors leading to ADEs are often due to restricted availability of information at the time of physician order writing. Objectives.-To develop, implement, and evaluate a computer alert system designed to correct errors that might lead to ADEs and to detect ADEs before maximum injury occurs. Design.-Prospective case series. Setting.-A 650-bed community teaching hospital in Phoenix, Ariz. Patients.-Consecutive sample of 9306 nonobstetrical adult patients admitted during the last 6 months of 1997. Interventions.-Thirty-seven drug-specific ADEs were targeted. Our hospital information system was programmed to generate alerts in clinical situations with increased risk for ADE-related injury. A clinical system was developed to ensure physician notification of alerts. Main Outcome Measures.-A true-positive alert was defined as one in which the physician wrote orders consistent with the alert recommendation after alert notification. Results.-During the 6-month study period, the alert system fired 1116 times and 596 were true-positive alerts (positive predictive value of 53%). The alerts identified opportunities to prevent patient injury secondary to ADEs at a rate of 64 per 1000 admissions. A total of 265 (44%) of the 596 true-positive alerts were unrecognized by the physician prior to alert notification. Conclusions.-Clinicians can use hospital information systems to detect opportunities to prevent patient injury secondary to a broad range of ADEs.	Good Samaritan Reg Med Ctr, Phoenix, AZ 85006 USA; Samaritan Hlth Syst, Phoenix, AZ USA; Desert Samaritan Med Ctr, Phoenix, AZ USA		Raschke, RA (corresponding author), Good Samaritan Reg Med Ctr, 1111 E McDowell Rd, Phoenix, AZ 85006 USA.	robert@samaritan.edu	Tao, Youyou/D-2367-2014	Raschke, Robert/0000-0003-3495-7065				BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BENNETT WM, 1994, DRUG PRESCRIBING REN, P19; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Dalton-Bunnow M F, 1993, Hosp Pharm, V28, P746; EDLAVITCH SA, 1988, ARCH INTERN MED, V148, P1499, DOI 10.1001/archinte.148.7.1499; Evans R S, 1993, Proc Annu Symp Comput Appl Med Care, P161; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; Garibaldi RA, 1998, NEW ENGL J MED, V338, P259, DOI 10.1056/NEJM199801223380411; GRASELA TH, 1993, AM J HOSP PHARM, V50, P1889, DOI 10.1093/ajhp/50.9.1889; JELLIFFE RW, 1973, ANN INTERN MED, V79, P604, DOI 10.7326/0003-4819-79-4-604; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KEITH MR, 1989, AM J HOSP PHARM, V46, P1809, DOI 10.1093/ajhp/46.9.1809; LARSON EB, 1987, ANN INTERN MED, V107, P169, DOI 10.7326/0003-4819-107-2-169; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; OCONNELL MB, 1992, ANN PHARMACOTHER, V26, P627, DOI 10.1177/106002809202600503; PESTOTNIK SL, 1993, ANN PHARMACOTHER, V27, P497, DOI 10.1177/106002809302700418; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; SCHROEDER CG, 1986, AM J HOSP PHARM, V43, P355, DOI 10.1093/ajhp/43.2.355; SHAPIRO S, 1971, J AMER MED ASSOC, V216, P467, DOI 10.1001/jama.216.3.467; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; WHIPPLE JK, 1994, ANN PHARMACOTHER, V28, P655, DOI 10.1177/106002809402800517; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292	33	249	253	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1317	1320		10.1001/jama.280.15.1317	http://dx.doi.org/10.1001/jama.280.15.1317			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794309				2022-12-28	WOS:000076472500022
J	Salter, B				Salter, B			Virtual politics in the new NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ E Anglia, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Salter, B (corresponding author), Univ E Anglia, Norwich NR4 7TJ, Norfolk, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1091	1091						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774321	Green Published			2022-12-28	WOS:000076577200076
J	Quirino, JP; Terabe, S				Quirino, JP; Terabe, S			Exceeding 5000-fold concentration of dilute analytes in micellar electrokinetic chromatography	SCIENCE			English	Article							ELECTROPHORESIS; STACKING	When a neutral analyte zone is injected into a charged pseudostationary phase, the Length of the zone is predicted to be narrowed by 1/(1 + k), where k is the retention factor. The conditions for zone narrowing to occur assume negligible electroosmotic flow, a relatively constant electric field along the capillary column, and no pseudostationary phase in the injected analyte mixture. The theoretically expected concentration enhancement was demonstrated experimentally. Consequently, the detection sensitivity of analytes in micellar electrokinetic chromatography (MEKC) can be improved significantly. For example, 9 to 18 parts per billion of an environmentally important racemic herbicide spiked in Lake water was separated by MEKC and detected by ultraviolet absorption.	Himeji Inst Technol, Fac Sci, Kamigori, Hyogo 6781297, Japan	University of Hyogo	Quirino, JP (corresponding author), Himeji Inst Technol, Fac Sci, Kamigori, Hyogo 6781297, Japan.		Quirino, Joselito/C-5965-2013	quirino, joselito/0000-0002-8275-9672				CHIEN RL, 1992, ANAL CHEM, V64, P489; Craig DB, 1996, ANAL CHEM, V68, P697, DOI 10.1021/ac950650z; LIU ZY, 1994, J CHROMATOGR A, V673, P125, DOI 10.1016/0021-9673(94)87065-9; NIELSEN KR, 1994, J CHROMATOGR A, V686, P283, DOI 10.1016/0021-9673(94)00770-5; Quirino JP, 1998, J CHROMATOGR A, V798, P251, DOI 10.1016/S0021-9673(97)01209-0; Quirino JP, 1997, J CHROMATOGR A, V791, P255, DOI 10.1016/S0021-9673(97)00796-6; Quirino JP, 1997, J CHROMATOGR A, V781, P119, DOI 10.1016/S0021-9673(97)00498-6; Quirino JP, 1998, J CHROMATOGR B, V714, P29, DOI 10.1016/S0378-4347(98)00063-2; QUIRINO JP, 1998, J CHROMATOGR, V70, P149; QUIRINO JP, 1998, J CHROMATOGR, V70, P1893; TERABE S, 1984, ANAL CHEM, V56, P111, DOI 10.1021/ac00265a031; TERABE S, 1989, TRAC-TREND ANAL CHEM, V8, P129, DOI 10.1016/0165-9936(89)85022-8; THOMPSON TJ, 1993, ANAL CHEM, V65, P900, DOI 10.1021/ac00055a012	13	617	646	2	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					465	468		10.1126/science.282.5388.465	http://dx.doi.org/10.1126/science.282.5388.465			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774271				2022-12-28	WOS:000076479600051
J	Voinnet, O; Vain, P; Angell, S; Baulcombe, DC				Voinnet, O; Vain, P; Angell, S; Baulcombe, DC			Systemic spread of sequence-specific transgene RNA degradation in plants is initiated by localized introduction of ectopic promoterless DNA	CELL			English	Article							GREEN FLUORESCENT PROTEIN; GENE-EXPRESSION; VIRUS-RESISTANCE; CHALCONE SYNTHASE; TOBACCO; METHYLATION; SUPPRESSION; REPORTER; TRANSCRIPTION; MORPHOGENESIS	Systemic, posttranscriptional silencing of transgenes in Nicotiana benthamiana was initiated in localized regions of the plant by introduction of transgene-homologous DNA fragments, including those without a promoter. Following this initiation step, a sequence-specific signal of gene silencing spread from cells that had received the ectopic DNA via a relay mechanism that employs plasmodesmatal and phloem channels. The nature of this mechanism, the mode of its initiation, and the ability of the signal to move long distances indicate the existence of a sequence-specific signaling mechanism in plants that may have roles in developmental control as well as in protection against transposons and viruses.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; John Innes Ctr Plant Sci Res, Cereals Res Dept, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Baulcombe, DC (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.			Voinnet, Olivier/0000-0001-6982-9544; Baulcombe, David/0000-0003-0780-6878				Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; BARRY C, 1993, P NATL ACAD SCI USA, V90, P4557, DOI 10.1073/pnas.90.10.4557; BAULCOMBE DC, 1995, PLANT J, V7, P1045, DOI 10.1046/j.1365-313X.1995.07061045.x; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; CHAPMAN S, 1992, PLANT J, V2, P549; CHRISTOU P, 1991, BIO-TECHNOL, V9, P957, DOI 10.1038/nbt1091-957; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; Ding B, 1997, PLANT J, V12, P931, DOI 10.1046/j.1365-313X.1997.12040931.x; Elmayan T, 1996, PLANT J, V9, P787, DOI 10.1046/j.1365-313X.1996.9060787.x; English JJ, 1997, PLANT J, V12, P597, DOI 10.1046/j.1365-313X.1997.00597.x; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; English JJ, 1997, PLANT J, V12, P1311, DOI 10.1046/j.1365-313x.1997.12061311.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HOBBS SLA, 1990, PLANT MOL BIOL, V15, P851, DOI 10.1007/BF00039425; Iglesias VA, 1997, PLANT CELL, V9, P1251, DOI 10.1105/tpc.9.8.1251; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; JORGENSEN R, 1995, PLANT PHYSIOL, V108, P14; Jorgensen R, 1992, AGBIOTECH NEWS INFOR, V4, P265; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Kunz C, 1996, PLANT J, V10, P437, DOI 10.1046/j.1365-313X.1996.10030437.x; LEISNER SM, 1993, BIOESSAYS, V15, P741, DOI 10.1002/bies.950151107; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Palauqui JC, 1996, PLANT PHYSIOL, V112, P1447, DOI 10.1104/pp.112.4.1447; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PALUKAITIS P, 1987, VIROLOGY, V158, P239, DOI 10.1016/0042-6822(87)90260-1; POETHIG RS, 1990, SCIENCE, V250, P923, DOI 10.1126/science.250.4983.923; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Roberts AG, 1997, PLANT CELL, V9, P1381, DOI 10.1105/tpc.9.8.1381; Ruiz F, 1998, MOL BIOL CELL, V9, P931, DOI 10.1091/mbc.9.4.931; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Sijen T, 1996, PLANT CELL, V8, P2277, DOI 10.1105/tpc.8.12.2277; Stam M, 1997, PLANT J, V12, P63, DOI 10.1046/j.1365-313X.1997.12010063.x; Vain P, 1998, THEOR APPL GENET, V96, P164, DOI 10.1007/s001220050723; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; WILLE AC, 1984, PLANTA, V160, P129, DOI 10.1007/BF00392861; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zupan J, 1997, CRIT REV PLANT SCI, V16, P279, DOI 10.1080/713608150	46	538	614	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					177	187		10.1016/S0092-8674(00)81749-3	http://dx.doi.org/10.1016/S0092-8674(00)81749-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790525	Bronze			2022-12-28	WOS:000076538300006
J	Roose, J; Molenaar, M; Peterson, J; Hurenkamp, J; Brantjes, H; Moerer, P; van de Wetering, M; Destree, O; Clevers, H				Roose, J; Molenaar, M; Peterson, J; Hurenkamp, J; Brantjes, H; Moerer, P; van de Wetering, M; Destree, O; Clevers, H			The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors	NATURE			English	Article							BETA-CATENIN; DEVELOPMENTAL EXPRESSION; SPEMANN ORGANIZER; FACTOR LEF-1; DROSOPHILA; EMBRYOS; CLONING; ENHANCER; COMPLEX; SPLIT	Tcf/Lef transcription factors mediate signalling from Wingless/ Wnt proteins by recruiting Armadillo/beta-catenin as a transcriptional co-activator(1-7). However, studies of Drosophila, Xenopus and Caenorhabditis elegans have indicated that Tcf factors may also be transcriptional repressors(6,8-13). Here we show that Tcf factors physically interact with members of the Groucho family of transcriptional repressors. In transient transfection assays, the Xenopus Groucho homologue XGrg-4 inhibited activation of transcription of synthetic Tcf reporter genes. In contrast, the naturally truncated Groucho-family member XGrg-5 enhanced transcriptional activation. Injection of XGrg-4 into Xenopus embryos repressed transcription of Siamois and Xnr-3, endogenous targets of beta-catenin-Tcf. Dorsal injection of XGrg-4 had a ventralizing effect on Xenopus embryos. Secondary-axis formation induced by a dominant-positive Armadillo-Tcf fusion protein was inhibited by XGrg-4 and enhanced by XGrg-5, These data indicate that expression of Tcf target genes is regulated by a balance between Armadillo and Groucho.	Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Clevers, H (corresponding author), Univ Utrecht Hosp, Dept Immunol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Choudhury BK, 1997, GENE, V195, P41, DOI 10.1016/S0378-1119(97)00150-9; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Han M, 1997, CELL, V90, P581, DOI 10.1016/S0092-8674(00)80517-6; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Laurent MN, 1997, DEVELOPMENT, V124, P4905; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X	30	554	572	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					608	612		10.1038/26989	http://dx.doi.org/10.1038/26989			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783587				2022-12-28	WOS:000076362900050
J	Farrell, B				Farrell, B			Efficient management of randomised controlled trials: nature or nurture	BRITISH MEDICAL JOURNAL			English	Article									Inst Hlth Sci, Oxford OX3 7LF, England	University of Oxford	Farrell, B (corresponding author), Inst Hlth Sci, Oxford OX3 7LF, England.							*COCHR COLL, 1997, COCHR LIB; *UK MRC, 1998, GOOD CLIN PRACT GUID; WARLOW C, 1990, BRIT MED J, V300, P180, DOI 10.1136/bmj.300.6718.180	3	26	27	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1236	1239		10.1136/bmj.317.7167.1236	http://dx.doi.org/10.1136/bmj.317.7167.1236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794870	Green Published			2022-12-28	WOS:000076963000035
J	Featherstone, K; Donovan, JL				Featherstone, K; Donovan, JL			Random allocation or allocation at random? Patients' perspectives of participation in a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; INFORMATION; WILLINGNESS; PREFERENCES; ATTITUDES; DECISIONS	Objectives To explore trial participants' understandings of randomisation. Design In this exploratory study, which used qualitative research methods, in-depth, semistructured interviews were carried out with 20 participants from the CLasP randomised controlled trial. Interviews were recorded on audio tape and fully transcribed. Data were analysed by comparing transcripts and describing emergent themes, using a grounded theory approach. Setting The CLasP study comprises three linked multicentre, pragmatic randomised controlled trials evaluating the effectiveness and cost effectiveness of laser therapy standard surgery and conservative management for men with lower urinary tract symptoms or urinary retention, or both, related to benign prostatic disease. Subjects 20 participants in the CLasP study were interviewed. Sampling was purposeful: men were included from each of the treatment arms, the two major centres, and at different points in the trial. Interventions and outcome measures Interviews used a checklist of topics to encourage participants to describe their experiences. Narratives concerning randomisation were compared to identify common themes, retaining the context of the discussion to allow detailed interpretation. Results Most participants recalled and described aspects of randomisation, such as the involvement of chance, comparison, and concealed allocation. Many found the concept of randomisation difficult, however, and developed alternative lay explanations to make sense of their experiences. Inaccurate patient information and lay interpretations of common trial terms caused confusion. Conclusions The provision of clear and accurate patient information is important, but this alone will not ensure consistent interpretation of concepts such as randomisation. Patients may need to discuss the purposes of randomisation in order to understand them fully enough to give bury informed consent	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Donovan, JL (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	jenny.donovan@bris.ac.uk		Featherstone, Katie/0000-0003-4999-8425				Altman DG, 1996, BRIT MED J, V313, P570; Bartholow BN, 1997, J ACQ IMMUN DEF SYND, V16, P108, DOI 10.1097/00042560-199710010-00006; BEVAN EG, 1993, BRIT J CLIN PHARMACO, V35, P204, DOI 10.1111/j.1365-2125.1993.tb05687.x; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; Burgess Robert C., FIELD RES SOURCEBOOK, P107; CASSILETH BR, 1982, JAMA-J AM MED ASSOC, V248, P968, DOI 10.1001/jama.248.8.968; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; Glaser B.G., 1965, AWARENESS DYING; Hammersley M., 1983, ETHNOGRAPHY PRINCIPL; HENZLOVA MJ, 1994, CONTROL CLIN TRIALS, V15, P284, DOI 10.1016/0197-2456(94)90044-2; Hudmon KS, 1996, CONTROL CLIN TRIALS, V17, P494, DOI 10.1016/S0197-2456(96)00063-3; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; LLEWELLYNTHOMAS HA, 1991, SOC SCI MED, V32, P35, DOI 10.1016/0277-9536(91)90124-U; MATTSON ME, 1985, CONTROL CLIN TRIALS, V6, P156, DOI 10.1016/0197-2456(85)90121-7; Mays N, 1996, QUALITATIVE RES HLTH; MCPHERSON K, 1994, J EPIDEMIOL COMMUN H, V48, P6, DOI 10.1136/jech.48.1.6; Miles M., 2013, QUALITATIVE DATA ANA; Pocock SJ., 2013, CLIN TRIALS PRACTICA; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Rimer BK, 1996, CANCER, V77, P2348, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2348::AID-CNCR25>3.3.CO;2-O; ROBERSON NL, 1994, CANCER, V74, P2687, DOI 10.1002/1097-0142(19941101)74:9+<2687::AID-CNCR2820741817>3.0.CO;2-B; Schron EB, 1997, J AM GERIATR SOC, V45, P934, DOI 10.1111/j.1532-5415.1997.tb02962.x; Schutz A., 1972, PHENOMENOLOGY SOCIAL; Senn S., 2021, THE BLIND DAT; SILVERMAN WA, 1996, LANCET, V347, P1714; SLEVIN M, 1995, BRIT J CANCER, V71, P1270, DOI 10.1038/bjc.1995.245; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; SUTHERLAND HJ, 1989, J ROY SOC MED, V82, P260, DOI 10.1177/014107688908200506; WILLIAMS G, 1984, SOCIOL HEALTH ILL, V6, P175, DOI 10.1111/1467-9566.ep10778250	29	186	186	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1177	1180		10.1136/bmj.317.7167.1177	http://dx.doi.org/10.1136/bmj.317.7167.1177			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138GF	9794849	Green Published, Bronze, Green Submitted, Green Accepted			2022-12-28	WOS:000076963000016
J	Duan, Y; Kollman, PA				Duan, Y; Kollman, PA			Pathways to a protein folding intermediate observed in a 1-microsecond simulation in aqueous solution	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; MESH EWALD METHOD; FREE-ENERGY; VILLIN HEADPIECE; WATER; APOMYOGLOBIN; PRINCIPLES; KINETICS; BINDING; MODELS	An implementation of classical molecular dynamics on parallel computers of increased efficiency has enabled a simulation of protein folding with explicit representation of water for 1 microsecond, about two orders of magnitude Longer than the Longest simulation of a protein in water reported to date. Starting with an unfolded state of villin headpiece subdomain, hydrophobic collapse and helix formation occur in an initial phase, followed by conformational readjustments. A marginally stable state, which has a Lifetime of about 150 nanoseconds, a favorable solvation free energy, and shows significant resemblance to the native structure, is observed; two pathways to this state have been found.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kollman, PA (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	pak@cgl.ucsf.edu	Duan, Yong/D-3475-2013	Duan, Yong/0000-0003-3793-5099	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029072] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29072] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO DOV, 1995, J MOL BIOL, V247, P501, DOI 10.1006/jmbi.1994.0156; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Ballew RM, 1996, P NATL ACAD SCI USA, V93, P5759, DOI 10.1073/pnas.93.12.5759; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOCZKO EM, 1993, J PHYS CHEM-US, V97, P4509, DOI 10.1021/j100119a043; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; Brooks III C. L., 1989, PROTEINS THEORETICAL; Burton RE, 1997, NAT STRUCT BIOL, V4, P305, DOI 10.1038/nsb0497-305; CHEATHAM TE, 1995, J AM CHEM SOC, V117, P4193, DOI 10.1021/ja00119a045; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DAGGETT V, 1992, P NATL ACAD SCI USA, V89, P5142, DOI 10.1073/pnas.89.11.5142; DAGGETT V, 1994, CURR OPIN STRUC BIOL, V4, P291, DOI 10.1016/S0959-440X(94)90322-0; Daura X, 1998, J MOL BIOL, V280, P925, DOI 10.1006/jmbi.1998.1885; Demchuk E, 1997, FOLD DES, V2, P35, DOI 10.1016/S1359-0278(97)00004-7; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; DILL KA, 1995, PROTEIN SCI, V4, P561; Dobson CM, 1997, CURR OPIN STRUC BIOL, V7, P1, DOI 10.1016/S0959-440X(97)80001-2; Duan Y, 1998, P NATL ACAD SCI USA, V95, P9897, DOI 10.1073/pnas.95.17.9897; DUAN Y, UNPUB; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fox T, 1996, PROTEINS, V25, P315, DOI 10.1002/(SICI)1097-0134(199607)25:3<315::AID-PROT4>3.0.CO;2-E; Gilmanshin R, 1997, P NATL ACAD SCI USA, V94, P3709, DOI 10.1073/pnas.94.8.3709; Hagen SJ, 1996, P NATL ACAD SCI USA, V93, P11615, DOI 10.1073/pnas.93.21.11615; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KARPEN ME, 1993, BIOCHEMISTRY-US, V32, P412, DOI 10.1021/bi00053a005; Kollman PA, 1996, ACCOUNTS CHEM RES, V29, P461, DOI 10.1021/ar9500675; KUMAR S, 1992, J COMPUT CHEM, V13, P1011, DOI 10.1002/jcc.540130812; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; Li AJ, 1995, PROTEIN ENG, V8, P1117, DOI 10.1093/protein/8.11.1117; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; McKnight CJ, 1996, J MOL BIOL, V260, P126; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; PLAXCO KW, 1998, COMMUNICATION; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SCHIFFER CA, 1995, BIOCHEMISTRY-US, V34, P15057, DOI 10.1021/bi00046a011; Shakhnovich E, 1998, CURR OPIN STRUC BIOL, V8, P65, DOI 10.1016/S0959-440X(98)80011-0; Shakhnovich EI, 1997, CURR OPIN STRUC BIOL, V7, P29, DOI 10.1016/S0959-440X(97)80005-X; Sheinerman FB, 1998, P NATL ACAD SCI USA, V95, P1562, DOI 10.1073/pnas.95.4.1562; Sheinerman FB, 1998, J MOL BIOL, V278, P439, DOI 10.1006/jmbi.1998.1688; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SKOLNICK J, 1990, SCIENCE, V250, P1121, DOI 10.1126/science.250.4984.1121; Thompson PA, 1997, BIOCHEMISTRY-US, V36, P9200, DOI 10.1021/bi9704764; TIRADORIVES J, 1993, BIOCHEMISTRY-US, V32, P4175, DOI 10.1021/bi00067a004; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; Williams S, 1996, BIOCHEMISTRY-US, V35, P691, DOI 10.1021/bi952217p	52	1127	1157	1	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					740	744		10.1126/science.282.5389.740	http://dx.doi.org/10.1126/science.282.5389.740			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784131				2022-12-28	WOS:000076607500050
J	Sackett, DL; Straus, SE				Sackett, DL; Straus, SE		Firm A Nuffield Dept Med	Finding and applying evidence during clinical rounds - The "evidence cart"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SETTINGS; IMPACT	Context.-Physicians need easy access to evidence for clinical decisions while they care for patients but, to our knowledge, no investigators have assessed use of evidence during rounds with house staff. Objective.-To determine if it was feasible to find and apply evidence during clinical rounds, using an "evidence cart" that contains multiple sources of evidence and the means for projecting and printing them. Design.-Descriptive feasibility study of use of evidence during 1 month (April 1997) and anonymous questionnaire (May 1997). Setting.-General medicine inpatient service. Patients.-Medical students, house staff, fellows, and attending consultant. Intervention.-Evidence cart that included 2 secondary sources developed by the department (critically appraised topics [CATs] and Redbook), Best Evidence, JAMA Rational Clinical Examination series, the Cochrane Library, MEDLINE, a physical examination textbook, a radiology anatomy textbook, and a Simulscope, which allows several people to listen simultaneously to the same signs on physical examination. Main Outcome Measures.-Number of times sources were used, type of sources searched and success of searches, time needed to search, and whether the search affected patient care. Results.-The evidence cart was used 98 times, but could not be taken on bedside rounds because of its bulk; hard copies of several sources were taken instead. When the evidence cart was used during team rounds and student rounds, some sources could be accessed quickly enough (10.2-25.4 seconds) to be practical on our service. Of 98 searches, 79 (81%) sought evidence that could affect diagnostic and/or treatment decisions. Seventy-one (90%) of 79 searches regarding patient management were successful, and when assessed from the perspective of the most junior team members responsible for each patient's evaluation and management, 37 (52%) of the 71 successful searches confirmed their current or tentative diagnostic or treatment plans, 18 (25%) led to a new diagnostic skill, an additional test, or a new management decision, and 16 (23%) corrected a previous clinical skill, diagnostic test, or treatment. When the cart was removed, the perceived need for evidence rose sharply, but a search for it was carried out only 12% of the time (5 searches performed out of the 41 times evidence was needed). Conclusions.-Making evidence quickly available to clinicians on a busy medical inpatient service using an evidence carl increased the extent to which evidence was sought and incorporated into patient care decisions.	Univ Oxford, Nuffield Dept Clin Med, Oxford, England	University of Oxford	Sackett, DL (corresponding author), John Radcliffe Hosp, NHS R&D Ctr Evidence Based Med, Level 5, Oxford OX3 9DU, England.							ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; *GOLD STAND MULT I, 1995, RAD AN; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; Haynes RB, 1996, EVIDENCE BASED MED, V1, P196; LANGDORF MI, 1995, ACAD EMERG MED, V2, P157, DOI 10.1111/j.1553-2712.1995.tb03185.x; MARSHALL JG, 1992, B MED LIBR ASSOC, V80, P169; MARSHALL JG, 1981, J MED EDUC, V56, P409; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; SACKETT DL, 1997, EVIDENCE BASED MED H, P9; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SAUVE JS, 1995, ANN R COLL PHYS SURG, V28, P396; Scientific American Medicine, 1997, SCI AM MED; Smith R, 1996, BRIT MED J, V313, P1062	13	212	215	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1336	1338		10.1001/jama.280.15.1336	http://dx.doi.org/10.1001/jama.280.15.1336			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794314	Bronze			2022-12-28	WOS:000076472500027
J	Guo, L; Lim, KB; Poduje, CM; Daniel, M; Gunn, JS; Hackett, M; Miller, SI				Guo, L; Lim, KB; Poduje, CM; Daniel, M; Gunn, JS; Hackett, M; Miller, SI			Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides	CELL			English	Article							SALMONELLA-TYPHIMURIUM VIRULENCE; ESCHERICHIA-COLI; PHOP-PHOQ; CYSTIC-FIBROSIS; ANTIBIOTICS; EXPRESSION; REGULON; SYSTEM; GENES; LIPOPOLYSACCHARIDES	The Salmonellae PhoP-PhoQ virulence regulators induce resistance to host cationic antimicrobial peptides (CAMP) after infection of vertebrate tissues, and M2+ or Ca2+ limitation. The PhoP-PhoQ activated gene, pagP, was identified as important to inducible CAMP resistance and increased acylation of lipid A, the major component of the outer leaflet of the outer membrane, pagP mutants demonstrated increased outer membrane permeability in response to CAMP, supporting the hypothesis that increased lipid A acylation is a CAMP resistance mechanism. Similarly, in response to Mg2+ limited growth, other enteric Gramnegative bacteria demonstrated increased lipid A acylation. Compounds that inhibit the ability to increase lipid A acylation may have utility as new antimicrobial agents.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health San Antonio	Miller, SI (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.	millersi@u.washington.edu	Gunn, John/E-3167-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030479] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI30479] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; DARVEAU RP, 1992, J CLIN INVEST, V90, P447, DOI 10.1172/JCI115880; DARVEAU RP, 1991, ANTIMICROB AGENTS CH, V35, P1153, DOI 10.1128/AAC.35.6.1153; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; ELLIOTT T, 1988, MOL GEN GENET, V213, P332, DOI 10.1007/BF00339599; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FU R, 1991, GENE, V100, P195; GABAY JE, 1994, SCIENCE, V264, P373, DOI 10.1126/science.8153623; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; GUNN JS, 1995, J BACTERIOL, V177, P5040, DOI 10.1128/jb.177.17.5040-5047.1995; GUNN JS, 1998, IN PRESS MICROB PATH; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Heithoff DM, 1997, P NATL ACAD SCI USA, V94, P934, DOI 10.1073/pnas.94.3.934; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; HILLENKAMP F, 1994, BIOLOGICAL MASS SPECTROMETRY: PRESENT AND FUTURE, P101; Hohmann EL, 1996, VACCINE, V14, P19, DOI 10.1016/0264-410X(95)00173-X; Hu KH, 1996, GENETICS, V143, P1521; JACOB L, 1994, CIBA F SYMP, V186, P197; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; Maniatis T., 1982, MOL CLONING; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MURRAY CK, 1996, ESCHERICHIA COLI SAL, P967; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RANA FR, 1990, FEBS LETT, V261, P464, DOI 10.1016/0014-5793(90)80616-Q; Skorupski K, 1996, GENE, V169, P47, DOI 10.1016/0378-1119(95)00793-8; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wang HL, 1998, ANAL CHEM, V70, P205, DOI 10.1021/ac971036l; Xu NX, 1997, J AM SOC MASS SPECTR, V8, P116, DOI 10.1016/S1044-0305(96)00233-4; YOST RA, 1990, METHOD ENZYMOL, V193, P154, DOI 10.1016/0076-6879(90)93415-H	50	485	499	4	45	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					189	198		10.1016/S0092-8674(00)81750-X	http://dx.doi.org/10.1016/S0092-8674(00)81750-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790526	Bronze			2022-12-28	WOS:000076538300007
J	Panju, AA; Hemmelgarn, BR; Guyatt, GH; Simel, DL				Panju, AA; Hemmelgarn, BR; Guyatt, GH; Simel, DL			Is this patient having a myocardial infarction?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY ROOM PATIENTS; CLINICAL-PREDICTION RULES; CORONARY-ARTERY DISEASE; MULTICENTER CHEST PAIN; METHODOLOGICAL STANDARDS; THROMBOLYTIC THERAPY; CARE-UNIT; DIAGNOSIS; HISTORY; ELECTROCARDIOGRAM	When faced with a patient with acute chest pain, clinicians must distinguish myocardial infarction (MI) from all other causes of acute chest pain, If MI is suspected, current therapeutic practice includes deciding whether to administer thrombolysis or primary percutaneous transluminal coronary angioplasty and whether to admit patients to a coronary care unit. The former decision is based on electrocardiographic (ECG) changes, including ST-segment elevation or left bundle-branch block, the latter on the likelihood of the patient's having unstable high-risk ischemia or MI without ECG changes. Despite advances in investigative modalities, a focused history and physical examination followed by an ECG remain the key tools for the diagnosis of MI. The most powerful features that increase the probability of MI, and their associated likelihood ratios (LRs), are new ST-segment elevation (LR range, 5.7-53.9); new Q wave (LR range, 5.3-24.8); chest pain radiating to both the left and right arm simultaneously (LR, 7.1); presence of a third heart sound (LR, 3.2); and hypotension (LR, 3.1). The most powerful features that decrease the probability of MI are a normal ECG result (LR range, 0.1-0.3), pleuritic chest pain (LR, 0.2), chest pain reproduced by palpation (LR range, 0.2-0.4), sharp or stabbing chest pain (LR, 0.3), and positional chest pain (LR, 0.3). Computer-derived algorithms that depend on clinical examination and ECG findings might improve the classification of patients according to the probability that an MI is causing their chest pain.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, McMaster Med Programme, Hamilton, ON L8N 3Z5, Canada; Duke Univ, Med Ctr, Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA	McMaster University; McMaster University; McMaster University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Panju, AA (corresponding author), McMaster Univ, Med Ctr, 1200 Main St W,Room 3X28, Hamilton, ON L8N 3Z5, Canada.		Hemmelgarn, Brenda R./I-6894-2012					BERGER JP, 1990, J INTERN MED, V227, P165, DOI 10.1111/j.1365-2796.1990.tb00138.x; BRAUNWALD E, 1994, CIRCULATION, V90, P613, DOI 10.1161/01.CIR.90.1.613; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DAVIES LG, 1958, BRIT HEART J, V20, P153; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; GADSBOLL N, 1989, EUR HEART J, V10, P1017, DOI 10.1093/oxfordjournals.eurheartj.a059414; GJORUP T, 1992, J INTERN MED, V231, P407, DOI 10.1111/j.1365-2796.1992.tb00952.x; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HERLIHY T, 1987, AM J CARDIOL, V60, P20, DOI 10.1016/0002-9149(87)90976-3; HICKAM DH, 1985, J CHRON DIS, V38, P91, DOI 10.1016/0021-9681(85)90012-8; Holleman DR, 1997, J GEN INTERN MED, V12, P165, DOI 10.1007/s11606-006-5024-6; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; JONSBU J, 1991, J INTERN MED, V229, P143, DOI 10.1111/j.1365-2796.1991.tb00322.x; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KARLSON BW, 1991, AM J CARDIOL, V68, P171, DOI 10.1016/0002-9149(91)90739-8; KEE F, 1993, BRIT MED J, V307, P1528, DOI 10.1136/bmj.307.6918.1528; KLAEBOE G, 1987, ACTA MED SCAND, V222, P27; KUDENCHUK PJ, 1991, J AM COLL CARDIOL, V17, P1486, DOI 10.1016/0735-1097(91)90636-N; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; MATHEWS MB, 1985, ANGINA PECTORIS, P2; NESS TJ, 1990, PAIN, V41, P167, DOI 10.1016/0304-3959(90)90021-5; Panju A, 1996, CAN MED ASSOC J, V155, P541; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; ROUAN GW, 1989, AM J CARDIOL, V64, P1087, DOI 10.1016/0002-9149(89)90857-6; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; Sgarbossa EB, 1996, NEW ENGL J MED, V334, P481, DOI 10.1056/NEJM199602223340801; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SOLOMON CG, 1989, AM J CARDIOL, V63, P772, DOI 10.1016/0002-9149(89)90040-4; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; TIERNEY WM, 1986, MED DECIS MAKING, V6, P12, DOI 10.1177/0272989X8600600103; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; YUSUF S, 1984, EUR HEART J, V5, P690, DOI 10.1093/oxfordjournals.eurheartj.a061728	43	168	192	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1256	1263		10.1001/jama.280.14.1256	http://dx.doi.org/10.1001/jama.280.14.1256			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786377				2022-12-28	WOS:000076357900033
J	Cavallo, RA; Cox, RT; Moline, MM; Roose, J; Polevoy, GA; Clevers, H; Peifer, M; Bejsovec, A				Cavallo, RA; Cox, RT; Moline, MM; Roose, J; Polevoy, GA; Clevers, H; Peifer, M; Bejsovec, A			Drosophila Tcf and Groucho interact to repress Wingless signalling activity	NATURE			English	Article							SEGMENT POLARITY GENE; BETA-CATENIN; CUBITUS INTERRUPTUS; TRANSCRIPTION; MELANOGASTER; EXPRESSION; ARMADILLO; COMPLEX; PROTEIN; LEF-1	Wingless/Wnt signalling directs cell-fate choices during embryonic development(1,2). Inappropriate reactivation of the pathway causes cancer(3-5). In Drosophila, signal transduction from Wingless stabilizes cytosolic Armadillo(1), which then forms a bipartite transcription factor with the HMG-box protein Drosophila Tcf (dTcf) and activates expression of Wingless-responsive genes(6-8) Here we report that in the absence of Armadillo, dTcf acts as a transcriptional repressor of Wingless-responsive genes, and we show that Groucho acts as a corepressor in this process. Reduction of dTcf activity partially suppresses wingless and armadillo mutant phenotypes, leading to derepression of Wingless-responsive genes. Furthermore, overexpression of wild-type dTcf enhances the phenotype of a weak wingless allele. Finally, mutations in the Drosophila groucho gene also suppress wingless and armadillo mutant phenotypes as Groucho physically interacts with dTcf and is required for its full repressor activity.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands	Northwestern University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Utrecht University; Utrecht University Medical Center	Bejsovec, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	bejsovec@nwu.edu	Peifer, Mark/A-1152-2010	Bejsovec, Amy/0000-0002-8019-5789; Peifer, Mark/0000-0003-1412-3987				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bejsovec Amy, 1996, Advances in Developmental Biochemistry, V4, P1, DOI 10.1016/S1064-2722(08)60056-0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; DECELIS JF, 1995, DEVELOPMENT, V121, P3467; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; Hepker J, 1997, DEVELOPMENT, V124, P549; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SCHRONS H, 1992, GENETICS, V132, P481; TIONG SYK, 1990, GENETICS, V124, P889; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404	26	576	596	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					604	608		10.1038/26982	http://dx.doi.org/10.1038/26982			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783586				2022-12-28	WOS:000076362900049
J	Nightingale, SL				Nightingale, SL			New safety information added to antiretroviral package inserts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1128	1128		10.1001/jama.280.13.1128	http://dx.doi.org/10.1001/jama.280.13.1128			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777799				2022-12-28	WOS:000076210800005
J	Saudou, F; Finkbeiner, S; Devys, D; Greenberg, ME				Saudou, F; Finkbeiner, S; Devys, D; Greenberg, ME			Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions	CELL			English	Article							DISEASE PROTEIN; CELL-LINES; LOCALIZATION; NEURONS; GENE; IDENTIFICATION; EXPRESSION; BRAIN; PRODUCT; SIGNAL	The mechanisms by which mutant huntingtin induces neurodegeneration were investigated using a cellular model that recapitulates features of neurodegeneration seen in Huntington's disease. When transfected into cultured striatal neurons, mutant huntingtin induces neurodegeneration by an apoptotic mechanism. Antiapoptotic compounds or neurotrophic factors protected neurons against mutant huntingtin. Blocking nuclear localization of mutant huntingtin suppressed its ability to form intranuclear inclusions and to induce neurodegeneration. However, the presence of inclusions did not correlate with huntingtin-induced death. The exposure of mutant huntingtin-transfected striatal neurons to conditions that suppress the formation of inclusions resulted in an increase in mutant huntingtin-induced death. These findings suggest that mutant huntingtin acts within the nucleus to induce neurodegeneration. However, intranuclear inclusions may reflect a cellular mechanism to protect against huntingtin-induced cell death.	Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, ULP, F-67404 Illkirch, Strasbourg, France	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Greenberg, ME (corresponding author), Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA.		SAUDOU, Frédéric/L-3454-2014	SAUDOU, Frédéric/0000-0001-6107-1046; Devys, Didier/0000-0001-9655-3512	NICHD NIH HHS [P30-HD 18655] Funding Source: Medline; NINDS NIH HHS [NS 28829] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; BESSERT DA, 1995, MOL BRAIN RES, V33, P165, DOI 10.1016/0169-328X(95)00124-B; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davies SW, 1998, LANCET, V351, P131, DOI 10.1016/S0140-6736(97)08360-8; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; Group T. H. D. C. R., 1993, CELL, V72, P971, DOI [10.1016/0092-8674(93)90585-E8458085, DOI 10.1016/0092-8674(93)90585-E8458085]; Gusella JF, 1996, COLD SPRING HARB SYM, V61, P615; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HEDREEN JC, 1995, J NEUROPATH EXP NEUR, V54, P105, DOI 10.1097/00005072-199501000-00013; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; NISHI K, 1994, J BIOL CHEM, V269, P6320; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; SAPP E, 1995, NEUROSCIENCE, V64, P397, DOI 10.1016/0306-4522(94)00427-7; Saudou F, 1996, COLD SPRING HARB SYM, V61, P639; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	38	1287	1315	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					55	66		10.1016/S0092-8674(00)81782-1	http://dx.doi.org/10.1016/S0092-8674(00)81782-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778247	Bronze			2022-12-28	WOS:000076242300010
J	Messerli, FH; Mittler, BS				Messerli, FH; Mittler, BS			Framingham at 50	LANCET			English	Editorial Material									Alton Ochsner Med Fdn & Ochsner Clin, Dept Internal Med, Hypertens Dis Sect, New Orleans, LA 70121 USA	Ochsner Health System	Messerli, FH (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Dept Internal Med, Hypertens Dis Sect, New Orleans, LA 70121 USA.		Messerli, Franz/AAR-4783-2021					BRODY JE, 1994, HEART DIS PERSIST ST; GORDAN T, 1968, FRAMINGHAM STUDY; HAY, 1931, BRIT M J, V2, P43; WHITE PD, 1931, MED MONOGRAPHS, P400	4	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1006	1006		10.1016/S0140-6736(05)60073-6	http://dx.doi.org/10.1016/S0140-6736(05)60073-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759741				2022-12-28	WOS:000076121800007
J	Meldrum, M				Meldrum, M			"A calculated risk": the Salk polio vaccine field trials of 1954	BRITISH MEDICAL JOURNAL			English	Article									NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Meldrum, M (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.			Meldrum, Marcia/0000-0003-0130-9299				BARLOW S, 1953, COMMUNICATION   1116; Benison Saul, 1967, TOM RIVERS REFLECTIO; Carter R., 1966, BREAKTHROUGH SAGA J; DUBLIN T, 1953, COMMUNICATION   1209; DUBLIN T, 1954, COMMUNICATION; ENDERS JF, 1954, MEDICINE, V33, P87, DOI 10.1097/00005792-195405000-00001; Francis T, 1955, AM J PUBLIC HEALTH N, V45, P1; MELDRUM ML, 1994, THESIS STATE U NEW Y; Smith Jane S., 1990, PATENTING SUN POLIO; VANRIPER H, 1953, COMMUNICATION   1201; VANRIPER H, 1953, COMMUNICATION   1119; 1953, NY TIMES        1110, P32	12	36	39	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1233	1236		10.1136/bmj.317.7167.1233	http://dx.doi.org/10.1136/bmj.317.7167.1233			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794869	Green Published			2022-12-28	WOS:000076963000034
J	Sanders, C; Egger, M; Donovan, J; Tallon, D; Frankel, S				Sanders, C; Egger, M; Donovan, J; Tallon, D; Frankel, S			Reporting on quality of life in randomised controlled trials: bibliographic study	BRITISH MEDICAL JOURNAL			English	Article							OF-LIFE; CLINICAL-TRIALS; HEALTH-STATUS; ENGLISH; ISSUES	Objectives To examine the frequency and quality of reporting on quality of life in randomised controlled trials. Design Search of the Cochrane Controlled Trials Register 1980 to 1997 to identify trials from all disciplines, from oncology, and from cardiovascular medicine that reported on quality of life. Assessment of abstracts from articles published from 1993 to 1996. Assessment of a sample of full reports with a standardised instrument. Main outcome measures Prevalence of reporting on quality of life. Conditions and interventions studied in trials reporting on quality of life. Quality of reporting on quality of life. Results During 1980-97 reporting on quality of life increased from 0.63% to 4.2% for trials from all disciplines, from 1.5% to 8.2% for cancer trials, and from 0.34% to 3.6% for cardiovascular trials. Of 364 abstracts, 65% reported on drug interventions. Of a sample of 61 full reports, authors of 48 (72%) used 62 established quality of life instruments. In 15 reports (22%) authors developed their own measures, and in 2 (3%) methods were unclear Response rates were given in 38 (57%), and complete reporting on all items and scales occurred in 31 (46%). Conclusions Less than 5% of all randomised controlled trials reported on quality of life, and this proportion was below 10% even for cancer trials. A plethora of instruments was used in different studies, and the reporting of methods and results was often inadequate. Standards for the measurement and reporting of quality of life in clinical trials research need to be developed.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Sanders, C (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.	Caroline.Sanders@bristol.ac.uk	Sanders, Caroline/G-8021-2014	Sanders, Caroline/0000-0002-0539-928X; Egger, Matthias/0000-0001-7462-5132				[Anonymous], 1995, LANCET, V1, P1; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BROCKER P, 1994, AGE AGEING, V23, P303, DOI 10.1093/ageing/23.4.303; *COCHR COLL, 1997, COCHR LIBR; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Fallowfield L, 1996, LANCET, V348, P421, DOI 10.1016/S0140-6736(05)64534-5; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GUYATT G, 1991, CONTROL CLIN TRIALS, V12, pS81, DOI 10.1016/S0197-2456(05)80014-5; GUYATT GH, 1986, CAN MED ASSOC J, V134, P889; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388; McNamee D, 1996, LANCET, V348, P562; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; NAUGHTON MJ, 1996, FUNDAMENTALS CLIN TR; PATRICK DL, 1990, ANNU REV PUBL HEALTH, V11, P165; RENNIE D, 1995, JAMA-J AM MED ASSOC, V273, P1054, DOI 10.1001/jama.273.13.1054; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; Streiner DL., 2001, HLTH MEASUREMENT SCA, V2nd; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	22	221	234	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1191	1194		10.1136/bmj.317.7167.1191	http://dx.doi.org/10.1136/bmj.317.7167.1191			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794853	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000076963000020
J	Thornley, B; Adams, C				Thornley, B; Adams, C			Content and quality of 2000 controlled trials in schizophrenia over 50 years	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIALS; CLINICAL-TRIALS; JOURNALS	Objective To provide a comprehensive survey of the content and quality of intervention studies relevant to the treatment of schizophrenia. Design Data were extracted from 2000 trials on the Cochrane Schizophrenia Group's register. Main outcome measures Type and date of publication, country of origin, language, size of study, treatment setting, participant group, interventions, outcomes, and quality of study. Results Hospital based drug trials undertaken in the United States were dominant in the sample (54%). Generally, studies were short (54% < 6 weeks), small (mean number of patients 65), and poorly reported (64% had a quality score of less than or equal to 2 (maximum score 5)). Over 600 different interventions were studied in these trials, and 640 different rating scales were used to measure outcome. Conclusions Half a century of studies of limited quality, duration, and clinical utility leave much scope for well planned, conducted, and reported trials. The drug regulatory authorities should stipulate that the results of both explanatory and pragmatic trials are necessary before a compound is given a licence for everyday use.	Cochrane Schizophrenia Grp, Oxford OX2 7LG, England		Adams, C (corresponding author), Cochrane Schizophrenia Grp, Summertown Pavil, Oxford OX2 7LG, England.							ADAMS CE, 1997, SCHIZOPHRENIA MODULE; ADAMS CE, IN PRESS SCHIZPHR RE; Ahmed I, 1998, ARCH GEN PSYCHIAT, V55, P754, DOI 10.1001/archpsyc.55.8.754; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; CHALMERS I, 1986, WHO CHRON, V40, P61; CHALMERS I, 1986, CONTROL CLIN TRIALS, V7, P306, DOI 10.1016/0197-2456(86)90038-3; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CHENG K, 1996, ISR J MED SCI S, V32, pS260; *COCHR COLL, 1996, COCHR LIB; Fahey T, 1995, J PUBLIC HEALTH MED, V17, P469; FREEMAN H, 1958, SCHIZOPHRENIA REV SY, P473; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Lent V, 1996, UROL RES, V24, P119, DOI 10.1007/BF00431090; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; NICOLUCCI A, 1989, JAMA-J AM MED ASSOC, V262, P2101, DOI 10.1001/jama.262.15.2101; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; SCHULZ KF, 1995, ONLINE J CURR CLIN T; SILAGY CA, 1993, BRIT MED J, V308, P897; VANDEKERCKHOVE P, 1993, BRIT J OBSTET GYNAEC, V100, P1005, DOI 10.1111/j.1471-0528.1993.tb15142.x	19	260	269	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1181	1184		10.1136/bmj.317.7167.1181	http://dx.doi.org/10.1136/bmj.317.7167.1181			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794850	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000076963000017
J	Baxter, C; Jones, R; Corr, L				Baxter, C; Jones, R; Corr, L			Time trend analysis and variations in prescribing lipid lowering drugs in general practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article									St Thomas Hosp, Dept Cardiol, London SE1 7EH, England; United Med & Dent Sch Guys & St Thomas Hosp, Dept Gen Practice, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Baxter, C (corresponding author), St Thomas Hosp, Dept Cardiol, London SE1 7EH, England.	c.baxter@iaxnet.co.uk						Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SPSS, 1989, SPSS WIND REL 6 0 1	4	47	47	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	1998	317	7166					1134	1135						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784452				2022-12-28	WOS:000076755100034
J	Stone, DH; Rimaz, S; Gilmour, WH				Stone, DH; Rimaz, S; Gilmour, WH			Prevalence of congenital anterior abdominal wall defects in the United Kingdom: comparison of regional registers	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Dept Child Hlth, Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ Glasgow, Dept Stat, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Stone, DH (corresponding author), Univ Glasgow, Dept Child Hlth, Epidemiol & Community Hlth Unit, Glasgow G3 8SJ, Lanark, Scotland.			Rimaz, Shahnaz/0000-0001-6869-5847				CALZOLARI E, 1995, AM J MED GENET, V58, P187, DOI 10.1002/ajmg.1320580218; Chalmers J, 1997, BRIT MED J, V314, P371; Dillon E, 1997, BRIT MED J, V314, P372; *EUROCAT WORK GROU, 1995, 6 EUROCAT WORK GROUP; Tan KH, 1996, BRIT MED J, V313, P903	5	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1118	1119						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784448				2022-12-28	WOS:000076755100029
J	Friedman, JM; Halaas, JL				Friedman, JM; Halaas, JL			Leptin and the regulation of body weight in mammals	NATURE			English	Review							OBESE GENE-PRODUCT; HUMAN OB GENE; CEREBROSPINAL-FLUID LEPTIN; NORMAL FEMALE MICE; NEUROPEPTIDE-Y; OB/OB MICE; ANOREXIA-NERVOSA; EXTREME OBESITY; DIABETIC MICE; FAT/FAT MICE	The assimilation, storage and use of energy from nutrients constitute a homeostatic: system that is essential for life. In vertebrates, the ability to store sufficient quantities of energy-dense triglyceride in adipose tissue allows survival during the frequent periods of food deprivation encountered during evolution. However, the presence of excess adipose tissue can be maladaptive. A complex physiological system has evolved to regulate fuel stores and energy balance at an optimum level. Leptin, a hormone secreted by adipose tissue, and its receptor are integral components of this system. Leptin also signals nutritional status to several other physiological systems and modulates their Function. Here we review the role of leptin in the control of body weight and its relevance to the pathogenesis of obesity.	Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Friedman, JM (corresponding author), Rockefeller Univ, Mol Genet Lab, 1230 York Ave, New York, NY 10021 USA.		sheng, jian/E-9474-2012					Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; BLACKBURN G, 1995, OBES RES, V3, pS211, DOI 10.1002/j.1550-8528.1995.tb00466.x; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Casanueva FF, 1997, BIOCHEM MOL MED, V60, P116, DOI 10.1006/bmme.1996.2564; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cohen SL, 1996, NATURE, V382, P589, DOI 10.1038/382589a0; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; CONSIDINE RV, 1996, NEW ENGL J MED, V334, P324; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; FREEDMAN MR, 1986, AM J PHYSIOL, V250, pR595, DOI 10.1152/ajpregu.1986.250.4.R595; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; Gardner JD, 1998, NAT NEUROSCI, V1, P103, DOI 10.1038/353; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Glaum SR, 1996, MOL PHARMACOL, V50, P230; Hakansson ML, 1998, J NEUROSCI, V18, P559; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Hetherington AW, 1942, AM J PHYSIOL, V136, P609, DOI 10.1152/ajplegacy.1942.136.4.609; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Ioffe E, 1998, P NATL ACAD SCI USA, V95, P11852, DOI 10.1073/pnas.95.20.11852; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; Kiess W, 1996, HORM METAB RES, V28, P708, DOI 10.1055/s-2007-979883; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Li C, 1998, J BIOL CHEM, V273, P10078, DOI 10.1074/jbc.273.16.10078; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; Mandrup S, 1997, P NATL ACAD SCI USA, V94, P4300, DOI 10.1073/pnas.94.9.4300; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Mantzoros C, 1997, J CLIN ENDOCR METAB, V82, P1845, DOI 10.1210/jc.82.6.1845; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1066, DOI 10.1210/jc.82.4.1066; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Matson CA, 1997, PEPTIDES, V18, P1275, DOI 10.1016/S0196-9781(97)00138-1; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; MILES PDG, 1991, P NATL ACAD SCI USA, V88, P1296, DOI 10.1073/pnas.88.4.1296; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Moon BC, 1997, GENOMICS, V42, P152, DOI 10.1006/geno.1997.4701; Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; OHIHAMAZAKI H, 1997, NATURE, V390, P165; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; PAN W, 1997, NATURE, V385, P165; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Ravussin E, 1997, NAT MED, V3, P238, DOI 10.1038/nm0297-238; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; ROHNERJEANRENAUD F, 1989, ENDOCRINOLOGY, V124, P733, DOI 10.1210/endo-124-2-733; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Satoh N, 1997, ENDOCRINOLOGY, V138, P947, DOI 10.1210/en.138.3.947; Satoh N, 1998, NEUROSCI LETT, V249, P107, DOI 10.1016/S0304-3940(98)00401-7; Schneider B.S., 1983, P251; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Sivitz WI, 1997, ENDOCRINOLOGY, V138, P3395, DOI 10.1210/en.138.8.3395; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Verploegen SABW, 1997, FEBS LETT, V405, P237, DOI 10.1016/S0014-5793(97)00192-0; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; Woods SC, 1996, NEUROSCI BIOBEHAV R, V20, P139, DOI 10.1016/0149-7634(95)00044-F; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	108	4137	4329	20	662	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1998	395	6704					763	770		10.1038/27376	http://dx.doi.org/10.1038/27376			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796811				2022-12-28	WOS:000076607400046
J	Lindberg, DAB; Humphreys, BL				Lindberg, DAB; Humphreys, BL			Medicine and health on the Internet - The good, the bad, and the ugly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INFORMATION		Natl Lib Med, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Lindberg, DAB (corresponding author), Natl Lib Med, 8600 Rockville Pike, Bethesda, MD 20894 USA.	lindberg@nlm.nih.gov						CUSHMAN FR, 1998, MILBANK Q; Delamothe T, 1998, BMJ-BRIT MED J, V316, P1109, DOI 10.1136/bmj.316.7138.1109; *DUBL COR MET, MET EL RES; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; LINDBERG DA, 1998, FISCAL YEAR 1999 PRE; LINDBERG DAB, 1995, JAMA-J AM MED ASSOC, V273, P1667, DOI 10.1001/jama.273.21.1667; LYNCH C, 1997, ARL BIMONTHLY NEWLSE, P194; Lyon BJ, 1998, B MED LIBR ASSOC, V86, P486; Masys DR, 1997, J AM MED INFORM ASSN, P340; Neame R, 1997, BRIT MED J, V314, P573, DOI 10.1136/bmj.314.7080.573; Redman PM, 1997, B MED LIBR ASSOC, V85, P325; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; *US DEP HHS, ADM SIMPL; Voge S, 1998, B MED LIBR ASSOC, V86, P326; WOOD FB, IN PRESS J AM MED IN	16	72	73	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1303	1304		10.1001/jama.280.15.1303	http://dx.doi.org/10.1001/jama.280.15.1303			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129PQ	9794299				2022-12-28	WOS:000076472500012
J	MacLeod, K; Backer, A; Laurent, G				MacLeod, K; Backer, A; Laurent, G			Who reads temporal information contained across synchronized and oscillatory spike trains?	NATURE			English	Article							ENCODING NEURAL ASSEMBLIES; VISUAL-CORTEX; NEURONS; REPRESENTATIONS; BRAIN	Our inferences about brain mechanisms underlying perception rely on whether it is possible for the brain to 'reconstruct' a stimulus from the information contained in the spike trains from many neurons(1-5). How the brain actually accomplishes this reconstruction remains largely unknown. Oscillatory and synchronized activities in the brain of mammals have been correlated with distinct behavioural states or the execution of complex cognitive tasks(6-11) and are proposed to participate in the 'binding' of individual features into more complex percepts(12-14). But if synchronization is indeed relevant, what senses it? In insects, oscillatory synchronized activity in the early olfactory system seems to be necessary for fine odour discrimination(15) and enables the encoding of information about a stimulus in spike times relative to the oscillatory 'clock'(16). Here we study the decoding of these coherent oscillatory signals. We identify a population of neurons downstream from the odour-activated, synchronized neuronal assemblies. These downstream neurons show odour responses whose specificity is degraded when their inputs are desynchronized. This degradation of selectivity consists of the appearance of responses to new odours and a loss of discrimination of spike trains evoked by different odours. Such loss of information is never observed in the upstream neurons whose activity is desynchronized. These results indicate that information encoded in time across ensembles of neurons converges onto single neurons downstream in the pathway.	CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA	California Institute of Technology	Laurent, G (corresponding author), CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA.	laurentg@cco.caltech.edu	MacLeod, Katrina/F-4595-2015; Laurent, Gilles/A-4583-2012	MacLeod, Katrina/0000-0003-0632-1158; Laurent, Gilles/0000-0002-2296-114X				ABBOTT LF, 1994, Q REV BIOPHYS, V27, P291, DOI 10.1017/S0033583500003024; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; BACON JP, 1977, BRAIN RES, V138, P359, DOI 10.1016/0006-8993(77)90753-3; Fries P, 1997, P NATL ACAD SCI USA, V94, P12699, DOI 10.1073/pnas.94.23.12699; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; HOMBERG U, 1984, J COMP PHYSIOL, V154, P825, DOI 10.1007/BF00610683; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; Leitch B, 1996, J COMP NEUROL, V372, P487; Li YS, 1997, J COMP NEUROL, V387, P631; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; Roelfsema PR, 1996, J COGNITIVE NEUROSCI, V8, P603, DOI 10.1162/jocn.1996.8.6.603; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SPARKS DL, 1990, COLD SH Q B, V55, P805; Stopfer M, 1997, NATURE, V390, P70, DOI 10.1038/36335; Victor JD, 1997, NETWORK-COMP NEURAL, V8, P127, DOI 10.1088/0954-898X/8/2/003; von der Malsburg C, 1981, CORRELATION THEORY B; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0	25	199	204	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					693	698		10.1038/27201	http://dx.doi.org/10.1038/27201			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790189				2022-12-28	WOS:000076472600051
J	Taylor, T; Specker, B; Robbins, J; Sperling, M; Ho, M; Ain, K; Bigos, ST; Brierley, J; Cooper, D; Haugen, B; Hay, I; Hertzberg, V; Klein, I; Klein, H; Ladenson, P; Nishiyama, R; Ross, D; Sherman, S; Maxon, HR				Taylor, T; Specker, B; Robbins, J; Sperling, M; Ho, M; Ain, K; Bigos, ST; Brierley, J; Cooper, D; Haugen, B; Hay, I; Hertzberg, V; Klein, I; Klein, H; Ladenson, P; Nishiyama, R; Ross, D; Sherman, S; Maxon, HR			Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma	ANNALS OF INTERNAL MEDICINE			English	Article						thyroid neoplasms; carcinoma, papillary, follicular; outcome and process assessment (health care); thyroidectomy; radiotherapy	EXTERNAL RADIOTHERAPY; NERVE PALSY; CANCER; IMPACT; OPERATIONS; THERAPY; SURGERY	Background: Treatment of differentiated thyroid cancer has been studied for many years, but the benefits of extensive initial thyroid surgery and the addition of radioiodine therapy or external radiation therapy remain controversial. Objective: To determine the relations among extent of surgery, radioiodine therapy, and external radiation therapy in the treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Design: Analysis of data from a multicenter study. Setting: 14 institutions in the United States and Canada participating in the National Thyroid Cancer Treatment Cooperative Study Registry. Patients: 385 patients with high-risk thyroid cancer (303 with papillary carcinoma and 82 with follicular carcinoma). Measurements: Death, disease progression, and disease-free survival. Results: Total or near-total thyroidectomy was done in 85.3% of patients with papillary carcinoma and 71.3% of patients with follicular cancer. Overall surgical complication rate was 14.3%. Total or near-total thyroidectomy improved overall survival (risk ratio [RR], 0.37 [95% CI, 0.18 to 0.75]) but not cancer-specific mortality, progression, or disease-free survival in patients with papillary cancer. No effect of extent of surgery was seen in patients with follicular thyroid cancer. Postoperative iodine-131 was given to 85.4% of patients with papillary cancer and 79.3% of patients with follicular cancer. In patients with papillary cancer, radioiodine therapy was associated with improvement in cancer-specific mortality (RR, 0.30 [CI, 0.09 to 0.93 by multivariate analysis only]) and progression (RR, 0.30 [CI, 0.13 to 0.72]). When tall-cell variants were excluded, the effect on outcome was not significant. After radioiodine therapy, patients with follicular thyroid cancer had improvement in overall mortality (RR, 0.17 [CI, 0.06 to 0.47]), cancer-specific mortality (RR, 0.12 [CI, 0.04 to 0.42]), progression (RR, 0.21 [CI, 0.08 to 0.56]), and disease-free survival (RR, 0.29 [CI, 0.08 to 1.01]). External radiation therapy to the neck was given to 18.5% of patients and was not associated with improved survival, lack of progression, or disease-free survival. Conclusions: This study supports improvement in overall and cancer-specific mortality among patients with papillary and follicular thyroid cancer after postoperative iodine-131 therapy. Radioiodine therapy was also associated with improvement in progression in patients with papillary cancer and improvement in progression and disease-free survival in patients with follicular carcinoma.	Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; Georgetown Univ, Med Ctr, Washington, DC 20007 USA; NIH, Bethesda, MD 20892 USA; Univ Kentucky, Med Ctr, Dept Med, Lexington, KY USA; Maine Med Ctr, Dept Pathol, Scarborough, ME 04074 USA; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; Sinai Hosp, Div Endocrine, Baltimore, MD 21215 USA; Univ Colorado, Hlth Sci Ctr, Div Endocrinol, Denver, CO 80262 USA; Mayo Clin & Mayo Fdn, Div Endocrinol W18, Rochester, MN 55905 USA; N Shore Univ Hosp, Manhasset, NY USA; Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; Massachusetts Gen Hosp, Thyroid Unit ACC730, Boston, MA 02114 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; Maine Med Ctr, Dept Pathol, Scarborough, ME 04074 USA	University System of Ohio; University of Cincinnati; Georgetown University; National Institutes of Health (NIH) - USA; University of Kentucky; Maine Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Sinai Hospital of Baltimore; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Mayo Clinic; Northwell Health; North Shore University Hospital; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Massachusetts General Hospital; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Maine Medical Center	Taylor, T (corresponding author), Bayer Pharmaceut, Metab Dept, 400 Morgan Lane, West Haven, CT 06516 USA.		Hay, Ian/AAH-8508-2019	Hay, Ian/0000-0002-5527-3909; Sherman, Steven/0000-0002-3079-5153				BENKER G, 1990, CANCER-AM CANCER SOC, V65, P1517, DOI 10.1002/1097-0142(19900401)65:7<1517::AID-CNCR2820650711>3.0.CO;2-K; CARCANGIU ML, 1985, CANCER, V55, P805, DOI 10.1002/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO;2-Z; DEGROOT LJ, 1991, SURGERY, V110, P936; DEGROOT LJ, 1990, J CLIN ENDOCR METAB, V71, P414, DOI 10.1210/jcem-71-2-414; DEMEURE MJ, 1990, ENDOCRIN METAB CLIN, V19, P663, DOI 10.1016/S0889-8529(18)30316-5; Farahati J, 1996, CANCER, V77, P172, DOI 10.1002/(SICI)1097-0142(19960101)77:1<172::AID-CNCR28>3.0.CO;2-1; GRANT CS, 1988, SURGERY, V104, P954; HOIE J, 1988, CANCER, V61, P1, DOI 10.1002/1097-0142(19880101)61:1<1::AID-CNCR2820610102>3.0.CO;2-R; JATZKO GR, 1994, SURGERY, V115, P139; JENSEN MH, 1990, OTOLARYNG HEAD NECK, V102, P51, DOI 10.1177/019459989010200109; MARTENSSON H, 1985, ARCH SURG-CHICAGO, V120, P475; MAXON HR, 1990, ENDOCRIN METAB CLIN, V19, P685, DOI 10.1016/S0889-8529(18)30317-7; MAZZAFERRI EL, 1991, MAYO CLIN PROC, V66, P105, DOI 10.1016/S0025-6196(12)61179-3; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; MAZZAFERRI EL, 1981, AM J MED, V70, P511, DOI 10.1016/0002-9343(81)90573-8; PASIEKA JL, 1993, CAN J SURG, V36, P298; ROBBINS J, 1991, ANN INTERN MED, V115, P133, DOI 10.7326/0003-4819-115-2-133; ROSSI RL, 1988, ARCH SURG-CHICAGO, V123, P569; SAMAAN NA, 1992, J CLIN ENDOCR METAB, V75, P714, DOI 10.1210/jc.75.3.714; SESSIONS RB, 1993, MED CLIN N AM, V77, P517, DOI 10.1016/S0025-7125(16)30237-1; SIMPSON WJ, 1988, INT J RADIAT ONCOL, V14, P1063, DOI 10.1016/0360-3016(88)90381-1; STAUNTON MD, 1976, BRIT J SURG, V63, P253, DOI 10.1002/bjs.1800630402; TUBIANA M, 1985, CANCER, V55, P2062, DOI 10.1002/1097-0142(19850501)55:9+<2062::AID-CNCR2820551406>3.0.CO;2-O; VICKERY AL, 1987, CANCER, V60, P2587, DOI 10.1002/1097-0142(19871201)60:11<2587::AID-CNCR2820601102>3.0.CO;2-O; WONG JB, 1990, ENDOCRIN METAB CLIN, V19, P741, DOI 10.1016/S0889-8529(18)30319-0	25	119	126	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					622	+		10.7326/0003-4819-129-8-199810150-00007	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786809				2022-12-28	WOS:000076431800004
J	Zhang, ZH; Hartmann, H; Do, VM; Abramowski, D; Sturchler-Pierrat, C; Staufenbiel, M; Sommer, B; van de Wetering, M; Clevers, H; Saftig, P; De Strooper, B; He, X; Yankner, BA				Zhang, ZH; Hartmann, H; Do, VM; Abramowski, D; Sturchler-Pierrat, C; Staufenbiel, M; Sommer, B; van de Wetering, M; Clevers, H; Saftig, P; De Strooper, B; He, X; Yankner, BA			Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis	NATURE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; MISSENSE MUTATIONS; PROTEIN; GENE; CELLS; LOCALIZATION; PLAQUES; BRAIN; MICE	Mutations of the presenilin-1 gene are a major cause of familial early-onset Alzheimer's disease(1-4). Presenilin-1 can associate with members of the catenin family of signalling proteins, but the significance of this association is unknown(5,6). Here we show that presenilin-1 forms a complex with beta-catenin in vivo that increases beta-catenin stability, Pathogenic mutations in the presenilin-1 gene reduce the ability of presenilin-1 to stabilize beta-catenin, and lead to increased degradation of beta-catenin in the brains of transgenic mice, Moreover, beta-catenin levels are markedly reduced in the brains of Alzheimer's disease patients with presenilin-1 mutations. Loss of beta-catenin signalling increases neuronal vulnerability to apoptosis induced by amyloid-beta protein, Thus, mutations in presenilin-1 may increase neuronal apoptosis by altering the stability of beta-catenin, predisposing individuals to early-onset Alzheimer's disease.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Novartis Pharma Ltd, Preclin Res, CH-4002 Basel, Switzerland; Univ Utrecht Hosp, Dept Immunol, NL-3508 GA Utrecht, Netherlands; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Katholieke Univ Leuven VIB, Ctr Human Genet, B-3000 Leuven, Belgium	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Novartis; Utrecht University; Utrecht University Medical Center; University of Gottingen; Flanders Institute for Biotechnology (VIB); KU Leuven	Yankner, BA (corresponding author), Harvard Univ, Sch Med, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.	Yankner@A1.tch.harvard.edu	De Strooper, Bart/F-6507-2012; Saftig, Paul/A-7966-2010; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; 				Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Busciglio J, 1997, J NEUROSCI, V17, P5101, DOI 10.1523/jneurosci.17-13-05101.1997; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 1997, J NEUROSCI, V17, P4212; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	28	457	501	2	15	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 15	1998	395	6703					698	702		10.1038/27208	http://dx.doi.org/10.1038/27208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790190				2022-12-28	WOS:000076472600052
J	Lin, SY; Chow, E; Hietala, V; Villeneuve, PR; Joannopoulos, JD				Lin, SY; Chow, E; Hietala, V; Villeneuve, PR; Joannopoulos, JD			Experimental demonstration of guiding and bending of electromagnetic waves in a photonic crystal	SCIENCE			English	Article							GUIDES	The routing and interconnection of optical signals through narrow channels and around sharp corners are important for large-scale all-optical circuit applications. A recent computational result suggests that photonic crystals may offer a novel way of achieving this goal by providing a mechanism for guiding light that is fundamentally different from traditional index guiding. Waveguiding in a photonic crystal and near 100 percent transmission of electromagnetic waves around sharp 90 degree corners were observed experimentally. Bending radii were made smaller than one wavelength.	Sandia Natl Labs, Albuquerque, NM 87185 USA; MIT, Dept Phys, Cambridge, MA 02139 USA	United States Department of Energy (DOE); Sandia National Laboratories; Massachusetts Institute of Technology (MIT)	Lin, SY (corresponding author), Sandia Natl Labs, POB 5800, Albuquerque, NM 87185 USA.	slin@sandia.gov	Joannopoulos, John D/E-6401-2013					CHEN JC, 1995, MICROW OPT TECHN LET, V10, P319, DOI 10.1002/mop.4650100605; HO KM, 1990, PHYS REV LETT, V65, P3152, DOI 10.1103/PhysRevLett.65.3152; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; LEUNG KM, 1990, PHYS REV LETT, V65, P2646, DOI 10.1103/PhysRevLett.65.2646; LIN SY, 1993, OPT LETT, V18, P1666, DOI 10.1364/OL.18.001666; MARCATILI EA, 1969, BELL SYST TECH J, V48, P2103, DOI 10.1002/j.1538-7305.1969.tb01167.x; Mekis A, 1996, PHYS REV LETT, V77, P3787, DOI 10.1103/PhysRevLett.77.3787; SIGALAS MM, P 14 ANN REV PROGR A, P144; SOZUER HS, 1993, J OPT SOC AM B, V10, P296, DOI 10.1364/JOSAB.10.000296; Taubes G, 1997, SCIENCE, V278, P1709, DOI 10.1126/science.278.5344.1709; WU C, 1996, SCI NEWS, V150, P309; YABLONOVITCH E, 1989, PHYS REV LETT, V63, P1950, DOI 10.1103/PhysRevLett.63.1950; Yeh C., 1994, APPL PHOTONICS, V1st, P337	14	662	699	8	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1998	282	5387					274	276		10.1126/science.282.5387.274	http://dx.doi.org/10.1126/science.282.5387.274			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765148	Green Submitted			2022-12-28	WOS:000076370200041
J	Porter, R				Porter, R			Can the stigma of mental illness be changed?	LANCET			English	Article									Wellcome Inst Hist Med, London NW1 2BE, England	University of London; University College London	Porter, R (corresponding author), Wellcome Inst Hist Med, 183 Euston Rd, London NW1 2BE, England.		Corbin, Melody/B-8937-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Gilman Sander, 1988, DIS REPRESENTATION M; Shorter E., 1992, PARALYSIS FATIGUE HI; Sontag S., 1979, ILLNESS METAPHOR	3	21	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1049	1050		10.1016/S0140-6736(98)07155-4	http://dx.doi.org/10.1016/S0140-6736(98)07155-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759765				2022-12-28	WOS:000076121800044
J	Sidhu, H; Hoppe, B; Hesse, A; Tenbrock, K; Bromme, S; Rietschel, E; Peck, AB				Sidhu, H; Hoppe, B; Hesse, A; Tenbrock, K; Bromme, S; Rietschel, E; Peck, AB			Absence of Oxalobacter formigenes in cystic fibrosis patients: A risk factor for hyperoxaluria	LANCET			English	Article							OXALATE DEGRADATION; UROLITHIASIS; SATURATION; CHILDREN; HUMANS	Background Patients with cystic fibrosis have an increased risk of hyperoxaluria, and of subsequent nephrocalcinosis and calcium-oxalate urolithiasis. Oxalate homoeostasis is controlled, in part, by the intestinal bacterium, Oxalobacter formigenes, The loss of this bacterium from the gut flora is associated with an increased risk of hyperoxaluria and calcium-oxalate urolithiasis. We investigated whether the absence of O formigenes and the presence of hyperoxaluria are correlated in cystic fibrosis (CF) patients. Methods Stool specimens from 43 patients with CF aged 3-9 years and from 21 similarly aged healthy volunteers were examined for O formigenes by culture and DNA analysis. At the same time, 24 h urine samples were collected and analysed for oxalate and other factors that promote or inhibit stone formation. Findings 15 (71%) of 21 healthy volunteers but only seven (16%) of 43 CF patients were colonised with O formigenes. Detection of O formigenes in six of these seven patients required DNA-based identification, suggesting low numbers of colony-forming units, and the CF patient with normal numbers of O formigenes was the only one of the 43 patients who had not been treated with antibiotics. All seven CF patients colonised with O formigenes had normal urinary oxalate levels, but 19 (53%) of 36 patients not colonised with O formigenes were hyperoxaluric, with the most severe hyperoxaluria occurring in young patients. Interpretation Absence of O formigenes from the intestinal tract of CF patients appears to lead to increased absorption of oxalate, thereby increasing the risk of hyperoxaluria and its complications (eg, nephrocalcinosis, urolithiasis), Prolonged widespread use of antibiotics, and alterations of the gastrointestinal tract that occur in CF, may induce a permanent decolonisation in CF patients.	Univ Florida, Coll Med, Dept Pathol & Lab Med, Gainesville, FL 32610 USA; Ixion Biotechnol, Div Oxalate Res, Alachua, FL USA; Northwestern Univ, Childrens Mem Hosp, Div Nephrol, Chicago, IL 60614 USA; Univ Bonn, Div Expt Urol, D-5300 Bonn, Germany; Univ Halle Wittenberg, Childrens Hosp, Halle, Germany; Univ Cologne, Childrens Hosp, Cologne, Germany	State University System of Florida; University of Florida; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; University of Bonn; Martin Luther University Halle Wittenberg; University of Cologne	Peck, AB (corresponding author), Univ Florida, Coll Med, Dept Pathol & Lab Med, POB 100275, Gainesville, FL 32610 USA.	peck.pathology@mail.health.ufl.edu						ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; ALLISON MJ, 1986, J NUTR, V116, P455, DOI 10.1093/jn/116.3.455; ARGENZIO RA, 1988, J NUTR, V118, P787, DOI 10.1093/jn/118.6.787; BENTUR L, 1990, J PEDIATR-US, V116, P556, DOI 10.1016/S0022-3476(05)81602-6; BINDER HJ, 1974, GASTROENTEROLOGY, V67, P441; BOHLES H, 1982, HELV PAEDIATR ACTA, V37, P267; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DOANE LT, 1989, NUTR RES, V9, P957, DOI 10.1016/S0271-5317(89)80056-9; DOBBINS JW, 1977, NEW ENGL J MED, V296, P298, DOI 10.1056/NEJM197702102960602; GOLDKIND L, 1986, GASTROENTEROLOGY, V90, P1431; GOLDKIND L, 1985, AM J GASTROENTEROL, V80, P860; HAN J, 1985, J TONGJI MED U, V15, P249; HATCH M, 1996, CALCIUM OXALATE BIOL, P217; HESSE A, 1986, CLIN CHIM ACTA, V160, P79, DOI 10.1016/0009-8981(86)90126-9; Hoppe B, 1997, J UROLOGY, V158, P557, DOI 10.1016/S0022-5347(01)64550-6; Hoppe B, 1998, PEDIATR NEPHROL, V12, P275, DOI 10.1007/s004670050452; Joseph DB, 1996, PEDIATRICS, V98, P108; KATZ SM, 1988, NEW ENGL J MED, V319, P263, DOI 10.1056/NEJM198808043190502; KLEINSCHMIDT K, 1993, UROLITHIASIS, V2, P439; Matthews LA, 1996, J UROLOGY, V155, P1563, DOI 10.1016/S0022-5347(01)66126-3; MODIGLIANI R, 1978, SCAND J GASTROENTERO, V13, P187, DOI 10.3109/00365527809181746; PARRIES G, 1995, UROLITHIASIS LATE CO, P393; ROBSON AM, 1971, J PEDIATR-US, V79, P42, DOI 10.1016/S0022-3476(71)80056-2; SEFTEL A, 1990, UROL CLIN N AM, V17, P159; Sidhu H, 1997, MOL DIAGN, V2, P89, DOI 10.1016/S1084-8592(97)80015-X; STAUFFER JQ, 1972, NEW ENGL J MED, V287, P412; STRANDVIK B, 1993, ACTA PAEDIATR, V82, P306, DOI 10.1111/j.1651-2227.1993.tb12667.x; WERNESS PG, 1985, J UROLOGY, V134, P1242, DOI 10.1016/S0022-5347(17)47703-2	28	171	172	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1026	1029		10.1016/S0140-6736(98)03038-4	http://dx.doi.org/10.1016/S0140-6736(98)03038-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759746				2022-12-28	WOS:000076121800012
J	Hrobjartsson, A; Gotzsche, PC; Gluud, C				Hrobjartsson, A; Gotzsche, PC; Gluud, C			The controlled clinical trial turns 100 years: Fibiger's trial of serum treatment of diphtheria	BRITISH MEDICAL JOURNAL			English	Article									Copenhagen Univ Hosp, HS Kommunehosp, Inst Prevent Med, Copenhagen Trial Unit,Ctr Clin Intervent Res, DK-1399 Copenhagen K, Denmark; HS Rigshosp, Nordic Cochrane Ctr, DK-2200 Copenhagen, Denmark	University of Copenhagen; Rigshospitalet	Gluud, C (corresponding author), Copenhagen Univ Hosp, HS Kommunehosp, Inst Prevent Med, Copenhagen Trial Unit,Ctr Clin Intervent Res, DK-1399 Copenhagen K, Denmark.		Gluud, Christian/AAY-1027-2021; Gluud, Christian/HGB-3191-2022	Gluud, Christian/0000-0002-8861-0799; 				[Anonymous], 1948, BMJ-BRIT MED J, V2, P769; BULL J P, 1959, J Chronic Dis, V10, P218, DOI 10.1016/0021-9681(59)90004-9; Clarke M, 1996, BMJ-BRIT MED J, V312, P1298, DOI 10.1136/bmj.312.7041.1298a; CLEMMESEN J, 1978, ACTA PATHOL MICROB S, V270, P1; Diehl HS, 1938, J AMER MED ASSOC, V111, P1168, DOI 10.1001/jama.1938.02790390024008; Fibiger J, 1898, HOSPITALSTIDENDE, V6, P309; Fisher R. A, 1925, STAT METHODS RES WOR, V1, DOI DOI 10.1111/J.2397-2335.1926.TB01837.X; GOTZSCHE PC, 1997, BIBL LAEGER, V189, P143; HACKING I, 1988, ISIS, V79, P427, DOI 10.1086/354775; HEIBERG P, 1897, BIBL LAEGER, V7, P1; LILIENFELD AM, 1982, B HIST MED, V56, P1; Pearson K, 1900, PHILOS MAG, V50, P157, DOI 10.1080/14786440009463897; Pierce CS., 1885, MEMOIRS NATL ACAD SC, V3, P73; RASCH G, 1951, Ugeskr Laeger, V113, P1625; Richet C, 1884, REV PHILOS FRANCE ET, V18, P609; ROUX ME, 1894, ANN I PASTEUR, V8, P640; Sorensen ST., 1896, HOSPITALSTIDENDE, V4, P621; STOLLEY PD, 1992, ANN INTERN MED, V116, P765, DOI 10.7326/0003-4819-116-9-765; TYLOR DB, 1946, AM J PYSIOL, V146, P458; Van Helmont J. A., 1662, ORIATRIKE PHYSICK RE, P526; WANSCHER O, 1877, DIPHTHERITIS CROUP S	21	34	37	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1243	1245		10.1136/bmj.317.7167.1243	http://dx.doi.org/10.1136/bmj.317.7167.1243			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794873	Green Published			2022-12-28	WOS:000076963000038
J	Kinmonth, AL; Woodcock, A; Griffin, S; Spiegal, N; Campbell, MJ				Kinmonth, AL; Woodcock, A; Griffin, S; Spiegal, N; Campbell, MJ		Diabetes Care Diagnosis Res Team	Randomised controlled trial of patient centred care of diabetes in general practice: impact on current wellbeing and future disease risk	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY; PARTICIPATION; INTERVENTIONS; COMMUNICATION; MELLITUS; DIETARY	Objective To assess the effect of additional training of practice nurses and general practitioners in patient centred care on the lifestyle and psychological and physiological status of patients with newly diagnosed type 2 diabetes. Design Pragmatic parallel group design, with randomisation between practice teams to routine care (comparison group) or routine care plus additional training (intervention group); analysis at one year, allowing for practice effects and stratifiers; self reporting by patients on communication with practitioners, satisfaction with treatment, style of care, and lifestyle. Setting 41 practices (21 in intervention group, 20 in comparison group) in a health region in southern England. Subjects 250/360 patients (aged 30-70 years) diagnosed with type 2 diabetes and completing follow up at one year (142 in intervention group, 108 in comparison group). Intervention 1.5 days' group training for the doctors and nurses-introducing evidence for and skills of patient centred care and a patient held booklet encouraging questions. Main outcome measures Quality of life, wellbeing, haemoglobin A(1c) and lipid concentrations, blood pressure, body mass index (kg/m(2)). Results Compared with patients in the C group, those in the intervention group reported better communication with the doctors (odds ratio 2.8; 95% confidence interval 1.8 to 4.3) and greater treatment satisfaction (1.6; 1.1 to 2.5) and wellbeing (difference in means (d) 2.8; 0.4 to 5.2). However, their body mass index was significantly higher (d = 2.0; 0.3 to 3.8), as were triglyceride concentrations (d = 0.4 mmol/l; 0.07 to 0.73 mmol/l), whereas knowledge scores were lower (d = -2.74; -0.23 to -5.25). Differences in lifestyle and glycaemic control were not significant Conclusions The findings suggest greater attention to the consultation process than to preventive care among trained practitioners; those committed to achieving the benefits of patient centred consulting should not lose the focus on disease management	Univ Southampton, Fac Hlth Med & Biol Sci, Aldermoor Hlth Ctr, Primary Med Care Grp, Southampton SO16 5ST, Hants, England; Willowbank Spicers, Alton GU4 2SJ, Hants, England	University of Southampton	Kinmonth, AL (corresponding author), Univ Forvie Site, Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England.	alk25@medschl.cam.ac.uk	Griffin, Simon J/K-3106-2013	Griffin, Simon J/0000-0002-2157-4797	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1995, Diabetes, V44, P1249; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bradley C., 1994, HDB PSYCHOL DIABETES, V1; *BRIT DIAB ASS, 1994, BAL BEG START OUT DI; DAVIS WK, 1988, DIABETES CARE, V11, P538, DOI 10.2337/diacare.11.7.538; EVANS BJ, 1987, BRIT J MED PSYCHOL, V60, P373, DOI 10.1111/j.2044-8341.1987.tb02756.x; GATLING W, 1988, DIABETIC MED, V5, P343, DOI 10.1111/j.1464-5491.1988.tb01002.x; GODIN G, 1985, Canadian Journal of Applied Sport Sciences, V10, P141; Green LW., 1995, STUDY PARTICIPATORY; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; Katz J., 1984, SILENT WORLD DOCTOR; Kinmonth AL, 1996, PATIENT EDUC COUNS, V29, P75, DOI 10.1016/0738-3991(96)00936-6; Little P, 1996, FAM PRACT, V13, P477, DOI 10.1093/fampra/13.5.477; MARTEAU TM, 1988, BRIT J CLIN PSYCHOL, V27, P381, DOI 10.1111/j.2044-8260.1988.tb00803.x; MELTON LJ, 1983, DIABETES CARE, V6, P75, DOI 10.2337/diacare.6.1.75; MURPHY E, 1992, THESIS U SOUTHAMPTON; PADGETT D, 1988, J CLIN EPIDEMIOL, V41, P1007, DOI 10.1016/0895-4356(88)90040-6; ROE L, 1994, FAM PRACT, V11, P375, DOI 10.1093/fampra/11.4.375; ROTER DL, 1977, HEALTH EDUC QUART, V5, P281, DOI 10.1177/109019817700500402; Roter DL, 1989, COMMUNICATING MED PA; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; Stewart M, 1995, PATIENT CTR MED TRAN; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; Sullivan FM, 1996, LANCET, V348, P941, DOI 10.1016/S0140-6736(96)05219-1; THOMPSON SC, 1990, HEALTH PSYCHOL, V9, P390, DOI 10.1037/0278-6133.9.4.390; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WOODCOCK A, IN PRESS PATIENT ED	27	324	329	0	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	1998	317	7167					1202	1208		10.1136/bmj.317.7167.1202	http://dx.doi.org/10.1136/bmj.317.7167.1202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138GF	9794859	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000076963000024
J	Shukla, J				Shukla, J			Predictability in the midst of chaos: A scientific basis for climate forecasting	SCIENCE			English	Article								The Earth's atmosphere is generally considered to be an example of a chaotic system that is sensitively dependent on initial conditions, It is shown here that certain regions of the atmosphere are an exception, Wind patterns and rainfall in certain regions of the tropics are so strongly determined by the temperature of the underlying sea surface that they do not show sensitive dependence on the initial conditions of the atmosphere. Therefore, it should be possible to predict the large-scale tropical circulation and rainfall for as Long as the ocean temperature can be predicted. If changes in tropical Pacific sea-surface temperature are quite Large, even the extratropical circulation over some regions, especially over the Pacific-North American sector, is predictable.	George Mason Univ, Fairfax, VA 22030 USA; Inst Global & Environm & Soc, Ctr Ocean Land Atmosphere, Beltsville, MD 20705 USA	George Mason University	Shukla, J (corresponding author), George Mason Univ, Fairfax, VA 22030 USA.							BARNETT TP, 1995, J CLIMATE, V8, P1005, DOI 10.1175/1520-0442(1995)008<1005:MCCF>2.0.CO;2; BENGTSSON L, 1993, SCIENCE, V261, P1026, DOI 10.1126/science.261.5124.1026; BRANKOVIC C, 1994, J CLIMATE, V7, P217, DOI 10.1175/1520-0442(1994)007<0217:POSAV>2.0.CO;2; Charney J.G., 1981, MONSOON DYNAMICS, P99, DOI [10.1017/cbo9780511897580.009, DOI 10.1017/CBO9780511897580.009]; KERR RA, 1994, SCIENCE, V266, P544, DOI 10.1126/science.266.5185.544; Kirtman BP, 1997, MON WEATHER REV, V125, P1231, DOI 10.1175/1520-0493(1997)125<1231:COAMWS>2.0.CO;2; Kumar A, 1997, J CLIMATE, V10, P83, DOI 10.1175/1520-0442(1997)010<0083:IAIOTO>2.0.CO;2; Latif M, 1998, J GEOPHYS RES-OCEANS, V103, P14375, DOI 10.1029/97JC03413; LORENZ EN, 1963, J ATMOS SCI, V20, P130, DOI 10.1175/1520-0469(1963)020<0130:DNF>2.0.CO;2; LORENZ EN, 1993, CHAOS, P181; *NAT RES COUNC, 1996, ACC LEG TOGA PROGR, P66; SEAGER R, 1989, J PHYS OCEANOGR, V19, P419, DOI 10.1175/1520-0485(1989)019<0419:MTPSST>2.0.CO;2; SHUKLA J, 1997, COLA TECH REP, V50, P1; SHUKLA J, 1981, ECMWF WORKSH REP, V21; Trenberth KE, 1998, J GEOPHYS RES-OCEANS, V103, P14291, DOI 10.1029/97JC01444; Xie PP, 1996, J CLIMATE, V9, P840, DOI 10.1175/1520-0442(1996)009<0840:AOGMPU>2.0.CO;2	16	327	348	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					728	731		10.1126/science.282.5389.728	http://dx.doi.org/10.1126/science.282.5389.728			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784127				2022-12-28	WOS:000076607500046
J	Berger, A				Berger, A			Science commentary: Vaginal viricides - Another way to tackle HIV transmission	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1053	1053						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774291				2022-12-28	WOS:000076577200027
J	Driscoll, NW; Haug, GH				Driscoll, NW; Haug, GH			A short circuit in thermohaline circulation: A cause for northern hemisphere glaciation?	SCIENCE			English	Article							ARCTIC-OCEAN; SEA; GREENLAND; TECTONICS; CLIMATE; BALANCE; HISTORY; OXYGEN	The cause of Northern Hemisphere glaciation about 3 million years ago remains uncertain. Closing the Panamanian Isthmus increased thermohaline circulation and enhanced moisture supply to high Latitudes, but the accompanying heat would have inhibited ice growth. One possible solution is that enhanced moisture transported to Eurasia also enhanced freshwater delivery to the Arctic via Siberian rivers. Freshwater input to the Arctic would facilitate sea ice formation, increase the albedo, and isolate the high heat capacity of the ocean from the atmosphere. It would also act as a negative feedback on the efficiency of the "conveyor belt" heat pump.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Univ Kiel, Forschungszentrum Marine Geowissen, D-24148 Kiel, Germany	Woods Hole Oceanographic Institution; University of Kiel	Driscoll, NW (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.							AAGAARD K, 1991, J GEOPHYS RES-OCEANS, V96, P20433, DOI 10.1029/91JC02013; Arthur M.A., 1989, P ODP SCI RESULTS, V105, P957, DOI DOI 10.2973/ODP.PROC.SR.105.118.1989; Broecker W.S., 1991, OCEANOGRAPHY, V4, P79, DOI DOI 10.5670/0CEAN0G.1991.07; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582; BROECKER WS, 1987, NAT HIST MAG, V97, P74; Cattle H., 1985, POLAR REC GR BRIT, V22, P485, DOI [10.1017/S0032247400005933, DOI 10.1017/S0032247400005933]; CHAMBERLAIN TC, 1906, J GEOL, V10, P363; DICKSON RR, 1988, PROG OCEANOGR, V20, P103, DOI 10.1016/0079-6611(88)90049-3; FLETCHER JO, 1978, POLAR RES, V3; HARRISON MT, 1992, SCIENCE, V255, P1663; Haug GH, 1998, NATURE, V393, P673, DOI 10.1038/31447; Hay WW, 1996, GEOL RUNDSCH, V85, P409, DOI 10.1007/BF02369000; Imbrie J, 1992, PALEOCEANOGRAPHY, V7, P701, DOI 10.1029/92PA02253; Kassens H., 1998, EOS T AM GEOPHYS UN, V79, P317, DOI DOI 10.1029/98EO00234; KEIGWIN L, 1982, SCIENCE, V217, P350, DOI 10.1126/science.217.4557.350; KEIGWIN LD, 1987, INITIAL REP DEEP SEA, V94, P911; LASKAR J, 1993, ASTRON ASTROPHYS, V270, P522; Macdonald AM, 1996, NATURE, V382, P436, DOI 10.1038/382436a0; Maier-Reimer E, 1990, PALEOCEANOGRAPHY, V5, P349, DOI 10.1029/PA005i003p00349; Manabe S, 1988, J CLIMATE, V1, P841, DOI 10.1175/1520-0442(1988)001<0841:TSEOAC>2.0.CO;2; MHYRE J, 1992, P ODP INIT REP, V151, P1; Mikolajewicz U, 1997, PALEOCEANOGRAPHY, V12, P429, DOI 10.1029/96PA03542; Miller KG, 1987, PALEOCEANOGRAPHY, V2, P1, DOI 10.1029/PA002i001p00001; MOLNAR P, 1975, SCIENCE, V189, P419, DOI 10.1126/science.189.4201.419; PARFENOV LM, 1995, TECTONICS, V14, P342, DOI 10.1029/94TC03088; Prell W.L., 1982, INITIAL REPORTS DEEP, P455, DOI DOI 10.2973/DSDP.PROC.68.120.1982; Raymo ME, 1989, PALEOCEANOGRAPHY, V4, P413, DOI 10.1029/PA004i004p00413; Raymo ME, 1992, PALEOCEANOGRAPHY, V7, P645, DOI 10.1029/92PA01609; Rea DK, 1998, PALEOCEANOGRAPHY, V13, P215, DOI 10.1029/98PA00123; RUDDIMAN WF, 1988, P ODP INIT REP, V108, P556; SCHLOSSER P, 1991, SCIENCE, V251, P1054, DOI 10.1126/science.251.4997.1054; SEMTNER AJ, 1984, CLIMATIC CHANGE, V6, P109, DOI 10.1007/BF00144608; Shackleton N.J., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P337, DOI 10.2973/odp.proc.sr.138.117.1995; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SHACKLETON NJ, 1984, INITIAL REP DEEP SEA, V81, P599, DOI 10.2973/dsdp.proc.81.116.1984; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; TIEDEMANN R, 1997, P ODP SCI RESULTS, V154, P299; TIEDERMANN R, 1991, THESIS U KIEL KIEL; Wust G., 1935, WISSENSCHAFTLICHE ER, P109; [No title captured]; 1997, EOS, V78, P597	41	161	169	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					436	438		10.1126/science.282.5388.436	http://dx.doi.org/10.1126/science.282.5388.436			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774262				2022-12-28	WOS:000076479600042
J	Kimura, K; Hirano, M; Kobayashi, R; Hirano, T				Kimura, K; Hirano, M; Kobayashi, R; Hirano, T			Phosphorylation and activation of 13S condensin by Cdc2 in vitro	SCIENCE			English	Article							MITOTIC CHROMOSOME CONDENSATION; TOPOISOMERASE-II; PROTEIN; SEGREGATION; CYCLE; DNA; P34(CDC2); MITOSIS; KINASE; FAMILY	13S condensin is a multisubunit protein complex essential for mitotic chromosome condensation in Xenopus egg extracts. Purified 135 condensin introduces positive supercoils into DNA in the presence of topoisomerase I and adenosine triphosphate in vitro. The supercoiling activity of 13S condensin was regulated by mitosis-specific phosphorylation. Immunodepletion, in vitro phospholylation, and peptide-mapping experiments indicated that Cdc2 is Likely to be the kinase that phosphorylates and activates 135 condensin. Multiple Cdc2 phosphorylation sites are clustered in the carboxyl-terminal domain of the XCAP-D2 (Xenopus chromosome-associated polypeptide D2) subunit. These results suggest that phosphorylation of 135 condensin by Cdc2 may trigger mitotic chromosome condensation in vitro.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Hirano, T (corresponding author), Cold Spring Harbor Lab, POB 100,Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926] Funding Source: NIH RePORTER; NCI NIH HHS [CA45508] Funding Source: Medline; NIGMS NIH HHS [GM53926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; KIMURA K, UNPUB; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; Masuda H, 1996, J CELL SCI, V109, P165; Murray A, 1993, CELL CYCLE INTRO; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SAWIN KE, 1992, J CELL SCI, V101, P303; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407	22	239	246	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					487	490		10.1126/science.282.5388.487	http://dx.doi.org/10.1126/science.282.5388.487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774278				2022-12-28	WOS:000076479600058
J	Wang, RB; Doolan, DL; Le, TP; Hedstrom, RC; Coonan, KM; Charoenvit, YP; Jones, TR; Hobart, P; Margalit, M; Ng, J; Weiss, WR; Sedegah, M; de Taisne, C; Norman, JA; Hoffman, SL				Wang, RB; Doolan, DL; Le, TP; Hedstrom, RC; Coonan, KM; Charoenvit, YP; Jones, TR; Hobart, P; Margalit, M; Ng, J; Weiss, WR; Sedegah, M; de Taisne, C; Norman, JA; Hoffman, SL			Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine	SCIENCE			English	Article							FALCIPARUM CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-FALCIPARUM; RHESUS-MONKEYS; CELL EPITOPES; PROTECTION; IMMUNIZATION; CHIMPANZEES; CANDIDATE; RESPONSES; IMMUNITY	CD8(+) cytotoxic T lymphocytes (CTLs) are critical for protection against intracellular pathogens but often have been difficult to induce by subunit vaccines in animals. DNA vaccines elicit protective CD8(+) T cell responses. Malaria-naive volunteers who were vaccinated with plasmid DNA encoding a malaria protein developed antigen-specific, genetically restricted, CD8(+) T cell-dependent CTLs. Responses were directed against all 10 peptides tested and were restricted by six human lymphocyte antigen (HLA) class I alleles. This first demonstration in healthy naive humans of the induction of CD8(+) CTLs by DNA vaccines, including CTLs that were restricted by multiple HLA alleles in the same individual, provides a foundation for further human testing of this potentially revolutionary vaccine technology.	USN, Med Res Inst, Malaria Program, Bethesda, MD 20889 USA; Henry M Jackson Fdn, Rockville, MD 20852 USA; WHO, Reg Off, Pan Amer Hlth Org, Washington, DC 20037 USA; USA, Med Res Inst Infect Dis, Div Med, Ft Detrick, MD 21701 USA; Vical, San Diego, CA 92121 USA; USN, Med Res Inst, US Dept Def, Bone Marrow Donor Program, Bethesda, MD 20889 USA; Pasteur Merieux Connaught France, F-69007 Lyon, France	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Pan American Health Organization; World Health Organization; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy	Hoffman, SL (corresponding author), USN, Med Res Inst, Malaria Program, Bethesda, MD 20889 USA.		Doolan, Denise L/F-1969-2015	Doolan, Denise/0000-0001-7354-8817				AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; BLUMTIROUVANZIAM U, 1995, J IMMUNOL, V154, P3922; Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526; Calarota S, 1998, LANCET, V351, P1320, DOI 10.1016/S0140-6736(97)09440-3; CAMPBELL JR, 1989, NUCLEIC ACIDS RES, V17, P5854, DOI 10.1093/nar/17.14.5854; Davis HL, 1996, P NATL ACAD SCI USA, V93, P7213, DOI 10.1073/pnas.93.14.7213; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Doolan DL, 1996, IMMUNOL RES, V15, P280, DOI 10.1007/BF02935313; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; DOOLAN DL, 1997, IMMUNITY, V7, P91; Fuller DH, 1996, J MED PRIMATOL, V25, P236, DOI 10.1111/j.1600-0684.1996.tb00021.x; GOOD MF, 1994, IMMUNOL LETT, V41, P95, DOI 10.1016/0165-2478(94)90114-7; Hedstrom RC, 1998, INT J MOL MED, V2, P29; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; Hoffman SL, 1997, IMMUNOL CELL BIOL, V75, P376, DOI 10.1038/icb.1997.59; Hoffman Stephen L., 1996, P35; Lanar DE, 1996, INFECT IMMUN, V64, P1666, DOI 10.1128/IAI.64.5.1666-1671.1996; LE T, UNPUB; Luke CJ, 1997, J INFECT DIS, V175, P91, DOI 10.1093/infdis/175.1.91; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; MALIK AU, UNPUB; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SEDEGAH M, 1992, J IMMUNOL, V149, P966; Tine JA, 1996, INFECT IMMUN, V64, P3833, DOI 10.1128/IAI.64.9.3833-3844.1996; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Wang RB, 1998, INFECT IMMUN, V66, P4193; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Yasutomi Y, 1996, J VIROL, V70, P678, DOI 10.1128/JVI.70.1.678-681.1996	32	639	681	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					476	480		10.1126/science.282.5388.476	http://dx.doi.org/10.1126/science.282.5388.476			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774275				2022-12-28	WOS:000076479600055
J	Zhang, Y; LeRoy, G; Seelig, HP; Lane, WS; Reinberg, D				Zhang, Y; LeRoy, G; Seelig, HP; Lane, WS; Reinberg, D			The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities	CELL			English	Article							TRANSCRIPTIONAL REPRESSION; CHROMATIN STRUCTURE; SACCHAROMYCES-CEREVISIAE; NEGATIVE REGULATOR; MI-2 AUTOANTIGEN; N-COR; YEAST; PROTEIN; RPD3; ACETYLATION	Histone acetylation and deacetylation were found to be catalyzed by structurally distinct, multisubunit complexes that mediate, respectively, activation and repression of transcription. ATP-dependent nucleosome remodeling, mediated by different multisubunit complexes, was thought to be involved only in transcription activation. Here we report the isolation of a protein complex that contains both histone deacetylation and ATP-dependent nucleosome remodeling activities. The complex contains the histone deacetylases HDAC1/2, histone-binding proteins, the dermatomyositis-specific autoantigen Mi2 beta, a polypeptide related to the metastasis-associated protein 1, and a novel polypeptide of 32 kDa. Patients with dermatomyositis have a high rate of malignancy. The finding that Mi2 beta exists in a complex containing histone deacetylase and nucleosome remodeling activities suggests a role for chromatin reorganization in cancer metastasis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucl Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Inst Immunol & Mol Genet, D-76133 Karlsruhe, Germany; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucl Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu		Zhang, Yi/0000-0002-2789-0811; Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-48518, 1F32GM19515-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AIRIO A, 1995, J RHEUMATOL, V22, P1300; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bulger M., 1994, METH MOL G, V5, P241; DeRubertis F, 1996, NATURE, V384, P589; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Harlow E., 1988, ANTIBODIES LAB MANUA; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HASSIG CA, 1997, CELL, V89, P331; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Seelig HP, 1996, ARTHRITIS RHEUM, V39, P1769, DOI 10.1002/art.1780391029; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Shorr AF, 1997, AM J MED SCI, V313, P249, DOI 10.1097/00000441-199704000-00011; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; TOH Y, 1994, J BIOL CHEM, V269, P22958; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; van Holde KE., 1989, SPRINGER SERIES MOL; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vannier D, 1996, GENETICS, V144, P1343; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	60	631	652	1	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					279	289		10.1016/S0092-8674(00)81758-4	http://dx.doi.org/10.1016/S0092-8674(00)81758-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790534	Bronze			2022-12-28	WOS:000076538300015
J	Ahmed, SH; Koob, GF				Ahmed, SH; Koob, GF			Transition from moderate to excessive drug intake: Change in hedonic set point	SCIENCE			English	Article							ADDICTION; COCAINE; TOLERANCE; DEPENDENCE; ABUSE	Differential access to cocaine self-administration produced two patterns of drug intake in rats. With 1 hour of access per session, drug intake remained low and stable. In contrast, with 6 hours of access, drug intake gradually escalated over days. After escalation, drug consumption was characterized by an increased early drug loading and an upward shift in the cocaine dose-response function, suggesting an increase in hedonic set point. After 1 month of abstinence, escalation of cocaine intake was reinstated to a higher level than before. These findings may provide an animal model for studying the development of excessive drug intake and the basis of addiction.	Scripps Res Inst, Dept Neuropharmacol, Div Psychopharmacol, La Jolla, CA 92037 USA	Scripps Research Institute	Ahmed, SH (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Div Psychopharmacol, CVN-7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		AHMED, Serge H/D-5236-2014	Ahmed, Serge/0000-0002-1225-9234	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008467, R01DA004398] Funding Source: NIH RePORTER; NIDA NIH HHS [DA08467, DA04398] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ahmed SH, 1997, PSYCHOPHARMACOLOGY, V132, P289, DOI 10.1007/s002130050347; Altman J, 1996, PSYCHOPHARMACOLOGY, V125, P285, DOI 10.1007/BF02246016; BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81; DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254; EDWARDS G, 1986, BRIT J ADDICT, V81, P171; EMMETTOGLESBY MW, 1993, DRUG ALCOHOL DEPEN, V32, P247, DOI 10.1016/0376-8716(93)90089-9; EMMETTOGLESBY MW, 1992, BEHAV PHARMACOL, V3, P193; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GOUDIE AJ, 1989, PSYCHOACTIVE DRUGS T; JOHANSON CE, 1976, PHARMACOL BIOCHEM BE, V4, P45, DOI 10.1016/0091-3057(76)90174-X; KALANT H, 1971, PHARMACOL REV, V23, P135; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; MARLATT GA, 1988, ANNU REV PSYCHOL, V39, P223, DOI 10.1146/annurev.ps.39.020188.001255; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; OBrien Cp E.R., 1986, BEHAV ANAL DRUG DEPE, P329; PICKENS R, 1978, HDB PSYCHOPHARMACOLO, P1; YOKEL RA, 1987, METHODS ASSESSING RE, P211; YOUNG SD, 1986, J ACCOUNT PUBLIC POL, V5, P5, DOI 10.1016/0278-4254(86)90003-7	22	818	836	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					298	300		10.1126/science.282.5387.298	http://dx.doi.org/10.1126/science.282.5387.298			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765157				2022-12-28	WOS:000076370200050
J	Dedysh, SN; Panikov, NS; Liesack, W; Grosskopf, R; Zhou, JZ; Tiedje, JM				Dedysh, SN; Panikov, NS; Liesack, W; Grosskopf, R; Zhou, JZ; Tiedje, JM			Isolation of acidophilic methane-oxidizing bacteria from northern peat wetlands	SCIENCE			English	Article							MONOOXYGENASE GENE-CLUSTER; METHANOTROPHIC BACTERIA; ATMOSPHERIC METHANE; CONSUMPTION; OXIDATION	Acidic northern wetlands are an important source of methane, one of the gases that contributes to global warming. Methane oxidation in the surface of these acidic wetlands can reduce the methane flux to the atmosphere up to 90 percent. Here the isolation of three methanotrophic microorganisms from three boreal forest sites is reported. They are moderately acidophilic organisms and have a soluble methane monooxygenase, In contrast to the known groups of methanotrophs, 16S ribosomal DNA sequence analysis shows that they are affiliated with the acidophilic heterotrophic bacterium Beijerinckia indica subsp. indica.	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; Russian Acad Sci, Inst Microbiol, Moscow 117811, Russia; Max Planck Inst Terr Mikrobiol, D-35043 Marburg, Germany	Michigan State University; Research Center of Biotechnology RAS; Russian Academy of Sciences; Max Planck Society	Tiedje, JM (corresponding author), Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA.	tiedjej@pilot.msu.edu	Dedysh, Svetlana/S-1655-2016	Dedysh, Svetlana/0000-0001-8903-8053; Liesack, Werner/0000-0002-9533-1552				Amaral JA, 1998, APPL ENVIRON MICROB, V64, P2397; BECKING JH, 1984, BERGEYS MANUAL SYSTE, V1, P311; CARDY DLN, 1991, MOL MICROBIOL, V5, P335, DOI 10.1111/j.1365-2958.1991.tb02114.x; Dedysh S. N., 1997, Mikrobiologiya, V66, P563; Dedysh S. N., 1997, Mikrobiologiya, V66, P569; Dedysh SN, 1998, APPL ENVIRON MICROB, V64, P922; DUNFIELD P, 1993, SOIL BIOL BIOCHEM, V25, P321, DOI 10.1016/0038-0717(93)90130-4; FELSENSTEIN J, 1993, PHYLIP VERSION 3 5C; FUNG I, 1991, J GEOPHYS RES-ATMOS, V96, P13033, DOI 10.1029/91JD01247; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; HANSON RS, 1991, PROCARYOTES, P661; Hein R, 1997, GLOBAL BIOGEOCHEM CY, V11, P43, DOI 10.1029/96GB03043; IMHOFF JF, 1991, PROCARYOTES, V2, P2141; KHALIL MAK, 1985, ATMOS ENVIRON, V19, P397, DOI 10.1016/0004-6981(85)90161-1; KING GM, 1992, ADV MICROB ECOL, V12, P431; KRUMHOLZ LR, 1995, FEMS MICROBIOL ECOL, V18, P215, DOI 10.1111/j.1574-6941.1995.tb00178.x; LIESACK W, 1994, INT J SYST BACTERIOL, V44, P753, DOI 10.1099/00207713-44-4-753; Maidak BL, 1996, NUCLEIC ACIDS RES, V24, P82, DOI 10.1093/nar/24.1.82; Matthews E, 1987, GLOBAL BIOGEOCHEM CY, V1, P61, DOI 10.1029/GB001i001p00061; McDonald IR, 1996, FEMS MICROBIOL ECOL, V21, P197, DOI 10.1111/j.1574-6941.1996.tb00347.x; MCDONALD IR, 1995, APPL ENVIRON MICROB, V61, P116, DOI 10.1128/AEM.61.1.116-121.1995; McDonald IR, 1997, APPL ENVIRON MICROB, V63, P1898, DOI 10.1128/AEM.63.5.1898-1904.1997; PANIKOV NS, 1993, J ECOL CHEM, V1, P7; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; Strunk O, 1996, ARB SOFTWARE ENV SEQ; SUNDH I, 1995, FEMS MICROBIOL ECOL, V18, P103, DOI 10.1111/j.1574-6941.1995.tb00167.x; Wise MG, 1997, APPL ENVIRON MICROB, V63, P1505, DOI 10.1128/AEM.63.4.1505-1514.1997; *WORLD MET ORG WDC, 1997, 4 WORLD MET ORG WDCG, P47; YAVITT JB, 1990, SOIL BIOL BIOCHEM, V22, P441, DOI 10.1016/0038-0717(90)90176-Z	29	104	117	6	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					281	284		10.1126/science.282.5387.281	http://dx.doi.org/10.1126/science.282.5387.281			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765151				2022-12-28	WOS:000076370200044
J	Almond, S				Almond, S			A memorable patient - The inflating lady	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1998	317	7167					1230	1230		10.1136/bmj.317.7167.1230	http://dx.doi.org/10.1136/bmj.317.7167.1230			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138GF	9794867	Green Published			2022-12-28	WOS:000076963000032
J	Carr, A; Cooper, DA				Carr, A; Cooper, DA			Lipodystrophy associated with an HIV-protease inhibitor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									St Vincents Hosp, Sydney, NSW 2010, Australia; Univ New S Wales, Sydney, NSW 2010, Australia	St Vincents Hospital Sydney; University of New South Wales Sydney	Carr, A (corresponding author), St Vincents Hosp, Sydney, NSW 2010, Australia.								0	75	79	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1296	1296		10.1056/NEJM199810293391806	http://dx.doi.org/10.1056/NEJM199810293391806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132XC	9791146				2022-12-28	WOS:000076655300006
J	Beecham, L				Beecham, L			Northern Ireland GPs complain of stress and workload	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1161	1161						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784475				2022-12-28	WOS:000076755100077
J	Unwin, N; Thomson, R; O'Byrne, AM; Laker, M; Armstrong, H				Unwin, N; Thomson, R; O'Byrne, AM; Laker, M; Armstrong, H			Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; HYPERTENSION; PRAVASTATIN; PREVENTION	Objective: To compare the implications of four widely used cholesterol screening and treatment guidelines by applying them to a population in the United Kingdom. Design: Guidelines were applied to population based data from a ness sectional study of cardiovascular disease and risk factors. Setting: Newcastle upon Tyne, United Kingdom. Subjects: General population sample (predominantly of European origin) of 322 men and 319 women aged 25-64 years. Main outcome measures: Proportions recommended for screening and treatment. Methods: Criteria from the British Hyperlipidaemia Association, the British Drugs and Therapeutics Bulletin (which used the Sheffield table), the European Atherosclerosis Society, and the American national cholesterol education programme were applied to the population. Results: Proportions recommended far treatment varied appreciably. Based on the British Drugs and Therapeutics Bulletin guidelines, treatment was recommended for 5.3% (95% confidence interval 2.9% to 7.7%) of men and 3.3% (1.5% to 5.3%) of women, while equivalent respective values were 4.6 (2.3 to 6.9) and 2.8 (1.0 to 4.6) for the British Hyperlipidaemia Association, 23% (18.4% to 27.6%) and 10.6% (7.3% to 14.0%) for the European Atherosclerosis Society, and 37.2% (31.9% to 42.5%) and 22.2%(17.6% to 26.8%) for the national cholesterol education programme. Only the British Hyperlipidaemia Association and Drugs and Therapeutics Bulletin guidelines recommend selective screening. Applying British Hyperlipidaemia Association guidelines, from 7.1% (4.3% to 9.9%) of men in level one to 56.7% (51.3% to 62.1%) of men in level three, and from 4.4% (2.1% to 6.7%) of women in level one to 54.4% (48.9% to 59.9%) of women in level three would have been recommended for cholesterol screening. Had the Drugs and Therapeutics Bulletin guidelines been applied, 22.2% (16.5% to 27.9%) of men and 12.2% (8.6% to 15.8%) of women would have been screened. Conclusions: Without evidence based guidelines, there are problems of variation. A consistent approach needs to be developed and agreed across the United Kingdom.	Newcastle Univ, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Newcastle Univ, Sch Med, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Cty Durham Hlth Author, Dept Publ Hlth, Durham DH1 5XZ, England; Newcastle Univ, Dept Clin Biochem & Metab Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Sunderland, Dept Physiol, Sunderland SR1 3SD, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; University of Sunderland	Unwin, N (corresponding author), Newcastle Univ, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.c.unwin@ncl.ac.uk		Unwin, Nigel/0000-0002-1368-1648				Bennett N, 1995, HLTH SURVEY ENGLAND; BETTERIDGE DJ, 1993, POSTGRAD MED J, V69, P359, DOI 10.1136/pgmj.69.811.359; COLDMAN AJ, 1988, J EPIDEMIOL COMMUN H, V42, P390, DOI 10.1136/jech.42.4.390; *DEP HLTH, 1998, HLTH SURV ENGL 96; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; Fahey TP, 1996, BMJ-BRIT MED J, V313, P93, DOI 10.1136/bmj.313.7049.93; Freemantle N, 1997, BMJ-BRIT MED J, V315, P826, DOI 10.1136/bmj.315.7112.826; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Harland JO, 1997, J EPIDEMIOL COMMUN H, V51, P636, DOI 10.1136/jech.51.6.636; *MAN HYP, 1996, DRUG THER B S, V34, P89; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; *NHS CTR REV DISS, 1998, EFF HLTH CARE; *NHS CTR REV DISS, 1994, EFFECTIVE HLTH CARE, V4; PEDERSEN TR, 1994, LANCET, V344, P1383; PETRIE JC, 1990, RECOMMENDATIONS BLOO; Prineas R., 1982, MINNESOTA CODE MANUA; PYORALA K, 1994, EUR HEART J, V15, P1300; Raine R, 1996, BRIT MED J, V313, P1368, DOI 10.1136/bmj.313.7069.1368; Ramsay LE, 1996, LANCET, V348, P1251, DOI 10.1016/S0140-6736(05)65536-5; Rose G, 1982, CARDIOVASCULAR SURVE; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; *STAND MED ADV COM, 1997, US STAT; Thomson R, 1998, BRIT MED J, V316, P509, DOI 10.1136/bmj.316.7130.509; THOMSON R, 1995, BMJ-BRIT MED J, V311, P237, DOI 10.1136/bmj.311.6999.237; Unwin N, 1997, J EPIDEMIOL COMMUN H, V51, P160, DOI 10.1136/jech.51.2.160	27	40	45	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	1998	317	7166					1125	1130						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784450				2022-12-28	WOS:000076755100032
J	Palazzo, M; Soni, N				Palazzo, M; Soni, N			Critical-care studies: redefining the rules	LANCET			English	Editorial Material							INTERLEUKIN-1 RECEPTOR ANTAGONIST; SEPTIC SHOCK; ILL PATIENTS; OXYGEN DELIVERY; CLINICAL-TRIAL; SEPSIS; CATHETERIZATION; THERAPY		Charing Cross Hosp, Imperial Coll Sch Med, Dept Anaesthesia & Intens Care, London W6 8RF, England; Chelsea & Westminster Hosp, London, England	Imperial College London; Imperial College London	Palazzo, M (corresponding author), Charing Cross Hosp, Imperial Coll Sch Med, Dept Anaesthesia & Intens Care, London W6 8RF, England.							ALEXANDER HR, 1992, SURGERY, V112, P188; [Anonymous], 1988, LANCET, V2, P349; Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CONNORS AF, 1983, NEW ENGL J MED, V308, P263, DOI 10.1056/NEJM198302033080508; EISENBERG PR, 1984, CRIT CARE MED, V12, P549, DOI 10.1097/00003246-198407000-00001; FISCHER E, 1992, J CLIN INVEST, V89, P1551, DOI 10.1172/JCI115748; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Meduri GU, 1998, CRIT CARE MED, V26, P630, DOI 10.1097/00003246-199804000-00003; SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801; TULLI G, 1998, CURR ANAESTH INTENSI, V9, P2	17	7	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1998	352	9136					1306	1307		10.1016/S0140-6736(98)02342-3	http://dx.doi.org/10.1016/S0140-6736(98)02342-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788478				2022-12-28	WOS:000076573800047
J	Bartsch, D; Casadio, A; Karl, KA; Serodio, P; Kandel, ER				Bartsch, D; Casadio, A; Karl, KA; Serodio, P; Kandel, ER			CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation	CELL			English	Article							ELEMENT-BINDING PROTEIN; CAMP-RESPONSIVE ELEMENT; APLYSIA SENSORY NEURONS; TARGETED MUTATION; GENE-EXPRESSION; CRITICAL PERIOD; TRANSCRIPTION; MEMORY; PHOSPHORYLATION; DROSOPHILA	Although CREB seems to be important for memory formation, it is not known which of the isoforms of CREB, CREM, or ATF1 are expressed in the neurons that undergo long-term synaptic changes and what roles they have in memory formation. We have found a single Aplysia CREB1 gene homologous to both mammalian CREB and CREM and have characterized in the sensory neurons that mediate gill-withdrawal reflex the expression and function of the three proteins that it encodes: CREB1a, CREB1b, and CREB1c. CREB1a is a transcriptional activator that is both necessary and, upon phosphorylation, sufficient for longterm facilitation. CREB1b is a repressor of long-term facilitation. Cytoplasmic CREB1c modulates both the short- and long-term facilitation. Thus, in the sensory neurons, CREB1 encodes a critical regulatory unit converting short- to long-term synaptic changes.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA; New York State Psychiat Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; New York State Psychiatry Institute	Bartsch, D (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, 630 W 168th St, New York, NY 10032 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45923-09] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GALLIOT B, 1995, DEVELOPMENT, V121, P1205; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HARLOW E, 1988, ANTIBODIES; Hermanson O, 1996, BIOCHEM BIOPH RES CO, V225, P256, DOI 10.1006/bbrc.1996.1163; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Nibuya M, 1996, J NEUROSCI, V16, P2365; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; Widnell KL, 1996, J PHARMACOL EXP THER, V276, P306; YIN JCP, 1995, MOL CELL BIOL, V15, P5123; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	34	285	291	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					211	223		10.1016/S0092-8674(00)81752-3	http://dx.doi.org/10.1016/S0092-8674(00)81752-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790528	hybrid			2022-12-28	WOS:000076538300009
J	Estes, JA; Tinker, MT; Williams, TM; Doak, DF				Estes, JA; Tinker, MT; Williams, TM; Doak, DF			Killer whale predation on sea otters linking oceanic and nearshore ecosystems	SCIENCE			English	Article							KELP FOREST; COMMUNITY; ALASKA; PACIFIC; DECLINE	After nearly a century of recovery from overhunting, sea otter populations are in abrupt decline over Large areas of western Alaska. Increased killer whale predation is the Likely cause of these declines. Elevated sea urchin density and the consequent deforestation of kelp beds in the nearshore community demonstrate that the otter's keystone role has been reduced or eliminated. This chain of interactions was probably initiated by anthropogenic changes in the offshore oceanic ecosystem.	Univ Calif Santa Cruz, US Geol Survey, Biol Resources Div, Santa Cruz, CA 95064 USA; Glenside Ecol Serv, Victoria, BC V8Z 5C8, Canada; Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Environm Studies Board, Santa Cruz, CA 95064 USA	United States Department of the Interior; United States Geological Survey; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Estes, JA (corresponding author), Univ Calif Santa Cruz, US Geol Survey, Biol Resources Div, A-316 Earth & Marine Sci Bldg, Santa Cruz, CA 95064 USA.		Tinker, Martin T/D-3249-2018	Tinker, Martin T/0000-0002-3314-839X				BAIRD RW, 1994, THESIS S FRASIER U V; BARRETTLENNARD LG, 1994, REPORT N PACIFIC U M; Carpenter S. R., 1993, TROPHIC CASCADES LAK; Costa D., UNPUB; DAYTON PK, 1975, FISH B-NOAA, V73, P230; DUGGINS DO, 1980, ECOLOGY, V61, P447, DOI 10.2307/1937405; DUGGINS DO, 1989, SCIENCE, V245, P170, DOI 10.1126/science.245.4914.170; ESTES JA, 1995, ECOL MONOGR, V65, P75, DOI 10.2307/2937159; ESTES JA, 1974, SCIENCE, V185, P1058, DOI 10.1126/science.185.4156.1058; Estes JA, 1997, MAR POLLUT BULL, V34, P486, DOI 10.1016/S0025-326X(96)00178-6; Estes JA, 1996, AQUATIC PREDATORS AND THEIR PREY, P65; ESTES JA, 1981, WORLDWIDE FURBEARER, P606; ESTES JA, 1977, TID26712 US EN RES D; EVANS TJ, 1997, 975 MMM US FISH WILD; FORD JKB, 1994, KILLER WHALES NATURA; HAIRSTON NG, 1960, AM NAT, V94, P421, DOI 10.1086/282146; HATFIELD BB, IN PRESS MAR MAMM SC; HEIMLICHBORAN JR, 1988, CAN J ZOOL, V66, P565, DOI 10.1139/z88-084; JESSUP D, COMMUNICATION; Kenyon KW., 1969, N AM FAUNA, V68, P1, DOI DOI 10.3996/NAFA.68.0001; Kriete B., 1995, THESIS U BRIT COLUMB; Merrick RL, 1997, CAN J FISH AQUAT SCI, V54, P1342, DOI 10.1139/cjfas-54-6-1342; National Research Council, 1996, BER SEA EC; PASCUAL MA, 1994, ECOL APPL, V4, P393, DOI 10.2307/1941942; Polis GA, 1996, AM NAT, V147, P813, DOI 10.1086/285880; Polis GA, 1997, ANNU REV ECOL SYST, V28, P289, DOI 10.1146/annurev.ecolsys.28.1.289; Power ME, 1996, BIOSCIENCE, V46, P609, DOI 10.2307/1312990; REED DC, 1984, ECOLOGY, V65, P937, DOI 10.2307/1938066; REESE S, 1998, THESIS U CALIFORNIA; Riedman M.L., 1990, US FISH WILDLIFE SER, V90, P1, DOI DOI 10.2307/1382334; Rotterman L.M., 1988, P237; SPRINGER A, 1993, ALASKA SEA GRANT REP, V9301, P14; STEINBERG PD, 1995, P NATL ACAD SCI USA, V92, P8145, DOI 10.1073/pnas.92.18.8145; VANBLARICOM GR, 1988, ECOLOGICAL STUDIS, V65; York Anne E., 1996, P259	35	861	881	14	830	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					473	476		10.1126/science.282.5388.473	http://dx.doi.org/10.1126/science.282.5388.473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774274				2022-12-28	WOS:000076479600054
J	Randolph, GJ; Beaulieu, S; Lebecque, S; Steinman, RM; Muller, WA				Randolph, GJ; Beaulieu, S; Lebecque, S; Steinman, RM; Muller, WA			Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; PERIPHERAL LYMPH; HUMAN BLOOD; MACROSIALIN; GENERATION; MIGRATION; ANTIGEN; PROTEIN	Essential to the dendritic cell system of antigen-presenting cells are the veiled dendritic cells that traverse afferent Lymph to enter lymph nodes, where they initiate immune responses. The origin of veiled cells, which were discovered 20 years ago, is unclear. Monocytes cultured with endothelium differentiated into dendritic cells within 2 days, particularly after phagocytosing particles in subendothelial collagen. These nascent dendritic cells migrated across the endothelium in the ablumenal-to-lumenal direction, as would occur during entry into Lymphatics. Monocytes that: remained in the subendothelial matrix became macrophages. Therefore, monocytes have two potential fates associated with distinct patterns of migration.	Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA; Schering Plough SpA, Lab Immunol Res, F-69571 Dardilly, France	Cornell University; Rockefeller University; Merck & Company	Randolph, GJ (corresponding author), Cornell Univ, Coll Med, Dept Pathol, 1300 York Ave,Room C-420, New York, NY 10021 USA.	GJRandol@mail.med.cornell.edu		lebecque, serge/0000-0003-4006-8061	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013013, R01AI040045, R01AI013013, R37AI040045] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46849] Funding Source: Medline; NIAID NIH HHS [AI40045, AI13013] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; BUJDOSO R, 1989, J EXP MED, V170, P1285, DOI 10.1084/jem.170.4.1285; DESAINTVIS B, IN PRESS IMMUNITY; DREXHAGE HA, 1979, CELL TISSUE RES, V202, P407, DOI 10.1007/BF00220434; FREY JR, 1957, INT ARCH ALLER A IMM, V11, P81, DOI 10.1159/000228405; KELLY RH, 1978, ANAT RECORD, V190, P5, DOI 10.1002/ar.1091900103; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; MACPHERSON GG, 1995, J IMMUNOL, V154, P1317; Matsuno K, 1996, J EXP MED, V183, P1865, DOI 10.1084/jem.183.4.1865; Mosialos G, 1996, AM J PATHOL, V148, P593; MULLER WA, 1992, J EXP MED, V176, P819, DOI 10.1084/jem.176.3.819; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; PUGH CW, 1983, J EXP MED, V157, P1758, DOI 10.1084/jem.157.6.1758; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Randolph GJ, 1996, J EXP MED, V183, P451, DOI 10.1084/jem.183.2.451; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SOKOLOWSKI J, 1978, LYMPHOLOGY, V11, P202; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; THOMAS R, 1993, J IMMUNOL, V150, P821; VANFURTH R, 1968, J EXP MED, V128, P415, DOI 10.1084/jem.128.3.415; ZHOU LJ, 1992, J IMMUNOL, V149, P735	26	634	670	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					480	483		10.1126/science.282.5388.480	http://dx.doi.org/10.1126/science.282.5388.480			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774276				2022-12-28	WOS:000076479600056
J	Pollack, HN; Huang, SP; Shen, PY				Pollack, HN; Huang, SP; Shen, PY			Climate change record in subsurface temperatures: A global perspective	SCIENCE			English	Article							BOREHOLE TEMPERATURES; GEOTHERMAL EVIDENCE; NORTH-AMERICA; HISTORIES; INFERENCE; CANADA	Analyses of underground temperature measurements from 358 boreholes in eastern North America, central Europe, southern Africa, and Australia indicate that, in the 20th century, the average surface temperature of Earth has increased by about 0.5 degrees C and that the 20th century has been the warmest of the past five centuries. The subsurface temperatures also indicate that Earth's mean surface temperature has increased by about 1.0 degrees C over the past five centuries. The geothermal data offer an independent confirmation of the unusual character of 20th-century climate that has emerged from recent multiproxy studies.	Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA; Univ Western Ontario, Dept Earth Sci, London, ON N6A 5B7, Canada	University of Michigan System; University of Michigan; Western University (University of Western Ontario)	Pollack, HN (corresponding author), Univ Michigan, Dept Geol Sci, 1006 CC Little Bldg, Ann Arbor, MI 48109 USA.							Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; BAKER DG, 1993, GEOPHYS RES LETT, V20, P371, DOI 10.1029/92GL02724; BELTRAMI H, 1992, GLOBAL PLANET CHANGE, V98, P167; BELTRAMI H, 1995, GLOBAL PLANET CHANGE, V11, P57, DOI 10.1016/0921-8181(95)00002-9; BELTRAMI H, 1992, GEOPHYS RES LETT, V19, P689, DOI 10.1029/92GL00671; Bodri L, 1997, GLOBAL PLANET CHANGE, V14, P163, DOI 10.1016/S0921-8181(96)00010-0; Bodri L, 1995, GLOBAL PLANET CHANGE, V11, P111, DOI 10.1016/0921-8181(95)00005-4; CERMAK V, 1971, PALAEOGEOGR PALAEOCL, V10, P1, DOI 10.1016/0031-0182(71)90043-5; CHAPMAN DS, 1992, GLOBAL PLANET CHANGE, V98, P269; CLOW GD, 1992, GLOBAL PLANET CHANGE, V98, P81; DEMING D, 1995, SCIENCE, V268, P1576, DOI 10.1126/science.268.5217.1576; Gosnold WD, 1997, GLOBAL PLANET CHANGE, V15, P33, DOI 10.1016/S0921-8181(97)00002-7; Harris RN, 1998, J GEOPHYS RES-SOL EA, V103, P7363, DOI 10.1029/97JB03297; Harris RN, 1997, SCIENCE, V275, P1618, DOI 10.1126/science.275.5306.1618; Huang SP, 1996, GEOPHYS RES LETT, V23, P257, DOI 10.1029/96GL00020; Huang SP, 1997, GEOPHYS RES LETT, V24, P1947, DOI 10.1029/97GL01846; Jones PD, 1998, HOLOCENE, V8, P455, DOI 10.1191/095968398667194956; Jones PD, 1997, J CLIMATE, V10, P2548, DOI 10.1175/1520-0442(1997)010<2548:ESEILS>2.0.CO;2; LACHENBRUCH AH, 1986, SCIENCE, V234, P689, DOI 10.1126/science.234.4777.689; Mann ME, 1998, SCIENCE, V280, P2029; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; Overpeck J, 1997, SCIENCE, V278, P1251, DOI 10.1126/science.278.5341.1251; Pollack HN, 1996, PURE APPL GEOPHYS, V147, P537, DOI 10.1007/BF00878843; POLLACK HN, 1993, SCI AM, V268, P44, DOI 10.1038/scientificamerican0693-44; Prabhakara C, 1998, GEOPHYS RES LETT, V25, P1927, DOI 10.1029/98GL01300; SHEN PY, 1991, J GEOPHYS RES-SOL EA, V96, P19965, DOI 10.1029/91JB01883; SHEN PY, 1995, J GEOPHYS RES-SOL EA, V100, P6383, DOI 10.1029/94JB03136; Shen PY, 1996, GLOBAL PLANET CHANGE, V14, P49, DOI 10.1016/0921-8181(96)00004-5; WANG K, 1992, GLOBAL PLANET CHANGE, V98, P129; WANG KL, 1992, J GEOPHYS RES-SOL EA, V97, P2095, DOI 10.1029/91JB02716; WANG KL, 1992, SCIENCE, V256, P1003, DOI 10.1126/science.256.5059.1003	31	149	156	3	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1998	282	5387					279	281		10.1126/science.282.5387.279	http://dx.doi.org/10.1126/science.282.5387.279			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765150				2022-12-28	WOS:000076370200043
J	Cherkin, DC; Deyo, RA; Battie, M; Street, J; Barlow, W				Cherkin, DC; Deyo, RA; Battie, M; Street, J; Barlow, W			A comparison of physical therapy, chiropractic manipulation, and provision of an educational booklet for the treatment of patients with low back pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH SURVEY SF-36; SPINAL MANIPULATION; NATURAL-HISTORY; NATIONAL SURVEY; PRIMARY-CARE; NECK PAIN; FOLLOW-UP; PHYSIOTHERAPY; MANAGEMENT; SYMPTOMS	Background and Methods There are few data on the relative effectiveness and costs of treatments for low back pain. We randomly assigned 321 adults with low back pain that persisted for seven days after a primary care visit to the McKenzie method of physical therapy, chiropractic manipulation, or a minimal intervention (provision of an educational booklet). Patients with sciatica were excluded. Physical therapy or chiropractic manipulation was provided for one month (the number of visits was determined by the practitioner but was limited to a maximum of nine); patients were followed for a total of two years. The bothersomeness of symptoms was measured on an 11-point scale, and the level of dysfunction was measured on the 24-point Roland Disability Scale. Results After adjustment for base-line differences, the chiropractic group had less severe symptoms than the booklet group at four weeks (P=0.02), and there was a trend toward less severe symptoms in the physical-therapy group (P=0.06). However, these differences were small and not significant after transformations of the data to adjust for their non-normal distribution. Differences in the extent of dysfunction among the groups were small and approached significance only at one year, with greater dysfunction in the booklet group than in the other two groups (P=0.05). For all outcomes, there were no significant differences between the physical-therapy and chiropractic groups and no significant differences among the groups in the numbers of days of reduced activity or missed work or in recurrences of back pain. About 75 percent of the subjects in the therapy groups rated their care as very good or excellent, as compared with about 30 percent of the subjects in the booklet group (P<0.001). Over a two year period, the mean costs of care were $437 for the physical-therapy group, $429 for the chiropractic group, and $153 for the booklet group. Conclusions For patients with low back pain, the McKenzie method of physical therapy and chiropractic manipulation had similar effects and costs, and patients receiving these treatments had only marginally better outcomes than those receiving the minimal intervention of an educational booklet. Whether the limited benefits of these treatments are worth the additional costs is open to question. (N Engl J Med 1998;339:1021-9.) (C) 1998, Massachusetts Medical Society.	Grp Hlth Ctr Hlth Studies, Dept Hlth Serv, Seattle, WA 98101 USA; Grp Hlth Ctr Hlth Studies, Dept Family Med, Seattle, WA 98101 USA; Grp Hlth Ctr Hlth Studies, Dept Med, Seattle, WA 98101 USA; Grp Hlth Ctr Hlth Studies, Dept Biostat, Seattle, WA 98101 USA; Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA; Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada	University of Washington; University of Washington Seattle; University of Alberta	Cherkin, DC (corresponding author), Grp Hlth Ctr Hlth Studies, Dept Hlth Serv, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.		Battie, Michele C/C-6155-2018	Battie, Michele C/0000-0001-8499-2040	AHRQ HHS [HS07915] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Assendelft W J, 1996, J Manipulative Physiol Ther, V19, P499; BATTIE MC, 1994, PHYS THER, V74, P219, DOI 10.1093/ptj/74.3.219; Bigos S, 1994, AHCPR PUBLICATION; Cherkin DC, 1996, SPINE, V21, P345, DOI 10.1097/00007632-199602010-00019; COXHEAD CE, 1981, LANCET, V1, P1065; CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389; DEYO RA, 1988, ARCH PHYS MED REHAB, V69, P1044; Donelson R, 1990, Orthop Rev, V19, P681; Fisher LD., 1997, BIOMETRICS, V53, P1182; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; HALDEMAN S, 1991, ADULT SPINE PRINCIPL, V2, P1581; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P551, DOI 10.1097/00005650-199406000-00002; Mckenzie R, 1985, TREAT YOUR OWN BACK; MCKENZIE RA, 1981, LUMBAR SPINE MECH DI; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; *NAT CTRL HLTH STA, 1986, VIT HLTH STAT, V10; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; ROLAND M, 1983, SPINE, V8, P145, DOI 10.1097/00007632-198303000-00005; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; SALKEVER DS, 1985, DHHS PUBLICATION; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989; Skargren EI, 1997, SPINE, V22, P2167, DOI 10.1097/00007632-199709150-00015; Sternbach RA, 1986, CLIN J PAIN, V2, P49, DOI DOI 10.1097/00002508-198602010-00008; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	33	404	412	0	58	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1021	1029		10.1056/NEJM199810083391502	http://dx.doi.org/10.1056/NEJM199810083391502			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126LL	9761803				2022-12-28	WOS:000076294800002
J	Hill, K; Model, K; Ryan, MT; Dietmeier, K; Martin, F; Wagner, R; Pfanner, N				Hill, K; Model, K; Ryan, MT; Dietmeier, K; Martin, F; Wagner, R; Pfanner, N			Tom40 forms the hydrophilic channel of the mitochondrial import pore for preproteins	NATURE			English	Article							OUTER-MEMBRANE PROTEIN; RECEPTOR COMPLEX; PRECURSOR PROTEINS; CELL VIABILITY; CONTACT SITES; TRANSLOCATION; IDENTIFICATION; RECOGNITION; PRESEQUENCE; MACHINERY	The mitochondrial outer membrane contains machinery for the import of preproteins encoded by nuclear genes(1-3). Eight different Tom (translocase of outer membrane) proteins have been identified that function as receptors and/or are related to a hypothetical general import pore. Many mitochondrial membrane channel activities have been described(4-7), including one related to Tim23 of the inner-membrane protein-import system(5); however, the pore-forming subunit(s) of the Tom machinery have not been identified until now. Here we describe the expression and functional reconstitution of Tom40, an integral membrane protein with mainly beta-sheet structure. Tom40 forms a cation-selective high-conductance channel that specifically binds to and transports mitochondrial-targeting sequences added to the cis side of the membrane. We conclude that Tom40 is the pore-forming subunit of the mitochondrial general import pore and that it constitutes a hydrophilic, similar to 22 Angstrom wide channel for the import of preproteins.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Osnabruck, Fachbereich Biol Chem, D-49034 Osnabruck, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany	University of Freiburg; University Osnabruck; University of Freiburg	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	pfanner@ruf.uni-freiburg.de	Ryan, Michael T/C-6673-2011; Ryan, Michael/X-2152-2019; Pfanner, Nikolaus/AAV-7878-2021	Ryan, Michael T/0000-0003-2586-8829; Ryan, Michael/0000-0003-2586-8829; 				Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; DIHANICH M, 1989, EUR J BIOCHEM, V181, P703, DOI 10.1111/j.1432-1033.1989.tb14780.x; HILLE B, 1992, IONIC CHANNELS EXCIT, pCH9; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Juin P, 1997, J BIOL CHEM, V272, P6044, DOI 10.1074/jbc.272.9.6044; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MORAN O, 1990, J BIOL CHEM, V265, P908; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schmid B, 1996, FEBS LETT, V381, P111, DOI 10.1016/0014-5793(96)00080-4; Smart OS, 1997, BIOPHYS J, V72, P1109, DOI 10.1016/S0006-3495(97)78760-5; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1989, NATURE, V338, P170, DOI 10.1038/338170a0	30	403	408	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1998	395	6701					516	521		10.1038/26780	http://dx.doi.org/10.1038/26780			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774109				2022-12-28	WOS:000076212200060
J	Jamison, KR				Jamison, KR			Stigma of manic depression: a psychologist's experience	LANCET			English	Editorial Material									Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Jamison, KR (corresponding author), Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD 21287 USA.							ROY A, 1985, PSYCHIAT CLIN N AM, V8, P377	1	11	11	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1053	1053		10.1016/S0140-6736(98)01052-6	http://dx.doi.org/10.1016/S0140-6736(98)01052-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123JJ	9759768				2022-12-28	WOS:000076121800047
